Page last updated: 2024-07-31 18:56:10
zd 6474
Description
CH 331: structure in first source [MeSH]
vandetanib : A quinazoline that is 7-[(1-methylpiperidin-4-yl)methoxy]quinazoline bearing additional methoxy and 4-bromo-2-fluorophenylamino substituents at positions 6 and 4 respectively. Used for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. [CHeBI]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 3081361 |
| CHEMBL ID | 24828 |
| SCHEMBL ID | 9044 |
| SCHEMBL ID | 21067679 |
| CHEBI ID | 49960 |
| MeSH ID | M0463675 |
Synonyms (121)
| Synonym |
|---|
| AC-5251 |
| vandetanib [usan:inn:ban:jan] |
| nsc 760766 |
| nsc 744325 |
| yo460oq37k , |
| unii-yo460oq37k |
| hsdb 8198 |
| bdbm21 |
| chembl24828 , |
| zd-6474 , |
| cid_3081361 |
| n-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine |
| zd6474 |
| vandetanib , |
| HY-10260 |
| AB01273969-01 |
| AB01273969-02 |
| ZD6 , |
| ch-331 , |
| zactima |
| azd-6474 |
| caprelsa |
| caprelsa (tn) |
| D06407 |
| 443913-73-3 |
| vandetanib (jan/usan/inn) |
| 2IVU |
| n-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine |
| n-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine |
| 4-quninazolinamine, n-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)- |
| vandetanib [inn] |
| zd 6474 |
| NCGC00167513-01 |
| zd-64 |
| 4-bromo-2-fluoro-n-[(4e)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4(1h)-ylidene]aniline |
| CHEBI:49960 , |
| gnf-pf-2188 , |
| nsc-760766 |
| EC-000.2359 |
| FT-0656736 |
| nsc-744325 |
| nsc744325 |
| quinazolin-4-amine, n-(4-bromo-2-fluorophenyl)-6-mthoxy-7-[(1-methyl-4-piperidinyl)methoxy]- |
| KINOME_3316 |
| nsc760766 |
| v-9402 |
| vandetanib;7-((4-aminocyclohexyl)methoxy)-n-(4-bromo-2-fluorophenyl)-6-methoxyquinazolin-4-amine |
| A25648 |
| NCGC00167513-02 |
| NCGC00167513-03 |
| dtxcid9026681 |
| tox21_112511 |
| cas-443913-73-3 |
| dtxsid1046681 , |
| c22h24brfn4o2 |
| HMS3244K04 |
| HMS3244L03 |
| HMS3244K03 |
| BCPP000023 |
| F9995-0087 , |
| CS-0130 |
| S1046 |
| AKOS015902350 |
| gtpl5717 |
| ch 331 |
| vandetanib [mi] |
| 4-quinazolinamine, n-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4- piperidinyl)methoxy)- |
| DB05294 |
| vandetanib [usan] |
| vandetanib [who-dd] |
| vandetanib [mart.] |
| vandetanib [jan] |
| vandetanib [orange book] |
| vandetanib [vandf] |
| smr002530472 |
| MLS006011672 |
| SCHEMBL9044 |
| NCGC00167513-04 |
| tox21_112511_1 |
| 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline |
| UHTHHESEBZOYNR-UHFFFAOYSA-N |
| n-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine |
| n-(4-bromo-2-fluoro-phenyl)-6-methoxy-7-[(1-methyl-4-piperidyl)methoxy]quinazolin-4-amine |
| 338992-00-0 |
| (4-bromo-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine |
| vandetanib (zd6474) |
| AB01273969_04 |
| mfcd07772346 |
| vandetanib (zactima) , |
| EX-A422 |
| SR-00000000462-2 |
| sr-00000000462 |
| HMS3654E11 |
| NCGC00167513-09 |
| 4-[(4-bromo-2-fluorophenyl)amino]-6-methoxy-7-[(1-methyl-4-piperidyl)methoxy]quinazoline |
| SW218092-2 |
| 4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-yl)methoxyquinazoline |
| AS-11067 |
| BCP01925 |
| Q7914515 |
| BRD-K77625799-001-01-0 |
| SB16919 |
| HMS3672C07 |
| SY027438 |
| AMY599 |
| SCHEMBL21067679 |
| CCG-269495 |
| 443913-73-3 (free base) |
| nsc800961 |
| nsc-800961 |
| bdbm50595124 |
| BV164508 |
| vandetanib- bio-x |
| EN300-265835 |
| 4-quinazolinamine, n-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)- |
| vandetanib (mart.) |
| 4-bromo-2-fluoro-n-((4e)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4(1h)-ylidene)aniline |
| l01xe12 |
| azd6474 |
| vandetanibum |
| Z2512943095 |
Roles (2)
Drug Classes (6)
| Class | Description |
|---|
| aromatic ether | Any ether in which the oxygen is attached to at least one aryl substituent. |
| secondary amine | A compound formally derived from ammonia by replacing two hydrogen atoms by hydrocarbyl groups. |
| quinazolines | Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives. |
| piperidines | |
| organobromine compound | A compound containing at least one carbon-bromine bond. |
| organofluorine compound | An organofluorine compound is a compound containing at least one carbon-fluorine bond. |
Pathways (1)
zd 6474 is involved in 1 pathway(s), involving a total of 22 unique proteins and 2 unique compounds
Protein Targets (520)
Potency Measurements
Inhibition Measurements
Activation Measurements
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) |
|---|
| Leukotriene C4 synthase | Cavia porcellus (domestic guinea pig) | Kd | 10.0000 | AID625128 |
| Bone morphogenetic protein receptor type-1B | Homo sapiens (human) | Kd | 15.1200 | AID1424922; AID624825 |
| Membrane-associated progesterone receptor component 1 | Homo sapiens (human) | Kd | 30.0000 | AID1425109 |
| Cell division cycle 7-related protein kinase | Homo sapiens (human) | Kd | 30.0000 | AID1424936 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit delta isoform | Homo sapiens (human) | Kd | 10.0000 | AID624974 |
| Serine/threonine-protein kinase PLK4 | Homo sapiens (human) | Kd | 8.1850 | AID1425121; AID256607; AID436044; AID625076 |
| Serine/threonine-protein kinase 25 | Homo sapiens (human) | Kd | 10.0000 | AID435329; AID625059 |
| ATP-dependent RNA helicase DDX3X | Homo sapiens (human) | Kd | 30.0000 | AID1424975 |
| Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit beta | Homo sapiens (human) | Kd | 10.0000 | AID624877 |
| Pyridoxal kinase | Homo sapiens (human) | Kd | 30.0000 | AID1425106 |
| Citron Rho-interacting kinase | Homo sapiens (human) | Kd | 11.2000 | AID1424954; AID435523; AID625065 |
| Serine/threonine-protein kinase RIO3 | Homo sapiens (human) | Kd | 10.0000 | AID435191; AID624926 |
| Dual specificity mitogen-activated protein kinase kinase 7 | Homo sapiens (human) | Kd | 10.0000 | AID624722 |
| Serine/threonine-protein kinase Chk1 | Homo sapiens (human) | Kd | 16.6667 | AID1424953; AID435396; AID624831 |
| Inhibitor of nuclear factor kappa-B kinase subunit beta | Homo sapiens (human) | Kd | 10.0000 | AID624836 |
| Peripheral plasma membrane protein CASK | Homo sapiens (human) | Kd | 10.0000 | AID624749 |
| Aurora kinase A | Homo sapiens (human) | Kd | 16.6667 | AID1424917; AID435518; AID624919 |
| Cyclin-G-associated kinase | Homo sapiens (human) | Kd | 6.1176 | AID1425009; AID1595619; AID256612; AID435821; AID625012 |
| Serine/threonine-protein kinase DCLK1 | Homo sapiens (human) | Kd | 10.0000 | AID435284; AID624966 |
| Inhibitor of nuclear factor kappa-B kinase subunit alpha | Homo sapiens (human) | Kd | 10.0000 | AID624832 |
| Muscle, skeletal receptor tyrosine-protein kinase | Homo sapiens (human) | Kd | 10.0000 | AID435678; AID625022 |
| Ephrin type-B receptor 6 | Homo sapiens (human) | Kd | 15.0380 | AID1424995; AID624957 |
| Peroxisomal acyl-coenzyme A oxidase 3 | Homo sapiens (human) | Kd | 30.0000 | AID1424896 |
| Mitogen-activated protein kinase 13 | Homo sapiens (human) | Kd | 10.0000 | AID624892 |
| 3-phosphoinositide-dependent protein kinase 1 | Homo sapiens (human) | Kd | 10.0000 | AID435189; AID624876 |
| Mitogen-activated protein kinase kinase kinase 13 | Homo sapiens (human) | Kd | 10.0000 | AID624965 |
| Death-associated protein kinase 3 | Homo sapiens (human) | Kd | 10.0000 | AID435155; AID435398; AID624834 |
| Mitogen-activated protein kinase kinase kinase 7 | Homo sapiens (human) | Kd | 10.0000 | AID624724 |
| Receptor-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | Kd | 0.0286 | AID1425155; AID256611; AID435935; AID624925 |
| Mitotic checkpoint serine/threonine-protein kinase BUB1 | Homo sapiens (human) | Kd | 30.0000 | AID1424926 |
| NUAK family SNF1-like kinase 1 | Homo sapiens (human) | Kd | 10.0000 | AID435150; AID625088 |
| Dynamin-like 120 kDa protein, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | AID1425097 |
| Phosphatidylinositol 4-phosphate 5-kinase type-1 gamma | Homo sapiens (human) | Kd | 10.0000 | AID624751 |
| Tyrosine-protein kinase JAK2 | Homo sapiens (human) | Kd | 10.0000 | AID435658; AID624973 |
| Eukaryotic translation initiation factor 5B | Homo sapiens (human) | Kd | 30.0000 | AID1424986 |
| Rho-associated protein kinase 2 | Homo sapiens (human) | Kd | 16.8000 | AID1425158; AID624969 |
| Serine/threonine-protein kinase ULK1 | Homo sapiens (human) | Kd | 20.0000 | AID1425208; AID624916 |
| Serine/threonine-protein kinase/endoribonuclease IRE1 | Homo sapiens (human) | Kd | 20.0000 | AID1424997; AID624835 |
| Ribosomal protein S6 kinase alpha-5 | Homo sapiens (human) | Kd | 14.0000 | AID1425162; AID435831; AID436051; AID624736; AID624967 |
| U5 small nuclear ribonucleoprotein 200 kDa helicase | Homo sapiens (human) | Kd | 30.0000 | AID1425174 |
| Ribosomal protein S6 kinase alpha-4 | Homo sapiens (human) | Kd | 14.0000 | AID1425161; AID435325; AID435441; AID624806; AID624927 |
| Serine/threonine-protein kinase 16 | Homo sapiens (human) | Kd | 16.6667 | AID1425179; AID435692; AID624775 |
| Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit gamma | Homo sapiens (human) | Kd | 10.0000 | AID624958 |
| Serine/threonine-protein kinase PAK 3 | Homo sapiens (human) | Kd | 10.0000 | AID435823; AID624873 |
| Cyclin-dependent kinase-like 5 | Homo sapiens (human) | Kd | 20.0000 | AID1424951; AID624905 |
| Serine/threonine-protein kinase 17B | Homo sapiens (human) | Kd | 10.0000 | AID435401; AID624942 |
| Serine/threonine-protein kinase 10 | Homo sapiens (human) | Kd | 1.3535 | AID1425177; AID256604; AID435677; AID625030 |
| Serine/threonine-protein kinase D3 | Homo sapiens (human) | Kd | 16.6667 | AID1425137; AID435554; AID625024 |
| Cyclin-dependent kinase 14 | Homo sapiens (human) | Kd | 10.0000 | AID435689; AID625070 |
| Structural maintenance of chromosomes protein 2 | Homo sapiens (human) | Kd | 30.0000 | AID1425173 |
| Mitogen-activated protein kinase kinase kinase 6 | Homo sapiens (human) | Kd | 20.0000 | AID1425050; AID624962 |
| Serine/threonine-protein kinase OSR1 | Homo sapiens (human) | Kd | 10.0000 | AID624977 |
| Mitogen-activated protein kinase kinase kinase kinase 4 | Homo sapiens (human) | Kd | 10.9333 | AID1425054; AID435910; AID624756 |
| Serine/threonine-protein kinase LATS1 | Homo sapiens (human) | Kd | 20.0000 | AID1425033; AID435529; AID624963 |
| Serine/threonine-protein kinase PAK 4 | Homo sapiens (human) | Kd | 16.6667 | AID1425100; AID435929; AID624811 |
| Serine/threonine-protein kinase Chk2 | Homo sapiens (human) | Kd | 10.0000 | AID624803 |
| Tyrosine-protein kinase ABL1 | Homo sapiens (human) | Kd | 0.1827 | AID1424890; AID256665; AID256666; AID256667; AID256668; AID256669; AID256670; AID256671; AID435146; AID435514; AID435515; AID435644; AID435775; AID435776; AID435897; AID624978; AID624979; AID624980; AID624981; AID624982; AID624983; AID624984; AID624985; AID624986; AID624987; AID624988; AID624989; AID624990; AID624991; AID624992 |
| Epidermal growth factor receptor | Homo sapiens (human) | Kd | 0.1711 | AID1424983; AID1595618; AID256664; AID435156; AID435157; AID435402; AID435525; AID435652; AID435653; AID435791; AID435792; AID435906; AID435907; AID624996; AID624997; AID624998; AID624999; AID625000; AID625001; AID625002; AID625003; AID625004; AID625005; AID625006; AID625007 |
| RAF proto-oncogene serine/threonine-protein kinase | Homo sapiens (human) | Kd | 10.0000 | AID435556; AID624897 |
| Receptor tyrosine-protein kinase erbB-2 | Homo sapiens (human) | Kd | 2.6000 | AID435796; AID624804 |
| High affinity nerve growth factor receptor | Homo sapiens (human) | Kd | 16.6667 | AID1425094; AID435201; AID624808 |
| Guanine nucleotide-binding protein G(i) subunit alpha-2 | Homo sapiens (human) | Kd | 30.0000 | AID1425011 |
| ADP/ATP translocase 2 | Homo sapiens (human) | Kd | 30.0000 | AID1425169 |
| Protein kinase C beta type | Homo sapiens (human) | Kd | 30.0000 | AID1425130 |
| Insulin receptor | Homo sapiens (human) | Kd | 16.6667 | AID1425026; AID435408; AID624784 |
| Tyrosine-protein kinase Lck | Homo sapiens (human) | Kd | 0.8115 | AID1425034; AID256657; AID435676; AID625013 |
| Tyrosine-protein kinase Fyn | Homo sapiens (human) | Kd | 9.1050 | AID1425008; AID256630; AID435800; AID624727 |
| Cyclin-dependent kinase 1 | Homo sapiens (human) | Kd | 30.0000 | AID1424937 |
| Glycogen phosphorylase, liver form | Homo sapiens (human) | Kd | 30.0000 | AID1425146 |
| Tyrosine-protein kinase Fes/Fps | Homo sapiens (human) | Kd | 16.6667 | AID1425003; AID435161; AID624852 |
| Macrophage colony-stimulating factor 1 receptor | Homo sapiens (human) | Kd | 1.2000 | AID435280; AID624995 |
| Adenine phosphoribosyltransferase | Homo sapiens (human) | Kd | 30.0000 | AID1424914 |
| Tyrosine-protein kinase Yes | Homo sapiens (human) | Kd | 7.6300 | AID1425212; AID256614; AID435328; AID625018 |
| Tyrosine-protein kinase Lyn | Homo sapiens (human) | Kd | 7.7325 | AID1425037; AID256628; AID435804; AID624862 |
| Proto-oncogene tyrosine-protein kinase receptor Ret | Homo sapiens (human) | Kd | 2.9449 | AID1425154; AID435323; AID435434; AID625121; AID625122; AID625123; AID625124 |
| Insulin-like growth factor 1 receptor | Homo sapiens (human) | Kd | 16.6667 | AID1425022; AID435164; AID624800 |
| Signal recognition particle receptor subunit alpha | Homo sapiens (human) | Kd | 30.0000 | AID1425176 |
| Cytochrome c1, heme protein, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | AID1424969 |
| Hepatocyte growth factor receptor | Homo sapiens (human) | Kd | 11.1000 | AID1425076; AID435312; AID624794; AID624795; AID624796 |
| Tyrosine-protein kinase HCK | Homo sapiens (human) | Kd | 8.7300 | AID1425017; AID256629; AID435311; AID624857 |
| Proto-oncogene tyrosine-protein kinase ROS | Homo sapiens (human) | Kd | 10.0000 | AID435192; AID624899 |
| Platelet-derived growth factor receptor beta | Homo sapiens (human) | Kd | 7.6065 | AID1425104; AID256661; AID435926; AID624875 |
| Tyrosine-protein kinase Fgr | Homo sapiens (human) | Kd | 8.1850 | AID1425005; AID256560; AID435798; AID625011 |
| Wee1-like protein kinase 2 | Homo sapiens (human) | Kd | 10.0000 | AID624746 |
| Uncharacterized serine/threonine-protein kinase SBK3 | Homo sapiens (human) | Kd | 10.0000 | AID624747 |
| Serine/threonine-protein kinase A-Raf | Homo sapiens (human) | Kd | 30.0000 | AID1424915 |
| Mast/stem cell growth factor receptor Kit | Homo sapiens (human) | Kd | 0.5515 | AID256660; AID435167; AID435410; AID435411; AID435675; AID435802; AID599957; AID599959; AID624786; AID624787; AID624788; AID624789; AID624790; AID624791; AID624792; AID624793 |
| Glycogen phosphorylase, brain form | Homo sapiens (human) | Kd | 30.0000 | AID1425145 |
| Breakpoint cluster region protein | Homo sapiens (human) | Kd | 0.8790 | AID1424919 |
| Serine/threonine-protein kinase pim-1 | Homo sapiens (human) | Kd | 20.0000 | AID1425111; AID435931; AID624878 |
| Fibroblast growth factor receptor 1 | Homo sapiens (human) | Kd | 9.1050 | AID1425004; AID256653; AID435526; AID625132 |
| DNA topoisomerase 2-alpha | Homo sapiens (human) | Kd | 30.0000 | AID1425202 |
| Myosin light chain kinase, smooth muscle | Gallus gallus (chicken) | Kd | 10.0000 | AID435413 |
| Cyclin-dependent kinase 4 | Homo sapiens (human) | Kd | 20.0000 | AID1424946; AID624780; AID624781 |
| ADP/ATP translocase 3 | Homo sapiens (human) | Kd | 30.0000 | AID1425170 |
| Inosine-5'-monophosphate dehydrogenase 2 | Homo sapiens (human) | Kd | 30.0000 | AID1425025 |
| Proto-oncogene tyrosine-protein kinase Src | Homo sapiens (human) | Kd | 7.5775 | AID1425175; AID256676; AID435195; AID625016 |
| cAMP-dependent protein kinase type II-alpha regulatory subunit | Homo sapiens (human) | Kd | 30.0000 | AID1425128 |
| Insulin receptor-related protein | Homo sapiens (human) | Kd | 10.0000 | AID435430; AID625075 |
| Serine/threonine-protein kinase B-raf | Homo sapiens (human) | Kd | 14.0000 | AID1424924; AID435901; AID435902; AID624946; AID624947 |
| Phosphorylase b kinase gamma catalytic chain, liver/testis isoform | Homo sapiens (human) | Kd | 14.3500 | AID1425110; AID256618; AID435930; AID624797 |
| Ribosyldihydronicotinamide dehydrogenase [quinone] | Homo sapiens (human) | Kd | 30.0000 | AID1425093 |
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | Kd | 0.2300 | AID435827; AID625034 |
| Tyrosine-protein kinase Fer | Homo sapiens (human) | Kd | 20.0000 | AID1425002; AID435160; AID625010 |
| Protein kinase C alpha type | Homo sapiens (human) | Kd | 30.0000 | AID1425129 |
| cAMP-dependent protein kinase catalytic subunit alpha | Homo sapiens (human) | Kd | 16.6667 | AID1425123; AID435932; AID624881 |
| Vascular endothelial growth factor receptor 1 | Homo sapiens (human) | Kd | 0.2600 | AID435429; AID624853 |
| General transcription and DNA repair factor IIH helicase subunit XPD | Homo sapiens (human) | Kd | 30.0000 | AID1424996 |
| Interferon-induced, double-stranded RNA-activated protein kinase | Homo sapiens (human) | Kd | 10.0000 | AID435555; AID624896 |
| Casein kinase II subunit alpha' | Homo sapiens (human) | Kd | 16.6667 | AID1424968; AID435789; AID624849 |
| Ras-related protein Rab-6A | Homo sapiens (human) | Kd | 30.0000 | AID1425150 |
| Serine/threonine-protein kinase MAK | Homo sapiens (human) | Kd | 10.0000 | AID625025 |
| Cyclin-dependent kinase 11B | Homo sapiens (human) | Kd | 10.0000 | AID435395; AID624708 |
| Ephrin type-A receptor 1 | Homo sapiens (human) | Kd | 10.1533 | AID1424987; AID435793; AID625008 |
| Fibroblast growth factor receptor 2 | Homo sapiens (human) | Kd | 2.5667 | AID256654; AID435290; AID625131 |
| Receptor tyrosine-protein kinase erbB-3 | Homo sapiens (human) | Kd | 0.1600 | AID624851 |
| Multifunctional protein ADE2 | Homo sapiens (human) | Kd | 30.0000 | AID1425098 |
| Fibroblast growth factor receptor 4 | Homo sapiens (human) | Kd | 6.1500 | AID435656; AID625130 |
| Fibroblast growth factor receptor 3 | Homo sapiens (human) | Kd | 3.4480 | AID256624; AID435291; AID435527; AID624782; AID624783 |
| cAMP-dependent protein kinase catalytic subunit gamma | Homo sapiens (human) | Kd | 30.0000 | AID1425125 |
| cAMP-dependent protein kinase catalytic subunit beta | Homo sapiens (human) | Kd | 16.6667 | AID1425124; AID435182; AID624882 |
| Ferrochelatase, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | AID1425001 |
| Ribosomal protein S6 kinase beta-1 | Homo sapiens (human) | Kd | 15.8000 | AID1425164; AID624906 |
| Tyrosine-protein kinase JAK1 | Homo sapiens (human) | Kd | 15.0000 | AID1425030; AID435165; AID624858; AID624859 |
| Protein kinase C eta type | Homo sapiens (human) | Kd | 10.0000 | AID436034; AID625049 |
| Cyclin-dependent kinase 2 | Homo sapiens (human) | Kd | 16.6667 | AID1424944; AID435785; AID624844 |
| Beta-adrenergic receptor kinase 1 | Homo sapiens (human) | Kd | 30.0000 | AID1424908 |
| Probable ATP-dependent RNA helicase DDX6 | Homo sapiens (human) | Kd | 30.0000 | AID1424977 |
| Activin receptor type-2A | Homo sapiens (human) | Kd | 10.0000 | AID436004; AID624838 |
| Mitogen-activated protein kinase 3 | Homo sapiens (human) | Kd | 16.6667 | AID1425061; AID436016; AID624885 |
| MAP/microtubule affinity-regulating kinase 3 | Homo sapiens (human) | Kd | 16.6667 | AID1425069; AID435659; AID624863 |
| Deoxycytidine kinase | Homo sapiens (human) | Kd | 30.0000 | AID1424970 |
| Mitogen-activated protein kinase 1 | Homo sapiens (human) | Kd | 20.0000 | AID1425056; AID435654; AID624713 |
| Ephrin type-A receptor 2 | Homo sapiens (human) | Kd | 8.5250 | AID1424988; AID256602; AID435908; AID624951 |
| Ephrin type-A receptor 3 | Homo sapiens (human) | Kd | 1.9333 | AID256601; AID435794; AID625009 |
| Ephrin type-A receptor 8 | Homo sapiens (human) | Kd | 0.1140 | AID256600; AID435287; AID625120 |
| Ephrin type-B receptor 2 | Homo sapiens (human) | Kd | 10.2933 | AID1424992; AID435288; AID625105 |
| Leukocyte tyrosine kinase receptor | Homo sapiens (human) | Kd | 0.5500 | AID435168; AID624743 |
| Non-receptor tyrosine-protein kinase TYK2 | Homo sapiens (human) | Kd | 18.0000 | AID1425207; AID435444; AID624912; AID624913 |
| UMP-CMP kinase | Homo sapiens (human) | Kd | 30.0000 | AID1424959 |
| Phosphatidylethanolamine-binding protein 1 | Homo sapiens (human) | Kd | 30.0000 | AID1425107 |
| Wee1-like protein kinase | Homo sapiens (human) | Kd | 16.6667 | AID1425210; AID435204; AID624914 |
| Heme oxygenase 2 | Homo sapiens (human) | Kd | 30.0000 | AID1425018 |
| Tyrosine-protein kinase receptor UFO | Homo sapiens (human) | Kd | 0.2500 | AID436007; AID624840; AID738491 |
| Mitogen-activated protein kinase 4 | Homo sapiens (human) | Kd | 10.0000 | AID436017; AID624886 |
| S-adenosylmethionine synthase isoform type-2 | Homo sapiens (human) | Kd | 30.0000 | AID1425071 |
| DnaJ homolog subfamily A member 1 | Homo sapiens (human) | Kd | 30.0000 | AID1424980 |
| RAC-alpha serine/threonine-protein kinase | Homo sapiens (human) | Kd | 16.6667 | AID1424910; AID435899; AID624994 |
| RAC-beta serine/threonine-protein kinase | Homo sapiens (human) | Kd | 16.6667 | AID1424911; AID435517; AID624839 |
| G protein-coupled receptor kinase 4 | Homo sapiens (human) | Kd | 10.0000 | AID624739 |
| Dual specificity protein kinase TTK | Homo sapiens (human) | Kd | 16.6667 | AID1425205; AID435203; AID624910 |
| DNA replication licensing factor MCM4 | Homo sapiens (human) | Kd | 30.0000 | AID1425072 |
| Prostaglandin G/H synthase 2 | Homo sapiens (human) | Kd | 10.0000 | AID625141 |
| Myosin-10 | Homo sapiens (human) | Kd | 30.0000 | AID1425079 |
| Tyrosine-protein kinase receptor Tie-1 | Homo sapiens (human) | Kd | 1.5000 | AID435198; AID625017 |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | Kd | 0.8333 | AID256631; AID436018; AID624854 |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | Kd | 0.7033 | AID256642; AID435327; AID624860 |
| Dual specificity mitogen-activated protein kinase kinase 2 | Homo sapiens (human) | Kd | 10.7333 | AID1425039; AID435169; AID625137 |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | Kd | 3.0836 | AID1425006; AID256620; AID435162; AID435310; AID435406; AID435407; AID435799; AID624934; AID624935; AID624936; AID624937; AID624938; AID624939; AID624940 |
| Bone morphogenetic protein receptor type-1A | Homo sapiens (human) | Kd | 16.6667 | AID1424921; AID435276; AID624945 |
| Activin receptor type-1B | Homo sapiens (human) | Kd | 20.0000 | AID1424901; AID435898; AID624943 |
| TGF-beta receptor type-1 | Homo sapiens (human) | Kd | 16.6667 | AID1425196; AID435938; AID624961 |
| Serine/threonine-protein kinase receptor R3 | Homo sapiens (human) | Kd | 0.4700 | AID435645; AID624778 |
| TGF-beta receptor type-2 | Homo sapiens (human) | Kd | 16.6667 | AID1425197; AID435693; AID624909 |
| Electron transfer flavoprotein subunit beta | Homo sapiens (human) | Kd | 30.0000 | AID1424999 |
| Tyrosine-protein kinase CSK | Homo sapiens (human) | Kd | 9.6750 | AID1424960; AID256649; AID435904; AID624948 |
| Glycine--tRNA ligase | Homo sapiens (human) | Kd | 30.0000 | AID1425010 |
| Protein kinase C iota type | Homo sapiens (human) | Kd | 20.0000 | AID1425133; AID624883 |
| Exosome RNA helicase MTR4 | Homo sapiens (human) | Kd | 30.0000 | AID1425168 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform | Homo sapiens (human) | Kd | 10.0000 | AID435552; AID436033; AID625036; AID625037; AID625038; AID625039; AID625040; AID625041; AID625042; AID625043; AID625044; AID625045 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | Homo sapiens (human) | Kd | 10.0000 | AID625046 |
| Serine/threonine-protein kinase mTOR | Homo sapiens (human) | Kd | 10.0000 | AID624972 |
| Megakaryocyte-associated tyrosine-protein kinase | Homo sapiens (human) | Kd | 10.0000 | AID624864 |
| Tyrosine-protein kinase Tec | Homo sapiens (human) | Kd | 16.6667 | AID1425193; AID435197; AID624908 |
| Tyrosine-protein kinase TXK | Homo sapiens (human) | Kd | 3.7000 | AID435443; AID624911 |
| Tyrosine-protein kinase ABL2 | Homo sapiens (human) | Kd | 7.5670 | AID1424891; AID256641; AID435777; AID624993 |
| Tyrosine-protein kinase FRK | Homo sapiens (human) | Kd | 6.2600 | AID1425007; AID1619515; AID256598; AID436019; AID624855 |
| G protein-coupled receptor kinase 6 | Homo sapiens (human) | Kd | 30.0000 | AID1425012 |
| Tyrosine-protein kinase ZAP-70 | Homo sapiens (human) | Kd | 10.0000 | AID435445; AID624744 |
| Tyrosine-protein kinase SYK | Homo sapiens (human) | Kd | 16.6667 | AID1425188; AID435442; AID624907 |
| 26S proteasome regulatory subunit 6B | Homo sapiens (human) | Kd | 30.0000 | AID1425141 |
| Mitogen-activated protein kinase 8 | Homo sapiens (human) | Kd | 16.6667 | AID1425063; AID435166; AID624889 |
| Mitogen-activated protein kinase 9 | Homo sapiens (human) | Kd | 16.6667 | AID1425064; AID435409; AID624717 |
| Dual specificity mitogen-activated protein kinase kinase 4 | Homo sapiens (human) | Kd | 10.0000 | AID435822; AID624902 |
| Dual specificity mitogen-activated protein kinase kinase 3 | Homo sapiens (human) | Kd | 16.6667 | AID1425040; AID436022; AID624894 |
| Phosphatidylinositol 5-phosphate 4-kinase type-2 alpha | Homo sapiens (human) | Kd | 30.0000 | AID1425113 |
| Casein kinase I isoform alpha | Homo sapiens (human) | Kd | 20.0000 | AID1424961; AID624846 |
| Casein kinase I isoform delta | Homo sapiens (human) | Kd | 16.6667 | AID1424962; AID435524; AID624716 |
| Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit gamma isoform | Homo sapiens (human) | Kd | 10.0000 | AID624879 |
| MAP kinase-activated protein kinase 2 | Homo sapiens (human) | Kd | 16.6667 | AID1425065; AID435180; AID624703 |
| Cyclin-dependent kinase 8 | Homo sapiens (human) | Kd | 10.0000 | AID435903; AID624829 |
| Elongation factor Tu, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | AID1425206 |
| Choline-phosphate cytidylyltransferase A | Homo sapiens (human) | Kd | 30.0000 | AID1425103 |
| Casein kinase I isoform epsilon | Homo sapiens (human) | Kd | 9.3750 | AID1424963; AID256644; AID435650; AID624847 |
| Very long-chain specific acyl-CoA dehydrogenase, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | AID1424894 |
| Dual specificity protein kinase CLK1 | Homo sapiens (human) | Kd | 16.6667 | AID1424955; AID435786; AID624764 |
| Dual specificity protein kinase CLK2 | Homo sapiens (human) | Kd | 16.6667 | AID1424956; AID435787; AID624932 |
| Dual specificity protein kinase CLK3 | Homo sapiens (human) | Kd | 16.6667 | AID1424957; AID436011; AID624931 |
| Glycogen synthase kinase-3 alpha | Homo sapiens (human) | Kd | 16.6667 | AID1425013; AID435801; AID625114 |
| Glycogen synthase kinase-3 beta | Homo sapiens (human) | Kd | 16.6667 | AID1425014; AID435163; AID624856 |
| Cyclin-dependent kinase 7 | Homo sapiens (human) | Kd | 14.7000 | AID1424949; AID435278; AID624845 |
| Cyclin-dependent kinase 9 | Homo sapiens (human) | Kd | 16.6667 | AID1424950; AID435279; AID624830 |
| Ras-related protein Rab-27A | Homo sapiens (human) | Kd | 30.0000 | AID1425149 |
| Tyrosine-protein kinase Blk | Homo sapiens (human) | Kd | 0.0660 | AID435646; AID624841 |
| Interleukin-1 receptor-associated kinase 1 | Homo sapiens (human) | Kd | 15.6000 | AID1425027; AID624837 |
| Ribosomal protein S6 kinase alpha-3 | Homo sapiens (human) | Kd | 16.6667 | AID1425160; AID435558; AID624960 |
| Cytoplasmic tyrosine-protein kinase BMX | Homo sapiens (human) | Kd | 10.0000 | AID435781; AID624842 |
| cAMP-dependent protein kinase catalytic subunit PRKX | Homo sapiens (human) | Kd | 10.0000 | AID436047; AID624976 |
| Serine/threonine-protein kinase Nek2 | Homo sapiens (human) | Kd | 16.6667 | AID1425086; AID435665; AID624869 |
| Serine/threonine-protein kinase Nek3 | Homo sapiens (human) | Kd | 20.0000 | AID1425087; AID624870 |
| Serine/threonine-protein kinase Nek4 | Homo sapiens (human) | Kd | 10.0000 | AID624904 |
| Tyrosine-protein kinase JAK3 | Homo sapiens (human) | Kd | 10.0000 | AID435674; AID624785 |
| Dual specificity mitogen-activated protein kinase kinase 6 | Homo sapiens (human) | Kd | 16.6667 | AID1425043; AID435911; AID624895 |
| Serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Kd | 16.6667 | AID1425120; AID435934; AID624975 |
| Death-associated protein kinase 1 | Homo sapiens (human) | Kd | 10.0000 | AID435283; AID624971 |
| LIM domain kinase 1 | Homo sapiens (human) | Kd | 16.6667 | AID1425035; AID435803; AID624861 |
| LIM domain kinase 2 | Homo sapiens (human) | Kd | 16.6667 | AID1425036; AID435294; AID625021 |
| Mitogen-activated protein kinase 12 | Homo sapiens (human) | Kd | 10.0000 | AID435438; AID624766 |
| Mitogen-activated protein kinase 10 | Homo sapiens (human) | Kd | 16.6667 | AID1425057; AID435293; AID624891 |
| Tyrosine--tRNA ligase, cytoplasmic | Homo sapiens (human) | Kd | 30.0000 | AID1425211 |
| 5'-AMP-activated protein kinase subunit gamma-1 | Homo sapiens (human) | Kd | 30.0000 | AID1425126 |
| 5'-AMP-activated protein kinase catalytic subunit alpha-2 | Homo sapiens (human) | Kd | 10.0000 | AID435149; AID625047 |
| Ephrin type-B receptor 3 | Homo sapiens (human) | Kd | 16.6667 | AID1424993; AID435159; AID624955 |
| Ephrin type-A receptor 5 | Homo sapiens (human) | Kd | 7.6975 | AID1424990; AID256591; AID435158; AID624737 |
| Ephrin type-B receptor 4 | Homo sapiens (human) | Kd | 8.4100 | AID1424994; AID256559; AID435404; AID624956 |
| Ephrin type-B receptor 1 | Homo sapiens (human) | Kd | 0.3733 | AID256590; AID435403; AID624954 |
| Ephrin type-A receptor 4 | Homo sapiens (human) | Kd | 9.3750 | AID1424989; AID256589; AID435795; AID624952 |
| Adenylate kinase 2, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | AID1424909 |
| Adenosine kinase | Homo sapiens (human) | Kd | 30.0000 | AID1424907 |
| Hormonally up-regulated neu tumor-associated kinase | Homo sapiens (human) | Kd | 4.1000 | AID625084 |
| Serine/threonine-protein kinase SIK1 | Homo sapiens (human) | Kd | 1.9000 | AID435560; AID624733 |
| Receptor-interacting serine/threonine-protein kinase 4 | Homo sapiens (human) | Kd | 0.6200 | AID624763 |
| Ras-related protein Rab-10 | Homo sapiens (human) | Kd | 30.0000 | AID1425148 |
| Cell division control protein 2 homolog | Plasmodium falciparum 3D7 | Kd | 10.0000 | AID624760 |
| Actin-related protein 3 | Homo sapiens (human) | Kd | 30.0000 | AID1424899 |
| Actin-related protein 2 | Homo sapiens (human) | Kd | 30.0000 | AID1424898 |
| Calcium-dependent protein kinase 1 | Plasmodium falciparum 3D7 | Kd | 10.0000 | AID624759 |
| GTP-binding nuclear protein Ran | Homo sapiens (human) | Kd | 30.0000 | AID1425153 |
| Tubulin alpha-1A chain | Rattus norvegicus (Norway rat) | Kd | 0.4800 | AID435797 |
| Casein kinase II subunit alpha | Homo sapiens (human) | Kd | 10.0000 | AID436012; AID624848 |
| Phosphatidylinositol 5-phosphate 4-kinase type-2 beta | Homo sapiens (human) | Kd | 10.0000 | AID435828; AID624915 |
| SRSF protein kinase 2 | Homo sapiens (human) | Kd | 10.0000 | AID435196; AID624768 |
| Casein kinase I isoform gamma-2 | Homo sapiens (human) | Kd | 16.6667 | AID1424965; AID435282; AID624833 |
| Mitogen-activated protein kinase kinase kinase 9 | Homo sapiens (human) | Kd | 10.0000 | AID435297; AID624706 |
| Serine/threonine-protein kinase PknB | Mycobacterium tuberculosis H37Rv | Kd | 10.0000 | AID624753 |
| Cyclin-dependent kinase 3 | Homo sapiens (human) | Kd | 20.0000 | AID1424945; AID435277; AID624828 |
| Cyclin-dependent kinase-like 1 | Homo sapiens (human) | Kd | 10.0000 | AID624941 |
| Cyclin-dependent kinase 6 | Homo sapiens (human) | Kd | 30.0000 | AID1424948 |
| Cyclin-dependent-like kinase 5 | Homo sapiens (human) | Kd | 16.6667 | AID1424947; AID436010; AID624970 |
| Cyclin-dependent kinase 16 | Homo sapiens (human) | Kd | 16.6667 | AID1424941; AID435925; AID625033 |
| Cyclin-dependent kinase 17 | Homo sapiens (human) | Kd | 16.6667 | AID1424942; AID435688; AID624776 |
| Protein kinase C epsilon type | Homo sapiens (human) | Kd | 10.0000 | AID435320; AID625014 |
| Dual specificity mitogen-activated protein kinase kinase 1 | Homo sapiens (human) | Kd | 11.2000 | AID1425038; AID435808; AID624893 |
| Angiopoietin-1 receptor | Homo sapiens (human) | Kd | 1.8667 | AID256617; AID435939; AID624799 |
| Mitogen-activated protein kinase kinase kinase 10 | Homo sapiens (human) | Kd | 10.0000 | AID435432; AID624867 |
| DNA topoisomerase 2-beta | Homo sapiens (human) | Kd | 30.0000 | AID1425203 |
| Protein kinase C theta type | Homo sapiens (human) | Kd | 20.0000 | AID1425134; AID435321; AID625051 |
| Activin receptor type-1 | Homo sapiens (human) | Kd | 10.1000 | AID1424900; AID435274; AID624819 |
| Macrophage-stimulating protein receptor | Homo sapiens (human) | Kd | 20.0000 | AID1425078; AID624868 |
| Focal adhesion kinase 1 | Homo sapiens (human) | Kd | 16.6667 | AID1425142; AID435184; AID624729 |
| Protein kinase C zeta type | Homo sapiens (human) | Kd | 30.0000 | AID1425135 |
| Protein kinase C delta type | Homo sapiens (human) | Kd | 16.6667 | AID1425131; AID435553; AID625048 |
| Tyrosine-protein kinase BTK | Homo sapiens (human) | Kd | 13.9000 | AID1424925; AID436008; AID624779 |
| Tyrosine-protein kinase receptor TYRO3 | Homo sapiens (human) | Kd | 0.0930 | AID435326; AID625057; AID738489 |
| Cyclin-dependent kinase 18 | Homo sapiens (human) | Kd | 10.0000 | AID435826; AID624874 |
| Activated CDC42 kinase 1 | Homo sapiens (human) | Kd | 16.6667 | AID1425201; AID435694; AID624807 |
| Epithelial discoidin domain-containing receptor 1 | Homo sapiens (human) | Kd | 0.4570 | AID1424972; AID435400; AID624850 |
| Tyrosine-protein kinase ITK/TSK | Homo sapiens (human) | Kd | 10.0000 | AID435292; AID625020 |
| Myotonin-protein kinase | Homo sapiens (human) | Kd | 10.0000 | AID435285; AID624950 |
| Mitogen-activated protein kinase kinase kinase kinase 2 | Homo sapiens (human) | Kd | 15.8000 | AID1425052; AID624959 |
| Mitogen-activated protein kinase kinase kinase 12 | Homo sapiens (human) | Kd | 10.0000 | AID624762 |
| Tyrosine-protein kinase Mer | Homo sapiens (human) | Kd | 1.4000 | AID436023; AID624767; AID738490 |
| Serine/threonine-protein kinase 4 | Homo sapiens (human) | Kd | 16.6667 | AID1425185; AID435433; AID625055 |
| 5'-AMP-activated protein kinase catalytic subunit alpha-1 | Homo sapiens (human) | Kd | 13.2500 | AID1425122; AID256638; AID435148; AID624773 |
| Serine/threonine-protein kinase PAK 1 | Homo sapiens (human) | Kd | 10.0000 | AID435318; AID624871 |
| Dual specificity mitogen-activated protein kinase kinase 5 | Homo sapiens (human) | Kd | 15.0245 | AID1425042; AID624721 |
| Mitogen-activated protein kinase 7 | Homo sapiens (human) | Kd | 16.6667 | AID1425062; AID435655; AID624888 |
| Serine/threonine-protein kinase PAK 2 | Homo sapiens (human) | Kd | 16.6667 | AID1425099; AID435439; AID624872 |
| Serine/threonine-protein kinase 3 | Homo sapiens (human) | Kd | 16.6667 | AID1425182; AID435662; AID625054 |
| Mitogen-activated protein kinase kinase kinase 1 | Homo sapiens (human) | Kd | 20.0000 | AID1425044; AID625026 |
| cGMP-dependent protein kinase 2 | Homo sapiens (human) | Kd | 10.0000 | AID435322; AID625053 |
| Integrin-linked protein kinase | Homo sapiens (human) | Kd | 30.0000 | AID1425024 |
| Rho-associated protein kinase 1 | Homo sapiens (human) | Kd | 20.0000 | AID1425157; AID625015 |
| Non-receptor tyrosine-protein kinase TNK1 | Homo sapiens (human) | Kd | 20.0000 | AID1425200; AID435833; AID624930 |
| Serine/threonine-protein kinase PRP4 homolog | Homo sapiens (human) | Kd | 10.0000 | AID624750 |
| Serine/threonine-protein kinase ATR | Homo sapiens (human) | Kd | 30.0000 | AID1424916 |
| Receptor-interacting serine/threonine-protein kinase 1 | Homo sapiens (human) | Kd | 10.0000 | AID435557; AID624924 |
| Calcium/calmodulin-dependent protein kinase type II subunit beta | Homo sapiens (human) | Kd | 10.0000 | AID435394; AID624827 |
| Calcium/calmodulin-dependent protein kinase type II subunit gamma | Homo sapiens (human) | Kd | 16.6667 | AID1424929; AID435784; AID624731 |
| Calcium/calmodulin-dependent protein kinase type II subunit delta | Homo sapiens (human) | Kd | 16.6667 | AID1424928; AID435647; AID624770 |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1A | Homo sapiens (human) | Kd | 20.0000 | AID1424981; AID624712 |
| Activin receptor type-2B | Homo sapiens (human) | Kd | 16.6667 | AID1424902; AID435147; AID624820 |
| Bone morphogenetic protein receptor type-2 | Homo sapiens (human) | Kd | 16.6667 | AID1424923; AID435780; AID624826 |
| Protein-tyrosine kinase 6 | Homo sapiens (human) | Kd | 0.3975 | AID1425144; AID256675; AID436049; AID625029 |
| cGMP-dependent protein kinase 1 | Homo sapiens (human) | Kd | 16.6667 | AID1425138; AID435546; AID625052 |
| Cyclin-dependent kinase 13 | Homo sapiens (human) | Kd | 20.0000 | AID1424940; AID624761 |
| Calcium/calmodulin-dependent protein kinase type 1 | Homo sapiens (human) | Kd | 10.0000 | AID436009; AID624922 |
| Inhibitor of nuclear factor kappa-B kinase subunit epsilon | Homo sapiens (human) | Kd | 16.6667 | AID1425023; AID435657; AID625074 |
| Protein-tyrosine kinase 2-beta | Homo sapiens (human) | Kd | 16.6667 | AID1425143; AID436048; AID624732 |
| Maternal embryonic leucine zipper kinase | Homo sapiens (human) | Kd | 16.6667 | AID1425074; AID435660; AID625087 |
| Structural maintenance of chromosomes protein 1A | Homo sapiens (human) | Kd | 30.0000 | AID1425172 |
| Chromodomain-helicase-DNA-binding protein 4 | Homo sapiens (human) | Kd | 30.0000 | AID1424952 |
| Serine/threonine-protein kinase D1 | Homo sapiens (human) | Kd | 10.0000 | AID436045; AID624884 |
| Serine/threonine-protein kinase 38 | Homo sapiens (human) | Kd | 10.0000 | AID625067 |
| Receptor tyrosine-protein kinase erbB-4 | Homo sapiens (human) | Kd | 0.4800 | AID624815 |
| Ribosomal protein S6 kinase alpha-2 | Homo sapiens (human) | Kd | 10.0000 | AID435830; AID436050; AID624805; AID625127 |
| Ephrin type-A receptor 7 | Homo sapiens (human) | Kd | 2.7333 | AID256585; AID435286; AID624953 |
| Delta(24)-sterol reductase | Homo sapiens (human) | Kd | 30.0000 | AID1424978 |
| Ribosomal protein S6 kinase alpha-1 | Homo sapiens (human) | Kd | 10.1600 | AID1425159; AID435690; AID435829; AID624900; AID624901 |
| Dual specificity testis-specific protein kinase 1 | Homo sapiens (human) | Kd | 12.4667 | AID1425194; AID435937; AID625056 |
| Myosin light chain kinase, smooth muscle | Homo sapiens (human) | Kd | 16.6667 | AID1425081; AID435664; AID624709 |
| Mitogen-activated protein kinase 11 | Homo sapiens (human) | Kd | 16.6667 | AID1425058; AID435551; AID624890 |
| Serine/threonine-protein kinase STK11 | Homo sapiens (human) | Kd | 16.6667 | AID1425178; AID435909; AID624798 |
| Rhodopsin kinase GRK1 | Homo sapiens (human) | Kd | 10.0000 | AID624898 |
| NT-3 growth factor receptor | Homo sapiens (human) | Kd | 10.0000 | AID435202; AID624765 |
| Serine/threonine-protein kinase N1 | Homo sapiens (human) | Kd | 16.6667 | AID1425117; AID435319; AID624745 |
| Serine/threonine-protein kinase N2 | Homo sapiens (human) | Kd | 16.6667 | AID1425118; AID435933; AID625050 |
| Mitogen-activated protein kinase 14 | Homo sapiens (human) | Kd | 16.6667 | AID1425059; AID435181; AID624714 |
| Calcium/calmodulin-dependent protein kinase type IV | Homo sapiens (human) | Kd | 16.6667 | AID1424930; AID435152; AID624843 |
| Mitogen-activated protein kinase kinase kinase 11 | Homo sapiens (human) | Kd | 16.6667 | AID1425045; AID435414; AID624866 |
| BDNF/NT-3 growth factors receptor | Homo sapiens (human) | Kd | 10.0000 | AID435564; AID625032 |
| Mitogen-activated protein kinase 6 | Homo sapiens (human) | Kd | 1.5000 | AID435289; AID624887 |
| Phosphorylase b kinase gamma catalytic chain, skeletal muscle/heart isoform | Homo sapiens (human) | Kd | 3.1000 | AID256639; AID436042; AID625035 |
| Discoidin domain-containing receptor 2 | Homo sapiens (human) | Kd | 10.2133 | AID1424973; AID435154; AID624777 |
| AP2-associated protein kinase 1 | Homo sapiens (human) | Kd | 16.6667 | AID1424889; AID435896; AID625089 |
| Myosin light chain kinase 3 | Homo sapiens (human) | Kd | 20.0000 | AID1425082; AID624738 |
| Uncharacterized aarF domain-containing protein kinase 5 | Homo sapiens (human) | Kd | 30.0000 | AID1424906 |
| Serine/threonine-protein kinase SBK1 | Homo sapiens (human) | Kd | 10.0000 | AID624812 |
| Mitogen-activated protein kinase kinase kinase 19 | Homo sapiens (human) | Kd | 0.9800 | AID625136 |
| Putative heat shock protein HSP 90-beta 2 | Homo sapiens (human) | Kd | 30.0000 | AID1425019 |
| Serine/threonine-protein kinase TNNI3K | Homo sapiens (human) | Kd | 2.8000 | AID435200; AID625097 |
| Rab-like protein 3 | Homo sapiens (human) | Kd | 30.0000 | AID1425151 |
| Leucine-rich repeat serine/threonine-protein kinase 2 | Homo sapiens (human) | Kd | 10.0000 | AID624740; AID624741 |
| Serine/threonine-protein kinase MRCK alpha | Homo sapiens (human) | Kd | 11.7333 | AID1424933; AID436024; AID624920 |
| Serine/threonine-protein kinase MRCK gamma | Homo sapiens (human) | Kd | 11.4667 | AID1424935; AID436013; AID625107 |
| Acyl-CoA dehydrogenase family member 10 | Homo sapiens (human) | Kd | 30.0000 | AID1424892 |
| Serine/threonine-protein kinase Nek5 | Homo sapiens (human) | Kd | 10.0000 | AID435534; AID624742 |
| Serine/threonine-protein kinase N3 | Homo sapiens (human) | Kd | 30.0000 | AID1425119 |
| Serine/threonine-protein kinase ULK3 | Homo sapiens (human) | Kd | 18.2000 | AID1425209; AID624818 |
| Dual serine/threonine and tyrosine protein kinase | Homo sapiens (human) | Kd | 10.0000 | AID624758 |
| Mitogen-activated protein kinase kinase kinase 15 | Homo sapiens (human) | Kd | 10.0000 | AID624801 |
| Uncharacterized protein FLJ45252 | Homo sapiens (human) | Kd | 30.0000 | AID1425147 |
| Acyl-CoA dehydrogenase family member 11 | Homo sapiens (human) | Kd | 30.0000 | AID1424893 |
| Serine/threonine-protein kinase/endoribonuclease IRE2 | Homo sapiens (human) | Kd | 30.0000 | AID1424998 |
| Serine/threonine-protein kinase MARK2 | Homo sapiens (human) | Kd | 16.6667 | AID1425068; AID435296; AID625106 |
| ATP-dependent RNA helicase DHX30 | Homo sapiens (human) | Kd | 30.0000 | AID1424979 |
| Serine/threonine-protein kinase TAO1 | Homo sapiens (human) | Kd | 20.0000 | AID1425189; AID625126 |
| STE20-related kinase adapter protein alpha | Homo sapiens (human) | Kd | 30.0000 | AID1425186 |
| Myosin-14 | Homo sapiens (human) | Kd | 30.0000 | AID1425080 |
| AarF domain-containing protein kinase 1 | Homo sapiens (human) | Kd | 30.0000 | AID1424904 |
| Serine/threonine-protein kinase tousled-like 2 | Homo sapiens (human) | Kd | 10.0000 | AID436054; AID624771 |
| Serine/threonine-protein kinase 32C | Homo sapiens (human) | Kd | 10.0000 | AID435834; AID624734 |
| Serine/threonine-protein kinase pim-3 | Homo sapiens (human) | Kd | 10.0000 | AID435679; AID624802 |
| ATP-dependent RNA helicase DDX42 | Homo sapiens (human) | Kd | 30.0000 | AID1424976 |
| Serine/threonine-protein kinase VRK2 | Homo sapiens (human) | Kd | 10.0000 | AID625058 |
| Myosin light chain kinase family member 4 | Homo sapiens (human) | Kd | 10.0000 | AID435691; AID624809 |
| Homeodomain-interacting protein kinase 1 | Homo sapiens (human) | Kd | 10.0000 | AID624726 |
| Calcium/calmodulin-dependent protein kinase type 1D | Homo sapiens (human) | Kd | 10.0000 | AID435393; AID625118 |
| Mitogen-activated protein kinase kinase kinase kinase 3 | Homo sapiens (human) | Kd | 11.0000 | AID1425053; AID435295; AID624921 |
| Cyclin-dependent kinase-like 3 | Homo sapiens (human) | Kd | 10.0000 | AID624822 |
| MAP kinase-activated protein kinase 5 | Homo sapiens (human) | Kd | 10.0000 | AID435806; AID624923 |
| Serine/threonine-protein kinase BRSK2 | Homo sapiens (human) | Kd | 10.0000 | AID435783; AID624929 |
| Serine/threonine-protein kinase NIM1 | Homo sapiens (human) | Kd | 10.0000 | AID624728 |
| Serine/threonine-protein kinase ULK2 | Homo sapiens (human) | Kd | 10.0000 | AID625085 |
| Misshapen-like kinase 1 | Homo sapiens (human) | Kd | 3.4000 | AID624813 |
| Serine/threonine-protein kinase DCLK2 | Homo sapiens (human) | Kd | 10.0000 | AID435651; AID624814 |
| Calcium/calmodulin-dependent protein kinase kinase 1 | Homo sapiens (human) | Kd | 10.0000 | AID435521; AID625143 |
| Casein kinase I isoform alpha-like | Homo sapiens (human) | Kd | 10.0000 | AID435281; AID624723 |
| Homeodomain-interacting protein kinase 4 | Homo sapiens (human) | Kd | 10.0000 | AID624720 |
| Myosin-IIIa | Homo sapiens (human) | Kd | 10.0000 | AID435170; AID625104 |
| Ankyrin repeat and protein kinase domain-containing protein 1 | Homo sapiens (human) | Kd | 10.0000 | AID436005; AID624735 |
| Serine/threonine-protein kinase Nek11 | Homo sapiens (human) | Kd | 10.0000 | AID624725 |
| Atypical kinase COQ8A, mitochondrial | Homo sapiens (human) | Kd | 13.0000 | AID1424905; AID435516; AID625116 |
| Phosphatidylinositol 5-phosphate 4-kinase type-2 gamma | Homo sapiens (human) | Kd | 20.0000 | AID1425115; AID625134 |
| Mitogen-activated protein kinase 15 | Homo sapiens (human) | Kd | 16.6667 | AID1425060; AID435405; AID624715 |
| Serine/threonine-protein kinase Nek9 | Homo sapiens (human) | Kd | 16.6667 | AID1425089; AID435171; AID624704 |
| Serine/threonine-protein kinase BRSK1 | Homo sapiens (human) | Kd | 10.0000 | AID435782; AID624702 |
| Serine/threonine-protein kinase 35 | Homo sapiens (human) | Kd | 0.0560 | AID624711 |
| Serine/threonine-protein kinase Nek7 | Homo sapiens (human) | Kd | 16.6667 | AID1425088; AID435666; AID624754 |
| Rhodopsin kinase GRK7 | Homo sapiens (human) | Kd | 10.0000 | AID624719 |
| Serine/threonine-protein kinase 32A | Homo sapiens (human) | Kd | 5.0000 | AID624821 |
| Myosin-IIIb | Homo sapiens (human) | Kd | 10.0000 | AID436032; AID624817 |
| ATP-dependent RNA helicase DDX1 | Homo sapiens (human) | Kd | 30.0000 | AID1424974 |
| Dual specificity tyrosine-phosphorylation-regulated kinase 2 | Homo sapiens (human) | Kd | 10.0000 | AID624918 |
| Cyclin-dependent kinase-like 2 | Homo sapiens (human) | Kd | 10.0000 | AID624928 |
| Mitogen-activated protein kinase kinase kinase kinase 1 | Homo sapiens (human) | Kd | 15.1667 | AID1425051; AID435431; AID624816 |
| Serine/threonine-protein kinase Sgk3 | Homo sapiens (human) | Kd | 10.0000 | AID625073 |
| Atypical kinase COQ8B, mitochondrial | Homo sapiens (human) | Kd | 1.7000 | AID435778; AID625135 |
| Aurora kinase B | Homo sapiens (human) | Kd | 16.6667 | AID1424918; AID435519; AID624772 |
| MAP/microtubule affinity-regulating kinase 4 | Homo sapiens (human) | Kd | 16.6667 | AID1425070; AID435924; AID625140 |
| Calcium/calmodulin-dependent protein kinase type 1G | Homo sapiens (human) | Kd | 10.0000 | AID435151; AID625119 |
| Serine/threonine-protein kinase Nek1 | Homo sapiens (human) | Kd | 16.6667 | AID1425085; AID435533; AID625068 |
| Cyclin-dependent kinase 15 | Homo sapiens (human) | Kd | 10.0000 | AID624718 |
| PAS domain-containing serine/threonine-protein kinase | Homo sapiens (human) | Kd | 30.0000 | AID1425102 |
| Calcium/calmodulin-dependent protein kinase kinase 2 | Homo sapiens (human) | Kd | 16.6667 | AID1424931; AID435648; AID625060 |
| EKC/KEOPS complex subunit TP53RK | Homo sapiens (human) | Kd | 30.0000 | AID1425204 |
| SRSF protein kinase 1 | Homo sapiens (human) | Kd | 10.0000 | AID435936; AID624903 |
| Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase | Homo sapiens (human) | Kd | 16.6667 | AID1425116; AID436043; AID624757 |
| Mitogen-activated protein kinase kinase kinase 5 | Homo sapiens (human) | Kd | 16.6667 | AID1425049; AID435412; AID625028 |
| Phosphatidylinositol 4-phosphate 5-kinase type-1 alpha | Homo sapiens (human) | Kd | 10.0000 | AID435190; AID624824 |
| Mitogen-activated protein kinase kinase kinase 3 | Homo sapiens (human) | Kd | 20.0000 | AID1425047; AID624865 |
| Eukaryotic translation initiation factor 2-alpha kinase 1 | Homo sapiens (human) | Kd | 20.0000 | AID1424984; AID625080 |
| Serine/threonine-protein kinase RIO1 | Homo sapiens (human) | Kd | 10.0000 | AID435324; AID625141 |
| MAP kinase-interacting serine/threonine-protein kinase 1 | Homo sapiens (human) | Kd | 0.3600 | AID435661; AID624823 |
| Serine/threonine-protein kinase RIO2 | Homo sapiens (human) | Kd | 10.0000 | AID625111 |
| Cyclin-dependent kinase 19 | Homo sapiens (human) | Kd | 10.0000 | AID435522; AID625094 |
| Transient receptor potential cation channel subfamily M member 6 | Homo sapiens (human) | Kd | 10.0000 | AID625110 |
| Testis-specific serine/threonine-protein kinase 1 | Homo sapiens (human) | Kd | 10.0000 | AID435940; AID625142 |
| Serine/threonine-protein kinase 33 | Homo sapiens (human) | Kd | 1.4000 | AID436053; AID625138 |
| Nucleolar GTP-binding protein 1 | Homo sapiens (human) | Kd | 30.0000 | AID1425016 |
| Serine/threonine-protein kinase D2 | Homo sapiens (human) | Kd | 16.6667 | AID1425136; AID436046; AID625102 |
| Serine/threonine-protein kinase DCLK3 | Homo sapiens (human) | Kd | 10.0000 | AID435399; AID624707 |
| NUAK family SNF1-like kinase 2 | Homo sapiens (human) | Kd | 16.6667 | AID1425095; AID435559; AID625139 |
| RNA cytidine acetyltransferase | Homo sapiens (human) | Kd | 30.0000 | AID1425083 |
| Serine/threonine-protein kinase SIK2 | Homo sapiens (human) | Kd | 10.2867 | AID1425166; AID436052; AID625095 |
| Myosin light chain kinase 2, skeletal/cardiac muscle | Homo sapiens (human) | Kd | 10.0000 | AID435415; AID624705 |
| STE20-like serine/threonine-protein kinase | Homo sapiens (human) | Kd | 7.5715 | AID1425171; AID256578; AID435832; AID625086 |
| Serine/threonine-protein kinase TAO3 | Homo sapiens (human) | Kd | 20.0000 | AID1425191; AID625101 |
| Homeodomain-interacting protein kinase 2 | Homo sapiens (human) | Kd | 10.0000 | AID625129 |
| Tyrosine-protein kinase Srms | Homo sapiens (human) | Kd | 1.9000 | AID435561; AID624710 |
| Homeodomain-interacting protein kinase 3 | Homo sapiens (human) | Kd | 10.0000 | AID625023 |
| Serine/threonine-protein kinase PLK3 | Homo sapiens (human) | Kd | 10.0000 | AID435183; AID624933 |
| dCTP pyrophosphatase 1 | Homo sapiens (human) | Kd | 30.0000 | AID1424971 |
| Dual specificity protein kinase CLK4 | Homo sapiens (human) | Kd | 16.6667 | AID1424958; AID435788; AID625125 |
| MAP kinase-interacting serine/threonine-protein kinase 2 | Homo sapiens (human) | Kd | 2.2667 | AID256576; AID435531; AID625108 |
| Serine/threonine-protein kinase Nek6 | Homo sapiens (human) | Kd | 10.0000 | AID435545; AID625079 |
| Casein kinase I isoform gamma-1 | Homo sapiens (human) | Kd | 16.6667 | AID1424964; AID435397; AID625128 |
| Serine/threonine-protein kinase PAK 6 | Homo sapiens (human) | Kd | 16.6667 | AID1425101; AID435188; AID625115 |
| SNF-related serine/threonine-protein kinase | Homo sapiens (human) | Kd | 10.0000 | AID624752 |
| Serine/threonine-protein kinase LATS2 | Homo sapiens (human) | Kd | 10.0000 | AID436021; AID625083 |
| Serine/threonine-protein kinase 36 | Homo sapiens (human) | Kd | 10.0000 | AID435562; AID625096 |
| Phenylalanine--tRNA ligase beta subunit | Homo sapiens (human) | Kd | 30.0000 | AID1425000 |
| BMP-2-inducible protein kinase | Homo sapiens (human) | Kd | 16.6667 | AID1424920; AID435275; AID625109 |
| Obg-like ATPase 1 | Homo sapiens (human) | Kd | 30.0000 | AID1425096 |
| Midasin | Homo sapiens (human) | Kd | 30.0000 | AID1425073 |
| Interleukin-1 receptor-associated kinase 4 | Homo sapiens (human) | Kd | 15.0375 | AID1425029; AID625098 |
| Serine/threonine-protein kinase 32B | Homo sapiens (human) | Kd | 10.0000 | AID436055; AID625112 |
| Mitogen-activated protein kinase kinase kinase 20 | Homo sapiens (human) | Kd | 13.4000 | AID1425213; AID435941; AID624755 |
| Cyclin-dependent kinase 12 | Homo sapiens (human) | Kd | 30.0000 | AID1424939 |
| Serine/threonine-protein kinase PLK2 | Homo sapiens (human) | Kd | 10.0000 | AID625063 |
| NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 | Homo sapiens (human) | Kd | 30.0000 | AID1425084 |
| Serine/threonine-protein kinase MARK1 | Homo sapiens (human) | Kd | 10.0000 | AID435807; AID625113 |
| Serine/threonine-protein kinase pim-2 | Homo sapiens (human) | Kd | 16.6667 | AID1425112; AID435440; AID625064 |
| Serine/threonine-protein kinase PAK 5 | Homo sapiens (human) | Kd | 10.0000 | AID435687; AID625117 |
| Serine/threonine-protein kinase 26 | Homo sapiens (human) | Kd | 16.6667 | AID1425181; AID435663; AID625103 |
| eIF-2-alpha kinase GCN2 | Homo sapiens (human) | Kd | 10.0000 | AID436020; AID624810 |
| Succinate--CoA ligase [ADP-forming] subunit beta, mitochondrial | Homo sapiens (human) | Kd | 30.0000 | AID1425187 |
| Serine/threonine-protein kinase NLK | Homo sapiens (human) | Kd | 16.6667 | AID1425090; AID435667; AID625100 |
| Phosphatidylinositol 4-kinase beta | Homo sapiens (human) | Kd | 10.0000 | AID624880 |
| Serine/threonine-protein kinase 17A | Homo sapiens (human) | Kd | 10.0000 | AID435790; AID624968 |
| STE20/SPS1-related proline-alanine-rich protein kinase | Homo sapiens (human) | Kd | 10.0000 | AID625071 |
| Ephrin type-A receptor 6 | Homo sapiens (human) | Kd | 0.0550 | AID256567; AID436015; AID624748 |
| 5'-AMP-activated protein kinase subunit gamma-2 | Homo sapiens (human) | Kd | 30.0000 | AID1425127 |
| Serine/threonine-protein kinase TBK1 | Homo sapiens (human) | Kd | 20.0000 | AID1425192; AID625072 |
| Septin-9 | Homo sapiens (human) | Kd | 30.0000 | AID1425165 |
| Death-associated protein kinase 2 | Homo sapiens (human) | Kd | 10.0000 | AID435153; AID625077 |
| Ribosomal protein S6 kinase alpha-6 | Homo sapiens (human) | Kd | 10.0960 | AID1425163; AID435193; AID435194; AID625081; AID625082 |
| TRAF2 and NCK-interacting protein kinase | Homo sapiens (human) | Kd | 9.6250 | AID1425199; AID256566; AID435563; AID625093 |
| Serine/threonine-protein kinase tousled-like 1 | Homo sapiens (human) | Kd | 10.0000 | AID435199; AID625069 |
| Serine/threonine-protein kinase TAO2 | Homo sapiens (human) | Kd | 20.0000 | AID1425190; AID625099 |
| Long-chain-fatty-acid--CoA ligase 5 | Homo sapiens (human) | Kd | 30.0000 | AID1424897 |
| ALK tyrosine kinase receptor | Homo sapiens (human) | Kd | 2.1000 | AID435779; AID624944 |
| SRSF protein kinase 3 | Homo sapiens (human) | Kd | 10.0000 | AID625078 |
| Serine/threonine-protein kinase ICK | Homo sapiens (human) | Kd | 20.0000 | AID1425021; AID625090 |
| Cyclin-dependent kinase 11A | Homo sapiens (human) | Kd | 10.0000 | AID435649; AID625133 |
| Aurora kinase C | Homo sapiens (human) | Kd | 1.5000 | AID436006; AID624769 |
| Calcium/calmodulin-dependent protein kinase type II subunit alpha | Homo sapiens (human) | Kd | 10.0000 | AID435520; AID624730 |
| RAC-gamma serine/threonine-protein kinase | Homo sapiens (human) | Kd | 16.6667 | AID1424912; AID435900; AID625019 |
| Serine/threonine-protein kinase 38-like | Homo sapiens (human) | Kd | 10.0000 | AID436025; AID625092 |
| Microtubule-associated serine/threonine-protein kinase 1 | Homo sapiens (human) | Kd | 10.0000 | AID625091 |
| Serine/threonine-protein kinase SIK3 | Homo sapiens (human) | Kd | 16.9500 | AID1425167; AID624774 |
| Mitogen-activated protein kinase kinase kinase 2 | Homo sapiens (human) | Kd | 20.0000 | AID1425046; AID625062 |
| Thyroid hormone receptor-associated protein 3 | Homo sapiens (human) | Kd | 30.0000 | AID1425198 |
| Dual specificity tyrosine-phosphorylation-regulated kinase 1B | Homo sapiens (human) | Kd | 10.0000 | AID436014; AID624964 |
| Mitogen-activated protein kinase kinase kinase kinase 5 | Homo sapiens (human) | Kd | 7.8525 | AID1425055; AID256565; AID435805; AID625061 |
| Receptor-interacting serine/threonine-protein kinase 3 | Homo sapiens (human) | Kd | 30.0000 | AID1425156 |
| Serine/threonine-protein kinase MRCK beta | Homo sapiens (human) | Kd | 11.6667 | AID1424934; AID435912; AID625031 |
| Interleukin-1 receptor-associated kinase 3 | Homo sapiens (human) | Kd | 16.6667 | AID1425028; AID435528; AID625066 |
| Serine/threonine-protein kinase 24 | Homo sapiens (human) | Kd | 16.6667 | AID1425180; AID435532; AID624917 |
| Casein kinase I isoform gamma-3 | Homo sapiens (human) | Kd | 16.6667 | AID1424966; AID435905; AID624949 |
| Mitogen-activated protein kinase kinase kinase 4 | Homo sapiens (human) | Kd | 11.9500 | AID1425048; AID256564; AID435530; AID625027 |
Other Measurements
Bioassays (1495)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1345914 | Human ret proto-oncogene (Type XIV RTKs: RET) | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1345502 | Human epidermal growth factor receptor (Type I RTKs: ErbB (epidermal growth factor) receptor family) | 2002 | Cancer research, Dec-15, Volume: 62, Issue:24
ISSN: 0008-5472 | ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. |
| AID1345506 | Human kinase insert domain receptor (Type IV RTKs: VEGF (vascular endothelial growth factor) receptor family) | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
ISSN: 0022-2623 | Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. |
| AID1345914 | Human ret proto-oncogene (Type XIV RTKs: RET) | 2002 | Cancer research, Dec-15, Volume: 62, Issue:24
ISSN: 0008-5472 | ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. |
| AID602156 | Novartis GNF Liver Stage Dataset: Malariabox Annotation | 2011 | Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
ISSN: 1095-9203 | Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347115 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347111 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347121 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347123 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
ISSN: 2211-1247 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID686947 | qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen | 2013 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
ISSN: 1464-3405 | Identification of potent Yes1 kinase inhibitors using a library screening approach. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347113 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347118 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347128 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347124 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347116 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347110 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells) | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347122 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347114 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347127 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347129 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X | |
| AID1347126 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347112 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347119 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347109 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347125 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347117 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID256563 | Average Binding Constant for ULK3 m; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425131 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256581 | Average Binding Constant for CAMK1G; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID625109 | Binding constant for BIKE kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256596 | Average Binding Constant for CLK2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425121 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425123 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435691 | Binding constant for SgK085 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625135 | Binding constant for ADCK4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624793 | Binding constant for KIT(V559D,V654A) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424952 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID490460 | Antiproliferative activity against human RET deficient LS 174T cells after 72 hrs by [3H]thymidine incorporation assay | 2010 | European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
ISSN: 1768-3254 | Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold. |
| AID256598 | Average Binding Constant for FRK; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425189 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625080 | Binding constant for EIF2AK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435552 | Binding constant for PIK3CA(E545K) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425180 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624942 | Binding constant for DRAK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624936 | Binding constant for FLT3(D835Y) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1564388 | Inhibition of N-terminal GST-tagged human VEGFR2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181ISSN: 1768-3254 | Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. |
| AID435907 | Binding constant for EGFR(L861Q) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424906 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1916985 | Cytotoxicity against human S1M180 cells in presence of topotecan | 2022 | European journal of medicinal chemistry, Nov-05, Volume: 241ISSN: 1768-3254 | Updated chemical scaffolds of ABCG2 inhibitors and their structure-inhibition relationships for future development. |
| AID738479 | Binding affinity to non phosphorylated ABL1 (unknown origin) at 75 uM after 1 hr relative to control | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID435181 | Binding constant for full-length p38-alpha | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425068 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624919 | Binding constant for AURKA kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624830 | Binding constant for CDK9 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256646 | Average Binding Constant for JAK1 (Kin.Dom. 1); NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID589575 | Inhibition of VEGFR-2 | 2011 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
ISSN: 1464-3405 | Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors. |
| AID256649 | Average Binding Constant for CSK; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425097 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1424955 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1895649 | Inhibition of VEGFR2 (unknown origin) | 2021 | Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
ISSN: 1520-4804 | Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. |
| AID1425109 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256611 | Average Binding Constant for RIPK2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624720 | Binding constant for HIPK4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1894166 | Antiproliferative activity against human Calu-6 cells assessed as cell growth inhibition incubated for 72 hrs by [3H]thymidine incorporation assay | 2021 | European journal of medicinal chemistry, Mar-15, Volume: 214ISSN: 1768-3254 | FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. |
| AID624828 | Binding constant for CDK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435660 | Binding constant for full-length MELK | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435312 | Binding constant for MET kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425185 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435779 | Binding constant for ALK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424924 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625085 | Binding constant for ULK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624717 | Binding constant for JNK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624918 | Binding constant for DYRK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435896 | Binding constant for AAK1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435283 | Binding constant for DAPK1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID436019 | Binding constant for FRK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424898 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435274 | Binding constant for ACVR1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435533 | Binding constant for NEK1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1337733 | Antiproliferative activity against human MCF7 cells measured after 48 hrs by MTT assay | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125ISSN: 1768-3254 | Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2. |
| AID435665 | Binding constant for NEK2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624728 | Binding constant for NIM1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624794 | Binding constant for MET kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624820 | Binding constant for ACVR2B kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435288 | Binding constant for EPHB2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435799 | Binding constant for FLT3 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425049 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624885 | Binding constant for ERK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435558 | Binding constant for RPS6KA3(Kin.Dom.1 - N-terminal) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625059 | Binding constant for YSK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425156 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624816 | Binding constant for HPK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624959 | Binding constant for MAP4K2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624994 | Binding constant for AKT1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435784 | Binding constant for CAMK2G kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1873226 | Inhibition of ABCG2 (unknown origin) expressed in human S1M180 cells assessed as intracellular accumulation of rhodamine 123 using rhodamine 123 as substrate by flow cytometry | 2022 | European journal of medicinal chemistry, Jul-05, Volume: 237ISSN: 1768-3254 | Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. |
| AID1735267 | Growth inhibition of mouse BaF3 cells harboring RET M918T mutant incubated for 3 days by MTT assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143ISSN: 1768-3254 | Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants. |
| AID624982 | Binding constant for ABL1(F317L)-phosphorylated kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624962 | Binding constant for ASK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435937 | Binding constant for TESK1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625032 | Binding constant for TRKB kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424961 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624810 | Binding constant for GCN2(Kin.Dom.2,S808G) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425198 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624722 | Binding constant for MKK7 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256650 | Average Binding Constant for PIM1; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1564394 | Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth at 0.5 uM after 48 hrs under hypoxic condition (200 uM CoCl2) by CCk-8 assay relative to control (Rvb = 65.84%) | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181ISSN: 1768-3254 | Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. |
| AID50766 | In vitro inhibition of Colony stimulating factor 1 receptor (CSF-1R) expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID256618 | Average Binding Constant for PHkg2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624718 | Binding constant for PFTAIRE2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624753 | Binding constant for PKNB(M.tuberculosis) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625052 | Binding constant for PRKG1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID305870 | Inhibition of VEGFR2 by HTRF assay | 2007 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
ISSN: 0960-894X | ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2. |
| AID435930 | Binding constant for PHKG2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624900 | Binding constant for RSK1(Kin.Dom.1-N-terminal) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1735273 | Inhibition of recombinant human RET using KKKSPGEYVNIEFG as substrate incubated for 15 mins followed by Mg/ATP addition and measured after 40 mins by [gamma-33P]-ATP assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143ISSN: 1768-3254 | Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants. |
| AID624981 | Binding constant for ABL1(F317L)-non phosphorylated kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256561 | Average Binding Constant for BTK; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624837 | Binding constant for IRAK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1283956 | Inhibition of human RET cytoplasmic domain (658 to 1114 residues) expressed in baculovirus system preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay | 2016 | European journal of medicinal chemistry, Apr-13, Volume: 112ISSN: 1768-3254 | The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. |
| AID1425004 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID599959 | Binding affinity to human KIT D816V mutant incubated for 1 hr by kinase binding assay | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
ISSN: 1768-3254 | Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives. |
| AID625049 | Binding constant for PRKCH kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1895756 | Inhibition of recombinant RET V804L (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method | 2021 | Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
ISSN: 1520-4804 | Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. |
| AID435408 | Binding constant for INSR kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624921 | Binding constant for MAP4K3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435149 | Binding constant for AMPK-alpha2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425086 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435560 | Binding constant for SNF1LK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624863 | Binding constant for MARK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID271137 | Dissociation constant, pKa of the compound | 2006 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
ISSN: 0960-894X | Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics. |
| AID624925 | Binding constant for RIPK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425151 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435406 | Binding constant for FLT3(D835H) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624872 | Binding constant for PAK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256635 | Average Binding Constant for CAMK2D; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435160 | Binding constant for FER kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424934 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425181 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435529 | Binding constant for LATS1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624731 | Binding constant for CAMK2G kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425010 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425110 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256585 | Average Binding Constant for EPHA7; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425210 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624709 | Binding constant for MYLK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624917 | Binding constant for MST3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624818 | Binding constant for ULK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625039 | Binding constant for PIK3CA(E545A) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435788 | Binding constant for CLK4 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID738489 | Binding affinity to TYRO3 (unknown origin) | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID624951 | Binding constant for EPHA2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435311 | Binding constant for HCK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424930 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435194 | Binding constant for RPS6KA6(Kin.Dom.2 - N-terminal) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435328 | Binding constant for YES kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256587 | Average Binding Constant for ACK1; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1895650 | Inhibition of VEGFR3 (unknown origin) | 2021 | Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
ISSN: 1520-4804 | Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. |
| AID1425204 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425162 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435399 | Binding constant for DCAMKL3 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625107 | Binding constant for DMPK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425117 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1424900 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624927 | Binding constant for RPS6KA4(Kin.Dom.2-C-terminal) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624706 | Binding constant for MLK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1548476 | Inhibition of RET V804M mutant (unknown origin)expressed in human BaF3 cells assessed as reduction in cell viability incubated for 48 hrs by celltiter glo luminescence cell viability assay | 2020 | ACS medicinal chemistry letters, Apr-09, Volume: 11, Issue:4
ISSN: 1948-5875 | Discovery and Optimization of wt-RET/KDR-Selective Inhibitors of RET |
| AID435280 | Binding constant for CSF1R kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624956 | Binding constant for EPHB4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435898 | Binding constant for ACVR1B kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625053 | Binding constant for PRKG2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425038 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID738475 | Binding affinity to MER (unknown origin) at 1 uM after 1 hr relative to control | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID1478069 | Inhibition of human VEGFR2 | 2018 | Journal of medicinal chemistry, 01-11, Volume: 61, Issue:1
ISSN: 1520-4804 | Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines. |
| AID625031 | Binding constant for MRCKB kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625114 | Binding constant for GSK3A kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1895759 | Inhibition of recombinant VEGFR2 (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method | 2021 | Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
ISSN: 1520-4804 | Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. |
| AID624910 | Binding constant for TTK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624903 | Binding constant for SRPK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256641 | Average Binding Constant for ABL2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624839 | Binding constant for AKT2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625090 | Binding constant for ICK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425082 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID589583 | Antiproliferative activity against human PC3 cells after 72 hrs by MTS assay | 2011 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
ISSN: 1464-3405 | Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors. |
| AID347658 | Inhibition of VEGFR2 by HTRF method | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
ISSN: 1464-3391 | Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2. |
| AID256600 | Average Binding Constant for EPHA8; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1164732 | Inhibition of RET (unknown origin) pre-incubated for 60 mins before substrate addition in presence of 9 uM ATP by microfluidic assay | 2014 | European journal of medicinal chemistry, Oct-30, Volume: 86ISSN: 1768-3254 | Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation. |
| AID435183 | Binding constant for PLK3 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425173 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1545497 | Inhibition of human EGFR | 2019 | European journal of medicinal chemistry, May-15, Volume: 170ISSN: 1768-3254 | Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. |
| AID624729 | Binding constant for FAK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256595 | Average Binding Constant for CLK3; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425085 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435653 | Binding constant for EGFR(L747-S752del, P753S) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256640 | Average Binding Constant for PTK2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID625092 | Binding constant for NDR2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID436007 | Binding constant for AXL kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID619787 | Cytotoxicity against human DLD1 cells assessed as cell viability at 1 uM after 3 days by colorimetric MTT assay | 2011 | European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
ISSN: 1768-3254 | Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents. |
| AID435318 | Binding constant for PAK1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435780 | Binding constant for BMPR2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425141 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624737 | Binding constant for EPHA5 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624769 | Binding constant for AURKC kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625101 | Binding constant for TAOK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624761 | Binding constant for CDC2L5 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435401 | Binding constant for full-length DRAK2 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256589 | Average Binding Constant for EPHA4; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID256574 | Average Binding Constant for STK3_m; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID449706 | NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested. | 2008 | Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
ISSN: 1091-6490 | In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. |
| AID1424893 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435415 | Binding constant for MYLK2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625110 | Binding constant for TRPM6 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256593 | Average Binding Constant for NEK2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID256588 | Average Binding Constant for PCTK1; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435932 | Binding constant for PKAC-alpha kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425127 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625073 | Binding constant for SGK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624842 | Binding constant for BMX kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624802 | Binding constant for PIM3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID436025 | Binding constant for NDR2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID619789 | Cytotoxicity against human MV4-11 cells assessed as cell viability at 1 uM after 3 days by colorimetric MTT assay | 2011 | European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
ISSN: 1768-3254 | Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents. |
| AID624992 | Binding constant for ABL1-phosphorylated kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624929 | Binding constant for BRSK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435517 | Binding constant for AKT2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625043 | Binding constant for PIK3CA(I800L) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625132 | Binding constant for FGFR1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625078 | Binding constant for SRPK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1588963 | Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay | 2019 | Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
ISSN: 1464-3391 | Design, synthesis, biological evaluation of benzoyl amide derivatives containing nitrogen heterocyclic ring as potential VEGFR-2 inhibitors. |
| AID624704 | Binding constant for NEK9 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID436034 | Binding constant for PRKCH kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624916 | Binding constant for ULK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435908 | Binding constant for EPHA2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424962 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624974 | Binding constant for PIK3CD kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425048 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435287 | Binding constant for EPHA8 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1548473 | Inhibition of recombinant N-Terminal GST-tagged human RET V804M mutant (658 to end residues) incubated for 15 mins followed by substrate addition and measured after 30 mins by TR-FRET assay | 2020 | ACS medicinal chemistry letters, Apr-09, Volume: 11, Issue:4
ISSN: 1948-5875 | Discovery and Optimization of wt-RET/KDR-Selective Inhibitors of RET |
| AID624759 | Binding constant for PFCDPK1(P.falciparum) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425101 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425146 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID738476 | Binding affinity to AXL (unknown origin) at 75 uM after 1 hr relative to control | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID625045 | Binding constant for PIK3CA(Q546K) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425042 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625071 | Binding constant for STK39 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624931 | Binding constant for CLK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624946 | Binding constant for BRAF kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625010 | Binding constant for FER kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1283960 | Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay | 2016 | European journal of medicinal chemistry, Apr-13, Volume: 112ISSN: 1768-3254 | The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. |
| AID1425017 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425009 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID436049 | Binding constant for PTK6 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424905 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435786 | Binding constant for full-length CLK1 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425125 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256597 | Average Binding Constant for CLK1; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624843 | Binding constant for CAMK4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425034 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1275245 | Inhibition of VEGFR2 (unknown origin) preincubated for 5 mins followed by addition of ATP/gastrin precursor(Tyr87) biotinylated peptide cocktail incubated for 30 mins by ELISA | 2016 | European journal of medicinal chemistry, Feb-15, Volume: 109ISSN: 1768-3254 | Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC. |
| AID588211 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1
ISSN: 1520-5010 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID1337731 | Inhibition of N-terminal GST-tagged human VEGFR-2 cytoplasmic domain (790 to 1356 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125ISSN: 1768-3254 | Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2. |
| AID1424977 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1633238 | Inhibition of VEGFR2 (unknown origin) | 2019 | European journal of medicinal chemistry, Apr-15, Volume: 168ISSN: 1768-3254 | Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors. |
| AID1735218 | Growth inhibition of mouse BaF3 cells incubated for 3 days by MTT assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143ISSN: 1768-3254 | Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants. |
| AID624726 | Binding constant for HIPK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425046 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624766 | Binding constant for p38-gamma kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435291 | Binding constant for FGFR3 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1895651 | Inhibition of PDGFRbeta (unknown origin) | 2021 | Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
ISSN: 1520-4804 | Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. |
| AID1425148 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435294 | Binding constant for full-length LIMK2 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435808 | Binding constant for full-length MEK1 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624995 | Binding constant for CSF1R kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256632 | Average Binding Constant for CDK2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1424974 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624876 | Binding constant for PDPK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625008 | Binding constant for EPHA1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425112 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624897 | Binding constant for RAF1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256668 | Average Binding Constant for ABL1(H396P); NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425211 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624792 | Binding constant for KIT(V559D,T670I) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID108335 | In vitro inhibition of Met proto-oncogene tyrosine kinase (c-Met) expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID1425212 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624785 | Binding constant for JAK3(JH1domain-catalytic) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425119 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425174 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425199 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435557 | Binding constant for RIPK1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435189 | Binding constant for full-length PDPK1 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1595616 | Antiproliferative activity against human UCH1 cells measured after 72 hrs by alamar blue assay | 2019 | Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804 | Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma. |
| AID625093 | Binding constant for TNIK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425170 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624807 | Binding constant for TNK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1735264 | Growth inhibition of human NIH3T3 cells harboring RET C634Y mutant incubated for 3 days by MTT assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143ISSN: 1768-3254 | Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants. |
| AID435777 | Binding constant for ABL2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424907 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1915569 | Cytotoxicity against human MCF7 cells | 2021 | European journal of medicinal chemistry, Jan-01, Volume: 209ISSN: 1768-3254 | Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. |
| AID624879 | Binding constant for PIK3CG kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1293770 | Antiproliferative activity against human DU145 cells after 72 hrs by MTT assay | 2016 | Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
ISSN: 1464-3405 | Synthesis and antitumor activity of ATB-429 derivatives containing a nitric oxide-releasing moiety. |
| AID436045 | Binding constant for PRKD1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425076 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1588959 | Inhibition of EGFR (unknown origin) incubated for 30 mins by enzyme immunoassay | 2019 | Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
ISSN: 1464-3391 | Design, synthesis, biological evaluation of benzoyl amide derivatives containing nitrogen heterocyclic ring as potential VEGFR-2 inhibitors. |
| AID624800 | Binding constant for IGF1R kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624960 | Binding constant for RSK2(Kin.Dom.1-N-terminal) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID93094 | In vitro inhibition of Insulin-like growth factor I receptor expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID216652 | Inhibition of VEGFR induced autophosphorylation of human Vascular endothelial growth factor receptor 2 (VEGFR2) transfected in CHO cells | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID625079 | Binding constant for NEK6 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1588966 | Cytotoxicity in HEK293T cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay | 2019 | Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
ISSN: 1464-3391 | Design, synthesis, biological evaluation of benzoyl amide derivatives containing nitrogen heterocyclic ring as potential VEGFR-2 inhibitors. |
| AID625033 | Binding constant for PCTK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425057 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435281 | Binding constant for full-length CSNK1A1L | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435157 | Binding constant for EGFR(G719C) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1548478 | Selectivity index, ratio of IC50 for KDR (unknown origin) expressed in BaF3 cells to IC50 for RET V804M mutant (unknown origin) expressed in human BaF3 cells | 2020 | ACS medicinal chemistry letters, Apr-09, Volume: 11, Issue:4
ISSN: 1948-5875 | Discovery and Optimization of wt-RET/KDR-Selective Inhibitors of RET |
| AID436044 | Binding constant for PLK4 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624991 | Binding constant for ABL1-non phosphorylated kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1735270 | Growth inhibition of human TT cells incubated for 10 days by MTT assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143ISSN: 1768-3254 | Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants. |
| AID1424911 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625133 | Binding constant for CDC2L2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256584 | Average Binding Constant for CAMK1D; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624963 | Binding constant for LATS1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435897 | Binding constant for ABL1(T315I) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624989 | Binding constant for ABL1(T315I)-phosphorylated kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424919 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435295 | Binding constant for MAP4K3 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624920 | Binding constant for MRCKA kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1293769 | Antiproliferative activity against human A549 cells after 72 hrs by MTT assay | 2016 | Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
ISSN: 1464-3405 | Synthesis and antitumor activity of ATB-429 derivatives containing a nitric oxide-releasing moiety. |
| AID435429 | Binding constant for FLT1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID259702 | Inhibitory activity against VEGFR2 by HTRF assay | 2006 | Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
ISSN: 0960-894X | N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II. |
| AID435168 | Binding constant for LTK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425202 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1548477 | Selectivity index, ratio of IC50 for RET (unknown origin) expressed in BaF3 cells to IC50 for RET V804M mutant (unknown origin) expressed in human BaF3 cells | 2020 | ACS medicinal chemistry letters, Apr-09, Volume: 11, Issue:4
ISSN: 1948-5875 | Discovery and Optimization of wt-RET/KDR-Selective Inhibitors of RET |
| AID435941 | Binding constant for ZAK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435939 | Binding constant for TIE2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435823 | Binding constant for full-length PAK3 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1735268 | Growth inhibition of mouse BaF3 cells harboring RET V804M mutant incubated for 3 days by MTT assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143ISSN: 1768-3254 | Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants. |
| AID1425089 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1275247 | Inhibition of HDAC in human HeLa cell nuclear extracts preincubated for 15 mins followed by addition of Fluor de Lys as substrate for 1 hr by fluorometric assay | 2016 | European journal of medicinal chemistry, Feb-15, Volume: 109ISSN: 1768-3254 | Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC. |
| AID624953 | Binding constant for EPHA7 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425040 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425022 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425023 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624784 | Binding constant for INSR kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624975 | Binding constant for PLK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425135 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435277 | Binding constant for full-length CDK3 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID295769 | Inhibition of human VEGFR2 in presence of 1 uM ATP | 2007 | Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
ISSN: 0968-0896 | Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. |
| AID435146 | Binding constant for ABL1(H396P) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256675 | Average Binding Constant for PTK6; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435562 | Binding constant for STK36 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435528 | Binding constant for IRAK3 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424912 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425187 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1895648 | Inhibition of VEGFR1 (unknown origin) | 2021 | Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
ISSN: 1520-4804 | Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. |
| AID1424947 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID738490 | Binding affinity to MER (unknown origin) | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID435445 | Binding constant for ZAP70 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435664 | Binding constant for MYLK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1895758 | Inhibition of recombinant RET M918T (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method | 2021 | Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
ISSN: 1520-4804 | Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. |
| AID1425208 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1564401 | Antitumour activity against human A549 cells xenografted in Balb/c mouse assessed as tumour growth inhibition at 10 mg/kg, po administered daily and mesured at day 17 relative to control | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181ISSN: 1768-3254 | Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. |
| AID1424933 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1424914 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256565 | Average Binding Constant for MAP4K5; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624824 | Binding constant for PIP5K1A kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID738227 | Binding affinity to MET (unknown origin) at 75 uM after 1 hr relative to control | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID256628 | Average Binding Constant for LYN; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435658 | Binding constant for JAK2(Kin.Dom.2/JH1 - catalytic) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425142 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID262071 | Inhibition of VEGFR1 by enzymatic assay | 2006 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
ISSN: 0960-894X | Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II. |
| AID1424986 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625094 | Binding constant for CDK11 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625088 | Binding constant for ARK5 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435276 | Binding constant for BMPR1A kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424979 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625098 | Binding constant for IRAK4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425150 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435651 | Binding constant for DCAMKL2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435801 | Binding constant for full-length GSK3A | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1588962 | Antiproliferative activity against human HeLa cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay | 2019 | Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
ISSN: 1464-3391 | Design, synthesis, biological evaluation of benzoyl amide derivatives containing nitrogen heterocyclic ring as potential VEGFR-2 inhibitors. |
| AID624928 | Binding constant for CDKL2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424953 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1256444 | Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
ISSN: 1464-3405 | Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase. |
| AID436021 | Binding constant for LATS2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624764 | Binding constant for CLK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID436018 | Binding constant for FLT4 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID219188 | In vitro inhibition of c-Abl tyrosine kinase expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID435197 | Binding constant for TEC kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624997 | Binding constant for EGFR(E746-A750del) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425178 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625064 | Binding constant for PIM2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435441 | Binding constant for RPS6KA4(Kin.Dom.2 - N-terminal) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435199 | Binding constant for TLK1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624725 | Binding constant for NEK11 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435678 | Binding constant for MUSK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425011 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1424928 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425037 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435278 | Binding constant for full-length CDK7 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425191 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624702 | Binding constant for BRSK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624938 | Binding constant for FLT3(K663Q) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435656 | Binding constant for FGFR4 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425054 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256659 | Average Binding Constant for DAPK3; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435832 | Binding constant for SLK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624973 | Binding constant for JAK2(JH1domain-catalytic) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1545496 | Inhibition of human recombinant VEGFR2 expressed in Sf21 insect cells by ELISA | 2019 | European journal of medicinal chemistry, May-15, Volume: 170ISSN: 1768-3254 | Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. |
| AID624985 | Binding constant for ABL1(M351T)-phosphorylated kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624813 | Binding constant for MINK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624754 | Binding constant for NEK7 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435163 | Binding constant for full-length GSK3B | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435791 | Binding constant for EGFR(E746-A750del) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624748 | Binding constant for EPHA6 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256616 | Average Binding Constant for CDK5; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID256608 | Average Binding Constant for MARK2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID449703 | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | 2008 | Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
ISSN: 1091-6490 | In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. |
| AID624711 | Binding constant for STK35 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624884 | Binding constant for PRKD1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625015 | Binding constant for ROCK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435319 | Binding constant for PKN1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256629 | Average Binding Constant for HCK; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425018 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256612 | Average Binding Constant for GAK; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID256591 | Average Binding Constant for EPHA5; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1424958 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1157579 | Displacement of [3H]colchicine from bovine brain tubulin after 10 mins | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
ISSN: 1520-4804 | Discovery of biarylaminoquinazolines as novel tubulin polymerization inhibitors. |
| AID624789 | Binding constant for KIT(D816V) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435934 | Binding constant for PLK1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624923 | Binding constant for MAPKAPK5 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624990 | Binding constant for ABL1(Y253F)-phosphorylated kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625113 | Binding constant for MARK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424936 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID490456 | Inhibition of human recombinant histidine-tagged ALK (103-1459) expressed in Sf9 cells by ELISA | 2010 | European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
ISSN: 1768-3254 | Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold. |
| AID84824 | Inhibition of human endothelial cell growth stimulate by vascular endothelial growth factor | 2002 | Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
ISSN: 0022-2623 | Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. |
| AID624988 | Binding constant for ABL1(T315I)-non phosphorylated kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624939 | Binding constant for FLT3(N841I) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256576 | Average Binding Constant for MKNK2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID256669 | Average Binding Constant for ABL1(M351T); NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID261930 | Inhibitory activity against VEGFR-2 using 2 uM ATP by HTRF assay | 2006 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
ISSN: 0960-894X | 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases. |
| AID625127 | Binding constant for RSK3(Kin.Dom.1-N-terminal) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624797 | Binding constant for PHKG2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID449704 | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | 2008 | Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
ISSN: 1091-6490 | In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. |
| AID435443 | Binding constant for TXK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625021 | Binding constant for LIMK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1588961 | Inhibition of PDGFR (unknown origin) incubated for 30 mins by enzyme immunoassay | 2019 | Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
ISSN: 1464-3391 | Design, synthesis, biological evaluation of benzoyl amide derivatives containing nitrogen heterocyclic ring as potential VEGFR-2 inhibitors. |
| AID625056 | Binding constant for TESK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID436043 | Binding constant for PKMYT1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425188 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435182 | Binding constant for full-length PKAC-beta | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256638 | Average Binding Constant for PRKAA1; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435279 | Binding constant for full-length CDK9 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435667 | Binding constant for full-length NLK | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435397 | Binding constant for CSNK1G1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435326 | Binding constant for TYRO3 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1779644 | Inhibition of EGFR (unknown origin) | 2021 | Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
ISSN: 1520-4804 | |
| AID1424920 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1502309 | Antiangiogenic activity against HUVEC incubated for 48 hrs by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140ISSN: 1768-3254 | Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer. |
| AID435310 | Binding constant for FLT3(ITD) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1548475 | Selectivity index, ratio of IC50 for N-terminal His6-tagged recombinant human KDR (790 to end residue) expressed in baculovirus in Sf21 insect cells to IC50 for recombinant N-Terminal GST-tagged human RET V804M mutant (658 to end residues) | 2020 | ACS medicinal chemistry letters, Apr-09, Volume: 11, Issue:4
ISSN: 1948-5875 | Discovery and Optimization of wt-RET/KDR-Selective Inhibitors of RET |
| AID435193 | Binding constant for RPS6KA6(Kin.Dom.1 - C-terminal) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435807 | Binding constant for MARK1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624887 | Binding constant for ERK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624980 | Binding constant for ABL1(F317I)-phosphorylated kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID436015 | Binding constant for EPHA6 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625007 | Binding constant for EGFR(T790M) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425175 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624767 | Binding constant for MERTK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435200 | Binding constant for full-length TNNI3K | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256594 | Average Binding Constant for BMX; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID305869 | Inhibition of VEGFR1 by HTRF assay | 2007 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
ISSN: 0960-894X | ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2. |
| AID435403 | Binding constant for EPHB1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435782 | Binding constant for BRSK1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424968 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435900 | Binding constant for AKT3 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424987 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624889 | Binding constant for JNK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625142 | Binding constant for TSSK1B kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID257073 | Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 100 uM glutathione | 2005 | Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
ISSN: 0022-2623 | 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2. |
| AID435152 | Binding constant for CAMK4 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435413 | Binding constant for MLCK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625002 | Binding constant for EGFR(L747-T751del,Sins) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID295766 | Inhibition of human EGFR in presence of 1 mM ATP at <10000 nM | 2007 | Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
ISSN: 0968-0896 | Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. |
| AID1337732 | Antiproliferative activity against human HT-29 cells measured after 48 hrs by MTT assay | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125ISSN: 1768-3254 | Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2. |
| AID624780 | Binding constant for CDK4-cyclinD1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435527 | Binding constant for FGFR3(G697C) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435191 | Binding constant for full-length RIOK3 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256670 | Average Binding Constant for ABL1(T315I); NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1424908 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1548474 | Selectivity index, ratio of IC50 for GST-tagged human RET expressed in baculovirus to IC50 for recombinant N-Terminal GST-tagged human RET V804M mutant (658 to end residues) | 2020 | ACS medicinal chemistry letters, Apr-09, Volume: 11, Issue:4
ISSN: 1948-5875 | Discovery and Optimization of wt-RET/KDR-Selective Inhibitors of RET |
| AID262070 | Inhibition of VEGFR2 by enzymatic assay | 2006 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
ISSN: 0960-894X | Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II. |
| AID256652 | Average Binding Constant for CAMK2B; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID436047 | Binding constant for full-length PRKX | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425130 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624781 | Binding constant for CDK4-cyclinD3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1720109 | Cytotoxicity against human MCF7 cells assessed as reduction in cell viability by MTT assay | 2020 | Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17
ISSN: 1520-4804 | Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy. |
| AID588213 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1
ISSN: 1520-5010 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID435516 | Binding constant for ADCK3 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625122 | Binding constant for RET(M918T) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256580 | Average Binding Constant for CAMKK2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624999 | Binding constant for EGFR(G719S) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625005 | Binding constant for EGFR(L861Q) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425100 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID436016 | Binding constant for full-length ERK1 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625096 | Binding constant for STK36 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624874 | Binding constant for PCTK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425171 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625083 | Binding constant for LATS2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256664 | Average Binding Constant for EGFR; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID84822 | Inhibition of basal unstimulated growth of human endothelial cell | 2002 | Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
ISSN: 0022-2623 | Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. |
| AID624724 | Binding constant for TAK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624834 | Binding constant for DAPK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624868 | Binding constant for MST1R kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435912 | Binding constant for MRCKB kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435556 | Binding constant for RAF1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435903 | Binding constant for CDK8 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435904 | Binding constant for full-length CSK | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID589582 | Antiproliferative activity against human EAhy926 cells at 10 uM after 72 hrs by MTS assay | 2011 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
ISSN: 1464-3405 | Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors. |
| AID624913 | Binding constant for TYK2(JH2domain-pseudokinase) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424922 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625046 | Binding constant for PIK3CB kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435644 | Binding constant for ABL1(E255K) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435440 | Binding constant for PIM2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID263457 | Inhibition of VEGFR2 phosphorylation in HEK293 cells by cell-based ELISA | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
ISSN: 0960-894X | Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. |
| AID625134 | Binding constant for PIP5K2C kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424963 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID738478 | Binding affinity to phosphorylated ABL1 (unknown origin) at 75 uM after 1 hr relative to control | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID738217 | Growth inhibition of human HT-29 cells at 10 uM after 72 hrs by MTT assay relative to control | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID624964 | Binding constant for DYRK1B kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435521 | Binding constant for CAMKK1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435792 | Binding constant for EGFR(S752-I759del) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425070 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425064 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1502308 | Inhibition of His-tagged human VEGFR2 at 40 uM incubated for 1 hr by HTRF assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140ISSN: 1768-3254 | Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer. |
| AID256653 | Average Binding Constant for FGFR1; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID216649 | In vitro inhibition of Vascular endothelial growth factor receptor 2 (VEGFR-2) | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID1283961 | Selectivity ratio of IC50 for KDR inhibition (unknown origin) expressed in mouse BA/F3 cells to IC50 for KIF5B/RET inhibition (unknown origin) expressed in mouse BA/F3 cells | 2016 | European journal of medicinal chemistry, Apr-13, Volume: 112ISSN: 1768-3254 | The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. |
| AID256623 | Average Binding Constant for MYLK2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624708 | Binding constant for CDC2L1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624779 | Binding constant for BTK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435826 | Binding constant for full-length PCTK3 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624860 | Binding constant for VEGFR2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624806 | Binding constant for RPS6KA4(Kin.Dom.1-N-terminal) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624908 | Binding constant for TEC kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625091 | Binding constant for MAST1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435804 | Binding constant for LYN kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424997 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435674 | Binding constant for JAK3(Kin.Dom.2/JH1 - catalytic) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424956 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425147 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435657 | Binding constant for full-length IKK-epsilon | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624915 | Binding constant for PIP5K2B kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256655 | Average Binding Constant for CSNK1G1; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID256606 | Average Binding Constant for STK16; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425163 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624848 | Binding constant for CSNK2A1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1283958 | Selectivity ratio of IC50 for recombinant His-tagged human KDR expressed in insect Sf21 cells to IC50 for human RET cytoplasmic domain (658 to 1114 residues) expressed in baculovirus system | 2016 | European journal of medicinal chemistry, Apr-13, Volume: 112ISSN: 1768-3254 | The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. |
| AID624971 | Binding constant for DAPK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435828 | Binding constant for full-length PIP5K2B | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256568 | Average Binding Constant for STK17A; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID625130 | Binding constant for FGFR4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424923 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625086 | Binding constant for SLK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625112 | Binding constant for YANK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625138 | Binding constant for STK33 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624738 | Binding constant for MLCK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256624 | Average Binding Constant for FGFR3; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID625087 | Binding constant for MELK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1337730 | Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system preincubated for 10 mins followed by FAM-labelled peptide substrate addition by caliper mobility shift assay | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125ISSN: 1768-3254 | Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2. |
| AID435444 | Binding constant for TYK2(Kin.Dom.2/JH1 - catalytic) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435679 | Binding constant for PIM3 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256601 | Average Binding Constant for EPHA3; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435442 | Binding constant for SYK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID449705 | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | 2008 | Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
ISSN: 1091-6490 | In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen. |
| AID624827 | Binding constant for CAMK2B kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425159 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425079 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1424918 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435201 | Binding constant for TRKA kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID436051 | Binding constant for RPS6KA5(Kin.Dom.2 - N-terminal) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256566 | Average Binding Constant for TNIK; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435151 | Binding constant for CAMK1G kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1588953 | Induction of apoptosis in human MCF7 cells incubated for 24 hrs by Annexin V-FITC/PI double staining based flow cytometry analysis | 2019 | Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
ISSN: 1464-3391 | Design, synthesis, biological evaluation of benzoyl amide derivatives containing nitrogen heterocyclic ring as potential VEGFR-2 inhibitors. |
| AID624864 | Binding constant for CTK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624791 | Binding constant for KIT(V559D) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1755834 | Inhibition of EGFR in human A-431 cells assessed as antiproliferative activity incubated for 48 hrs by MTS method | 2021 | European journal of medicinal chemistry, Jan-15, Volume: 210ISSN: 1768-3254 | Metronidazole-conjugates: A comprehensive review of recent developments towards synthesis and medicinal perspective. |
| AID625013 | Binding constant for LCK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID738218 | Growth inhibition of human KB cells at 10 uM after 72 hrs by MTT assay relative to control | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID624970 | Binding constant for CDK5 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624775 | Binding constant for STK16 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1293767 | Antiproliferative activity against human PANC1 cells after 72 hrs by MTT assay | 2016 | Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
ISSN: 1464-3405 | Synthesis and antitumor activity of ATB-429 derivatives containing a nitric oxide-releasing moiety. |
| AID625077 | Binding constant for DAPK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID305871 | Inhibition of VEGFR2 by cell-based assay | 2007 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 17, Issue:5
ISSN: 0960-894X | ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2. |
| AID624869 | Binding constant for NEK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID436024 | Binding constant for MRCKA kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624765 | Binding constant for TRKC kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425069 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1564396 | Antiproliferative activity against human NCI-H446 cells assessed as inhibition of cell growth at 0.5 uM in hypoxia condition (200 uM CoCl2) and under irradiation at 8 Gy for 24 hrs and measured after 24 hrs by CCK8 assay (Rvb = 68.77%) | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181ISSN: 1768-3254 | Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. |
| AID1895760 | Inhibition of recombinant CCDC6-RET (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method | 2021 | Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
ISSN: 1520-4804 | Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. |
| AID624893 | Binding constant for MEK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624739 | Binding constant for GRK4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624966 | Binding constant for DCAMKL1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425190 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256645 | Average Binding Constant for JAK2 (Kin.Dom. 2); NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID256613 | Average Binding Constant for Aurora2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435154 | Binding constant for DDR2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435936 | Binding constant for full-length SRPK1 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435515 | Binding constant for ABL1(Q252H) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625128 | Binding constant for CSNK1G1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425154 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425201 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435561 | Binding constant for SRMS kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1595619 | Binding affinity to wild-type human partial length GAK (G13 to Y338 residues) expressed in bacterial expression system by Kinomescan method | 2019 | Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804 | Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma. |
| AID624743 | Binding constant for LTK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID436032 | Binding constant for MYO3B kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625106 | Binding constant for MARK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435410 | Binding constant for KIT kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256572 | Average Binding Constant for STK36; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624760 | Binding constant for PFPK5(P.falciparum) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425157 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435790 | Binding constant for DRAK1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1588964 | Antiproliferative activity against human MCF7 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay | 2019 | Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
ISSN: 1464-3391 | Design, synthesis, biological evaluation of benzoyl amide derivatives containing nitrogen heterocyclic ring as potential VEGFR-2 inhibitors. |
| AID1425122 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256575 | Average Binding Constant for NEK6; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425196 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1588965 | Antiproliferative activity against human A549 cells assessed as inhibition of cell proliferation incubated for 48 hrs by MTT assay | 2019 | Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
ISSN: 1464-3391 | Design, synthesis, biological evaluation of benzoyl amide derivatives containing nitrogen heterocyclic ring as potential VEGFR-2 inhibitors. |
| AID435655 | Binding constant for ERK5 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425044 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435677 | Binding constant for LOK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1894163 | Inhibition of VEGFR3 (unknown origin) by ELISA | 2021 | European journal of medicinal chemistry, Mar-15, Volume: 214ISSN: 1768-3254 | FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. |
| AID599957 | Binding affinity to human KIT incubated for 1 hr by kinase binding assay | 2011 | European journal of medicinal chemistry, Jun, Volume: 46, Issue:6
ISSN: 1768-3254 | Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives. |
| AID435325 | Binding constant for RPS6KA4(Kin.Dom.1 - C-terminal) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424950 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435830 | Binding constant for RPS6KA2(Kin.Dom.2 - C-terminal) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435797 | Binding constant for ERBB4 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435438 | Binding constant for full-length p38-gamma | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID295773 | Ratio of IC50 for VEGFR2 in presence of 1 mM ATP to IC50 for VEGFR2 in presence of 1 uM ATP | 2007 | Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
ISSN: 0968-0896 | Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. |
| AID1425053 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID436010 | Binding constant for full-length CDK5 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425027 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624796 | Binding constant for MET(Y1235D) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624861 | Binding constant for LIMK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1564412 | Antiproliferative activity against human NCI-H446 cells assessed as hypoxic sensitive enhancement ratio in presence of CoCl2 | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181ISSN: 1768-3254 | Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. |
| AID738216 | Growth inhibition of human PC3 cells at 10 uM after 72 hrs by MTT assay relative to control | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID1424967 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425115 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1424994 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256625 | Average Binding Constant for PAK3; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425006 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435530 | Binding constant for MAP3K4 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435662 | Binding constant for MST2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625118 | Binding constant for CAMK1D kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425136 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID259703 | Inhibitory activity against VEGFR1 by HTRF assay | 2006 | Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
ISSN: 0960-894X | N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II. |
| AID625131 | Binding constant for FGFR2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424989 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425133 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435901 | Binding constant for BRAF kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1283959 | Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay | 2016 | European journal of medicinal chemistry, Apr-13, Volume: 112ISSN: 1768-3254 | The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. |
| AID256672 | Average Binding Constant for CAMK2G; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435409 | Binding constant for full-length JNK2 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID436012 | Binding constant for full-length CSNK2A1 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435659 | Binding constant for full-length MARK3 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424944 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1424970 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624755 | Binding constant for ZAK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256573 | Average Binding Constant for PAK6; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435650 | Binding constant for full-length CSNK1E | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624907 | Binding constant for SYK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256663 | Average Binding Constant for INSR; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435293 | Binding constant for JNK3 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435796 | Binding constant for ERBB2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624752 | Binding constant for SNRK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625038 | Binding constant for PIK3CA(E542K) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435649 | Binding constant for CDC2L2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425118 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID738215 | Growth inhibition of human MCF7 cells at 10 uM after 72 hrs by MTT assay relative to control | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID625023 | Binding constant for HIPK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424902 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624719 | Binding constant for GRK7 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425071 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID588212 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1
ISSN: 1520-5010 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID624762 | Binding constant for DLK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID490459 | Antiproliferative activity against human TPC1 cells expressing RET/PCT1 after 72 hrs by [3H]thymidine incorporation assay | 2010 | European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
ISSN: 1768-3254 | Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold. |
| AID256590 | Average Binding Constant for EPHB1; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID738491 | Binding affinity to AXL (unknown origin) | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID1424978 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624933 | Binding constant for PLK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625089 | Binding constant for AAK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435153 | Binding constant for full-length DAPK2 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625063 | Binding constant for PLK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256604 | Average Binding Constant for STK10; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435203 | Binding constant for TTK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425084 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1564399 | Downregulation of VEGF expression in human A549 cells at 5 uM after 24 hrs under normoxic condition by q-PCR analysis relative to control | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181ISSN: 1768-3254 | Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. |
| AID624877 | Binding constant for PIK3C2B kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625061 | Binding constant for MAP4K5 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435393 | Binding constant for CAMK1D kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435652 | Binding constant for EGFR(L747-E749del, A750P) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624984 | Binding constant for ABL1(H396P)-phosphorylated kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424996 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1876282 | Inhibition of SRC (unknown origin) | 2022 | Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
ISSN: 1520-4804 | Kinase Inhibitors as Underexplored Antiviral Agents. |
| AID624924 | Binding constant for RIPK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435805 | Binding constant for MAP4K5 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID262072 | Inhibition of VEGFR2 in 293 adenovirus transfected kidney cells by cell-based ELISA assay | 2006 | Bioorganic & medicinal chemistry letters, Mar-01, Volume: 16, Issue:5
ISSN: 0960-894X | Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II. |
| AID625108 | Binding constant for MKNK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435645 | Binding constant for ACVRL1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624968 | Binding constant for DRAK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID216922 | In vitro inhibition of Vascular endothelial growth factor receptor 3 [VEGFR-3(Flt-4)] expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID1425026 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID271127 | Free drug level in rat plasma at 37 degC | 2006 | Bioorganic & medicinal chemistry letters, Sep-15, Volume: 16, Issue:18
ISSN: 0960-894X | Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics. |
| AID256569 | Average Binding Constant for PAK7/PAK5; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID589578 | Inhibition of recombinant human VEGFR-2-mediated poly(Glu4Tyr) phosphorylation after 1 hr | 2011 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
ISSN: 1464-3405 | Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors. |
| AID624867 | Binding constant for MLK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425205 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256564 | Average Binding Constant for MAP3K4; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID625000 | Binding constant for EGFR(L747-E749del, A750P) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1588960 | Inhibition of bFGFR (unknown origin) incubated for 30 mins by enzyme immunoassay | 2019 | Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
ISSN: 1464-3391 | Design, synthesis, biological evaluation of benzoyl amide derivatives containing nitrogen heterocyclic ring as potential VEGFR-2 inhibitors. |
| AID256571 | Average Binding Constant for BIKE; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID40729 | Mean % inhibition of lymph node metastasis in B16 mouse administration. | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID1424915 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624855 | Binding constant for FRK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256662 | Average Binding Constant for ERBB2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID625084 | Binding constant for HUNK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424951 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1595617 | Antiproliferative activity against human UCH2 cells measured after 72 hrs by alamar blue assay | 2019 | Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804 | Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma. |
| AID1915578 | Inhibition of VEGFR2 (unknown origin) | 2021 | European journal of medicinal chemistry, Jan-01, Volume: 209ISSN: 1768-3254 | Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. |
| AID435694 | Binding constant for TNK2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624832 | Binding constant for IKK-alpha kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624790 | Binding constant for KIT(L576P) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424981 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256665 | Average Binding Constant for ABL1; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID625016 | Binding constant for SRC kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435322 | Binding constant for PRKG2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624805 | Binding constant for RSK3(Kin.Dom.2-C-terminal) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424889 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625041 | Binding constant for PIK3CA(H1047L) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435150 | Binding constant for ARK5 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435906 | Binding constant for EGFR(L747-T751del,Sins) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256577 | Average Binding Constant for CLK4; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435525 | Binding constant for EGFR(L858R) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435663 | Binding constant for full-length MST4 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435546 | Binding constant for PRKG1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1735266 | Growth inhibition of mouse BaF3 cells harboring RET V804L mutant incubated for 3 days by MTT assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143ISSN: 1768-3254 | Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants. |
| AID1595618 | Binding affinity to wild-type human partial length EGFR (R669 to V1011 residues) expressed in bacterial expression system by Kinomescan method | 2019 | Journal of medicinal chemistry, 05-09, Volume: 62, Issue:9
ISSN: 1520-4804 | Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma. |
| AID1425161 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435196 | Binding constant for full-length SRPK2 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435822 | Binding constant for MEK4 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625051 | Binding constant for PRKCQ kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425106 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435693 | Binding constant for TGFBR2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256619 | Average Binding Constant for RPS6KA3 (Kin.Dom. 1); NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435204 | Binding constant for WEE1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625069 | Binding constant for TLK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624947 | Binding constant for BRAF(V600E) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624776 | Binding constant for PCTK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1204917 | Inhibition of RET (unknown origin) | 2015 | Journal of medicinal chemistry, May-14, Volume: 58, Issue:9
ISSN: 1520-4804 | Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer. |
| AID624976 | Binding constant for PRKX kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425060 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425166 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1424909 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425098 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID619792 | Cytotoxicity against human DLD1 cells assessed as cell viability at 10 uM after 3 days by colorimetric MTT assay | 2011 | European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
ISSN: 1768-3254 | Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents. |
| AID1424972 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425058 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624829 | Binding constant for CDK8 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID66624 | Inhibition of epidermal growth factor receptor kinase activity at a concentration of 2 uM of ATP | 2002 | Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
ISSN: 0022-2623 | Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. |
| AID435794 | Binding constant for EPHA3 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624777 | Binding constant for DDR2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256634 | Average Binding Constant for CSNK1G2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435522 | Binding constant for CDK11 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435329 | Binding constant for YSK1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435661 | Binding constant for full-length MKNK1 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435931 | Binding constant for PIM1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1564413 | Antiproliferative activity against human NCI-H446 cells assessed as hypoxic sensitive enhancement ratio in presence of Cocl2 under irradiation | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181ISSN: 1768-3254 | Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. |
| AID624772 | Binding constant for AURKB kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435167 | Binding constant for KIT(V559D) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624817 | Binding constant for MYO3B kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256579 | Average Binding Constant for MAP3K5; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID347657 | Inhibition of FGFR1/VEGFR2 chimeric construct expressed in HEK293 cells by ELISA | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
ISSN: 1464-3391 | Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2. |
| AID1424940 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624888 | Binding constant for ERK5 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435675 | Binding constant for KIT(V559D,T670I) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424931 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625024 | Binding constant for PRKD3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435147 | Binding constant for ACVR2B kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624996 | Binding constant for EGFR kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425000 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425012 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256621 | Average Binding Constant for CAMK2A; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624846 | Binding constant for CSNK1A1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624821 | Binding constant for YANK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625117 | Binding constant for PAK7 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435439 | Binding constant for PAK2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425001 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435396 | Binding constant for CHEK1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1293766 | Antiproliferative activity against human HT-29 cells after 72 hrs by MTT assay | 2016 | Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
ISSN: 1464-3405 | Synthesis and antitumor activity of ATB-429 derivatives containing a nitric oxide-releasing moiety. |
| AID1545498 | Invivo inhibition of neo-vascularisation in human A549 cells xenografted in athymic mouse at 50 mg/kg/day, po administered for 5 days measured after 24 hrs of last dose by light microscopy | 2019 | European journal of medicinal chemistry, May-15, Volume: 170ISSN: 1768-3254 | Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry. |
| AID1425209 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID216619 | Mean % inhibition of induced angiogenesis by Vascular endothelial growth factor (VEGF) at a peroral dose of 50 mg/kg in mice | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID256627 | Average Binding Constant for RPS6KA2 (Kin.Dom. 1); NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID625012 | Binding constant for GAK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID637249 | Inhibition of human GST-tagged VEGFR2 intracellular domain using biotin-aminohexyl-EEEEYFELVAKKKK-NH2 as substrate after 30 mins by HTRF assay | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
ISSN: 1464-3405 | Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase. |
| AID1394718 | Inhibition of wild type recombinant human RET using peptide as substrate by fluorimetric analysis | 2018 | European journal of medicinal chemistry, Apr-25, Volume: 150ISSN: 1768-3254 | Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors. |
| AID435795 | Binding constant for EPHA4 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424925 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624763 | Binding constant for RIPK4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256602 | Average Binding Constant for EPHA2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID256570 | Average Binding Constant for PIM2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624823 | Binding constant for MKNK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624815 | Binding constant for ERBB4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424998 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1418441 | Antiproliferative activity against human A549 cells after 72 hrs by CellTiter-Glo assay | 2018 | Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20
ISSN: 1464-3391 | Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors. |
| AID625019 | Binding constant for AKT3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624825 | Binding constant for BMPR1B kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624798 | Binding constant for LKB1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625072 | Binding constant for TBK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624774 | Binding constant for QSK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1511394 | Inhibition of EGFR (unknown origin) | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
ISSN: 1464-3391 | Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo. |
| AID1895668 | Inhibition of EGFR (unknown origin) | 2021 | Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
ISSN: 1520-4804 | Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. |
| AID625048 | Binding constant for PRKCD kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID84823 | Inhibition of human endothelial cell growth stimulate by endothelial growth factor | 2002 | Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
ISSN: 0022-2623 | Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. |
| AID624735 | Binding constant for ANKK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624727 | Binding constant for FYN kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435432 | Binding constant for MLK2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624882 | Binding constant for PKAC-beta kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625068 | Binding constant for NEK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625037 | Binding constant for PIK3CA(C420R) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624853 | Binding constant for FLT1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625003 | Binding constant for EGFR(L858R) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625103 | Binding constant for MST4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435275 | Binding constant for BIKE kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624954 | Binding constant for EPHB1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425176 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435829 | Binding constant for RPS6KA1(Kin.Dom.2 - C-terminal) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624716 | Binding constant for CSNK1D kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424971 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435523 | Binding constant for CIT kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435534 | Binding constant for NEK5 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID589580 | Antiproliferative activity against human HT-29 cells at 10 uM after 72 hrs by MTS assay | 2011 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
ISSN: 1464-3405 | Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors. |
| AID619793 | Cytotoxicity against human A549 cells assessed as cell viability at 10 uM after 3 days by colorimetric MTT assay | 2011 | European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
ISSN: 1768-3254 | Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents. |
| AID625095 | Binding constant for SIK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256643 | Average Binding Constant for CAMK1; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID490461 | Antiproliferative activity against human RET deficient ARO cells after 72 hrs by [3H]thymidine incorporation assay | 2010 | European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
ISSN: 1768-3254 | Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold. |
| AID435929 | Binding constant for PAK4 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624723 | Binding constant for CSNK1A1L kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624901 | Binding constant for RSK1(Kin.Dom.2-C-terminal) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256562 | Average Binding Constant for PAK4; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425059 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID261931 | Inhibitory activity against VEGFR-1 using 2 uM ATP by HTRF assay | 2006 | Bioorganic & medicinal chemistry letters, Mar-15, Volume: 16, Issue:6
ISSN: 0960-894X | 2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases. |
| AID256654 | Average Binding Constant for FGFR2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435647 | Binding constant for CAMK2D kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID738477 | Binding affinity to AXL (unknown origin) at 1 uM after 1 hr relative to control | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID624859 | Binding constant for JAK1(JH1domain-catalytic) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435297 | Binding constant for MLK1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425062 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425186 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625067 | Binding constant for NDR1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID73451 | In vitro inhibition of Fibroblast growth factor receptor expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID1735217 | Growth inhibition of human NIH3T3 cells incubated for 3 days by MTT assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143ISSN: 1768-3254 | Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants. |
| AID53175 | In vitro inhibition of Cyclin-dependent kinase 1 (CDK-1) expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID435910 | Binding constant for MAP4K4 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435524 | Binding constant for full-length CSNK1D | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425116 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425007 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425192 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625082 | Binding constant for RSK4(Kin.Dom.2-C-terminal) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624965 | Binding constant for LZK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624892 | Binding constant for p38-delta kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435553 | Binding constant for PRKCD kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625070 | Binding constant for PFTK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425197 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256666 | Average Binding Constant for ABL1(Q252H); NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624911 | Binding constant for TXK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624819 | Binding constant for ACVR1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1779635 | Inhibition of VEGFR2 (unknown origin) | 2021 | Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
ISSN: 1520-4804 | |
| AID435292 | Binding constant for ITK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256631 | Average Binding Constant for FLT4; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425137 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435407 | Binding constant for FLT3(D835Y) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624803 | Binding constant for CHEK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435559 | Binding constant for SNARK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435532 | Binding constant for MST3 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID295762 | Inhibition of human EGFR in presence of 1 uM ATP | 2007 | Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
ISSN: 0968-0896 | Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. |
| AID1424942 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625047 | Binding constant for AMPK-alpha2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624840 | Binding constant for AXL kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424965 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435290 | Binding constant for FGFR2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435520 | Binding constant for CAMK2A kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624750 | Binding constant for PRP4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624826 | Binding constant for BMPR2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425164 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435284 | Binding constant for DCAMKL1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624983 | Binding constant for ABL1(H396P)-non phosphorylated kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256592 | Average Binding Constant for LIMK1; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435911 | Binding constant for MEK6 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425177 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID619785 | Cytotoxicity against human A549 cells assessed as cell viability at 1 uM after 3 days by colorimetric MTT assay | 2011 | European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
ISSN: 1768-3254 | Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents. |
| AID624977 | Binding constant for OSR1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425096 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625020 | Binding constant for ITK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID738224 | Binding affinity to TYRO3 (unknown origin) at 75 uM after 1 hr relative to control | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID624875 | Binding constant for PDGFRB kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256651 | Average Binding Constant for DAPK2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425107 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID73628 | Inhibition of fms-like tyrosine kinase receptor (Flt-1) kinase activity at a concentration of 2 uM of ATP | 2002 | Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
ISSN: 0022-2623 | Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. |
| AID624808 | Binding constant for TRKA kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256673 | Average Binding Constant for PAK1; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID256582 | Average Binding Constant for NEK9; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425194 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425052 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1275246 | Antiproliferative activity against human MCF7 cells after 48 hrs by MTT assay | 2016 | European journal of medicinal chemistry, Feb-15, Volume: 109ISSN: 1768-3254 | Design, synthesis and biological evaluation of N-phenylquinazolin-4-amine hybrids as dual inhibitors of VEGFR-2 and HDAC. |
| AID625026 | Binding constant for MAP3K1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424916 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624898 | Binding constant for GRK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424995 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435909 | Binding constant for full-length LKB1 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425179 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624914 | Binding constant for WEE1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256626 | Average Binding Constant for NTRK1; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624768 | Binding constant for SRPK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625044 | Binding constant for PIK3CA(M1043I) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425120 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625136 | Binding constant for YSK4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425063 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID241758 | Inhibition of human Vascular endothelial growth factor receptor 2 | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
ISSN: 0022-2623 | Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. |
| AID624844 | Binding constant for CDK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1256443 | Inhibition of human HDAC in HeLa cell nuclear extract by fluorometric assay using Fluor de Lys substrate | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
ISSN: 1464-3405 | Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase. |
| AID624969 | Binding constant for ROCK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425129 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256610 | Average Binding Constant for Aurora3; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1735272 | Inhibition of recombinant human RET V804M mutant using KKKVSRSGLYRSP as substrate incubated for 15 mins followed by Mg/ATP addition and measured after 40 mins by [gamma-33P]-ATP assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143ISSN: 1768-3254 | Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants. |
| AID1293768 | Antiproliferative activity against human MCF7 cells after 72 hrs by MTT assay | 2016 | Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
ISSN: 1464-3405 | Synthesis and antitumor activity of ATB-429 derivatives containing a nitric oxide-releasing moiety. |
| AID435554 | Binding constant for PRKD3 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425029 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425145 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425203 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID40730 | Mean % inhibition of primary tumor growth in B16 mouse administration | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID624782 | Binding constant for FGFR3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435289 | Binding constant for ERK3 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624746 | Binding constant for WEE2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256607 | Average Binding Constant for STK18; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435402 | Binding constant for EGFR(G719S) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1894164 | Inhibition of HER1 (unknown origin) by ELISA | 2021 | European journal of medicinal chemistry, Mar-15, Volume: 214ISSN: 1768-3254 | FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. |
| AID435394 | Binding constant for CAMK2B kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424941 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256586 | Average Binding Constant for STK4; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1256442 | Inhibition VEGFR2 (unknown origin) for 30 mins by ELISA | 2015 | Bioorganic & medicinal chemistry letters, Nov-15, Volume: 25, Issue:22
ISSN: 1464-3405 | Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase. |
| AID435158 | Binding constant for EPHA5 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425047 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1270933 | Inhibition of recombinant VGFR-2 (unknown origin) | 2016 | European journal of medicinal chemistry, Jan-01, Volume: 107ISSN: 1768-3254 | 1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation. |
| AID1424937 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID219509 | In vitro inhibition of c-SRC kinase expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID436048 | Binding constant for full-length PTK2B | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1895639 | Inhibition of RET (unknown origin) | 2021 | Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
ISSN: 1520-4804 | Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. |
| AID256637 | Average Binding Constant for JNK2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID256620 | Average Binding Constant for FLT3; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435781 | Binding constant for full-length BMX | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256658 | Average Binding Constant for p38-beta; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID256657 | Average Binding Constant for LCK; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425102 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624881 | Binding constant for PKAC-alpha kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256674 | Average Binding Constant for PKMYT1; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624967 | Binding constant for RPS6KA5(Kin.Dom.2-C-terminal) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435327 | Binding constant for VEGFR2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624899 | Binding constant for ROS1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID436023 | Binding constant for MERTK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424935 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID161407 | In vitro inhibition of Platelet-derived growth factor receptor beta expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID435687 | Binding constant for PAK7/PAK5 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424959 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435935 | Binding constant for RIPK2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435412 | Binding constant for MAP3K5 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID213568 | In vitro inhibition of Tyrosine protein kinase receptor TIE-2 expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID625011 | Binding constant for FGR kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624773 | Binding constant for AMPK-alpha1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435184 | Binding constant for PTK2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425019 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1424929 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435806 | Binding constant for MAPKAPK5 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256622 | Average Binding Constant for JNK1; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624799 | Binding constant for TIE2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435654 | Binding constant for full-length ERK2 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1502306 | Cytotoxicity in human MCF7 cells assessed as inhibition of cell growth incubated for 48 hrs by MTT assay | 2017 | European journal of medicinal chemistry, Nov-10, Volume: 140ISSN: 1768-3254 | Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer. |
| AID624831 | Binding constant for CHEK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425124 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435171 | Binding constant for NEK9 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625057 | Binding constant for TYRO3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID490455 | Inhibition of human recombinant histidine-tagged ABL (230-517) expressed in Sf9 cells by ELISA | 2010 | European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
ISSN: 1768-3254 | Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold. |
| AID624871 | Binding constant for PAK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624944 | Binding constant for ALK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624904 | Binding constant for NEK4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625004 | Binding constant for EGFR(L858R,T790M) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625060 | Binding constant for CAMKK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424894 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID436042 | Binding constant for full-length PHKG1 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID86729 | Mean % inhibition of induced angiogenesis by Heparin-binding growth factor 2 at a peroral dose of 50 mg/kg in mice | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID1425087 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435800 | Binding constant for FYN kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424948 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID436055 | Binding constant for full-length YANK2 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624849 | Binding constant for CSNK2A2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435902 | Binding constant for BRAF(V600E) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424960 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625123 | Binding constant for RET(V804L) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425008 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID619791 | Cytotoxicity against human MV4-11 cells assessed as cell viability at 10 uM after 3 days by colorimetric MTT assay | 2011 | European journal of medicinal chemistry, Oct, Volume: 46, Issue:10
ISSN: 1768-3254 | Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents. |
| AID625018 | Binding constant for YES kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID259704 | Inhibitory activity against VEGFR2 transiently transfected in 293 adenovirus transfected kidney cells by ELISA | 2006 | Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
ISSN: 0960-894X | N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II. |
| AID1425065 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624838 | Binding constant for ACVR2A kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1751470 | Inhibition of VEGFR2 (unknown origin) | 2021 | Bioorganic & medicinal chemistry letters, 09-15, Volume: 48ISSN: 1464-3405 | Angiokinase inhibition of VEGFR-2, PDGFR and FGFR and cell growth inhibition in lung cancer: Design, synthesis, biological evaluation and molecular docking of novel azaheterocyclic coumarin derivatives. |
| AID625022 | Binding constant for MUSK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435164 | Binding constant for IGF1R kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID295768 | Ratio of IC50 for EGFR in presence of 1 mM ATP to IC50 for EGFR in presence of 1 uM ATP | 2007 | Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
ISSN: 0968-0896 | Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. |
| AID435531 | Binding constant for MKNK2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624783 | Binding constant for FGFR3(G697C) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256599 | Average Binding Constant for TTK; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1779636 | Inhibition of VEGFR3 (unknown origin) | 2021 | Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
ISSN: 1520-4804 | |
| AID1425080 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425099 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624930 | Binding constant for TNK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435286 | Binding constant for EPHA7 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435689 | Binding constant for full-length PFTK1 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435926 | Binding constant for PDGFRB kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624771 | Binding constant for TLK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435192 | Binding constant for ROS1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256560 | Average Binding Constant for FGR; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624890 | Binding constant for p38-beta kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID341898 | Inhibition of VEGF-induced HUVEC proliferation | 2008 | Journal of medicinal chemistry, Aug-14, Volume: 51, Issue:15
ISSN: 1520-4804 | Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. |
| AID1424984 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625105 | Binding constant for EPHB2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435834 | Binding constant for YANK3 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424892 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID589576 | Inhibition of EGFR | 2011 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
ISSN: 1464-3405 | Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors. |
| AID624721 | Binding constant for MEK5 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435783 | Binding constant for full-length BRSK2 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435166 | Binding constant for full-length JNK1 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625055 | Binding constant for MST1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624836 | Binding constant for IKK-beta kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425021 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625125 | Binding constant for CLK4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425073 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425035 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1424966 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425028 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435324 | Binding constant for full-length RIOK1 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624742 | Binding constant for NEK5 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1418439 | Antiproliferative activity against human MGHU3 cells after 72 hrs by CellTiter-Glo assay | 2018 | Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20
ISSN: 1464-3391 | Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors. |
| AID624935 | Binding constant for FLT3(D835H) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435776 | Binding constant for ABL1(Y253F) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID738225 | Binding affinity to TYRO3 (unknown origin) at 1 uM after 1 hr relative to control | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID1418440 | Antiproliferative activity against human RT112 cells after 72 hrs by CellTiter-Glo assay | 2018 | Bioorganic & medicinal chemistry, 11-01, Volume: 26, Issue:20
ISSN: 1464-3391 | Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors. |
| AID1425013 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425158 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624851 | Binding constant for ERBB3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425005 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256676 | Average Binding Constant for SRC; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID625035 | Binding constant for PHKG1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424969 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1424890 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID436014 | Binding constant for full-length DYRK1B | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425078 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425128 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1424983 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625034 | Binding constant for PDGFRA kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425143 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624733 | Binding constant for SIK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624883 | Binding constant for PRKCI kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425003 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1424999 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435648 | Binding constant for CAMKK2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624902 | Binding constant for MEK4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624957 | Binding constant for EPHB6 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624705 | Binding constant for MYLK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624940 | Binding constant for FLT3(R834Q) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424985 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435827 | Binding constant for PDGFRA kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1337734 | Antiproliferative activity against human H460 cells measured after 48 hrs by MTT assay | 2017 | European journal of medicinal chemistry, Jan-05, Volume: 125ISSN: 1768-3254 | Design and discovery of 4-anilinoquinazoline-urea derivatives as dual TK inhibitors of EGFR and VEGFR-2. |
| AID436005 | Binding constant for ANKK1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625140 | Binding constant for MARK4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID257075 | Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 1 mm ATP | 2005 | Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
ISSN: 0022-2623 | 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2. |
| AID625062 | Binding constant for MAP3K2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256647 | Average Binding Constant for SYK; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624811 | Binding constant for PAK4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425083 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435405 | Binding constant for ERK8 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1887635 | Inhibition of EGFR L858R/T790M/C797S triple mutant (unknown origin) | 2022 | Journal of medicinal chemistry, 01-27, Volume: 65, Issue:2
ISSN: 1520-4804 | Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer. |
| AID624866 | Binding constant for MLK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID69880 | In vitro inhibition of Epidermal growth factor receptor (HER-1,ErbB) expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID1424921 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625124 | Binding constant for RET(V804M) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435400 | Binding constant for DDR1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435411 | Binding constant for KIT(D816V) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624756 | Binding constant for MAP4K4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425039 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624801 | Binding constant for MAP3K15 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1564393 | Antiproliferative activity against human A549 cells assessed as inhibition of cell growth at 0.5 uM after 48 hrs under hypoxic condition (200 uM CoCl2) by CCk-8 assay relative to control (Rvb = 59.94%) | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181ISSN: 1768-3254 | Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. |
| AID624712 | Binding constant for DYRK1A kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID436011 | Binding constant for full-length CLK3 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256648 | Average Binding Constant for RPS6KA5 (Kin.Dom 1); NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435551 | Binding constant for full-length p38-beta | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624932 | Binding constant for CLK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID436009 | Binding constant for full-length CAMK1 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID73308 | Inhibition fibroblast growth factor receptor TK kinase activity at a concentration of 2 uM | 2002 | Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
ISSN: 0022-2623 | Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. |
| AID1425160 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624812 | Binding constant for SBK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624873 | Binding constant for PAK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425094 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435198 | Binding constant for TIE1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435646 | Binding constant for BLK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435161 | Binding constant for FES kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424917 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435320 | Binding constant for PRKCE kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625139 | Binding constant for SNARK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435321 | Binding constant for PRKCQ kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425105 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624854 | Binding constant for FLT4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256661 | Average Binding Constant for PDGFRB; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1564402 | Antitumour activity against human A549 cells xenografted in Balb/c mouse assessed as increase in tumour volume at 10 mg/kg, po administered daily and mesured after 7 days | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181ISSN: 1768-3254 | Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. |
| AID625099 | Binding constant for TAOK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425056 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256609 | Average Binding Constant for AAK1; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425134 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624795 | Binding constant for MET(M1250T) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624870 | Binding constant for NEK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425025 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425206 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435180 | Binding constant for MAPKAPK2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624850 | Binding constant for DDR1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425093 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425111 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435431 | Binding constant for MAP4K1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435162 | Binding constant for FLT3(N841I) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624880 | Binding constant for PIK4CB kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424945 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435170 | Binding constant for MYO3A kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1895757 | Inhibition of recombinant RET V804M (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method | 2021 | Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
ISSN: 1520-4804 | Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. |
| AID256656 | Average Binding Constant for p38-alpha; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID625040 | Binding constant for PIK3CA(E545K) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625009 | Binding constant for EPHA3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256559 | Average Binding Constant for EPHB4; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425155 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256630 | Average Binding Constant for FYN; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624847 | Binding constant for CSNK1E kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256671 | Average Binding Constant for ABL1(Y253F); NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425200 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1564391 | Cytotoxicity against human A549 cells assessed as inhibition of cell growth at 0.5 uM after 48 hrs under normoxic condition by CCk-8 assay relative to control | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181ISSN: 1768-3254 | Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. |
| AID435159 | Binding constant for EPHB3 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256578 | Average Binding Constant for SLK; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624952 | Binding constant for EPHA4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425207 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624715 | Binding constant for ERK8 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1157567 | Inhibition of EGFR (unknown origin) assessed as incorporation of [32P] gamma-ATP in to myelin basic protein after 30 mins by autoradiographic analysis | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
ISSN: 1520-4804 | Discovery of biarylaminoquinazolines as novel tubulin polymerization inhibitors. |
| AID436050 | Binding constant for RPS6KA2(Kin.Dom.1 - N-terminal) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435434 | Binding constant for RET kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435940 | Binding constant for full-length TSSK1 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424946 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256639 | Average Binding Constant for PHkg1; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1424901 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624950 | Binding constant for DMPK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID365969 | Inhibition of VEGFR2 | 2008 | Bioorganic & medicinal chemistry letters, Aug-01, Volume: 18, Issue:15
ISSN: 1464-3405 | Synthesis and evaluation of heteroaryl-ketone derivatives as a novel class of VEGFR-2 inhibitors. |
| AID625126 | Binding constant for TAOK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID538338 | Inhibition of recombinant VEGFR2 after 1 hr by fluorescence polarization assay | 2010 | European journal of medicinal chemistry, Nov, Volume: 45, Issue:11
ISSN: 1768-3254 | Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors. |
| AID256583 | Average Binding Constant for CAMKK1; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624895 | Binding constant for MEK6 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425002 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625076 | Binding constant for PLK4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624937 | Binding constant for FLT3(ITD) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624835 | Binding constant for ERN1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425033 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625058 | Binding constant for VRK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1895755 | Inhibition of wildtype RET (unknown origin) incubated for 120 mins by Perkin Elmer electrophoretic mobility shift platform method | 2021 | Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
ISSN: 1520-4804 | Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. |
| AID1425126 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1894162 | Inhibition of VEGFR2 (unknown origin) by ELISA | 2021 | European journal of medicinal chemistry, Mar-15, Volume: 214ISSN: 1768-3254 | FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. |
| AID435692 | Binding constant for STK16 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID436060 | Selectivity for VEGFR2 as proportion of 290 kinases in screen with similar potency; non-selective = 1 highly selective = 0 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435831 | Binding constant for RPS6KA5(Kin.Dom.1 - C-terminal) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624787 | Binding constant for KIT(A829P) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625143 | Binding constant for CAMKK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID263456 | Inhibition of VEGFR1 phosphorylation in presence of 2 uM ATP by HTRF assay | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
ISSN: 0960-894X | Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. |
| AID256642 | Average Binding Constant for VEGFR2; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425140 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435155 | Binding constant for full-length DLK | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256633 | Average Binding Constant for PRKACA; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID625100 | Binding constant for NLK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624909 | Binding constant for TGFBR2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435282 | Binding constant for full-length CSNK1G2 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID436017 | Binding constant for ERK4 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625050 | Binding constant for PKN2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624934 | Binding constant for FLT3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624778 | Binding constant for ACVRL1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425045 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435518 | Binding constant for AURKA kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID738214 | Growth inhibition of African green monkey Vero cells at 10 uM after 72 hrs by MTT assay relative to control | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID625104 | Binding constant for MYO3A kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256644 | Average Binding Constant for CSNK1E; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID295765 | Inhibition of human EGFR in presence of 1 mM ATP | 2007 | Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
ISSN: 0968-0896 | Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. |
| AID1564392 | Cytotoxicity against human NCI-H446 cells assessed as inhibition of cell growth at 0.5 uM after 48 hrs under normoxic condition by CCk-8 assay relative to control | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181ISSN: 1768-3254 | Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. |
| AID624894 | Binding constant for MEK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1599794 | Inhibition of recombinant human C-terminal His-tagged/N-terminal GST-tagged EGFR (668 to 1210 residues) T790M/L858R/C797S mutant expressed in baculovirus expression system using poly (Glu,Tyr) 4:1 as substrate incubated for 1 hr in presence of ATP by ELIS | 2019 | ACS medicinal chemistry letters, Jun-13, Volume: 10, Issue:6
ISSN: 1948-5875 | Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFR |
| AID435148 | Binding constant for AMPK-alpha1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624993 | Binding constant for ABL2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435169 | Binding constant for full-length MEK2 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425061 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625111 | Binding constant for RIOK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1564400 | Downregulation of VEGF expression in human A549 cells at 5 uM after 24 hrs under hypoxic condition by q-PCR analysis relative to control | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181ISSN: 1768-3254 | Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. |
| AID256636 | Average Binding Constant for JNK3; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1425213 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625115 | Binding constant for PAK6 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624814 | Binding constant for DCAMKL2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435404 | Binding constant for EPHB4 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1588958 | Inhibition of VEGFR2 (unknown origin) incubated for 30 mins by enzyme immunoassay | 2019 | Bioorganic & medicinal chemistry, 09-01, Volume: 27, Issue:17
ISSN: 1464-3391 | Design, synthesis, biological evaluation of benzoyl amide derivatives containing nitrogen heterocyclic ring as potential VEGFR-2 inhibitors. |
| AID435563 | Binding constant for TNIK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID216648 | In vitro inhibition of Vascular endothelial growth factor receptor 2 (VEGFR-2) expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID1424976 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1424926 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425030 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID436054 | Binding constant for TLK2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID257072 | Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP | 2005 | Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
ISSN: 0022-2623 | 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2. |
| AID1424954 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425074 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1157568 | Inhibition of FGFR1 (unknown origin) assessed as incorporation of [32P] gamma-ATP in to myelin basic protein after 30 mins by autoradiographic analysis | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
ISSN: 1520-4804 | Discovery of biarylaminoquinazolines as novel tubulin polymerization inhibitors. |
| AID216653 | Inhibition of vascular endothelial growth factor receptor 2 kinase activity at a concentration of 2 uM | 2002 | Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
ISSN: 0022-2623 | Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. |
| AID295771 | Inhibition of human VEGFR2 in presence of 1 mM ATP | 2007 | Bioorganic & medicinal chemistry, Jun-01, Volume: 15, Issue:11
ISSN: 0968-0896 | Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. |
| AID435924 | Binding constant for MARK4 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625102 | Binding constant for PRKD2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256605 | Average Binding Constant for STK17B; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID256677 | Average Binding Constant for STK38L; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1293771 | Antiproliferative activity against human HL60 cells after 72 hrs by MTT assay | 2016 | Bioorganic & medicinal chemistry letters, May-01, Volume: 26, Issue:9
ISSN: 1464-3405 | Synthesis and antitumor activity of ATB-429 derivatives containing a nitric oxide-releasing moiety. |
| AID1157569 | Inhibition of Abl1 (unknown origin) assessed as incorporation of [32P] gamma-ATP in to myelin basic protein after 30 mins by autoradiographic analysis | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
ISSN: 1520-4804 | Discovery of biarylaminoquinazolines as novel tubulin polymerization inhibitors. |
| AID435787 | Binding constant for CLK2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1157571 | Inhibition of bovine brain tubulin polymerization after 20 mins by turbidimetry analysis | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
ISSN: 1520-4804 | Discovery of biarylaminoquinazolines as novel tubulin polymerization inhibitors. |
| AID435555 | Binding constant for PRKR kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435202 | Binding constant for TRKC kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425014 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624961 | Binding constant for TGFBR1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625129 | Binding constant for HIPK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435433 | Binding constant for full-length MST1 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435666 | Binding constant for full-length NEK7 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624833 | Binding constant for CSNK1G2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624730 | Binding constant for CAMK2A kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624906 | Binding constant for S6K1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624852 | Binding constant for FES kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435688 | Binding constant for full-length PCTK2 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624734 | Binding constant for YANK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1564395 | Antiproliferative activity against human A549 cells assessed as inhibition of cell growth at 0.5 uM in hypoxia condition (200 uM CoCl2) and under irradiation at 8 Gy for 24 hrs and measured after 24 hrs by CCK8 assay (Rvb = 64.135%) | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181ISSN: 1768-3254 | Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. |
| AID435925 | Binding constant for PCTK1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID436020 | Binding constant for GCN2(Kin.Dom.2,S808G) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1915571 | Inhibition of HDAC (unknown origin) | 2021 | European journal of medicinal chemistry, Jan-01, Volume: 209ISSN: 1768-3254 | Comprehensive review for anticancer hybridized multitargeting HDAC inhibitors. |
| AID738480 | Binding affinity to phosphorylated ABL1 (unknown origin) at 1 uM after 1 hr relative to control | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID436004 | Binding constant for ACVR2A kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624757 | Binding constant for PKMYT1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435821 | Binding constant for GAK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424897 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435798 | Binding constant for FGR kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435802 | Binding constant for KIT(V559D,V654A) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID738481 | Binding affinity to non phosphorylated ABL1 (unknown origin) at 1 uM after 1 hr relative to control | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID1424973 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID436022 | Binding constant for full-length MEK3 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425104 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1424990 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624912 | Binding constant for TYK2(JH1domain-catalytic) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435514 | Binding constant for ABL1(M351T) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624747 | Binding constant for SgK110 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625141 | Binding constant for RIOK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624707 | Binding constant for DCAMKL3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624822 | Binding constant for CDKL3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424957 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624736 | Binding constant for RPS6KA5(Kin.Dom.1-N-terminal) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624943 | Binding constant for ACVR1B kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624941 | Binding constant for CDKL1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624948 | Binding constant for CSK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424993 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624856 | Binding constant for GSK3B kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625065 | Binding constant for CIT kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625042 | Binding constant for PIK3CA(H1047Y) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425055 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID69879 | In vitro inhibition of Epidermal growth factor receptor expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID1425095 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625028 | Binding constant for ASK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425072 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425088 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425144 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435323 | Binding constant for RET(M918T) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435296 | Binding constant for MARK2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1564389 | Inhibition of N-terminal GST-tagged human EGFR cytoplasmic domain (669 to 1210 residues) expressed in baculovirus expression system using FAM-22 peptide as substrate incubated for 10 mins followed by substrate addition by caliper method | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181ISSN: 1768-3254 | Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. |
| AID624751 | Binding constant for PIP5K1C kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425182 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425036 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1895655 | Inhibition of c-kit (unknown origin) | 2021 | Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
ISSN: 1520-4804 | Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. |
| AID435933 | Binding constant for PKN2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425168 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1735271 | Inhibition of recombinant human RET V804L mutant using KKKVSRSGLYRSP as substrate incubated for 15 mins followed by Mg/ATP addition and measured after 40 mins by [gamma-33P]-ATP assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143ISSN: 1768-3254 | Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants. |
| AID624972 | Binding constant for MTOR kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435676 | Binding constant for LCK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424891 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624922 | Binding constant for CAMK1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID248370 | Inhibition of basic FGF-induced proliferation of human umbilical vein endothelial cells | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
ISSN: 0022-2623 | Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. |
| AID256614 | Average Binding Constant for YES; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624786 | Binding constant for KIT kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID248240 | Inhibition of VEGF-induced proliferation of human umbilical vein endothelial cells | 2005 | Journal of medicinal chemistry, Mar-10, Volume: 48, Issue:5
ISSN: 0022-2623 | Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. |
| AID1424975 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624713 | Binding constant for ERK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1510860 | Inhibition of VEGFR2 (unknown origin) | 2019 | European journal of medicinal chemistry, Oct-01, Volume: 179ISSN: 1768-3254 | Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma. |
| AID490454 | Inhibition of human recombinant histidine-tagged RET (700-1020) expressed in Sf9 cells by ELISA | 2010 | European journal of medicinal chemistry, Jul, Volume: 45, Issue:7
ISSN: 1768-3254 | Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold. |
| AID256617 | Average Binding Constant for TEK; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID436008 | Binding constant for full-length BTK | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624845 | Binding constant for CDK7 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425103 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435938 | Binding constant for TGFBR1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1564397 | Antiproliferative activity against human A549 cells assessed as hypoxic sensitive enhancement ratio in presence of CoCl2 | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181ISSN: 1768-3254 | Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. |
| AID624905 | Binding constant for CDKL5 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1895652 | Inhibition of FGFR1 (unknown origin) | 2021 | Journal of medicinal chemistry, 08-26, Volume: 64, Issue:16
ISSN: 1520-4804 | Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development. |
| AID263455 | Inhibition of VEGFR2 phosphorylation in presence of 2 uM ATP by HTRF assay | 2006 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 16, Issue:7
ISSN: 0960-894X | Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. |
| AID624891 | Binding constant for JNK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625030 | Binding constant for LOK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624978 | Binding constant for ABL1(E255K)-phosphorylated kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID436052 | Binding constant for full-length SNF1LK2 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID436006 | Binding constant for full-length AURKC | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425138 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1425149 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625120 | Binding constant for EPHA8 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625029 | Binding constant for BRK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID216631 | In vitro inhibition of Vascular endothelial growth factor receptor 1 (VEGFR-1) expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID625054 | Binding constant for MST2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424980 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435398 | Binding constant for DAPK3 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID347672 | Inhibition of VEGF-stimulated HUVEC cell proliferation treated before 2 hrs of VEGF challenge assessed after 3 days by [3H]thymidine incorporation assay | 2009 | Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
ISSN: 1464-3391 | Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2. |
| AID624703 | Binding constant for MAPKAPK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435395 | Binding constant for CDC2L1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435156 | Binding constant for EGFR kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624745 | Binding constant for PKN1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624858 | Binding constant for JAK1(JH2domain-pseudokinase) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624865 | Binding constant for MAP3K3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624896 | Binding constant for PRKR kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435785 | Binding constant for full-length CDK2 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625119 | Binding constant for CAMK1G kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID73452 | In vitro inhibition of Fibroblast growth factor receptor 1 expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID1283957 | Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay | 2016 | European journal of medicinal chemistry, Apr-13, Volume: 112ISSN: 1768-3254 | The discovery of 2-substituted phenol quinazolines as potent RET kinase inhibitors with improved KDR selectivity. |
| AID256615 | Average Binding Constant for p38-gamma; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435778 | Binding constant for full-length ADCK4 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624788 | Binding constant for KIT(D816H) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID589577 | Inhibition of human EGFR-mediated poly(Glu4Tyr) phosphorylation after 1 hr | 2011 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
ISSN: 1464-3405 | Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors. |
| AID625036 | Binding constant for PIK3CA kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425081 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID738226 | Binding affinity to MET (unknown origin) at 1 uM after 1 hr relative to control | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID435803 | Binding constant for full-length LIMK1 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435165 | Binding constant for JAK1(Kin.Dom.1/JH2 - pseudokinase) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435905 | Binding constant for full-length CSNK1G3 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625097 | Binding constant for TNNI3K kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424899 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID256603 | Average Binding Constant for FER; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID435526 | Binding constant for FGFR1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425165 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID589662 | Antiproliferative activity against human MCF7 cells after 72 hrs by MTS assay | 2011 | Bioorganic & medicinal chemistry letters, Apr-01, Volume: 21, Issue:7
ISSN: 1464-3405 | Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors. |
| AID1564398 | Antiproliferative activity against human A549 cells assessed as hypoxic sensitive enhancement ratio in presence of Cocl2 under irradiation | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181ISSN: 1768-3254 | Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. |
| AID624749 | Binding constant for CASK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624857 | Binding constant for HCK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID637250 | Antiproliferative activity against VEGF-stimulated HUVEC after 48 hrs by sulforhodamine B assay | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
ISSN: 1464-3405 | Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase. |
| AID1425132 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625027 | Binding constant for MAP3K4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625017 | Binding constant for TIE1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID108256 | In vitro inhibition of Mast/stem cell growth factor receptor (c-Kit kinase) expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID624945 | Binding constant for BMPR1A kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1735269 | Growth inhibition of mouse BaF3 cells over expressing wild type RET incubated for 3 days by MTT assay | 2018 | European journal of medicinal chemistry, Jan-01, Volume: 143ISSN: 1768-3254 | Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants. |
| AID435195 | Binding constant for SRC kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624986 | Binding constant for ABL1(Q252H)-non phosphorylated kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625001 | Binding constant for EGFR(L747-S752del, P753S) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624949 | Binding constant for CSNK1G3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624886 | Binding constant for ERK4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624841 | Binding constant for BLK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625081 | Binding constant for RSK4(Kin.Dom.1-N-terminal) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624741 | Binding constant for LRRK2(G2019S) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425043 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624770 | Binding constant for CAMK2D kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424939 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625121 | Binding constant for RET kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424949 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1157570 | Inhibition of Src (unknown origin) assessed as incorporation of [32P] gamma-ATP in to myelin basic protein after 30 mins by autoradiographic analysis | 2014 | Journal of medicinal chemistry, Jun-12, Volume: 57, Issue:11
ISSN: 1520-4804 | Discovery of biarylaminoquinazolines as novel tubulin polymerization inhibitors. |
| AID435793 | Binding constant for EPHA1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624926 | Binding constant for RIOK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435188 | Binding constant for PAK6 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID625074 | Binding constant for IKK-epsilon kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625075 | Binding constant for INSRR kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435414 | Binding constant for MLK3 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624744 | Binding constant for ZAP70 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435564 | Binding constant for TRKB kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425016 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435789 | Binding constant for full-length CSNK2A2 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID161408 | In vitro inhibition of Platelet-derived growth factor receptor beta expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID256660 | Average Binding Constant for KIT; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID624740 | Binding constant for LRRK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425172 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624958 | Binding constant for PIK3C2G kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425193 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1424904 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624987 | Binding constant for ABL1(Q252H)-phosphorylated kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425113 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435190 | Binding constant for full-length PIP5K1A | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425169 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624979 | Binding constant for ABL1(F317I)-non phosphorylated kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID257074 | Inhibition of poly(Glu4-Tyr)peptide phosphorylation by recombinant VEGFR2 at 10 uM ATP and in presence of 5% mouse plasma | 2005 | Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
ISSN: 0022-2623 | 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2. |
| AID436046 | Binding constant for PRKD2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425050 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624955 | Binding constant for EPHB3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424988 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID625137 | Binding constant for MEK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID637269 | Solubility of the compound in water | 2012 | Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
ISSN: 1464-3405 | Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase. |
| AID1425090 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID216632 | In vitro inhibition of Vascular endothelial growth factor receptor 1 (VEGFR-1) expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID435285 | Binding constant for DMPK kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID256667 | Average Binding Constant for ABL1(E255K); NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID1564408 | Toxicity in Balb/c mouse xenografted with human A549 cells assessed as reduction in body weight at 10 mg/kg, po measured up to 8 days | 2019 | European journal of medicinal chemistry, Nov-01, Volume: 181ISSN: 1768-3254 | Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors. |
| AID1894165 | Antiproliferative activity against human A549 cells assessed as cell growth inhibition incubated for 72 hrs by [3H]thymidine incorporation assay | 2021 | European journal of medicinal chemistry, Mar-15, Volume: 214ISSN: 1768-3254 | FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application. |
| AID1424992 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624758 | Binding constant for RIPK5 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID435430 | Binding constant for INSRR kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435545 | Binding constant for NEK6 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1425167 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624862 | Binding constant for LYN kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625014 | Binding constant for PRKCE kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1424896 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID436033 | Binding constant for PIK3CA kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624878 | Binding constant for PIM1 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625006 | Binding constant for EGFR(S752-I759del) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624710 | Binding constant for SRMS kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625116 | Binding constant for ADCK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624714 | Binding constant for p38-alpha kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID625066 | Binding constant for IRAK3 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425024 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID435899 | Binding constant for AKT1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435519 | Binding constant for AURKB kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435690 | Binding constant for RPS6KA1(Kin.Dom.1 - N-terminal) kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435833 | Binding constant for full-length TNK1 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID1424910 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID1424964 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID738474 | Binding affinity to MER (unknown origin) at 75 uM after 1 hr relative to control | 2013 | European journal of medicinal chemistry, Mar, Volume: 61ISSN: 1768-3254 | Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation. |
| AID625025 | Binding constant for MAK kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1511395 | Inhibition of VEGFR2 (unknown origin) | 2019 | Bioorganic & medicinal chemistry, 10-15, Volume: 27, Issue:20
ISSN: 1464-3391 | Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo. |
| AID213567 | In vitro inhibition of Tyrosine protein kinase receptor TIE-2 (Tek) expressed in baculovirus | 2002 | Journal of medicinal chemistry, Dec-19, Volume: 45, Issue:26
ISSN: 0022-2623 | Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors. |
| AID257076 | Inhibitory activity against VEGF stimulated autophosphorylation of VEGFR2 expressed in KDR15 cells | 2005 | Journal of medicinal chemistry, Dec-01, Volume: 48, Issue:24
ISSN: 0022-2623 | 2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2. |
| AID436013 | Binding constant for DMPK2 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID624998 | Binding constant for EGFR(G719C) kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425153 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624809 | Binding constant for MYLK4 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID624732 | Binding constant for PYK2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID1425051 | Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry | 2017 | Science (New York, N.Y.), 12-01, Volume: 358, Issue:6367
ISSN: 1095-9203 | The target landscape of clinical kinase drugs. |
| AID624804 | Binding constant for ERBB2 kinase domain | 2011 | Nature biotechnology, Oct-30, Volume: 29, Issue:11
ISSN: 1546-1696 | Comprehensive analysis of kinase inhibitor selectivity. |
| AID256567 | Average Binding Constant for EPHA6; NA=Not Active at 10 uM | 2005 | Nature biotechnology, Mar, Volume: 23, Issue:3
ISSN: 1087-0156 | A small molecule-kinase interaction map for clinical kinase inhibitors. |
| AID436053 | Binding constant for full-length STK33 | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID435775 | Binding constant for ABL1 kinase domain | 2008 | Nature biotechnology, Jan, Volume: 26, Issue:1
ISSN: 1546-1696 | A quantitative analysis of kinase inhibitor selectivity. |
| AID493040 | Navigating the Kinome | 2011 | Nature chemical biology, Apr, Volume: 7, Issue:4
ISSN: 1552-4469 | Navigating the kinome. |
| AID1347160 | Primary screen NINDS Rhodamine qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347159 | Primary screen GU Rhodamine qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1508612 | NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling | 2017 | Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3
ISSN: 1464-3391 | Highly predictive and interpretable models for PAMPA permeability. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
ISSN: 1083-351X | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
ISSN: 1083-351X | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X | |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1508591 | NCATS Rat Liver Microsome Stability Profiling | 2020 | Scientific reports, 11-26, Volume: 10, Issue:1
ISSN: 2045-2322 | Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models. |
| AID1645848 | NCATS Kinetic Aqueous Solubility Profiling | 2019 | Bioorganic & medicinal chemistry, 07-15, Volume: 27, Issue:14
ISSN: 1464-3391 | Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity. |
| AID1645871 | NCATS Parallel Artificial Membrane Permeability Assay (PAMPA) Profiling in pH 5 buffer | 2022 | Bioorganic & medicinal chemistry, 02-15, Volume: 56ISSN: 1464-3391 | Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID504749 | qHTS profiling for inhibitors of Plasmodium falciparum proliferation | 2011 | Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
ISSN: 1095-9203 | Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets. |
| AID1795660 | VEGF-R Kinase Inhibition Assay from Article 10.1021/jm011022e: \\Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.\\ | 2002 | Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
ISSN: 0022-2623 | Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. |
| AID1796330 | Homogeneous Time-resolved Fluorescence (HTRF) Assay from Article 10.1016/j.bmcl.2005.10.058: \\N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II.\\ | 2006 | Bioorganic & medicinal chemistry letters, Feb, Volume: 16, Issue:3
ISSN: 0960-894X | N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II. |
Research
Studies (614)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 164 (26.71) | 29.6817 |
| 2010's | 387 (63.03) | 24.3611 |
| 2020's | 63 (10.26) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 88 (14.13%) | 5.53% |
| Reviews | 131 (21.03%) | 6.00% |
| Case Studies | 43 (6.90%) | 4.05% |
| Observational | 2 (0.32%) | 0.25% |
| Other | 359 (57.62%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| quinacrine | | acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound | antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vanilmandelic acid | | 2-hydroxy monocarboxylic acid;
aromatic ether;
phenols | human metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(2,4-dichlorophenoxy)butyric acid | | aromatic ether;
monocarboxylic acid;
organochlorine compound | agrochemical;
phenoxy herbicide;
synthetic auxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| win 52035 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| win 52084 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(nonyloxy)tryptamine | | aromatic ether;
primary amino compound;
tryptamines | serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methylbufotenin | | aromatic ether;
tertiary amino compound;
tryptamine alkaloid | hallucinogen;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-methoxytryptamine | | aromatic ether;
primary amino compound;
tryptamines | 5-hydroxytryptamine 2A receptor agonist;
5-hydroxytryptamine 2B receptor agonist;
5-hydroxytryptamine 2C receptor agonist;
antioxidant;
cardioprotective agent;
human metabolite;
mouse metabolite;
neuroprotective agent;
radiation protective agent;
serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ro 48-8071 | | aromatic ether;
aromatic ketone;
bromobenzenes;
monofluorobenzenes;
olefinic compound;
tertiary amino compound | antineoplastic agent;
EC 5.4.99.7 (lanosterol synthase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rtki cpd | | aromatic ether;
monochlorobenzenes;
quinazolines | antineoplastic agent;
antiviral agent;
epidermal growth factor receptor antagonist;
geroprotector | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amsacrine | | acridines;
aromatic ether;
sulfonamide | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aristolochic acid i | | aristolochic acids;
aromatic ether;
C-nitro compound;
cyclic acetal;
monocarboxylic acid;
organic heterotetracyclic compound | carcinogenic agent;
metabolite;
mutagen;
nephrotoxin;
toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,4-dihydroxy-7-methoxy-1,4-benzoxazin-3-one | | aromatic ether;
benzoxazine;
cyclic hydroxamic acid;
lactol | allelochemical;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bufetolol | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bufexamac | | aromatic ether;
hydroxamic acid | antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bunitrolol | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bupranolol | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| verapamil | | aromatic ether;
nitrile;
polyether;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cgp 12177 | | aromatic ether;
benzimidazoles;
secondary alcohol;
secondary amino compound | beta-adrenergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ciglitazone | | aromatic ether;
thiazolidinone | antineoplastic agent;
insulin-sensitizing drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cirazoline | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clofibrate | | aromatic ether;
ethyl ester;
monochlorobenzenes | anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clofibric acid | | aromatic ether;
monocarboxylic acid;
monochlorobenzenes | anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| colchicine, (+-)-isomer | | acetamides;
alkaloid;
aromatic ether;
carbotricyclic compound | microtubule-destabilising agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| croconazole | | aromatic ether;
conazole antifungal drug;
imidazole antifungal drug;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cypermethrin | | aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organochlorine compound | agrochemical;
molluscicide;
pyrethroid ester acaricide;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| racemethorphan | | aromatic ether;
morphinane alkaloid;
morphinane-like compound;
organic heterotetracyclic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dibucaine | | aromatic ether;
monocarboxylic acid amide;
tertiary amino compound | topical anaesthetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dilacor xr | | acetate ester;
aromatic ether;
benzothiazepine;
lactam;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| domiphen | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| donepezil | | aromatic ether;
indanones;
piperidines;
racemate | EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| epirizole | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethacrynic acid | | aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid | EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethoxyquin | | aromatic ether;
quinolines | antifungal agrochemical;
food antioxidant;
genotoxin;
geroprotector;
herbicide;
Hsp90 inhibitor;
neuroprotective agent;
UDP-glucuronosyltransferase activator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethoxzolamide | | aromatic ether;
benzothiazoles;
sulfonamide | antiglaucoma drug;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-hexyloxybenzamide | | aromatic ether;
benzamides | antifungal agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carbonyl cyanide p-trifluoromethoxyphenylhydrazone | | aromatic ether;
hydrazone;
nitrile;
organofluorine compound | ATP synthase inhibitor;
geroprotector;
ionophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenofibrate | | aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes | antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenvalerate | | aromatic ether;
carboxylic ester;
monochlorobenzenes | pyrethroid ester acaricide;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flecainide | | aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines | anti-arrhythmia drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluoxetine | | (trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gallamine triethiodide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gemfibrozil | | aromatic ether | antilipemic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| haloprogin | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| indomethacin | | aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole | analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ipriflavone | | aromatic ether;
isoflavones | bone density conservation agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ly 171883 | | acetophenones;
aromatic ether;
phenols;
tetrazoles | anti-asthmatic drug;
leukotriene antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mephenesin | | aromatic ether;
glycerol ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methocarbamol | | aromatic ether;
carbamate ester;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methoctramine | | aromatic ether;
tetramine | muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methoxsalen | | aromatic ether;
psoralens | antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| metoprolol | | aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound | antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mexiletine | | aromatic ether;
primary amino compound | anti-arrhythmia drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| midodrine | | amino acid amide;
aromatic ether;
secondary alcohol | alpha-adrenergic agonist;
prodrug;
sympathomimetic agent;
vasoconstrictor agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clorgyline | | aromatic ether;
dichlorobenzene;
terminal acetylenic compound;
tertiary amino compound | antidepressant;
EC 1.4.3.4 (monoamine oxidase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nefazodone | | aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles | alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nimesulide | | aromatic ether;
C-nitro compound;
sulfonamide | cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nisoxetine | | aromatic ether;
secondary amino compound | adrenergic uptake inhibitor;
antidepressant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide | | aromatic ether;
C-nitro compound;
sulfonamide | antineoplastic agent;
cyclooxygenase 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| omeprazole | | aromatic ether;
benzimidazoles;
pyridines;
sulfoxide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxprenolol | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pantoprazole | | aromatic ether;
benzimidazoles;
organofluorine compound;
pyridines;
sulfoxide | anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pd 153035 | | aromatic amine;
aromatic ether;
bromobenzenes;
quinazolines;
secondary amino compound | EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pentamidine | | aromatic ether;
carboxamidine;
diether | anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phenacetin | | acetamides;
aromatic ether | cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pioglitazone | | aromatic ether;
pyridines;
thiazolidinediones | antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| piretanide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pramoxine | | aromatic ether;
morpholines | local anaesthetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prazosin | | aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| primaquine | | aminoquinoline;
aromatic ether;
N-substituted diamine | antimalarial | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| proglumetacin | | aromatic ether;
benzamides;
carboxylic ester;
monochlorobenzenes;
N-acylindole;
N-alkylpiperazine | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
lipoxygenase inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| propoxur | | aromatic ether;
carbamate ester | acaricide;
agrochemical;
carbamate insecticide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pyrilamine | | aromatic ether;
ethylenediamine derivative | H1-receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulfadimethoxine | | aromatic ether;
pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
antimicrobial agent;
drug allergen;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tetrahydropapaverine | | aromatic ether;
benzylisoquinoline alkaloid;
benzyltetrahydroisoquinoline;
polyether;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tilorone | | aromatic ether;
diether;
fluoren-9-ones;
tertiary amino compound | anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
interferon inducer;
nicotinic acetylcholine receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ultram | | aromatic ether;
tertiary alcohol;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triclosan | | aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols | antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| viloxazine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| wb 4101 | | aromatic ether;
benzodioxine;
secondary amino compound | alpha-adrenergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,3',5-triiodothyropropionic acid | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methacetin | | acetamides;
aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mestranol | | 17beta-hydroxy steroid;
aromatic ether;
terminal acetylenic compound | prodrug;
xenoestrogen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| visnagin | | aromatic ether;
furanochromone;
polyketide | anti-inflammatory agent;
antihypertensive agent;
EC 1.1.1.37 (malate dehydrogenase) inhibitor;
phytotoxin;
plant metabolite;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-tert-butyl-4-hydroxyanisole | | aromatic ether;
phenols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mecoprop | | aromatic ether;
monocarboxylic acid;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phenetidine | | aromatic ether;
substituted aniline | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-methyl-4-chlorophenoxy gamma-butyric acid | | aromatic ether;
monocarboxylic acid;
monochlorobenzenes | environmental contaminant;
phenoxy herbicide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-bromophenyl phenyl ether | | aromatic ether;
organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| di-(4-aminophenyl)ether | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phenyl ether | | aromatic ether | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diglycidyl resorcinol ether | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phenetole | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| scoparone | | aromatic ether;
coumarins | anti-allergic agent;
anti-inflammatory agent;
antihypertensive agent;
antilipemic drug;
immunosuppressive agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dimethoxyphenylethylamine | | alkaloid;
aromatic ether;
phenylethylamine | allergen;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dichlorprop | | aromatic ether;
dichlorobenzene;
monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-tert-butyl-4-hydroxyanisole | | aromatic ether;
phenols | antioxidant;
human xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethyl vanillin | | aromatic ether;
benzaldehydes;
phenols | antioxidant;
flavouring agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzethonium chloride | | aromatic ether;
chloride salt;
quaternary ammonium salt | antibacterial agent;
antifungal agent;
antiseptic drug;
antiviral agent;
disinfectant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| peucedanin | | aromatic ether;
furanocoumarin;
lactone | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phenetidine | | aromatic ether;
primary amino compound;
substituted aniline | drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-methoxybenzoxazolinone | | aromatic ether;
benzoxazole | antibacterial agent;
anticonvulsant;
antifungal agent;
muscle relaxant;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-anisidine | | aromatic ether;
substituted aniline | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| domiphen bromide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dibrompropamidine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-Ethoxyphenol | | aromatic ether;
phenols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bulbocapnine | | aporphine alkaloid;
aromatic ether;
oxacycle;
phenols | EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor;
EC 1.4.3.22 (diamine oxidase) inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzydamine | | aromatic ether;
indazoles;
tertiary amino compound | analgesic;
central nervous system stimulant;
hallucinogen;
local anaesthetic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| xylocholine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-methoxycatechol | | aromatic ether;
catechols | G-protein-coupled receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-phenoxypropanoic acid | | aromatic ether;
carboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-methoxyquinoline | | aromatic ether;
quinolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| metaxalone | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| heliamine | | aromatic ether;
diether;
isoquinoline alkaloid;
isoquinolines | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,4,6-trichlorophenyl 4-nitrophenyl ether | | aromatic ether;
C-nitro compound;
chlorobenzenes | EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| etridiazol | | aromatic ether;
organochlorine compound;
thiadiazole antifungal agent;
thiadiazoles | antifungal agrochemical;
nitrification inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| toliprolol | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-methoxyindoleacetic acid | | aromatic ether;
indole-3-acetic acids | antibacterial agent;
Brassica napus metabolite;
carcinogenic agent;
human urinary metabolite;
marine xenobiotic metabolite;
rat metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| iproclozide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phenoxyacetic acid | | aromatic ether;
monocarboxylic acid | allergen;
Aspergillus metabolite;
human xenobiotic metabolite;
plant growth retardant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nafenopin | | aromatic ether;
monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methyl vanillate | | aromatic ether;
benzoate ester;
phenols | antioxidant;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-methoxyindole-2-carboxylic acid | | aromatic ether;
indolecarboxylic acid | EC 1.8.1.4 (dihydrolipoyl dehydrogenase) inhibitor;
hypoglycemic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-isopropoxyphenol | | aromatic ether;
phenols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dehydroemetine | | aromatic ether;
isoquinolines;
pyridoisoquinoline | antileishmanial agent;
antimalarial;
antiprotozoal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,2-epoxy-3-(p-nitrophenoxy)propane | | aromatic ether;
C-nitro compound;
epoxide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| laurolitsine | | aporphine alkaloid;
aromatic ether;
phenols | HIV-1 integrase inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| metocurine iodide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ac 45594 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-phenoxybenzylalcohol | | aromatic ether;
benzyl alcohols | marine xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| devrinol | | aromatic ether;
monocarboxylic acid amide;
naphthalenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluorodifen | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| acridine half-mustard | | aminoacridines;
aromatic ether;
organochlorine compound;
secondary amino compound | mutagen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| precocene i | | aromatic ether;
chromenes | plant metabolite;
precocenes | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxadiazon | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lofexidine | | aromatic ether;
carboxamidine;
dichlorobenzene;
imidazoles | alpha-adrenergic agonist;
antihypertensive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alclofenac | | aromatic ether;
monocarboxylic acid;
monochlorobenzenes | drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phenylglycidyl ether | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phenoxyethanol | | aromatic ether;
glycol ether;
primary alcohol | antiinfective agent;
central nervous system depressant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| metipranolol | | acetate ester;
aromatic ether;
propanolamine;
secondary amino compound | anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| silybin | | aromatic ether;
benzodioxine;
flavonolignan;
polyphenol;
secondary alpha-hydroxy ketone | antineoplastic agent;
antioxidant;
hepatoprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxamethacin | | aromatic ether;
hydroxamic acid;
N-acylindole;
organochlorine compound | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| canadine | | aromatic ether;
berberine alkaloid;
organic heteropentacyclic compound;
oxacycle | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-ethoxycoumarin | | aromatic ether;
coumarins | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| medifoxamine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlormethoxynil | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| climbazole | | aromatic ether;
hemiaminal ether;
imidazoles;
ketone;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-hexyloxyaniline | | aromatic ether;
substituted aniline | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ticrynafen | | aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid;
thiophenes | antihypertensive agent;
hepatotoxic agent;
loop diuretic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-(2,4-dichlorophenoxy)phenoxy)propionic acid | | aromatic ether;
dichlorobenzene;
diether;
monocarboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bezafibrate | | aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes | antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxyfluorofen | | aromatic ether | EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triadimefon | | aromatic ether;
hemiaminal ether;
ketone;
monochlorobenzenes;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| levobunolol | | aromatic ether;
cyclic ketone;
propanolamine | antiglaucoma drug;
beta-adrenergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dichlorfop-methyl | | aromatic ether;
dichlorobenzene;
diether;
methyl ester | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| decamethrin | | aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organobromine compound | agrochemical;
antifeedant;
calcium channel agonist;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triadimenol | | aromatic ether;
conazole fungicide;
hemiaminal ether;
monochlorobenzenes;
secondary alcohol;
triazole fungicide | antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triclopyr | | aromatic ether;
chloropyridine;
monocarboxylic acid | agrochemical;
environmental contaminant;
herbicide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prenalterol | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| st 1059 | | aromatic ether;
primary amino compound;
secondary alcohol | alpha-adrenergic agonist;
sympathomimetic agent;
vasoconstrictor agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| paroxetine | | aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines | antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| acifluorfen | | aromatic ether;
benzoic acids;
C-nitro compound;
monocarboxylic acid;
organochlorine compound;
organofluorine compound | agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bopindolol | | aromatic ether;
benzoate ester;
methylindole;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenpropathrin, (+-)-isomer | | aromatic ether;
cyclopropanecarboxylate ester | agrochemical;
pyrethroid ester acaricide;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triflumuron | | aromatic ether;
benzoylurea insecticide;
monochlorobenzenes;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flutolanil | | (trifluoromethyl)benzenes;
aromatic ether;
benzamides;
benzanilide fungicide | antifungal agrochemical;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenoxaprop ethyl | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triclabendazole | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4,5-amino-3,5-dichloro-6-fluoro-2-pyridinyloxyacetic acid | | aminopyridine;
aromatic ether;
monocarboxylic acid;
organochlorine compound;
organofluorine compound | environmental contaminant;
herbicide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluvalinate | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
nitrile;
organochlorine acaricide;
organochlorine insecticide;
organofluorine acaricide;
organofluorine insecticide | agrochemical;
pyrethroid ester acaricide;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| haloxyfop | | aromatic ether;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluazifop-butyl | | aromatic ether;
carboxylic ester;
organofluorine compound;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fomesafen | | aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-sulfonylcarboxamide;
organofluorine compound;
phenols | agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenoxycarb | | aromatic ether;
carbamate ester | environmental contaminant;
insecticide;
juvenile hormone mimic;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| quizalofop-ethyl | | aromatic ether;
ethyl ester;
organochlorine compound;
quinoxaline derivative | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cetamolol | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| atomoxetine | | aromatic ether;
secondary amino compound;
toluenes | adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methyl bensulfuron | | aromatic ether;
methyl ester;
N-sulfonylurea;
pyrimidines | agrochemical;
EC 2.2.1.6 (acetolactate synthase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| itraconazole | | aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles | EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| loxtidine | | aromatic ether;
piperidines;
primary alcohol;
triazoles | H2-receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| disoxaril | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorimuron ethyl | | aromatic ether;
ethyl ester;
N-sulfonylurea;
organochlorine pesticide;
pyrimidines;
sulfamoylbenzoate | agrochemical;
EC 2.2.1.6 (acetolactate synthase) inhibitor;
proherbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tepoxalin | | aromatic ether;
hydroxamic acid;
monochlorobenzenes;
pyrazoles | antipyretic;
apoptosis inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
immunomodulator;
lipoxygenase inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| esmolol | | aromatic ether;
ethanolamines;
methyl ester;
secondary alcohol;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pioglitazone hydrochloride | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aripiprazole | | aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone | drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulfametrole | | aromatic ether;
substituted aniline;
sulfonamide antibiotic;
thiadiazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| propamidine | | aromatic ether;
guanidines;
polyether | antimicrobial agent;
antiseptic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hexamidine | | aromatic ether;
guanidines;
polyether | antimicrobial agent;
antiseptic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| o-4-methylthymine | | aromatic ether;
methylthymine | human metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenclofenac | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tetraiodothyroacetic acid | | 2-halophenol;
aromatic ether;
iodophenol;
monocarboxylic acid | apoptosis inducer;
human metabolite;
thyroid hormone | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluazuron | | aromatic ether;
chloropyridine;
monochlorobenzenes;
N-acylurea;
organochlorine acaricide;
organofluorine acaricide;
phenylureas | acaricide;
mite growth regulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| etiroxate | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| etofamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| d 888 | | aromatic ether;
nitrile;
tertiary amino compound | anti-arrhythmia drug;
calcium channel blocker;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| esreboxetine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| guaethol | | aromatic ether;
phenols;
volatile organic compound | flavouring agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| spiramide | | aromatic ether;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound | dopaminergic antagonist;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5'-nitro-2'-propoxyacetanilide | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| suberosin | | aromatic ether;
coumarins | anticoagulant;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-methoxyestradiol | | 17beta-hydroxy steroid;
3-hydroxy steroid;
aromatic ether;
phenols | estrogen;
human metabolite;
rat metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| toltrazuril | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| plafibride | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cinitapride | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| isoscopoletin | | aromatic ether;
hydroxycoumarin | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethofenprox | | aromatic ether | pyrethroid ether insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| uk 68798 | | aromatic ether;
sulfonamide;
tertiary amino compound | anti-arrhythmia drug;
potassium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hp 873 | | 1,2-benzoxazoles;
aromatic ether;
aromatic ketone;
methyl ketone;
monoamine;
organofluorine compound;
piperidines;
tertiary amino compound | dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenoxypropazine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluphenacur | | aromatic ether;
benzoylurea insecticide;
dichlorobenzene;
N-acylurea;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amezinium | | aromatic ether;
primary arylamine;
pyridazinium ion | adrenergic uptake inhibitor;
antihypotensive agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
sympathomimetic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rubrofusarin | | aromatic ether;
benzochromenone;
phenols;
polyketide | biological pigment;
EC 1.14.18.1 (tyrosinase) inhibitor;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triasulfuron | | 1,3,5-triazines;
aromatic ether;
N-sulfonylurea;
organochlorine compound | agrochemical;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dauricine | | aromatic ether;
bisbenzylisoquinoline alkaloid;
isoquinolines;
phenols;
tertiary amino compound | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| uvaretin | | aromatic ether;
dihydrochalcones;
polyketide;
resorcinol | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fangchinoline | | aromatic ether;
bisbenzylisoquinoline alkaloid;
macrocycle | anti-HIV-1 agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prochloraz | | amide fungicide;
aromatic ether;
conazole fungicide;
imidazole fungicide;
imidazoles;
trichlorobenzene;
ureas | antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| stictic acid | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pramoxine hydrochloride | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-methoxybenzylamine | | aralkylamino compound;
aromatic ether;
primary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| xanthurenic acid 8-methyl ether | | aromatic ether;
monohydroxyquinoline;
quinolinemonocarboxylic acid | carcinogenic agent;
metabolite;
mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| adriamycinol | | aminoglycoside;
anthracycline antibiotic;
aromatic ether;
deoxy hexoside;
p-quinones;
phenols;
polyol;
tetracenequinones | cardiotoxic agent;
drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| difenoconazole | | aromatic ether;
conazole fungicide;
cyclic ketal;
dioxolane;
triazole fungicide;
triazoles | antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| a 8947 | | aromatic ether;
biaryl;
N-sulfonylurea;
pyrazole pesticide;
tetrazoles | EC 2.2.1.6 (acetolactate synthase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thifluzamide | | 1,3-thiazoles;
anilide fungicide;
aromatic amide;
aromatic ether;
dibromobenzene;
organofluorine compound | antifungal agrochemical;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethylhydrocupreine | | aromatic ether;
cinchona alkaloid | EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7,8-dihydromethysticin | | 2-pyranones;
aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4,5-dimethoxy-2-nitrobenzaldehyde | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bisphenol f diglycidyl ether | | aromatic ether;
diarylmethane;
epoxide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oryzemate | | 1,2-benzisothiazole;
aromatic ether;
benzothiazole fungicide;
sulfone | antifungal agrochemical;
plant activator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bitertanol | | aromatic ether;
biphenyls;
secondary alcohol;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluazifop | | aromatic ether;
monocarboxylic acid;
organofluorine compound;
pyridines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diflufenican | | (trifluoromethyl)benzenes;
aromatic ether;
pyridinecarboxamide | carotenoid biosynthesis inhibitor;
environmental contaminant;
herbicide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hexafluoron | | aromatic ether;
benzoylurea insecticide;
dichlorobenzene;
N-acylurea;
organochlorine insecticide;
organofluorine insecticide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diethofencarb | | aromatic ether;
carbamate ester;
carbanilate fungicide | antifungal agrochemical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pyriproxyfen | | aromatic ether;
pyridines | juvenile hormone mimic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methyl 2-(((((4-ethoxy-6-(methylamino)-1,3,5-triazin-2-yl)amino)carbonyl)amino)sulfonyl)benzoate | | aromatic ether;
benzoate ester;
diamino-1,3,5-triazine;
methyl ester;
N-sulfonylurea | EC 2.2.1.6 (acetolactate synthase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dpx e9636 | | aromatic ether;
N-sulfonylurea;
pyridines;
pyrimidines;
sulfone | environmental contaminant;
herbicide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aclonifen | | aromatic ether;
C-nitro compound;
monochlorobenzenes;
primary amino compound;
substituted aniline | agrochemical;
carotenoid biosynthesis inhibitor;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cinosulfuron | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clodinafop-propargyl | | aromatic ether;
carboxylic ester;
organochlorine compound;
organofluorine compound;
propyzamide;
pyridines | agrochemical;
EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triflusulfuron-methyl | | 1,3,5-triazines;
aromatic ether;
benzoate ester;
methyl ester;
N-sulfonylurea;
organofluorine compound;
tertiary amino compound | agrochemical;
EC 2.2.1.6 (acetolactate synthase) inhibitor;
proherbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vestitol | | aromatic ether;
hydroxyisoflavans;
methoxyisoflavan | anti-inflammatory agent;
phytoalexin;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| laudanine | | aromatic ether;
benzylisoquinoline alkaloid;
benzyltetrahydroisoquinoline;
phenols;
racemate | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cryptopleurine | | alkaloid antibiotic;
alkaloid;
aromatic ether;
organic heteropentacyclic compound | antineoplastic agent;
antiviral agent;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-hydroxymethylmexiletine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-hydroxymexiletine | | aromatic ether;
phenols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cloquintocet-mexyl | | aromatic ether;
carboxylic ester;
organochlorine compound;
quinolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| novaluron | | aromatic ether;
benzoylurea insecticide;
monochlorobenzenes;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bursehernin | | aromatic ether;
benzodioxoles;
butan-4-olide;
lignan | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,2',4,4'-tetrabromodiphenyl ether | | aromatic ether;
organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| allocryptopine | | aromatic ether;
cyclic acetal;
cyclic ketone;
dibenzazecine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sporidesmin | | aromatic ether;
cyclic ketone;
diketone;
organic disulfide;
organic heteropentacyclic compound;
organochlorine compound;
secondary alcohol;
tertiary alcohol;
tertiary amino compound | mycotoxin;
Wnt signalling activator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| syringaresinol | | aromatic ether;
furofuran;
lignan;
polyether;
polyphenol | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| p-methoxy-n-methylphenethylamine | | aromatic ether;
secondary amino compound | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aflatoxin q1 | | aflatoxin;
aromatic ether;
aromatic ketone | carcinogenic agent;
human xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| u 73122 | | aromatic ether;
aza-steroid;
maleimides | EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyfluthrin | | aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organochlorine compound;
organofluorine compound | agrochemical;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| norverapamil | | aromatic ether;
nitrile;
polyether;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fumitremorgin a | | aromatic ether;
diol;
indole alkaloid;
organic heterohexacyclic compound;
organic peroxide | mycotoxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| deguelin | | aromatic ether;
diether;
organic heteropentacyclic compound;
rotenones | angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
mitochondrial NADH:ubiquinone reductase inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aristolochic acid ii | | aristolochic acids;
aromatic ether;
C-nitro compound;
cyclic acetal;
monocarboxylic acid;
organic heterotetracyclic compound | carcinogenic agent;
metabolite;
mutagen;
nephrotoxin;
toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tephrosin | | aromatic ether;
cyclic ketone;
organic heteropentacyclic compound;
rotenones | antineoplastic agent;
metabolite;
pesticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alpha-hydroxymetoprolol | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(tetradecyloxy)-2-furancarboxylic acid | | aromatic ether;
furoic acid | antineoplastic agent;
apoptosis inducer;
EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor;
PPARalpha agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tafenoquine | | (trifluoromethyl)benzenes;
aminoquinoline;
aromatic ether;
primary amino compound;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-hydroxymethylomeprazole | | aromatic ether;
benzimidazoles;
pyridines;
sulfoxide | drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mosapride | | aromatic ether;
benzamides;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
secondary carboxamide;
substituted aniline;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ym 12617 | | aromatic ether;
secondary amino compound;
sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gefitinib | | aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cgp 28392 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sodium-binding benzofuran isophthalate | | 1-benzofurans;
aromatic ether;
crown compound;
tetracarboxylic acid | fluorochrome | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| garenoxacin | | aromatic ether;
cyclopropanes;
isoindoles;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic | antibacterial drug;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ay 25545 | | acetate ester;
aromatic ether;
C-glycosyl compound;
naphthoisochromene;
olefinic compound;
phenols;
tertiary amine | antimicrobial agent;
antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| reboxetine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| b 823-08 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyclazosin | | aromatic amide;
aromatic ether;
furans;
monocarboxylic acid amide;
quinazolines;
quinoxaline derivative | adenosine A2A receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ivabradine | | aromatic ether;
benzazepine;
carbobicyclic compound;
tertiary amino compound | cardiotonic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| febuxostat | | 1,3-thiazolemonocarboxylic acid;
aromatic ether;
nitrile | EC 1.17.3.2 (xanthine oxidase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| marsupsin | | 1-benzofurans;
aromatic ether;
polyphenol | antilipemic drug;
hypoglycemic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6,6'-bieckol | | aromatic ether;
oxacycle;
phlorotannin | anti-HIV-1 agent;
metabolite;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| xibenolol | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cicloprolol | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chs 828 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-methoxyphenoxy)propanoic acid | | aromatic ether;
carboxylic acid | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| moxifloxacin | | aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antibacterial drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rp 73401 | | aromatic ether;
benzamides;
chloropyridine;
monocarboxylic acid amide | anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
phosphodiesterase IV inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,2',4,4',5,5'-hexabrominated diphenyl ether | | aromatic ether;
organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| varespladib | | aromatic ether;
benzenes;
dicarboxylic acid monoamide;
indoles;
monocarboxylic acid;
primary carboxamide | anti-inflammatory drug;
antidote;
EC 3.1.1.4 (phospholipase A2) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| birb 796 | | aromatic ether;
morpholines;
naphthalenes;
pyrazoles;
ureas | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
immunomodulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| schizandrin b | | aromatic ether;
cyclic acetal;
organic heterotetracyclic compound;
oxacycle;
tannin | anti-asthmatic agent;
anti-inflammatory agent;
antilipemic drug;
antioxidant;
apoptosis inhibitor;
hepatoprotective agent;
nephroprotective agent;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| s 23121 | | aromatic ether;
dicarboximide;
monochlorobenzenes;
monofluorobenzenes;
pyrroline;
terminal acetylenic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| acrovestone | | acetophenones;
aromatic ether;
olefinic compound;
polyphenol | antioxidant;
EC 1.14.18.1 (tyrosinase) inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| corytuberine | | aporphine alkaloid;
aromatic ether;
organic heterotetracyclic compound;
polyphenol;
tertiary amino compound | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| actinodaphine | | aporphine alkaloid;
aromatic ether;
organic heteropentacyclic compound;
phenols;
secondary amino compound | antibacterial agent;
antifungal agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite;
platelet aggregation inhibitor;
topoisomerase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| isohomovanillic acid | | aromatic ether;
phenols;
phenylacetic acids | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,5-diiodothyropropionic acid | | aromatic ether;
monocarboxylic acid;
organoiodine compound;
phenols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7,8-dihydro-5,6-dehydrokawain | | 2-pyranones;
aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-amino-2-methoxypyrimidine | | aminopyrimidine;
aromatic ether;
methylcytosine | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aristolochic acid D | | aristolochic acids;
aromatic ether;
C-nitro compound;
cyclic acetal;
monocarboxylic acid;
organic heterotetracyclic compound | carcinogenic agent;
metabolite;
nephrotoxin;
toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| myricanone | | aromatic ether;
cyclic ketone;
diarylheptanoid;
methoxybenzenes;
phenols | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pannarin | | aldehyde;
aromatic ether;
depsidones;
organic heterotricyclic compound;
organochlorine compound;
phenols | antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
lichen metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aminopotentidine | | aromatic ether;
benzamides;
guanidines;
nitrile;
piperidines;
substituted aniline | H2-receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aristolochic acid c | | aristolochic acids;
aromatic ether;
C-nitro compound;
cyclic acetal;
monocarboxylic acid;
organic heterotetracyclic compound | carcinogenic agent;
metabolite;
mutagen;
nephrotoxin;
toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pluviatolide | | aromatic ether;
benzodioxoles;
butan-4-olide;
lignan;
phenols | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| erysodine | | aromatic ether;
diether;
Erythrina alkaloid;
organic heterotetracyclic compound;
phenols | antiparasitic agent;
nicotinic antagonist;
phytogenic insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| erlotinib | | aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound | antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rubrofusarin B | | aromatic ether;
benzochromenone;
naphtho-gamma-pyrone;
phenols;
polyketide | Aspergillus metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ly 293111 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| enrasentan | | aromatic ether;
benzodioxoles;
indanes;
monocarboxylic acid;
monomethoxybenzene;
primary alcohol | antihypertensive agent;
endothelin receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| quizalofop | | aromatic ether;
monocarboxylic acid;
organochlorine compound;
quinoxaline derivative | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyhalofop-butyl | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyperin | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aflatoxin b1 | | aflatoxin;
aromatic ether;
aromatic ketone | carcinogenic agent;
human metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| etravirine | | aminopyrimidine;
aromatic ether;
dinitrile;
organobromine compound | antiviral agent;
HIV-1 reverse transcriptase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-o-methyllicoricidin | | aromatic ether;
hydroxyisoflavans;
methoxyisoflavan | antibacterial agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pronuciferine | | aromatic ether;
cyclic ketone;
isoquinoline alkaloid;
isoquinolines;
organic heterotetracyclic compound | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dronedarone | | 1-benzofurans;
aromatic ether;
aromatic ketone;
sulfonamide;
tertiary amino compound | anti-arrhythmia drug;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| famoxadone | | aromatic ether;
carbohydrazide;
oxazolidinone | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cimicoxib | | aromatic ether;
imidazoles;
organochlorine compound;
organofluorine compound;
sulfonamide | cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sorafenib | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide | angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dabuzalgron | | aromatic ether;
imidazoles;
monochlorobenzenes;
sulfonamide | alpha-adrenergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fonsecin | | aromatic ether;
cyclic hemiketal;
heptaketide;
naphtho-gamma-pyrone;
phenols | Aspergillus metabolite;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lasofoxifene | | aromatic ether;
N-alkylpyrrolidine;
naphthols;
tetralins | antineoplastic agent;
bone density conservation agent;
cardioprotective agent;
estrogen receptor agonist;
estrogen receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (+-)-Dihydromethysticin | | 2-pyranones;
aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[2-[2-(2-aminophenoxy)ethoxy]ethoxy]aniline | | aromatic ether;
substituted aniline | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chondocurine (1beta)-(+-)-isomer | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-methyl-4-prop-2-enoxy-2-pyrimidinone | | aromatic ether;
pyrimidone | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| noscapine | | aromatic ether;
benzylisoquinoline alkaloid;
cyclic acetal;
isobenzofuranone;
organic heterobicyclic compound;
organic heterotricyclic compound;
tertiary amino compound | antineoplastic agent;
antitussive;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[4-(3-methyl-4-nitrophenoxy)butoxy]benzonitrile | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lariciresinol | | aromatic ether;
lignan;
oxolanes;
phenols;
primary alcohol | antifungal agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tryptoquivaline | | aromatic ether;
indole alkaloid;
organic heteropentacyclic compound | breast cancer resistance protein inhibitor;
mycotoxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-methoxyestrone | | 17-oxo steroid;
3-hydroxy steroid;
alicyclic ketone;
aromatic ether;
phenolic steroid;
phenols | human metabolite;
mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| win 54954 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| silychristin | | 1-benzofurans;
aromatic ether;
flavonolignan;
polyphenol;
secondary alpha-hydroxy ketone | lipoxygenase inhibitor;
metabolite;
prostaglandin antagonist;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cleomiscosin a | | aromatic ether;
delta-lactone;
organic heterotricyclic compound;
phenols;
primary alcohol | anti-inflammatory agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bispyribac | | aromatic ether;
benzoic acids;
monocarboxylic acid;
pyrimidines | herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| petunidin-3-glucoside | | anthocyanin cation;
aromatic ether;
beta-D-glucoside | antioxidant;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| malvidin-3-glucoside | | anthocyanin cation;
aromatic ether;
beta-D-glucoside | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dioncophylline c | | aromatic ether;
biaryl;
isoquinoline alkaloid;
isoquinolines;
methoxynaphthalene;
methylnaphthalenes;
naphthols | antimalarial;
antiplasmodial drug;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| stigmatellin | | aromatic ether;
chromones;
olefinic compound;
phenols | bacterial metabolite;
quinol oxidation site inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| roflumilast | | aromatic ether;
benzamides;
chloropyridine;
cyclopropanes;
organofluorine compound | anti-asthmatic drug;
phosphodiesterase IV inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| teniposide | | aromatic ether;
beta-D-glucoside;
cyclic acetal;
furonaphthodioxole;
gamma-lactone;
monosaccharide derivative;
phenols;
thiophenes | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prinomastat | | aromatic ether;
hydroxamic acid;
pyridines;
sulfonamide;
thiomorpholines | antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor;
matrix metalloproteinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| posaconazole | | aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles | trypanocidal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gancaonin I | | 1-benzofurans;
aromatic ether;
resorcinols | antibacterial agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glycyrin | | aromatic ether;
coumarins;
hydroxyisoflavans | antibacterial agent;
metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glyasperin D | | aromatic ether;
hydroxyisoflavans;
methoxyisoflavan | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| licoricidin | | aromatic ether;
hydroxyisoflavans;
methoxyisoflavan | antibacterial agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| egonol | | 1-benzofurans;
aromatic ether;
benzodioxoles;
primary alcohol | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-ethylharmine | | aromatic ether;
beta-carbolines;
semisynthetic derivative | anti-HIV agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pf 1163a | | aromatic ether;
lactam;
macrolide antibiotic;
secondary alcohol | antifungal agent;
Penicillium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pf 1163b | | aromatic ether;
lactam;
macrolide antibiotic | antifungal agent;
Penicillium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| licocoumarone | | 1-benzofurans;
aromatic ether;
resorcinols | antibacterial agent;
apoptosis inducer;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(4-chloro-2-methylphenoxy)-n-hydroxybutanamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-22807 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[2-(3-methylphenoxy)ethyl]-1H-1,2,4-triazole-5-carboxamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| piperlactam s | | alkaloid;
aromatic ether;
gamma-lactam;
organic heterotetracyclic compound;
phenols | anti-inflammatory agent;
antioxidant;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5,5-dioxo-1-(4-phenoxyphenyl)-3a,4,6,6a-tetrahydro-3H-thieno[3,4-b]pyrrol-2-one | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| antofine | | alkaloid antibiotic;
alkaloid;
aromatic ether;
organic heteropentacyclic compound | angiogenesis inhibitor;
anti-inflammatory agent;
antimicrobial agent;
antineoplastic agent;
antiviral agent;
phytotoxin;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| xanthohumol | | aromatic ether;
chalcones;
polyphenol | anti-HIV-1 agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.3.1.20 (diacylglycerol O-acyltransferase) inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-phenoxy-N-(2-pyridinyl)butanamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-amino-4-(2-ethoxyphenyl)-3-propyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile | | aromatic ether;
pyranopyrazole | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[4-[4-[[1-oxo-2-(1-pyrrolidinyl)ethyl]amino]phenoxy]phenyl]-2-(1-pyrrolidinyl)acetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(3,4-diethoxyphenyl)-5-(2-furanyl)-1,3,4-oxadiazole | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[5-(phenoxymethyl)-4-(2-phenylethyl)-1,2,4-triazol-3-yl]thio]acetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(8-methyl-2,5,11,14-tetraoxa-8-azabicyclo[13.4.0]nonadeca-1(15),16,18-trien-17-yl)ethanol | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[2-(3-phenoxypropyl)-5-tetrazolyl]pyridine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-cyclohexyl-5-(2-phenoxyethylthio)tetrazole | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(5-ethyl-1,3,4-thiadiazol-2-yl)-2-[[5-[(3-methylphenoxy)methyl]-1,3,4-oxadiazol-2-yl]thio]acetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-amino-4-[3-ethoxy-4-[2-(4-morpholinyl)ethoxy]phenyl]-3-ethyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile | | aromatic ether;
pyranopyrazole | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[5-[(2,3-dimethylphenoxy)methyl]-4-methyl-1,2,4-triazol-3-yl]thio]-1-thiophen-2-ylethanone | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (1-methyl-2-imidazolyl)-(4-phenylmethoxyphenyl)methanol | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(3-butoxyphenyl)-1,3,4-thiadiazol-2-amine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(2-ethoxy-6-methyl-3-pyridinyl)-5-(2-pyridinyl)-1,2,4-oxadiazole | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3,4,5-triethoxyphenyl)-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazole | | aromatic ether;
triazolothiadiazole | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(1-benzotriazolyl)-5-(2-methoxyphenoxy)benzene-1,2-dicarbonitrile | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-cyclohexyl-3-[(3-methylphenoxy)methyl]-1H-1,2,4-triazole-5-thione | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-ethoxy-9-nitro-5H-benzo[b][1,4]benzoxazepin-6-one | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[4-(2-quinoxalinyl)phenoxy]benzene-1,2-dicarbonitrile | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-amino-1,2,5-oxadiazol-3-yl)-5-(phenoxymethyl)-4-triazolecarboxylic acid ethyl ester | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-ethylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-chloro-3-methylphenoxy)-N-(1H-1,2,4-triazol-5-yl)acetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-[(4-ethylphenoxy)methyl]-N-(2-pyridinylmethyl)-2-furancarboxamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-methoxy-3,5-dimethyl-2-thiazolo[4,5-d]pyrimidinethione | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[4-(4-ethylphenyl)-2-thiazolyl]carbamic acid phenyl ester | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-bromo-4-methylphenoxy)-N-(2-pyridinylmethyl)acetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[[3-(4-chlorophenoxy)phenyl]methyl]-4-ethylpiperazine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-methoxy-4-[(4-methyl-1,4-diazepan-1-yl)methyl]-6-nitrophenol | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[[4-(ethylamino)-6-(methylthio)-1,3,5-triazin-2-yl]oxy]benzoic acid ethyl ester | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-ethyl-3-[[4-(2-methylpropoxy)phenyl]methylthio]-1H-1,2,4-triazole | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [4-[(2-fluorophenyl)methoxy]phenyl]-(1-pyrrolidinyl)methanethione | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-[(2-chlorophenoxy)methyl]-3-pyridin-4-yl-1,2,4-oxadiazole | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(4-phenylmethoxyphenyl)thiadiazole | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-methyl-2-[[4-methyl-5-[(4-nitrophenoxy)methyl]-1,2,4-triazol-3-yl]thio]acetamide | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[5-(4-ethoxyphenyl)-1,3,4-oxadiazol-2-yl]thio]-1-(4-morpholinyl)ethanone | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(3-pyridinyloxy)benzene-1,2-dicarbonitrile | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-tert-butyl-2-(4-chloro-3-methylphenoxy)acetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2-furanylmethyl)-3-(4-phenoxyphenyl)thiourea | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2-methylpropyl)-3-(4-phenoxyphenyl)thiourea | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-cyclopentyl-3-(4-phenoxyphenyl)thiourea | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-[(4-ethoxyphenoxy)methyl]-N-(3-pyridinyl)-2-furancarboxamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2,3-dimethylphenoxy)-N-pyridin-4-ylacetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-[(2-chlorophenoxy)methyl]-N-(2-thiazolyl)-2-furancarboxamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-2-furancarboxamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(4,5-dihydrothiazol-2-yl)-2-(2-methylphenoxy)acetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(2-fluorophenoxy)-1-methyl-3-nitro-1,2,4-triazole | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-methyl-5-(1-naphthalenyloxy)-4-nitroimidazole | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| curcumin | | aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol | anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3,4-dimethoxyphenyl)-3-(2-methoxy-5-nitrophenyl)urea | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-cyclopentyl-3-(2-phenoxyphenyl)thiourea | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(1-ethyl-2-benzimidazolyl)-5-[(4-methyl-2-nitrophenoxy)methyl]-2-furancarboxamide | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-chloro-12-(4-methoxyphenyl)sulfonylquinoxalino[2,3-b][1,4]benzoxazine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3-methoxy-5-nitrophenyl)-3-(4-methylphenyl)urea | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-bromo-4-chlorophenoxy)-N-cyclohexyl-N-methylacetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-furanyl-[4-(4-phenoxyphenyl)sulfonyl-1-piperazinyl]methanone | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(2-methoxyphenoxy)-N-(3-pyridinyl)benzenesulfonamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3-chlorophenyl)-3-(2-phenoxyphenyl)thiourea | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[3-[2-(1-azepanyl)-4,5-dicyanophenoxy]phenyl]acetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,5-dimethoxy-N-(4-phenoxyphenyl)benzenesulfonamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[[4-(dimethylamino)-6-(4-morpholinyl)-1,3,5-triazin-2-yl]oxy]benzoic acid methyl ester | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-5-methyl-3-phenyl-4-isoxazolecarboxamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[4-[[4-(2-chloro-6-nitrophenoxy)phenyl]methoxy]phenyl]ethanone | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[4-[[2-(4-hydroxyphenyl)-1,3-dioxo-5-isoindolyl]oxy]phenyl]-2,2-dimethylpropanamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[[4-(4-chlorophenoxy)anilino]-sulfanylidenemethyl]benzamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-fluorophenoxy)-N-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)acetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[[3-chloro-5-(trifluoromethyl)-2-pyridinyl]oxy]-N-propan-2-ylbenzenesulfonamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(4-tert-butylphenoxy)-5-methoxy-2-phenylpyrimidine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-phenoxy-2-phenyl-5-pyrimidinecarboxylic acid ethyl ester | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Src Inhibitor-1 | | aromatic ether;
polyether;
quinazolines;
secondary amino compound | EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[2,5-dioxo-6-(4-phenoxyphenyl)-3-pyrano[3,2-c]pyridinyl]benzamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-chlorophenoxy)-4-(dimethylamino)-3-pyridinecarbonitrile | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-methyl-5-[2-(2-methylphenoxy)ethyl]-2-sulfanylidene-1H-pyrimidin-4-one | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(4-chlorophenoxy)-1-(4-morpholinyl)-1-butanone | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N4-ethyl-6-[2-(4-methylphenoxy)ethylthio]-N2-propan-2-yl-1,3,5-triazine-2,4-diamine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(phenylmethyl)-3-[2-(4-propoxyphenyl)ethyl]-1H-1,2,4-triazole-5-thione | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[[1-oxo-3-(4-propan-2-yloxyphenyl)propyl]amino]-3-(phenylmethyl)thiourea | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[3-(3-methylphenoxy)-5-nitrophenyl]-2-(3-nitro-1,2,4-triazol-1-yl)acetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-bis(2-fluorophenoxy)phosphoryl-3,4-dimethylaniline | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[4-(2-ethoxyanilino)-6-(4-ethoxyanilino)-2-pyrimidinyl]methylidene]propanedinitrile | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-methyl-3-[(4-pentoxyphenyl)methylthio]-1H-1,2,4-triazole | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4,5-dichloro-1-[2-(4-chlorophenoxy)ethyl]imidazole | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-butyl-3-(4-phenoxyphenyl)thiourea | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(3-cyano-2-thiophenyl)-2-[4-(1,3,4-oxadiazol-2-yl)phenoxy]acetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-bromophenyl)-5-[(2-chlorophenoxy)methyl]-1,3,4-oxadiazole | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(4-ethoxyphenyl)-N-(3,4,5,6-tetrahydro-2H-azepin-7-yl)-1,3,4-oxadiazol-2-amine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(4-chloro-2-methylphenoxy)-1-(4-morpholinyl)-1-butanone | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N9-(4-butoxyphenyl)-6,8,10-triazaspiro[4.5]deca-6,9-diene-7,9-diamine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[2-(4-chlorophenoxy)ethylthio]pyrimidine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(3-phenoxypropyl)-3-(3-pyridinyl)-1,2,4-oxadiazole | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(3-ethoxy-2-prop-2-enoxyphenyl)methyl]-2-thiazolamine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-bromophenoxy)-N-(2-pyridinylmethyl)acetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[2-[(4-chlorophenyl)thio]ethoxy]-3-ethoxybenzaldehyde | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3-fluorophenyl)-4-(4-hydroxy-3-methoxy-5-nitrophenyl)-4H-pyridine-3,5-dicarboxylic acid diethyl ester | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(2-ethoxyphenyl)-3H-1,3,4-oxadiazole-2-thione | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-tert-butyl-4-(2-fluorophenoxy)-1-butanamine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-butyl-4-phenoxy-1-butanamine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[3-[[diethylamino(sulfanylidene)methyl]thio]-1-oxopropyl]carbamic acid (4-methylphenyl) ester | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,3-dimethyl-5-[[2-[2-(4-nitrophenoxy)ethoxy]phenyl]methylidene]-1,3-diazinane-2,4,6-trione | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[2-[2-(4-bromo-2-chlorophenoxy)ethoxy]ethyl]morpholine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[2-(3-ethylphenoxy)ethyl]propanedioic acid diethyl ester | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,3-dihydro-1,4-dioxin-5-carboxylic acid [2-[4-[4-(2-methylbutan-2-yl)phenoxy]anilino]-2-oxoethyl] ester | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[3-(2-bromo-4-chlorophenoxy)propyl]-4-methylpiperidine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N4-(2-methoxyphenyl)benzene-1,4-diamine | | aromatic ether;
substituted aniline | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(1H-benzimidazol-2-ylthio)butanoic acid [2-oxo-2-(4-phenoxyanilino)ethyl] ester | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-phenoxybenzoic acid [2-(2-furanylmethylamino)-2-oxoethyl] ester | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[2,5-dimethyl-1-(phenylmethyl)-3-pyrrolyl]-2-[4-(1,3,4-oxadiazol-2-yl)phenoxy]ethanone | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[6-amino-1-(2-methylpropyl)-2,4-dioxo-5-pyrimidinyl]-2-(2-methylphenoxy)-N-(2-methylpropyl)acetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[[6-[(2-methyl-5-thieno[2,3-e][1,3]benzothiazolyl)oxy]-3-pyridinyl]sulfonyl]morpholine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(3-fluorophenoxy)-8-nitroisoquinoline | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[4-(2-prop-2-enylphenoxy)butyl]pyrrolidine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2,4-dibromophenoxy)-N-[oxo-(propan-2-ylamino)methyl]acetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-phenoxyphenyl 4-hydroxypiperidine-1-carboxylate | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N'-benzoyl-5-(3,5-dichlorophenoxy)-2-furancarbohydrazide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[2-[(4-chlorophenoxy)methyl]-4-thiazolyl]ethanone | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(benzyloxy)-2-(hydroxymethyl)-1,4-dihydropyridin-4-one | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-aminophenoxy)isophthalonitrile | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N5-(2-chloro-6-phenoxybenzyl)-1H-1,2,4-triazole-3,5-diamine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(2-chloro-6-phenoxyphenyl)methyl]benzenesulfonamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[5-(tert-butyl)-3-isoxazolyl]-N'-[2-(trifluoromethoxy)phenyl]urea | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(4-methoxyphenoxy)-2-imidazo[1,2-b]pyridazinecarboxylic acid ethyl ester | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-fluoro-N-[2,2,2-trichloro-1-[[(4-methoxy-2-nitroanilino)-sulfanylidenemethyl]amino]ethyl]acetamide | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-amino-4-(4,5-dimethoxy-2-nitrophenyl)-7,7-dimethyl-5-oxo-6,8-dihydro-4H-1-benzopyran-3-carbonitrile | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,4-dichloro-N-[2,2,2-trichloro-1-[[(4-methoxy-2-nitroanilino)-sulfanylidenemethyl]amino]ethyl]benzamide | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-anilino-3-[4-(3-anilino-2-hydroxypropoxy)phenoxy]-2-propanol | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[4-(3-ethoxyphenoxy)butyl]imidazole | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-2-oxolanecarboxamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[[2-(2,4-difluorophenoxy)-1-oxopropyl]amino]-3-(2-oxolanylmethyl)thiourea | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[[(5-bromo-6-methyl-2-pyridinyl)amino]-sulfanylidenemethyl]-2-(2-chlorophenoxy)acetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(4-chlorophenyl)sulfonyl-methylamino]-N-(4-methoxy-2-nitrophenyl)acetamide | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-oxido-3-(4-phenoxyphenyl)-4a,5,6,7,8,8a-hexahydroquinoxalin-1-ium 1-oxide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2-fluorophenyl)-3-(4-methoxy-2-nitrophenyl)urea | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[5-[(2-fluorophenoxy)methyl]-4-prop-2-enyl-1,2,4-triazol-3-yl]thio]-N-[(2-furanylmethylamino)-oxomethyl]acetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyclopropanecarboxylic acid [2-oxo-2-(4-phenoxyanilino)ethyl] ester | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| toremifene | | aromatic ether;
organochlorine compound;
tertiary amine | antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dieckol | | aromatic ether;
oxacycle;
phlorotannin | anticoagulant;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
hepatoprotective agent;
metabolite;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| naproxol | | aromatic ether | antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tamoxifen n-oxide | | aromatic ether;
tertiary amine oxide | anti-estrogen;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diafenthiuron | | aromatic ether;
thiourea acaricide;
thiourea insecticide | oxidative phosphorylation inhibitor;
proinsecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ospemifene | | aromatic ether;
organochlorine compound;
primary alcohol | anti-inflammatory agent;
antineoplastic agent;
estrogen receptor modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tandutinib | | aromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
piperidines;
quinazolines;
tertiary amino compound | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| adefovir | | aromatic ether;
aromatic ketone;
biaryl;
cyclic ketone;
naphtho-gamma-pyrone;
organooxygen heterocyclic antibiotic;
polyphenol | antimalarial;
Aspergillus metabolite;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-chloro-N-[2,2,2-trichloro-1-[[(4-methoxy-2-nitroanilino)-sulfanylidenemethyl]amino]ethyl]benzamide | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(2-hydroxyethyl)-4-[2-nitro-4-(trifluoromethyl)phenoxy]benzamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N'-[2-[(4-amino-5-cyano-2-pyrimidinyl)thio]-1-oxoethyl]-2-(4-methylphenoxy)acetohydrazide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(2-methyl-4-thiazolyl)methyl]-4-phenoxybenzenesulfonamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-amino-4-(2-ethoxy-4-hydroxyphenyl)-3-propyl-2,4-dihydropyrano[2,3-c]pyrazole-5-carbonitrile | | aromatic ether;
pyranopyrazole | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[(2-ethoxyphenyl)methyl]-3-thiophen-2-ylurea | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| quinoxyfen | | aromatic ether;
monofluorobenzenes;
organochlorine compound;
quinolines | antifungal agrochemical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nafadotride | | aromatic ether;
naphthalenecarboxamide;
nitrile;
pyrrolidines;
tertiary amino compound | dopaminergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(1-naphthalenyl)-3-[[2-(2-nitrophenoxy)-1-oxoethyl]amino]urea | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-methyl-1,3-bis(phenylmethoxy)benzene | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4,6-dimethoxypyrimidin-2-yl)-3-(2-ethoxyphenoxysulfonyl)urea | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[(4-ethylphenoxy)methyl]-4-(6-methylheptan-2-yl)-1H-1,2,4-triazole-5-thione | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-chloro-N-(2-methyl-6-oxo-5H-benzo[b][1,4]benzoxazepin-8-yl)acetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(benzenesulfonyl)-4-(2,6-dimethylphenoxy)-2-phenylpyrimidine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(2-methylphenoxy)-6-phenylfuro[2,3-d]pyrimidine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[4-(2-chlorophenoxy)butyl]imidazole | | aromatic ether;
imidazoles;
monochlorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(2-chlorophenyl)-4-[[(2-methoxy-4-nitroanilino)-sulfanylidenemethyl]hydrazo]-4-oxobutanamide | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(2-methoxy-4-nitrophenyl)-2-[(1-methyl-2-imidazolyl)thio]acetamide | | aromatic ether;
C-nitro compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[4-(phenoxymethyl)-2-thiazolyl]-1-adamantanecarboxamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hydroxypioglitazone | | aromatic ether;
pyridines;
thiazolidinediones | human xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sc 560 | | aromatic ether;
monochlorobenzenes;
organofluorine compound;
pyrazoles | angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
cyclooxygenase 1 inhibitor;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sc-19220 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-methyl-4-(3-phenoxyphenyl)-2-sulfanylidene-3,4-dihydro-1H-pyrimidine-6-carboxylic acid ethyl ester | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 8-[4-(4-fluorophenoxy)-3-nitrophenyl]-7-(2-hydroxyethyl)-3-(phenylmethyl)purine-2,6-dione | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-phenoxybenzoic acid [2-oxo-2-(propan-2-ylamino)ethyl] ester | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-bromophenoxy)-N'-[2-[(4-methyl-1,2,4-triazol-3-yl)thio]-1-oxoethyl]acetohydrazide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-methoxyanilino)-2-(2-phenylmethoxyphenyl)acetonitrile | | aromatic ether;
substituted aniline | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(4-phenoxyphenyl)-2-(1,2,3,4-tetrahydroisoquinolin-1-yl)acetamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(3,4-dimethoxyphenyl)-3-(2-furanylmethyl)-4-imino-5H-[1]benzopyrano[2,3-d]pyrimidin-8-ol | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,3-dimethyl-1,5-dinitro-6-phenoxy-3-azoniabicyclo[3.3.1]non-6-ene | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fraxin | | aromatic ether;
beta-D-glucoside;
hydroxycoumarin | anti-inflammatory agent;
hepatoprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fraxetin | | aromatic ether;
hydroxycoumarin | anti-inflammatory agent;
antibacterial agent;
antimicrobial agent;
antioxidant;
apoptosis inducer;
apoptosis inhibitor;
Arabidopsis thaliana metabolite;
hepatoprotective agent;
hypoglycemic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5,6-dehydrokawain | | 2-pyranones;
aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| jtk-303 | | aromatic ether;
monochlorobenzenes;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone | HIV-1 integrase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| coniferin | | aromatic ether;
cinnamyl alcohol beta-D-glucoside;
monosaccharide derivative | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| daphnoretin | | aromatic ether;
hydroxycoumarin | antineoplastic agent;
antiviral agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| kavain | | 2-pyranones;
aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methysticin | | 2-pyranones;
aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| yangonin | | 2-pyranones;
aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hinokiflavone | | aromatic ether;
biflavonoid;
hydroxyflavone | antineoplastic agent;
metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gentiacaulein | | aromatic ether;
polyphenol;
xanthones | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gentisin | | aromatic ether;
polyphenol;
xanthones | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| isogentisin | | aromatic ether;
polyphenol;
xanthones | EC 1.4.3.4 (monoamine oxidase) inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mangostin | | aromatic ether;
phenols;
xanthones | antimicrobial agent;
antineoplastic agent;
antioxidant;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,8-dihydroxy-3,7-dimethoxyxanthone | | aromatic ether;
polyphenol;
xanthones | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| swerchirin | | aromatic ether;
phenols;
xanthones | hypoglycemic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,2,8-trihydroxy-6-methoxyxanthone | | aromatic ether;
polyphenol;
xanthones | antioxidant;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| wedelolactone | | aromatic ether;
coumestans;
delta-lactone;
polyphenol | antineoplastic agent;
apoptosis inducer;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
hepatoprotective agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyhalothrin | | aromatic ether;
cyclopropanecarboxylate ester;
nitrile;
organochlorine compound;
organofluorine compound | agrochemical;
pyrethroid ester acaricide;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sofalcone | | aromatic ether;
chalcones;
monocarboxylic acid | anti-ulcer drug;
antibacterial agent;
gastrointestinal drug;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| neticonazole | | aromatic ether;
benzenes;
conazole antifungal drug;
enamine;
imidazole antifungal drug;
imidazoles;
methyl sulfide | antifungal drug;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pibutidine | | aromatic ether;
cyclobutenones;
olefinic compound;
piperidines;
primary amino compound;
pyridines;
secondary amino compound | anti-ulcer drug;
H2-receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| purmorphamine | | aromatic ether;
morpholines;
purines;
secondary amino compound | osteogenesis regulator;
SMO receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 8-(2-chlorophenyl)-3-(4-ethoxyphenyl)-6-oxo-2,4,7,8-tetrahydropyrido[2,1-b][1,3,5]thiadiazine-9-carbonitrile | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ro 41-5253 | | aromatic ether;
benzoic acids;
sulfone;
thiochromane | apoptosis inducer;
retinoic acid receptor alpha antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glycycoumarin | | aromatic ether;
coumarins;
resorcinols | antispasmodic drug;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| isoginkgetin | | aromatic ether;
biflavonoid | antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| neoglycyrol | | aromatic ether;
coumestans;
delta-lactone;
polyphenol | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rhamnazin | | aromatic ether;
dimethoxyflavone;
phenols;
trihydroxyflavone | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bosutinib | | aminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bw b70c | | aromatic ether;
hydroxamic acid;
organofluorine compound;
ureas | EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lichexanthone | | aromatic ether;
phenols;
xanthones | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alternariol monomethyl ether | | aromatic ether;
benzochromenone | antifungal agent;
fungal metabolite;
mycotoxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| decussatin | | aromatic ether;
phenols;
xanthones | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bedaquiline | | aromatic ether;
naphthalenes;
organobromine compound;
quinolines;
tertiary alcohol;
tertiary amino compound | antitubercular agent;
ATP synthase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dimethomorph | | aromatic ether;
enamide;
monochlorobenzenes;
morpholine fungicide;
tertiary carboxamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benanomicin b | | aromatic ether;
disaccharide derivative;
L-alanine derivative;
polyketide;
polyphenol;
pradimicin;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pradimicin b | | aromatic ether;
L-alanine derivative;
monosaccharide derivative;
polyketide;
polyphenol;
pradimicin;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,7-dihydroxy-4-methoxyxanthone | | aromatic ether;
phenols;
xanthones | metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pradimicin a | | aromatic ether;
carboxylic acid;
disaccharide derivative;
L-alanine derivative;
p-quinones;
polyphenol;
pradimicin;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clodinafop | | aromatic ether;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
pyridines | EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor;
phenoxy herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ici 118551 | | aromatic ether;
indanes;
secondary alcohol;
secondary amino compound | beta-adrenergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ochnaflavone | | aromatic ether;
biflavonoid;
hydroxyflavone | anti-inflammatory agent;
antiatherogenic agent;
antibacterial agent;
EC 3.1.1.4 (phospholipase A2) inhibitor;
leukotriene antagonist;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(4-fluorophenoxy)-6-methoxy-2-(4-methoxyphenyl)-1-benzothiophene 1-oxide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flavasperone | | aromatic ether;
naphtho-gamma-pyrone;
phenols | acyl-CoA:cholesterol acyltransferase 2 inhibitor;
antiviral agent;
Aspergillus metabolite;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-hydroxycordoin | | aromatic ether;
chalcones;
polyphenol | anti-inflammatory agent;
antibacterial agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-feruloylserotonin | | aromatic ether;
cinnamamides;
hydroxyindoles;
phenols;
secondary carboxamide | plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tyrphostin ag825 | | aromatic ether;
benzothiazoles;
enamide;
nitrile;
organic sulfide;
phenols;
primary carboxamide | epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| kresoxim-methyl | | aromatic ether;
methoxyiminoacetate strobilurin antifungal agent;
methyl ester;
oxime O-ether | antifungal agrochemical;
environmental contaminant;
mitochondrial cytochrome-bc1 complex inhibitor;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-methoxy-3,6-diphenyl-1,2,4-triazine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pyrachlostrobin | | aromatic ether;
carbamate ester;
carbanilate fungicide;
methoxycarbanilate strobilurin antifungal agent;
monochlorobenzenes;
pyrazoles | antifungal agrochemical;
environmental contaminant;
mitochondrial cytochrome-bc1 complex inhibitor;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| piericidin a | | aromatic ether;
methylpyridines;
monohydroxypyridine;
secondary allylic alcohol | antimicrobial agent;
bacterial metabolite;
EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor;
mitochondrial respiratory-chain inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| metrafenone | | aromatic ether;
aryl phenyl ketone fungicide;
benzophenones;
organobromine compound | antifungal agrochemical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-fluoro-3-(trifluoromethyl)phenoxy)-n-(phenylmethyl)butanamide | | (trifluoromethyl)benzenes;
aromatic ether;
monocarboxylic acid amide;
monofluorobenzenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| b 43 | | aromatic amine;
aromatic ether;
cyclopentanes;
primary amino compound;
pyrrolopyrimidine | EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(4-phenylbutoxy)psoralen | | aromatic ether;
benzenes;
psoralens | geroprotector;
immunosuppressive agent;
potassium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-ia-85380 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| yunaconitine | | acetate ester;
aromatic ether;
benzoate ester;
bridged compound;
diterpene alkaloid;
organic heteropolycyclic compound;
polyether;
secondary alcohol;
tertiary alcohol;
tertiary amino compound | antifeedant;
human urinary metabolite;
phytotoxin;
plant metabolite;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ru 58668 | | 17beta-hydroxy steroid;
3-hydroxy steroid;
aromatic ether;
organofluorine compound;
sulfone | anti-estrogen;
antineoplastic agent;
estrogen receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| altenusin | | aromatic ether;
carboxybiphenyl;
catechols;
hydroxybiphenyls;
polyphenol | antifungal agent;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gw 501516 | | 1,3-thiazoles;
aromatic ether;
aryl sulfide;
monocarboxylic acid;
organofluorine compound | carcinogenic agent;
PPARbeta/delta agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bay 58-2667 | | aromatic ether;
benzoic acids;
dicarboxylic acid;
tertiary amino compound | antihypertensive agent;
soluble guanylate cyclase activator;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| camostat | | aromatic ether;
phenols | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lenvatinib | | aromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nsc 716970 | | aromatic amine;
aromatic ether;
indolecarboxamide;
organochlorine compound | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lobeglitazone | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| noviflumuron | | aromatic ether;
benzoylurea insecticide;
dichlorobenzene;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| etomoxir | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fr 148083 | | aromatic ether;
macrolide;
phenols;
secondary alcohol;
secondary alpha-hydroxy ketone | antibacterial agent;
antineoplastic agent;
metabolite;
NF-kappaB inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 9-methoxycanthin-6-one | | aromatic ether;
indole alkaloid;
organic heterotetracyclic compound | antineoplastic agent;
antiplasmodial drug;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sb 3ct compound | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| varespladib methyl | | aromatic ether;
benzenes;
indoles;
methyl ester;
primary carboxamide | anti-inflammatory drug;
antidote;
EC 3.1.1.4 (phospholipase A2) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dapagliflozin | | aromatic ether;
C-glycosyl compound;
monochlorobenzenes | hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| naveglitazar | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tivozanib | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zm 447439 | | aromatic ether;
benzamides;
morpholines;
polyether;
quinazolines;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
Aurora kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ustiloxin b | | aromatic ether;
heterodetic cyclic peptide;
macrocycle;
phenols;
secondary alcohol;
secondary carboxamide;
sulfoxide | Aspergillus metabolite;
microtubule-destabilising agent;
mycotoxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hypothemycin | | aromatic ether;
diol;
enone;
epoxide;
macrolide;
phenols;
polyketide;
secondary alpha-hydroxy ketone | antifungal agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tryprostatin a | | aromatic ether;
dipeptide;
indole alkaloid;
indoles;
pyrrolopyrazine | breast cancer resistance protein inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cediranib | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-iodothyronamine | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n,n-dipropyl-2-(4-methoxy-3-(2-phenylethoxy)phenyl)ethylamine monohydrochloride | | aromatic ether;
hydrochloride;
methoxybenzenes;
tertiary amino compound | antipsychotic agent;
receptor modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rubraxanthone | | aromatic ether;
polyphenol;
xanthones | antibacterial agent;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7,8-Dihydroyangonin | | 2-pyranones;
aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sch 51344 | | aromatic amine;
aromatic ether;
primary alcohol;
pyrazoloquinoline;
secondary amino compound | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ancistroealaine a | | aromatic ether;
biaryl;
isoquinoline alkaloid;
isoquinolines;
methoxynaphthalene;
methylnaphthalenes | antileishmanial agent;
antiplasmodial drug;
metabolite;
trypanocidal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pimavanserin | | aromatic ether;
monofluorobenzenes;
piperidines;
tertiary amino compound;
ureas | 5-hydroxytryptamine 2A receptor inverse agonist;
antipsychotic agent;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tolfenpyrad | | aromatic amide;
aromatic ether;
organochlorine compound;
pyrazole insecticide | agrochemical;
antifungal agent;
EC 1.3.5.1 [succinate dehydrogenase (quinone)] inhibitor;
mitochondrial NADH:ubiquinone reductase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| SIS3 free base | | aromatic ether;
enamide;
isoquinolines;
monocarboxylic acid amide;
pyrrolopyridine;
tertiary carboxamide | Smad3 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| apixaban | | aromatic ether;
lactam;
piperidones;
pyrazolopyridine | anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bibw 2992 | | aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dihydrokavain | | 2-pyranones;
aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| troglitazone sulfate | | aromatic ether;
thiazolidinone | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| arisugacin | | aromatic ether;
delta-lactone;
enone;
organic heterotetracyclic compound;
tertiary alcohol | antimicrobial agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
metabolite;
Penicillium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| saracatinib | | aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fonsecinone a | | aromatic ether;
aromatic ketone;
biaryl;
cyclic ketone;
naphtho-gamma-pyrone;
polyphenol | antibacterial agent;
Aspergillus metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| crenolanib | | aminopiperidine;
aromatic ether;
benzimidazoles;
oxetanes;
quinolines;
tertiary amino compound | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aiphanol | | aromatic ether;
benzodioxine;
lignan;
stilbenoid | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nigerloxin | | aromatic ether;
benzamides;
benzoic acids;
phenols;
styrenes | antioxidant;
Aspergillus metabolite;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
lipoxygenase inhibitor;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| msdc-0160 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dihydroxanthohumol | | aromatic ether;
dihydrochalcones;
polyphenol | EC 1.14.13.39 (nitric oxide synthase) inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| PB28 | | aromatic ether;
piperazines;
tetralins | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
sigma-2 receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-phloroeckol | | aromatic ether;
phlorotannin | antioxidant;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,5-dimethoxy-4-hydroxybenzyl alcohol-4-O-beta-D-glucopyranoside | | aromatic ether;
benzyl alcohols;
beta-D-glucoside;
monosaccharide derivative;
primary alcohol | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| PDGF receptor tyrosine kinase inhibitor III | | aromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
quinazolines;
tertiary amino compound | EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluoxastrobin | | aromatic ether;
dioxazine;
monochlorobenzenes;
organofluorine compound;
oxime O-ether;
pyrimidines;
strobilurin antifungal agent | antifungal agrochemical;
mitochondrial cytochrome-bc1 complex inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flumorph | | aromatic ether;
enamide;
morpholines;
organofluorine compound;
tertiary carboxamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| regorafenib | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide | antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| erastin | | aromatic ether;
diether;
monochlorobenzenes;
N-acylpiperazine;
N-alkylpiperazine;
quinazolines;
tertiary carboxamide | antineoplastic agent;
ferroptosis inducer;
voltage-dependent anion channel inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| brivanib | | aromatic ether;
diether;
fluoroindole;
pyrrolotriazine;
secondary alcohol | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fg-4592 | | aromatic ether;
isoquinolines;
N-acylglycine | EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor;
EC 1.14.11.29 (hypoxia-inducible factor-proline dioxygenase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| picoxystrobin | | aromatic ether;
enoate ester;
enol ether;
methoxyacrylate strobilurin antifungal agent;
organofluorine compound;
pyridines | antifungal agrochemical;
mitochondrial cytochrome-bc1 complex inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cenicriviroc | | aromatic ether;
benzazocine;
diether;
imidazoles;
secondary carboxamide;
sulfoxide | anti-HIV agent;
anti-inflammatory agent;
antirheumatic drug;
chemokine receptor 2 antagonist;
chemokine receptor 5 antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mandipropamid | | aromatic ether;
monocarboxylic acid amide;
monochlorobenzenes;
terminal acetylenic compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glyceryl ferulate | | 1-monoglyceride;
aromatic ether;
enoate ester;
phenols | antioxidant;
plant metabolite;
ultraviolet filter | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ki 8751 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ceratamine a | | alkaloid;
aromatic ether;
cyclic ketone;
organic heterobicyclic compound;
organobromine compound;
secondary amino compound;
tertiary amine | antimitotic;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azd 8931 | | aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
tertiary amino compound | EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bay94 9172 | | (18)F radiopharmaceutical;
aromatic ether;
polyether;
secondary amino compound;
stilbenoid;
substituted aniline | radioactive imaging agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| olodaterol | | aromatic ether;
benzoxazine;
phenols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dorsomorphin | | aromatic ether;
piperidines;
pyrazolopyrimidine;
pyridines | bone morphogenetic protein receptor antagonist;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cj-042794 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hu 308 | | aromatic ether;
bridged compound;
carbobicyclic compound;
primary allylic alcohol;
synthetic cannabinoid | anti-inflammatory agent;
antihypertensive agent;
apoptosis inhibitor;
bone density conservation agent;
CB2 receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ki11502 | | aromatic ether;
benzamides;
quinolines;
thioureas | antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| apremilast | | aromatic ether;
N-acetylarylamine;
phthalimides;
sulfone | non-steroidal anti-inflammatory drug;
phosphodiesterase IV inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| PF-00835231 | | aromatic ether;
indolecarboxamide;
L-leucine derivative;
primary alcohol;
pyrrolidin-2-ones;
secondary carboxamide | anticoronaviral agent;
drug metabolite;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine | | aminopyridine;
aromatic ether;
dichlorobenzene;
organofluorine compound;
pyrazolylpiperidine;
racemate | antineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chir-265 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aminocandin | | aromatic ether;
echinocandin;
homodetic cyclic peptide | antiinfective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zk 756326 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bay 60-6583 | | aminopyridine;
aromatic ether;
aryl sulfide;
cyanopyridine;
cyclopropanes;
monocarboxylic acid amide | adenosine A2B receptor agonist;
anti-inflammatory agent;
cardioprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| empagliflozin | | aromatic ether;
C-glycosyl compound;
monochlorobenzenes;
tetrahydrofuryl ether | hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[5-(4-ethoxyphenyl)-3-isoxazolyl]-N-[(4-methylphenyl)methyl]butanamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bgt226 | | aromatic ether;
imidazoquinoline;
N-arylpiperazine;
organofluorine compound;
pyridines | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-desmethylrosiglitazone | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(5-methyl-3-nitro-1-pyrazolyl)-N-[3-(4-methylphenoxy)-5-nitrophenyl]butanamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| verruculogen | | aromatic ether;
diol;
indole alkaloid;
organic heterohexacyclic compound;
organic peroxide | Aspergillus metabolite;
GABA modulator;
mycotoxin;
Penicillium metabolite;
potassium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-O-feruloyl-beta-D-glucose | | aromatic ether;
beta-D-glucoside;
cinnamate ester;
phenols | antioxidant;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,2',4,5'-tetrabromodiphenyl ether | | aromatic ether;
organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hexabromodiphenyl ether 154 | | aromatic ether;
organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bde 183 | | aromatic ether;
organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| l-798106 | | aromatic ether;
bromobenzenes;
N-sulfonylcarboxamide | prostaglandin receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aflatoxin m1 | | aflatoxin;
aromatic ether;
aromatic ketone;
tertiary alcohol | Aspergillus metabolite;
human xenobiotic metabolite;
mammalian metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| macitentan | | aromatic ether;
organobromine compound;
pyrimidines;
ring assembly;
sulfamides | antihypertensive agent;
endothelin receptor antagonist;
orphan drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| CDN1163 | | aromatic ether;
quinolines;
secondary carboxamide | SERCA activator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| e 7050 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(5-chloro-2-thiophenyl)methyl]-5-[(2,6-difluorophenoxy)methyl]-3-isoxazolecarboxamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dafadine C | | aromatic amide;
aromatic ether;
difluorobenzene;
isoxazoles;
N-acylpiperidine;
pyridines | P450 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dafadine B | | aromatic amide;
aromatic ether;
isoxazoles;
monochlorobenzenes;
monofluorobenzenes;
N-acylpiperidine;
pyridines | P450 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[5-(5-methyl-2-thiophenyl)-1,3,4-oxadiazol-2-yl]-N-[2-(3-pyridinyloxy)propyl]propanamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| violaceol II | | aromatic ether;
catechols;
resorcinols | mycotoxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pamapimod | | aromatic amine;
aromatic ether;
difluorobenzene;
diol;
primary alcohol;
pyridopyrimidine;
secondary amino compound | antirheumatic drug;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk690693 | | 1,2,5-oxadiazole;
acetylenic compound;
aromatic amine;
aromatic ether;
imidazopyridine;
piperidines;
primary amino compound;
tertiary alcohol | antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cnf 2024 | | 2-aminopurines;
aromatic ether;
organochlorine compound;
pyridines | antineoplastic agent;
Hsp90 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| uk 453,061 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 8-{1-[4-(dimethylamino)phenyl]-3-(pyrrolidin-1-yl)propyl}-5,7-dimethoxy-4-pentyl-2H-chromen-2-one | | aromatic ether;
coumarins;
pyrrolidines;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zm323881 | | aromatic ether;
benzyl ether;
fluorophenol;
halophenol;
monofluorobenzenes;
organic cation;
quinazolines;
secondary amino compound;
substituted aniline | vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| compound w | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[4-[2-[(2-methylpropan-2-yl)oxy]anilino]-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| interiotherin b | | aromatic ether;
fatty acid ester;
lignan;
organic heteropentacyclic compound;
oxacycle | anti-HIV agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5,7-dihydroxy-3-(3-hydroxy-4-methoxybenzyl)-6-methoxychroman-4-one | | aromatic ether;
homoisoflavonoid;
polyphenol | angiogenesis modulating agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ph 797804 | | aromatic ether;
benzamides;
organobromine compound;
organofluorine compound;
pyridone | anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diorcinol | | aromatic ether;
phenols | fungal metabolite;
marine metabolite;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[4-(2-phenoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[4-(1-pyrrolidinyl)-6-[2-(trifluoromethoxy)anilino]-1,3,5-triazin-2-yl]amino]ethanol | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[4-(5-chloro-2-ethoxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[4-(5-chloro-2-propan-2-yloxyanilino)-6-(1-pyrrolidinyl)-1,3,5-triazin-2-yl]amino]ethanol | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mk 5108 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lde225 | | aminopyridine;
aromatic ether;
benzamides;
biphenyls;
morpholines;
organofluorine compound;
tertiary amino compound | antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-azepanyl-[5-[(4-chloro-3,5-dimethylphenoxy)methyl]-3-isoxazolyl]methanone | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(1-((5-((2,6-dimethylphenoxy)methyl)-3-isoxazolyl)carbonyl)-4-piperidinyl)pyridine | | aromatic amide;
aromatic ether;
isoxazoles;
N-acylpiperidine;
pyridines | geroprotector;
P450 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dafadine D | | aromatic amide;
aromatic ether;
isoxazoles;
N-acylpiperidine;
organofluorine compound;
pyridines | P450 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[(1-ethyl-3-methyl-4-pyrazolyl)methyl]-N-[4-(2-fluorophenoxy)phenyl]-4-piperidinecarboxamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dafadine O | | aromatic amide;
aromatic ether;
isoxazoles;
N-acylpiperidine;
pyridines;
ring assembly | P450 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-[(3,4-dimethylphenoxy)methyl]-N-methyl-N-(4-oxanylmethyl)-3-isoxazolecarboxamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pci 32765 | | acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide | antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| florbetapir f 18 | | (18)F radiopharmaceutical;
aromatic ether;
organofluorine compound;
pyridines;
substituted aniline | radioactive imaging agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| AMG-208 | | aromatic ether;
quinolines;
triazolopyridazine | antineoplastic agent;
c-Met tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-methoxyspirotryprostatin b | | aromatic ether;
azaspiro compound;
indole alkaloid;
indolones | antineoplastic agent;
Aspergillus metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lucitanib | | aromatic ether;
cyclopropanes;
naphthalenecarboxamide;
primary amino compound;
quinolines | antineoplastic agent;
fibroblast growth factor receptor antagonist;
vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| act-132577 | | aromatic ether;
organobromine compound;
pyrimidines;
sulfamides | antihypertensive agent;
drug metabolite;
endothelin receptor antagonist;
xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cabozantinib | | aromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| poziotinib | | acrylamides;
aromatic ether;
dichlorobenzene;
diether;
monofluorobenzenes;
N-acylpiperidine;
quinazolines;
secondary amino compound;
substituted aniline | antineoplastic agent;
apoptosis inducer;
epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk 2126458 | | aromatic ether;
difluorobenzene;
pyridazines;
pyridines;
quinolines;
sulfonamide | anticoronaviral agent;
antineoplastic agent;
autophagy inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk 1363089 | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-8-yl]-3-propan-2-ylurea | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl(methylsulfonyl)amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-3-propan-2-ylurea | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-cyclohexyl-1-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[[oxo-(propan-2-ylamino)methyl]amino]-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methylurea | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-cyclohexyl-1-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-10-[[oxo-(propan-2-ylamino)methyl]amino]-3,4-dihydro-2H-1,5-benzoxazocin-2-yl]methyl]-1-methylurea | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[(4-phenoxyphenyl)methyl]amino]methyl]-6-oxo-3,4-dihydro-2H-1,5-benzoxazocin-10-yl]-4-pyridinecarboxamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3,5-dimethyl-4-isoxazolyl)-3-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-(methylaminomethyl)-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]urea | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| monepantel | | (trifluoromethyl)benzenes;
aromatic ether;
aryl sulfide;
nitrile;
secondary carboxamide | anthelminthic drug;
nematicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| an2728 | | aromatic ether;
benzoxaborole;
nitrile | antipsoriatic;
non-steroidal anti-inflammatory drug;
phosphodiesterase IV inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| grazoprevir | | aromatic ether;
azamacrocycle;
carbamate ester;
cyclopropanes;
lactam;
N-sulfonylcarboxamide;
quinoxaline derivative | antiviral drug;
hepatitis C protease inhibitor;
hepatoprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hordatine a | | aromatic ether;
benzofurans;
dicarboxylic acid diamide;
guanidines;
phenols | adrenergic antagonist;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| kavain | | 2-pyranones;
aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-chloro-2-(3,5-dimethylphenyl)-4-(4-methoxyphenoxy)-3-pyridazinone | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tak-632 | | (trifluoromethyl)benzenes;
aromatic ether;
benzothiazoles;
cyclopropylcarboxamide;
monofluorobenzenes;
nitrile;
secondary carboxamide | antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
necroptosis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lrrk2-in1 | | aromatic amine;
aromatic ether;
N-acylpiperidine;
N-alkylpiperazine;
pyrimidobenzodiazepine;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| quinolobactin | | aromatic ether;
monohydroxyquinoline;
phenols;
quinolinemonocarboxylic acid | bacterial metabolite;
siderophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| AZD1979 | | aromatic ether;
azaspiro compound;
carboxamide;
N-acylazetidine;
oxadiazole;
oxaspiro compound;
oxetanes | melanin-concentrating hormone receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ML240 | | aromatic amine;
aromatic ether;
benzimidazoles;
primary amino compound;
quinazolines;
secondary amino compound | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aripiprazole lauroxil | | aromatic ether;
delta-lactam;
dichlorobenzene;
dodecanoate ester;
N-alkylpiperazine;
N-arylpiperazine;
quinolone | H1-receptor antagonist;
prodrug;
second generation antipsychotic;
serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| abt-199 | | aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine | antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| xl765 | | aromatic amine;
aromatic ether;
benzamides;
quinoxaline derivative;
sulfonamide | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| DMH1 | | aromatic ether;
pyrazolopyrimidine;
quinolines | antineoplastic agent;
bone morphogenetic protein receptor antagonist;
protein kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide | | aromatic ether;
methylpyridines;
olefinic compound;
quinazolines;
secondary amino compound;
secondary carboxamide;
toluenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pf 4800567 | | aromatic ether;
monochlorobenzenes;
oxanes;
pyrazolopyrimidine | EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| propenylphosphonic acid | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| abt-333 | | aromatic ether;
naphthalenes;
pyrimidone;
sulfonamide | antiviral drug;
nonnucleoside hepatitis C virus polymerase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| naloxegol | | aromatic ether;
organic heteropentacyclic compound;
phenols;
polyether;
tertiary alcohol | cathartic;
mu-opioid receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ceritinib | | aminopyrimidine;
aromatic ether;
organochlorine compound;
piperidines;
secondary amino compound;
sulfone | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| MK-8353 | | aromatic ether;
dihydropyridine;
indazoles;
methyl sulfide;
N-alkylpyrrolidine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
triazoles | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| HG-10-102-01 | | aminopyrimidine;
aromatic ether;
monocarboxylic acid amide;
morpholines;
organochlorine compound;
secondary amino compound | EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(5-methyl-2-furanyl)methylideneamino]-2-phenoxybenzamide | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| saroglitazar | | aromatic ether;
methyl sulfide;
monocarboxylic acid;
pyrroles | hypoglycemic agent;
PPARalpha agonist;
PPARgamma agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fertaric acid | | aromatic ether;
cinnamate ester;
dicarboxylic acid;
phenols;
tetraric acid derivative | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[4-(4-chlorophenoxy)-2-(trifluoromethyl)phenyl]-1-(1H-1,2,4-triazol-1-yl)propan-2-ol | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
tertiary alcohol;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pf-06463922 | | aminopyridine;
aromatic ether;
azamacrocycle;
benzamides;
cyclic ether;
monofluorobenzenes;
nitrile;
organic heterotetracyclic compound;
pyrazoles | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| DDR1-IN-1 | | (trifluoromethyl)benzenes;
aromatic ether;
benzamides;
N-alkylpiperazine;
oxindoles;
secondary carboxamide | EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ldc4297 | | aromatic ether;
piperidines;
pyrazoles;
pyrazolotriazine;
secondary amino compound | antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| MLI-2 | | aromatic ether;
cyclopropanes;
indazoles;
morpholines;
pyrimidines;
tertiary amino compound | EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ap20187 | | aromatic ether;
carboxylic ester;
N-acylpiperidine;
tertiary amino compound | ligand | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methysticin | | 2-pyranones;
aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| biliatresone | | aromatic ether;
aromatic ketone;
benzodioxoles;
enone;
phenols | plant metabolite;
toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tak 491 | | 1,2,4-oxadiazole;
aromatic ether;
benzimidazoles;
carboxylic ester;
cyclic carbonate ester;
dioxolane | angiotensin receptor antagonist;
antihypertensive agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azilsartan | | 1,2,4-oxadiazole;
aromatic ether;
benzimidazolecarboxylic acid | angiotensin receptor antagonist;
antihypertensive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hydrazinocurcumin | | aromatic ether;
olefinic compound;
polyphenol;
pyrazoles | angiogenesis modulating agent;
antineoplastic agent;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mirodenafil | | aromatic ether;
N-alkylpiperazine;
primary alcohol;
pyrrolopyrimidine;
sulfonamide | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cerulomycin | | aldoxime;
aromatic ether;
bipyridines;
pyridine alkaloid | antineoplastic agent;
bacterial metabolite;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| undecylprodigiosin | | alkaloid;
aromatic ether;
tripyrrole | antibacterial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
biological pigment;
immunosuppressive agent;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sb-590885 | | aromatic ether;
imidazoles;
ketoxime;
pyridines;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[4-(trifluoromethoxy)phenyl]methylthio]-1,5,6,7-tetrahydrocyclopenta[d]pyrimidin-4-one | | aromatic ether | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| PF-07304814 | | aromatic ether;
indolecarboxamide;
L-leucine derivative;
phosphate monoester;
pyrrolidin-2-ones;
secondary carboxamide | anticoronaviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bisoprolol | | secondary alcohol;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| brimonidine | | imidazoles;
quinoxaline derivative;
secondary amine | adrenergic agonist;
alpha-adrenergic agonist;
antihypertensive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| minaprine | | morpholines;
pyridazines;
secondary amine | antidepressant;
antiparkinson drug;
cholinergic drug;
dopamine uptake inhibitor;
serotonin uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nortriptyline | | organic tricyclic compound;
secondary amine | adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pindolol | | indoles;
secondary amine | antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
serotonergic antagonist;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| propranolol | | naphthalenes;
propanolamine;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methylaniline | | methylaniline;
phenylalkylamine;
secondary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pyrroles | | pyrrole;
secondary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| piperidine | | azacycloalkane;
piperidines;
saturated organic heteromonocyclic parent;
secondary amine | base;
catalyst;
human metabolite;
non-polar solvent;
plant metabolite;
protic solvent;
reagent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methamphetamine | | amphetamines;
secondary amine | central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dobutamine | | catecholamine;
secondary amine | beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-phenylamino-1,2-propanediol | | glycol;
secondary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-methyl-5-pyridin-4-yl-1,3,4-thiadiazol-2-amine | | secondary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(methylamino)-3H-1,3,4-thiadiazole-2-thione | | secondary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-methyl-n-(pyridin-3-ylmethyl)isoxazol-3-amine | | secondary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rasagiline | | indanes;
secondary amine;
terminal acetylenic compound | EC 1.4.3.4 (monoamine oxidase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-methyl-6-phenyl-3-(2-pyridinyl)-1,2,4-triazin-5-amine | | secondary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tln 4601 | | dibenzodiazepine;
farnesane sesquiterpenoid;
olefinic compound;
secondary amine;
triol | antineoplastic agent;
antioxidant;
cathepsin L (EC 3.4.22.15) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alfuzosin | | monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol | alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bunazosin | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cgs 15943 | | aromatic amine;
biaryl;
furans;
organochlorine compound;
primary amino compound;
quinazolines;
triazoloquinazoline | adenosine A1 receptor antagonist;
adenosine A2A receptor antagonist;
antineoplastic agent;
central nervous system stimulant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cl 387785 | | bromobenzenes;
quinazolines;
secondary carboxamide;
ynamide | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| doxazosin | | aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines | alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| whi p97 | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ketanserin | | aromatic ketone;
organofluorine compound;
piperidines;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| metolazone | | organochlorine compound;
quinazolines;
sulfonamide | antihypertensive agent;
diuretic;
ion transport inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pd168393 | | acrylamides;
bromobenzenes;
quinazolines;
secondary carboxamide;
substituted aniline | epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| terazosin | | furans;
piperazines;
primary amino compound;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methaqualone | | quinazolines | GABA agonist;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| quinethazone | | quinazolines | antihypertensive agent;
diuretic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| quinazolines | | azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mecloqualone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| quinelorane | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| halofuginone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glycosine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| febrifugine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,3-trimethylene-4-quinazolone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenquizone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenazaquin | | quinazolines | acaricide;
mitochondrial NADH:ubiquinone reductase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluquinconazole | | conazole fungicide;
dichlorobenzene;
organofluorine compound;
quinazolines;
triazole fungicide;
triazoles | antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glyantrypine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| canertinib | | monochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lapatinib | | furans;
organochlorine compound;
organofluorine compound;
quinazolines | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (5-amino-3-triazolo[1,5-a]quinazolinyl)-(4-morpholinyl)methanone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mrs 1220 | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-deoxyvasicine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-benzylquinazolin-4-amine | | benzenes;
quinazolines;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-hydroxy-3-methoxyphenyl)-3-(2-methoxyphenyl)-1,2-dihydroquinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(cyclohexylmethyl)-5,6,7,8-tetrahydrotetrazolo[5,1-b]quinazolin-9-amine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(2-pyridinylmethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[5,1-b]quinazolin-9-amine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[2-methyl-4-oxo-3-(phenylmethyl)-7-(1-piperidinyl)-6-quinazolinyl]-3-pyridinecarboxamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(6-ethoxy-1,3-benzothiazol-2-yl)-2-[[3-(2-furanylmethyl)-4-oxo-2-quinazolinyl]thio]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-pyridin-4-yl-2,3-dihydro-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[3-(trifluoromethyl)phenyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(2-cyclohexyl-4-quinazolinyl)thio]-N-(4-methyl-1,2,5-oxadiazol-3-yl)acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[[[[3-[(4-chlorophenyl)methyl]-2-methyl-4-oxo-6-quinazolinyl]amino]-oxomethyl]amino]propanoic acid ethyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[2-(3,4-dihydro-2H-quinolin-1-yl)-2-oxoethyl]thio]-3-ethyl-4-quinazolinone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(3-ethyl-4-oxo-2-quinazolinyl)thio]acetic acid cyclohexyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-thiophen-2-yl-2,3-dihydro-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(pyridin-4-yl)-4-(pyrrolidin-1-yl)quinazoline | | pyridines;
pyrrolidines;
quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-methyl-6-pyridin-4-yl-6H-benzimidazolo[1,2-c]quinazoline | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[2-[(2-methoxy-2-oxoethyl)thio]-4-oxo-3-quinazolinyl]oxy]acetic acid methyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(1,3-benzoxazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-methoxy-2-(3-pyridinylmethylthio)-4-quinazolinone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,5,5-trimethyl-2-sulfanylidene-1,6-dihydrobenzo[h]quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N1-(6-bromo-4-quinazolinyl)-N4,N4-dimethylbenzene-1,4-diamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(3-fluorophenyl)-2-(pyridin-4-yl)quinazolin-4-amine | | aromatic amine;
monofluorobenzenes;
pyridines;
quinazolines;
secondary amino compound;
substituted aniline | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-methyl-2-[2-(4-methyl-5-thiazolyl)ethylthio]-4-quinazolinone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(4-oxo-3-quinazolinyl)acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-bromo-3-phenyl-2-sulfanylidene-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-methyl-2-(4-methylphenyl)-N-(1-methylpiperidin-4-yl)quinazolin-4-amine | | piperidines;
quinazolines;
tertiary amino compound;
toluenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-furanyl)-3-(6-methyl-2-pyridinyl)-4-quinazolinone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-methoxyphenyl)-3-(3-pyridinyl)-4-quinazolinone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-phenyl-1H-quinazoline-4-thione | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(ethylthio)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(3-methyl-4-oxo-2-quinazolinyl)thio]-N-phenylacetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,3-dimethyl-6-(4-morpholinylsulfonyl)quinazoline-2,4-dione | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6,7-dimethoxy-3-phenyl-1H-quinazoline-2,4-dione | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-methoxy-4-methyl-2-[(2-methylphenyl)methylthio]quinazoline | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-chlorophenyl)-4-propan-2-yloxyquinazoline | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-bromo-1,2,3,9-tetrahydropyrrolo[2,1-b]quinazoline | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(3-methoxyphenyl)-4-propan-2-yloxyquinazoline | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[2-(5-methyl-2-thiophenyl)-2-oxoethyl]thio]-3-phenyl-4-quinazolinone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(phenylmethyl)-2-[[4-(trifluoromethyl)-5,6-dihydrobenzo[h]quinazolin-2-yl]thio]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(6-amino-2-methyl-4-oxo-3-quinazolinyl)-N-(2-methylphenyl)acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-amino-3-[(2-chlorophenyl)methyl]-2-propyl-4-quinazolinone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-chlorophenyl)-N-[2-(4-morpholinyl)ethyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(4-ethoxycarbonylanilino)-2-quinazolinecarboxylic acid ethyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(4-anilinoanilino)-2-quinazolinecarboxylic acid ethyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[2-(3,4-dihydro-1H-isoquinolin-2-yl)-2-oxoethyl]thio]-3-phenyl-4-quinazolinone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(2,4-dimethoxyphenyl)-2-(1-pyrrolidinyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(4-oxo-3-quinazolinyl)-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)propanamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-methoxy-N-[2-[(4-nitrophenyl)methylthio]-4-oxo-3-quinazolinyl]benzamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(4-methoxyphenyl)-2-(3-nitrophenyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(2-tert-butyl-4-quinazolinyl)thio]-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[[2-(phenylmethyl)-4-quinazolinyl]thio]ethanone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(2-propyl-4-quinazolinyl)thio]-N-(4,5,6,7-tetrahydro-1,3-benzothiazol-2-yl)acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3,4-dihydro-1H-isoquinolin-2-yl)-2-[(2-propyl-4-quinazolinyl)thio]ethanone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(5-methyl-3-isoxazolyl)-2-[(2-propan-2-yl-4-quinazolinyl)thio]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6,7-dimethoxy-N-[(4-methylphenyl)methyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 9-methyl-5,6,7,8-tetrahydrotetrazolo[5,1-b]quinazoline | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(2,4-dichlorophenyl)methylthio]-6,7-dimethoxy-3-(thiophen-2-ylmethyl)-4-quinazolinimine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-chloro-N-(2-furanylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-methoxy-N-(8-methyl-[1,3]dioxolo[4,5-g]quinazolin-6-yl)benzamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| SMER 28 | | organobromine compound;
quinazolines;
secondary amino compound | autophagy inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-methoxy-2-(4-propoxyphenyl)quinazoline | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-butoxy-3-phenyl-4-quinazolinone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N,N-dibutyl-2-(pyridin-4-yl)quinazolin-4-amine | | pyridines;
quinazolines;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-chloro-N-(8-methyl-[1,3]dioxolo[4,5-g]quinazolin-6-yl)benzamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-bromophenyl)-5-[(7-nitro-4-quinazolinyl)oxymethyl]-1,3,4-oxadiazole | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[[4-(2-benzofuranyl)-2-thiazolyl]methyl]-2-[(dimethylamino)methyl]-4-quinazolinone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(benzenesulfonyl)-N-(3-methylphenyl)-5-triazolo[1,5-a]quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[2-[[3-(4-methylphenyl)-5-triazolo[1,5-a]quinazolinyl]amino]ethyl]benzenesulfonamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-bromo-3-[4-nitro-3-(trifluoromethyl)phenyl]-2-propyl-4-quinazolinone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 12-oxo-N-(4-phenyl-2-thiazolyl)-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazoline-3-carboxamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4,5-dimethyl-2-[[1-oxo-2-(4-quinazolinyloxy)ethyl]amino]-3-thiophenecarboxylic acid ethyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-[(6,8-dichloro-4-quinazolinyl)oxymethyl]-5-thiazolo[3,2-a]pyrimidinone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(2,3-dihydro-1H-inden-5-yl)-2-[[3-(2-fluorophenyl)-4-oxo-2-quinazolinyl]thio]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[3-(2,4-difluorophenyl)-4-oxo-2-quinazolinyl]thio]-N-(2,3-dihydro-1H-inden-5-yl)acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[3-[(4-fluorophenyl)methyl]-4-oxo-2-quinazolinyl]thio]-N-(thiophen-2-ylmethyl)acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(2-furanylmethyl)-4-oxo-N,N-dipropyl-2-sulfanylidene-1H-quinazoline-7-carboxamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-(4-quinazolinyloxymethyl)-5-thiazolo[3,2-a]pyrimidinone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N'-(4-quinazolinyl)acetohydrazide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-methyl-N'-(4-quinazolinyl)benzohydrazide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-{3-[(2-phenylquinazolin-4-yl)amino]phenyl}acetamide | | acetamide;
aromatic amine;
quinazolines;
secondary amino compound;
substituted aniline | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(2,3-dihydro-1H-inden-5-yl)-2-[(4-oxo-3-phenyl-2-quinazolinyl)thio]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(3-butyl-4-oxo-2-quinazolinyl)thio]-N-cyclopropylacetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N4-(5-Fluoro-4-imino-3,4-dihydroquinazolin-3-yl)isonicotinamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-sulfanylidene-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(4-chlorophenyl)methyl]-4-(prop-2-enylthio)quinazoline | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-nitrophenyl)-N-(2-oxolanylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-chloro-2-methyl-3-(4-pyridylmethyl)-3,4-dihydroquinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(7-chloro-4-quinazolinyl)oxy]-1-(2,3-dihydro-1,4-benzodioxin-6-yl)ethanone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,3-dimethyl-1-[[9-(methylthio)-5,6-dihydrothieno[3,4-h]quinazolin-2-yl]thio]-2-butanone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4,6,7-Trimethyl-2-quinazolinyl)guanidine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-19241 | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-19663 | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[7-(2-furanyl)-5-oxo-7,8-dihydro-6H-quinazolin-2-yl]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2,4-dichlorophenyl)-3-(phenylmethyl)-1,2-dihydroquinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(3-methoxyphenyl)-3,4,5,6-tetrahydro-1H-benzo[h]quinazoline-2-thione | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[[3-[2-(1-cyclohexenyl)ethyl]-4-oxo-2-sulfanylidene-1H-quinazolin-7-yl]-oxomethyl]-1-piperazinecarboxylic acid ethyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(3-nitrophenyl)-N-(phenylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(2-furanylmethyl)-2-phenyl-1,2-dihydroquinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LSM-19894 | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| importazole | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(1,3-benzothiazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6,7-dimethoxy-3-(2-oxolanylmethyl)-2-sulfanylidene-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(6-quinolinyl)-1,3,4,6,7,8-hexahydroquinazoline-2,5-dione | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 9-phenyl-1,5,6,7,8,9-hexahydro-[1,2,4]triazolo[5,1-b]quinazoline | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(3-butan-2-yl-4-oxo-2-quinazolinyl)thio]propanenitrile | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| altanserin | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[3,5-dimethyl-1-[(4-methylphenyl)methyl]-4-pyrazolyl]-2-[[4-(trifluoromethyl)-5,6-dihydrobenzo[h]quinazolin-2-yl]thio]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(methylthio)-6-phenyl-6,7-dihydro-5H-[1,2,4]triazolo[5,1-b]quinazolin-8-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N'-[2-[(2-cyclohexyl-4-quinazolinyl)thio]-1-oxoethyl]-2-methylpropanehydrazide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3,5-dimethyl-1-piperidinyl)-2-[[2-(thiophen-2-ylmethyl)-4-quinazolinyl]thio]ethanone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ml106 | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(1,3-benzodioxol-5-yl)-N-(2-furanylmethyl)-N-methyl-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(2-furanylmethyl)-6-(3-methoxyphenyl)-N-methyl-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(1,3-benzodioxol-5-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(2-chlorophenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3-furanyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3-pyridinyl)-N-(3-pyridinylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3-furanyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3-methoxyphenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(2-chlorophenyl)-N-(2-furanylmethyl)-N-methyl-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3-methoxyphenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3-furanyl)-N-(3-pyridinylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(3-methylphenyl)methyl]-6-(3-pyridinyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[5-[[2-(3-methoxypropylamino)-2-oxoethyl]thio]-3-oxo-2H-imidazo[1,2-c]quinazolin-2-yl]-N-(phenylmethyl)acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[6-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-6-oxohexyl]-2-sulfanylidene-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[2-[butyl(methyl)amino]ethyl]-6-(4-morpholinyl)-2-sulfanylidene-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(3-chlorophenyl)-2-[6,7-dimethoxy-2,4-dioxo-3-(2-oxolanylmethyl)-1-quinazolinyl]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,4-dioxo-3-pentyl-N-[3-(1-piperidinyl)propyl]-1H-quinazoline-7-carboxamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(3-oxo-2-propan-2-yl-2H-imidazo[1,2-c]quinazolin-5-yl)thio]-N-[2-(4-sulfamoylphenyl)ethyl]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(6-benzimidazolo[1,2-c]quinazolinylthio)-N-(2-furanylmethyl)acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(3-methylanilino)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[4-(1,4-dioxa-8-azaspiro[4.5]decan-8-yl)-4-oxobutyl]-6,7-diethoxy-2-sulfanylidene-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5a,6,7,8,9,10-hexahydro-5H-azepino[2,1-b]quinazolin-12-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(1,3-benzodioxol-5-ylmethyl)-3-cyclopentyl-2,4-dioxo-1H-quinazoline-7-carboxamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6,7-diethoxy-3-[3-(2-oxo-1-pyrrolidinyl)propyl]-2-sulfanylidene-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(1,3-benzodioxol-5-yl)-3-hydroxy-1,2-dihydroquinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(6,7-diethoxy-4-oxo-2-sulfanylidene-1H-quinazolin-3-yl)-N-(2-furanylmethyl)pentanamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-chloro-3-[2-(diethylamino)ethyl]-2-sulfanylidene-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,4-dioxo-3-(2-oxolanylmethyl)-N-pentyl-1H-quinazoline-7-carboxamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[1,3-dioxo-3-[(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)amino]propyl]-1-piperazinecarboxylic acid ethyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-butyl-2-[[6-(4-morpholinyl)-4-oxo-3-(2-phenylethyl)-2-quinazolinyl]thio]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6,7-diethoxy-3-(3-methoxypropyl)-2-sulfanylidene-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| savirin | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[(6,7-diethoxy-2,4-dioxo-1H-quinazolin-3-yl)methyl]-N-(3-methoxypropyl)-1-cyclohexanecarboxamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6,7-dimethoxy-4-(2-oxolanylmethylamino)-1H-quinazoline-2-thione | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(5-methyl-1H-pyrazol-3-yl)-2-[[3-oxo-2-(phenylmethyl)-2H-imidazo[1,2-c]quinazolin-5-yl]thio]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(4-chlorophenyl)-2-(1-pyrrolidinyl)-4-quinazolinone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[2,4-dioxo-3-(phenylmethyl)-1-quinazolinyl]-N-(5-methyl-3-isoxazolyl)acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-methylanilino)-[1,3,4]thiadiazolo[2,3-b]quinazolin-5-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[4-oxo-2-[[2-oxo-2-[(phenylmethyl)amino]ethyl]thio]-3-quinazolinyl]-1-piperidinecarboxylic acid ethyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-hydroxy-2-(2-hydroxy-3-methoxyphenyl)-1,2-dihydroquinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)-3-(3-pyridinylmethyl)thiourea | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[3-(N-ethylanilino)propyl]-6-(4-morpholinyl)-2-sulfanylidene-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 8-methylene-7-(phenylmethyl)-5H-[1,3]dioxolo[4,5-g]quinazoline-6-thione | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[4-methoxy-3-(4-morpholinylmethyl)phenyl]-3-(phenylmethyl)-1,2-dihydroquinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(4-oxo-2-phenyl-1,2-dihydroquinazolin-3-yl)benzenesulfonamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[2-[(3-nitrophenyl)methylthio]-4-oxo-3-quinazolinyl]benzamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-chloro-3-hydroxy-2-[3-(trifluoromethyl)phenyl]-4-quinazolinone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,5-diethyl-2-(3-hydroxypropylamino)-5-methyl-6H-benzo[h]quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(2-methoxyphenyl)-2-methyl-4-oxo-1H-quinazoline-2-carboxylic acid methyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-butyl-1-methyl-3-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)thiourea | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N,N-diethyl-2-[[7-[(4-methoxyphenyl)methyl]-8-oxo-[1,3]dioxolo[4,5-g]quinazolin-6-yl]thio]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(4-morpholinyl)-3-(2-phenylethyl)-2-sulfanylidene-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(1,3-benzodioxol-5-ylmethyl)-6-[6-(4-morpholinyl)-4-oxo-2-sulfanylidene-1H-quinazolin-3-yl]hexanamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[4-oxo-2-(2-pyridinyl)-1,2-dihydroquinazolin-3-yl]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[3-(1-azepanylsulfonyl)-4-methylphenyl]-2-(4-quinazolinylthio)acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(2-fluorophenyl)-4-oxo-2-sulfanylidene-1H-quinazoline-7-carboxylic acid methyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-bromophenyl)-3-[3-(4-morpholinyl)propyl]-1,2-dihydroquinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sch 79797 | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,5-diethyl-2-(2-hydroxyethylamino)-5-methyl-6H-benzo[h]quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-(5-bromo-1h-indol-3-yl)ethyl)-3-(1-methylethoxyphenyl)-4-(3h)-quinazolinone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[2-[4-(dimethylamino)phenyl]-4-oxo-1,2-dihydroquinazolin-3-yl]carbamic acid ethyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-morpholinyl)-10-pyridazino[6,1-b]quinazolinone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(4-ethylphenyl)-2-[[3-[3-(4-methyl-1-piperidinyl)propyl]-4-oxo-2-quinazolinyl]thio]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(3-{[2-(2-fluorophenyl)quinazolin-4-yl]amino}phenyl)acetamide | | acetamide;
aromatic amine;
monofluorobenzenes;
quinazolines;
secondary amino compound;
substituted aniline | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-cyclohexyl-3-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)thiourea | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(2-methoxyethyl)-4-oxo-3-[3-(2-oxo-1-pyrrolidinyl)propyl]-2-sulfanylidene-1H-quinazoline-7-carboxamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(4-propan-2-ylphenyl)-3,4,5,6-tetrahydro-1H-benzo[h]quinazolin-2-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(6-bromo-4-oxo-2-sulfanylidene-1H-quinazolin-3-yl)-N-[2-(4-sulfamoylphenyl)ethyl]hexanamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(3-methoxyphenyl)-2-[(4-oxo-3-propyl-2-quinazolinyl)thio]-2-phenylacetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-thiophen-2-yl-N-(thiophen-2-ylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(1-benzylpiperidin-4-yl)-2-(pyridin-3-yl)quinazolin-4-amine | | aromatic amine;
piperidines;
pyridines;
quinazolines;
secondary amino compound;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-oxo-3-quinazolinyl)-N-[3-(1-piperidinylsulfonyl)phenyl]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[2-(4-methoxyphenyl)-4-oxo-1,2-dihydroquinazolin-3-yl]carbamic acid ethyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-chloro-3-[2-(1-cyclohexenyl)ethyl]-2-sulfanylidene-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[2-[[2-[(5-methyl-1H-pyrazol-3-yl)amino]-2-oxoethyl]thio]-4-oxo-3-quinazolinyl]-N-(phenylmethyl)butanamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[3-butyl-6-(4-morpholinyl)-4-oxo-2-quinazolinyl]thio]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(3,4-dimethoxyphenyl)-3,4,5,6-tetrahydro-1H-benzo[h]quinazoline-2-thione | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[3-(1-benzotriazolylmethyl)-4-methoxyphenyl]-3-(4-methoxyphenyl)-1,2-dihydroquinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-cycloheptyl-3-(2-methoxyethyl)-2,4-dioxo-1H-quinazoline-7-carboxamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cb676475 | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,5-dioxo-2,4-dihydropyrrolo[1,2-a]quinazoline-3-carboxylic acid ethyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| GSK3-XIII | | aromatic amine;
pyrazoles;
quinazolines;
secondary amino compound | EC 2.7.11.26 (tau-protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(1,3-benzoxazol-2-ylamino)-7,7-dimethyl-4-(2-pyridinyl)-1,4,6,8-tetrahydroquinazolin-5-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[2-(2-fluorophenyl)ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[5,1-b]quinazolin-9-amine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(1,3-benzodioxol-5-ylmethyl)-6-chloro-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[3-(4-morpholinyl)propyl]-2,4-dioxo-3-(2-phenylethyl)-1H-quinazoline-7-carboxamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(2-methoxyethyl)-2,4-dioxo-N-pentyl-1H-quinazoline-7-carboxamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(1-amino-1-oxopropan-2-yl)thio]-3-butyl-4-oxo-7-quinazolinecarboxylic acid methyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ic 87114 | | 6-aminopurines;
biaryl;
quinazolines | EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| linagliptin | | aminopiperidine;
quinazolines | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sotrastaurin | | indoles;
maleimides;
N-alkylpiperazine;
N-arylpiperazine;
quinazolines | anticoronaviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunosuppressive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| luotonin a | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azd 1152 | | anilide;
monoalkyl phosphate;
monofluorobenzenes;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
Aurora kinase inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pf 00299804 | | enamide;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lapatinib ditosylate | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| idelalisib | | aromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound | antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(2-methoxyethyl)-2-[[3-[(4-methoxyphenyl)methyl]-6-(4-morpholinyl)-4-oxo-2-quinazolinyl]thio]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxo-N-propan-2-ylbutanamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-butyl-N-methyl-4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxobutanamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[4-[1-[(2-fluorophenyl)methyl]-2,4-dioxo-3-quinazolinyl]phenyl]-N-(2-oxolanylmethyl)acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[6,7-dimethoxy-3-(3-methoxyphenyl)-2,4-dioxo-1-quinazolinyl]-N-(5-methyl-1H-pyrazol-3-yl)acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-butyl-3-[1-[(2,5-dimethylphenyl)methyl]-2,4-dioxo-3-quinazolinyl]propanamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[(4-methylphenyl)methyl]-2,4-dioxo-N-(phenylmethyl)-3-prop-2-enyl-7-quinazolinecarboxamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[(4-methoxyphenyl)methyl]-N-(3-methoxypropyl)-2,4-dioxo-1H-quinazoline-7-carboxamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[1-(4-bromophenoxy)butyl]-8,9-dimethoxy-3H-[1,2,4]triazolo[1,5-c]quinazoline-5-thione | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azd 1152-hqpa | | anilide;
monofluorobenzenes;
primary alcohol;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
Aurora kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[3-(diethylamino)propyl]-4-[(2-methyl-[1,2,4]triazolo[1,5-c]quinazolin-5-yl)hydrazo]-4-oxobutanamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(3-ethynylphenyl)-6,7-dimethoxy-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chaetominine | | indole alkaloid;
lactam;
organic heterotetracyclic compound;
quinazolines | metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[3-(1-azepanyl)propyl]-3-[(4-methoxyphenyl)methyl]-2,4-dioxo-1H-quinazoline-7-carboxamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[6-(4-morpholinyl)-4-oxo-3-(2-phenylethyl)-2-quinazolinyl]thio]-N-(2-oxolanylmethyl)acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[2-[2-(1-piperidinyl)ethyl]-[1,2,4]triazolo[1,5-c]quinazolin-5-yl]thio]-N-[2-(4-sulfamoylphenyl)ethyl]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(4-methylphenyl)-5-oxo-N-propyl-8-thiazolo[2,3-b]quinazolinecarboxamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(4-methylphenyl)-5-oxo-8-thiazolo[2,3-b]quinazolinecarboxamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3,5-dimethyl-4-isoxazolyl)-N-[(3-methoxyphenyl)methyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3,5-dimethyl-4-isoxazolyl)-N-[(2-ethoxyphenyl)methyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[4-[[[6-(3,5-dimethyl-4-isoxazolyl)-4-quinazolinyl]amino]methyl]phenyl]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3,5-dimethyl-4-isoxazolyl)-N-[(1-methyl-2-piperidinyl)methyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3,5-dimethyl-4-isoxazolyl)-N-[1-(2-furanyl)ethyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3,5-dimethyl-4-isoxazolyl)-N-[(3-methyl-2-thiophenyl)methyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[2-[(6-chloro-4-quinazolinyl)amino]ethyl]phenol | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ast 1306 | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[2-(phenoxymethyl)-4-quinazolinyl]thio]acetic acid methyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[4-[[5-[5-hydroxy-4-oxo-3-(phenylmethyl)-1,2-dihydroquinazolin-2-yl]-2-methoxyphenyl]methoxy]phenyl]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(2-furanylmethyl)-N-methyl-6-(1-methyl-5-indolyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(2-chlorophenyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3-methoxyphenyl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(3-methylphenyl)methyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(2-chlorophenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3-chlorophenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3-pyridinyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3-methylphenyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(1-methyl-5-indolyl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(thiophen-2-ylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(1,3-benzodioxol-5-ylmethyl)-6-(2,3-dihydro-1,4-benzodioxin-6-yl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-(3-pyridinylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(1,3-benzodioxol-5-yl)-N-[(3-fluorophenyl)methyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3-chlorophenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3-methylphenyl)-N-(3-pyridinylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(1,3-benzodioxol-5-yl)-N-(3-pyridinylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(1,3-benzodioxol-5-ylmethyl)-6-(2-chlorophenyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(1,3-benzodioxol-5-ylmethyl)-6-(3-pyridinyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(1,3-benzodioxol-5-ylmethyl)-6-(3-furanyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(2-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3-chlorophenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3-methoxyphenyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(4-methyl-2-thiophenyl)methyl]-6-(3-pyridinyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(1,3-benzodioxol-5-yl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(2,3-dihydro-1,4-benzodioxin-6-yl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(3-furanyl)-N-[(4-methyl-2-thiophenyl)methyl]-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[5-(3-hydroxy-4-oxo-1,2-dihydroquinazolin-2-yl)-2-furanyl]benzonitrile | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[5-(2-fluorophenyl)-2-furanyl]-3-hydroxy-1,2-dihydroquinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-hydroxy-2-(5-thiophen-2-yl-2-furanyl)-1,2-dihydroquinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[5-(3-fluorophenyl)-2-furanyl]-3-hydroxy-1,2-dihydroquinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-hydroxy-2-[5-[4-(trifluoromethyl)phenyl]-2-furanyl]-1,2-dihydroquinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-(1,3-benzodioxol-5-yl)-N-methyl-N-(thiophen-2-ylmethyl)-4-quinazolinamine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cp 466722 | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [5-[4-[(5-methyl-2-furanyl)methylamino]-6-quinazolinyl]-2-furanyl]methanol | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| unc 0638 | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| unc 0321 | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ncgc00242364 | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[4-(3-chloro-4-fluoroanilino)-7-[[(3S)-3-oxolanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-methoxy-n-(3-methyl-2-oxo-1,2,3,4-tetrahydroquinazolin-6-yl)benzenesulfonamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nu 1025 | | phenols;
quinazolines | EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[amino-[(6-methoxy-4-methyl-2-quinazolinyl)amino]methylidene]-3-phenylurea | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-oxo-2-(trifluoromethyl)-1H-quinazoline-6-carboxylic acid ethyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-hydroxyquinazoline | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(3,4-dihydro-1H-isoquinolin-2-ylmethyl)-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(2-methyl-2,3-dihydroindol-1-yl)methyl]-4-oxo-1H-quinazoline-7-carboxylic acid methyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[[5,7-bis(ethylamino)-[1,2,4]triazolo[4,3-a][1,3,5]triazin-3-yl]thio]methyl]-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(4-oxo-1H-quinazolin-2-yl)propanoic acid (3,5-dimethyl-4-isoxazolyl)methyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(1,3-benzodioxol-5-ylmethyl)-3-methoxy-N-[(4-oxo-1H-quinazolin-2-yl)methyl]benzamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-cyclopentyl-1-[(4-oxo-1H-quinazolin-2-yl)methyl]-3-(phenylmethyl)urea | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6,8-dibromo-2-[[[4-(difluoromethoxy)phenyl]methyl-methylamino]methyl]-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(5'-chloro-2'-phosphoryloxyphenyl)-6-chloro-4-(3h)-quinazolinone | | aryl phosphate;
monochlorobenzenes;
quinazolines | fluorochrome | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glycosminine | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(4-oxo-1H-quinazolin-2-yl)methyl]-N-(2-phenylethyl)butanamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-methoxyphenyl)-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(7-methoxy-4-methyl-2-quinazolinyl)amino]-5,6-dimethyl-1H-pyrimidin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6,7-dimethoxy-2-[(1H-1,2,4-triazol-5-ylthio)methyl]-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(dimethylamino)methyl]-4-spiro[1,6-dihydrobenzo[h]quinazoline-5,1'-cyclohexane]one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(diethylaminomethyl)-4-spiro[1,6-dihydrobenzo[h]quinazoline-5,1'-cyclohexane]one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[5-(3-chlorophenyl)-2-furanyl]-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(6-ethyl-4-methyl-2-quinazolinyl)amino]-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(2-pyridinylthio)methyl]-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5,5-diethyl-2-(2-hydroxyethylamino)-1,6-dihydrobenzo[h]quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[(7-chloro-4-oxo-1H-quinazolin-2-yl)methyl]-4-piperidinecarboxamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-ethyl-2-[(4-oxo-1H-quinazolin-2-yl)methylthio]-4-quinazolinone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6,7-dimethoxy-2-[[methyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]methyl]-1H-quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(6-ethyl-4-methyl-2-quinazolinyl)amino]-6-(methoxymethyl)-1H-pyrimidin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5,5-diethyl-2-hydrazinyl-1,6-dihydrobenzo[h]quinazolin-4-one | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(3-ethoxypropyl)-1-[(4-oxo-1H-quinazolin-2-yl)methyl]-1-(phenylmethyl)thiourea | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chrysogine | | cyclic amide;
quinazoline alkaloid;
quinazolines;
secondary alcohol;
secondary amide | Aspergillus metabolite;
biological pigment;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(cyclohexylamino)-oxomethyl]-2-[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]acetamide | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7-[[ethyl-[(4-oxo-1H-quinazolin-2-yl)methyl]amino]methyl]-5-thiazolo[3,2-a]pyrimidinone | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[(6-ethyl-4-oxo-3-prop-2-enyl-2-thieno[2,3-d]pyrimidinyl)thio]methyl]-4-oxo-1H-quinazoline-7-carboxylic acid methyl ester | | quinazolines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ARS-1620 | | quinazolines | antineoplastic agent;
antiviral agent;
inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| astemizole | | benzimidazoles;
piperidines | anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| biperiden | | piperidines;
tertiary alcohol;
tertiary amino compound | antidote to sarin poisoning;
antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist;
parasympatholytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clebopride | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cycrimine | | piperidines;
tertiary alcohol;
tertiary amino compound | antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyproheptadine | | piperidines;
tertiary amine | anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diphenidol | | benzenes;
piperidines;
tertiary alcohol | antiemetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diphenylpyraline | | piperidines;
tertiary amine | cholinergic antagonist;
H1-receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dipyridamole | | piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol | adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dyclonine | | aromatic ketone;
piperidines | topical anaesthetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| eperisone | | aromatic ketone;
piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethyl piperidinoacetylaminobenzoate | | benzoate ester;
piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fentanyl | | anilide;
monocarboxylic acid amide;
piperidines | adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fexofenadine | | piperidines;
tertiary amine | anti-allergic agent;
H1-receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flavoxate | | carboxylic ester;
flavones;
piperidines;
tertiary amino compound | antispasmodic drug;
muscarinic antagonist;
parasympatholytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glutethimide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ifenprodil | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ketotifen | | cyclic ketone;
olefinic compound;
organic heterotricyclic compound;
organosulfur heterocyclic compound;
piperidines;
tertiary amino compound | anti-asthmatic drug;
H1-receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| loperamide | | monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol | anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mazaticol | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mefloquine hydrochloride | | organofluorine compound;
piperidines;
quinolines;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methylphenidate | | beta-amino acid ester;
methyl ester;
piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methixene | | piperidines;
thioxanthenes | antiparkinson drug;
histamine antagonist;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| perhexiline | | piperidines | cardiovascular drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pridinol | | piperidines;
tertiary alcohol | antiparkinson drug;
muscle relaxant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ritanserin | | organofluorine compound;
piperidines;
thiazolopyrimidine | antidepressant;
antipsychotic agent;
anxiolytic drug;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| roxatidine acetate | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sb 220025 | | aminopyrimidine;
imidazoles;
organofluorine compound;
piperidines | angiogenesis inhibitor;
anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| spiperone | | aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound | alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thioridazine | | phenothiazines;
piperidines | alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tipepidine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vesamicol | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diphemanil methylsulfate | | piperidines;
quaternary ammonium salt | bronchodilator agent;
muscarinic antagonist;
parasympatholytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phencyclidine | | benzenes;
piperidines | anaesthetic;
neurotoxin;
NMDA receptor antagonist;
psychotropic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pempidine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-methylpiperidine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| jervine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ketobemidone | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phenoperidine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzetimide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| piminodine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dexetimide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(4-chlorophenyl)-4-hydroxypiperidine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sufentanil | | anilide;
ether;
piperidines;
thiophenes | anaesthesia adjuvant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| encainide | | benzamides;
piperidines | anti-arrhythmia drug;
sodium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alfentanil | | monocarboxylic acid amide;
piperidines | central nervous system depressant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
peripheral nervous system drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| miglustat | | piperidines;
tertiary amino compound | anti-HIV agent;
EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| levocabastine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| preclamol | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tzu 0460 | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| eliprodil | | monochlorobenzenes;
monofluorobenzenes;
piperidines;
secondary alcohol;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tirofiban | | L-tyrosine derivative;
piperidines;
sulfonamide | anticoagulant;
fibrin modulating drug;
platelet glycoprotein-IIb/IIIa receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-methylfentanyl | | monocarboxylic acid amide;
piperidines | mu-opioid receptor agonist;
opioid analgesic;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carfentanil | | methyl ester;
piperidines;
tertiary amino compound;
tertiary carboxamide | mu-opioid receptor agonist;
opioid analgesic;
tranquilizing drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| f 7302 | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-fluorofentanyl | | monocarboxylic acid amide;
organofluorine compound;
piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tenocyclidine | | piperidines;
tertiary amino compound;
thiophenes | central nervous system stimulant;
hallucinogen;
neuroprotective agent;
NMDA receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| terikalant | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| repaglinide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sufotidine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fagomine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-nitrophenyl)piperidine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fentanyl isothiocyanate | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ritalinic acid | | monocarboxylic acid;
piperidines | drug metabolite;
marine xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenpropidine | | piperidines;
tertiary amine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sk&f 95282 | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| biperiden hydrochloride | | hydrochloride;
piperidines;
tertiary alcohol | antiparkinson drug;
muscarinic antagonist;
parasympatholytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phenglutarimide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gr 113808 | | indolyl carboxylate ester;
piperidines;
sulfonamide | serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alphaprodine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lofentanil | | methyl ester;
piperidines;
tertiary amino compound;
tertiary carboxamide | mu-opioid receptor agonist;
opioid analgesic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(1-(2-benzo(b)thienyl)cyclohexyl)piperidine | | 1-benzothiophenes;
piperidines;
tertiary amino compound | dopamine uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| picaridin | | carboxylic acid;
piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(4-piperidyl)isoxazol-3-ol | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ku 1257 | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| l 733060 | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-(n-benzylpiperidin-4-yl)-4-iodobenzamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| l 741626 | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| migalastat | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zanapezil | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| anacoline iodide | | dioxolane;
piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| norfentanyl | | anilide;
monocarboxylic acid amide;
piperidines | drug metabolite;
opioid analgesic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| miglitol | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| magellanine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tecomine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyclopamine | | piperidines | glioma-associated oncogene inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| isofagomine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| efinaconazole | | conazole antifungal drug;
olefinic compound;
organofluorine compound;
piperidines;
tertiary alcohol;
tertiary amino compound;
triazole antifungal drug | EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(1,3-benzodioxol-5-yl)-1-[4-(4-morpholinylsulfonyl)phenyl]-4-piperidinecarboxamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(1-adamantyl)-4-(1,3-benzodioxol-5-yl)-4-hydroxy-1-piperidinecarboxamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[(1,3-dimethyl-2,6-dioxo-7-propyl-8-purinyl)thio]-N-[2-(1-piperidinyl)phenyl]acetamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-methyl-N-[3-[1-(phenylmethyl)-4-piperidinyl]-2,4-dihydro-1H-1,3,5-triazin-6-yl]benzenesulfonamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(2-benzamidoethylamino)-1-piperidinecarboxylic acid ethyl ester | | carboxylic acid;
piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[3-(dimethylamino)-2,2-dimethylpropyl]-1-[(2-hydroxyphenyl)methyl]-4-piperidinecarboxamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(2-ethoxyphenyl)-1-[4-(1-pyrrolidinylsulfonyl)phenyl]-4-piperidinecarboxamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4,6-dimethyl-2-pyrimidinyl)-4-piperidinecarboxylic acid | | carboxylic acid;
piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(4-{[2-(pyridin-3-yl)piperidin-1-yl]sulfonyl}phenyl)acetamide | | acetamides;
piperidines;
pyridines;
sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vesamicol | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(1-oxo-2-thiophen-2-ylethyl)-4-piperidinecarboxylic acid ethyl ester | | carboxylic acid;
piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-Piperidinobenzoic acid | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-methylphenoxy)-N-[2-(4-methyl-1-piperidinyl)phenyl]acetamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(phenylmethyl)-5-[4-(phenylmethyl)-1-piperidinyl]-4-oxazolecarbonitrile | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(phenylmethyl)-N'-(2,4,6-trimethylphenyl)sulfonyl-4-piperidinecarbohydrazide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[2-[(4-methyl-2-oxo-1-benzopyran-7-yl)oxy]-1-oxoethyl]-4-phenyl-4-piperidinecarboxylic acid | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-1,3-diazaspiro[4.6]undecane-2,4-dione | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[1-(phenylmethyl)-4-piperidinyl]-3-(2,4,4-trimethylpentan-2-yl)thiourea | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[4-(phenylmethyl)-1-piperidinyl]thieno[2,3-d]pyrimidine | | piperidines;
thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyclohexanecarboxylic acid [2-oxo-2-[4-(1-piperidinyl)anilino]ethyl] ester | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[1-(phenylmethyl)-4-piperidinyl]-3-(2-propan-2-ylphenyl)thiourea | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-ethylphenyl)-3-[1-(phenylmethyl)-4-piperidinyl]thiourea | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tempo | | aminoxyls;
piperidines | catalyst;
ferroptosis inhibitor;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-maleimido-2,2,6,6-tetramethylpiperidinooxyl | | aminoxyls;
dicarboximide;
maleimides;
piperidines | radical scavenger;
spin label | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(4-bromophenyl)-4-(2-methoxyphenyl)-1-piperidinecarbothioamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N1-(1-benzyl-4-piperidyl)-4-chlorobenzene-1-sulfonamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,3-dimethyl-1-[4-(trifluoromethoxy)phenyl]piperidine-2,6-dione | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[(3,5-dimethylisoxazol-4-yl)sulfonyl]piperidine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(benzenesulfonyl)-1-[(4-chlorophenyl)methyl]-4-piperidinecarboxylic acid ethyl ester | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-benzyl-6-hydroxy-2-azabicyclo[2.2.2]octan-3-one | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-methyl-N-[1-(phenylmethyl)-4-piperidinyl]-4-thieno[2,3-d]pyrimidinamine | | piperidines;
thienopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[1-(2-chloro-6-fluorobenzyl)-4-piperidinyl]-N'-(4-fluorophenyl)urea | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [4-(2-methoxyphenyl)-1-piperidinyl]-(5-methyl-1-phenyl-4-pyrazolyl)methanone | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-acetamidobenzenesulfonic acid [2-(1-piperidinyl)phenyl] ester | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3-phenylpropanoyl)-4-piperidinecarboxylic acid | | carboxylic acid;
piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-fluoro-N-[2-(1-piperidinyl)phenyl]benzenesulfonamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2-fluorophenyl)-3-[2-(1-piperidinyl)phenyl]urea | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(1-piperidinyl)-3-[[3-(trifluoromethyl)phenyl]sulfonylamino]benzoic acid ethyl ester | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[(3-chlorophenyl)methyl]-N,N-diethyl-3-piperidinecarboxamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-hydroxy-5-nitro-2-phenyl-N-[1-(phenylmethyl)-4-piperidinyl]-4-triazolimine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3-chlorophenyl)-3-[[1-[(2,5-dimethoxyphenyl)methyl]-4-piperidinyl]methyl]urea | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[2-hydroxy-3-[4-(2-methylbutan-2-yl)phenoxy]propyl]-4-piperidinecarboxylic acid ethyl ester | | carboxylic acid;
piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| femoxetine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-phenyl-1-(4-phenylbutyl)piperidine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(1h-imidazol-4-ylmethyl)piperidine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-phenylspiro[7-oxa-1-azabicyclo[2.2.1]heptane-2,1'-cyclopentane] | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,5-dimethyl-2,6-bis(4-methylphenyl)-4-piperidinone | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[2-[(4-chlorophenyl)thio]-1-oxopropyl]-4-piperidinecarboxylic acid ethyl ester | | carboxylic acid;
piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[9-[(4-fluorophenyl)methyl]-9-azabicyclo[3.3.1]nonan-3-yl]-3-(2-phenylphenyl)urea | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(2-fluorophenyl)-1-[[1-[(4-methoxyphenyl)methyl]-5-tetrazolyl]methyl]-4-piperidinol | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(3-methylphenyl)-3-[[1-[4-(4-morpholinylsulfonyl)phenyl]-4-piperidinyl]methyl]urea | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2-methylphenyl)-3-[[1-[4-(4-morpholinylsulfonyl)phenyl]-4-piperidinyl]methyl]urea | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[2-[3-(N-ethylanilino)propylamino]-3,4-dioxo-1-cyclobutenyl]-4-piperidinecarboxylic acid ethyl ester | | carboxylic acid;
piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[2-(3,4-dimethoxyphenyl)ethyl]-1-[(3,4-dimethoxyphenyl)methyl]-N-methyl-3-piperidinecarboxamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[[2-(3-ethylanilino)-3,4-dioxo-1-cyclobutenyl]amino]-1-piperidinecarboxylic acid ethyl ester | | carboxylic acid;
piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,4-dimethyl-6-[[4-(phenylmethyl)-1-piperidinyl]sulfonyl]quinoxaline-2,3-dione | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[(3-chlorophenyl)methyl]-N-methyl-N-(phenylmethyl)-3-piperidinecarboxamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[4-[3-(4-methoxyphenyl)-1H-pyrazol-5-yl]-1-piperidinyl]-3-nitrobenzoic acid methyl ester | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzoic acid [[1-(4-nitrophenyl)-4-piperidinylidene]amino] ester | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[(4-chlorophenyl)methyl]-4-(4-chlorophenyl)sulfonyl-4-piperidinecarboxylic acid ethyl ester | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[3-[(2-methoxyphenyl)sulfamoyl]-4-(1-piperidinyl)phenyl]-3-(3-methylphenyl)urea | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[(6-hydroxy-2-methyl-5-thiazolo[3,2-b][1,2,4]triazolyl)-(3,4,5-trimethoxyphenyl)methyl]-4-piperidinecarboxylic acid methyl ester | | carboxylic acid;
piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-pyrrolidinyl-[1-[(2,3,4-trimethoxyphenyl)methyl]-3-piperidinyl]methanone | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[1-[4-(diethylamino)phenyl]-4a-hydroxy-1,3,4,5,6,7,8,8a-octahydroisoquinolin-2-yl]-N-phenylacetamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(hexylamino)-1-[4-(phenylmethyl)-1-piperidinyl]ethanone | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LY-310762 | | aromatic ketone;
monofluorobenzenes;
oxindoles;
piperidines;
tertiary amino compound | receptor modulator;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(4-morpholinylsulfonyl)-2-(1-piperidinyl)benzoic acid [2-[[(3-methylbutylamino)-oxomethyl]amino]-2-oxoethyl] ester | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-methyl-2,6-diphenyl-7-oxa-1-azabicyclo[2.2.1]heptane | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(3-isoxazolyl)-3-nitro-4-(1-piperidinyl)benzamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-4-(4-methyl-1-piperidinyl)-3-nitrobenzamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-phenyl-N-[1-(phenylmethyl)-4-piperidinyl]-4-quinazolinamine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-carbamoyl-2-nitrophenyl)-4-piperidinecarboxylic acid methyl ester | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(1,3-benzodioxol-5-yl)-4-(4-methyl-1-piperidinyl)-3-nitrobenzamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-[2-furanyl-[4-(phenylmethyl)-1-piperidinyl]methyl]-6-thiazolo[3,2-b][1,2,4]triazolol | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-nitro-6-(3-nitrophenyl)-2-piperidinone | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-nitro-4-[2-[1-(phenylmethyl)-4-piperidinylidene]hydrazinyl]benzenesulfonamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[4-[(4-methyl-1-piperidinyl)methyl]phenyl]-1-[5-(1-pyrrolyl)-1,3,4-thiadiazol-2-yl]-4-piperidinecarboxamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| palbociclib | | aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2-chlorophenyl)-3-[4-(1-piperidinylmethyl)phenyl]urea | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| opc-67683 | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ro 25-6981 | | benzenes;
phenols;
piperidines;
secondary alcohol;
tertiary amino compound | anticonvulsant;
antidepressant;
neuroprotective agent;
NMDA receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pd 174494 | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-ethoxy-N-[1-(phenylmethyl)-4-piperidinyl]benzamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-demethylloperamide | | monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol | drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bms201038 | | (trifluoromethyl)benzenes;
benzamides;
fluorenes;
piperidines | anticholesteremic drug;
MTP inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| casopitant | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rolapitant | | azaspiro compound;
ether;
organofluorine compound;
piperidines;
pyrrolidin-2-ones | antiemetic;
neurokinin-1 receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| at 7867 | | monochlorobenzenes;
piperidines;
pyrazoles | antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| at 7519 | | dichlorobenzene;
piperidines;
pyrazoles;
secondary carboxamide | antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alogliptin | | nitrile;
piperidines;
primary amino compound;
pyrimidines | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-o-desmethyl donepezil | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nvp-tae684 | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [3-[(2-methylphenyl)methyl]-1-[(5-methyl-2-thiophenyl)methyl]-3-piperidinyl]methanol | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-fluoro-5-methoxyphenyl)-5-methyl-4-[(4-phenyl-1-piperidinyl)methyl]oxazole | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [3-[(3-chlorophenyl)methyl]-1-[(7-methoxy-1,3-benzodioxol-5-yl)methyl]-3-piperidinyl]methanol | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[4-[1-(2-fluorophenyl)-4-piperidinyl]-1-[(3-methoxyphenyl)methyl]-2-piperazinyl]ethanol | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [1-[(1,2-dimethyl-3-indolyl)methyl]-4-[[3-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]methanol | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [1-(2-benzofuranylmethyl)-4-[[3-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]methanol | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(5-isoquinolinylmethyl)-4-[(3-methoxyphenyl)methyl]-4-piperidinecarboxylic acid ethyl ester | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[[4-[(4-chlorophenyl)methyl]-4-(hydroxymethyl)-1-piperidinyl]-oxomethyl]-4,5-dihydro-1H-pyridazin-6-one | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(2-chloro-4-methylphenyl)-3-[[1-[(3-chlorophenyl)methyl]-4-piperidinyl]methyl]urea | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(12-oxo-7,8,9,10-tetrahydro-6H-azepino[2,1-b]quinazolin-2-yl)-3-[3-[4-(phenylmethyl)-1-piperidinyl]propyl]thiourea | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-hydroxy-2-(3-methylphenyl)-5-nitro-N-[1-(phenylmethyl)-4-piperidinyl]-4-triazolimine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[3-(4-methoxyphenyl)-1H-pyrazol-5-yl]-1-[[3-(trifluoromethyl)phenyl]methyl]piperidine | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gdc-0973 | | aromatic amine;
difluorobenzene;
N-acylazetidine;
organoiodine compound;
piperidines;
secondary amino compound;
tertiary alcohol | antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| WAY-316606 | | (trifluoromethyl)benzenes;
piperidines;
secondary amino compound;
sulfonamide;
sulfone | secreted frizzled-related protein 1 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-butyl-4-(phenylmethyl)-1-piperidinecarbothioamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alcaftadine | | aldehyde;
imidazobenzazepine;
piperidines;
tertiary amino compound | anti-allergic agent;
H1-receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(2-methylpropyl)-4-(phenylmethyl)-1-piperidinecarbothioamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(phenylmethyl)-N-prop-2-enyl-1-piperidinecarbothioamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[2-[1-[(4-methoxy-3-methylphenyl)methyl]-4-piperidinyl]-3-pyrazolyl]-4-phenylbutanamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[[3-(4-chlorophenyl)-5-isoxazolyl]methyl]-1-[(2-methylpropan-2-yl)oxy-oxomethyl]-4-piperidinecarboxylic acid | | carboxylic acid;
piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2,6-dimethylphenoxy)-N-[2-(1-piperidinyl)phenyl]acetamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| niraparib | | benzenes;
indazoles;
piperidines;
primary carboxamide | antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ipi-926 | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| asp3026 | | aromatic amine;
diamino-1,3,5-triazine;
monomethoxybenzene;
N-methylpiperazine;
piperidines;
secondary amino compound;
sulfone | antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 6.1.1.6 (lysine--tRNA ligase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bix 01294 | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pf 3845 | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glasdegib | | benzimidazoles;
nitrile;
phenylureas;
piperidines | antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[3-methoxy-4-[[4-(2-propan-2-ylsulfonylanilino)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]phenyl]-4-piperidinol | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[4-[[4-amino-5-chloro-6-(2-propan-2-ylsulfonylanilino)-2-pyrimidinyl]amino]-3-methoxyphenyl]-4-piperidinecarboxamide | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,3-dimethoxy-N-[4-(1-piperidinyl)phenyl]aniline | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ulixacaltamide | | benzamides;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
secondary carboxamide | non-narcotic analgesic;
T-type calcium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Mps1-IN-2 | | piperidines | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gilteritinib | | aromatic amine;
monomethoxybenzene;
N-methylpiperazine;
oxanes;
piperidines;
primary carboxamide;
pyrazines;
secondary amino compound | antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alectinib | | aromatic ketone;
morpholines;
nitrile;
organic heterotetracyclic compound;
piperidines | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk2879552 | | benzenes;
benzoic acids;
cyclopropanes;
monocarboxylic acid;
piperidines;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
EC 1.14.99.66 (lysine-specific histone demethylase 1A) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| PF-06446846 | | benzamides;
monochloropyridine;
piperidines;
tertiary carboxamide;
triazolopyridine | antilipemic drug;
EC 3.4.21.61 (kexin) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromhexine | | organobromine compound;
substituted aniline;
tertiary amino compound | mucolytic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromodiphenhydramine | | organobromine compound;
tertiary amino compound | antimicrobial agent;
H1-receptor antagonist;
muscarinic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromisovalum | | N-acylurea;
organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| liquid crystal polymer | | conazole fungicide;
dichlorobenzene;
organobromine compound;
oxolanes;
triazole fungicide;
triazoles | antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| halothane | | haloalkane;
organobromine compound;
organochlorine compound;
organofluorine compound | inhalation anaesthetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nsc 664704 | | indolobenzazepine;
lactam;
organobromine compound | cardioprotective agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
geroprotector | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| naled | | dialkyl phosphate;
organobromine compound;
organochlorine compound;
organophosphate insecticide | acaricide;
agrochemical;
antibacterial agent;
antifungal agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pipobroman | | N-acylpiperazine;
organobromine compound;
tertiary carboxamide | alkylating agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulfobromophthalein | | 2-benzofurans;
organobromine compound;
organosulfonic acid;
phenols | dye | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tribromoethanol | | alcohol;
organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromthymol blue | | 2,1-benzoxathiole;
arenesulfonate ester;
organobromine compound;
polyphenol;
sultone | acid-base indicator;
dye;
two-colour indicator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| brompheniramine | | organobromine compound;
pyridines | anti-allergic agent;
H1-receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-bromo-2-chloroethane | | haloalkane;
organobromine compound;
organochlorine compound | mutagen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromphenol blue | | 2,1-benzoxathiole;
arenesulfonate ester;
organobromine compound;
phenols;
sultone | acid-base indicator;
dye;
two-colour indicator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromcresol purple | | 2,1-benzoxathiole;
arenesulfonate ester;
organobromine compound;
polyphenol;
sultone | acid-base indicator;
dye;
two-colour indicator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromacil | | organobromine compound;
pyrimidone | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromochlorodifluoromethane | | one-carbon compound;
organobromine compound;
organochlorine compound;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| perflubron | | haloalkane;
organobromine compound;
perfluorinated compound | blood substitute;
radioopaque medium | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| eosine yellowish-(ys) | | organic sodium salt;
organobromine compound | fluorochrome;
histological dye | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-bromo-2,4-dinitrobenzene | | C-nitro compound;
organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-bromo-2-chlorophenol | | halophenol;
monochlorobenzenes;
organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-bromo-2-naphthol | | naphthols;
organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cincreasin | | benzoxazole;
organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 8-bromo cyclic adenosine monophosphate | | 3',5'-cyclic purine nucleotide;
adenyl ribonucleotide;
organobromine compound | antidepressant;
protein kinase agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,3,7,8-tetrabromodibenzo-4-dioxin | | dibenzodioxine;
organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromfenac | | aromatic amino acid;
benzophenones;
organobromine compound;
substituted aniline | non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,2-dibromo-2,4-dicyanobutane | | aliphatic nitrile;
organobromine compound | allergen;
sensitiser | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-bromo-4-chloro-3-indolyl beta-galactoside | | beta-D-galactoside;
D-aldohexose derivative;
indolyl carbohydrate;
organobromine compound;
organochlorine compound | chromogenic compound | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-bromo-4-chloro-3-indoxyl phosphate | | aryl phosphate;
indoles;
organobromine compound;
organochlorine compound | chromogenic compound | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromosuccinimide | | dicarboximide;
organobromine compound;
pyrrolidinone | reagent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromopyruvate | | 2-oxo monocarboxylic acid;
organobromine compound;
oxo carboxylic acid | alkylating agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gr 117289 | | 1-benzofurans;
biaryl;
imidazolyl carboxylic acid;
monocarboxylic acid;
organobromine compound;
organochlorine compound;
tetrazoles | angiotensin receptor antagonist;
antihypertensive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-bromo-2-naphthyl-beta-galactopyranoside | | beta-D-galactoside;
organobromine compound | chromogenic compound | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromoacetaldehyde | | organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| monobromobimane | | organobromine compound;
pyrazolopyrazole | fluorochrome | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dibromobimane | | organobromine compound;
pyrazolopyrazole | fluorochrome | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-bromo-3-(bromomethyl)-7-methyl-2,3,7-trichloro-1-octene | | monoterpenoid;
organobromine compound;
organochlorine compound | algal metabolite;
antineoplastic agent;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| eosine-5-isothiocyanate | | isothiocyanate;
organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-bromo-2-(4-chlorophenyl)-5-(trifluoromethyl)-1h-pyrrole-3-carbonitrile | | monochlorobenzenes;
nitrile;
organobromine compound;
organochlorine acaricide;
organochlorine insecticide;
organofluorine acaricide;
organofluorine insecticide;
pyrroles | acaricide;
antifouling biocide;
insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-bromophenyl)-5-(2-methylphenyl)-1,3,4-oxadiazole | | organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mitobronitol | | alcohol;
organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pyrabactin | | naphthalenes;
organobromine compound;
pyridines;
sulfonamide | abscisic acid receptor agonist;
hormone;
plant growth regulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-amino-4-[(4-bromophenyl)methylthio]-3-azaspiro[5.5]undeca-1,4-diene-1,5-dicarbonitrile | | organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-bromophenyl)-3,5-dimethyl-4-oxido-6-phenylpyrazin-1-ium 1-oxide | | organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-bromophenyl)thiazolidine | | organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| wiskostatin | | carbazoles;
organobromine compound;
secondary alcohol;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[1-(4-bromophenyl)ethyl]cyclobutanecarboxamide | | organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromohydrin pyrophosphate | | alkyl diphosphate;
organobromine compound | phosphoantigen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mitolactol | | alcohol;
organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-azakenpaullone | | lactam;
organic heterotetracyclic compound;
organobromine compound;
organonitrogen heterocyclic compound | EC 2.7.11.26 (tau-protein kinase) inhibitor;
Wnt signalling activator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lonafarnib | | benzocycloheptapyridine;
heteroarylpiperidine;
N-acylpiperidine;
organobromine compound;
organochlorine compound;
ureas | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-bromouridine triphosphate | | organobromine compound;
pyrimidine ribonucleoside 5'-triphosphate | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[4-(4-bromophenyl)phenyl]sulfonylamino]-3-methylbutanoic acid | | biphenyls;
organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ageladine a | | alkaloid;
aromatic amine;
imidazopyridine;
organobromine compound;
pyrroles | angiogenesis inhibitor;
antineoplastic agent;
matrix metalloproteinase inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| jaspamide b | | cyclodepsipeptide;
organobromine compound | animal metabolite;
antineoplastic agent;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| massadine | | alkaloid;
guanidines;
organobromine compound;
pyrrolecarboxamide | animal metabolite;
EC 2.5.1.59 (protein geranylgeranyltransferase type I) inhibitor;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorantranilipole | | monochlorobenzenes;
organobromine compound;
pyrazole insecticide;
pyrazoles;
pyridines;
secondary carboxamide | ryanodine receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| laurinterol | | organobromine compound;
phenols;
sesquiterpenoid | antibacterial agent;
apoptosis inducer;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyantraniliprole | | nitrile;
organobromine compound;
organochlorine compound;
pyrazole insecticide;
pyridines;
secondary carboxamide | ryanodine receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromophycolide a | | diterpenoid;
macrolide;
organobromine compound;
phenols;
tertiary alcohol | anti-HIV agent;
antibacterial agent;
antifungal agent;
antimalarial;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dibromophakellin | | alkaloid;
guanidines;
organobromine compound | alpha-adrenergic agonist;
animal metabolite;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (E,E)-1-bromo-2,5-bis-(4-hydroxystyryl)benzene | | organobromine compound;
polyphenol | fluorescent dye | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lesinurad | | aryl sulfide;
cyclopropanes;
monocarboxylic acid;
naphthalenes;
organobromine compound;
triazoles | uricosuric drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| AZ3451 | | benzimidazoles;
benzodioxoles;
nitrile;
organobromine compound;
secondary carboxamide | anti-inflammatory agent;
autophagy inducer;
PAR2 negative allosteric modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 8-bromocyclic gmp | | 3',5'-cyclic purine nucleotide;
organobromine compound | muscle relaxant;
protein kinase G agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 8-bromo-2'-deoxyguanosine | | guanosines;
organobromine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benefin | | C-nitro compound;
organofluorine compound;
substituted aniline;
tertiary amino compound | agrochemical;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| celecoxib | | organofluorine compound;
pyrazoles;
sulfonamide;
toluenes | cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cgs 12066 | | N-arylpiperazine;
organofluorine compound;
pyrroloquinoxaline | serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| citalopram | | 2-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diflunisal | | monohydroxybenzoic acid;
organofluorine compound | non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| droperidol | | aromatic ketone;
benzimidazoles;
organofluorine compound | anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| enflurane | | ether;
organochlorine compound;
organofluorine compound | anaesthetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flucytosine | | aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone | prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fludiazepam | | 1,4-benzodiazepinone;
organochlorine compound;
organofluorine compound | anxiolytic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flufenamic acid | | aromatic amino acid;
organofluorine compound | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluphenazine | | N-alkylpiperazine;
organofluorine compound;
phenothiazines | anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flumazenil | | ethyl ester;
imidazobenzodiazepine;
organofluorine compound | antidote to benzodiazepine poisoning;
GABA antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flumequine | | 3-oxo monocarboxylic acid;
organofluorine compound;
pyridoquinoline;
quinolone antibiotic | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluorouracil | | nucleobase analogue;
organofluorine compound | antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluphenazine depot | | decanoate ester;
N-alkylpiperazine;
organofluorine compound;
phenothiazines | dopaminergic antagonist;
phenothiazine antipsychotic drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vanoxerine | | ether;
N-alkylpiperazine;
organofluorine compound;
tertiary amino compound | dopamine uptake inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| haloperidol | | aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol | antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| isoflurane | | organofluorine compound | inhalation anaesthetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methoxyflurane | | ether;
organochlorine compound;
organofluorine compound | hepatotoxic agent;
inhalation anaesthetic;
nephrotoxic agent;
non-narcotic analgesic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ofloxacin | | 3-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pipamperone | | aromatic ketone;
bipiperidines;
monocarboxylic acid amide;
organofluorine compound;
tertiary amino compound | dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| risperidone | | 1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine | alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sb 202190 | | imidazoles;
organofluorine compound;
phenols;
pyridines | apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sevoflurane | | ether;
organofluorine compound | central nervous system depressant;
inhalation anaesthetic;
platelet aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluoroacetic acid | | haloacetic acid;
organofluorine compound | EC 4.2.1.3 (aconitate hydratase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gatifloxacin | | N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tosufloxacin | | 1,8-naphthyridine derivative;
amino acid;
aminopyrrolidine;
monocarboxylic acid;
organofluorine compound;
primary amino compound;
quinolone antibiotic;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trifluoperazine | | N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines | antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triflupromazine | | organofluorine compound;
phenothiazines;
tertiary amine | anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zardaverine | | organofluorine compound;
pyridazinone | anti-asthmatic drug;
bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
peripheral nervous system drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| floxuridine | | nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trifluridine | | nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dinitrofluorobenzene | | C-nitro compound;
organofluorine compound | agrochemical;
allergen;
chromatographic reagent;
EC 2.7.3.2 (creatine kinase) inhibitor;
protein-sequencing agent;
spectrophotometric reagent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,1-difluoroethylene | | olefinic compound;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,1,1-trifluoro-2-chloroethane | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chloropentafluoroethane | | organochlorine compound;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-fluoroadenosine | | adenosines;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| perfluorotributylamine | | organofluorine compound | blood substitute;
greenhouse gas;
solvent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-fluorouridine | | organofluorine compound;
uridines | mutagen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-fluorotryptophan | | non-proteinogenic alpha-amino acid;
organofluorine compound;
tryptophan derivative | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| difluoroacetic acid | | monocarboxylic acid;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluroxene | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,3,4,5,6-pentafluorobenzyl alcohol | | benzyl alcohols;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-fluoroadenine | | organofluorine compound;
purines | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-dichlorofluoromethylthio-n',n'-dimethyl-n-p-tolylsulfamide | | organochlorine compound;
organofluorine compound;
phenylsulfamide fungicide;
sulfamides | antifungal agrochemical;
genotoxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hexafluoroisopropanol | | organofluorine compound;
secondary alcohol | drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dichlofluanid | | organochlorine compound;
organofluorine compound;
phenylsulfamide fungicide;
sulfamides | acaricide;
antifungal agrochemical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pimozide | | benzimidazoles;
heteroarylpiperidine;
organofluorine compound | antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-fluorocytidine | | cytidines;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| doxifluridine | | organofluorine compound;
pyrimidine 5'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fludarabine phosphate | | nucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate | antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flubendazole | | aromatic ketone;
benzimidazoles;
carbamate ester;
organofluorine compound | antinematodal drug;
teratogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flunixin | | aminopyridine;
organofluorine compound;
pyridinemonocarboxylic acid | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| desflurane | | organofluorine compound | inhalation anaesthetic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| temafloxacin | | amino acid;
monocarboxylic acid;
N-arylpiperazine;
organofluorine compound;
quinolone antibiotic;
quinolone;
secondary amino compound;
tertiary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sertindole | | heteroarylpiperidine;
imidazolidinone;
organochlorine compound;
organofluorine compound;
phenylindole | alpha-adrenergic antagonist;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gemcitabine hydrochloride | | hydrochloride;
organofluorine compound | anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral drug;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
immunosuppressive agent;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gemcitabine | | organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| emtricitabine | | monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| capecitabine | | carbamate ester;
cytidines;
organofluorine compound | antimetabolite;
antineoplastic agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| efavirenz | | acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| heptafluorobutyric anhydride | | acyclic carboxylic anhydride;
organofluorine compound | chromatographic reagent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| perfluorotripropylamine | | organofluorine compound | blood substitute | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-fluoropyruvate | | 2-oxo monocarboxylic acid;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flunoxaprofen | | 1,3-benzoxazoles;
monocarboxylic acid;
organofluorine compound | antirheumatic drug;
hepatotoxic agent;
non-steroidal anti-inflammatory drug;
protein kinase C agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| halopropane | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| enrofloxacin | | cyclopropanes;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone | antibacterial agent;
antimicrobial agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flurithromycin | | cyclic ketone;
erythromycin derivative;
organofluorine compound;
semisynthetic derivative | antibacterial drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nebivolol | | chromanes;
diol;
organofluorine compound;
secondary alcohol;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nucleocidin | | 6-aminopurines;
adenosines;
diol;
organofluorine compound;
sulfamate ester | antibacterial agent;
bacterial metabolite;
nucleoside antibiotic;
protein synthesis inhibitor;
trypanocidal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluoroacetaldehyde | | aldehyde;
organofluorine compound | cardiotoxic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fc 75 | | alkyltetrahydrofuran;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tetraconazole | | dichlorobenzene;
ether;
organofluorine compound;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hei 712 | | organofluorine compound;
quinolone | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-(2,4-dichloro-5-(4-(difluoromethyl)-4,5-dihydro-3-methyl-5-oxo-1h-1,2,4-triazol-1-yl)phenyl)methanesulfonamide | | dichlorobenzene;
organofluorine compound;
sulfonamide;
triazoles | agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fludioxonil | | benzodioxoles;
nitrile;
organofluorine compound;
pyrroles | androgen antagonist;
antifungal agrochemical;
estrogen receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cloransulam-methyl | | methyl ester;
monochlorobenzenes;
organofluorine compound;
sulfonamide;
triazolopyrimidines | agrochemical;
EC 2.2.1.6 (acetolactate synthase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dithiopyr | | organofluorine compound;
pyridines;
thioester | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| s 53482 | | benzoxazine;
dicarboximide;
organofluorine compound;
terminal acetylenic compound | agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide;
teratogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fulvestrant | | 17beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide | antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluoromethyl 2,2-difluoro-1-(trifluoromethyl)vinyl ether | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| florfenicol | | organochlorine compound;
organofluorine compound;
secondary alcohol;
secondary carboxamide;
sulfone | antimicrobial agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| paliperidone | | 1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine;
secondary alcohol | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sc 58125 | | organofluorine compound;
pyrazoles;
sulfone | antineoplastic agent;
cyclooxygenase 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clofarabine | | adenosines;
organofluorine compound | antimetabolite;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-fluoromethylornithine | | organofluorine compound;
ornithine derivative | EC 2.6.1.13 (ornithine aminotransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nitroflurbiprofen | | biphenyls;
carboxylic ester;
nitrate ester;
organofluorine compound | cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
geroprotector;
non-steroidal anti-inflammatory drug;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ezogabine | | carbamate ester;
organofluorine compound;
secondary amino compound;
substituted aniline | anticonvulsant;
potassium channel modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-fluorowillardiine | | L-alanine derivative;
non-proteinogenic L-alpha-amino acid;
organofluorine compound | AMPA receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| perfluoro-n-methyldecahydroisoquinoline | | organofluorine compound | blood substitute | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fc 80 | | alkyltetrahydrofuran;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ezetimibe | | azetidines;
beta-lactam;
organofluorine compound | anticholesteremic drug;
antilipemic drug;
antimetabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-fluorouridine 5'-phosphate | | organofluorine compound;
pyrimidine ribonucleoside 5'-monophosphate | drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cox 189 | | amino acid;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
secondary amino compound | cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| jte 522 | | 1,3-oxazoles;
organofluorine compound;
sulfonamide | cyclooxygenase 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trifluoromethionine | | L-methionine derivative;
non-proteinogenic L-alpha-amino acid;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diflomotecan | | epsilon-lactone;
organic heteropentacyclic compound;
organofluorine compound;
organonitrogen heterocyclic compound;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5',5',5'-trifluoroleucine | | leucine derivative;
non-proteinogenic alpha-amino acid;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sorbinil | | azaspiro compound;
chromanes;
imidazolidinone;
organofluorine compound;
oxaspiro compound | antioxidant;
EC 1.1.1.21 (aldehyde reductase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| linezolid | | acetamides;
morpholines;
organofluorine compound;
oxazolidinone | antibacterial drug;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2'-deoxy-2-fluoroadenosine | | adenosines;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 8-(2-chloro-3,4,5-trimethoxybenzyl)-2-fluoro-9-pent-4-yn-1-yl-9H-purin-6-amine | | 6-aminopurines;
acetylenic compound;
methoxybenzenes;
monochlorobenzenes;
organofluorine compound | antineoplastic agent;
Hsp90 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| favipiravir | | hydroxypyrazine;
organofluorine compound;
primary carboxamide | anticoronaviral agent;
antiviral drug;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ck-0944666 | | benzamides;
indoles;
organofluorine compound | actin polymerisation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(3-Chloro-2-fluorophenyl)-2,3-dihydroisothiazol-3-one | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[(3-fluorophenyl)methyl-(3-pyridinylmethyl)amino]-4-oxobutanoic acid | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| transfluthrin | | carboxylic ester;
cyclopropanes;
organochlorine compound;
organofluorine compound | pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(4-fluorophenyl)-3H-thiazole-2-thione | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-chlorophenyl)-5-(4-fluorophenyl)-1,3,4-oxadiazole | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[(4-fluorophenyl)methyl]-2-thiophen-2-ylacetamide | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(cycloheptylideneamino)-3-(4-fluorophenyl)thiourea | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(2-fluorophenyl)-5-phenyl-4-thieno[2,3-d][1,3]oxazinone | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulindac | | monocarboxylic acid;
organofluorine compound;
sulfoxide | analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-cyano-N'-(2-fluorophenyl)carbamimidothioic acid [2-(tert-butylamino)-2-oxoethyl] ester | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-(4-fluorobenzyl)urea | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N1-(3-chloro-4-fluorophenyl)-2-(methylthio)acetamide | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethyl 1-[4-(4-chlorobenzenesulfonamido)phenyl]-5-(trifluoromethyl)pyrazole-4-carboxylate | | ethyl ester;
monochlorobenzenes;
organofluorine compound;
pyrazoles;
sulfonamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| S-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl] 5-(phenylethynyl)furan-2-carbothioate | | acetylenic compound;
furans;
organofluorine compound;
thioester;
triazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-[1-(4-fluorophenyl)ethyl]-3-thiophen-2-yl-1H-1,2,4-triazole-5-thione | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-fluorophenyl)-1-cyclopentanecarboxylic acid [2-(2,6-dimethyl-4-morpholinyl)-2-oxoethyl] ester | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| deracoxib | | organofluorine compound;
pyrazoles;
sulfonamide | cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6,8-difluoro-4-(pyridin-3-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline | | organic heterotricyclic compound;
organofluorine compound;
pyridines;
secondary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-(4-fluorophenyl)-N-methyl-3,4-dihydro-1H-pyrrolo[1,2-a]pyrazine-2-carbothioamide | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-[[2-[3-(4-fluorophenyl)-5-thiophen-2-yl-3,4-dihydropyrazol-2-yl]-2-oxoethyl]thio]acetic acid butyl ester | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-[(2-fluorophenyl)methyl]-4-pyrazolamine | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[2,2-dichloro-1-(3-fluoro-4-methylphenyl)ethyl]-1,1-bis(phenylmethyl)urea | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ro 60-0175 | | indoles;
organochlorine compound;
organofluorine compound;
primary amino compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| arachidonyltrifluoromethane | | fatty acid derivative;
ketone;
olefinic compound;
organofluorine compound | EC 3.1.1.4 (phospholipase A2) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulindac sulfide | | aryl sulfide;
monocarboxylic acid;
organofluorine compound | antineoplastic agent;
apoptosis inducer;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | | dihydroxy monocarboxylic acid;
indoles;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulindac sulfone | | monocarboxylic acid;
organofluorine compound;
sulfone | apoptosis inducer;
cyclooxygenase 2 inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one | | organic heterotetracyclic compound;
organofluorine compound | EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| z-val-ala-asp(ome)-fluoromethylketone | | carbamate ester;
organofluorine compound;
tripeptide | apoptosis inhibitor;
protease inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| robenacoxib | | aromatic amino acid;
monocarboxylic acid;
organofluorine compound;
phenylacetic acids;
secondary amino compound | cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| acrinathrin | | cyclopropanecarboxylate ester;
organofluorine compound | pyrethroid ester acaricide;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bifenthrin | | carboxylic ester;
cyclopropanecarboxylate ester;
cyclopropanes;
organochlorine compound;
organofluorine compound | pyrethroid ester acaricide;
pyrethroid ester insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| netupitant | | aminopyridine;
monocarboxylic acid amide;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
toluenes | antiemetic;
neurokinin-1 receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flibanserin | | benzimidazoles;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound | antidepressant;
serotonergic agonist;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nepicastat | | 1,3-dihydroimidazole-2-thiones;
organofluorine compound;
primary amino compound;
tetralins | EC 1.14.17.1 (dopamine beta-monooxygenase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flonicamid | | nitrile;
organofluorine compound;
pyridinecarboxamide | environmental contaminant;
insecticide;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(5-(4-fluorophenyl)-3-(trifluoromethyl)-1h-pyrazol-1-yl)benzenesulfonamide | | organofluorine compound;
pyrazoles;
sulfonamide | cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| paliperidone palmitate | | 1,2-benzoxazoles;
fatty acid ester;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cangrelor | | adenosine 5'-phosphate;
aryl sulfide;
nucleoside triphosphate analogue;
organochlorine compound;
organofluorine compound;
secondary amino compound | P2Y12 receptor antagonist;
platelet aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tafluprost | | isopropyl ester;
organofluorine compound;
prostaglandins Falpha | prostaglandin receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ticagrelor | | aryl sulfide;
hydroxyether;
organofluorine compound;
secondary amino compound;
triazolopyrimidines | P2Y12 receptor antagonist;
platelet aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| am 694 | | aromatic ketone;
indoles;
organofluorine compound;
organoiodine compound;
synthetic cannabinoid | cannabinoid receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rucaparib | | azepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound | antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| NNC 55-0396 (free base) | | benzimidazoles;
cyclopropanecarboxylate ester;
organofluorine compound;
tertiary amino compound;
tetralins | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
neuroprotective agent;
potassium channel blocker;
T-type calcium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| osu 03012 | | antibiotic antifungal drug;
aromatic amide;
glycine derivative;
organofluorine compound;
phenanthrenes;
pyrazoles | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vorapaxar | | carbamate ester;
lactone;
naphthofuran;
organofluorine compound;
pyridines | cardiovascular drug;
platelet aggregation inhibitor;
protease-activated receptor-1 antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azd 6244 | | benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound | anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| r-138727 | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluopicolide | | benzamide fungicide;
benzamides;
dichlorobenzene;
monochloropyridine;
organofluorine compound | antifungal agrochemical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gamendazole | | alpha,beta-unsaturated monocarboxylic acid;
dichlorobenzene;
indazoles;
olefinic compound;
organofluorine compound | antispermatogenic agent;
eukaryotic translation elongation factor 1alpha 1 inhibitor;
Hsp90 inhibitor;
synthetic oral contraceptive | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tedizolid | | carbamate ester;
organofluorine compound;
oxazolidinone;
primary alcohol;
pyridines;
tetrazoles | antimicrobial agent;
drug metabolite;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rx-3117 | | organofluorine compound;
primary allylic alcohol;
triol | antimetabolite;
antineoplastic agent;
apoptosis inducer;
DNA synthesis inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bay 63-2521 | | aminopyrimidine;
carbamate ester;
organofluorine compound;
pyrazolopyridine | antihypertensive agent;
soluble guanylate cyclase activator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| penthiopyrad | | aromatic amide;
organofluorine compound;
pyrazoles;
thiophenes | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tedizolid phosphate | | carbamate ester;
organofluorine compound;
oxazolidinone;
phosphate monoester;
pyridines;
tetrazoles | antimicrobial agent;
prodrug;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tavaborole | | benzoxaborole;
organofluorine compound | antifungal agent;
EC 6.1.1.4 (leucine--tRNA ligase) inhibitor;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tembotrione | | aromatic ketone;
beta-triketone;
cyclic ketone;
ether;
monochlorobenzenes;
organofluorine compound;
sulfone | agrochemical;
carotenoid biosynthesis inhibitor;
EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| finafloxacin | | cyclopropanes;
monocarboxylic acid;
nitrile;
organofluorine compound;
quinolone;
secondary amino compound;
tertiary amino compound | antibacterial drug;
antimicrobial agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zstk474 | | benzimidazoles;
morpholines;
organofluorine compound;
triamino-1,3,5-triazine | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trifloxystrobin | | methoxyiminoacetate strobilurin antifungal agent;
methyl ester;
organofluorine compound;
oxime O-ether | antifungal agrochemical;
mitochondrial cytochrome-bc1 complex inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-fluoro-1,3-dimethyl-N-[2-(4-methylpentan-2-yl)phenyl]pyrazole-4-carboxamide | | aromatic amide;
organofluorine compound;
pyrazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-(2-(1,1'-bicyclopropyl)-2-ylphenyl)-3-(difluoromethyl)-1-methyl-1h-pyrazole-4-carboxamide | | aromatic amide;
cyclopropanes;
organofluorine compound;
pyrazoles;
ring assembly | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trametinib | | acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly | anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| butafenacil | | benzoate ester;
diester;
monochlorobenzenes;
olefinic compound;
organofluorine compound | EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| buparlisib | | aminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lumacaftor | | aromatic amide;
benzodioxoles;
benzoic acids;
cyclopropanes;
organofluorine compound;
pyridines | CFTR potentiator;
orphan drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ro5126766 | | aryloxypyrimidine;
coumarins;
organofluorine compound;
pyridines;
sulfamides | antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulfoxaflor | | nitrile;
organofluorine compound;
pyridines;
sulfoximide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azd 7545 | | benzamides;
monochlorobenzenes;
organofluorine compound;
secondary carboxamide;
sulfone;
tertiary alcohol;
tertiary carboxamide | EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor;
hypoglycemic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| canagliflozin | | C-glycosyl compound;
organofluorine compound;
thiophenes | hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| navitoclax | | aryl sulfide;
monochlorobenzenes;
morpholines;
N-sulfonylcarboxamide;
organofluorine compound;
piperazines;
secondary amino compound;
sulfone;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dcc-2036 | | organofluorine compound;
phenylureas;
pyrazoles;
pyridinecarboxamide;
quinolines | tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pexidartinib | | aminopyridine;
organochlorine compound;
organofluorine compound;
pyrrolopyridine;
secondary amino compound | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| TAK-580 | | 1,3-thiazolecarboxamide;
aminopyrimidine;
chloropyridine;
organofluorine compound;
pyrimidinecarboxamide;
secondary carboxamide | antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dabrafenib | | 1,3-thiazoles;
aminopyrimidine;
organofluorine compound;
sulfonamide | anticoronaviral agent;
antineoplastic agent;
B-Raf inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sofosbuvir | | isopropyl ester;
L-alanyl ester;
nucleotide conjugate;
organofluorine compound;
phosphoramidate ester | antiviral drug;
hepatitis C protease inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| [5-fluoro-1-(4-isopropylbenzylidene)-2-methylinden-3-yl]acetic acid | | organofluorine compound | non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| torin 1 | | N-acylpiperazine;
N-arylpiperazine;
organofluorine compound;
pyridoquinoline;
quinolines | antineoplastic agent;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ro 4929097 | | dibenzoazepine;
dicarboxylic acid diamide;
lactam;
organofluorine compound | EC 3.4.23.46 (memapsin 2) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| torin 2 | | aminopyridine;
organofluorine compound;
primary amino compound;
pyridoquinoline | antineoplastic agent;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk2656157 | | biaryl;
indoles;
methylpyridines;
organofluorine compound;
pyrrolopyrimidine;
tertiary carboxamide | antineoplastic agent;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
PERK inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-[9-(dichloromethylene)-1,2,3,4-tetrahydro-1,4-methanonaphthalen-5-yl]-3-(difluoromethyl)-1-methylpyrazole-4-carboxamide | | aromatic amide;
bridged compound;
olefinic compound;
organochlorine compound;
organofluorine compound;
pyrazoles | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vericiguat | | aminopyrimidine;
carbamate ester;
organofluorine compound;
pyrazolopyridine | antihypertensive agent;
soluble guanylate cyclase activator;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pacific blue succinimidyl ester | | hydroxycoumarin;
N-hydroxysuccinimide ester;
organofluorine compound | fluorochrome | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(difluoromethyl)-N-methoxy-1-methyl-N-[1-(2,4,6-trichlorophenyl)propan-2-yl]pyrazole-4-carboxamide | | aromatic amide;
monocarboxylic acid amide;
organofluorine compound;
pyrazoles;
trichlorobenzene | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxathiapiprolin | | 1,3-thiazoles;
isoxazoline;
N-acylpiperidine;
organofluorine compound;
pyrazoles;
tertiary carboxamide | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-[[5-(4-fluoro-2-hydroxyphenyl)-2-furanyl]methylidene]thiazolidine-2,4-dione | | halophenol;
organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| LimKi 3 | | 1,3-thiazoles;
dichlorobenzene;
organofluorine compound;
pyrazoles;
secondary carboxamide | LIM kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ledipasvir | | azaspiro compound;
benzimidazole;
bridged compound;
carbamate ester;
carboxamide;
fluorenes;
imidazoles;
L-valine derivative;
N-acylpyrrolidine;
organofluorine compound | antiviral drug;
hepatitis C protease inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ivosidenib | | cyanopyridine;
monochlorobenzenes;
organofluorine compound;
pyrrolidin-2-ones;
secondary carboxamide;
tertiary carboxamide | antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| as 1842856 | | organofluorine compound;
primary amino compound;
quinolinemonocarboxylic acid;
quinolone;
secondary amino compound;
tertiary amino compound | anti-obesity agent;
antineoplastic agent;
apoptosis inducer;
autophagy inhibitor;
forkhead box protein O1 inhibitor;
hypoglycemic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| praliciguat | | aminopyrimidine;
isoxazoles;
monofluorobenzenes;
organofluorine compound;
pyrazoles;
secondary amino compound;
tertiary alcohol | anti-inflammatory agent;
antihypertensive agent;
soluble guanylate cyclase activator;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| enasidenib | | 1,3,5-triazines;
aminopyridine;
aromatic amine;
organofluorine compound;
secondary amino compound;
tertiary alcohol | antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| MMP-9-IN-1 | | aromatic compound;
organic sulfide;
organofluorine compound;
pyrimidone;
secondary carboxamide | antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(2,5-difluorophenyl)-N-(2-oxolanylmethyl)-6H-1,3,4-thiadiazin-2-amine | | organofluorine compound | | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nirmatrelvir | | azabicyclohexane;
nitrile;
organofluorine compound;
pyrrolidin-2-ones;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide | anticoronaviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| cgp 52411 | | phthalimides | geroprotector;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| emodin | | trihydroxyanthraquinone | antineoplastic agent;
laxative;
plant metabolite;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hydroxy-2-naphthalenyl-methyl phosphonic acid trisacetoxymethylester | | acetate ester;
naphthalenes;
organic phosphonate | tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| leflunomide | | (trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide | antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-NA-PP1 | | pyrazolopyrimidine | tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| imatinib | | aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines | antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| picropodophyllin | | furonaphthodioxole;
lignan;
organic heterotetracyclic compound | antineoplastic agent;
insulin-like growth factor receptor 1 antagonist;
plant metabolite;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| imatinib mesylate | | methanesulfonate salt | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| canertinib | | monochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lapatinib | | furans;
organochlorine compound;
organofluorine compound;
quinazolines | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sorafenib | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide | angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pd 173955 | | aryl sulfide;
dichlorobenzene;
methyl sulfide;
pyridopyrimidine | tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| s 1033 | | (trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide | anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,3',4,5'-tetrahydroxystilbene | | catechols;
polyphenol;
resorcinols;
stilbenol | antineoplastic agent;
apoptosis inducer;
geroprotector;
hypoglycemic agent;
plant metabolite;
protein kinase inhibitor;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dasatinib | | 1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-tert-butyl-3-naphthalen-1-ylmethyl-1h-pyrazolo(3,4-d)pyrimidin-4-ylemine | | pyrazolopyrimidine | tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| biochanin a | | 4'-methoxyisoflavones;
7-hydroxyisoflavones | antineoplastic agent;
EC 3.5.1.99 (fatty acid amide hydrolase) inhibitor;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| genistein | | 7-hydroxyisoflavones | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| butein | | chalcones;
polyphenol | antineoplastic agent;
antioxidant;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
geroprotector;
hypoglycemic agent;
plant metabolite;
radiosensitizing agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| herbimycin | | 1,4-benzoquinones;
lactam;
macrocycle | antimicrobial agent;
apoptosis inducer;
herbicide;
Hsp90 inhibitor;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bosutinib | | aminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| monorden | | cyclic ketone;
enone;
epoxide;
macrolide antibiotic;
monochlorobenzenes;
phenols | antifungal agent;
metabolite;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| axitinib | | aryl sulfide;
benzamides;
indazoles;
pyridines | antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hki 272 | | nitrile;
quinolines | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| masitinib | | 1,3-thiazoles;
benzamides;
N-alkylpiperazine;
pyridines | antineoplastic agent;
antirheumatic drug;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pazopanib | | aminopyrimidine;
indazoles;
sulfonamide | angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bibw 2992 | | aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| regorafenib | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide | antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ponatinib | | (trifluoromethyl)benzenes;
acetylenic compound;
benzamides;
imidazopyridazine;
N-methylpiperazine | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| PP121 | | aromatic amine;
cyclopentanes;
pyrazolopyrimidine;
pyrrolopyridine | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dcc-2036 | | organofluorine compound;
phenylureas;
pyrazoles;
pyridinecarboxamide;
quinolines | tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cabozantinib | | aromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thiopental sodium | | organochlorine compound;
piperazines;
pyrimidines | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| teriflunomide | | (trifluoromethyl)benzenes;
aromatic amide;
enamide;
enol;
nitrile;
secondary carboxamide | drug metabolite;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
hepatotoxic agent;
non-steroidal anti-inflammatory drug;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| protocatechuic acid | | catechols;
dihydroxybenzoic acid | antineoplastic agent;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.14.11.2 (procollagen-proline dioxygenase) inhibitor;
human xenobiotic metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aminolevulinic acid | | 4-oxo monocarboxylic acid;
amino acid zwitterion;
delta-amino acid | antineoplastic agent;
dermatologic drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite;
prodrug;
Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gallic acid | | trihydroxybenzoic acid | antineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| perillic acid | | alpha,beta-unsaturated monocarboxylic acid;
cyclohexenecarboxylic acid | antineoplastic agent;
human metabolite;
mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pk 11195 | | aromatic amide;
isoquinolines;
monocarboxylic acid amide;
monochlorobenzenes | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pd 173074 | | aromatic amine;
biaryl;
dimethoxybenzene;
pyridopyrimidine;
tertiary amino compound;
ureas | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aminopropionitrile | | aminopropionitrile | antineoplastic agent;
antirheumatic drug;
collagen cross-linking inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(n,n-hexamethylene)amiloride | | aromatic amine;
azepanes;
guanidines;
monocarboxylic acid amide;
organochlorine compound;
pyrazines | antineoplastic agent;
apoptosis inducer;
odorant receptor antagonist;
sodium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7,8-dihydroxyflavone | | dihydroxyflavone | antidepressant;
antineoplastic agent;
antioxidant;
plant metabolite;
tropomyosin-related kinase B receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ro 48-8071 | | aromatic ether;
aromatic ketone;
bromobenzenes;
monofluorobenzenes;
olefinic compound;
tertiary amino compound | antineoplastic agent;
EC 5.4.99.7 (lanosterol synthase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rtki cpd | | aromatic ether;
monochlorobenzenes;
quinazolines | antineoplastic agent;
antiviral agent;
epidermal growth factor receptor antagonist;
geroprotector | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alfuzosin | | monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol | alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| am 251 | | amidopiperidine;
carbohydrazide;
dichlorobenzene;
organoiodine compound;
pyrazoles | antidepressant;
antineoplastic agent;
apoptosis inducer;
CB1 receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| am 580 | | amidobenzoic acid;
tetralins | antineoplastic agent;
retinoic acid receptor alpha/beta agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aminoglutethimide | | dicarboximide;
piperidones;
substituted aniline | adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amsacrine | | acridines;
aromatic ether;
sulfonamide | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| anastrozole | | nitrile;
triazoles | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azathioprine | | aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine | antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azelaic acid | | alpha,omega-dicarboxylic acid;
dicarboxylic fatty acid | antibacterial agent;
antineoplastic agent;
dermatologic drug;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| berberine | | alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound | antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| buformin | | biguanides | antineoplastic agent;
antiviral agent;
geroprotector;
hypoglycemic agent;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| busulfan | | methanesulfonate ester | alkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| camostat | | benzoate ester;
carboxylic ester;
diester;
guanidines;
tertiary carboxamide | anti-inflammatory agent;
anticoronaviral agent;
antifibrinolytic drug;
antihypertensive agent;
antineoplastic agent;
antiviral agent;
serine protease inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carmustine | | N-nitrosoureas;
organochlorine compound | alkylating agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cgs 15943 | | aromatic amine;
biaryl;
furans;
organochlorine compound;
primary amino compound;
quinazolines;
triazoloquinazoline | adenosine A1 receptor antagonist;
adenosine A2A receptor antagonist;
antineoplastic agent;
central nervous system stimulant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chelerythrine | | benzophenanthridine alkaloid;
organic cation | antibacterial agent;
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorambucil | | aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound | alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ci 994 | | acetamides;
benzamides;
substituted aniline | antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ciglitazone | | aromatic ether;
thiazolidinone | antineoplastic agent;
insulin-sensitizing drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cl 387785 | | bromobenzenes;
quinazolines;
secondary carboxamide;
ynamide | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clioquinol | | monohydroxyquinoline;
organochlorine compound;
organoiodine compound | antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clofibric acid | | aromatic ether;
monocarboxylic acid;
monochlorobenzenes | anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dacarbazine | | imidazoles;
monocarboxylic acid amide;
triazene derivative | alkylating agent;
antineoplastic agent;
carcinogenic agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dequalinium | | quinolinium ion | antifungal agent;
antineoplastic agent;
antiseptic drug;
mitochondrial NADH:ubiquinone reductase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,3'-diindolylmethane | | indoles | antineoplastic agent;
P450 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| disulfiram | | organic disulfide;
organosulfur acaricide | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| doxazosin | | aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines | alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ebselen | | benzoselenazole | anti-inflammatory drug;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 3.5.4.1 (cytosine deaminase) inhibitor;
EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor;
enzyme mimic;
ferroptosis inhibitor;
genotoxin;
hepatoprotective agent;
neuroprotective agent;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ellipticine | | indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound;
polycyclic heteroarene | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| embelin | | dihydroxy-1,4-benzoquinones | antimicrobial agent;
antineoplastic agent;
hepatitis C protease inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| etanidazole | | C-nitro compound;
imidazoles;
monocarboxylic acid amide | alkylating agent;
antineoplastic agent;
prodrug;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| etidronate | | 1,1-bis(phosphonic acid) | antineoplastic agent;
bone density conservation agent;
chelator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluorouracil | | nucleobase analogue;
organofluorine compound | antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flutamide | | (trifluoromethyl)benzenes;
monocarboxylic acid amide | androgen antagonist;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| miltefosine | | phosphocholines;
phospholipid | anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| beta-thujaplicin | | cyclic ketone;
enol;
monoterpenoid | antibacterial agent;
antifungal agent;
antineoplastic agent;
antiplasmodial drug;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hydroxyurea | | one-carbon compound;
ureas | antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ifosfamide | | ifosfamides | alkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| indole-3-carbinol | | indolyl alcohol | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| beta-lapachone | | benzochromenone;
orthoquinones | anti-inflammatory agent;
antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| letrozole | | nitrile;
triazoles | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lomustine | | N-nitrosoureas;
organochlorine compound | alkylating agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-anilino-5,8-quinolinedione | | aminoquinoline;
aromatic amine;
p-quinones;
quinolone | antineoplastic agent;
EC 4.6.1.2 (guanylate cyclase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(dimethylamino)-n-(7-(hydroxyamino)-7-oxoheptyl)benzamide | | benzamides;
hydroxamic acid;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| meclofenamic acid | | aminobenzoic acid;
organochlorine compound;
secondary amino compound | analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vitamin k 3 | | 1,4-naphthoquinones;
vitamin K | angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methoxsalen | | aromatic ether;
psoralens | antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nocodazole | | aromatic ketone;
benzimidazoles;
carbamate ester;
thiophenes | antimitotic;
antineoplastic agent;
microtubule-destabilising agent;
tubulin modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| midazolam | | imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound | anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mitoxantrone | | dihydroxyanthraquinone | analgesic;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| entinostat | | benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n(1), n(12)-diethylspermine | | polyazaalkane;
secondary amino compound;
substituted spermine;
tetramine | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nilutamide | | (trifluoromethyl)benzenes;
C-nitro compound;
imidazolidinone | androgen antagonist;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nortriptyline | | organic tricyclic compound;
secondary amine | adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide | | aromatic ether;
C-nitro compound;
sulfonamide | antineoplastic agent;
cyclooxygenase 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxyphenbutazone | | phenols;
pyrazolidines | antimicrobial agent;
antineoplastic agent;
antipyretic;
drug metabolite;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pd 158780 | | aromatic amine;
bromobenzenes;
diamine;
pyridopyrimidine;
secondary amino compound | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-phenylbutyric acid | | monocarboxylic acid | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oxophenylarsine | | arsine oxides | antineoplastic agent;
apoptosis inducer;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phloretin | | dihydrochalcones | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pipobroman | | N-acylpiperazine;
organobromine compound;
tertiary carboxamide | alkylating agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pj-34 | | phenanthridines;
secondary carboxamide;
tertiary amino compound | angiogenesis inhibitor;
anti-inflammatory agent;
antiatherosclerotic agent;
antineoplastic agent;
apoptosis inducer;
cardioprotective agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| procarbazine | | benzamides;
hydrazines | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| salicylsalicylic acid | | benzoate ester;
benzoic acids;
phenols;
salicylates | antineoplastic agent;
antirheumatic drug;
EC 3.5.2.6 (beta-lactamase) inhibitor;
hypoglycemic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| semustine | | N-nitrosoureas;
organochlorine compound | alkylating agent;
antineoplastic agent;
carcinogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| streptonigrin | | pyridines;
quinolone | antimicrobial agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| SU6656 | | oxindoles;
sulfonamide | antineoplastic agent;
Aurora kinase inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vorinostat | | dicarboxylic acid diamide;
hydroxamic acid | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulforaphane | | isothiocyanate;
sulfoxide | antineoplastic agent;
antioxidant;
EC 3.5.1.98 (histone deacetylase) inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| suramin | | naphthalenesulfonic acid;
phenylureas;
secondary carboxamide | angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| temozolomide | | imidazotetrazine;
monocarboxylic acid amide;
triazene derivative | alkylating agent;
antineoplastic agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| terazosin | | furans;
piperazines;
primary amino compound;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,2'-thiodiethanol | | aliphatic sulfide;
diol | antineoplastic agent;
antioxidant;
metabolite;
solvent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tilorone | | aromatic ether;
diether;
fluoren-9-ones;
tertiary amino compound | anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
interferon inducer;
nicotinic acetylcholine receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| troglitazone | | chromanes;
thiazolidinone | anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole | | aromatic primary alcohol;
furans;
indazoles | antineoplastic agent;
apoptosis inducer;
platelet aggregation inhibitor;
soluble guanylate cyclase activator;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mitomycin | | mitomycin | alkylating agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prednisolone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| floxuridine | | nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prednisone | | 11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| estrone | | 17-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols | antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azauridine | | N-glycosyl-1,2,4-triazine | antimetabolite;
antineoplastic agent;
drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mechlorethamine hydrochloride | | hydrochloride | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| allyl isothiocyanate | | alkenyl isothiocyanate;
isothiocyanate | antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
lachrymator;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vincristine | | acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid | antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methyltestosterone | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
enone | anabolic agent;
androgen;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dromostanolone | | 17beta-hydroxy steroid;
3-oxo-5alpha-steroid;
anabolic androgenic steroid | anabolic agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromodeoxyuridine | | pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tributyrin | | butyrate ester;
triglyceride | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug;
protective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethyl methanesulfonate | | methanesulfonate ester | alkylating agent;
antineoplastic agent;
carcinogenic agent;
genotoxin;
mutagen;
teratogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triaziquone | | 1,4-benzoquinones;
aziridines | alkylating agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tubercidin | | antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
ribonucleoside | antimetabolite;
antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cytarabine | | beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside | antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trifluridine | | nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| medroxyprogesterone acetate | | 20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester | adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluoxymesterone | | 11beta-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid;
fluorinated steroid | anabolic agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rotenone | | organic heteropentacyclic compound;
rotenones | antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| acetopyrrothine | | acetamides;
dithiolopyrrolone antibiotic | angiogenesis inhibitor;
antibacterial agent;
antifungal agent;
antineoplastic agent;
bacterial metabolite;
chelator;
EC 2.7.7.6 (RNA polymerase) inhibitor;
marine metabolite;
protein synthesis inhibitor;
toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phenformin | | biguanides | antineoplastic agent;
geroprotector;
hypoglycemic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dibenzoylmethane | | aromatic ketone;
beta-diketone | antimutagen;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| suramin sodium | | organic sodium salt | angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pyrazolanthrone | | anthrapyrazole;
aromatic ketone;
cyclic ketone | antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diazooxonorleucine | | amino acid zwitterion;
diazo compound;
ketone;
non-proteinogenic L-alpha-amino acid | analgesic;
antibacterial agent;
antimetabolite;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
bacterial metabolite;
EC 2.4.2.14 (amidophosphoribosyltransferase) inhibitor;
EC 3.5.1.2 (glutaminase) inhibitor;
EC 6.3.4.2 [CTP synthase (glutamine hydrolyzing)] inhibitor;
EC 6.3.5.1 [NAD(+) synthase (glutamine-hydrolysing)] inhibitor;
EC 6.3.5.2 [GMP synthase (glutamine-hydrolysing)] inhibitor;
EC 6.3.5.3 (phosphoribosylformylglycinamidine synthase) inhibitor;
EC 6.3.5.4 [asparagine synthase (glutamine-hydrolysing)] inhibitor;
EC 6.3.5.5 [carbamoyl-phosphate synthase (glutamine-hydrolysing)] inhibitor;
glutamine antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azacitidine | | N-glycosyl-1,3,5-triazine;
nucleoside analogue | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diazomethane | | diazo compound | alkylating agent;
antineoplastic agent;
carcinogenic agent;
poison | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| procarbazine hydrochloride | | hydrochloride | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| naphthazarin | | hydroxy-1,4-naphthoquinone | acaricide;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
geroprotector;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| liriodenine | | alkaloid antibiotic;
cyclic ketone;
organic heteropentacyclic compound;
oxacycle;
oxoaporphine alkaloid | antifungal agent;
antimicrobial agent;
antineoplastic agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lucanthone | | thioxanthenes | adjuvant;
antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
mutagen;
photosensitizing agent;
prodrug;
schistosomicide drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| plumbagin | | hydroxy-1,4-naphthoquinone;
phenols | anticoagulant;
antineoplastic agent;
immunological adjuvant;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aloe emodin | | aromatic primary alcohol;
dihydroxyanthraquinone | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| emetine | | isoquinoline alkaloid;
pyridoisoquinoline | antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thymoquinone | | 1,4-benzoquinones | adjuvant;
anti-inflammatory agent;
antidepressant;
antineoplastic agent;
antioxidant;
cardioprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| podophyllotoxin | | furonaphthodioxole;
lignan;
organic heterotetracyclic compound | antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| physcione | | dihydroxyanthraquinone | anti-inflammatory agent;
antibacterial agent;
antifungal agent;
antineoplastic agent;
apoptosis inducer;
hepatoprotective agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dequalinium chloride | | organic chloride salt | antifungal agent;
antineoplastic agent;
antiseptic drug;
mitochondrial NADH:ubiquinone reductase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-methyl-1-(1-methylethyl)-3-cyclohexen-1-ol | | terpineol;
tertiary alcohol | anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
antiparasitic agent;
apoptosis inducer;
plant metabolite;
volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| formestane | | 17-oxo steroid;
3-oxo-Delta(4) steroid;
enol;
hydroxy steroid | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chlorotrianisene | | chloroalkene | antineoplastic agent;
estrogen receptor modulator;
xenoestrogen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| megestrol acetate | | 20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester | antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| toyocamycin | | antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
nitrile;
ribonucleoside | antimetabolite;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-hydroxyacetanilide | | acetamides;
phenols | anti-inflammatory agent;
antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
platelet aggregation inhibitor;
xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methoxyacetic acid | | ether;
monocarboxylic acid | antineoplastic agent;
apoptosis inducer;
human xenobiotic metabolite;
mutagen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hadacidin | | aldehyde;
monocarboxylic acid;
N-hydroxy-alpha-amino-acid | antimicrobial agent;
antineoplastic agent;
Penicillium metabolite;
teratogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-fluoroadenine | | organofluorine compound;
purines | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tetramethylpyrazine | | alkaloid;
pyrazines | antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| guanazole | | aromatic amine;
triazoles | antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diallyl trisulfide | | organic trisulfide | anti-inflammatory agent;
antilipemic drug;
antineoplastic agent;
antioxidant;
antiprotozoal drug;
apoptosis inducer;
estrogen receptor antagonist;
insecticide;
platelet aggregation inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diallyl disulfide | | organic disulfide | antifungal agent;
antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phenethyl isothiocyanate | | isothiocyanate | antineoplastic agent;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glaucine | | aporphine alkaloid;
organic heterotetracyclic compound;
polyether;
tertiary amino compound | antibacterial agent;
antineoplastic agent;
antitussive;
muscle relaxant;
NF-kappaB inhibitor;
plant metabolite;
platelet aggregation inhibitor;
rat metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| acadesine | | 1-ribosylimidazolecarboxamide;
aminoimidazole;
nucleoside analogue | antineoplastic agent;
platelet aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| doxifluridine | | organofluorine compound;
pyrimidine 5'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| megestrol | | 17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone | antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mitomycin a | | ether;
mitomycin | alkylating agent;
antimicrobial agent;
antineoplastic agent;
toxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cladribine | | organochlorine compound;
purine 2'-deoxyribonucleoside | antineoplastic agent;
immunosuppressive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tabersonine | | alkaloid ester;
methyl ester;
monoterpenoid indole alkaloid;
organic heteropentacyclic compound | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vidarabine | | beta-D-arabinoside;
purine nucleoside | antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyclophosphamide | | hydrate | alkylating agent;
antineoplastic agent;
carcinogenic agent;
immunosuppressive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| helenalin | | cyclic ketone;
gamma-lactone;
organic heterotricyclic compound;
secondary alcohol;
sesquiterpene lactone | anti-inflammatory agent;
antineoplastic agent;
metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| etidronate disodium | | organic sodium salt | antineoplastic agent;
bone density conservation agent;
chelator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| camptothecin | | delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| isopentenyladenosine | | N-ribosyl-N(6)-isopentenyladenine;
nucleoside analogue | antineoplastic agent;
plant growth regulator;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nsc-145,668 | | hydrochloride | antimetabolite;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ancitabine | | diol;
organic heterotricyclic compound | antimetabolite;
antineoplastic agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clodronic acid | | 1,1-bis(phosphonic acid);
one-carbon compound;
organochlorine compound | antineoplastic agent;
bone density conservation agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tetradecanoylphorbol acetate | | acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester | antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| streptozocin | | N-acylglucosamine;
N-nitrosoureas | antimicrobial agent;
antineoplastic agent;
DNA synthesis inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| daunorubicin | | aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones | antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fludarabine phosphate | | nucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate | antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,6-diaminopurine | | 2,6-diaminopurines;
primary amino compound | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| silybin | | aromatic ether;
benzodioxine;
flavonolignan;
polyphenol;
secondary alpha-hydroxy ketone | antineoplastic agent;
antioxidant;
hepatoprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glucaric acid | | glucaric acid | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| paclitaxel | | taxane diterpenoid;
tetracyclic diterpenoid | antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| etoposide | | beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound | antineoplastic agent;
DNA synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| promegestone | | 20-oxo steroid;
3-oxo-Delta(4) steroid | antineoplastic agent;
progesterone receptor agonist;
progestin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| perfosfamide | | nitrogen mustard;
organochlorine compound;
peroxol;
phosphorodiamide | alkylating agent;
antineoplastic agent;
drug allergen;
immunosuppressive agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nimustine | | aminopyrimidine;
N-nitrosoureas;
organochlorine compound | alkylating agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lonidamine | | dichlorobenzene;
indazoles;
monocarboxylic acid | antineoplastic agent;
antispermatogenic agent;
EC 2.7.1.1 (hexokinase) inhibitor;
geroprotector | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vindesine | | methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
primary carboxamide;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| epirubicin | | aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diaziquone | | 1,4-benzoquinones;
aziridines;
carbamate ester;
enamine | alkylating agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| midazolam hydrochloride | | hydrochloride;
imidazobenzodiazepine | anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oltipraz | | 1,2-dithiole;
pyrazines | angiogenesis modulating agent;
antimutagen;
antineoplastic agent;
antioxidant;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
neurotoxin;
protective agent;
schistosomicide drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fazarabine | | N-glycosyl-1,3,5-triazine;
nucleoside analogue | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mitoxantrone hydrochloride | | hydrochloride | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bisantrene | | anthracenes;
hydrazone;
imidazolidines | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| swainsonine | | indolizidine alkaloid | antineoplastic agent;
EC 3.2.1.114 (mannosyl-oligosaccharide 1,3-1,6-alpha-mannosidase) inhibitor;
immunological adjuvant;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lovastatin | | delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring) | anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cabergoline | | N-acylurea | antineoplastic agent;
antiparkinson drug;
dopamine agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nitrogenase stabilizing-protective protein, bacteria | | N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide | androgen antagonist;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bmy 25067 | | C-nitro compound;
organic disulfide | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| brequinar | | biphenyls;
monocarboxylic acid;
monofluorobenzenes;
quinolinemonocarboxylic acid | anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral agent;
EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor;
immunosuppressive agent;
pyrimidine synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| imiquimod | | imidazoquinoline | antineoplastic agent;
interferon inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aromasil | | 17-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cidofovir anhydrous | | phosphonic acids;
pyrimidone | anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| topotecan | | pyranoindolizinoquinoline | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gemcitabine hydrochloride | | hydrochloride;
organofluorine compound | anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral drug;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
immunosuppressive agent;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gemcitabine | | organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| irinotecan | | carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| capecitabine | | carbamate ester;
cytidines;
organofluorine compound | antimetabolite;
antineoplastic agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nelfinavir mesylate | | methanesulfonate salt | antineoplastic agent;
HIV protease inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nelfinavir | | aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound | antineoplastic agent;
HIV protease inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| betulinic acid | | hydroxy monocarboxylic acid;
pentacyclic triterpenoid | anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| baicalin | | dihydroxyflavone;
glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative | antiatherosclerotic agent;
antibacterial agent;
anticoronaviral agent;
antineoplastic agent;
antioxidant;
cardioprotective agent;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
ferroptosis inhibitor;
neuroprotective agent;
non-steroidal anti-inflammatory drug;
plant metabolite;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ro 5-3335 | | 1,4-benzodiazepinone;
organochlorine compound;
pyrroles | anti-HIV-1 agent;
antineoplastic agent;
HIV-1 Tat inhibitor;
RUNX1 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| plerixafor | | azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound | anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| epigallocatechin gallate | | flavans;
gallate ester;
polyphenol | antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| salvin | | abietane diterpenoid;
carbotricyclic compound;
catechols;
monocarboxylic acid | angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
food preservative;
HIV protease inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,2,3,4,6-pentakis-O-galloyl-beta-D-glucose | | gallate ester;
galloyl beta-D-glucose | anti-inflammatory agent;
antineoplastic agent;
geroprotector;
hepatoprotective agent;
plant metabolite;
radiation protective agent;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pyrrolidine dithiocarbamate | | dithiocarbamic acids;
pyrrolidines | anticonvulsant;
antineoplastic agent;
geroprotector;
neuroprotective agent;
NF-kappaB inhibitor;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| triptonide | | butenolide;
cyclic ketone;
diterpene triepoxide;
organic heteroheptacyclic compound | anti-inflammatory agent;
antineoplastic agent;
immunosuppressive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3'-deoxyadenosine 5'-triphosphate | | purine ribonucleoside 5'-triphosphate | antifungal agent;
antimetabolite;
antineoplastic agent;
antiviral agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-methoxyestradiol | | 17beta-hydroxy steroid;
3-hydroxy steroid | angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| toxoflavin | | carbonyl compound;
pyrimidotriazine | antibacterial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
toxin;
virulence factor;
Wnt signalling inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lupulon | | beta-bitter acid | angiogenesis inhibitor;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pinocembrin | | (2S)-flavan-4-one;
dihydroxyflavanone | antineoplastic agent;
antioxidant;
metabolite;
neuroprotective agent;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tangeretin | | pentamethoxyflavone | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethinylestradiol-3-sulfate | | 17beta-hydroxy steroid;
steroid sulfate | antineoplastic agent;
estrogen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lonazolac | | monocarboxylic acid;
monochlorobenzenes;
pyrazoles | antineoplastic agent;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromopyruvate | | 2-oxo monocarboxylic acid;
organobromine compound;
oxo carboxylic acid | alkylating agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| enrofloxacin | | cyclopropanes;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone | antibacterial agent;
antimicrobial agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dexrazoxane | | razoxane | antineoplastic agent;
cardiovascular drug;
chelator;
immunosuppressive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| masoprocol | | nordihydroguaiaretic acid | antineoplastic agent;
hypoglycemic agent;
lipoxygenase inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dw a 2114r | | platinum coordination entity;
pyrrolidines | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prednisolone phosphate | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
glucocorticoid;
steroid phosphate;
tertiary alpha-hydroxy ketone | anti-inflammatory agent;
antineoplastic agent;
glucocorticoid receptor agonist;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hesperetin | | 3'-hydroxyflavanones;
4'-methoxyflavanones;
monomethoxyflavanone;
trihydroxyflavanone | antineoplastic agent;
antioxidant;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sesamin | | benzodioxoles;
furofuran;
lignan | antineoplastic agent;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| betulin | | diol;
pentacyclic triterpenoid | analgesic;
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nobiletin | | methoxyflavone | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alantolactone | | naphthofuran;
olefinic compound;
sesquiterpene lactone | antineoplastic agent;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| kaurenoic acid | | ent-kaurane diterpenoid | anti-HIV-1 agent;
antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dehydrocostus lactone | | gamma-lactone;
guaiane sesquiterpenoid;
organic heterotricyclic compound;
sesquiterpene lactone | antimycobacterial drug;
antineoplastic agent;
apoptosis inducer;
cyclooxygenase 2 inhibitor;
metabolite;
trypanocidal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| xanthomicrol | | dihydroxyflavone;
trimethoxyflavone | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| voacamine | | alkaloid ester;
methyl ester;
monoterpenoid indole alkaloid;
organic heteropentacyclic compound;
tertiary amino compound | angiogenesis inhibitor;
antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| brazilin | | catechols;
organic heterotetracyclic compound;
tertiary alcohol | anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
biological pigment;
hepatoprotective agent;
histological dye;
NF-kappaB inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| uvaretin | | aromatic ether;
dihydrochalcones;
polyketide;
resorcinol | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fangchinoline | | aromatic ether;
bisbenzylisoquinoline alkaloid;
macrocycle | anti-HIV-1 agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| maslinic acid | | dihydroxy monocarboxylic acid;
pentacyclic triterpenoid | anti-inflammatory agent;
antineoplastic agent;
antioxidant;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tetrazolium violet | | organic chloride salt | antineoplastic agent;
apoptosis inducer;
dye | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| irinotecan hydrochloride | | hydrochloride | antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(3-methyl-1-triazeno)imidazole-4-carboxamide | | imidazoles;
monocarboxylic acid amide;
triazene derivative | alkylating agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hydroxyguanidine | | guanidines;
one-carbon compound | antineoplastic agent;
antiviral agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cryptolepine | | indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound | anti-inflammatory agent;
antimalarial;
antineoplastic agent;
cysteine protease inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bexarotene | | benzoic acids;
naphthalenes;
retinoid | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,4-dihydroxyphenylethanol | | catechols;
primary alcohol | antineoplastic agent;
antioxidant;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| terreic acid | | arene epoxide;
diketone;
monohydroxy-1,4-benzoquinones;
tertiary alpha-hydroxy ketone | antibacterial agent;
antineoplastic agent;
Aspergillus metabolite;
EC 2.3.1.* (acyltransferase transferring other than amino-acyl group) inhibitor;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
mycotoxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-methylumbelliferyl glucuronide | | beta-D-glucosiduronic acid;
coumarins;
monosaccharide derivative | antineoplastic agent;
chromogenic compound;
hyaluronan synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 9-hydroxyellipticine | | organic heterotetracyclic compound;
organonitrogen heterocyclic compound | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nimustine | | hydrochloride | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| beta-peltatin | | furonaphthodioxole;
gamma-lactone;
lignan;
organic heterotetracyclic compound;
phenols | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alpha-peltatin | | furonaphthodioxole;
gamma-lactone;
lignan;
organic heterotetracyclic compound;
phenols | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cryptopleurine | | alkaloid antibiotic;
alkaloid;
aromatic ether;
organic heteropentacyclic compound | antineoplastic agent;
antiviral agent;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sugiol | | abietane diterpenoid;
carbotricyclic compound;
cyclic terpene ketone;
meroterpenoid;
phenols | antineoplastic agent;
antioxidant;
antiviral agent;
plant metabolite;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| eupatorin | | dihydroxyflavone;
polyphenol;
trimethoxyflavone | anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
Brassica napus metabolite;
calcium channel blocker;
P450 inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1-methyltryptophan | | non-proteinogenic alpha-amino acid;
tryptophan derivative | antineoplastic agent;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| atromentin | | dihydroxy-1,4-benzoquinones;
polyphenol | antibacterial agent;
anticoagulant;
antineoplastic agent;
apoptosis inducer;
biological pigment;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diosgenin | | 3beta-sterol;
hexacyclic triterpenoid;
sapogenin;
spiroketal | antineoplastic agent;
antiviral agent;
apoptosis inducer;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alpha-glutamyltryptophan | | dipeptide | angiogenesis modulating agent;
antineoplastic agent;
immunomodulator;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fulvestrant | | 17beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide | antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ici 164384 | | 17beta-hydroxy steroid;
3-hydroxy steroid;
tertiary carboxamide | anti-estrogen;
antineoplastic agent;
estrogen receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sn 38 | | delta-lactone;
phenols;
pyranoindolizinoquinoline;
tertiary alcohol | antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 5.99.1.2 (DNA topoisomerase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hc toxin | | homodetic cyclic peptide;
tetrapeptide | antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
metabolite;
phytotoxin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| deguelin | | aromatic ether;
diether;
organic heteropentacyclic compound;
rotenones | angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
mitochondrial NADH:ubiquinone reductase inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fingolimod | | aminodiol;
primary amino compound | antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cafestol | | diterpenoid;
furans;
organic heteropentacyclic compound;
primary alcohol;
tertiary alcohol | angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
hypoglycemic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tamibarotene | | dicarboxylic acid monoamide;
retinoid;
tetralins | antineoplastic agent;
retinoic acid receptor alpha/beta agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ecteinascidin 743 | | acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound | alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| homoorientin | | flavone C-glycoside;
tetrahydroxyflavone | antineoplastic agent;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| kahweol | | diterpenoid;
furans;
organic heteropentacyclic compound;
primary alcohol;
tertiary alcohol | angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| selenomethylselenocysteine | | non-proteinogenic alpha-amino acid;
selenocysteines | antineoplastic agent;
human metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tephrosin | | aromatic ether;
cyclic ketone;
organic heteropentacyclic compound;
rotenones | antineoplastic agent;
metabolite;
pesticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(tetradecyloxy)-2-furancarboxylic acid | | aromatic ether;
furoic acid | antineoplastic agent;
apoptosis inducer;
EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor;
PPARalpha agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sc 58125 | | organofluorine compound;
pyrazoles;
sulfone | antineoplastic agent;
cyclooxygenase 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| marimastat | | hydroxamic acid;
secondary carboxamide | antineoplastic agent;
matrix metalloproteinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1'-acetoxychavicol acetate | | acetate ester;
phenylpropanoid | antineoplastic agent;
NF-kappaB inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clofarabine | | adenosines;
organofluorine compound | antimetabolite;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dioscin | | hexacyclic triterpenoid;
spiroketal;
spirostanyl glycoside;
trisaccharide derivative | anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 1.14.18.1 (tyrosinase) inhibitor;
hepatoprotective agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ginsenoside rh2 | | 12beta-hydroxy steroid;
20-hydroxy steroid;
beta-D-glucoside;
ginsenoside;
tetracyclic triterpenoid | antineoplastic agent;
apoptosis inducer;
bone density conservation agent;
cardioprotective agent;
hepatoprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trapoxin a | | epoxide;
homodetic cyclic peptide;
ketone | antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| celastrol | | monocarboxylic acid;
pentacyclic triterpenoid | anti-inflammatory drug;
antineoplastic agent;
antioxidant;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Hsp90 inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4'-demethylepipodophyllotoxin | | furonaphthodioxole;
organic heterotetracyclic compound;
phenols | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aminolevulinic acid hydrochloride | | hydrochloride | antineoplastic agent;
dermatologic drug;
photosensitizing agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gefitinib | | aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cgp 42112a | | benzyl ester;
oligopeptide;
pyridinecarboxamide | angiotensin receptor agonist;
anti-inflammatory agent;
antineoplastic agent;
neuroprotective agent;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vadimezan | | monocarboxylic acid;
xanthones | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rubimaillin | | benzochromene;
methyl ester;
phenols | acyl-CoA:cholesterol acyltransferase 2 inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
neuroprotective agent;
NF-kappaB inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-carbamoylimidazolium 5-olate | | hydroxyimidazole;
monocarboxylic acid amide | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nsc 224070 | | 1,4-benzoquinones;
aziridines;
enamine;
primary alcohol;
secondary amino compound | alkylating agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| psorospermin | | epoxide;
organic heterotetracyclic compound;
xanthones | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ay 25545 | | acetate ester;
aromatic ether;
C-glycosyl compound;
naphthoisochromene;
olefinic compound;
phenols;
tertiary amine | antimicrobial agent;
antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methotrexate | | dicarboxylic acid;
monocarboxylic acid amide;
pteridines | abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,7-dihydroxytropolone | | alpha-hydroxy ketone;
cyclic ketone;
enol;
triol | antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| delphinidin | | 5-hydroxyanthocyanidin | antineoplastic agent;
biological pigment;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tamsulosin | | 5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide | alpha-adrenergic antagonist;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| saintopin | | tetracenequinones | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
fungal metabolite;
intercalator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-bromo-3-(bromomethyl)-7-methyl-2,3,7-trichloro-1-octene | | monoterpenoid;
organobromine compound;
organochlorine compound | algal metabolite;
antineoplastic agent;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ilomastat | | hydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid | anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| abiraterone | | 3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines | antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| yakuchinone-a | | ketone;
monomethoxybenzene;
phenols | antineoplastic agent;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pomalidomide | | aromatic amine;
dicarboximide;
isoindoles;
piperidones | angiogenesis inhibitor;
antineoplastic agent;
immunomodulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tempol | | aminoxyls;
hydroxypiperidine | anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
catalyst;
hepatoprotective agent;
nephroprotective agent;
neuroprotective agent;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| selenomethylselenocysteine | | amino acid zwitterion;
L-selenocysteine derivative;
non-proteinogenic L-alpha-amino acid;
Se-methylselenocysteine | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 10-propargyl-10-deazaaminopterin | | N-acyl-L-glutamic acid;
pteridines;
terminal acetylenic compound | antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| docetaxel | | hydrate;
secondary alpha-hydroxy ketone | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| docetaxel anhydrous | | secondary alpha-hydroxy ketone;
tetracyclic diterpenoid | antimalarial;
antineoplastic agent;
photosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lonafarnib | | 4-{2-[4-(3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-yl)piperidin-1-yl]-2-oxoethyl}piperidine-1-carboxamide | antineoplastic agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aclacinomycin | | aminoglycoside;
anthracycline;
deoxy hexoside;
methyl ester;
monosaccharide derivative;
phenols;
polyketide;
tertiary alcohol;
tetracenequinones;
zwitterion | antimicrobial agent;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-azauridine-5'-monophosphate | | N-glycosyl-1,2,4-triazine;
nucleoside monophosphate analogue | antineoplastic agent;
EC 4.1.1.23 (orotidine-5'-phosphate decarboxylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ptk 787 | | succinate salt | angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vatalanib | | monochlorobenzenes;
phthalazines;
pyridines;
secondary amino compound | angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyc 682 | | nitrile;
nucleoside analogue;
secondary carboxamide | antimetabolite;
antineoplastic agent;
DNA synthesis inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methyl 5-aminolevulinate hydrochloride | | hydrochloride | antineoplastic agent;
dermatologic drug;
photosensitizing agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methyl 5-aminolevulinate | | delta-amino acid ester | antineoplastic agent;
dermatologic drug;
photosensitizing agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tipifarnib | | imidazoles;
monochlorobenzenes;
primary amino compound;
quinolone | antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aklavinone | | anthracycline;
methyl ester;
tertiary alcohol;
tetracenequinones | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| actinodaphine | | aporphine alkaloid;
aromatic ether;
organic heteropentacyclic compound;
phenols;
secondary amino compound | antibacterial agent;
antifungal agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite;
platelet aggregation inhibitor;
topoisomerase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| i-677 | | L-serine derivative;
non-proteinogenic L-alpha-amino acid | antimetabolite;
antimicrobial agent;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| anonaine | | aporphine alkaloid;
organic heteropentacyclic compound;
oxacycle | antineoplastic agent;
antiplasmodial drug;
trypanocidal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4'-demethyldesoxypodophyllotoxin | | furonaphthodioxole;
gamma-lactone;
lignan;
methoxybenzenes;
phenols | antineoplastic agent;
antioxidant;
immunosuppressive agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| salvigenin | | monohydroxyflavone;
trimethoxyflavone | antilipemic drug;
antineoplastic agent;
apoptosis inhibitor;
autophagy inducer;
hypoglycemic agent;
immunomodulator;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| deferrioxamine e | | cyclic desferrioxamine;
cyclic hydroxamic acid;
macrocycle | antineoplastic agent;
bacterial metabolite;
marine metabolite;
siderophore | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ampelopsin | | dihydromyricetin;
secondary alpha-hydroxy ketone | antineoplastic agent;
antioxidant;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methylselenic acid | | one-carbon compound;
organoselenium compound | antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
human xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| acetyl aleuritolic acid | | acetate ester;
monocarboxylic acid;
pentacyclic triterpenoid | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| withanolide d | | 20-hydroxy steroid;
4-hydroxy steroid;
delta-lactone;
enone;
epoxy steroid;
ergostanoid;
secondary alcohol;
tertiary alcohol;
withanolide | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| myricanone | | aromatic ether;
cyclic ketone;
diarylheptanoid;
methoxybenzenes;
phenols | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cirsilineol | | dihydroxyflavone;
trimethoxyflavone | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pannarin | | aldehyde;
aromatic ether;
depsidones;
organic heterotricyclic compound;
organochlorine compound;
phenols | antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
lichen metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-methylthiohexyl isothiocyanate | | isothiocyanate;
methyl sulfide | antineoplastic agent;
Arabidopsis thaliana metabolite;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pectolinarin | | dimethoxyflavone;
disaccharide derivative;
glycosyloxyflavone;
monohydroxyflavanone;
rutinoside | anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| albicanol | | carbobicyclic compound;
homoallylic alcohol;
primary alcohol;
sesquiterpenoid | antifeedant;
antifungal agent;
antineoplastic agent;
fungal metabolite;
mammalian metabolite;
marine metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-o-methylembelin | | enol ether;
monohydroxy-1,4-benzoquinones | antileishmanial agent;
antineoplastic agent;
hepatitis C protease inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| asperphenamate | | benzamides;
carboxylic ester;
L-phenylalanine derivative | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| erlotinib | | aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound | antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| erlotinib hydrochloride | | hydrochloride;
terminal acetylenic compound | antineoplastic agent;
protein kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| corynoline | | benzophenanthridine alkaloid;
cyclic acetal;
isoquinolines;
organic heterohexacyclic compound;
secondary alcohol | antineoplastic agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hepatoprotective agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| helioxanthin | | benzodioxoles;
furonaphthodioxole;
lignan | anti-HBV agent;
antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| top 53 | | furonaphthodioxole;
gamma-lactone;
organic heterotetracyclic compound;
phenols;
tertiary amino compound | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-heptadecylresorcinol | | 5-alkylresorcinol | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| minquartynoic acid | | acetylenic fatty acid;
hydroxy polyunsaturated fatty acid;
long-chain fatty acid;
straight-chain fatty acid;
tetrayne | antimalarial;
antineoplastic agent;
antiviral agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| scutellarin | | glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative;
trihydroxyflavone | antineoplastic agent;
proteasome inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ergolide | | acetate ester;
cyclic ketone;
gamma-lactone;
organic heterotricyclic compound;
sesquiterpene lactone | anti-inflammatory agent;
antineoplastic agent;
metabolite;
NF-kappaB inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,5-dihydroxybenzyl alcohol | | aromatic primary alcohol;
phenols | antineoplastic agent;
antioxidant;
apoptosis inhibitor;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chrysosplenol c | | trihydroxyflavone;
trimethoxyflavone | antineoplastic agent;
antiviral agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lanperisone | | 2-methyl-3-(pyrrolidin-1-yl)-1-[4-(trifluoromethyl)phenyl]propan-1-one | antineoplastic agent;
calcium channel blocker;
ferroptosis inducer;
muscle relaxant;
voltage-gated sodium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (-)-gallocatechin gallate | | catechin;
gallate ester;
polyphenol | antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human xenobiotic metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| orantinib | | monocarboxylic acid;
oxindoles;
pyrroles | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| firocoxib | | butenolide;
cyclopropanes;
enol ether;
sulfone | antineoplastic agent;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-(4-morpholinoanilino)-6-cyclohexylaminopurine | | morpholines;
purines;
secondary amino compound;
tertiary amino compound | adenosine A3 receptor antagonist;
antineoplastic agent;
Aurora kinase inhibitor;
cell dedifferentiation agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lenalidomide | | aromatic amine;
dicarboximide;
isoindoles;
piperidones | angiogenesis inhibitor;
antineoplastic agent;
immunomodulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lasofoxifene | | aromatic ether;
N-alkylpyrrolidine;
naphthols;
tetralins | antineoplastic agent;
bone density conservation agent;
cardioprotective agent;
estrogen receptor agonist;
estrogen receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| l 778,123 | | hydrochloride | antineoplastic agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
EC 2.5.1.59 (protein geranylgeranyltransferase type I) inhibitor;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| l 778,123 | | imidazoles;
monochlorobenzenes;
nitrile;
piperazinone;
tertiary amino compound | antineoplastic agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
EC 2.5.1.59 (protein geranylgeranyltransferase type I) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide | | chloroindole;
organochlorine compound;
sulfonamide | antineoplastic agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diflomotecan | | epsilon-lactone;
organic heteropentacyclic compound;
organofluorine compound;
organonitrogen heterocyclic compound;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| demecolcine | | alkaloid;
secondary amino compound | antineoplastic agent;
microtubule-destabilising agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dromostanolone propionate | | 3-oxo-5alpha-steroid;
steroid ester | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vincaleukoblastine | | acetate ester;
indole alkaloid fundamental parent;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid | antineoplastic agent;
immunosuppressive agent;
microtubule-destabilising agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vincristine sulfate | | organic sulfate salt | antineoplastic agent;
geroprotector | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| anisomycin | | monohydroxypyrrolidine;
organonitrogen heterocyclic antibiotic | anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
antiparasitic agent;
bacterial metabolite;
DNA synthesis inhibitor;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| estramustine | | 17beta-hydroxy steroid;
carbamate ester;
organochlorine compound | alkylating agent;
antineoplastic agent;
radiation protective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| withaferin a | | 27-hydroxy steroid;
4-hydroxy steroid;
delta-lactone;
enone;
epoxy steroid;
ergostanoid;
primary alcohol;
secondary alcohol;
withanolide | antineoplastic agent;
apoptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| noscapine | | aromatic ether;
benzylisoquinoline alkaloid;
cyclic acetal;
isobenzofuranone;
organic heterobicyclic compound;
organic heterotricyclic compound;
tertiary amino compound | antineoplastic agent;
antitussive;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| homoharringtonine | | alkaloid ester;
enol ether;
organic heteropentacyclic compound;
tertiary alcohol | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| acivicin | | isoxazoles;
non-proteinogenic L-alpha-amino acid;
organochlorine compound | antileishmanial agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor;
glutamine antagonist;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| elesclomol | | carbohydrazide;
thiocarbonyl compound | antineoplastic agent;
apoptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| wortmannin | | acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound | anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rocaglamide | | monocarboxylic acid amide;
monomethoxybenzene;
organic heterotricyclic compound | antileishmanial agent;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| anthricin | | furonaphthodioxole;
gamma-lactone;
lignan;
methoxybenzenes | antineoplastic agent;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| acronine | | acridone derivatives;
alkaloid | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| taiwanin c | | benzodioxoles;
furonaphthodioxole;
lignan | antineoplastic agent;
plant metabolite;
platelet aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| o-(chloroacetylcarbamoyl)fumagillol | | carbamate ester;
organochlorine compound;
semisynthetic derivative;
sesquiterpenoid;
spiro-epoxide | angiogenesis inhibitor;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
methionine aminopeptidase 2 inhibitor;
retinoic acid receptor alpha antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bortezomib | | amino acid amide;
L-phenylalanine derivative;
pyrazines | antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gant 61 | | aminal;
dialkylarylamine;
pyridines;
substituted aniline;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
glioma-associated oncogene inhibitor;
Hedgehog signaling pathway inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carnosine | | amino acid zwitterion;
dipeptide | anticonvulsant;
antineoplastic agent;
antioxidant;
Daphnia magna metabolite;
geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| puromycin | | puromycins | antiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pentostatin | | coformycins | antimetabolite;
antineoplastic agent;
Aspergillus metabolite;
bacterial metabolite;
EC 3.5.4.4 (adenosine deaminase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| canaline | | amino acid zwitterion;
non-proteinogenic L-alpha-amino acid | antimetabolite;
antineoplastic agent;
phytogenic insecticide;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hippeastrine | | delta-lactone;
indole alkaloid;
organic heteropentacyclic compound;
secondary alcohol | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| peonidin | | 5-hydroxyanthocyanidin | antineoplastic agent;
antioxidant;
apoptosis inducer;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glaucarubinone | | carboxylic ester;
organic heteropentacyclic compound;
quassinoid;
secondary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone;
tetrol | antimalarial;
antineoplastic agent;
geroprotector;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| helveticoside | | 14beta-hydroxy steroid;
5beta-hydroxy steroid;
cardenolide glycoside;
digitoxoside;
monosaccharide derivative;
steroid aldehyde;
steroid lactone | antineoplastic agent;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ginsenoside re | | 12beta-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
3beta-hydroxy steroid;
beta-D-glucoside;
disaccharide derivative;
ginsenoside;
tetracyclic triterpenoid | anti-inflammatory agent;
antineoplastic agent;
antioxidant;
nephroprotective agent;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ginsenoside rf | | 12beta-hydroxy steroid;
20-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
3beta-hydroxy steroid;
beta-D-glucoside;
disaccharide derivative;
ginsenoside;
tetracyclic triterpenoid | antineoplastic agent;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ferruginol | | abietane diterpenoid;
carbotricyclic compound;
meroterpenoid;
phenols | antibacterial agent;
antineoplastic agent;
plant metabolite;
protective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| stevioside | | beta-D-glucoside;
bridged compound;
diterpene glycoside;
ent-kaurane diterpenoid;
tetracyclic diterpenoid | anti-inflammatory agent;
antineoplastic agent;
antioxidant;
hypoglycemic agent;
plant metabolite;
sweetening agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| decursinol | | cyclic ether;
delta-lactone;
organic heterotricyclic compound;
secondary alcohol | analgesic;
antineoplastic agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| naringin | | (2S)-flavan-4-one;
4'-hydroxyflavanones;
dihydroxyflavanone;
disaccharide derivative;
neohesperidoside | anti-inflammatory agent;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| eugeniin | | beta-D-glucoside;
ellagitannin;
gallate ester;
lactone | anti-HSV-1 agent;
antifungal agent;
antineoplastic agent;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| knipholone | | aromatic ketone;
dihydroxyanthraquinone;
methoxybenzenes;
methyl ketone;
polyphenol;
resorcinols | antineoplastic agent;
antioxidant;
antiplasmodial drug;
leukotriene antagonist;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gingerol | | beta-hydroxy ketone;
guaiacols | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mucronulatol | | hydroxyisoflavans;
methoxyisoflavan | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| syringaresinol | | syringaresinol | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| enkephalin, methionine | | pentapeptide;
peptide zwitterion | analgesic;
antineoplastic agent;
delta-opioid receptor agonist;
human metabolite;
mu-opioid receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| devazepide | | 1,4-benzodiazepinone;
indolecarboxamide | antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sodium arsenite | | arsenic molecular entity;
inorganic sodium salt | antibacterial agent;
antifungal agent;
antineoplastic agent;
carcinogenic agent;
herbicide;
insecticide;
rodenticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| surfactin c | | cyclodepsipeptide;
lipopeptide antibiotic;
macrocyclic lactone | antibacterial agent;
antifungal agent;
antineoplastic agent;
antiviral agent;
metabolite;
platelet aggregation inhibitor;
surfactant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| kerriamycin b | | angucycline antibiotic | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carubicin | | aminoglycoside antibiotic;
anthracycline antibiotic;
p-quinones;
tertiary alpha-hydroxy ketone;
tetracenequinones | antineoplastic agent;
apoptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tretinoin | | retinoic acid;
vitamin A | anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| docosahexaenoate | | docosahexaenoic acid;
omega-3 fatty acid | algal metabolite;
antineoplastic agent;
Daphnia tenebrosa metabolite;
human metabolite;
mouse metabolite;
nutraceutical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| eicosapentaenoic acid | | icosapentaenoic acid;
omega-3 fatty acid | anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mycophenolic acid | | 2-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols | anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| formycin | | formycin | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| neocarzinostatin chromophore | | cyclopentacyclononaoxirene;
D-galactosaminide;
dioxolane;
monosaccharide derivative;
naphthoate ester | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| epothilone b | | epothilone;
epoxide | antineoplastic agent;
apoptosis inducer;
microtubule-stabilising agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| adenosine-5'-(n-ethylcarboxamide) | | adenosines;
monocarboxylic acid amide | adenosine A1 receptor agonist;
adenosine A2A receptor agonist;
antineoplastic agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n(1)-guanyl-1,7-diaminoheptane | | guanidines;
primary amino compound | antineoplastic agent;
EC 2.5.1.46 (deoxyhypusine synthase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diethylstilbestrol | | olefinic compound;
polyphenol | antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bms 214662 | | benzenes;
benzodiazepine;
imidazoles;
nitrile;
sulfonamide;
thiophenes | antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| epothilone a | | epothilone;
epoxide | antineoplastic agent;
metabolite;
microtubule-stabilising agent;
tubulin modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 8-(2-chloro-3,4,5-trimethoxybenzyl)-2-fluoro-9-pent-4-yn-1-yl-9H-purin-6-amine | | 6-aminopurines;
acetylenic compound;
methoxybenzenes;
monochlorobenzenes;
organofluorine compound | antineoplastic agent;
Hsp90 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alitretinoin | | retinoic acid | antineoplastic agent;
keratolytic drug;
metabolite;
retinoid X receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| afimoxifene | | phenols;
tertiary amino compound | antineoplastic agent;
estrogen receptor antagonist;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aclarubicin | | aminoglycoside;
anthracycline;
methyl ester;
phenols;
polyketide;
tetracenequinones;
trisaccharide derivative;
zwitterion | antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| teniposide | | aromatic ether;
beta-D-glucoside;
cyclic acetal;
furonaphthodioxole;
gamma-lactone;
monosaccharide derivative;
phenols;
thiophenes | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| steviol | | bridged compound;
ent-kaurane diterpenoid;
monocarboxylic acid;
tertiary allylic alcohol;
tetracyclic diterpenoid | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tiazofurin | | 1,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide | antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aphidicolin | | tetracyclic diterpenoid | antimicrobial agent;
antimitotic;
antineoplastic agent;
antiviral drug;
apoptosis inducer;
Aspergillus metabolite;
DNA synthesis inhibitor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azaserine | | carboxylic ester;
diazo compound;
L-serine derivative;
non-proteinogenic L-alpha-amino acid | antifungal agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
glutamine antagonist;
immunosuppressive agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| melphalan | | L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound | alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prinomastat | | aromatic ether;
hydroxamic acid;
pyridines;
sulfonamide;
thiomorpholines | antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor;
matrix metalloproteinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rubitecan | | C-nitro compound;
delta-lactone;
pyranoindolizinoquinoline;
semisynthetic derivative;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| arsenic trioxide | | arsenic oxide | antineoplastic agent;
insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rhapontin | | rhaponticin | angiogenesis inhibitor;
anti-allergic agent;
anti-inflammatory agent;
antilipemic drug;
antineoplastic agent;
apoptosis inducer;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
hypoglycemic agent;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| isoliquiritigenin | | chalcones | antineoplastic agent;
biological pigment;
EC 1.14.18.1 (tyrosinase) inhibitor;
GABA modulator;
geroprotector;
metabolite;
NMDA receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| antofine | | alkaloid antibiotic;
alkaloid;
aromatic ether;
organic heteropentacyclic compound | angiogenesis inhibitor;
anti-inflammatory agent;
antimicrobial agent;
antineoplastic agent;
antiviral agent;
phytotoxin;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| xanthohumol | | aromatic ether;
chalcones;
polyphenol | anti-HIV-1 agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.3.1.20 (diacylglycerol O-acyltransferase) inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vedelianin | | cyclic ether;
organic heterotricyclic compound;
resorcinols;
stilbenoid | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amygdalin | | amygdalin | antineoplastic agent;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trilostane | | 17beta-hydroxy steroid;
3-hydroxy steroid;
androstanoid;
epoxy steroid;
nitrile | abortifacient;
antineoplastic agent;
EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| leuprolide acetate | | acetate salt | antineoplastic agent;
gonadotropin releasing hormone agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| leuprolide | | oligopeptide | anti-estrogen;
antineoplastic agent;
gonadotropin releasing hormone agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mercaptopurine | | aryl thiol;
purines;
thiocarbonyl compound | anticoronaviral agent;
antimetabolite;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| iFSP1 | | aromatic amine;
nitrile;
primary amino compound;
pyridobenzimidazole;
toluenes | antineoplastic agent;
ferroptosis inducer;
ferroptosis suppressor protein 1 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-iodo-6-phenylpyrimidine | | biaryl;
organoiodine compound;
pyrimidines | antineoplastic agent;
apoptosis inducer;
macrophage migration inhibitory factor inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oncrasin-1 | | arenecarbaldehyde;
indoles;
monochlorobenzenes | antineoplastic agent;
apoptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| curcumin | | aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol | anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cct018159 | | benzodioxine;
pyrazoles;
resorcinols | antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulindac | | monocarboxylic acid;
organofluorine compound;
sulfoxide | analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aurapten | | coumarins;
monoterpenoid | antihypertensive agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
dopaminergic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
gamma-secretase modulator;
gastrointestinal drug;
hepatoprotective agent;
matrix metalloproteinase inhibitor;
neuroprotective agent;
plant metabolite;
PPARalpha agonist;
vulnerary | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| xl147 | | aromatic amine;
benzothiadiazole;
quinoxaline derivative;
sulfonamide | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mcb-613 | | cyclic ketone;
enone;
pyridines | antineoplastic agent;
steroid receptor coactivator stimulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thioguanine anhydrous | | 2-aminopurines | anticoronaviral agent;
antimetabolite;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tamoxifen | | stilbenoid;
tertiary amino compound | angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| stattic | | 1-benzothiophenes;
C-nitro compound;
sulfone | antineoplastic agent;
radiosensitizing agent;
STAT3 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| krn 7000 | | glycophytoceramide;
N-acyl-beta-D-galactosylphytosphingosine | allergen;
antigen;
antineoplastic agent;
epitope;
immunological adjuvant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 10058-F4 | | olefinic compound;
thiazolidinone | antineoplastic agent;
apoptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| monastrol | | enoate ester;
ethyl ester;
phenols;
racemate;
thioureas | antileishmanial agent;
antimitotic;
antineoplastic agent;
EC 3.5.1.5 (urease) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| toremifene | | aromatic ether;
organochlorine compound;
tertiary amine | antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| u 0126 | | aryl sulfide;
dinitrile;
enamine;
substituted aniline | antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| beauvericin | | cyclodepsipeptide | antibiotic insecticide;
antifungal agent;
antineoplastic agent;
apoptosis inhibitor;
fungal metabolite;
ionophore;
mycotoxin;
P450 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nelarabine | | beta-D-arabinoside;
monosaccharide derivative;
purine nucleoside | antineoplastic agent;
DNA synthesis inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bms 387032 | | 1,3-oxazoles;
1,3-thiazoles;
organic sulfide;
piperidinecarboxamide;
secondary carboxamide | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| manool | | labdane diterpenoid;
tertiary alcohol | antibacterial agent;
antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amrubicin | | anthracycline antibiotic;
methyl ketone;
primary amino compound;
quinone;
tetracenes | antineoplastic agent;
prodrug;
topoisomerase II inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ospemifene | | aromatic ether;
organochlorine compound;
primary alcohol | anti-inflammatory agent;
antineoplastic agent;
estrogen receptor modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tandutinib | | aromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
piperidines;
quinazolines;
tertiary amino compound | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| emetine dihydrochloride | | hydrochloride | anticoronaviral agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bigelovin | | acetate ester;
cyclic ketone;
gamma-lactone;
organic heterotricyclic compound;
sesquiterpene lactone | antineoplastic agent;
apoptosis inducer;
immunomodulator;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| l 663536 | | aryl sulfide;
indoles;
monocarboxylic acid;
monochlorobenzenes | antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
leukotriene antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione | | benzenes;
thiadiazolidine | anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sc 560 | | aromatic ether;
monochlorobenzenes;
organofluorine compound;
pyrazoles | angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
cyclooxygenase 1 inhibitor;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alsterpaullone | | C-nitro compound;
caprolactams;
organic heterotetracyclic compound | anti-HIV-1 agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ginkgetin | | biflavonoid;
hydroxyflavone;
methoxyflavone;
ring assembly | anti-HSV-1 agent;
antineoplastic agent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| eupatilin | | dihydroxyflavone;
trimethoxyflavone | anti-inflammatory agent;
anti-ulcer drug;
antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| quercetin | | 7-hydroxyflavonol;
pentahydroxyflavone | antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vitexin | | C-glycosyl compound;
trihydroxyflavone | antineoplastic agent;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
plant metabolite;
platelet aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| apigenin | | trihydroxyflavone | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| luteolin | | 3'-hydroxyflavonoid;
tetrahydroxyflavone | angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| calcitriol | | D3 vitamins;
hydroxycalciol;
triol | antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| herbacetin | | 7-hydroxyflavonol;
pentahydroxyflavone | angiogenesis inhibitor;
anti-inflammatory agent;
antilipemic drug;
antineoplastic agent;
apoptosis inducer;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hymecromone | | hydroxycoumarin | antineoplastic agent;
hyaluronic acid synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chrysoeriol | | monomethoxyflavone;
trihydroxyflavone | antineoplastic agent;
antioxidant;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dexmedetomidine | | trihydroxyflavone;
trimethoxyflavone | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bryostatin 1 | | acetate ester;
bryostatins;
cyclic hemiketal;
enoate ester;
methyl ester;
organic heterotetracyclic compound;
secondary alcohol | alpha-secretase activator;
anti-HIV-1 agent;
antineoplastic agent;
marine metabolite;
protein kinase C agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| quercetin 3-o-glucopyranoside | | beta-D-glucoside;
monosaccharide derivative;
quercetin O-glucoside;
tetrahydroxyflavone | antineoplastic agent;
antioxidant;
antipruritic drug;
bone density conservation agent;
geroprotector;
histamine antagonist;
osteogenesis regulator;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 9-deoxy-9,10-didehydro-12,13-didehydro-13,14-dihydroprostaglandin d2 | | prostaglandins J;
secondary alcohol | antineoplastic agent;
antiviral agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pyrvinium | | quinolinium ion | anthelminthic drug;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyclobenzaprine | | 9,11,13-octadecatrienoic acid | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cucurbitacin i | | cucurbitacin;
tertiary alpha-hydroxy ketone | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| daphnoretin | | aromatic ether;
hydroxycoumarin | antineoplastic agent;
antiviral agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| costunolide | | germacranolide;
heterobicyclic compound | anthelminthic drug;
antiinfective agent;
antineoplastic agent;
antiparasitic agent;
antiviral drug;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| eupatolide | | gamma-lactone;
germacranolide;
homoallylic alcohol;
secondary alcohol | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oleuropein | | beta-D-glucoside;
catechols;
diester;
methyl ester;
pyrans;
secoiridoid glycoside | anti-inflammatory agent;
antihypertensive agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
NF-kappaB inhibitor;
nutraceutical;
plant metabolite;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| agathisflavone | | biaryl;
biflavonoid;
hydroxyflavone | antineoplastic agent;
antiviral agent;
hepatoprotective agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| baicalein | | trihydroxyflavone | angiogenesis inhibitor;
anti-inflammatory agent;
antibacterial agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
EC 4.1.1.17 (ornithine decarboxylase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hormone antagonist;
plant metabolite;
prostaglandin antagonist;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chrysin | | 7-hydroxyflavonol;
dihydroxyflavone | anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diosmetin | | 3'-hydroxyflavonoid;
monomethoxyflavone;
trihydroxyflavone | angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
bone density conservation agent;
cardioprotective agent;
plant metabolite;
tropomyosin-related kinase B receptor agonist;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hinokiflavone | | aromatic ether;
biflavonoid;
hydroxyflavone | antineoplastic agent;
metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hispidulin | | monomethoxyflavone;
trihydroxyflavone | anti-inflammatory agent;
anticonvulsant;
antineoplastic agent;
antioxidant;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gartanin | | polyphenol;
xanthones | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mangostin | | aromatic ether;
phenols;
xanthones | antimicrobial agent;
antineoplastic agent;
antioxidant;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| norathyriol | | polyphenol;
xanthones | antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| morin | | 7-hydroxyflavonol;
pentahydroxyflavone | angiogenesis modulating agent;
anti-inflammatory agent;
antibacterial agent;
antihypertensive agent;
antineoplastic agent;
antioxidant;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
hepatoprotective agent;
metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| morusin | | extended flavonoid;
trihydroxyflavone | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| myricetin | | 7-hydroxyflavonol;
hexahydroxyflavone | antineoplastic agent;
antioxidant;
cyclooxygenase 1 inhibitor;
food component;
geroprotector;
hypoglycemic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| robustaflavone | | biflavonoid;
hydroxyflavone;
ring assembly | anti-HBV agent;
antineoplastic agent;
antioxidant;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tricetin | | pentahydroxyflavone | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| wogonin | | dihydroxyflavone;
monomethoxyflavone | angiogenesis inhibitor;
antineoplastic agent;
cyclooxygenase 2 inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| daidzein | | 7-hydroxyisoflavones | antineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
phytoestrogen;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| astringin | | beta-D-glucoside;
monosaccharide derivative;
polyphenol;
stilbenoid | antineoplastic agent;
antioxidant;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pterostilbene | | diether;
methoxybenzenes;
stilbenol | anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
hypoglycemic agent;
neuroprotective agent;
neurotransmitter;
plant metabolite;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| irilone | | hydroxyisoflavone;
organic heterotricyclic compound;
oxacycle | antineoplastic agent;
immunomodulator;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| caffeic acid phenethyl ester | | alkyl caffeate ester | anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
antioxidant;
antiviral agent;
immunomodulator;
metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| wedelolactone | | aromatic ether;
coumestans;
delta-lactone;
polyphenol | antineoplastic agent;
apoptosis inducer;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
hepatoprotective agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| maytansine | | alpha-amino acid ester;
carbamate ester;
epoxide;
maytansinoid;
organic heterotetracyclic compound;
organochlorine compound | antimicrobial agent;
antimitotic;
antineoplastic agent;
plant metabolite;
tubulin modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rottlerin | | aromatic ketone;
benzenetriol;
chromenol;
enone;
methyl ketone | anti-allergic agent;
antihypertensive agent;
antineoplastic agent;
apoptosis inducer;
K-ATP channel agonist;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tectochrysin | | monohydroxyflavone;
monomethoxyflavone | antidiarrhoeal drug;
antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| plaunotol | | diterpenoid;
primary alcohol | anti-ulcer drug;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
nephroprotective agent;
plant metabolite;
vulnerary | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tranilast | | amidobenzoic acid;
cinnamamides;
dimethoxybenzene;
secondary carboxamide | anti-allergic agent;
anti-asthmatic drug;
antineoplastic agent;
aryl hydrocarbon receptor agonist;
calcium channel blocker;
hepatoprotective agent;
nephroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tocotrienol, beta | | tocotrienol;
vitamin E | antineoplastic agent;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gamma-tocotrienol | | tocotrienol;
vitamin E | antineoplastic agent;
antioxidant;
apoptosis inducer;
hepatoprotective agent;
plant metabolite;
radiation protective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tocotrienol, delta | | tocotrienol;
vitamin E | anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bone density conservation agent;
NF-kappaB inhibitor;
plant metabolite;
radiation protective agent;
Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4'-hydroxychalcone | | chalcones;
phenols | anti-inflammatory agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| isotretinoin | | retinoic acid | antineoplastic agent;
keratolytic drug;
teratogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 9,11-linoleic acid | | octadeca-9,11-dienoic acid | anti-inflammatory agent;
antiatherogenic agent;
antineoplastic agent;
apoptosis inducer;
bacterial xenobiotic metabolite;
human metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| camostat mesylate | | methanesulfonate salt | anti-inflammatory agent;
anticoronaviral agent;
antifibrinolytic drug;
antihypertensive agent;
antineoplastic agent;
antiviral agent;
serine protease inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sirolimus | | antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol | antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3',4',7-trihydroxyisoflavone | | 7-hydroxyisoflavones | antineoplastic agent;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alvocidib | | dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound | antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fenretinide | | monocarboxylic acid amide;
retinoid | antineoplastic agent;
antioxidant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| geldanamycin | | 1,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound | antimicrobial agent;
antineoplastic agent;
antiviral agent;
cysteine protease inhibitor;
Hsp90 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-oxoretinol | | cyclic ketone;
enone;
primary allylic alcohol;
retinoid | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid | | benzoic acids;
naphthalenes;
retinoid | antineoplastic agent;
retinoic acid receptor agonist;
teratogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vinorelbine | | acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
ring assembly;
vinca alkaloid | antineoplastic agent;
photosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| centaureidin | | trihydroxyflavone;
trimethoxyflavone | antineoplastic agent;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,3'-di-o-methylquercetin | | 3'-methoxyflavones;
dimethoxyflavone;
trihydroxyflavone | antibacterial agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethyl caffeate | | alkyl caffeate ester;
ethyl ester;
hydroxycinnamic acid | anti-inflammatory agent;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| andrographolide | | carbobicyclic compound;
gamma-lactone;
labdane diterpenoid;
primary alcohol;
secondary alcohol | anti-HIV agent;
anti-inflammatory drug;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| isoginkgetin | | aromatic ether;
biflavonoid | antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cudraflavone c | | tetrahydroxyflavone | antibacterial agent;
antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| neobavaisoflavone | | 7-hydroxyisoflavones | antineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
plant metabolite;
platelet aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| neoglycyrol | | aromatic ether;
coumestans;
delta-lactone;
polyphenol | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5,7-dihydroxy-6-methoxy-2-phenylchromen-4-one | | dihydroxyflavone;
monomethoxyflavone | antineoplastic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| spiraeoside | | beta-D-glucoside;
flavonols;
monosaccharide derivative;
quercetin O-glucoside;
tetrahydroxyflavone | antineoplastic agent;
antioxidant;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rhamnazin | | aromatic ether;
dimethoxyflavone;
phenols;
trihydroxyflavone | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oridonin | | cyclic hemiketal;
enone;
ent-kaurane diterpenoid;
organic heteropentacyclic compound;
secondary alcohol | angiogenesis inhibitor;
anti-asthmatic agent;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pd 166866 | | biaryl;
dimethoxybenzene;
primary arylamine;
pyridopyrimidine;
ureas | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| semaxinib | | olefinic compound;
oxindoles;
pyrroles | angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| su 11248 | | monocarboxylic acid amide;
pyrroles | angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| palbociclib | | aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mitoguazone | | guanidines;
hydrazone | antineoplastic agent;
apoptosis inducer;
EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| reumycin | | carbonyl compound;
pyrimidotriazine | antimicrobial agent;
antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ergosterol-5,8-peroxide | | 3beta-sterol;
ergostanoid;
organic peroxide;
phytosterols | antimycobacterial drug;
antineoplastic agent;
metabolite;
trypanocidal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ermanin | | dihydroxyflavone;
dimethoxyflavone | anti-inflammatory agent;
antimycobacterial drug;
antineoplastic agent;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| romidepsin | | cyclodepsipeptide;
heterocyclic antibiotic;
organic disulfide | antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulindac sulfide | | aryl sulfide;
monocarboxylic acid;
organofluorine compound | antineoplastic agent;
apoptosis inducer;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bay 11-7085 | | benzenes;
nitrile;
sulfone | anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
ferroptosis inducer;
NF-kappaB inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| macluraxanthone b | | phenols;
xanthones | anti-HIV agent;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flavokawain b | | chalcones;
dimethoxybenzene;
phenols | anti-inflammatory agent;
antileishmanial agent;
antineoplastic agent;
apoptosis inducer;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tamsulosin hydrochloride | | hydrochloride | alpha-adrenergic antagonist;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| batimastat | | hydroxamic acid;
L-phenylalanine derivative;
organic sulfide;
secondary carboxamide;
thiophenes;
triamide | angiogenesis inhibitor;
antineoplastic agent;
matrix metalloproteinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glyceryl behenate | | 1-monoglyceride;
fatty acid ester | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| jaceosidin | | dimethoxyflavone;
trihydroxyflavone | anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5,7,3'-trihydroxy-3,4'-dimethoxyflavone | | dimethoxyflavone;
trihydroxyflavone | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pederin | | cyclic ketal;
diol;
oxanes;
polyketide;
secondary alcohol;
secondary carboxamide | antimitotic;
antineoplastic agent;
bacterial metabolite;
vesicant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| artocarpin lectin | | monomethoxyflavone;
trihydroxyflavone | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cisplatin | | diamminedichloroplatinum | antineoplastic agent;
apoptosis inducer;
cross-linking reagent;
ferroptosis inducer;
genotoxin;
mutagen;
nephrotoxin;
photosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bleomycin | | bleomycin | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| beta-aminopropionitrile fumarate (2:1) | | fumarate salt | antineoplastic agent;
antirheumatic drug;
collagen cross-linking inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gamma-mangostin | | phenols;
xanthones | antineoplastic agent;
plant metabolite;
protein kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| demethoxycurcumin | | beta-diketone;
diarylheptanoid;
enone;
polyphenol | anti-inflammatory agent;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cystothiazole a | | 1,3-thiazoles;
biaryl;
enoate ester;
enol ether;
methyl ester;
organonitrogen heterocyclic antibiotic | antifungal agent;
antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lespenefril | | alpha-L-rhamnoside;
dihydroxyflavone;
glycosyloxyflavone;
monosaccharide derivative;
polyphenol | anti-inflammatory agent;
antidepressant;
antineoplastic agent;
apoptosis inducer;
bone density conservation agent;
hypoglycemic agent;
immunomodulator;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| baohuoside i | | glycosyloxyflavone | anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| arglabin | | epoxide;
gamma-lactone;
organic heterotetracyclic compound;
sesquiterpene lactone | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one | | enone;
pyridines | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.1.105 (6-phosphofructo-2-kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ma-1 | | carboxamidine;
organochlorine compound;
pyrimidone;
pyrrolidines | antineoplastic agent;
EC 2.4.2.4 (thymidine phosphorylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| apratoxin a | | 1,3-thiazoles;
apratoxin | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| coronardine | | alkaloid ester;
methyl ester;
monoterpenoid indole alkaloid;
organic heteropentacyclic compound | antileishmanial agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ascofuranone | | dihydroxybenzaldehyde;
meroterpenoid;
monochlorobenzenes;
olefinic compound;
resorcinols;
sesquiterpenoid;
tetrahydrofuranone | angiogenesis inhibitor;
antilipemic drug;
antineoplastic agent;
antiprotozoal drug;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| columbianadin | | alpha,beta-unsaturated carboxylic ester;
furanocoumarin | anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
hepatoprotective agent;
plant metabolite;
rat metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| germacrone | | germacrane sesquiterpenoid;
olefinic compound | androgen antagonist;
anti-inflammatory agent;
antifeedant;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antioxidant;
antitussive;
antiviral agent;
apoptosis inducer;
autophagy inducer;
hepatoprotective agent;
insecticide;
neuroprotective agent;
plant metabolite;
volatile oil component | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rhizoxin | | 1,3-oxazoles;
epoxide;
macrolide antibiotic | antimitotic;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sibiromycin | | aminoglycoside antibiotic;
hemiaminal;
phenols;
pyrrolobenzodiazepine | antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bryostatin 2 | | bryostatins;
cyclic hemiketal;
enoate ester;
methyl ester;
organic heterotetracyclic compound;
secondary alcohol | antineoplastic agent;
marine metabolite;
protein kinase C agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| manumycin | | enamide;
epoxide;
organic heterobicyclic compound;
polyketide;
secondary carboxamide;
tertiary alcohol | antiatherosclerotic agent;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thermozymocidin | | alpha-amino fatty acid;
hydroxy monocarboxylic acid;
non-proteinogenic alpha-amino acid;
sphingoid | antifungal agent;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
EC 2.3.1.50 (serine C-palmitoyltransferase) inhibitor;
fungal metabolite;
immunosuppressive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| asukamycin | | enamide;
epoxide;
organic heterobicyclic compound;
polyketide;
secondary carboxamide;
tertiary alcohol | antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| everolimus | | cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol | anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 13(S)-HODE | | HODE | antineoplastic agent;
human xenobiotic metabolite;
mouse metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ixabepilone | | 1,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle | antineoplastic agent;
microtubule-destabilising agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| salvianolic acid B | | 1-benzofurans;
catechols;
dicarboxylic acid;
enoate ester;
polyphenol | anti-inflammatory agent;
antidepressant;
antineoplastic agent;
antioxidant;
apoptosis inducer;
autophagy inhibitor;
cardioprotective agent;
hepatoprotective agent;
hypoglycemic agent;
neuroprotective agent;
osteogenesis regulator;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| l 744832 | | benzenes;
ether;
isopropyl ester;
secondary carboxamide;
sulfone;
thiol | antineoplastic agent;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor;
geroprotector | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sophoraflavanone a | | (2S)-flavan-4-one;
4'-hydroxyflavanones;
trihydroxyflavanone | antibacterial agent;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tanespimycin | | 1,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound;
secondary amino compound | antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| manzamine a | | alkaloid;
beta-carbolines;
isoquinolines | animal metabolite;
anti-HSV-1 agent;
antimalarial;
antineoplastic agent;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aureothin | | 4-pyranones;
C-nitro compound;
ketene acetal;
olefinic compound;
oxolanes | antibacterial agent;
antifungal agent;
antineoplastic agent;
antiparasitic agent;
bacterial metabolite;
EC 1.6.5.3 [NADH:ubiquinone reductase (H(+)-translocating)] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fostriecin | | 2-pyranones;
olefinic compound;
phosphate monoester;
polyketide;
primary allylic alcohol;
secondary allylic alcohol;
triol | antineoplastic agent;
apoptosis inhibitor;
bacterial metabolite;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
topoisomerase II inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| artesunate | | artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid | antimalarial;
antineoplastic agent;
ferroptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ru 58668 | | 17beta-hydroxy steroid;
3-hydroxy steroid;
aromatic ether;
organofluorine compound;
sulfone | anti-estrogen;
antineoplastic agent;
estrogen receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| soblidotin | | tetrapeptide | antineoplastic agent;
apoptosis inducer;
microtubule-destabilising agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| beta-elemene | | beta-elemene | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| laulimalide | | carboxylic ester;
epoxide;
macrolide;
secondary alcohol;
secondary allylic alcohol | animal metabolite;
antimitotic;
antineoplastic agent;
marine metabolite;
microtubule-stabilising agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| jwh-133 | | benzochromene;
dibenzopyran;
organic heterotricyclic compound | analgesic;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inhibitor;
CB2 receptor agonist;
opioid analgesic;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| belinostat | | hydroxamic acid;
olefinic compound;
sulfonamide | antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| on 01910 | | N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.21 (polo kinase) inhibitor;
microtubule-destabilising agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| panobinostat | | cinnamamides;
hydroxamic acid;
methylindole;
secondary amino compound | angiogenesis modulating agent;
antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bml 210 | | dicarboxylic acid diamide | antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bufalin | | 14beta-hydroxy steroid;
3beta-hydroxy steroid | animal metabolite;
anti-inflammatory agent;
antineoplastic agent;
cardiotonic drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alpha-solanine | | glycoalkaloid;
organic heterohexacyclic compound;
steroid saponin;
trisaccharide derivative | antineoplastic agent;
apoptosis inducer;
phytotoxin;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rhosin | | D-tryptophan derivative;
hydrazone;
quinoxaline derivative | antineoplastic agent;
RhoA inhibitor;
RhoC inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| s-allylcysteine | | L-alpha-amino acid zwitterion;
S-hydrocarbyl-L-cysteine | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-hydroxy-9-cis-octadecenoic acid | | 2-hydroxy fatty acid;
hydroxy monounsaturated fatty acid;
long-chain fatty acid | antihypertensive agent;
antineoplastic agent;
apoptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dolastatin 10 | | 1,3-thiazoles;
tetrapeptide | animal metabolite;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
microtubule-destabilising agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| plitidepsin | | didemnin | anticoronaviral agent;
antineoplastic agent;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| abiraterone acetate | | pyridines;
sterol ester | antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lenvatinib | | aromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nsc 716970 | | aromatic amine;
aromatic ether;
indolecarboxamide;
organochlorine compound | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pd 0325901 | | difluorobenzene;
hydroxamic acid ester;
monofluorobenzenes;
organoiodine compound;
propane-1,2-diols;
secondary amino compound | antineoplastic agent;
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| midostaurin | | benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound | antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| jasplakinolide | | cyclodepsipeptide;
phenols | actin polymerisation inducer;
animal metabolite;
antifungal agent;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| muromonab-cd3 | | alkaloid;
macrocycle;
organic heteropentacyclic compound;
organonitrogen heterocyclic compound;
oxacycle;
tertiary amino compound | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
IP3 receptor antagonist;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ginsenoside m1 | | 12beta-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
3beta-hydroxy steroid;
beta-D-glucoside;
ginsenoside;
tetracyclic triterpenoid | anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
hepatoprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cabazitaxel | | tetracyclic diterpenoid | antineoplastic agent;
microtubule-stabilising agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| elisidepsin | | cyclodepsipeptide | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fr 148083 | | aromatic ether;
macrolide;
phenols;
secondary alcohol;
secondary alpha-hydroxy ketone | antibacterial agent;
antineoplastic agent;
metabolite;
NF-kappaB inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mocetinostat | | aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline | antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tln 4601 | | dibenzodiazepine;
farnesane sesquiterpenoid;
olefinic compound;
secondary amine;
triol | antineoplastic agent;
antioxidant;
cathepsin L (EC 3.4.22.15) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| scio-469 | | aromatic amide;
aromatic ketone;
chloroindole;
dicarboxylic acid diamide;
indolecarboxamide;
monofluorobenzenes;
N-acylpiperazine;
N-alkylpiperazine | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tmc-95a | | indoles;
lactam;
macrocycle;
phenols;
secondary alcohol;
tertiary alcohol | antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
fungal metabolite;
proteasome inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cp 724714 | | 2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide | antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
hepatotoxic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 9-methoxycanthin-6-one | | aromatic ether;
indole alkaloid;
organic heterotetracyclic compound | antineoplastic agent;
antiplasmodial drug;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| topopyrone c | | naphthochromene;
p-quinones;
phenols | antimicrobial agent;
antineoplastic agent;
antiviral agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
Penicillium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pi103 | | aromatic amine;
morpholines;
organic heterotricyclic compound;
phenols;
tertiary amino compound | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-chloro-6-(1-(2-iminopyrrolidinyl) methyl)uracil hydrochloride | | hydrochloride;
iminium salt | antineoplastic agent;
EC 2.4.2.4 (thymidine phosphorylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fty 720p | | monoalkyl phosphate;
primary alcohol;
primary amino compound | antineoplastic agent;
immunosuppressive agent;
sphingosine-1-phosphate receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hmr 1275 | | hydrochloride | antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zm 447439 | | aromatic ether;
benzamides;
morpholines;
polyether;
quinazolines;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
Aurora kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ginsenoside f2 | | 12beta-hydroxy steroid;
beta-D-glucoside;
ginsenoside;
tetracyclic triterpenoid | antineoplastic agent;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ginsenoside rg3 | | ginsenoside;
glycoside;
tetracyclic triterpenoid | angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| es-285 | | amino alcohol;
sphingoid | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nidulalin a | | methyl ester;
phenols;
xanthones | antimicrobial agent;
antineoplastic agent;
Penicillium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hypothemycin | | aromatic ether;
diol;
enone;
epoxide;
macrolide;
phenols;
polyketide;
secondary alpha-hydroxy ketone | antifungal agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rucaparib | | azepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound | antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| jte 607 | | hydrochloride | anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
cardioprotective agent;
CPSF3 inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pasireotide | | homodetic cyclic peptide;
peptide hormone | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| npi 2358 | | 2,5-diketopiperazines;
benzenes;
imidazoles;
olefinic compound | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
microtubule-destabilising agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rubraxanthone | | aromatic ether;
polyphenol;
xanthones | antibacterial agent;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| NNC 55-0396 (free base) | | benzimidazoles;
cyclopropanecarboxylate ester;
organofluorine compound;
tertiary amino compound;
tetralins | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
neuroprotective agent;
potassium channel blocker;
T-type calcium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sr 11302 | | alpha,beta-unsaturated monocarboxylic acid;
retinoid;
toluenes | antineoplastic agent;
AP-1 antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sch 51344 | | aromatic amine;
aromatic ether;
primary alcohol;
pyrazoloquinoline;
secondary amino compound | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4alpha-methylergosta-8,24(28)-dien-3,7,11-trione-26-oic acid | | 11-oxo steroid;
3-oxo steroid;
7-oxo steroid;
ergostanoid;
monocarboxylic acid;
steroid acid | anti-inflammatory agent;
antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| osu 03012 | | antibiotic antifungal drug;
aromatic amide;
glycine derivative;
organofluorine compound;
phenanthrenes;
pyrazoles | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ly2090314 | | diazepinoindole;
imidazopyridine;
maleimides;
monofluorobenzenes;
piperidinecarboxamide;
ureas | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
Wnt signalling activator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cerberin | | acetate ester;
cardenolide glycoside;
monosaccharide derivative | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pateamine a | | 1,3-thiazoles;
macrodiolide;
olefinic compound;
primary amino compound;
tertiary amino compound | antineoplastic agent;
antiviral agent;
eukaryotic initiation factor 4F inhibitor;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-hydroxytaxol | | taxane diterpenoid;
tetracyclic diterpenoid | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| avenanthramide b | | amidobenzoic acid;
cinnamamides;
monohydroxybenzoic acid;
monomethoxybenzene;
phenols;
secondary carboxamide | antineoplastic agent;
apoptosis inducer;
phytoalexin | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ageladine a | | alkaloid;
aromatic amine;
imidazopyridine;
organobromine compound;
pyrroles | angiogenesis inhibitor;
antineoplastic agent;
matrix metalloproteinase inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ly-2157299 | | aromatic amide;
methylpyridines;
monocarboxylic acid amide;
pyrrolopyrazole;
quinolines | antineoplastic agent;
TGFbeta receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azd 6244 | | benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound | anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azd2858 | | aromatic amine;
N-methylpiperazine;
pyrazines;
pyridines;
secondary carboxamide;
sulfonamide | antineoplastic agent;
bone density conservation agent;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
Wnt signalling activator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bl1521 | | enamide;
hydroxamic acid;
monocarboxylic acid amide | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| jte 013 | | chloropyridine;
pyrazolopyridine | anti-asthmatic agent;
anti-inflammatory agent;
antineoplastic agent;
osteogenesis regulator;
pro-angiogenic agent;
sphingosine-1-phosphate receptor 2 antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| holomycin | | acetamides;
dithiolopyrrolone antibiotic | antibacterial agent;
antineoplastic agent;
bacterial metabolite;
chelator;
EC 2.7.7.6 (RNA polymerase) inhibitor;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| binimetinib | | benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monofluorobenzenes;
secondary amino compound | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aee 788 | | 6-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist;
trypanocidal drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| saracatinib | | aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| crenolanib | | aminopiperidine;
aromatic ether;
benzimidazoles;
oxetanes;
quinolines;
tertiary amino compound | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trilobacin | | butenolide;
polyketide;
triol | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| manassantin b | | benzodioxoles;
dimethoxybenzene;
lignan;
oxolanes;
secondary alcohol | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pha 665752 | | dichlorobenzene;
enamide;
indolones;
N-acylpyrrolidine;
pyrrolecarboxamide;
secondary carboxamide;
sulfone;
tertiary carboxamide | antineoplastic agent;
c-Met tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| PB28 | | aromatic ether;
piperazines;
tetralins | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
sigma-2 receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tmc-95b | | indoles;
lactam;
macrocycle;
phenols;
secondary alcohol;
tertiary alcohol | antimicrobial agent;
antineoplastic agent;
fungal metabolite;
proteasome inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fr 901464 | | acetate ester;
cyclic hemiketal;
monocarboxylic acid amide;
pyrans;
spiro-epoxide | antimicrobial agent;
antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| vinflunine | | acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
semisynthetic derivative;
vinca alkaloid | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| homocamptothecin | | epsilon-lactone;
organic heteropentacyclic compound;
organonitrogen heterocyclic compound;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,5-dimethoxy-4-hydroxybenzyl alcohol-4-O-beta-D-glucopyranoside | | aromatic ether;
benzyl alcohols;
beta-D-glucoside;
monosaccharide derivative;
primary alcohol | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| jaspamide b | | cyclodepsipeptide;
organobromine compound | animal metabolite;
antineoplastic agent;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ossamycin | | cyclic hemiketal;
macrolide antibiotic;
organic heterotetracyclic compound;
secondary alcohol;
spiroketal;
tertiary alcohol | antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nigranoic acid | | dicarboxylic acid;
tetracyclic triterpenoid | antineoplastic agent;
HIV-1 reverse transcriptase inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| esculeoside a | | azaspiro compound;
oxaspiro compound;
saponin;
steroid alkaloid;
steroid saponin | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azadirone | | acetate ester;
cyclic terpene ketone;
furans;
limonoid;
tetracyclic triterpenoid | antineoplastic agent;
antiplasmodial drug;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| iejimalide b | | ether;
formamides;
macrolide | antineoplastic agent;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| migrastatin | | ether;
macrolide antibiotic;
piperidones;
secondary alcohol | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cembra-2,7,11-triene-4,6-diol | | cembrane diterpenoid | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,3,6,8-tetrahydroxy-1-(3-methylbut-2-enyl)-5-(2-methylbut-3-en-2-yl)-9h-xanthen-9-one | | polyphenol;
xanthones | anti-inflammatory agent;
antineoplastic agent;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| at 7867 | | monochlorobenzenes;
piperidines;
pyrazoles | antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ym 155 | | organic bromide salt | antineoplastic agent;
apoptosis inducer;
survivin suppressant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bielschowskysin | | acetate ester;
cyclic acetal;
diterpenoid;
gamma-lactone;
organic heterohexacyclic compound | antimalarial;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| erastin | | aromatic ether;
diether;
monochlorobenzenes;
N-acylpiperazine;
N-alkylpiperazine;
quinazolines;
tertiary carboxamide | antineoplastic agent;
ferroptosis inducer;
voltage-dependent anion channel inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| abt-737 | | aromatic amine;
aryl sulfide;
biphenyls;
C-nitro compound;
monochlorobenzenes;
N-arylpiperazine;
N-sulfonylcarboxamide;
secondary amino compound;
tertiary amino compound | anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| brivanib | | aromatic ether;
diether;
fluoroindole;
pyrrolotriazine;
secondary alcohol | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rx-3117 | | organofluorine compound;
primary allylic alcohol;
triol | antimetabolite;
antineoplastic agent;
apoptosis inducer;
DNA synthesis inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ascochlorin | | cyclohexanones;
dihydroxybenzaldehyde;
meroterpenoid;
monochlorobenzenes;
olefinic compound;
resorcinols;
sesquiterpenoid | angiogenesis inhibitor;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| spiculoic acid a | | carbobicyclic compound;
cyclic ketone;
oxo monocarboxylic acid;
styrenes | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N(2)-([biphenyl]-4-ylsulfonyl)-N-hydroxy-N(2)-isopropoxy-D-valinamide | | D-valine derivative;
hydroxamic acid | antineoplastic agent;
autophagy inducer;
EC 3.4.24.24 (gelatinase A) inhibitor;
melanin synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| at 7519 | | dichlorobenzene;
piperidines;
pyrazoles;
secondary carboxamide | antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ym 216391 | | 1,3-oxazoles;
1,3-thiazoles;
azamacrocycle;
benzenes;
heterodetic cyclic peptide | antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| marizomib | | beta-lactone;
gamma-lactam;
organic heterobicyclic compound;
organochlorine compound;
salinosporamide | antineoplastic agent;
proteasome inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| er-086526 | | cyclic ketal;
cyclic ketone;
macrocycle;
polycyclic ether;
polyether;
primary amino compound | antineoplastic agent;
microtubule-destabilising agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| obolactone | | 2-pyranones;
4-pyranones | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| episilvestrol | | dioxanes;
ether;
methyl ester;
organic heterotricyclic compound | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| abt 869 | | aromatic amine;
indazoles;
phenylureas | angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azd 1152 | | anilide;
monoalkyl phosphate;
monofluorobenzenes;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
Aurora kinase inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pf 00299804 | | enamide;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ki11502 | | aromatic ether;
benzamides;
quinolines;
thioureas | antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carfilzomib | | epoxide;
morpholines;
tetrapeptide | antineoplastic agent;
proteasome inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine | | aminopyridine;
aromatic ether;
dichlorobenzene;
organofluorine compound;
pyrazolylpiperidine;
racemate | antineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| idelalisib | | aromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound | antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| crizotinib | | 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine | antineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zstk474 | | benzimidazoles;
morpholines;
organofluorine compound;
triamino-1,3,5-triazine | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trametinib | | acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly | anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lyoniresinol | | dimethoxybenzene;
lignan;
polyphenol;
primary alcohol;
tetralins | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| GDC-0879 | | indanes;
ketoxime;
primary alcohol;
pyrazoles;
pyridines | antineoplastic agent;
B-Raf inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| physalin b | | enone;
lactone;
organic heteroheptacyclic compound;
physalin | antimalarial;
antimicrobial agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amrubicinol | | diastereoisomeric mixture;
quinone;
secondary alcohol;
tetracenes | antineoplastic agent;
apoptosis inducer;
topoisomerase II inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| silvestrol | | dioxanes;
ether;
methyl ester;
organic heterotricyclic compound | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| at 13387 | | benzamides;
isoindoles;
N-alkylpiperazine;
resorcinols;
tertiary carboxamide | antineoplastic agent;
Hsp90 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cytotrienin a | | cyclopropanecarboxylate ester;
ether;
hydroquinones;
lactam;
macrocycle;
secondary alcohol | antibacterial agent;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dactolisib | | imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bgt226 | | aromatic ether;
imidazoquinoline;
N-arylpiperazine;
organofluorine compound;
pyridines | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2'-methoxykurarinone | | 4'-hydroxyflavanones;
dihydroxyflavanone;
dimethoxyflavanone | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gedunin | | acetate ester;
enone;
epoxide;
furans;
lactone;
limonoid;
organic heteropentacyclic compound;
pentacyclic triterpenoid | antimalarial;
antineoplastic agent;
Hsp90 inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| monascin | | alpha,beta-unsaturated ketone;
gamma-lactone;
organic heterotricyclic compound;
polyketide | antilipemic drug;
antineoplastic agent;
fungal metabolite;
PPARgamma agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| monascorubrin | | azaphilone;
enone;
gamma-lactone;
polyketide;
triketone | anti-inflammatory agent;
antineoplastic agent;
biological pigment;
food colouring;
fungal metabolite;
Hsp90 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5,7-dihydroxy-2-methyl-8-(4-(3-hydroxy-1-methyl)-piperidinyl)-4h-1-benzopyran-4-one | | alkaloid;
chromones;
hydroxypiperidine;
resorcinols;
tertiary amino compound | anti-inflammatory agent;
anti-ulcer drug;
anticholesteremic drug;
antileishmanial agent;
antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
fungal metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| SYC-435 | | benzenes;
cyclic hydroxamic acid;
pyridone | antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ligstroside | | beta-D-glucoside;
diester;
methyl ester;
phenols;
pyrans;
secoiridoid glycoside | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mogrol | | hydroxy seco-steroid;
tetracyclic triterpenoid | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| simalikalactone D | | cyclic ether;
delta-lactone;
enone;
organic heteropentacyclic compound;
quassinoid;
secondary alcohol;
secondary alpha-hydroxy ketone;
triol | antimalarial;
antineoplastic agent;
antiviral agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-methyl-5-pentylbenzene-1,3-diol | | resorcinols | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mdv 3100 | | (trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound | androgen antagonist;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azd 1152-hqpa | | anilide;
monofluorobenzenes;
primary alcohol;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
Aurora kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| adonixanthin | | carotenone;
cyclic ketone;
secondary alcohol | algal metabolite;
animal metabolite;
antineoplastic agent;
bacterial metabolite;
marine metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| schweinfurthin g | | cyclic ether;
organic heterotricyclic compound;
resorcinols;
stilbenoid | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| abarelix | | polypeptide | antineoplastic agent;
hormone antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| forapin | | peptidyl amide;
polypeptide | animal metabolite;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.13 (protein kinase C) inhibitor;
hepatoprotective agent;
neuroprotective agent;
venom | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gastrin 17 | | gastrin | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gdc-0973 | | aromatic amine;
difluorobenzene;
N-acylazetidine;
organoiodine compound;
piperidines;
secondary amino compound;
tertiary alcohol | antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| buparlisib | | aminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tubocapsanolide a | | 4-hydroxy steroid;
delta-lactone;
enone;
epoxy steroid;
ergostanoid;
secondary alcohol;
withanolide | antineoplastic agent;
NF-kappaB inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ro5126766 | | aryloxypyrimidine;
coumarins;
organofluorine compound;
pyridines;
sulfamides | antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pevonedistat | | cyclopentanols;
indanes;
pyrrolopyrimidine;
secondary amino compound;
sulfamidate | antineoplastic agent;
apoptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tg101209 | | N-alkylpiperazine;
N-arylpiperazine;
pyrimidines;
secondary amino compound;
sulfonamide | antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk690693 | | 1,2,5-oxadiazole;
acetylenic compound;
aromatic amine;
aromatic ether;
imidazopyridine;
piperidines;
primary amino compound;
tertiary alcohol | antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cnf 2024 | | 2-aminopurines;
aromatic ether;
organochlorine compound;
pyridines | antineoplastic agent;
Hsp90 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ku 0063794 | | benzyl alcohols;
monomethoxybenzene;
morpholines;
pyridopyrimidine;
tertiary amino compound | antineoplastic agent;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| respirantin | | benzamides;
cyclodepsipeptide;
formamides;
phenols | antimicrobial agent;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sm 164 | | benzenes;
organic heterobicyclic compound;
secondary carboxamide;
triazoles | antineoplastic agent;
apoptosis inducer;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| berkeleydione | | beta-diketone;
cyclic terpene ketone;
meroterpenoid;
methyl ester;
organic heterotetracyclic compound;
terpene lactone;
tertiary alcohol;
tertiary alpha-hydroxy ketone | antineoplastic agent;
cysteine protease inhibitor;
Penicillium metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lucidenic acid n | | cyclic terpene ketone;
dioxo monocarboxylic acid;
secondary alcohol;
tetracyclic triterpenoid | antineoplastic agent;
EC 3.1.1.8 (cholinesterase) inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromophycolide a | | diterpenoid;
macrolide;
organobromine compound;
phenols;
tertiary alcohol | anti-HIV agent;
antibacterial agent;
antifungal agent;
antimalarial;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nnc 55-0396 | | hydrochloride | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
neuroprotective agent;
potassium channel blocker;
T-type calcium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| meclofenamate sodium anhydrous | | hydrate | analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| brequinar sodium | | organic sodium salt | anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral agent;
EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor;
immunosuppressive agent;
pyrimidine synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| borrelidin | | aliphatic nitrile;
diol;
macrolide;
monocarboxylic acid;
secondary alcohol | antifungal agent;
antimalarial;
antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| olaparib | | cyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines | antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| plx 4720 | | aromatic ketone;
difluorobenzene;
organochlorine compound;
pyrrolopyridine;
sulfonamide | antineoplastic agent;
B-Raf inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lcl161 | | 1,3-thiazoles;
aromatic ketone;
L-alanine derivative;
monofluorobenzenes;
N-acylpyrrolidine | antineoplastic agent;
apoptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aspergillide b | | bridged compound;
cyclic ether;
macrolide;
secondary alcohol | antineoplastic agent;
Aspergillus metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tenovin-6 | | monocarboxylic acid amide;
tertiary amino compound;
thioureas | antineoplastic agent;
p53 activator;
Sir2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lde225 | | aminopyridine;
aromatic ether;
benzamides;
biphenyls;
morpholines;
organofluorine compound;
tertiary amino compound | antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gdc 0449 | | benzamides;
monochlorobenzenes;
pyridines;
sulfone | antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist;
teratogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bms 754807 | | pyrazoles;
pyridines;
pyrrolidines;
pyrrolotriazine | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| marinopyrrole a | | aromatic ketone;
organochlorine compound;
phenols;
pyrroles | antibacterial agent;
antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| delanzomib | | C-terminal boronic acid peptide;
phenylpyridine;
secondary alcohol;
threonine derivative | antineoplastic agent;
apoptosis inducer;
proteasome inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| grassypeptolide | | cyclodepsipeptide;
macrocycle | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pci 32765 | | acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide | antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| spiruchostatin b | | macrocyclic lactone;
organic disulfide;
organic heterobicyclic compound;
spiruchostatin | antineoplastic agent;
bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| AMG-208 | | aromatic ether;
quinolines;
triazolopyridazine | antineoplastic agent;
c-Met tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sch772984 | | biaryl;
indazoles;
N-acylpiperazine;
N-alkylpyrrolidine;
N-arylpiperazine;
pyridines;
pyrimidines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary amino compound;
tertiary carboxamide | analgesic;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| papuamide b | | cyclodepsipeptide;
olefinic compound;
secondary alcohol;
tertiary alcohol | anti-HIV-1 agent;
antineoplastic agent;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| antroquinonol d | | enol ether;
enone;
secondary alcohol | antineoplastic agent;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| quizartinib | | benzoimidazothiazole;
isoxazoles;
morpholines;
phenylureas | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
necroptosis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-methoxyspirotryprostatin b | | aromatic ether;
azaspiro compound;
indole alkaloid;
indolones | antineoplastic agent;
Aspergillus metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| niraparib | | benzenes;
indazoles;
piperidines;
primary carboxamide | antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| niraparib | | 2-[4-(piperidin-3-yl)phenyl]-2H-indazole-7-carboxamide | antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| navitoclax | | aryl sulfide;
monochlorobenzenes;
morpholines;
N-sulfonylcarboxamide;
organofluorine compound;
piperazines;
secondary amino compound;
sulfone;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lucitanib | | aromatic ether;
cyclopropanes;
naphthalenecarboxamide;
primary amino compound;
quinolines | antineoplastic agent;
fibroblast growth factor receptor antagonist;
vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chondramide c | | chondramide;
indoles;
phenols | antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide | | aminopyrimidine;
benzamides;
morpholines;
nitrile;
secondary amino compound;
tertiary amino compound | anti-anaemic agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cetrorelix | | oligopeptide | antineoplastic agent;
GnRH antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| histrelin | | oligopeptide | antineoplastic agent;
gonadotropin releasing hormone agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| salvileucalin b | | bridged compound;
diterpenoid;
furans;
gamma-lactone | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| incb-018424 | | nitrile;
pyrazoles;
pyrrolopyrimidine | antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| poziotinib | | acrylamides;
aromatic ether;
dichlorobenzene;
diether;
monofluorobenzenes;
N-acylpiperidine;
quinazolines;
secondary amino compound;
substituted aniline | antineoplastic agent;
apoptosis inducer;
epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| asp3026 | | aromatic amine;
diamino-1,3,5-triazine;
monomethoxybenzene;
N-methylpiperazine;
piperidines;
secondary amino compound;
sulfone | antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 6.1.1.6 (lysine--tRNA ligase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| entrectinib | | benzamides;
difluorobenzene;
indazoles;
N-methylpiperazine;
oxanes;
secondary amino compound;
secondary carboxamide | antibacterial agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pexidartinib | | aminopyridine;
organochlorine compound;
organofluorine compound;
pyrrolopyridine;
secondary amino compound | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| TAK-580 | | 1,3-thiazolecarboxamide;
aminopyrimidine;
chloropyridine;
organofluorine compound;
pyrimidinecarboxamide;
secondary carboxamide | antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glasdegib | | benzimidazoles;
nitrile;
phenylureas;
piperidines | antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk 2126458 | | aromatic ether;
difluorobenzene;
pyridazines;
pyridines;
quinolines;
sulfonamide | anticoronaviral agent;
antineoplastic agent;
autophagy inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ixazomib | | benzamides;
boronic acids;
dichlorobenzene;
glycine derivative | antineoplastic agent;
apoptosis inducer;
drug metabolite;
orphan drug;
proteasome inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cx 5461 | | diazepine;
naphthyridine derivative;
organic heterotetracyclic compound;
pyrazines;
secondary carboxamide | antineoplastic agent;
apoptosis inducer;
EC 2.7.7.6 (RNA polymerase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol | | benzyl alcohols;
morpholines;
pyridopyrimidine;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| plx4032 | | aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide | antineoplastic agent;
B-Raf inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| GDC-0623 | | hydroxamic acid ester;
imidazopyridine;
monofluorobenzenes;
organoiodine compound;
primary alcohol;
secondary amino compound;
substituted aniline | antineoplastic agent;
apoptosis inducer;
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| INDY | | benzothiazoles;
enone;
organic hydroxy compound | antineoplastic agent;
drug metabolite;
EC 2.7.12.1 (dual-specificity kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 7,8-dihydroxyflavanone | | dihydroxyflavanone | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dabrafenib | | 1,3-thiazoles;
aminopyrimidine;
organofluorine compound;
sulfonamide | anticoronaviral agent;
antineoplastic agent;
B-Raf inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cblc137 | | aromatic ketone;
carbazoles;
methyl ketone;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
NF-kappaB inhibitor;
p53 activator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2,3-dihydro-3beta-O-sulfate withaferin A | | 27-hydroxy steroid;
4-hydroxy steroid;
delta-lactone;
epoxy steroid;
ergostanoid;
primary alcohol;
steroid sulfate;
withanolide | antineoplastic agent;
metabolite;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| leachianone a | | 4'-hydroxyflavanones;
monomethoxyflavanone;
trihydroxyflavanone | antimalarial;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| EG00229 | | benzothiadiazole;
dicarboxylic acid monoamide;
L-arginine derivative;
secondary carboxamide;
sulfonamide;
thiophenes | angiogenesis inhibitor;
antineoplastic agent;
neuropilin receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| jadomycin b | | glycoside;
jadomycin;
organic heteropentacyclic compound | antibacterial agent;
antineoplastic agent;
apoptosis inducer;
Aurora kinase inhibitor;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tak-632 | | (trifluoromethyl)benzenes;
aromatic ether;
benzothiazoles;
cyclopropylcarboxamide;
monofluorobenzenes;
nitrile;
secondary carboxamide | antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
necroptosis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chondramide a | | chondramide;
indoles;
phenols | antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| englerin a | | cinnamate ester;
glycolate ester;
guaiane sesquiterpenoid | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lrrk2-in1 | | aromatic amine;
aromatic ether;
N-acylpiperidine;
N-alkylpiperazine;
pyrimidobenzodiazepine;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| jq1 compound | | carboxylic ester;
organochlorine compound;
tert-butyl ester;
thienotriazolodiazepine | angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bromodomain-containing protein 4 inhibitor;
cardioprotective agent;
ferroptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ML-210 | | C-nitro compound;
diarylmethane;
isoxazoles;
monochlorobenzenes;
N-acylpiperazine;
N-alkylpiperazine;
tertiary carboxamide | antineoplastic agent;
EC 1.11.1.9 (glutathione peroxidase) inhibitor;
ferroptosis inducer;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| eurycomanone | | cyclic ether;
delta-lactone;
enone;
organic heteropentacyclic compound;
pentol;
quassinoid;
secondary alcohol;
secondary alpha-hydroxy ketone;
tertiary alcohol | antimalarial;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gilteritinib | | aromatic amine;
monomethoxybenzene;
N-methylpiperazine;
oxanes;
piperidines;
primary carboxamide;
pyrazines;
secondary amino compound | antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alectinib | | aromatic ketone;
morpholines;
nitrile;
organic heterotetracyclic compound;
piperidines | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ML240 | | aromatic amine;
aromatic ether;
benzimidazoles;
primary amino compound;
quinazolines;
secondary amino compound | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| torin 1 | | N-acylpiperazine;
N-arylpiperazine;
organofluorine compound;
pyridoquinoline;
quinolines | antineoplastic agent;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| abt-199 | | aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine | antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pracinostat | | benzimidazole;
hydroxamic acid;
olefinic compound;
tertiary amino compound | antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| physalin f | | enone;
epoxy steroid;
lactone;
physalin | antileishmanial agent;
antimalarial;
antineoplastic agent;
apoptosis inducer;
immunosuppressive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| xl765 | | aromatic amine;
aromatic ether;
benzamides;
quinoxaline derivative;
sulfonamide | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| DMH1 | | aromatic ether;
pyrazolopyrimidine;
quinolines | antineoplastic agent;
bone morphogenetic protein receptor antagonist;
protein kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| torin 2 | | aminopyridine;
organofluorine compound;
primary amino compound;
pyridoquinoline | antineoplastic agent;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oligomycin a | | antibiotic antifungal agent;
diketone;
oligomycin;
pentol | antineoplastic agent;
EC 3.6.3.14 (H(+)-transporting two-sector ATPase) inhibitor;
nematicide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea | | aminopyrimidine;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
phenylureas | antineoplastic agent;
fibroblast growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3alpha,12alpha-dihydroxy-4alpha-methylergosta-8,24(28)-dien-7,11-dione-26-oic acid | | 11-oxo steroid;
12alpha-hydroxy steroid;
3alpha-hydroxy steroid;
7-oxo steroid;
monocarboxylic acid;
secondary alpha-hydroxy ketone;
steroid acid | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3alpha-hydroxy-4alpha-methylergosta-8,24(28)-dien-7,11-dione-26-oic acid | | 11-oxo steroid;
3alpha-hydroxy steroid;
7-oxo steroid;
monocarboxylic acid;
steroid acid | antineoplastic agent;
cholinergic antagonist;
metabolite;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chir 98014 | | aminopyrimidine;
C-nitro compound;
diaminopyridine;
dichlorobenzene;
imidazoles;
secondary amino compound | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
hypoglycemic agent;
tau aggregation inhibitor;
Wnt signalling activator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk2656157 | | biaryl;
indoles;
methylpyridines;
organofluorine compound;
pyrrolopyrimidine;
tertiary carboxamide | antineoplastic agent;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
PERK inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-(2-(5-methoxy-2-oxo-2,3-dihydro-1h-indol-3-yl)ethyl)acetamide | | acetamides;
hydroxyindoles;
tryptamines | antineoplastic agent;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| coumermycin | | aromatic amide;
coumarins;
glycoside;
heteroarenecarboxylate ester;
pyrroles | antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
DNA synthesis inhibitor;
Hsp90 inhibitor;
topoisomerase IV inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lfm a13 | | aromatic amide;
dibromobenzene;
enamide;
enol;
nitrile;
secondary carboxamide | antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 2.7.11.21 (polo kinase) inhibitor;
geroprotector;
platelet aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| AZD3463 | | aminopiperidine;
aminopyrimidine;
indoles;
monomethoxybenzene;
organochlorine compound;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| calicheamicin gamma(1)i | | calicheamicin;
enediyne antibiotic;
organoiodine compound | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| asperfuranone | | 2-benzofurans;
cyclic ketone;
diol;
polyketide;
secondary alcohol;
tertiary alcohol;
tertiary alpha-hydroxy ketone | antineoplastic agent;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ceritinib | | aminopyrimidine;
aromatic ether;
organochlorine compound;
piperidines;
secondary amino compound;
sulfone | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pelabresib | | monochlorobenzenes;
organic heterotricyclic compound;
primary carboxamide | antineoplastic agent;
bromodomain-containing protein 4 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| MK-8353 | | aromatic ether;
dihydropyridine;
indazoles;
methyl sulfide;
N-alkylpyrrolidine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
triazoles | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk2879552 | | benzenes;
benzoic acids;
cyclopropanes;
monocarboxylic acid;
piperidines;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
EC 1.14.99.66 (lysine-specific histone demethylase 1A) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ssr128129e | | organic sodium salt | antineoplastic agent;
fibroblast growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aspergillide a | | bridged compound;
cyclic ether;
macrolide;
secondary alcohol | antineoplastic agent;
Aspergillus metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| capilliposide b | | alpha-L-arabinopyranoside;
bridged compound;
cyclic ether;
diol;
hexacyclic triterpenoid;
hexanoate ester;
lactol;
secondary alcohol;
tetrasaccharide derivative;
triterpenoid saponin | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| brasilicardin a | | benzoate ester;
carbotricyclic compound;
diterpenoid;
N-acetyl-D-glucosaminide;
non-proteinogenic alpha-amino acid;
phenols | antimicrobial agent;
antineoplastic agent;
bacterial metabolite;
immunosuppressive agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| surfactin A | | cyclodepsipeptide;
lipopeptide antibiotic;
macrocyclic lactone | antibacterial agent;
antifungal agent;
antineoplastic agent;
antiviral agent;
metabolite;
surfactant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| acp-196 | | aromatic amine;
benzamides;
imidazopyrazine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
ynone | antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk343 | | aminopyridine;
indazoles;
N-alkylpiperazine;
N-arylpiperazine;
pyridone;
secondary carboxamide | antineoplastic agent;
apoptosis inducer;
EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| myriaporone 3 | | beta-hydroxy ketone;
epoxide;
lactol;
oxanes;
primary alcohol;
secondary alcohol | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| GSK1059615 | | pyridines;
quinolines;
thiazolidinone | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| osimertinib | | acrylamides;
aminopyrimidine;
biaryl;
indoles;
monomethoxybenzene;
secondary amino compound;
secondary carboxamide;
substituted aniline;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ivosidenib | | cyanopyridine;
monochlorobenzenes;
organofluorine compound;
pyrrolidin-2-ones;
secondary carboxamide;
tertiary carboxamide | antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| phleomycin d1 | | bi-1,3-thiazole;
chelate-forming peptide;
disaccharide derivative;
glycopeptide;
guanidines | antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ly3009120 | | aminotoluene;
aromatic amine;
biaryl;
monofluorobenzenes;
phenylureas;
pyridopyrimidine;
secondary amino compound | antineoplastic agent;
apoptosis inducer;
autophagy inducer;
B-Raf inhibitor;
necroptosis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pf-06463922 | | aminopyridine;
aromatic ether;
azamacrocycle;
benzamides;
cyclic ether;
monofluorobenzenes;
nitrile;
organic heterotetracyclic compound;
pyrazoles | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| as 1842856 | | organofluorine compound;
primary amino compound;
quinolinemonocarboxylic acid;
quinolone;
secondary amino compound;
tertiary amino compound | anti-obesity agent;
antineoplastic agent;
apoptosis inducer;
autophagy inhibitor;
forkhead box protein O1 inhibitor;
hypoglycemic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| physalin d | | 5alpha-hydroxy steroid;
6beta-hydroxy steroid;
cyclic ether;
enone;
lactone;
organic heteroheptacyclic compound;
physalin | antimalarial;
antimycobacterial drug;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| acarbose | | chondramide;
indoles;
organochlorine compound;
phenols | antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sr9243 | | bromobenzenes;
sulfonamide;
sulfone | antineoplastic agent;
apoptosis inducer;
liver X receptor inverse agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| CCT251545 | | azaspiro compound;
chloropyridine;
pyrazoles | antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
Wnt signalling inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ldc4297 | | aromatic ether;
piperidines;
pyrazoles;
pyrazolotriazine;
secondary amino compound | antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hg-9-91-01 | | aminopyrimidine;
dimethoxybenzene;
N-alkylpiperazine;
N-arylpiperazine;
phenylureas;
secondary amino compound | antineoplastic agent;
salt-inducible kinase 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cigb-300 | | heterodetic cyclic peptide;
polypeptide | angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| chondramide d | | chondramide;
indoles;
phenols | antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bassianolide | | cyclodepsipeptide;
cyclooctadepsipeptide | antineoplastic agent;
fungal metabolite;
insecticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| enasidenib | | 1,3,5-triazines;
aminopyridine;
aromatic amine;
organofluorine compound;
secondary amino compound;
tertiary alcohol | antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| BDA-366 | | anthraquinone;
epoxide;
secondary alcohol;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
apoptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ebc-46 | | diester;
diterpenoid;
organic heteropentacyclic compound;
phorbol ester | antineoplastic agent;
plant metabolite;
protein kinase C agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| THZ531 | | aminopyrimidine;
enamide;
indoles;
N-acylpiperidine;
organochlorine compound;
secondary amino compound;
secondary carboxamide | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| can 508 | | aromatic amine;
monoazo compound;
phenols;
pyrazoles | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| levoleucovorin | | 5-formyltetrahydrofolic acid | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rifampin | | cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion | angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azaguanine | | nucleobase analogue;
triazolopyrimidines | antimetabolite;
antineoplastic agent;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pemetrexed | | N-acyl-L-glutamic acid;
pyrrolopyrimidine | antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tirapazamine | | aromatic amine;
benzotriazines;
N-oxide | antibacterial agent;
antineoplastic agent;
apoptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pyrazofurin | | C-glycosyl compound;
pyrazoles | antimetabolite;
antimicrobial agent;
antineoplastic agent;
EC 4.1.1.23 (orotidine-5'-phosphate decarboxylase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| MMP-9-IN-1 | | aromatic compound;
organic sulfide;
organofluorine compound;
pyrimidone;
secondary carboxamide | antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hydrazinocurcumin | | aromatic ether;
olefinic compound;
polyphenol;
pyrazoles | angiogenesis modulating agent;
antineoplastic agent;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 9-arabinofuranosylguanine | | beta-D-arabinoside;
purine nucleoside | antineoplastic agent;
DNA synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cerulomycin | | aldoxime;
aromatic ether;
bipyridines;
pyridine alkaloid | antineoplastic agent;
bacterial metabolite;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| undecylprodigiosin | | alkaloid;
aromatic ether;
tripyrrole | antibacterial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
biological pigment;
immunosuppressive agent;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ver 52296 | | aromatic amide;
isoxazoles;
monocarboxylic acid amide;
morpholines;
resorcinols | angiogenesis inhibitor;
antineoplastic agent;
Hsp90 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1h-indole-5-carbonitrile | | hydroxyindoles;
morpholines;
nitrile;
pyridines;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
tau aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| XL413 | | benzofuropyrimidine;
organochlorine compound;
pyrrolidines | antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pp242 | | aromatic amine;
biaryl;
hydroxyindoles;
phenols;
primary amino compound;
pyrazolopyrimidine | antineoplastic agent;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| marineosin a | | azaspiro compound;
ether;
macrocycle;
oxaspiro compound;
pyrroles | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| marineosin b | | azaspiro compound;
ether;
macrocycle;
oxaspiro compound;
pyrroles | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ARS-1620 | | quinazolines | antineoplastic agent;
antiviral agent;
inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sotorasib | | acrylamides;
methylpyridines;
monofluorobenzenes;
N-acylpiperazine;
phenols;
pyridopyrimidine;
tertiary amino compound;
tertiary carboxamide | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| canertinib | | monochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lapatinib | | furans;
organochlorine compound;
organofluorine compound;
quinazolines | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sorafenib | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide | angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bosutinib | | aminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bibw 2992 | | aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| regorafenib | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide | antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dcc-2036 | | organofluorine compound;
phenylureas;
pyrazoles;
pyridinecarboxamide;
quinolines | tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cabozantinib | | aromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines | antineoplastic agent;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ro 48-8071 | | aromatic ether;
aromatic ketone;
bromobenzenes;
monofluorobenzenes;
olefinic compound;
tertiary amino compound | antineoplastic agent;
EC 5.4.99.7 (lanosterol synthase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rtki cpd | | aromatic ether;
monochlorobenzenes;
quinazolines | antineoplastic agent;
antiviral agent;
epidermal growth factor receptor antagonist;
geroprotector | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alfuzosin | | monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol | alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amsacrine | | acridines;
aromatic ether;
sulfonamide | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cgs 15943 | | aromatic amine;
biaryl;
furans;
organochlorine compound;
primary amino compound;
quinazolines;
triazoloquinazoline | adenosine A1 receptor antagonist;
adenosine A2A receptor antagonist;
antineoplastic agent;
central nervous system stimulant | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ciglitazone | | aromatic ether;
thiazolidinone | antineoplastic agent;
insulin-sensitizing drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cl 387785 | | bromobenzenes;
quinazolines;
secondary carboxamide;
ynamide | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clofibric acid | | aromatic ether;
monocarboxylic acid;
monochlorobenzenes | anticholesteremic drug;
antilipemic drug;
antineoplastic agent;
herbicide;
marine xenobiotic metabolite;
PPARalpha agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| doxazosin | | aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines | alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluorouracil | | nucleobase analogue;
organofluorine compound | antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methoxsalen | | aromatic ether;
psoralens | antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nortriptyline | | organic tricyclic compound;
secondary amine | adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide | | aromatic ether;
C-nitro compound;
sulfonamide | antineoplastic agent;
cyclooxygenase 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pipobroman | | N-acylpiperazine;
organobromine compound;
tertiary carboxamide | alkylating agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| terazosin | | furans;
piperazines;
primary amino compound;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tilorone | | aromatic ether;
diether;
fluoren-9-ones;
tertiary amino compound | anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
interferon inducer;
nicotinic acetylcholine receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| floxuridine | | nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trifluridine | | nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-fluoroadenine | | organofluorine compound;
purines | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| doxifluridine | | organofluorine compound;
pyrimidine 5'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fludarabine phosphate | | nucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate | antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| silybin | | aromatic ether;
benzodioxine;
flavonolignan;
polyphenol;
secondary alpha-hydroxy ketone | antineoplastic agent;
antioxidant;
hepatoprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gemcitabine hydrochloride | | hydrochloride;
organofluorine compound | anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral drug;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
immunosuppressive agent;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gemcitabine | | organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| capecitabine | | carbamate ester;
cytidines;
organofluorine compound | antimetabolite;
antineoplastic agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromopyruvate | | 2-oxo monocarboxylic acid;
organobromine compound;
oxo carboxylic acid | alkylating agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| enrofloxacin | | cyclopropanes;
N-alkylpiperazine;
N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone | antibacterial agent;
antimicrobial agent;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| uvaretin | | aromatic ether;
dihydrochalcones;
polyketide;
resorcinol | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fangchinoline | | aromatic ether;
bisbenzylisoquinoline alkaloid;
macrocycle | anti-HIV-1 agent;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
neuroprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cryptopleurine | | alkaloid antibiotic;
alkaloid;
aromatic ether;
organic heteropentacyclic compound | antineoplastic agent;
antiviral agent;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fulvestrant | | 17beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide | antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| deguelin | | aromatic ether;
diether;
organic heteropentacyclic compound;
rotenones | angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
mitochondrial NADH:ubiquinone reductase inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tephrosin | | aromatic ether;
cyclic ketone;
organic heteropentacyclic compound;
rotenones | antineoplastic agent;
metabolite;
pesticide | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-(tetradecyloxy)-2-furancarboxylic acid | | aromatic ether;
furoic acid | antineoplastic agent;
apoptosis inducer;
EC 6.4.1.2 (acetyl-CoA carboxylase) inhibitor;
PPARalpha agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sc 58125 | | organofluorine compound;
pyrazoles;
sulfone | antineoplastic agent;
cyclooxygenase 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clofarabine | | adenosines;
organofluorine compound | antimetabolite;
antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gefitinib | | aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ay 25545 | | acetate ester;
aromatic ether;
C-glycosyl compound;
naphthoisochromene;
olefinic compound;
phenols;
tertiary amine | antimicrobial agent;
antineoplastic agent;
bacterial metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-bromo-3-(bromomethyl)-7-methyl-2,3,7-trichloro-1-octene | | monoterpenoid;
organobromine compound;
organochlorine compound | algal metabolite;
antineoplastic agent;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| actinodaphine | | aporphine alkaloid;
aromatic ether;
organic heteropentacyclic compound;
phenols;
secondary amino compound | antibacterial agent;
antifungal agent;
antineoplastic agent;
apoptosis inducer;
plant metabolite;
platelet aggregation inhibitor;
topoisomerase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| myricanone | | aromatic ether;
cyclic ketone;
diarylheptanoid;
methoxybenzenes;
phenols | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pannarin | | aldehyde;
aromatic ether;
depsidones;
organic heterotricyclic compound;
organochlorine compound;
phenols | antimicrobial agent;
antineoplastic agent;
apoptosis inducer;
lichen metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| erlotinib | | aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound | antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lasofoxifene | | aromatic ether;
N-alkylpyrrolidine;
naphthols;
tetralins | antineoplastic agent;
bone density conservation agent;
cardioprotective agent;
estrogen receptor agonist;
estrogen receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diflomotecan | | epsilon-lactone;
organic heteropentacyclic compound;
organofluorine compound;
organonitrogen heterocyclic compound;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| noscapine | | aromatic ether;
benzylisoquinoline alkaloid;
cyclic acetal;
isobenzofuranone;
organic heterobicyclic compound;
organic heterotricyclic compound;
tertiary amino compound | antineoplastic agent;
antitussive;
apoptosis inducer;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 8-(2-chloro-3,4,5-trimethoxybenzyl)-2-fluoro-9-pent-4-yn-1-yl-9H-purin-6-amine | | 6-aminopurines;
acetylenic compound;
methoxybenzenes;
monochlorobenzenes;
organofluorine compound | antineoplastic agent;
Hsp90 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| teniposide | | aromatic ether;
beta-D-glucoside;
cyclic acetal;
furonaphthodioxole;
gamma-lactone;
monosaccharide derivative;
phenols;
thiophenes | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prinomastat | | aromatic ether;
hydroxamic acid;
pyridines;
sulfonamide;
thiomorpholines | antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor;
matrix metalloproteinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| antofine | | alkaloid antibiotic;
alkaloid;
aromatic ether;
organic heteropentacyclic compound | angiogenesis inhibitor;
anti-inflammatory agent;
antimicrobial agent;
antineoplastic agent;
antiviral agent;
phytotoxin;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| xanthohumol | | aromatic ether;
chalcones;
polyphenol | anti-HIV-1 agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.3.1.20 (diacylglycerol O-acyltransferase) inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| curcumin | | aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol | anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulindac | | monocarboxylic acid;
organofluorine compound;
sulfoxide | analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| toremifene | | aromatic ether;
organochlorine compound;
tertiary amine | antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ospemifene | | aromatic ether;
organochlorine compound;
primary alcohol | anti-inflammatory agent;
antineoplastic agent;
estrogen receptor modulator | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tandutinib | | aromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
piperidines;
quinazolines;
tertiary amino compound | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sc 560 | | aromatic ether;
monochlorobenzenes;
organofluorine compound;
pyrazoles | angiogenesis modulating agent;
antineoplastic agent;
apoptosis inducer;
cyclooxygenase 1 inhibitor;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| daphnoretin | | aromatic ether;
hydroxycoumarin | antineoplastic agent;
antiviral agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hinokiflavone | | aromatic ether;
biflavonoid;
hydroxyflavone | antineoplastic agent;
metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mangostin | | aromatic ether;
phenols;
xanthones | antimicrobial agent;
antineoplastic agent;
antioxidant;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| wedelolactone | | aromatic ether;
coumestans;
delta-lactone;
polyphenol | antineoplastic agent;
apoptosis inducer;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
hepatoprotective agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| isoginkgetin | | aromatic ether;
biflavonoid | antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| neoglycyrol | | aromatic ether;
coumestans;
delta-lactone;
polyphenol | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rhamnazin | | aromatic ether;
dimethoxyflavone;
phenols;
trihydroxyflavone | antineoplastic agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| palbociclib | | aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulindac sulfide | | aryl sulfide;
monocarboxylic acid;
organofluorine compound | antineoplastic agent;
apoptosis inducer;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ru 58668 | | 17beta-hydroxy steroid;
3-hydroxy steroid;
aromatic ether;
organofluorine compound;
sulfone | anti-estrogen;
antineoplastic agent;
estrogen receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lenvatinib | | aromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nsc 716970 | | aromatic amine;
aromatic ether;
indolecarboxamide;
organochlorine compound | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fr 148083 | | aromatic ether;
macrolide;
phenols;
secondary alcohol;
secondary alpha-hydroxy ketone | antibacterial agent;
antineoplastic agent;
metabolite;
NF-kappaB inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tln 4601 | | dibenzodiazepine;
farnesane sesquiterpenoid;
olefinic compound;
secondary amine;
triol | antineoplastic agent;
antioxidant;
cathepsin L (EC 3.4.22.15) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 9-methoxycanthin-6-one | | aromatic ether;
indole alkaloid;
organic heterotetracyclic compound | antineoplastic agent;
antiplasmodial drug;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zm 447439 | | aromatic ether;
benzamides;
morpholines;
polyether;
quinazolines;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
Aurora kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hypothemycin | | aromatic ether;
diol;
enone;
epoxide;
macrolide;
phenols;
polyketide;
secondary alpha-hydroxy ketone | antifungal agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
fungal metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rucaparib | | azepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound | antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rubraxanthone | | aromatic ether;
polyphenol;
xanthones | antibacterial agent;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| NNC 55-0396 (free base) | | benzimidazoles;
cyclopropanecarboxylate ester;
organofluorine compound;
tertiary amino compound;
tetralins | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
neuroprotective agent;
potassium channel blocker;
T-type calcium channel blocker | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sch 51344 | | aromatic amine;
aromatic ether;
primary alcohol;
pyrazoloquinoline;
secondary amino compound | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| osu 03012 | | antibiotic antifungal drug;
aromatic amide;
glycine derivative;
organofluorine compound;
phenanthrenes;
pyrazoles | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ageladine a | | alkaloid;
aromatic amine;
imidazopyridine;
organobromine compound;
pyrroles | angiogenesis inhibitor;
antineoplastic agent;
matrix metalloproteinase inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azd 6244 | | benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound | anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| saracatinib | | aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| crenolanib | | aminopiperidine;
aromatic ether;
benzimidazoles;
oxetanes;
quinolines;
tertiary amino compound | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| PB28 | | aromatic ether;
piperazines;
tetralins | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
sigma-2 receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3,5-dimethoxy-4-hydroxybenzyl alcohol-4-O-beta-D-glucopyranoside | | aromatic ether;
benzyl alcohols;
beta-D-glucoside;
monosaccharide derivative;
primary alcohol | antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| jaspamide b | | cyclodepsipeptide;
organobromine compound | animal metabolite;
antineoplastic agent;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| at 7867 | | monochlorobenzenes;
piperidines;
pyrazoles | antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| erastin | | aromatic ether;
diether;
monochlorobenzenes;
N-acylpiperazine;
N-alkylpiperazine;
quinazolines;
tertiary carboxamide | antineoplastic agent;
ferroptosis inducer;
voltage-dependent anion channel inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| brivanib | | aromatic ether;
diether;
fluoroindole;
pyrrolotriazine;
secondary alcohol | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rx-3117 | | organofluorine compound;
primary allylic alcohol;
triol | antimetabolite;
antineoplastic agent;
apoptosis inducer;
DNA synthesis inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| at 7519 | | dichlorobenzene;
piperidines;
pyrazoles;
secondary carboxamide | antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azd 1152 | | anilide;
monoalkyl phosphate;
monofluorobenzenes;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
Aurora kinase inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pf 00299804 | | enamide;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ki11502 | | aromatic ether;
benzamides;
quinolines;
thioureas | antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine | | aminopyridine;
aromatic ether;
dichlorobenzene;
organofluorine compound;
pyrazolylpiperidine;
racemate | antineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| idelalisib | | aromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound | antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zstk474 | | benzimidazoles;
morpholines;
organofluorine compound;
triamino-1,3,5-triazine | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trametinib | | acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly | anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bgt226 | | aromatic ether;
imidazoquinoline;
N-arylpiperazine;
organofluorine compound;
pyridines | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azd 1152-hqpa | | anilide;
monofluorobenzenes;
primary alcohol;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
Aurora kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gdc-0973 | | aromatic amine;
difluorobenzene;
N-acylazetidine;
organoiodine compound;
piperidines;
secondary amino compound;
tertiary alcohol | antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| buparlisib | | aminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ro5126766 | | aryloxypyrimidine;
coumarins;
organofluorine compound;
pyridines;
sulfamides | antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk690693 | | 1,2,5-oxadiazole;
acetylenic compound;
aromatic amine;
aromatic ether;
imidazopyridine;
piperidines;
primary amino compound;
tertiary alcohol | antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cnf 2024 | | 2-aminopurines;
aromatic ether;
organochlorine compound;
pyridines | antineoplastic agent;
Hsp90 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bromophycolide a | | diterpenoid;
macrolide;
organobromine compound;
phenols;
tertiary alcohol | anti-HIV agent;
antibacterial agent;
antifungal agent;
antimalarial;
antineoplastic agent;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lde225 | | aminopyridine;
aromatic ether;
benzamides;
biphenyls;
morpholines;
organofluorine compound;
tertiary amino compound | antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pci 32765 | | acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide | antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| AMG-208 | | aromatic ether;
quinolines;
triazolopyridazine | antineoplastic agent;
c-Met tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 6-methoxyspirotryprostatin b | | aromatic ether;
azaspiro compound;
indole alkaloid;
indolones | antineoplastic agent;
Aspergillus metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| niraparib | | benzenes;
indazoles;
piperidines;
primary carboxamide | antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| navitoclax | | aryl sulfide;
monochlorobenzenes;
morpholines;
N-sulfonylcarboxamide;
organofluorine compound;
piperazines;
secondary amino compound;
sulfone;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lucitanib | | aromatic ether;
cyclopropanes;
naphthalenecarboxamide;
primary amino compound;
quinolines | antineoplastic agent;
fibroblast growth factor receptor antagonist;
vascular endothelial growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| poziotinib | | acrylamides;
aromatic ether;
dichlorobenzene;
diether;
monofluorobenzenes;
N-acylpiperidine;
quinazolines;
secondary amino compound;
substituted aniline | antineoplastic agent;
apoptosis inducer;
epidermal growth factor receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| asp3026 | | aromatic amine;
diamino-1,3,5-triazine;
monomethoxybenzene;
N-methylpiperazine;
piperidines;
secondary amino compound;
sulfone | antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 6.1.1.6 (lysine--tRNA ligase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pexidartinib | | aminopyridine;
organochlorine compound;
organofluorine compound;
pyrrolopyridine;
secondary amino compound | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| TAK-580 | | 1,3-thiazolecarboxamide;
aminopyrimidine;
chloropyridine;
organofluorine compound;
pyrimidinecarboxamide;
secondary carboxamide | antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| glasdegib | | benzimidazoles;
nitrile;
phenylureas;
piperidines | antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk 2126458 | | aromatic ether;
difluorobenzene;
pyridazines;
pyridines;
quinolines;
sulfonamide | anticoronaviral agent;
antineoplastic agent;
autophagy inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dabrafenib | | 1,3-thiazoles;
aminopyrimidine;
organofluorine compound;
sulfonamide | anticoronaviral agent;
antineoplastic agent;
B-Raf inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tak-632 | | (trifluoromethyl)benzenes;
aromatic ether;
benzothiazoles;
cyclopropylcarboxamide;
monofluorobenzenes;
nitrile;
secondary carboxamide | antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
necroptosis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lrrk2-in1 | | aromatic amine;
aromatic ether;
N-acylpiperidine;
N-alkylpiperazine;
pyrimidobenzodiazepine;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gilteritinib | | aromatic amine;
monomethoxybenzene;
N-methylpiperazine;
oxanes;
piperidines;
primary carboxamide;
pyrazines;
secondary amino compound | antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| alectinib | | aromatic ketone;
morpholines;
nitrile;
organic heterotetracyclic compound;
piperidines | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ML240 | | aromatic amine;
aromatic ether;
benzimidazoles;
primary amino compound;
quinazolines;
secondary amino compound | antineoplastic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| torin 1 | | N-acylpiperazine;
N-arylpiperazine;
organofluorine compound;
pyridoquinoline;
quinolines | antineoplastic agent;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| abt-199 | | aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine | antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| xl765 | | aromatic amine;
aromatic ether;
benzamides;
quinoxaline derivative;
sulfonamide | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| DMH1 | | aromatic ether;
pyrazolopyrimidine;
quinolines | antineoplastic agent;
bone morphogenetic protein receptor antagonist;
protein kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| torin 2 | | aminopyridine;
organofluorine compound;
primary amino compound;
pyridoquinoline | antineoplastic agent;
mTOR inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk2656157 | | biaryl;
indoles;
methylpyridines;
organofluorine compound;
pyrrolopyrimidine;
tertiary carboxamide | antineoplastic agent;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
PERK inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ceritinib | | aminopyrimidine;
aromatic ether;
organochlorine compound;
piperidines;
secondary amino compound;
sulfone | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| MK-8353 | | aromatic ether;
dihydropyridine;
indazoles;
methyl sulfide;
N-alkylpyrrolidine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
triazoles | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gsk2879552 | | benzenes;
benzoic acids;
cyclopropanes;
monocarboxylic acid;
piperidines;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
EC 1.14.99.66 (lysine-specific histone demethylase 1A) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ivosidenib | | cyanopyridine;
monochlorobenzenes;
organofluorine compound;
pyrrolidin-2-ones;
secondary carboxamide;
tertiary carboxamide | antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pf-06463922 | | aminopyridine;
aromatic ether;
azamacrocycle;
benzamides;
cyclic ether;
monofluorobenzenes;
nitrile;
organic heterotetracyclic compound;
pyrazoles | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| as 1842856 | | organofluorine compound;
primary amino compound;
quinolinemonocarboxylic acid;
quinolone;
secondary amino compound;
tertiary amino compound | anti-obesity agent;
antineoplastic agent;
apoptosis inducer;
autophagy inhibitor;
forkhead box protein O1 inhibitor;
hypoglycemic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ldc4297 | | aromatic ether;
piperidines;
pyrazoles;
pyrazolotriazine;
secondary amino compound | antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| enasidenib | | 1,3,5-triazines;
aminopyridine;
aromatic amine;
organofluorine compound;
secondary amino compound;
tertiary alcohol | antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| MMP-9-IN-1 | | aromatic compound;
organic sulfide;
organofluorine compound;
pyrimidone;
secondary carboxamide | antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| hydrazinocurcumin | | aromatic ether;
olefinic compound;
polyphenol;
pyrazoles | angiogenesis modulating agent;
antineoplastic agent;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cerulomycin | | aldoxime;
aromatic ether;
bipyridines;
pyridine alkaloid | antineoplastic agent;
bacterial metabolite;
marine metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| undecylprodigiosin | | alkaloid;
aromatic ether;
tripyrrole | antibacterial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
biological pigment;
immunosuppressive agent;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ARS-1620 | | quinazolines | antineoplastic agent;
antiviral agent;
inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| acetic acid | | monocarboxylic acid | antimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acetamide | | acetamides;
carboximidic acid;
monocarboxylic acid amide;
N-acylammonia | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| adenine | | 6-aminopurines;
purine nucleobase | Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| allantoin | | imidazolidine-2,4-dione;
ureas | Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite;
vulnerary | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| quinacrine | | acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound | antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor | 2008 | 2011 | 14.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| betaine | | amino-acid betaine;
glycine derivative | fundamental metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carnitine | | amino-acid betaine | human metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| citric acid, anhydrous | | tricarboxylic acid | antimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| salicylic acid | | monohydroxybenzoic acid | algal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bupropion | | aromatic ketone;
monochlorobenzenes;
secondary amino compound | antidepressant;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aminocaproic acid | | amino acid zwitterion;
epsilon-amino acid;
omega-amino fatty acid | antifibrinolytic drug;
hematologic agent;
metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| creatine | | glycine derivative;
guanidines;
zwitterion | geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lactic acid | | 2-hydroxy monocarboxylic acid | algal metabolite;
Daphnia magna metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dimethyl sulfoxide | | sulfoxide;
volatile organic compound | alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| formaldehyde | | aldehyde;
one-carbon compound | allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glycine | | alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid | EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glycerol | | alditol;
triol | algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hydroquinone | | benzenediol;
hydroquinones | antioxidant;
carcinogenic agent;
cofactor;
Escherichia coli metabolite;
human xenobiotic metabolite;
mouse metabolite;
skin lightening agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| inositol | | cyclitol;
hexol | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| niacinamide | | pyridine alkaloid;
pyridinecarboxamide;
vitamin B3 | anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| niacin | | pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3 | antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| orotic acid | | pyrimidinemonocarboxylic acid | Escherichia coli metabolite;
metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-aminobenzoic acid | | aminobenzoic acid;
aromatic amino-acid zwitterion | allergen;
Escherichia coli metabolite;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenol | | phenols | antiseptic drug;
disinfectant;
human xenobiotic metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenylacetic acid | | benzenes;
monocarboxylic acid;
phenylacetic acids | allergen;
Aspergillus metabolite;
auxin;
EC 6.4.1.1 (pyruvate carboxylase) inhibitor;
Escherichia coli metabolite;
human metabolite;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite;
toxin | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyrazinamide | | monocarboxylic acid amide;
N-acylammonia;
pyrazines | antitubercular agent;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyridoxal phosphate | | methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6 phosphate | coenzyme;
cofactor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyridoxine | | hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
vitamin B6 | cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thiamine | | primary alcohol;
vitamin B1 | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| uracil | | pyrimidine nucleobase;
pyrimidone | allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| urea | | isourea;
monocarboxylic acid amide;
one-carbon compound | Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| catechin | | hydroxyflavan | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid | | non-proteinogenic alpha-amino acid | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| b 844-39 | | diarylmethane | | 2017 | 2022 | 4.5 | medium | 0 | 0 | 0 | 0 | 1 | 1 |
| menthol | | p-menthane monoterpenoid;
secondary alcohol | volatile oil component | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1,3-dipropyl-8-cyclopentylxanthine | | oxopurine | adenosine A1 receptor antagonist;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pk 11195 | | aromatic amide;
isoquinolines;
monocarboxylic acid amide;
monochlorobenzenes | antineoplastic agent | 2013 | 2020 | 6.8 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| pd 173074 | | aromatic amine;
biaryl;
dimethoxybenzene;
pyridopyrimidine;
tertiary amino compound;
ureas | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nsc-267703 | | anthracycline | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| 4,5,6,7-tetrabromo-2-azabenzimidazole | | | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| jtv519 | | | | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| phenytoin | | imidazolidine-2,4-dione | anticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| abt 702 | | bipyridines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acebutolol | | aromatic amide;
ethanolamines;
ether;
monocarboxylic acid amide;
propanolamine;
secondary amino compound | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympathomimetic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acetaminophen | | acetamides;
phenols | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acetazolamide | | monocarboxylic acid amide;
sulfonamide;
thiadiazoles | anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2010 | 2021 | 8.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| acetohexamide | | acetophenones;
N-sulfonylurea | hypoglycemic agent;
insulin secretagogue | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acetohydroxamic acid | | acetohydroxamic acids;
carbohydroximic acid | algal metabolite;
EC 3.5.1.5 (urease) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dactinomycin | | cyclodepsipeptide | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| rtki cpd | | aromatic ether;
monochlorobenzenes;
quinazolines | antineoplastic agent;
antiviral agent;
epidermal growth factor receptor antagonist;
geroprotector | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 1-aminoindan-1,5-dicarboxylic acid | | | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| albendazole | | aryl sulfide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester | anthelminthic drug;
microtubule-destabilising agent;
tubulin modulator | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| albuterol | | phenols;
phenylethanolamines;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| alfuzosin | | monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol | alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| alprazolam | | organochlorine compound;
triazolobenzodiazepine | anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| amantadine | | adamantanes;
primary aliphatic amine | analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ambroxol | | aromatic amine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aminoglutethimide | | dicarboximide;
piperidones;
substituted aniline | adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pimagedine | | guanidines;
one-carbon compound | EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 1.4.3.4 (monoamine oxidase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| theophylline | | dimethylxanthine | adenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amiodarone | | 1-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound | cardiovascular drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dan 2163 | | aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone | environmental contaminant;
second generation antipsychotic;
xenobiotic | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| amitriptyline | | carbotricyclic compound;
tertiary amine | adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amlexanox | | monocarboxylic acid;
pyridochromene | anti-allergic agent;
anti-ulcer drug;
non-steroidal anti-inflammatory drug | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| amlodipine | | dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound | antihypertensive agent;
calcium channel blocker;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amobarbital | | barbiturates | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amodiaquine | | aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amsacrine | | acridines;
aromatic ether;
sulfonamide | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| anastrozole | | nitrile;
triazoles | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| anethole trithione | | methoxybenzenes | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| anthralin | | anthracenes | antipsoriatic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aspirin | | benzoic acids;
phenyl acetates;
salicylates | anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| astemizole | | benzimidazoles;
piperidines | anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist | 2008 | 2020 | 9.0 | low | 0 | 0 | 0 | 1 | 4 | 0 |
| atenolol | | ethanolamines;
monocarboxylic acid amide;
propanolamine | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| azathioprine | | aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine | antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| baclofen | | amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound | central nervous system depressant;
GABA agonist;
muscle relaxant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| barbital | | barbiturates | drug allergen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bendazac | | indazoles;
monocarboxylic acid | non-steroidal anti-inflammatory drug;
radical scavenger | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benzbromarone | | 1-benzofurans;
aromatic ketone | uricosuric drug | 2010 | 2022 | 6.4 | low | 0 | 0 | 0 | 1 | 3 | 1 |
| berberine | | alkaloid antibiotic;
berberine alkaloid;
botanical anti-fungal agent;
organic heteropentacyclic compound | antilipemic drug;
antineoplastic agent;
antioxidant;
EC 1.1.1.141 [15-hydroxyprostaglandin dehydrogenase (NAD(+))] inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.13.11.52 (indoleamine 2,3-dioxygenase) inhibitor;
EC 1.21.3.3 (reticuline oxidase) inhibitor;
EC 2.1.1.116 [3'-hydroxy-N-methyl-(S)-coclaurine 4'-O-methyltransferase] inhibitor;
EC 2.1.1.122 [(S)-tetrahydroprotoberberine N-methyltransferase] inhibitor;
EC 2.7.11.10 (IkappaB kinase) inhibitor;
EC 3.1.1.4 (phospholipase A2) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
hypoglycemic agent;
metabolite;
potassium channel blocker | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bicalutamide | | (trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bay h 4502 | | biphenyls;
imidazoles | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-cyano-3-(3,4-dihydroxyphenyl)-N-(phenylmethyl)-2-propenamide | | hydroxycinnamic acid | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| bisindolylmaleimide i | | | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| bisoprolol | | secondary alcohol;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bromisovalum | | N-acylurea;
organobromine compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| brotizolam | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bufexamac | | aromatic ether;
hydroxamic acid | antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| bumetanide | | amino acid;
benzoic acids;
sulfonamide | diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bupivacaine | | aromatic amide;
piperidinecarboxamide;
tertiary amino compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| buspirone | | azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines | anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| busulfan | | methanesulfonate ester | alkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| butalbital | | barbiturates | analgesic;
sedative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cadralazine | | organic molecular entity | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| caffeine | | purine alkaloid;
trimethylxanthine | adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| verapamil | | aromatic ether;
nitrile;
polyether;
tertiary amino compound | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| candesartan cilexetil | | biphenyls | | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| carbamazepine | | dibenzoazepine;
ureas | analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carisoprodol | | carbamate ester | muscle relaxant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carmustine | | N-nitrosoureas;
organochlorine compound | alkylating agent;
antineoplastic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carprofen | | carbazoles;
organochlorine compound | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug;
photosensitizing agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carvedilol | | carbazoles;
secondary alcohol;
secondary amino compound | alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent | 2010 | 2020 | 7.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| celecoxib | | organofluorine compound;
pyrazoles;
sulfonamide;
toluenes | cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cetirizine | | ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines | anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic | 2010 | 2020 | 7.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| chelerythrine | | benzophenanthridine alkaloid;
organic cation | antibacterial agent;
antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| chloral hydrate | | aldehyde hydrate;
ethanediol;
organochlorine compound | general anaesthetic;
mouse metabolite;
sedative;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlorambucil | | aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound | alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlorcyclizine | | diarylmethane | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| chlordiazepoxide | | benzodiazepine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlormezanone | | 1,3-thiazine;
lactam;
monochlorobenzenes;
sulfone | antipsychotic agent;
anxiolytic drug;
muscle relaxant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chloroquine | | aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug | 2008 | 2019 | 12.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| chloroxylenol | | monochlorobenzenes;
phenols | antiseptic drug;
disinfectant;
molluscicide | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlorpheniramine | | monochlorobenzenes;
pyridines;
tertiary amino compound | anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlorpromazine | | organochlorine compound;
phenothiazines;
tertiary amine | anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlorpropamide | | monochlorobenzenes;
N-sulfonylurea | hypoglycemic agent;
insulin secretagogue | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlorzoxazone | | 1,3-benzoxazoles;
heteroaryl hydroxy compound;
organochlorine compound | muscle relaxant;
sedative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ci 994 | | acetamides;
benzamides;
substituted aniline | antineoplastic agent;
EC 3.5.1.98 (histone deacetylase) inhibitor | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| cimetidine | | aliphatic sulfide;
guanidines;
imidazoles;
nitrile | adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aricine | | cinchona alkaloid | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| cinoxacin | | cinnolines;
oxacycle;
oxo carboxylic acid | antibacterial drug;
antiinfective agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ciprofibrate | | cyclopropanes;
monocarboxylic acid;
organochlorine compound | antilipemic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ciprofloxacin | | aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion | antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cisapride | | benzamides | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| citalopram | | 2-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clioquinol | | monohydroxyquinoline;
organochlorine compound;
organoiodine compound | antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clobazam | | 1,4-benzodiazepinone;
organochlorine compound | anticonvulsant;
anxiolytic drug;
GABA modulator | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clofazimine | | monochlorobenzenes;
phenazines | dye;
leprostatic drug;
non-steroidal anti-inflammatory drug | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| clofibrate | | aromatic ether;
ethyl ester;
monochlorobenzenes | anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clofilium | | benzenes;
organic amino compound | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clomiphene | | tertiary amine | estrogen antagonist;
estrogen receptor modulator | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clonidine | | clonidine;
imidazoline | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clotiazepam | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clotrimazole | | conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes | antiinfective agent;
environmental contaminant;
xenobiotic | 2008 | 2011 | 14.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| cyclandelate | | carboxylic ester;
secondary alcohol | vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyclosporine | | | | 2017 | 2020 | 5.5 | high | 0 | 0 | 0 | 0 | 2 | 0 |
| cyproheptadine | | piperidines;
tertiary amine | anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| danthron | | dihydroxyanthraquinone | apoptosis inducer;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dapsone | | substituted aniline;
sulfone | anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| deferoxamine | | acyclic desferrioxamine | bacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dequalinium | | quinolinium ion | antifungal agent;
antineoplastic agent;
antiseptic drug;
mitochondrial NADH:ubiquinone reductase inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amphetamine | | primary amine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| eflornithine | | alpha-amino acid;
fluoroamino acid | trypanocidal drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diazepam | | 1,4-benzodiazepinone;
organochlorine compound | anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diazoxide | | benzothiadiazine;
organochlorine compound;
sulfone | antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diclofenac | | amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound | antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ddt | | benzenoid aromatic compound;
chlorophenylethane;
monochlorobenzenes;
organochlorine insecticide | bridged diphenyl acaricide;
carcinogenic agent;
endocrine disruptor;
persistent organic pollutant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diflunisal | | monohydroxybenzoic acid;
organofluorine compound | non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diphenhydramine | | ether;
tertiary amino compound | anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dipyridamole | | piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol | adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| disopyramide | | monocarboxylic acid amide;
pyridines;
tertiary amino compound | anti-arrhythmia drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| disulfiram | | organic disulfide;
organosulfur acaricide | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| valproic acid | | branched-chain fatty acid;
branched-chain saturated fatty acid | anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| n(6),n(6)-dimethyladenine | | tertiary amine | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| doxepin | | dibenzooxepine;
tertiary amino compound | antidepressant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| droperidol | | aromatic ketone;
benzimidazoles;
organofluorine compound | anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nsc-526417 | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| econazole | | dichlorobenzene;
ether;
imidazoles;
monochlorobenzenes | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| enflurane | | ether;
organochlorine compound;
organofluorine compound | anaesthetic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| enoxacin | | 1,8-naphthyridine derivative;
amino acid;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-arylpiperazine;
quinolone antibiotic | antibacterial drug;
DNA synthesis inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| estazolam | | triazoles;
triazolobenzodiazepine | anticonvulsant;
anxiolytic drug;
GABA modulator | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethacrynic acid | | aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid | EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethoxzolamide | | aromatic ether;
benzothiazoles;
sulfonamide | antiglaucoma drug;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| etodolac | | monocarboxylic acid;
organic heterotricyclic compound | antipyretic;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| brl 42810 | | 2-aminopurines;
acetate ester | antiviral drug;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| felbamate | | carbamate ester | anticonvulsant;
neuroprotective agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| felodipine | | dichlorobenzene;
dihydropyridine;
ethyl ester;
methyl ester | anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fenbendazole | | aryl sulfide;
benzimidazoles;
carbamate ester | antinematodal drug | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| fenofibrate | | aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes | antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| berotek | | resorcinols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fentanyl | | anilide;
monocarboxylic acid amide;
piperidines | adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| flecainide | | aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines | anti-arrhythmia drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fluconazole | | conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug | environmental contaminant;
P450 inhibitor;
xenobiotic | 2010 | 2021 | 8.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| flucytosine | | aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone | prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| flufenamic acid | | aromatic amino acid;
organofluorine compound | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| flumazenil | | ethyl ester;
imidazobenzodiazepine;
organofluorine compound | antidote to benzodiazepine poisoning;
GABA antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| flunitrazepam | | 1,4-benzodiazepinone;
C-nitro compound;
monofluorobenzenes | anxiolytic drug;
GABAA receptor agonist;
sedative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fluorouracil | | nucleobase analogue;
organofluorine compound | antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fluoxetine | | (trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| flurbiprofen | | fluorobiphenyl;
monocarboxylic acid | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| flutamide | | (trifluoromethyl)benzenes;
monocarboxylic acid amide | androgen antagonist;
antineoplastic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fomepizole | | pyrazoles | antidote;
EC 1.1.1.1 (alcohol dehydrogenase) inhibitor;
protective agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| furosemide | | chlorobenzoic acid;
furans;
sulfonamide | environmental contaminant;
loop diuretic;
xenobiotic | 2010 | 2022 | 9.0 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| gemfibrozil | | aromatic ether | antilipemic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gentian violet | | iminium ion | antibacterial agent;
antifungal agent | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| glafenine | | aminoquinoline;
carboxylic ester;
glycol;
organochlorine compound;
secondary amino compound | inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gliclazide | | N-sulfonylurea | hypoglycemic agent;
insulin secretagogue;
radical scavenger | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glutethimide | | piperidines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glyburide | | monochlorobenzenes;
N-sulfonylurea | anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| go 6976 | | indolocarbazole;
organic heterohexacyclic compound | EC 2.7.11.13 (protein kinase C) inhibitor | 2011 | 2020 | 7.2 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| gossypol | | | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| guaiazulene | | sesquiterpene | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gw8510 | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide | | bromobenzenes;
isoquinolines;
olefinic compound;
secondary amino compound;
sulfonamide | EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| fasudil | | isoquinolines;
N-sulfonyldiazepane | antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent | 2010 | 2017 | 11.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| haloperidol | | aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol | antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 2010 | 2022 | 6.4 | low | 0 | 0 | 0 | 1 | 3 | 1 |
| halothane | | haloalkane;
organobromine compound;
organochlorine compound;
organofluorine compound | inhalation anaesthetic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexachlorophene | | bridged diphenyl fungicide;
polyphenol;
trichlorobenzene | acaricide;
antibacterial agent;
antifungal agrochemical;
antiseptic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| miltefosine | | phosphocholines;
phospholipid | anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexahydrosiladifenidol | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hexestrol | | stilbenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexetidine | | organic heteromonocyclic compound;
organonitrogen heterocyclic compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexobarbital | | barbiturates | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| homochlorocyclizine | | diarylmethane | | 2017 | 2022 | 4.5 | medium | 0 | 0 | 0 | 0 | 3 | 1 |
| hydralazine | | azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines | antihypertensive agent;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hydrochlorothiazide | | benzothiadiazine;
organochlorine compound;
sulfonamide | antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hydroxyurea | | one-carbon compound;
ureas | antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hydroxyzine | | hydroxyether;
monochlorobenzenes;
N-alkylpiperazine | anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist | 2010 | 2020 | 7.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| ibuprofen | | monocarboxylic acid | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenelzine | | primary amine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lidocaine | | benzenes;
monocarboxylic acid amide;
tertiary amino compound | anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| alverine | | tertiary amine | antispasmodic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| idebenone | | 1,4-benzoquinones;
primary alcohol | antioxidant;
ferroptosis inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ifenprodil | | piperidines | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| ifosfamide | | ifosfamides | alkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| imipramine | | dibenzoazepine | adrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amrinone | | bipyridines | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| indapamide | | indoles;
organochlorine compound;
sulfonamide | antihypertensive agent;
diuretic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| indirubin-3'-monoxime | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| indomethacin | | aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole | analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iohexol | | benzenedicarboxamide;
organoiodine compound | environmental contaminant;
radioopaque medium;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iodipamide | | benzoic acids;
organoiodine compound;
secondary carboxamide | radioopaque medium | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iproniazid | | carbohydrazide;
pyridines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| avapro | | azaspiro compound;
biphenylyltetrazole | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isoflurane | | organofluorine compound | inhalation anaesthetic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isoniazid | | carbohydrazide | antitubercular agent;
drug allergen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-propanol | | secondary alcohol;
secondary fatty alcohol | protic solvent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isoproterenol | | catechols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isoxsuprine | | alkylbenzene | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isradipine | | benzoxadiazole;
dihydropyridine;
isopropyl ester;
methyl ester | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| itraconazole | | piperazines | | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline | | | | 2016 | 2017 | 7.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| 1-(2-naphthalenyl)-3-[(phenylmethyl)-propan-2-ylamino]-1-propanone | | naphthalenes | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| nsc 664704 | | indolobenzazepine;
lactam;
organobromine compound | cardioprotective agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
geroprotector | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ketamine | | cyclohexanones;
monochlorobenzenes;
secondary amino compound | analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic | 2010 | 2020 | 7.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| ketanserin | | aromatic ketone;
organofluorine compound;
piperidines;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ketoconazole | | dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ketoprofen | | benzophenones;
oxo monocarboxylic acid | antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic | 2010 | 2020 | 7.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| khellin | | furanochromone;
organic heterotricyclic compound;
oxacycle | anti-asthmatic agent;
bronchodilator agent;
cardiovascular drug;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| labetalol | | benzamides;
benzenes;
phenols;
primary carboxamide;
salicylamides;
secondary alcohol;
secondary amino compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lamotrigine | | 1,2,4-triazines;
dichlorobenzene;
primary arylamine | anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lansoprazole | | benzimidazoles;
pyridines;
sulfoxide | anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| beta-lapachone | | benzochromenone;
orthoquinones | anti-inflammatory agent;
antineoplastic agent;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| leflunomide | | (trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide | antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| letrozole | | nitrile;
triazoles | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lg 100268 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lofepramine | | aromatic ketone;
dibenzoazepine;
monochlorobenzenes;
tertiary amino compound | antidepressant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lomustine | | N-nitrosoureas;
organochlorine compound | alkylating agent;
antineoplastic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| loperamide | | monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol | anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| losartan | | biphenylyltetrazole;
imidazoles | angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| 2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one | | chromones;
morpholines;
organochlorine compound | autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector | 2011 | 2022 | 7.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| malathion | | diester;
ethyl ester;
organic thiophosphate | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diisopropyl 1,3-dithiol-2-ylidenemalonate | | isopropyl ester | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mazindol | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mebendazole | | aromatic ketone;
benzimidazoles;
carbamate ester | antinematodal drug;
microtubule-destabilising agent;
tubulin modulator | 2010 | 2022 | 6.4 | low | 0 | 0 | 0 | 1 | 3 | 1 |
| meclizine | | diarylmethane | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| meclofenoxate | | monocarboxylic acid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mefenamic acid | | aminobenzoic acid;
secondary amino compound | analgesic;
antipyretic;
antirheumatic drug;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mefloquine hydrochloride | | organofluorine compound;
piperidines;
quinolines;
secondary alcohol | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| vitamin k 3 | | 1,4-naphthoquinones;
vitamin K | angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| meperidine | | ethyl ester;
piperidinecarboxylate ester;
tertiary amino compound | antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mephenesin | | aromatic ether;
glycerol ether | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| mephenytoin | | imidazolidine-2,4-dione | anticonvulsant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mepivacaine | | piperidinecarboxamide | drug allergen;
local anaesthetic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| meprobamate | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mesalamine | | amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols | non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| metformin | | guanidines | environmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| methadone | | benzenes;
diarylmethane;
ketone;
tertiary amino compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methoxsalen | | aromatic ether;
psoralens | antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methoxyflurane | | ether;
organochlorine compound;
organofluorine compound | hepatotoxic agent;
inhalation anaesthetic;
nephrotoxic agent;
non-narcotic analgesic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methyl salicylate | | benzoate ester;
methyl ester;
salicylates | flavouring agent;
insect attractant;
metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methylphenidate | | beta-amino acid ester;
methyl ester;
piperidines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methyprylon | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| metoclopramide | | benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound | antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| metoprolol | | aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound | antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| metronidazole | | C-nitro compound;
imidazoles;
primary alcohol | antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic | 2010 | 2021 | 8.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| metyrapone | | aromatic ketone | antimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mianserin | | dibenzoazepine | adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| miconazole | | dichlorobenzene;
ether;
imidazoles | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| midazolam | | imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound | anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| minoxidil | | dialkylarylamine;
tertiary amino compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mirtazapine | | benzazepine;
tetracyclic antidepressant | alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
oneirogen;
serotonergic antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mitotane | | diarylmethane | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mitoxantrone | | dihydroxyanthraquinone | analgesic;
antineoplastic agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| moclobemide | | benzamides;
monochlorobenzenes;
morpholines | antidepressant;
environmental contaminant;
xenobiotic | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| modafinil | | monocarboxylic acid amide;
sulfoxide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| moxisylyte | | monoterpenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| entinostat | | benzamides;
carbamate ester;
primary amino compound;
pyridines;
substituted aniline | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor | 2013 | 2021 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| deet | | benzamides;
monocarboxylic acid amide | environmental contaminant;
insect repellent;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| n-acetyl-4-nitrophenylserinol | | | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| nabumetone | | methoxynaphthalene;
methyl ketone | cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nalidixic acid | | 1,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic | antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nefazodone | | aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles | alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nevirapine | | cyclopropanes;
dipyridodiazepine | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nialamide | | organonitrogen compound;
organooxygen compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nicardipine | | benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| niceritrol | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| niclosamide | | benzamides;
C-nitro compound;
monochlorobenzenes;
salicylanilides;
secondary carboxamide | anthelminthic drug;
anticoronaviral agent;
antiparasitic agent;
apoptosis inducer;
molluscicide;
piscicide;
STAT3 inhibitor | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| nifedipine | | C-nitro compound;
dihydropyridine;
methyl ester | calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| niflumic acid | | aromatic carboxylic acid;
pyridines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nilutamide | | (trifluoromethyl)benzenes;
C-nitro compound;
imidazolidinone | androgen antagonist;
antineoplastic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nimesulide | | aromatic ether;
C-nitro compound;
sulfonamide | cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nimodipine | | 2-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester | antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| nisoldipine | | C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
methyl ester | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nitrazepam | | 1,4-benzodiazepinone;
C-nitro compound | anticonvulsant;
antispasmodic drug;
drug metabolite;
GABA modulator;
sedative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nitrendipine | | C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester | antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| nitroglycerin | | nitroglycerol | explosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nizatidine | | 1,3-thiazoles;
C-nitro compound;
carboxamidine;
organic sulfide;
tertiary amino compound | anti-ulcer drug;
cholinergic drug;
H2-receptor antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| masoprocol | | catechols;
lignan;
tetrol | antioxidant;
ferroptosis inhibitor;
geroprotector;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| norfloxacin | | fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic | 2010 | 2021 | 8.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| nortriptyline | | organic tricyclic compound;
secondary amine | adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| olomoucine | | 2,6-diaminopurines;
ethanolamines | EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| olprinone | | bipyridines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| omeprazole | | aromatic ether;
benzimidazoles;
pyridines;
sulfoxide | | 2010 | 2022 | 9.0 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| ondansetron | | carbazoles | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| orphenadrine | | ether;
tertiary amino compound | antidyskinesia agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxamniquine | | aromatic primary alcohol;
C-nitro compound;
quinolines;
secondary amino compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxaprozin | | 1,3-oxazoles;
monocarboxylic acid | analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxazepam | | 1,4-benzodiazepinone;
organochlorine compound | anxiolytic drug;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxethazaine | | amino acid amide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxibendazole | | benzimidazoles;
carbamate ester | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| oxiracetam | | organonitrogen compound;
organooxygen compound | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| oxprenolol | | aromatic ether | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxybenzone | | hydroxybenzophenone;
monomethoxybenzene | dermatologic drug;
environmental contaminant;
protective agent;
ultraviolet filter;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxyphenbutazone | | phenols;
pyrazolidines | antimicrobial agent;
antineoplastic agent;
antipyretic;
drug metabolite;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aminosalicylic acid | | aminobenzoic acid;
phenols | antitubercular agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-(2'-methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-iodobenzamido)ethyl)piperazine | | | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| pantoprazole | | aromatic ether;
benzimidazoles;
organofluorine compound;
pyridines;
sulfoxide | anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
environmental contaminant;
xenobiotic | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| papaverine | | benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines | antispasmodic drug;
vasodilator agent | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pd 153035 | | aromatic amine;
aromatic ether;
bromobenzenes;
quinazolines;
secondary amino compound | EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist | 2007 | 2019 | 9.2 | low | 0 | 0 | 0 | 1 | 4 | 0 |
| pemoline | | 1,3-oxazoles | central nervous system stimulant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pentamidine | | aromatic ether;
carboxamidine;
diether | anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pentobarbital | | barbiturates | GABAA receptor agonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pentoxifylline | | oxopurine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| perazine | | N-alkylpiperazine;
N-methylpiperazine;
phenothiazines | dopaminergic antagonist;
phenothiazine antipsychotic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| perphenazine | | N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines | antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug | 2010 | 2020 | 7.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| phenacetin | | acetamides;
aromatic ether | cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenobarbital | | barbiturates | anticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenolphthalein | | phenols | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenoxybenzamine | | aromatic amine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenylbutazone | | pyrazolidines | antirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| moxonidine | | organohalogen compound;
pyrimidines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 3,3',4,5'-tetrahydroxystilbene | | stilbenoid | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| pimobendan | | benzimidazoles;
pyridazinone | cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| pinacidil | | pyridines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pioglitazone | | aromatic ether;
pyridines;
thiazolidinediones | antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pipemidic acid | | amino acid;
monocarboxylic acid;
N-arylpiperazine;
pyridopyrimidine;
quinolone antibiotic | antibacterial drug;
DNA synthesis inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| piperazine | | azacycloalkane;
piperazines;
saturated organic heteromonocyclic parent | anthelminthic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ag 1879 | | aromatic amine;
monochlorobenzenes;
pyrazolopyrimidine | beta-adrenergic antagonist;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector | 2011 | 2020 | 7.2 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| praziquantel | | isoquinolines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| prazosin | | aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| primaquine | | aminoquinoline;
aromatic ether;
N-substituted diamine | antimalarial | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| primidone | | pyrimidone | anticonvulsant;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| probenecid | | benzoic acids;
sulfonamide | uricosuric drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| probucol | | dithioketal;
polyphenol | anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| procainamide | | benzamides | anti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| procarbazine | | benzamides;
hydrazines | antineoplastic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| prochlorperazine | | N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines | alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| promethazine | | phenothiazines;
tertiary amine | anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pronethalol | | naphthalenes | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| propafenone | | aromatic ketone;
secondary alcohol;
secondary amino compound | anti-arrhythmia drug | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| propofol | | phenols | anticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| propranolol | | naphthalenes;
propanolamine;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyridinolcarbamate | | pyridines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyrimethamine | | aminopyrimidine;
monochlorobenzenes | antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2008 | 2011 | 14.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| rabeprazole | | benzimidazoles;
pyridines;
sulfoxide | anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one | | indoles | | 2013 | 2020 | 7.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| ranitidine | | aralkylamine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| opc 12759 | | secondary carboxamide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| riluzole | | benzothiazoles | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| risperidone | | 1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine | alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ro 31-8220 | | imidothiocarbamic ester;
indoles;
maleimides | EC 2.7.11.13 (protein kinase C) inhibitor | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| rofecoxib | | butenolide;
sulfone | analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ropinirole | | indolones;
tertiary amine | antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| salicylamide | | phenols;
salicylamides | antirheumatic drug;
non-narcotic analgesic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sb 206553 | | pyrroloindole | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sb 220025 | | aminopyrimidine;
imidazoles;
organofluorine compound;
piperidines | angiogenesis inhibitor;
anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 2011 | 2013 | 12.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| sb 239063 | | imidazoles | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sb 202190 | | imidazoles;
organofluorine compound;
phenols;
pyridines | apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 2005 | 2013 | 14.4 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| scriptaid | | isoquinolines | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sevoflurane | | ether;
organofluorine compound | central nervous system depressant;
inhalation anaesthetic;
platelet aggregation inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sibutramine | | organochlorine compound;
tertiary amino compound | anti-obesity agent;
serotonin uptake inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfadiazine | | pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
antimicrobial agent;
antiprotozoal drug;
coccidiostat;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sk&f 86002 | | imidazoles | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sotalol | | ethanolamines;
secondary alcohol;
secondary amino compound;
sulfonamide | anti-arrhythmia drug;
beta-adrenergic antagonist;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-phenylbutyric acid, sodium salt | | organic sodium salt | EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector;
neuroprotective agent;
orphan drug;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| imatinib | | aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines | antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor | 2005 | 2022 | 10.2 | low | 0 | 0 | 0 | 2 | 6 | 3 |
| vorinostat | | dicarboxylic acid diamide;
hydroxamic acid | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor | 2010 | 2021 | 7.2 | low | 0 | 0 | 0 | 1 | 7 | 1 |
| sulfadimethoxine | | aromatic ether;
pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
antimicrobial agent;
drug allergen;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfamerazine | | pyrimidines;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
drug allergen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfameter | | pyrimidines;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
leprostatic drug;
renal agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfamethazine | | pyrimidines;
sulfonamide antibiotic;
sulfonamide | antibacterial drug;
antiinfective agent;
antimicrobial agent;
carcinogenic agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
ligand;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfamethizole | | sulfonamide antibiotic;
sulfonamide;
thiadiazoles | antiinfective agent;
antimicrobial agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfamethoxazole | | isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfanilamide | | substituted aniline;
sulfonamide antibiotic;
sulfonamide | antibacterial agent;
drug allergen;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2010 | 2021 | 8.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| sulfaphenazole | | primary amino compound;
pyrazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antibacterial drug;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor;
P450 inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfapyridine | | pyridines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
dermatologic drug;
drug allergen;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfasalazine | | | | 2010 | 2022 | 9.0 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| sulfinpyrazone | | pyrazolidines;
sulfoxide | uricosuric drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol | | alkylbenzene | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulpiride | | benzamides;
N-alkylpyrrolidine;
sulfonamide | antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| suprofen | | aromatic ketone;
monocarboxylic acid;
thiophenes | antirheumatic drug;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| suramin | | naphthalenesulfonic acid;
phenylureas;
secondary carboxamide | angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-[4-(1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine | | stilbenoid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gatifloxacin | | N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2010 | 2011 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| tegafur | | organohalogen compound;
pyrimidines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| temazepam | | benzodiazepine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| temozolomide | | imidazotetrazine;
monocarboxylic acid amide;
triazene derivative | alkylating agent;
antineoplastic agent;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| terbutaline | | phenylethanolamines;
resorcinols | anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| terfenadine | | diarylmethane | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tetracaine | | benzoate ester;
tertiary amino compound | local anaesthetic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thalidomide | | phthalimides;
piperidones | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thiabendazole | | 1,3-thiazoles;
benzimidazole fungicide;
benzimidazoles | antifungal agrochemical;
antinematodal drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thioridazine | | phenothiazines;
piperidines | alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| tiaprofenic acid | | aromatic ketone;
monocarboxylic acid;
thiophenes | drug allergen;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ticlopidine | | monochlorobenzenes;
thienopyridine | anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tiopronin | | N-acyl-amino acid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tizanidine | | benzothiadiazole;
imidazoles | alpha-adrenergic agonist;
muscle relaxant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tolazamide | | N-sulfonylurea | hypoglycemic agent;
potassium channel blocker | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tolbutamide | | N-sulfonylurea | human metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tolperisone | | aromatic ketone | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]-N,N-dimethylethanamine | | stilbenoid | | 2017 | 2020 | 5.5 | high | 0 | 0 | 0 | 0 | 2 | 0 |
| ultram | | aromatic ether;
tertiary alcohol;
tertiary amino compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tranexamic acid | | amino acid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trazodone | | monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine | adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| triclosan | | aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols | antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trifluperidol | | aromatic ketone | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| triflupromazine | | organofluorine compound;
phenothiazines;
tertiary amine | anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trimethadione | | oxazolidinone | anticonvulsant;
geroprotector | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trimethoprim | | aminopyrimidine;
methoxybenzenes | antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| troglitazone | | chromanes;
thiazolidinone | anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| tyrphostin a9 | | alkylbenzene | geroprotector | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| delavirdine | | aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 6,18,30-trimethyl-3,9,12,15,21,24,27,33,36-nona(propan-2-yl)-1,7,13,19,25,31-hexaoxa-4,10,16,22,28,34-hexazacyclohexatriacontane-2,5,8,11,14,17,20,23,26,29,32,35-dodecone | | cyclodepsipeptide | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| venlafaxine | | cyclohexanols;
monomethoxybenzene;
tertiary alcohol;
tertiary amino compound | adrenergic uptake inhibitor;
analgesic;
antidepressant;
dopamine uptake inhibitor;
environmental contaminant;
serotonin uptake inhibitor;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vesnarinone | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vigabatrin | | gamma-amino acid | anticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| whi p180 | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 3-(5'-hydroxymethyl-2'-furyl)-1-benzylindazole | | aromatic primary alcohol;
furans;
indazoles | antineoplastic agent;
apoptosis inducer;
platelet aggregation inhibitor;
soluble guanylate cyclase activator;
vasodilator agent | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| ici 204,219 | | carbamate ester;
indoles;
N-sulfonylcarboxamide | anti-asthmatic agent;
leukotriene antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zolpidem | | imidazopyridine | central nervous system depressant;
GABA agonist;
sedative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zotepine | | dibenzothiepine;
tertiary amino compound | alpha-adrenergic drug;
second generation antipsychotic;
serotonergic drug | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| guanidine hydrochloride | | one-carbon compound;
organic chloride salt | protein denaturant | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| hydrocortisone acetate | | cortisol ester;
tertiary alpha-hydroxy ketone | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cortisone acetate | | corticosteroid hormone | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mitomycin | | mitomycin | alkylating agent;
antineoplastic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| prednisolone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| estriol | | 16alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid | estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| reserpine | | alkaloid ester;
methyl ester;
yohimban alkaloid | adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| cephaloridine | | beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative | antibacterial drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phentolamine | | imidazoles;
phenols;
substituted aniline;
tertiary amino compound | alpha-adrenergic antagonist;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sorbitol | | glucitol | cathartic;
Escherichia coli metabolite;
food humectant;
human metabolite;
laxative;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite;
sweetening agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| floxuridine | | nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| piperonyl butoxide | | benzodioxoles | pesticide synergist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bromouracil | | nucleobase analogue;
pyrimidines | mutagen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 3,3',5-triiodothyroacetic acid | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| histamine dihydrochloride | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thyroxine | | 2-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine | antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dextroamphetamine | | 1-phenylpropan-2-amine | adrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carbachol | | ammonium salt;
carbamate ester | cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| norethindrone acetate | | 3-oxo-Delta(4) steroid;
acetate ester;
terminal acetylenic compound | progestin;
synthetic oral contraceptive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| spironolactone | | 3-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester | aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyclobarbital | | barbiturates | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| allobarbital | | barbiturates | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| penicillamine | | non-proteinogenic alpha-amino acid;
penicillamine | antirheumatic drug;
chelator;
copper chelator;
drug allergen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trichlorfon | | organic phosphonate;
organochlorine compound;
phosphonic ester | agrochemical;
anthelminthic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
insecticide | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| prednisone | | 11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| estrone | | 17-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols | antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxandrolone | | 17beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid;
oxa-steroid | anabolic agent;
androgen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dehydroepiandrosterone | | 17-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
androstanoid | androgen;
human metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nad | | NAD | geroprotector | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| penicillin g | | penicillin allergen;
penicillin | antibacterial drug;
drug allergen;
epitope | 2010 | 2021 | 8.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| pilocarpine | | pilocarpine | antiglaucoma drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| triiodothyronine | | 2-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine | human metabolite;
mouse metabolite;
thyroid hormone | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chloramphenicol | | C-nitro compound;
carboxamide;
diol;
organochlorine compound | antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor | 2010 | 2021 | 8.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| glutamine | | amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid | EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cetrimonium bromide | | organic bromide salt;
quaternary ammonium salt | detergent;
surfactant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vincristine | | acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid | antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| physostigmine | | carbamate ester;
indole alkaloid | antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sucrose | | glycosyl glycoside | algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethinyl estradiol | | 17-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound | xenoestrogen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| testosterone propionate | | steroid ester | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| apomorphine | | aporphine alkaloid | alpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aminopyrine | | pyrazolone;
tertiary amino compound | antipyretic;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methyltestosterone | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
enone | anabolic agent;
androgen;
antineoplastic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tetrabenazine | | benzoquinolizine;
cyclic ketone;
tertiary amino compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cephalothin | | azabicycloalkene;
beta-lactam antibiotic allergen;
carboxylic acid;
cephalosporin;
semisynthetic derivative;
thiophenes | antibacterial drug;
antimicrobial agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| uridine | | uridines | drug metabolite;
fundamental metabolite;
human metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| kanamycin a | | kanamycins | bacterial metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenylephrine | | phenols;
phenylethanolamines;
secondary amino compound | alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| levodopa | | amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid | allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| niridazole | | 1,3-thiazoles;
C-nitro compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carbaryl | | carbamate ester;
naphthalenes | acaricide;
agrochemical;
carbamate insecticide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant growth retardant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lactose | | lactose | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methionine | | aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid | antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Mebutamate | | organic molecular entity | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| colchicine | | alkaloid;
colchicine | anti-inflammatory agent;
gout suppressant;
mutagen | 2010 | 2022 | 5.4 | low | 0 | 0 | 0 | 1 | 3 | 3 |
| cycloheximide | | antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol | anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| norethindrone | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol | progestin;
synthetic oral contraceptive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| norethynodrel | | oxo steroid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benziodarone | | aromatic ketone | | 2010 | 2020 | 7.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| ampicillin | | beta-lactam antibiotic;
penicillin allergen;
penicillin | antibacterial drug | 2010 | 2021 | 8.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| mannitol | | mannitol | allergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cytarabine | | beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside | antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| medroxyprogesterone acetate | | 20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester | adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mestranol | | 17beta-hydroxy steroid;
aromatic ether;
terminal acetylenic compound | prodrug;
xenoestrogen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methaqualone | | quinazolines | GABA agonist;
sedative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trypan blue | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| cordycepin | | 3'-deoxyribonucleoside;
adenosines | antimetabolite;
nucleoside antibiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tryptophan | | erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan | antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| arginine | | arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trichloroacetic acid | | monocarboxylic acid;
organochlorine compound | carcinogenic agent;
metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| triamcinolone acetonide | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone | anti-allergic agent;
anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| allylpropymal | | barbiturates | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| butobarbital | | barbiturates | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trichloroethylene | | chloroethenes | inhalation anaesthetic;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dehydrocholic acid | | 12-oxo steroid;
3-oxo-5beta-steroid;
7-oxo steroid;
oxo-5beta-cholanic acid | gastrointestinal drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyclizine | | N-alkylpiperazine | antiemetic;
central nervous system depressant;
cholinergic antagonist;
H1-receptor antagonist;
local anaesthetic | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methylprednisolone | | 6-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phanquinone | | orthoquinones | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| isosorbide dinitrate | | glucitol derivative;
nitrate ester | nitric oxide donor;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| synephrine | | ethanolamines;
phenethylamine alkaloid;
phenols | alpha-adrenergic agonist;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benzoyl peroxide | | carbonyl compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trehalose | | trehalose | Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| triclocarban | | dichlorobenzene;
monochlorobenzenes;
phenylureas | antimicrobial agent;
antiseptic drug;
disinfectant;
environmental contaminant;
xenobiotic | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| diphenan | | diarylmethane | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| 1,3-diphenylurea | | phenylureas | cytokinin;
plant metabolite | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2-phenylacetamide | | monocarboxylic acid amide | mouse metabolite | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| furan | | furans;
mancude organic heteromonocyclic parent;
monocyclic heteroarene | carcinogenic agent;
hepatotoxic agent;
Maillard reaction product | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ergotamine | | peptide ergot alkaloid | alpha-adrenergic agonist;
mycotoxin;
non-narcotic analgesic;
oxytocic;
serotonergic agonist;
vasoconstrictor agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| neostigmine bromide | | bromide salt | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenformin | | biguanides | antineoplastic agent;
geroprotector;
hypoglycemic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mephobarbital | | barbiturates | anticonvulsant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexachlorobenzene | | aromatic fungicide;
chlorobenzenes | antifungal agrochemical;
carcinogenic agent;
persistent organic pollutant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trinitrotoluene | | trinitrotoluene | explosive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| framycetin | | aminoglycoside | allergen;
antibacterial drug;
Escherichia coli metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyrazolanthrone | | anthrapyrazole;
aromatic ketone;
cyclic ketone | antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector | 2005 | 2022 | 12.0 | low | 0 | 0 | 0 | 2 | 1 | 1 |
| meglumine | | hexosamine;
secondary amino compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cinchophen | | quinolines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-tert-octylphenol | | alkylbenzene | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| tetraphenylborate | | | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| yohimbine | | methyl 17-hydroxy-20xi-yohimban-16-carboxylate | alpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mequinol | | methoxybenzenes;
phenols | metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| quinestrol | | 17-hydroxy steroid;
terminal acetylenic compound | xenoestrogen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cycloguanil hydrochloride | | hydrochloride;
organic molecular entity | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| cycloguanil | | triazines | antifolate;
antiinfective agent;
antimalarial;
antiparasitic agent;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dydrogesterone | | 20-oxo steroid;
3-oxo-Delta(4) steroid | progestin | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1,3-benzodioxole | | benzodioxole | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| triphenyltetrazolium | | organic cation | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ephedrine | | phenethylamine alkaloid;
phenylethanolamines | bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlormadinone acetate | | corticosteroid hormone | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2,3-dimercaptosuccinic acid | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| ethamivan | | methoxybenzenes;
phenols | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| evans blue | | organic sodium salt | fluorochrome;
histological dye;
sodium channel blocker;
teratogenic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| testosterone enanthate | | heptanoate ester;
sterol ester | androgen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aminophylline | | mixture | bronchodilator agent;
cardiotonic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| azacitidine | | N-glycosyl-1,3,5-triazine;
nucleoside analogue | antineoplastic agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| phenyramidol | | aminopyridine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carbutamide | | benzenes;
sulfonamide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nandrolone decanoate | | steroid ester | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methysergide | | ergoline alkaloid | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| bucladesine | | 3',5'-cyclic purine nucleotide;
butanamides;
butyrate ester | agonist;
cardiotonic drug;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| betamethasone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | anti-asthmatic agent;
anti-inflammatory drug;
immunosuppressive agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| perflubron | | haloalkane;
organobromine compound;
perfluorinated compound | blood substitute;
radioopaque medium | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyproterone acetate | | 20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
chlorinated steroid;
steroid ester | androgen antagonist;
geroprotector;
progestin | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dextropropoxyphene | | 1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate | mu-opioid receptor agonist;
opioid analgesic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glycyrrhetinic acid | | cyclic terpene ketone;
hydroxy monocarboxylic acid;
pentacyclic triterpenoid | immunomodulator;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chenodeoxycholic acid | | bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid | human metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| berbamine | | phenylpropanoid | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| plumbagin | | hydroxy-1,4-naphthoquinone;
phenols | anticoagulant;
antineoplastic agent;
immunological adjuvant;
metabolite | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| emetine | | isoquinoline alkaloid;
pyridoisoquinoline | antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor | 2008 | 2022 | 7.8 | low | 0 | 0 | 0 | 1 | 4 | 1 |
| dihydralazine | | phthalazines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenylpropanolamine | | amphetamines;
phenethylamine alkaloid | plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dihydroergotamine | | ergot alkaloid;
semisynthetic derivative | dopamine agonist;
non-narcotic analgesic;
serotonergic agonist;
sympatholytic agent;
vasoconstrictor agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| podophyllotoxin | | furonaphthodioxole;
lignan;
organic heterotetracyclic compound | antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator | 2010 | 2022 | 7.2 | low | 0 | 0 | 0 | 1 | 4 | 1 |
| hesperidin | | 3'-hydroxyflavanones;
4'-methoxyflavanones;
dihydroxyflavanone;
disaccharide derivative;
flavanone glycoside;
monomethoxyflavanone;
rutinoside | mutagen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dequalinium chloride | | organic chloride salt | antifungal agent;
antineoplastic agent;
antiseptic drug;
mitochondrial NADH:ubiquinone reductase inhibitor | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| chlormethiazole | | thiazoles | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methamphetamine | | amphetamines;
secondary amine | central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gentian violet | | organic chloride salt | anthelminthic drug;
antibacterial agent;
antifungal agent;
antiseptic drug;
histological dye | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| hematoporphyrin | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| formestane | | 17-oxo steroid;
3-oxo-Delta(4) steroid;
enol;
hydroxy steroid | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lactulose | | glycosylfructose | gastrointestinal drug;
laxative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| megestrol acetate | | 20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester | antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acetylcysteine | | acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid | antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| n-methylpiperidine | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Berberine chloride (TN) | | organic molecular entity | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| erythromycin stearate | | aminoglycoside | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| erythromycin | | cyclic ketone;
erythromycin | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hydroxychloroquine sulfate | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 9,10-dimethylanthracene | | | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| vinblastine | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| etonitazene | | | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| estradiol valerate | | steroid ester | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| c 137 | | | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| vancomycin | | glycopeptide | antibacterial drug;
antimicrobial agent;
bacterial metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| d-alpha tocopherol | | alpha-tocopherol | algal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dronabinol | | benzochromene;
diterpenoid;
phytocannabinoid;
polyketide | cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amiloride hydrochloride, anhydrous | | hydrochloride | diuretic;
sodium channel blocker | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amiloride | | aromatic amine;
guanidines;
organochlorine compound;
pyrazines | diuretic;
sodium channel blocker | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clothiapine | | dibenzothiazepine | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| pimozide | | benzimidazoles;
heteroarylpiperidine;
organofluorine compound | antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benperidol | | aromatic ketone | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| 7-hydroxychlorpromazine | | phenothiazines | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| sulfadoxine | | pyrimidines;
sulfonamide | antibacterial drug;
antimalarial | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acadesine | | 1-ribosylimidazolecarboxamide;
aminoimidazole;
nucleoside analogue | antineoplastic agent;
platelet aggregation inhibitor | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| stavudine | | dihydrofuran;
nucleoside analogue;
organic molecular entity | antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| doxifluridine | | organofluorine compound;
pyrimidine 5'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| palmatine | | berberine alkaloid;
organic heterotetracyclic compound | plant metabolite | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| iproclozide | | aromatic ether | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| streptomycin | | antibiotic antifungal drug;
antibiotic fungicide;
streptomycins | antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4,6-diamino-2,2-dimethyl-1,2-dihydro-1-phenyl-s-triazine | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cladribine | | organochlorine compound;
purine 2'-deoxyribonucleoside | antineoplastic agent;
immunosuppressive agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| carbenicillin disodium | | organic sodium salt | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dehydroemetine | | aromatic ether;
isoquinolines;
pyridoisoquinoline | antileishmanial agent;
antimalarial;
antiprotozoal drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benorilate | | carbonyl compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trimetazidine | | aromatic amine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| floxacillin | | penicillin allergen;
penicillin | antibacterial drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| buquinolate | | | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| vidarabine | | beta-D-arabinoside;
purine nucleoside | antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tiadenol | | aliphatic sulfide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zalcitabine | | pyrimidine 2',3'-dideoxyribonucleoside | antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| camptothecin | | delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite | 2010 | 2020 | 7.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| stanozolol | | 17beta-hydroxy steroid;
anabolic androgenic steroid;
organic heteropentacyclic compound;
tertiary alcohol | anabolic agent;
androgen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clodronic acid | | 1,1-bis(phosphonic acid);
one-carbon compound;
organochlorine compound | antineoplastic agent;
bone density conservation agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| xipamide | | benzamides | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| selegiline | | selegiline;
terminal acetylenic compound | geroprotector | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| levamisole | | 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole | antinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thiamphenicol | | monocarboxylic acid amide;
sulfone | antimicrobial agent;
immunosuppressive agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pizotyline | | benzocycloheptathiophene | histamine antagonist;
muscarinic antagonist;
serotonergic antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isosorbide-5-mononitrate | | glucitol derivative;
nitrate ester | nitric oxide donor;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thenalidine | | dialkylarylamine;
tertiary amino compound | | 2017 | 2022 | 4.5 | medium | 0 | 0 | 0 | 0 | 3 | 1 |
| danazol | | 17beta-hydroxy steroid;
terminal acetylenic compound | anti-estrogen;
estrogen antagonist;
geroprotector | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| daunorubicin | | aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones | antineoplastic agent;
bacterial metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carbimazole | | 1,3-dihydroimidazole-2-thiones;
carbamate ester | antithyroid drug;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bromocriptine | | indole alkaloid | antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist | 2010 | 2020 | 7.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| triamcinolone | | 11beta-hydroxy steroid;
16alpha-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | anti-allergic agent;
anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxyphenisatin | | indoles | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tetrachloroethylene | | chlorocarbon;
chloroethenes | nephrotoxic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ursodeoxycholic acid | | bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid | human metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| butachlor | | aromatic amide;
organochlorine compound;
tertiary carboxamide | environmental contaminant;
herbicide;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rose bengal b disodium salt | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glutamic acid | | glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dexchlorpheniramine | | chlorphenamine | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| cefazolin | | beta-lactam antibiotic allergen;
cephalosporin;
tetrazoles;
thiadiazoles | antibacterial drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amoxicillin | | penicillin allergen;
penicillin | antibacterial drug | 2010 | 2021 | 8.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| timolol | | timolol | anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dv 1006 | | | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| nicergoline | | organic heterotetracyclic compound;
organonitrogen heterocyclic compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxcarbazepine | | cyclic ketone;
dibenzoazepine | anticonvulsant;
drug allergen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amineptin | | amino acid;
carbocyclic fatty acid;
carbotricyclic compound;
secondary amino compound | antidepressant;
dopamine uptake inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zidovudine | | azide;
pyrimidine 2',3'-dideoxyribonucleoside | antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pirprofen | | pyrroline | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tobramycin | | amino cyclitol glycoside | antibacterial agent;
antimicrobial agent;
toxin | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| paclitaxel | | taxane diterpenoid;
tetracyclic diterpenoid | antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent | 2010 | 2014 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| etoposide | | beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound | antineoplastic agent;
DNA synthesis inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dobutamine | | catecholamine;
secondary amine | beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| propranolol glycol | | | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| ribavirin | | 1-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide | anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amikacin | | alpha-D-glucoside;
amino cyclitol glycoside;
aminoglycoside;
carboxamide | antibacterial drug;
antimicrobial agent;
nephrotoxin | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| climbazole | | aromatic ether;
hemiaminal ether;
imidazoles;
ketone;
monochlorobenzenes | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| ticrynafen | | aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid;
thiophenes | antihypertensive agent;
hepatotoxic agent;
loop diuretic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methyldopa | | L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid | alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bezafibrate | | aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes | antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sq-11725 | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diltiazem | | 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate | antihypertensive agent;
calcium channel blocker;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lonidamine | | dichlorobenzene;
indazoles;
monocarboxylic acid | antineoplastic agent;
antispermatogenic agent;
EC 2.7.1.1 (hexokinase) inhibitor;
geroprotector | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benoxaprofen | | 1,3-benzoxazoles;
monocarboxylic acid;
monochlorobenzenes | antipsoriatic;
antipyretic;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
hepatotoxic agent;
nephrotoxin;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
protein kinase C agonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| permethrin | | cyclopropanecarboxylate ester;
cyclopropanes | agrochemical;
ectoparasiticide;
pyrethroid ester acaricide;
pyrethroid ester insecticide;
scabicide | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pirfenidone | | pyridone | antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mefloquine | | [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol | antimalarial | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| desogestrel | | 17beta-hydroxy steroid;
terminal acetylenic compound | contraceptive drug;
progestin;
synthetic oral contraceptive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| triadimenol | | aromatic ether;
conazole fungicide;
hemiaminal ether;
monochlorobenzenes;
secondary alcohol;
triazole fungicide | antifungal agrochemical;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
xenobiotic metabolite | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| muzolimine | | dichlorobenzene | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acarbose | | tetrasaccharide derivative | EC 3.2.1.1 (alpha-amylase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
geroprotector;
hypoglycemic agent | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| epirubicin | | aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| desflurane | | organofluorine compound | inhalation anaesthetic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| naphthoxybutanolcyclohexylamine | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| piperacillin | | penicillin allergen;
penicillin | antibacterial drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| paroxetine | | aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines | antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| triciribine phosphate | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| captopril | | alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cefoperazone | | cephalosporin | antibacterial drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| staurosporine | | indolocarbazole alkaloid;
organic heterooctacyclic compound | apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector | 2005 | 2021 | 10.2 | low | 0 | 0 | 0 | 2 | 5 | 2 |
| foscarnet sodium | | one-carbon compound;
organic sodium salt | antiviral drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| moxalactam | | cephalosporin;
oxacephem | antibacterial drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nicorandil | | nitrate ester;
pyridinecarboxamide | potassium channel opener;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cefadroxil anhydrous | | cephalosporin | antibacterial drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| encainide | | benzamides;
piperidines | anti-arrhythmia drug;
sodium channel blocker | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amonafide | | isoquinolines | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| cefaclor anhydrous | | cephalosporin | antibacterial drug;
drug allergen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| miglustat | | piperidines;
tertiary amino compound | anti-HIV agent;
EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cefotetan | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lovastatin | | delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring) | anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| flupirtine | | aminopyridine | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| chaetochromin | | | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| enoximone | | aromatic ketone | | 2010 | 2020 | 7.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| piritrexim | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| simvastatin | | delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic) | EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pravastatin | | 3-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic) | anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| atomoxetine hydrochloride | | hydrochloride | adrenergic uptake inhibitor;
antidepressant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| quinapril | | dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gepirone | | N-arylpiperazine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mifepristone | | 3-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound | abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| itraconazole | | aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles | EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pravadoline | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sparfloxacin | | fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zileuton | | 1-benzothiophenes;
ureas | anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| niguldipine | | diarylmethane | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clopidogrel | | methyl ester;
monochlorobenzenes;
thienopyridine | anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cidofovir anhydrous | | phosphonic acids;
pyrimidone | anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| topotecan | | pyranoindolizinoquinoline | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| eliprodil | | monochlorobenzenes;
monofluorobenzenes;
piperidines;
secondary alcohol;
tertiary amino compound | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bromfenac | | aromatic amino acid;
benzophenones;
organobromine compound;
substituted aniline | non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gemcitabine | | organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aripiprazole | | aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone | drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| atorvastatin | | aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic) | environmental contaminant;
xenobiotic | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| lamivudine | | monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol | allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| duloxetine | | duloxetine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| irinotecan | | carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| valsartan | | biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| adefovir dipivoxil | | 6-aminopurines;
carbonate ester;
ether;
organic phosphonate | antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| capecitabine | | carbamate ester;
cytidines;
organofluorine compound | antimetabolite;
antineoplastic agent;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| adenosine | | adenosines;
purines D-ribonucleoside | analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| halofuginone | | quinazolines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ortho-cept | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| verapamil hydrochloride | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cefprozil | | cephalosporin;
semisynthetic derivative | antibacterial drug | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol | | stilbenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| efavirenz | | acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2010 | 2022 | 9.0 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| nelfinavir | | aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound | antineoplastic agent;
HIV protease inhibitor | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| doxapram hydrochloride | | hydrochloride | central nervous system stimulant | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| propamidine | | aromatic ether;
guanidines;
polyether | antimicrobial agent;
antiseptic drug | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1,5-anhydroglucitol | | anhydro sugar | human metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| norharman | | beta-carbolines;
mancude organic heterotricyclic parent | fungal metabolite;
marine metabolite | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| betulinic acid | | hydroxy monocarboxylic acid;
pentacyclic triterpenoid | anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amprenavir | | carbamate ester;
sulfonamide;
tetrahydrofuryl ester | antiviral drug;
HIV protease inhibitor | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| thionine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| neocuproine | | phenanthrolines | chelator;
copper chelator | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mefloquine hydrochloride | | hydrochloride | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glutathione disulfide | | glutathione derivative;
organic disulfide | Escherichia coli metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bendamustine | | benzimidazoles | | 2010 | 2021 | 9.3 | medium | 0 | 0 | 0 | 1 | 1 | 1 |
| erdosteine | | N-acyl-amino acid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aloxistatin | | epoxide;
ethyl ester;
L-leucine derivative;
monocarboxylic acid amide | anticoronaviral agent;
cathepsin B inhibitor | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| caroverine | | quinoxaline derivative | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| indocate | | | | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| mizolastine | | benzimidazoles | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cgs 9343b | | benzimidazoles | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| intoplicine | | pyridoindole | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| telmisartan | | benzimidazoles;
biphenyls;
carboxybiphenyl | angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic | 2010 | 2022 | 9.0 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| dexfenfluramine | | fenfluramine | appetite depressant;
serotonergic agonist;
serotonin uptake inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-methoxyestradiol | | 17beta-hydroxy steroid;
3-hydroxy steroid | angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| toxoflavin | | carbonyl compound;
pyrimidotriazine | antibacterial agent;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite;
toxin;
virulence factor;
Wnt signalling inhibitor | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| N(4)-acetylsulfathiazole | | 1,3-thiazoles;
acetamides;
sulfonamide | marine xenobiotic metabolite | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| cyclizine hydrochloride | | | | 2017 | 2020 | 5.5 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| 2,3-trimethylene-4-quinazolone | | quinazolines | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| medetomidine | | imidazoles | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sertraline | | dichlorobenzene;
secondary amino compound;
tetralins | antidepressant;
serotonin uptake inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| picosulfate sodium | | aryl sulfate;
pyridines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| selfotel | | non-proteinogenic alpha-amino acid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| plasmenylserine | | O-phosphoserine | EC 1.4.7.1 [glutamate synthase (ferredoxin)] inhibitor;
EC 2.5.1.49 (O-acetylhomoserine aminocarboxypropyltransferase) inhibitor;
EC 4.3.1.10 (serine-sulfate ammonia-lyase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dienogest | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
aliphatic nitrile;
steroid hormone | progesterone receptor agonist;
progestin;
synthetic oral contraceptive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| quinocide | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1,3-dimethyluric acid | | oxopurine | metabolite | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| morphazinamide | | morpholines;
pyrazines;
secondary carboxamide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2,2',2''-terpyridine | | terpyridines | chelator | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| danofloxacin | | quinolines | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| dexrazoxane | | razoxane | antineoplastic agent;
cardiovascular drug;
chelator;
immunosuppressive agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clobetasone butyrate | | organic molecular entity | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| voriconazole | | conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug | P450 inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| secnidazole | | C-nitro compound;
imidazoles;
secondary alcohol | epitope | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cletoquine | | | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| nitrefazole | | imidazoles | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| alacepril | | dipeptide;
thioacetate ester | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cyclobutyrol | | hydroxy monocarboxylic acid | bile therapy drug | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| terlipressin | | polypeptide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ubenimex | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methotrimeprazine | | phenothiazines;
tertiary amine | anticoronaviral agent;
cholinergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
non-narcotic analgesic;
phenothiazine antipsychotic drug;
serotonergic antagonist | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| honokiol | | biphenyls | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| isoflavone | | isoflavones | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| jatrorrhizine | | alkaloid | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clevudine | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lycorine | | indolizidine alkaloid | anticoronaviral agent;
antimalarial;
plant metabolite;
protein synthesis inhibitor | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| picropodophyllin | | furonaphthodioxole;
lignan;
organic heterotetracyclic compound | antineoplastic agent;
insulin-like growth factor receptor 1 antagonist;
plant metabolite;
tyrosine kinase inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 9-methoxyellipticine | | | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| 3-aminophenoxazone | | phenoxazine | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| bathophenanthroline | | benzenes;
phenanthrolines | chelator | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| tetrandrine | | bisbenzylisoquinoline alkaloid;
isoquinolines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 3-deazaneplanocin | | | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| fascaplysine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| LSM-4272 | | beta-carbolines | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tryptanthrine | | alkaloid antibiotic;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound | | 2008 | 2020 | 9.0 | low | 0 | 0 | 0 | 1 | 4 | 0 |
| atovaquone | | hydroxy-1,2-naphthoquinone | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 2-chlorodiazepam | | | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| Polycartine B | | phenazines | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| rosiglitazone | | aminopyridine;
thiazolidinediones | EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aminoquinuride dihydrochloride | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| clarithromycin | | macrolide antibiotic | antibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethylhydrocupreine | | aromatic ether;
cinchona alkaloid | EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 2,4-diamino-5,6-dihydro-6,6-dimethyl-5-(4'-methoxyphenyl)-s-triazine | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nicotine | | 3-(1-methylpyrrolidin-2-yl)pyridine | anxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cinchonine | | (8xi)-cinchonan-9-ol;
cinchona alkaloid | metabolite | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| thioproperazine mesylate | | phenothiazines | | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| n(6)-(delta(2)-isopentenyl)adenine | | 6-isopentenylaminopurine | cytokinin | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| lopinavir | | amphetamines;
dicarboxylic acid diamide | anticoronaviral agent;
antiviral drug;
HIV protease inhibitor | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| 7-chloro-4-aminoquinoline | | aminoquinoline | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mmv665852 | | | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| 4-methyl-N-(phenylmethyl)benzenesulfonamide | | sulfonamide | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| 1,3,4,10-Tetrahydro-9(2H)-acridinone | | acridines | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| eupatorin | | dihydroxyflavone;
polyphenol;
trimethoxyflavone | anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
Brassica napus metabolite;
calcium channel blocker;
P450 inhibitor;
vasodilator agent | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| wr 158122 | | | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| zpck | | | | 2019 | 2020 | 4.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| 10-deazaaminopterin | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sr141716 | | amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles | anti-obesity agent;
appetite depressant;
CB1 receptor antagonist | 2010 | 2022 | 6.4 | low | 0 | 0 | 0 | 1 | 3 | 1 |
| bosentan anhydrous | | primary alcohol;
pyrimidines;
sulfonamide | antihypertensive agent;
endothelin receptor antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| selenomethionine | | amino acid zwitterion;
selenomethionine | plant metabolite | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| vinpocetine | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| (6R)-7-[4-(dimethylamino)phenyl]-N-hydroxy-4,6-dimethyl-7-oxohepta-2,4-dienamide | | aromatic ketone | | 2017 | 2020 | 5.5 | high | 0 | 0 | 0 | 0 | 2 | 0 |
| dihydroergocristine | | ergot alkaloid | adrenergic antagonist;
vasodilator agent | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| n-(2'-(dimethylamino)ethyl)acridine-4-carboxamide | | | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| perindopril | | alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| deguelin | | aromatic ether;
diether;
organic heteropentacyclic compound;
rotenones | angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
mitochondrial NADH:ubiquinone reductase inhibitor;
plant metabolite | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fingolimod | | aminodiol;
primary amino compound | antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist | 2010 | 2020 | 7.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| triptolide | | diterpenoid;
epoxide;
gamma-lactam;
organic heteroheptacyclic compound | antispermatogenic agent;
plant metabolite | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tesmilifene | | diarylmethane | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| benzamil | | guanidines;
pyrazines | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ecteinascidin 743 | | acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound | alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 3',4'-dichlorobenzamil | | guanidines;
pyrazines | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nitisinone | | (trifluoromethyl)benzenes;
C-nitro compound;
cyclohexanones;
mesotrione | EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| marimastat | | hydroxamic acid;
secondary carboxamide | antineoplastic agent;
matrix metalloproteinase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clofarabine | | adenosines;
organofluorine compound | antimetabolite;
antineoplastic agent | 2010 | 2021 | 8.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| sr 48692 | | N-acyl-amino acid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| elacridar | | | | 2013 | 2022 | 6.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| cleistanthin b | | beta-D-glucoside;
cleistanthins;
monosaccharide derivative | alpha-adrenergic antagonist;
antihypertensive agent;
diuretic | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| n-acetyltyramine | | acetamides;
tyramines | animal metabolite;
Aspergillus metabolite;
bacterial metabolite;
marine metabolite;
quorum sensing inhibitor | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mitiglinide | | benzenes;
monocarboxylic acid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sr 27897 | | indolyl carboxylic acid | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| saccharolactone | | aldarolactone;
delta-lactone | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 1,3-di(4-imidazolinophenoxyl)propane | | | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| imatinib mesylate | | methanesulfonate salt | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gefitinib | | aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 2005 | 2022 | 10.5 | low | 0 | 0 | 0 | 5 | 10 | 3 |
| n-(n-(3-carboxyoxirane-2-carbonyl)leucyl)isoamylamine | | leucine derivative | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine | | adenosines;
monocarboxylic acid amide;
organoiodine compound | adenosine A3 receptor agonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bay x 1005 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| norketamine | | organochlorine compound | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| indatraline | | indanes | | 2019 | 2020 | 4.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| lestaurtinib | | indolocarbazole | | 2011 | 2017 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| gyki 53655 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methotrexate | | dicarboxylic acid;
monocarboxylic acid amide;
pteridines | abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent | 2010 | 2020 | 7.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| salvinorin a | | organic heterotricyclic compound;
organooxygen compound | metabolite;
oneirogen | 2019 | 2022 | 3.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| antiprimod | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulbactam | | penicillanic acids | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 7h-pyrido(4,3-c)carbazole | | | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| olmesartan medoxomil | | biphenyls | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-diethoxyphosphorylmethyl-n-(4-bromo-2-cyanophenyl)benzamide | | | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| n,n-di-n-hexyl-2-(4-fluorophenyl)indole-3-acetamide | | phenylindole | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| ilomastat | | hydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid | anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ml-3000 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ns 1608 | | ureas | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| imiloxan | | benzodioxine | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| l 741626 | | piperidines | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| cl 246738 | | | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| febuxostat | | 1,3-thiazolemonocarboxylic acid;
aromatic ether;
nitrile | EC 1.17.3.2 (xanthine oxidase) inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cd 437 | | adamantanes;
monocarboxylic acid;
naphthoic acid;
phenols | apoptosis inducer;
retinoic acid receptor gamma agonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 10-propargyl-10-deazaaminopterin | | N-acyl-L-glutamic acid;
pteridines;
terminal acetylenic compound | antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| docetaxel | | hydrate;
secondary alpha-hydroxy ketone | antineoplastic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| docetaxel anhydrous | | secondary alpha-hydroxy ketone;
tetracyclic diterpenoid | antimalarial;
antineoplastic agent;
photosensitizing agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| perifosine | | ammonium betaine;
phospholipid | EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 2013 | 2017 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| atazanavir | | carbohydrazide | antiviral drug;
HIV protease inhibitor | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| levofloxacin | | 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic | antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor | 2010 | 2021 | 8.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| ezetimibe | | azetidines;
beta-lactam;
organofluorine compound | anticholesteremic drug;
antilipemic drug;
antimetabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dx 8951 | | pyranoindolizinoquinoline | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| cariporide | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tezosentan | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mk 767 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ptk 787 | | succinate salt | angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist | 2002 | 2002 | 22.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| vatalanib | | monochlorobenzenes;
phthalazines;
pyridines;
secondary amino compound | angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist | 2002 | 2017 | 15.8 | low | 0 | 0 | 0 | 12 | 5 | 0 |
| moxifloxacin | | aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antibacterial drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ruboxistaurin | | | | 2005 | 2017 | 13.6 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| jtt 501 | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bazedoxifene acetate | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| naproxen | | methoxynaphthalene;
monocarboxylic acid | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| canertinib dihydrochloride | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| canertinib | | monochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines | antineoplastic agent;
tyrosine kinase inhibitor | 2005 | 2019 | 10.9 | low | 0 | 0 | 0 | 2 | 5 | 0 |
| birb 796 | | aromatic ether;
morpholines;
naphthalenes;
pyrazoles;
ureas | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
immunomodulator | 2005 | 2013 | 14.2 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| tipifarnib | | imidazoles;
monochlorobenzenes;
primary amino compound;
quinolone | antineoplastic agent;
apoptosis inducer;
EC 2.5.1.58 (protein farnesyltransferase) inhibitor | 2013 | 2020 | 6.8 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| celastrol methyl ester | | carboxylic ester | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cyc 202 | | 2,6-diaminopurines | antiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 2005 | 2022 | 9.8 | low | 0 | 0 | 0 | 3 | 6 | 1 |
| epiberberine | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2-phenyl-4-oxohydroquinoline | | | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| paromomycin | | amino cyclitol glycoside;
aminoglycoside antibiotic | anthelminthic drug;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| avasimibe | | monoterpenoid | | 2010 | 2020 | 7.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| biotin | | biotins;
vitamin B7 | coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| atropine | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cypripedin | | phenanthrol | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| sb 203580 | | imidazoles;
monofluorobenzenes;
pyridines;
sulfoxide | EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent | 2005 | 2022 | 12.4 | low | 0 | 0 | 0 | 2 | 4 | 1 |
| enzastaurin | | indoles;
maleimides | | 2011 | 2017 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| erlotinib | | aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound | antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor | 2005 | 2022 | 8.4 | low | 0 | 0 | 0 | 2 | 10 | 4 |
| piboserod | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| l 163191 | | | | 2013 | 2022 | 5.8 | medium | 0 | 0 | 0 | 0 | 4 | 1 |
| dizocilpine | | secondary amino compound;
tetracyclic antidepressant | anaesthetic;
anticonvulsant;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| bd 1047 | | primary amine | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| respinomycin d | | | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| azacrin | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| s-benzylcysteine | | S-aryl-L-cysteine zwitterion | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| chelidonine | | alkaloid antibiotic;
alkaloid fundamental parent;
benzophenanthridine alkaloid | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| troleandomycin | | acetate ester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyketide;
semisynthetic derivative | EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| orantinib | | monocarboxylic acid;
oxindoles;
pyrroles | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| lapatinib | | furans;
organochlorine compound;
organofluorine compound;
quinazolines | antineoplastic agent;
tyrosine kinase inhibitor | 2005 | 2022 | 7.7 | low | 0 | 0 | 0 | 2 | 10 | 5 |
| deferasirox | | benzoic acids;
monocarboxylic acid;
phenols;
triazoles | iron chelator | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tbc-11251 | | benzodioxoles | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sorafenib | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide | angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor | 2005 | 2022 | 9.0 | low | 0 | 0 | 0 | 3 | 13 | 4 |
| lenalidomide | | aromatic amine;
dicarboximide;
isoindoles;
piperidones | angiogenesis inhibitor;
antineoplastic agent;
immunomodulator | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| N-[4-(3-chloro-4-fluoroanilino)-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide | | aminoquinoline | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| roxindole | | indoles | alpha-adrenergic antagonist;
serotonergic drug | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| sr 142806 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| conidendrin | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| sitosterol, (3beta)-isomer | | 3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
C29-steroid;
phytosterols;
stigmastane sterol | anticholesteremic drug;
antioxidant;
mouse metabolite;
plant metabolite;
sterol methyltransferase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acetoxycycloheximide | | | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| (R)-Roemerine | | isoquinoline alkaloid | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| Porfiromycine | | mitomycin | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| anisomycin | | monohydroxypyrrolidine;
organonitrogen heterocyclic antibiotic | anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
antiparasitic agent;
bacterial metabolite;
DNA synthesis inhibitor;
protein synthesis inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benzarone | | 1-benzofurans | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| estramustine | | 17beta-hydroxy steroid;
carbamate ester;
organochlorine compound | alkylating agent;
antineoplastic agent;
radiation protective agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nsc 95397 | | 1,4-naphthoquinones | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| 4-methyl-2-quinazolinamine | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| noscapine | | aromatic ether;
benzylisoquinoline alkaloid;
cyclic acetal;
isobenzofuranone;
organic heterobicyclic compound;
organic heterotricyclic compound;
tertiary amino compound | antineoplastic agent;
antitussive;
apoptosis inducer;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-glycineamide-5-chlorophenyl-2-pyrryl ketone | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| homoharringtonine | | alkaloid ester;
enol ether;
organic heteropentacyclic compound;
tertiary alcohol | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
protein synthesis inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| elesclomol | | carbohydrazide;
thiocarbonyl compound | antineoplastic agent;
apoptosis inducer | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2-guanidine-4-methylquinazoline | | | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| niguldipine hydrochloride | | | | 2019 | 2020 | 4.5 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| o-(chloroacetylcarbamoyl)fumagillol | | carbamate ester;
organochlorine compound;
semisynthetic derivative;
sesquiterpenoid;
spiro-epoxide | angiogenesis inhibitor;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
methionine aminopeptidase 2 inhibitor;
retinoic acid receptor alpha antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| jatrorrhizine chloride | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| 2,5-bis(5-hydroxymethyl-2-thienyl)furan | | thiophenes | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| nsc 663284 | | quinolone | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bortezomib | | amino acid amide;
L-phenylalanine derivative;
pyrazines | antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ritonavir | | 1,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas | antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic | 2010 | 2022 | 6.4 | low | 0 | 0 | 0 | 1 | 3 | 1 |
| bardoxolone methyl | | cyclohexenones | | 2013 | 2019 | 8.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| mensacarcin | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| tryptoquivaline | | aromatic ether;
indole alkaloid;
organic heteropentacyclic compound | breast cancer resistance protein inhibitor;
mycotoxin | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| nexavar | | organosulfonate salt | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nsc 23766 | | aminopyrimidine;
aminoquinoline;
primary amino compound;
secondary amino compound;
tertiary amino compound | antiviral agent;
apoptosis inducer;
EC 3.6.5.2 (small monomeric GTPase) inhibitor;
muscarinic antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Destruxin B | | cyclodepsipeptide | | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| glucosamine | | D-glucosamine | Escherichia coli metabolite;
geroprotector;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bekanamycin | | kanamycins | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| puromycin | | puromycins | antiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| tosylphenylalanyl chloromethyl ketone | | alpha-chloroketone;
sulfonamide | alkylating agent;
serine proteinase inhibitor | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| quinidine | | cinchona alkaloid | alpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker | 2008 | 2011 | 14.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| meropenem | | alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide | antibacterial agent;
antibacterial drug;
drug allergen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| griseofulvin | | 1-benzofurans;
antibiotic antifungal drug;
benzofuran antifungal drug;
organochlorine compound;
oxaspiro compound | antibacterial agent;
Penicillium metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| digitoxin | | cardenolide glycoside | EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| saquinavir | | L-asparagine derivative;
quinolines | antiviral drug;
HIV protease inhibitor | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| abacavir | | 2,6-diaminopurines | antiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| netilmicin | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trimethaphan camsylate | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| erythromycin estolate | | aminoglycoside sulfate salt;
erythromycin derivative | enzyme inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cephaelin | | pyridoisoquinoline | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cyclopamine | | piperidines | glioma-associated oncogene inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 6-prenylchrysin | | 7-hydroxyflavonol;
dihydroxyflavone | | 2022 | 2022 | 2.0 | high | 0 | 0 | 0 | 0 | 0 | 2 |
| devazepide | | 1,4-benzodiazepinone;
indolecarboxamide | antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tolterodine | | tertiary amine | antispasmodic drug;
muscarinic antagonist;
muscle relaxant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| doxorubicin hydrochloride | | anthracycline | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| erythromycin ethylsuccinate | | cyclic ketone;
erythromycin derivative;
ethyl ester;
succinate ester | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ao 128 | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acarbose | | amino cyclitol;
glycoside | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trichostatin a | | antibiotic antifungal agent;
hydroxamic acid;
trichostatin | bacterial metabolite;
EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector | 2008 | 2021 | 8.0 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| tretinoin | | retinoic acid;
vitamin A | anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| retinol | | retinol;
vitamin A | human metabolite;
mouse metabolite;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| alpha-D-fructofuranose 1,6-bisphosphate | | D-fructofuranose 1,6-bisphosphate | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| docosahexaenoate | | docosahexaenoic acid;
omega-3 fatty acid | algal metabolite;
antineoplastic agent;
Daphnia tenebrosa metabolite;
human metabolite;
mouse metabolite;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oleic acid | | octadec-9-enoic acid | antioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tacrolimus | | macrolide lactam | bacterial metabolite;
immunosuppressive agent | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| cerivastatin | | dihydroxy monocarboxylic acid;
pyridines;
statin (synthetic) | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rosuvastatin | | dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrimidines;
statin (synthetic);
sulfonamide | anti-inflammatory agent;
antilipemic drug;
cardioprotective agent;
CETP inhibitor;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cocaine | | benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid | adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| eicosapentaenoic acid | | icosapentaenoic acid;
omega-3 fatty acid | anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mycophenolic acid | | 2-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols | anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clindamycin | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fosfomycin | | epoxide;
phosphonic acids | antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zithromax | | macrolide antibiotic | antibacterial drug;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pd 173955 | | aryl sulfide;
dichlorobenzene;
methyl sulfide;
pyridopyrimidine | tyrosine kinase inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| drf 2725 | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gw 3965 | | diarylmethane | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| epothilone b | | epothilone;
epoxide | antineoplastic agent;
apoptosis inducer;
microtubule-stabilising agent | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| y 27632 | | aromatic amide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| diethylstilbestrol | | olefinic compound;
polyphenol | antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 6-bromoindirubin-3'-oxime | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| purvalanol b | | purvalanol | protein kinase inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| y-700 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| repsox | | pyrazolopyridine | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alitretinoin | | retinoic acid | antineoplastic agent;
keratolytic drug;
metabolite;
retinoid X receptor agonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| decitabine | | 2'-deoxyribonucleoside | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| teniposide | | aromatic ether;
beta-D-glucoside;
cyclic acetal;
furonaphthodioxole;
gamma-lactone;
monosaccharide derivative;
phenols;
thiophenes | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ketoconazole | | cis-1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| wr-142,490 | | [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol | antimalarial | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| artenimol | | | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dactinomycin | | actinomycin | mutagen | 2008 | 2011 | 14.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| tiazofurin | | 1,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide | antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| melphalan | | L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound | alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1,3,6-trimethylpyrimido[5,4-e][1,2,4]triazine-5,7-dione | | pyrimidotriazine | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| sitafloxacin | | fluoroquinolone antibiotic;
quinolines;
quinolone antibiotic | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tenofovir | | nucleoside analogue;
phosphonic acids | antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| posaconazole | | aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles | trypanocidal drug | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| rubitecan | | C-nitro compound;
delta-lactone;
pyranoindolizinoquinoline;
semisynthetic derivative;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| micafungin | | antibiotic antifungal drug;
echinocandin | antiinfective agent | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| 4,4-difluoro-N-[(1S)-3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-phenylpropyl]-1-cyclohexanecarboxamide | | tropane alkaloid | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| riboflavin | | flavin;
vitamin B2 | anti-inflammatory agent;
antioxidant;
cofactor;
Escherichia coli metabolite;
food colouring;
fundamental metabolite;
human urinary metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2'-c-methylcytidine | | | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| sodium bicarbonate | | one-carbon compound;
organic sodium salt | antacid;
food anticaking agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sodium acetate, anhydrous | | organic sodium salt | NMR chemical shift reference compound | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sodium benzoate | | organic sodium salt | algal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dipyrone | | organic sodium salt | anti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ditiocarb sodium | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| jp-1302 | | | | 2008 | 2022 | 7.8 | high | 0 | 0 | 0 | 1 | 4 | 1 |
| 7-chloro-5,10-dihydrothieno[3,4-b][1,5]benzodiazepin-4-one | | benzodiazepine | | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| carbenoxolone | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tenatoprazole | | imidazopyridine | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| 7-hydroxy-2-methoxy-1,4-phenanthrenedione | | | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| discodermolide | | diterpenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cannabidiol | | olefinic compound;
phytocannabinoid;
resorcinols | antimicrobial agent;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cgp 60474 | | substituted aniline | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| s 1033 | | (trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide | anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor | 2011 | 2022 | 5.9 | low | 0 | 0 | 0 | 0 | 6 | 3 |
| 5-[(2-fluoroanilino)methyl]-8-quinolinol | | hydroxyquinoline | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| benidipine hydrochloride | | | | 2017 | 2020 | 5.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| benidipine | | | | 2019 | 2022 | 3.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| (1S,2R)-2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol | | alkylbenzene | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| propylthiouracil | | pyrimidinethione | antidote to paracetamol poisoning;
antimetabolite;
antioxidant;
antithyroid drug;
carcinogenic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
hormone antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-[2-hydroxy-6,7-dimethoxy-4-(4-morpholinyl)-1-naphthalenyl]-N-phenylacetamide | | naphthols | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| 2-(1,3-benzoxazol-2-ylamino)-5-spiro[1,6,7,8-tetrahydroquinazoline-4,1'-cyclopentane]one | | quinazolines | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| prothionamide | | pyridines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlorprothixene | | chlorprothixene | | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| chlorprothixene | | chlorprothixene | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| etomidate | | ethyl ester;
imidazoles | intravenous anaesthetic;
sedative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mercaptopurine | | aryl thiol;
purines;
thiocarbonyl compound | anticoronaviral agent;
antimetabolite;
antineoplastic agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| jrf 12 | | | | 2017 | 2022 | 4.5 | medium | 0 | 0 | 0 | 0 | 3 | 1 |
| N4-(3-chlorophenyl)-6-methyl-N2-(phenylmethyl)pyrimidine-2,4-diamine | | aralkylamine | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| rg108 | | indolyl carboxylic acid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nitrofurylacrylic acid | | | | 2021 | 2021 | 3.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| n-(4-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| 5-amino-3-(4-methoxyphenyl)-4-oxo-1-thieno[3,4-d]pyridazinecarboxylic acid ethyl ester | | methoxybenzenes;
substituted aniline | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| stf 083010 | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| 2,6-bis(benzimidazol-2-yl)pyridine | | benzimidazoles | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 4-(4-(4-chloro-phenyl)thiazol-2-ylamino)phenol | | substituted aniline | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 3-hydroxypyridine, sodium salt | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| N-(3-cyano-4,5,6,7-tetrahydro-1-benzothiophen-2-yl)-1-naphthalenecarboxamide | | naphthalenecarboxamide | | 2013 | 2020 | 6.8 | high | 0 | 0 | 0 | 0 | 4 | 0 |
| n-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine | | | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| N-[4-(1-azepanyl)phenyl]-2-chloroacetamide | | anilide | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| N-(4-methylphenyl)carbamic acid (cyclopentylideneamino) ester | | toluenes | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| (2'-(4-aminophenyl)-(2,5'-bi-1h-benzimidazol)-5-amine) | | benzimidazoles | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| 5-[(2-bromoanilino)methyl]-8-quinolinol | | hydroxyquinoline | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| 3-amino-n-(4-methoxybenzyl)-4,6-dimethylthieno(2,3-b)pyridine-2-carboxamide | | | | 2011 | 2020 | 7.2 | medium | 0 | 0 | 0 | 0 | 4 | 0 |
| 1,4,8-trimethyl-12-quinolino[2,3-b]quinolinamine | | aminoquinoline | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| N-[(2-methoxyphenyl)methyl]-4-(1-piperidinyl)aniline | | aromatic amine | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| curcumin | | aromatic ether;
beta-diketone;
diarylheptanoid;
enone;
polyphenol | anti-inflammatory agent;
antifungal agent;
antineoplastic agent;
biological pigment;
contraceptive drug;
dye;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
EC 1.1.1.21 (aldehyde reductase) inhibitor;
EC 1.1.1.25 (shikimate dehydrogenase) inhibitor;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
EC 1.8.1.9 (thioredoxin reductase) inhibitor;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
flavouring agent;
food colouring;
geroprotector;
hepatoprotective agent;
immunomodulator;
iron chelator;
ligand;
lipoxygenase inhibitor;
metabolite;
neuroprotective agent;
nutraceutical;
radical scavenger | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| cct018159 | | benzodioxine;
pyrazoles;
resorcinols | antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor | 2011 | 2013 | 12.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| 1-[4-(4-bromophenyl)-2-thiazolyl]-4-piperidinecarboxamide | | piperidinecarboxamide | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| secinh3 | | triazoles | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| jk184 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 5-[[2-(trifluoromethyl)anilino]methyl]-8-quinolinol | | hydroxyquinoline | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| N-[3-[2-[(4-methyl-2-pyridinyl)amino]-4-thiazolyl]phenyl]acetamide | | acetamides;
anilide | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| 2-furanyl-(4,4,8-trimethyl-1-sulfanylidene-5-dithiolo[3,4-c]quinolinyl)methanone | | aromatic amide;
heteroarene | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| 1-(6-methoxy-2,2,4-trimethyl-1-quinolinyl)-2-[[5-(4-methylphenyl)-1,3,4-oxadiazol-2-yl]thio]ethanone | | quinolines | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| 5-bromo-N-(5-cyclohexyl-1,3,4-thiadiazol-2-yl)-2-thiophenecarboxamide | | aromatic amide;
thiophenes | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| 6-amino-1-[2-(3,4-dimethoxyphenyl)ethyl]-2-sulfanylidene-4-pyrimidinone | | dimethoxybenzene | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| N-[4-[(3,4-dimethyl-5-isoxazolyl)sulfamoyl]phenyl]-6,8-dimethyl-2-(2-pyridinyl)-4-quinolinecarboxamide | | aromatic amide | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| N-[5-[(4-chlorophenoxy)methyl]-1,3,4-thiadiazol-2-yl]-5-methyl-3-phenyl-4-isoxazolecarboxamide | | aromatic ether | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| methimazole | | 1,3-dihydroimidazole-2-thiones | antithyroid drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| stk295900 | | | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| 3-chloro-1-(2,5-dimethoxyphenyl)-4-(1-piperidinyl)pyrrole-2,5-dione | | maleimides | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| Src Inhibitor-1 | | aromatic ether;
polyether;
quinazolines;
secondary amino compound | EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| 6-(4-methyl-1-piperazinyl)-2-(3,4,5-trimethoxyphenyl)-1H-benzimidazole | | benzimidazoles | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| 1-[2-(3,4-dimethoxyphenyl)ethyl]-6-propyl-2-sulfanylidene-7,8-dihydro-5H-pyrimido[4,5-d]pyrimidin-4-one | | dimethoxybenzene | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| sulindac | | monocarboxylic acid;
organofluorine compound;
sulfoxide | analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| capsaicin | | capsaicinoid | non-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| terbinafine | | acetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine | EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-phenyl-N-[4-(2-thiazolylsulfamoyl)phenyl]-4-quinolinecarboxamide | | quinolines | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| xl147 | | aromatic amine;
benzothiadiazole;
quinoxaline derivative;
sulfonamide | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| N9-(4-butoxyphenyl)-6,8,10-triazaspiro[4.5]deca-6,9-diene-7,9-diamine | | aromatic ether | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| N-[2-[5-(1,3-benzothiazol-2-yl)-3-ethyl-1-phenyl-2-benzimidazol-3-iumyl]ethenyl]-N-methylaniline | | benzimidazoles | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| 3-(2,5-dimethyl-1-phenyl-3-pyrrolyl)-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine | | pyrroles | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| thioguanine anhydrous | | 2-aminopurines | anticoronaviral agent;
antimetabolite;
antineoplastic agent | 2010 | 2021 | 8.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| tacrine hydrochloride | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sodium propionate | | organic sodium salt | antifungal drug;
food preservative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| digoxin | | cardenolide glycoside;
steroid saponin | anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| streptozocin | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tamoxifen citrate | | citrate salt | angiogenesis inhibitor;
anticoronaviral agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tamoxifen | | stilbenoid;
tertiary amino compound | angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator | 2010 | 2021 | 8.0 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| hc-067047 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bi-78d3 | | aryl sulfide | | 2013 | 2020 | 6.8 | medium | 0 | 0 | 0 | 0 | 4 | 0 |
| 4-(1-adamantyl)-2-methyl-1,3-thiazole | | thiazoles | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| ethionamide | | pyridines;
thiocarboxamide | antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-amino-6-[4-(6-chloro-2-pyridinyl)-1-piperazinyl]pyridine-3,5-dicarbonitrile | | piperazines;
pyridines | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| gsk 3787 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1-(4-fluorophenyl)-3-[4-(4-fluorophenyl)-2-methyl-5-(trifluoromethyl)-3-pyrazolyl]urea | | pyrazoles;
ring assembly | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| 3,3-dimethyl-5-oxo-5-[(3-phenyl-1H-pyrazol-5-yl)amino]pentanoic acid | | pyrazoles;
ring assembly | | 2018 | 2018 | 6.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| kartogenin | | | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| cancidas | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| methyl-thiohydantoin-tryptophan | | organonitrogen compound;
organooxygen compound | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2-(4,6,7-Trimethyl-2-quinazolinyl)guanidine | | quinazolines | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| polysulfide rubber | | | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| 2-[2-chloro-6-ethoxy-4-[(3-methyl-5-oxo-1-phenyl-4-pyrazolylidene)methyl]phenoxy]acetic acid methyl ester | | monocarboxylic acid | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-(5-(4-methoxyphenyl)-3-phenyl-4,5-dihydro-1h-pyrazol-1-yl)benzenesulfonamide | | sulfonamide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lch-7749944 | | | | 2011 | 2019 | 9.0 | high | 0 | 0 | 0 | 0 | 2 | 0 |
| 4-(4-nitrophenyl)-N-prop-2-enyl-1-piperazinecarbothioamide | | piperazines | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| fusidic acid | | 11alpha-hydroxy steroid;
3alpha-hydroxy steroid;
alpha,beta-unsaturated monocarboxylic acid;
steroid acid;
steroid antibiotic;
sterol ester | EC 2.7.1.33 (pantothenate kinase) inhibitor;
Escherichia coli metabolite;
protein synthesis inhibitor | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| estrone sulfate | | 17-oxo steroid;
steroid sulfate | human metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hmr 3647 | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| LSM-1318 | | oxa-steroid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| toremifene | | aromatic ether;
organochlorine compound;
tertiary amine | antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator | 2010 | 2019 | 9.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| u 0126 | | aryl sulfide;
dinitrile;
enamine;
substituted aniline | antineoplastic agent;
antioxidant;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
osteogenesis regulator;
vasoconstrictor agent | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| rwj 67657 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| telaprevir | | cyclopentapyrrole;
cyclopropanes;
oligopeptide;
pyrazines | antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nelarabine | | beta-D-arabinoside;
monosaccharide derivative;
purine nucleoside | antineoplastic agent;
DNA synthesis inhibitor;
prodrug | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 6-methyl-2-(phenylethynyl)pyridine | | acetylenic compound;
methylpyridines | anxiolytic drug;
metabotropic glutamate receptor antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bms 387032 | | 1,3-oxazoles;
1,3-thiazoles;
organic sulfide;
piperidinecarboxamide;
secondary carboxamide | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 2008 | 2017 | 12.2 | low | 0 | 0 | 0 | 1 | 5 | 0 |
| droloxifene | | stilbenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| or 1259 | | hydrazone;
nitrile;
pyridazinone | anti-arrhythmia drug;
cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gestodene | | steroid | estrogen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| orlistat | | beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative | anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| idoxifene | | stilbenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sf 2370 | | bridged compound;
gamma-lactam;
methyl ester;
organic heterooctacyclic compound | antimicrobial agent;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
tropomyosin-related kinase B receptor antagonist | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tandutinib | | aromatic ether;
N-arylpiperazine;
N-carbamoylpiperazine;
phenylureas;
piperidines;
quinazolines;
tertiary amino compound | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 2005 | 2017 | 13.1 | medium | 0 | 0 | 0 | 2 | 5 | 0 |
| vx-745 | | aryl sulfide;
dichlorobenzene;
difluorobenzene;
pyrimidopyridazine | anti-inflammatory drug;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 2005 | 2022 | 10.3 | medium | 0 | 0 | 0 | 2 | 7 | 1 |
| corlanor | | hydrochloride | cardiotonic drug | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| dasatinib | | 1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor | 2008 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 8 | 3 |
| ha 1100 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 7-epi-hydroxystaurosporine | | | | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| silybin | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| N-methyl-2-[[3-[2-(2-pyridinyl)ethenyl]-1H-indazol-6-yl]thio]benzamide | | aryl sulfide | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| N-[2-(diethylamino)ethyl]-5-[(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide | | indoles | | 2011 | 2020 | 7.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| compound 968 | | benzophenanthridine | EC 3.5.1.2 (glutaminase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nih-12848 | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| 5-bromo-1-(1-oxopropyl)-N,N-dipropyl-2,3-dihydroindole-7-sulfonamide | | indoles | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| 2,4-dioxo-3-pentyl-N-[3-(1-piperidinyl)propyl]-1H-quinazoline-7-carboxamide | | quinazolines | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| [1-(3-methylphenyl)-5-benzimidazolyl]-(1-piperidinyl)methanone | | benzimidazoles | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| 2-[[(6-bromo-1H-imidazo[4,5-b]pyridin-2-yl)thio]methyl]benzonitrile | | imidazopyridine | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| N-cyclohexyl-5,6,7,8-tetrahydro-4H-cyclohepta[d]isoxazole-3-carboxamide | | aromatic amide;
heteroarene | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| 3-[(3-fluorophenyl)methyl]-8-[4-(4-fluorophenyl)-4-oxobutyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one | | aromatic ketone | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| sb-224289 | | 1,2,4-oxadiazole;
azaspiro compound;
benzamides;
organic heterotetracyclic compound | serotonergic antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-[[7-[(4-fluorophenyl)methyl]-1,3-dimethyl-2,6-dioxo-8-purinyl]methyl]-1-piperazinecarboxylic acid ethyl ester | | oxopurine | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| gw 7647 | | aryl sulfide;
monocarboxylic acid;
ureas | PPARalpha agonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| N,N-dimethylcarbamodithioic acid (1-acetamido-2,2,2-trichloroethyl) ester | | organonitrogen compound;
organosulfur compound | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| 6-bromo-2-(4-methylphenyl)-N-[(1-methyl-4-pyrazolyl)methyl]-4-quinolinecarboxamide | | quinolines | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| chloramine-t | | organic sodium salt | allergen;
antifouling biocide;
disinfectant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| l 663536 | | aryl sulfide;
indoles;
monocarboxylic acid;
monochlorobenzenes | antineoplastic agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
leukotriene antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| LSM-1924 | | organic heterotricyclic compound;
organooxygen compound | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| 2-[(3-ethyl-7-methyl-4-oxo-6,8-dihydro-5H-pyrido[2,3]thieno[2,4-b]pyrimidin-2-yl)thio]-N-(2-phenylethyl)acetamide | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| 1-[6-(4-chlorophenyl)-5-imidazo[2,1-b]thiazolyl]-N-[(3,4-dichlorophenyl)methoxy]methanimine | | imidazoles | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| N4-ethyl-N6,1,2-trimethyl-N4-phenylpyrimidin-1-ium-4,6-diamine | | aromatic amine;
tertiary amino compound | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| ferrostatin-1 | | ethyl ester;
primary arylamine;
substituted aniline | antifungal agent;
antioxidant;
ferroptosis inhibitor;
neuroprotective agent;
radiation protective agent;
radical scavenger | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| 2-[[2-[2-(2,3-dihydro-1,4-benzodioxin-6-ylamino)-2-oxoethyl]-1-oxo-5-isoquinolinyl]oxy]propanoic acid ethyl ester | | isoquinolines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sch 79797 | | quinazolines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 6-(2-methyl-1-piperidinyl)-5-nitro-4-pyrimidinamine | | C-nitro compound | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| ver-49009 | | aromatic amide;
monochlorobenzenes;
monomethoxybenzene;
pyrazoles;
resorcinols | Hsp90 inhibitor | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| flosequinan | | quinolines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1h-imidazol-2-yl)benzamide | | benzamides;
benzodioxoles;
imidazoles;
pyridines | EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 2008 | 2013 | 13.2 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| rabeprazole(1-) | | organic nitrogen anion | | 2019 | 2020 | 4.5 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| tolcapone | | 2-nitrophenols;
benzophenones;
catechols | antiparkinson drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1-(4-Fluorophenyl)-3-(3-(4-fluorophenyl)-3-hydroxypropyl)-4-(4-hydroxyphenyl)azetidin-2-one | | monobactam | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| alsterpaullone | | C-nitro compound;
caprolactams;
organic heterotetracyclic compound | anti-HIV-1 agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor | 2011 | 2022 | 7.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| imd 0354 | | benzamides | | 2011 | 2017 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| ex 527 | | carbazoles;
monocarboxylic acid amide;
organochlorine compound | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ncgc00099374 | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| 2-nitro-4-[(6-nitro-4-quinolinyl)amino]-N-[4-(pyridin-4-ylamino)phenyl]benzamide | | benzamides | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| sq 109 | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| quercetin | | 7-hydroxyflavonol;
pentahydroxyflavone | antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger | 2013 | 2018 | 8.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| dinoprostone | | prostaglandins E | human metabolite;
mouse metabolite;
oxytocic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dinoprost | | monocarboxylic acid;
prostaglandins Falpha | human metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acacetin | | dihydroxyflavone;
monomethoxyflavone | anticonvulsant;
plant metabolite | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| apigenin | | trihydroxyflavone | antineoplastic agent;
metabolite | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| luteolin | | 3'-hydroxyflavonoid;
tetrahydroxyflavone | angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
c-Jun N-terminal kinase inhibitor;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
immunomodulator;
nephroprotective agent;
plant metabolite;
radical scavenger;
vascular endothelial growth factor receptor antagonist | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| calcitriol | | D3 vitamins;
hydroxycalciol;
triol | antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| beta carotene | | carotenoid beta-end derivative;
cyclic carotene | antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| alprostadil | | prostaglandins E | anticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyclosporine | | | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cholecalciferol | | D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone | geroprotector;
human metabolite | 2010 | 2021 | 8.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| kaempferol | | 7-hydroxyflavonol;
flavonols;
tetrahydroxyflavone | antibacterial agent;
geroprotector;
human blood serum metabolite;
human urinary metabolite;
human xenobiotic metabolite;
plant metabolite | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| genistein | | 7-hydroxyisoflavones | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
geroprotector;
human urinary metabolite;
phytoestrogen;
plant metabolite;
tyrosine kinase inhibitor | 2013 | 2022 | 5.8 | low | 0 | 0 | 0 | 0 | 4 | 1 |
| amphotericin b | | antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic | antiamoebic agent;
antiprotozoal drug;
bacterial metabolite | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| clavulanic acid | | oxapenam | antibacterial drug;
anxiolytic drug;
bacterial metabolite;
EC 3.5.2.6 (beta-lactamase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pulmicort | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic acetal;
glucocorticoid;
primary alpha-hydroxy ketone | anti-inflammatory drug;
bronchodilator agent;
drug allergen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxymetholone | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| montelukast | | aliphatic sulfide;
monocarboxylic acid;
quinolines | anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mycophenolate mofetil | | carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound | anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug | 2010 | 2020 | 7.5 | medium | 0 | 0 | 0 | 1 | 3 | 0 |
| entacapone | | 2-nitrophenols;
catechols;
monocarboxylic acid amide;
nitrile | antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| astaxanthine | | carotenol;
carotenone | animal metabolite;
anticoagulant;
antioxidant;
food colouring;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bruceantin | | triterpenoid | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| chrysin | | 7-hydroxyflavonol;
dihydroxyflavone | anti-inflammatory agent;
antineoplastic agent;
antioxidant;
EC 2.7.11.18 (myosin-light-chain kinase) inhibitor;
hepatoprotective agent;
plant metabolite | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| diosmin | | dihydroxyflavanone;
disaccharide derivative;
glycosyloxyflavone;
monomethoxyflavone;
rutinoside | anti-inflammatory agent;
antioxidant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| daidzein | | 7-hydroxyisoflavones | antineoplastic agent;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
phytoestrogen;
plant metabolite | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| cynarine | | alkyl caffeate ester;
quinic acid | plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sdz psc 833 | | homodetic cyclic peptide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| l 660,711 | | quinolines | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| coenzyme q10 | | ubiquinones | antioxidant;
ferroptosis inhibitor;
human metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tectochrysin | | monohydroxyflavone;
monomethoxyflavone | antidiarrhoeal drug;
antineoplastic agent;
plant metabolite | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| tranilast | | amidobenzoic acid;
cinnamamides;
dimethoxybenzene;
secondary carboxamide | anti-allergic agent;
anti-asthmatic drug;
antineoplastic agent;
aryl hydrocarbon receptor agonist;
calcium channel blocker;
hepatoprotective agent;
nephroprotective agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| etretinate | | enoate ester;
ethyl ester;
retinoid | keratolytic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isotretinoin | | retinoic acid | antineoplastic agent;
keratolytic drug;
teratogenic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| misoprostol | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| neticonazole | | aromatic ether;
benzenes;
conazole antifungal drug;
enamine;
imidazole antifungal drug;
imidazoles;
methyl sulfide | antifungal drug;
EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| ozagrel | | cinnamic acids | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pitavastatin | | cyclopropanes;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
quinolines;
statin (synthetic) | antioxidant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| alatrofloxacin mesylate | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| N-(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoylethanolamine | | endocannabinoid;
N-acylethanolamine 22:6 | | 2017 | 2022 | 4.5 | medium | 0 | 0 | 0 | 0 | 3 | 1 |
| n-oleoylethanolamine | | endocannabinoid;
N-(long-chain-acyl)ethanolamine;
N-acylethanolamine 18:1 | EC 3.5.1.23 (ceramidase) inhibitor;
geroprotector;
PPARalpha agonist | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| codeine | | morphinane alkaloid;
organic heteropentacyclic compound | antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyclosporine | | homodetic cyclic peptide | anti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| natamycin | | antibiotic antifungal drug;
dicarboxylic acid monoester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyene antibiotic | antifungal agrochemical;
antimicrobial food preservative;
apoptosis inducer;
bacterial metabolite;
ophthalmology drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acitretin | | acitretin;
alpha,beta-unsaturated monocarboxylic acid;
retinoid | keratolytic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dothiepin | | dothiepin | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| levetiracetam | | pyrrolidin-2-ones | anticonvulsant;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nalorphine | | morphinane alkaloid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| naloxone | | morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol | antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxymorphone | | morphinane alkaloid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sirolimus | | antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol | antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 2010 | 2022 | 7.7 | low | 0 | 0 | 0 | 1 | 1 | 1 |
| topiramate | | cyclic ketal;
ketohexose derivative;
sulfamate ester | anticonvulsant;
sodium channel blocker | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| alpha-zearalenol | | macrolide | | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| trichomonacid | | | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| alvocidib | | dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound | antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 2005 | 2022 | 12.0 | low | 0 | 0 | 0 | 3 | 3 | 1 |
| seocalcitol | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fenretinide | | monocarboxylic acid amide;
retinoid | antineoplastic agent;
antioxidant | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| topiroxostat | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| geldanamycin | | 1,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound | antimicrobial agent;
antineoplastic agent;
antiviral agent;
cysteine protease inhibitor;
Hsp90 inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| morphine | | morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound | anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| demycarosylturimycin h | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| su 9516 | | | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| N-(4-bromo-3-methylphenyl)-2,5-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine | | triazolopyrimidines | | 2008 | 2020 | 9.0 | high | 0 | 0 | 0 | 1 | 4 | 0 |
| N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(2-methoxyethyl)-3-oxo-1H-isoindole-4-carboxamide | | isoindoles | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| ter 199 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| arachidonylcyclopropylamide | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sb 277011 | | | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| iloprost | | carbobicyclic compound;
monocarboxylic acid;
secondary alcohol | platelet aggregation inhibitor;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ly 320135 | | benzofurans | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pd 166285 | | | | 2011 | 2013 | 12.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| sb 223412 | | | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| sr 59230a | | tetralins | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| vinorelbine | | acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
ring assembly;
vinca alkaloid | antineoplastic agent;
photosensitizing agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide | | pyrimidines | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| cgp 71683 a | | naphthalenes;
sulfonic acid derivative | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| kn 62 | | piperazines | | 2013 | 2020 | 6.8 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| su 6656 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| MeJA | | Jasmonate derivatives | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| furazolidone | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fluvoxamine | | (trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime | antidepressant;
anxiolytic drug;
serotonin uptake inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| casein kinase ii | | | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 1h-pyrrole-2,5-dione, 3-(1-methyl-1h-indol-3-yl)-4-(1-methyl-6-nitro-1h-indol-3-yl)- | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| pd 161570 | | | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| bosutinib | | aminoquinoline;
aromatic ether;
dichlorobenzene;
N-methylpiperazine;
nitrile;
tertiary amino compound | antineoplastic agent;
tyrosine kinase inhibitor | 2011 | 2022 | 5.8 | low | 0 | 0 | 0 | 0 | 3 | 2 |
| semaxinib | | olefinic compound;
oxindoles;
pyrroles | angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist | 2002 | 2013 | 15.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| orantinib | | | | 2010 | 2017 | 10.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| su 11248 | | monocarboxylic acid amide;
pyrroles | angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist | 2005 | 2022 | 8.7 | low | 0 | 0 | 0 | 3 | 13 | 4 |
| m475271 | | | | 2019 | 2019 | 5.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| palbociclib | | aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 2011 | 2022 | 6.5 | low | 0 | 0 | 0 | 0 | 6 | 2 |
| jnj-7706621 | | sulfonamide | | 2008 | 2020 | 9.9 | medium | 0 | 0 | 0 | 1 | 6 | 0 |
| fosbretabulin | | stilbenoid | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2-(dimethylaminostyryl)-1-ethylpyridinium | | pyridinium ion | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | | dihydroxy monocarboxylic acid;
indoles;
organofluorine compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| molsidomine | | ethyl ester;
morpholines;
oxadiazole;
zwitterion | antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| naltrexone | | cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound | antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dextromethorphan | | 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene | antitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cefixime | | cephalosporin | antibacterial drug;
drug allergen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lisinopril | | dipeptide | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ramipril | | azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid monoester;
dipeptide;
ethyl ester | bradykinin receptor B2 agonist;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| indinavir sulfate | | dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide | HIV protease inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 3,3',4,5'-tetramethoxy-trans-stilbene | | | | 2022 | 2022 | 2.0 | medium | 0 | 0 | 0 | 0 | 0 | 2 |
| virginiamycin factor s1 | | cyclodepsipeptide;
macrolide antibiotic | antibacterial drug;
bacterial metabolite | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| enalapril | | dicarboxylic acid monoester;
dipeptide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nitrofurazone | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cisplatin | | diamminedichloroplatinum | antineoplastic agent;
apoptosis inducer;
cross-linking reagent;
ferroptosis inducer;
genotoxin;
mutagen;
nephrotoxin;
photosensitizing agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bleomycin | | bleomycin | antineoplastic agent;
metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| enalaprilat anhydrous | | dicarboxylic acid;
dipeptide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| imidapril | | dicarboxylic acid monoester;
dipeptide;
ethyl ester;
imidazolidines;
N-acylurea;
secondary amino compound | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulindac sulfone | | monocarboxylic acid;
organofluorine compound;
sulfone | apoptosis inducer;
cyclooxygenase 2 inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ximelagatran | | amidoxime;
azetidines;
carboxamide;
ethyl ester;
hydroxylamines;
secondary amino compound;
secondary carboxamide;
tertiary carboxamide | anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug;
serine protease inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ceftriaxone | | 1,2,4-triazines;
1,3-thiazoles;
cephalosporin;
oxime O-ether | antibacterial drug;
drug allergen;
EC 3.5.2.6 (beta-lactamase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| penicillin v | | 1,1'-diethyl-2,2'-cyanine;
quinolines | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| trandolapril | | dicarboxylic acid monoester;
dipeptide;
ethyl ester;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one | | organic heterotetracyclic compound;
organofluorine compound | EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vx680 | | N-arylpiperazine | | 2008 | 2017 | 12.2 | low | 0 | 0 | 0 | 1 | 5 | 0 |
| guanabenz acetate | | dichlorobenzene | geroprotector | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hydrocortisone acetate, (11beta)-isomer | | | | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| famotidine | | 1,3-thiazoles;
guanidines;
sulfonamide | anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fenoterol | | hydrobromide | beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent | 2019 | 2020 | 4.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| xib 4035 | | | | 2008 | 2022 | 7.8 | high | 0 | 0 | 0 | 1 | 4 | 1 |
| cefotaxime | | 1,3-thiazoles;
cephalosporin;
oxime O-ether | antibacterial drug;
drug allergen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aztreonam | | beta-lactam antibiotic allergen;
monobactam | antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 10-hydroxy-3-methyl-8-pentyl-2,4-dihydro-1H-[1]benzopyrano[3,4-c]pyridin-5-one | | pyridochromene | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| gw-5074 | | | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| proguanil | | biguanides;
monochlorobenzenes | antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| rifamycin sv | | acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterotetracyclic compound;
polyphenol;
rifamycins | antimicrobial agent;
antitubercular agent;
bacterial metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| epoprostenol sodium | | prostanoid | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-((4-pyridyl)methyl)amino-n-(3-(trifluoromethyl)phenyl)benzamide | | | | 2002 | 2010 | 17.9 | high | 0 | 0 | 0 | 7 | 0 | 0 |
| d 4476 | | imidazoles | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cyc 116 | | | | 2011 | 2017 | 10.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| bay 19-8004 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lumefantrine | | fluorenes;
monochlorobenzenes;
secondary alcohol;
tertiary amine | antimalarial | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| everolimus | | cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol | anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ixabepilone | | 1,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle | antineoplastic agent;
microtubule-destabilising agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ekb 569 | | aminoquinoline;
monocarboxylic acid amide;
monochlorobenzenes;
nitrile | protein kinase inhibitor | 2005 | 2019 | 12.8 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| axitinib | | aryl sulfide;
benzamides;
indazoles;
pyridines | antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist | 2010 | 2019 | 9.3 | low | 0 | 0 | 0 | 1 | 5 | 0 |
| pai 039 | | indole-3-acetic acids | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rilpivirine | | aminopyrimidine;
nitrile | EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| belotecan | | pyranoindolizinoquinoline | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| azlocillin | | penicillin allergen;
penicillin;
semisynthetic derivative | antibacterial drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1-azakenpaullone | | lactam;
organic heterotetracyclic compound;
organobromine compound;
organonitrogen heterocyclic compound | EC 2.7.11.26 (tau-protein kinase) inhibitor;
Wnt signalling activator | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| a 419259 | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gdp 366 | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| norgestimate | | ketoxime;
steroid ester;
terminal acetylenic compound | contraceptive drug;
progestin;
synthetic oral contraceptive | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| b 43 | | aromatic amine;
aromatic ether;
cyclopentanes;
primary amino compound;
pyrrolopyrimidine | EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| gw2974 | | pyridopyrimidine | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-(2' methoxyphenyl)-1-(2'-(n-(2''-pyridinyl)-4-fluorobenzamido)ethyl)piperazine | | | | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| dantrolene sodium | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nitrofurantoin | | imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic | antibacterial drug;
antiinfective agent;
hepatotoxic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| suloctidil | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methiazole | | benzimidazoles;
carbamate ester | | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| sb 218795 | | quinolines | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| bvt.948 | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| 2-[[6-[(phenylmethyl)amino]-9-propan-2-yl-2-purinyl]amino]ethanol | | thiopurine | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| nifurtimox | | nitrofuran antibiotic | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ispinesib | | benzamides | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fk 866 | | benzamides;
N-acylpiperidine | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| roxithromycin | | roxithromycin | environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| a 38503 | | | | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| artesunate | | artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid | antimalarial;
antineoplastic agent;
ferroptosis inducer | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| edatrexate | | glutamic acid derivative | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| beraprost | | enyne;
monocarboxylic acid;
organic heterotricyclic compound;
secondary alcohol;
secondary allylic alcohol | anti-inflammatory agent;
antihypertensive agent;
platelet aggregation inhibitor;
prostaglandin receptor agonist;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lanreotide | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| temsirolimus | | macrolide lactam | | 2013 | 2017 | 9.0 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| pd 184352 | | aminobenzoic acid | | 2011 | 2022 | 8.7 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| isavuconazole | | 1,3-thiazoles;
conazole antifungal drug;
difluorobenzene;
nitrile;
tertiary alcohol;
triazole antifungal drug | EC 1.14.13.70 (sterol 14alpha-demethylase) inhibitor;
ergosterol biosynthesis inhibitor;
orphan drug | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| lu 208075 | | diarylmethane | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bibx 1382bs | | substituted aniline | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| on 01910 | | N-[2-methoxy-5-({[2-(2,4,6-trimethoxyphenyl)ethenyl]sulfonyl}methyl)phenyl]glycine | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.21 (polo kinase) inhibitor;
microtubule-destabilising agent | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hdac-42 | | amidobenzoic acid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acetylcarnitine | | O-acetylcarnitine;
saturated fatty acyl-L-carnitine | human metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| parthenolide | | sesquiterpene lactone | drug allergen;
inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug | 2017 | 2019 | 6.0 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| a 770041 | | aromatic amide | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| krn 633 | | | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| [4-[[4-(1-benzothiophen-2-yl)-2-pyrimidinyl]amino]phenyl]-[4-(1-pyrrolidinyl)-1-piperidinyl]methanone | | benzamides;
N-acylpiperidine | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nifurtoinol | | hydrazone;
imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic | antibacterial drug;
antiinfective agent;
hepatotoxic agent | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| fosinopril | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| vacuolin-1 | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 5-amino-4-oxo-3-phenyl-1-thieno[3,4-d]pyridazinecarboxylic acid | | organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| iniparib | | carbonyl compound;
organohalogen compound | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mk 0752 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gw 501516 | | 1,3-thiazoles;
aromatic ether;
aryl sulfide;
monocarboxylic acid;
organofluorine compound | carcinogenic agent;
PPARbeta/delta agonist | 2013 | 2020 | 6.8 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| eflucimibe | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| av 412 | | | | 2013 | 2017 | 9.0 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| ag-041r | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| telatinib | | | | 2010 | 2017 | 10.7 | medium | 0 | 0 | 0 | 1 | 2 | 0 |
| y-39983 | | pyrrolopyridine | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dolastatin 10 | | 1,3-thiazoles;
tetrapeptide | animal metabolite;
antineoplastic agent;
apoptosis inducer;
marine metabolite;
microtubule-destabilising agent | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| cp 547632 | | | | 2011 | 2017 | 10.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| timcodar | | | | 2022 | 2022 | 2.0 | medium | 0 | 0 | 0 | 0 | 0 | 1 |
| bms345541 | | quinoxaline derivative | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| spc-839 | | | | 2013 | 2020 | 6.4 | medium | 0 | 0 | 0 | 0 | 5 | 0 |
| lenvatinib | | aromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist | 2010 | 2019 | 8.7 | low | 0 | 0 | 0 | 1 | 5 | 0 |
| andarine | | acetamides;
anilide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| adw 742 | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gw843682x | | (trifluoromethyl)benzenes | | 2011 | 2013 | 12.0 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| pd 0325901 | | difluorobenzene;
hydroxamic acid ester;
monofluorobenzenes;
organoiodine compound;
propane-1,2-diols;
secondary amino compound | antineoplastic agent;
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor | 2013 | 2017 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| midostaurin | | benzamides;
gamma-lactam;
indolocarbazole;
organic heterooctacyclic compound | antineoplastic agent;
EC 2.7.11.13 (protein kinase C) inhibitor | 2008 | 2020 | 9.5 | low | 0 | 0 | 0 | 1 | 7 | 0 |
| ag 14361 | | benzimidazoles | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| etomoxir | | aromatic ether | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sb 265610 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cgp 71683 a | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| px-866 | | acetate ester;
delta-lactone;
organic heterotetracyclic compound;
tertiary amino compound | EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| valnemulin | | | | 2019 | 2020 | 4.5 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| pentagastrin | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nu 7026 | | organic heterotricyclic compound;
organooxygen compound | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| sb 242235 | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ripasudil | | isoquinolines | | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| fr 148083 | | aromatic ether;
macrolide;
phenols;
secondary alcohol;
secondary alpha-hydroxy ketone | antibacterial agent;
antineoplastic agent;
metabolite;
NF-kappaB inhibitor | 2013 | 2022 | 6.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| mocetinostat | | aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline | antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| osi 930 | | aromatic amide | | 2013 | 2020 | 6.8 | medium | 0 | 0 | 0 | 0 | 5 | 0 |
| ki 20227 | | | | 2011 | 2013 | 12.0 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| scio-469 | | aromatic amide;
aromatic ketone;
chloroindole;
dicarboxylic acid diamide;
indolecarboxamide;
monofluorobenzenes;
N-acylpiperazine;
N-alkylpiperazine | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 2013 | 2017 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| ticagrelor | | aryl sulfide;
hydroxyether;
organofluorine compound;
secondary amino compound;
triazolopyrimidines | P2Y12 receptor antagonist;
platelet aggregation inhibitor | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| ssr 69071 | | pyridopyrimidine | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| l 692585 | | peptide | | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| cp 724714 | | 2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide | antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
hepatotoxic agent | 2008 | 2019 | 10.2 | medium | 0 | 0 | 0 | 1 | 3 | 0 |
| pi103 | | aromatic amine;
morpholines;
organic heterotricyclic compound;
phenols;
tertiary amino compound | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor | 2008 | 2020 | 10.2 | low | 0 | 0 | 0 | 1 | 7 | 0 |
| sb 210313 | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| hmn-214 | | | | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| gw 4064 | | stilbenoid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nnc 26-9100 | | aminopyridine | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| gentamicin sulfate | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-(3-chlorobenzyloxy)-6-(piperazin-1-yl)pyrazine | | | | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| norketotifen | | organosulfur heterocyclic compound | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| tgx 221 | | pyridopyrimidine | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sa 4503 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ic 87114 | | 6-aminopurines;
biaryl;
quinazolines | EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| zibotentan | | phenylpyridine | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tivozanib | | aromatic ether | | 2010 | 2022 | 7.1 | low | 0 | 0 | 0 | 1 | 5 | 1 |
| zm 447439 | | aromatic ether;
benzamides;
morpholines;
polyether;
quinazolines;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
Aurora kinase inhibitor | 2011 | 2019 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| hki 272 | | nitrile;
quinolines | antineoplastic agent;
tyrosine kinase inhibitor | 2007 | 2019 | 9.7 | low | 0 | 0 | 0 | 1 | 5 | 0 |
| tofacitinib | | N-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound | antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 2008 | 2021 | 10.5 | low | 0 | 0 | 0 | 1 | 4 | 1 |
| bibr 1532 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n-(6-chloro-7-methoxy-9h-beta-carbolin-8-yl)-2-methylnicotinamide | | | | 2011 | 2020 | 8.0 | high | 0 | 0 | 0 | 0 | 5 | 0 |
| rucaparib | | azepinoindole;
caprolactams;
organofluorine compound;
secondary amino compound | antineoplastic agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | 2011 | 2013 | 12.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| cediranib | | aromatic ether | | 2009 | 2017 | 12.2 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| tae226 | | morpholines | | 2011 | 2022 | 6.2 | low | 0 | 0 | 0 | 0 | 4 | 1 |
| gw0742 | | monocarboxylic acid | | 2013 | 2020 | 6.8 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| ps1145 | | beta-carbolines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tak-715 | | benzamides | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bay 41-8543 | | pyrazolopyridine | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| u 18666a | | hydrochloride | antiviral agent;
EC 1.3.1.72 (Delta(24)-sterol reductase) inhibitor;
Hedgehog signaling pathway inhibitor;
nicotinic antagonist;
sterol biosynthesis inhibitor | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| chir 99021 | | aminopyridine;
aminopyrimidine;
cyanopyridine;
diamine;
dichlorobenzene;
imidazoles;
secondary amino compound | EC 2.7.11.26 (tau-protein kinase) inhibitor | 2011 | 2013 | 12.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| ym 201636 | | aromatic amide | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| sb 525334 | | quinoxaline derivative | | 2013 | 2020 | 6.8 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| way-362450 | | indoles | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ly2090314 | | diazepinoindole;
imidazopyridine;
maleimides;
monofluorobenzenes;
piperidinecarboxamide;
ureas | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
Wnt signalling activator | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| masitinib | | 1,3-thiazoles;
benzamides;
N-alkylpiperazine;
pyridines | antineoplastic agent;
antirheumatic drug;
tyrosine kinase inhibitor | 2011 | 2017 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| bx795 | | ureas | | 2013 | 2022 | 5.8 | low | 0 | 0 | 0 | 0 | 4 | 1 |
| ly-2157299 | | aromatic amide;
methylpyridines;
monocarboxylic acid amide;
pyrrolopyrazole;
quinolines | antineoplastic agent;
TGFbeta receptor antagonist | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pazopanib | | aminopyrimidine;
indazoles;
sulfonamide | angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist | 2008 | 2019 | 11.3 | low | 0 | 0 | 0 | 3 | 7 | 0 |
| sepantronium | | organic cation | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| azd 6244 | | benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound | anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 2010 | 2022 | 7.2 | low | 0 | 0 | 0 | 1 | 6 | 2 |
| su 14813 | | | | 2008 | 2017 | 12.2 | high | 0 | 0 | 0 | 1 | 3 | 0 |
| 1-(2-(1-adamantyl)ethyl)-1-pentyl-3-(3-(4-pyridyl)propyl)urea | | | | 2013 | 2020 | 6.8 | high | 0 | 0 | 0 | 0 | 4 | 0 |
| apilimod | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| bibw 2992 | | aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
tyrosine kinase inhibitor | 2011 | 2021 | 6.6 | low | 0 | 0 | 0 | 0 | 4 | 1 |
| bay 61-3606 | | pyrimidines | | 2011 | 2020 | 7.2 | high | 0 | 0 | 0 | 0 | 4 | 0 |
| N-(3-cyanophenyl)-2'-methyl-5'-(5-methyl-1,3,4-oxadiazol-2-yl)biphenyl-4-carboxamide | | 1,3,4-oxadiazoles;
benzamides;
biphenyls;
nitrile | EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| artenimol | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ar c155858 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| binimetinib | | benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monofluorobenzenes;
secondary amino compound | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sotrastaurin | | indoles;
maleimides;
N-alkylpiperazine;
N-arylpiperazine;
quinazolines | anticoronaviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunosuppressive agent | 2011 | 2017 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| aee 788 | | 6-{4-[(4-ethylpiperazin-1-yl)methyl]phenyl}-N-(1-phenylethyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist;
trypanocidal drug | 2008 | 2017 | 11.8 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| saracatinib | | aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent | 2013 | 2022 | 6.0 | low | 0 | 0 | 0 | 0 | 4 | 1 |
| sd-208 | | | | 2013 | 2020 | 6.8 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| ko 143 | | beta-carbolines;
tert-butyl ester | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| vx 702 | | phenylpyridine | | 2011 | 2017 | 10.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| crenolanib | | aminopiperidine;
aromatic ether;
benzimidazoles;
oxetanes;
quinolines;
tertiary amino compound | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 2017 | 2020 | 5.8 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| tg100-115 | | pteridines | | 2011 | 2017 | 10.0 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| cj 033466 | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| cc 401 | | pyrazoles;
ring assembly | | 2017 | 2020 | 5.8 | high | 0 | 0 | 0 | 0 | 4 | 0 |
| bms 599626 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| exel-7647 | | | | 2017 | 2019 | 6.0 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| volasertib | | | | 2013 | 2017 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| pha 665752 | | dichlorobenzene;
enamide;
indolones;
N-acylpyrrolidine;
pyrrolecarboxamide;
secondary carboxamide;
sulfone;
tertiary carboxamide | antineoplastic agent;
c-Met tyrosine kinase inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| PB28 | | aromatic ether;
piperazines;
tetralins | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
sigma-2 receptor agonist | 2013 | 2022 | 5.8 | medium | 0 | 0 | 0 | 0 | 4 | 1 |
| arterolane | | | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| vinflunine | | acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
semisynthetic derivative;
vinca alkaloid | antineoplastic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| baci-im | | homodetic cyclic peptide;
polypeptide;
zwitterion | antibacterial agent;
antimicrobial agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| azd 7762 | | aromatic amide;
thiophenes | | 2013 | 2017 | 9.0 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| cariprazine | | | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| krp-203 | | | | 2013 | 2020 | 6.8 | high | 0 | 0 | 0 | 0 | 4 | 0 |
| mk 0354 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| regorafenib | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide | antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor | 2013 | 2022 | 5.4 | low | 0 | 0 | 0 | 0 | 7 | 2 |
| at 7867 | | monochlorobenzenes;
piperidines;
pyrazoles | antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| acetic acid 2-[4-methyl-8-(4-morpholinylsulfonyl)-1,3-dioxo-2-pyrrolo[3,4-c]quinolinyl]ethyl ester | | pyrroloquinoline | | 2013 | 2020 | 6.8 | high | 0 | 0 | 0 | 0 | 4 | 0 |
| 6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one | | methoxybenzenes;
substituted aniline | | 2011 | 2017 | 11.0 | medium | 0 | 0 | 0 | 0 | 4 | 0 |
| ptc 124 | | oxadiazole;
ring assembly | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| degrasyn | | | | 2019 | 2020 | 4.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| brivanib | | aromatic ether;
diether;
fluoroindole;
pyrrolotriazine;
secondary alcohol | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
drug metabolite;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist | 2011 | 2017 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| icg 001 | | peptide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cvt-6883 | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mp470 | | N-arylpiperazine | | 2013 | 2017 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| rgb 286638 | | | | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| np 031112 | | benzenes;
naphthalenes;
thiadiazolidine | anti-inflammatory agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
neuroprotective agent | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nu 7441 | | dibenzothiophenes | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| at 7519 | | dichlorobenzene;
piperidines;
pyrazoles;
secondary carboxamide | antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 2011 | 2017 | 10.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| bms-690514 | | | | 2017 | 2019 | 6.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| bi 2536 | | | | 2011 | 2020 | 7.8 | low | 0 | 0 | 0 | 0 | 6 | 0 |
| inno-406 | | biaryl | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| r 1487 | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| nvp-ast487 | | | | 2008 | 2011 | 13.8 | high | 0 | 0 | 0 | 1 | 3 | 0 |
| kw 2449 | | | | 2011 | 2017 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| danusertib | | piperazines | | 2013 | 2017 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| N-[4-(2-tert-butylphenyl)sulfonylphenyl]-2,3,4-trihydroxy-5-[(2-propan-2-ylphenyl)methyl]benzamide | | benzamides | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| N-[5-[[5-[(4-acetyl-1-piperazinyl)-oxomethyl]-4-methoxy-2-methylphenyl]thio]-2-thiazolyl]-4-[(3,3-dimethylbutan-2-ylamino)methyl]benzamide | | benzamides | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| abt 869 | | aromatic amine;
indazoles;
phenylureas | angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 2008 | 2017 | 12.2 | low | 0 | 0 | 0 | 1 | 5 | 0 |
| azd 8931 | | aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
tertiary amino compound | EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
epidermal growth factor receptor antagonist | 2017 | 2019 | 5.7 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| arq 197 | | indoles | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| azd 1152 | | anilide;
monoalkyl phosphate;
monofluorobenzenes;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
Aurora kinase inhibitor;
prodrug | 2011 | 2022 | 6.3 | high | 0 | 0 | 0 | 0 | 5 | 1 |
| pf 00299804 | | enamide;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 2017 | 2022 | 4.4 | low | 0 | 0 | 0 | 0 | 3 | 2 |
| ridaforolimus | | macrolide lactam | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dorsomorphin | | aromatic ether;
piperidines;
pyrazolopyrimidine;
pyridines | bone morphogenetic protein receptor antagonist;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor | 2013 | 2022 | 6.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| ac 261066 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ch 4987655 | | | | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-n-(2,2-dimethylprpyl)-3-pyridinecarboxamide | | phenylpyridine | | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| carfilzomib | | epoxide;
morpholines;
tetrapeptide | antineoplastic agent;
proteasome inhibitor | 2013 | 2020 | 6.8 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| gw9508 | | aromatic amine | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cc-930 | | | | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine | | aminopyridine;
aromatic ether;
dichlorobenzene;
organofluorine compound;
pyrazolylpiperidine;
racemate | antineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| jnj 26854165 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pf 573228 | | quinolines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gw 2580 | | | | 2008 | 2013 | 13.2 | medium | 0 | 0 | 0 | 1 | 4 | 0 |
| tak 285 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| idelalisib | | aromatic amine;
organofluorine compound;
purines;
quinazolines;
secondary amino compound | antineoplastic agent;
apoptosis inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 2013 | 2021 | 6.2 | low | 0 | 0 | 0 | 0 | 5 | 1 |
| crizotinib | | 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine | antineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 2011 | 2017 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| 5-(5,6-dimethoxy-1-benzimidazolyl)-3-[(2-methylsulfonylphenyl)methoxy]-2-thiophenecarbonitrile | | benzimidazoles | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-[2-(2-chloro-4-fluoroanilino)-5-methyl-4-pyrimidinyl]-N-[(1S)-1-(3-chlorophenyl)-2-hydroxyethyl]-1H-pyrrole-2-carboxamide | | aromatic amide;
heteroarene | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| osi 906 | | cyclobutanes;
quinolines | | 2011 | 2017 | 10.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| ly2109761 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| chir-265 | | aromatic ether | | 2008 | 2017 | 12.0 | medium | 0 | 0 | 0 | 1 | 4 | 0 |
| motesanib | | pyridinecarboxamide | | 2008 | 2020 | 9.9 | high | 0 | 0 | 0 | 2 | 8 | 0 |
| fostamatinib | | | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| az-628 | | benzamides | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| jnj 28312141 | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| trametinib | | acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly | anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector | 2013 | 2022 | 6.2 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| mln8054 | | benzazepine | | 2008 | 2017 | 12.4 | low | 0 | 0 | 0 | 1 | 4 | 0 |
| pf-562,271 | | indoles | | 2011 | 2020 | 7.8 | high | 0 | 0 | 0 | 0 | 6 | 0 |
| pha 767491 | | pyrrolopyridine | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| GDC-0879 | | indanes;
ketoxime;
primary alcohol;
pyrazoles;
pyridines | antineoplastic agent;
B-Raf inhibitor | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| gpi 15427 | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gliocladin c | | | | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| sb 706504 | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| jnj-26483327 | | | | 2017 | 2019 | 6.0 | high | 0 | 0 | 0 | 0 | 2 | 0 |
| ly2603618 | | ureas | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| veliparib | | benzimidazoles | EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ku-0060648 | | dibenzothiophenes | | 2013 | 2020 | 6.8 | high | 0 | 0 | 0 | 0 | 4 | 0 |
| tg100801 | | | | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| dactolisib | | imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor | 2011 | 2017 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| bgt226 | | aromatic ether;
imidazoquinoline;
N-arylpiperazine;
organofluorine compound;
pyridines | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor | 2017 | 2022 | 5.0 | high | 0 | 0 | 0 | 0 | 4 | 1 |
| palomid 529 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pf 03491390 | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chidamide | | benzamides | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| tomaymycin | | tomaymycin | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| n-desmethyldanofloxacin | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| rabeprazole sodium | | organic sodium salt | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| a-484954 | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tosedostat | | carboxylic ester;
hydroxamic acid;
secondary carboxamide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 3-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide | | organochlorine compound | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| mdv 3100 | | (trifluoromethyl)benzenes;
benzamides;
imidazolidinone;
monofluorobenzenes;
nitrile;
thiocarbonyl compound | androgen antagonist;
antineoplastic agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ku 60019 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gsk 461364 | | (trifluoromethyl)benzenes | | 2011 | 2017 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| n-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| azd 1152-hqpa | | anilide;
monofluorobenzenes;
primary alcohol;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
Aurora kinase inhibitor | 2008 | 2020 | 9.5 | high | 0 | 0 | 0 | 1 | 7 | 0 |
| CDN1163 | | aromatic ether;
quinolines;
secondary carboxamide | SERCA activator | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| nvp-tae684 | | piperidines | | 2011 | 2013 | 12.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| enmd 2076 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| N-(3-ethynylphenyl)-6,7-dimethoxy-4-quinazolinamine | | quinazolines | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amodiaquine hydrochloride | | | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| 4-methyl-3-(2-(2-morpholinoethylamino)quinazolin-6-yl)-n-(3-(trifluoromethyl)phenyl)benzamide | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| gsk 269962a | | | | 2011 | 2020 | 8.0 | high | 0 | 0 | 0 | 0 | 5 | 0 |
| e 7050 | | aromatic ether | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone | | pyrazolopyridine | | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| tak-901 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tannins | | tannin | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gramicidin a | | | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| N-methyl-3-[5-(3-phenylpropyl)-1,3,4-oxadiazol-2-yl]-N-(3-thiophenylmethyl)propanamide | | benzenes | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| a-83-01 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 3-[(1-methyl-3-indolyl)methylidene]-1H-pyrrolo[3,2-b]pyridin-2-one | | indoles | | 2011 | 2013 | 12.0 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| vx-770 | | aromatic amide;
monocarboxylic acid amide;
phenols;
quinolone | CFTR potentiator;
orphan drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gdc-0973 | | aromatic amine;
difluorobenzene;
N-acylazetidine;
organoiodine compound;
piperidines;
secondary amino compound;
tertiary alcohol | antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| buparlisib | | aminopyridine;
aminopyrimidine;
morpholines;
organofluorine compound | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 2013 | 2017 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| azd 1480 | | | | 2013 | 2017 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| azd8330 | | pyridinecarboxamide | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pha 848125 | | | | 2017 | 2020 | 5.8 | medium | 0 | 0 | 0 | 0 | 4 | 0 |
| ro5126766 | | aryloxypyrimidine;
coumarins;
organofluorine compound;
pyridines;
sulfamides | antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tg101209 | | N-alkylpiperazine;
N-arylpiperazine;
pyrimidines;
secondary amino compound;
sulfonamide | antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fedratinib | | sulfonamide | | 2011 | 2017 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| gsk690693 | | 1,2,5-oxadiazole;
acetylenic compound;
aromatic amine;
aromatic ether;
imidazopyridine;
piperidines;
primary amino compound;
tertiary alcohol | antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor | 2011 | 2017 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| cnf 2024 | | 2-aminopurines;
aromatic ether;
organochlorine compound;
pyridines | antineoplastic agent;
Hsp90 inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ku 0063794 | | benzyl alcohols;
monomethoxybenzene;
morpholines;
pyridopyrimidine;
tertiary amino compound | antineoplastic agent;
mTOR inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| azd 7545 | | benzamides;
monochlorobenzenes;
organofluorine compound;
secondary carboxamide;
sulfone;
tertiary alcohol;
tertiary carboxamide | EC 2.7.11.2 - [pyruvate dehydrogenase (acetyl-transferring)] kinase inhibitor;
hypoglycemic agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nvp-bhg712 | | benzamides | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| azd5438 | | sulfonamide | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nutlin-3b | | Nutlin;
piperazinone | anticoronaviral agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pf 04217903 | | quinolines | | 2011 | 2020 | 7.8 | high | 0 | 0 | 0 | 0 | 6 | 0 |
| 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1-pyrazolyl]propanenitrile | | pyrrolopyrimidine | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| gdc 0941 | | indazoles;
morpholines;
piperazines;
sulfonamide;
thienopyrimidine | EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 2011 | 2021 | 9.4 | low | 0 | 0 | 0 | 0 | 4 | 1 |
| sm 164 | | benzenes;
organic heterobicyclic compound;
secondary carboxamide;
triazoles | antineoplastic agent;
apoptosis inducer;
radiosensitizing agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rs 39604 | | hydrochloride | serotonergic antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 5-[[4-(4-acetylphenyl)-1-piperazinyl]sulfonyl]-1,3-dihydroindol-2-one | | aromatic ketone | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| icotinib | | | | 2017 | 2019 | 6.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| ph 797804 | | aromatic ether;
benzamides;
organobromine compound;
organofluorine compound;
pyridone | anti-inflammatory agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 2011 | 2022 | 7.0 | medium | 0 | 0 | 0 | 0 | 6 | 1 |
| pha 408 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gsk 1016790a | | 1-benzothiophenes;
aromatic primary alcohol;
dichlorobenzene;
N-acylpiperazine;
sulfonamide;
tertiary carboxamide | TRPV4 agonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| kx-01 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mesna | | organosulfonic acid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cerivastatin sodium | | organic sodium salt;
statin (synthetic) | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| monensin | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| oxacillin sodium | | organic sodium salt | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sodium diatrizoate | | organic sodium salt;
organoiodine compound | radioopaque medium | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| olaparib | | cyclopropanes;
monofluorobenzenes;
N-acylpiperazine;
phthalazines | antineoplastic agent;
apoptosis inducer;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| srt1720 | | | | 2013 | 2022 | 5.8 | low | 0 | 0 | 0 | 0 | 4 | 1 |
| plx 4720 | | aromatic ketone;
difluorobenzene;
organochlorine compound;
pyrrolopyridine;
sulfonamide | antineoplastic agent;
B-Raf inhibitor | 2011 | 2013 | 12.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| mk 5108 | | aromatic ether | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cx 4945 | | | | 2013 | 2017 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| cudc 101 | | | | 2013 | 2021 | 6.2 | medium | 0 | 0 | 0 | 0 | 3 | 1 |
| purfalcamine | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| arry-614 | | | | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| tak 593 | | | | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| mln 8237 | | benzazepine | | 2011 | 2017 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| lde225 | | aminopyridine;
aromatic ether;
benzamides;
biphenyls;
morpholines;
organofluorine compound;
tertiary amino compound | antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gdc 0449 | | benzamides;
monochlorobenzenes;
pyridines;
sulfone | antineoplastic agent;
Hedgehog signaling pathway inhibitor;
SMO receptor antagonist;
teratogenic agent | 2013 | 2022 | 6.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| sgx 523 | | aryl sulfide;
biaryl;
pyrazoles;
quinolines;
triazolopyridazine | c-Met tyrosine kinase inhibitor;
nephrotoxic agent | 2011 | 2017 | 10.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| bms 754807 | | pyrazoles;
pyridines;
pyrrolidines;
pyrrolotriazine | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 2017 | 2020 | 5.8 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| bms 777607 | | aromatic amide | | 2013 | 2018 | 8.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| sgi 1776 | | imidazoles | | 2013 | 2017 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| pci 32765 | | acrylamides;
aromatic amine;
aromatic ether;
N-acylpiperidine;
pyrazolopyrimidine;
tertiary carboxamide | antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 2013 | 2021 | 7.0 | low | 0 | 0 | 0 | 0 | 2 | 1 |
| ponatinib | | (trifluoromethyl)benzenes;
acetylenic compound;
benzamides;
imidazopyridazine;
N-methylpiperazine | antineoplastic agent;
tyrosine kinase inhibitor | 2013 | 2022 | 5.6 | low | 0 | 0 | 0 | 0 | 6 | 3 |
| amg 900 | | | | 2013 | 2017 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| mk-1775 | | piperazines | | 2011 | 2017 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| AMG-208 | | aromatic ether;
quinolines;
triazolopyridazine | antineoplastic agent;
c-Met tyrosine kinase inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bag956 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| quizartinib | | benzoimidazothiazole;
isoxazoles;
morpholines;
phenylureas | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
necroptosis inhibitor | 2011 | 2020 | 7.8 | low | 0 | 0 | 0 | 0 | 6 | 0 |
| PP121 | | aromatic amine;
cyclopentanes;
pyrazolopyrimidine;
pyrrolopyridine | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
tyrosine kinase inhibitor | 2011 | 2020 | 7.2 | high | 0 | 0 | 0 | 0 | 4 | 0 |
| at13148 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| N-[4-[3-[[[7-(hydroxyamino)-7-oxoheptyl]amino]-oxomethyl]-5-isoxazolyl]phenyl]carbamic acid tert-butyl ester | | carbamate ester | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tak 733 | | | | 2013 | 2017 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| mk 2206 | | organic heterotricyclic compound | EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 2013 | 2017 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| navitoclax | | aryl sulfide;
monochlorobenzenes;
morpholines;
N-sulfonylcarboxamide;
organofluorine compound;
piperazines;
secondary amino compound;
sulfone;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor | 2013 | 2020 | 6.8 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| sns 314 | | ureas | | 2011 | 2017 | 10.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| jzl 184 | | benzodioxoles | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gsk 650394 | | phenylpyridine | | 2017 | 2022 | 4.5 | medium | 0 | 0 | 0 | 0 | 3 | 1 |
| lucitanib | | aromatic ether;
cyclopropanes;
naphthalenecarboxamide;
primary amino compound;
quinolines | antineoplastic agent;
fibroblast growth factor receptor antagonist;
vascular endothelial growth factor receptor antagonist | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pf-04691502 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide | | aminopyrimidine;
benzamides;
morpholines;
nitrile;
secondary amino compound;
tertiary amino compound | anti-anaemic agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 2013 | 2017 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| dcc-2036 | | organofluorine compound;
phenylureas;
pyrazoles;
pyridinecarboxamide;
quinolines | tyrosine kinase inhibitor | 2013 | 2020 | 6.8 | medium | 0 | 0 | 0 | 0 | 5 | 0 |
| cabozantinib | | aromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines | antineoplastic agent;
tyrosine kinase inhibitor | 2013 | 2022 | 5.9 | low | 0 | 0 | 0 | 0 | 11 | 2 |
| defactinib | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ly2584702 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| N-(2,6-difluorophenyl)-5-[3-[2-[5-ethyl-2-methoxy-4-[4-(4-methylsulfonyl-1-piperazinyl)-1-piperidinyl]anilino]-4-pyrimidinyl]-2-imidazo[1,2-a]pyridinyl]-2-methoxybenzamide | | benzamides | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| incb-018424 | | nitrile;
pyrazoles;
pyrrolopyrimidine | antineoplastic agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 2011 | 2017 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| poziotinib | | acrylamides;
aromatic ether;
dichlorobenzene;
diether;
monofluorobenzenes;
N-acylpiperidine;
quinazolines;
secondary amino compound;
substituted aniline | antineoplastic agent;
apoptosis inducer;
epidermal growth factor receptor antagonist | 2017 | 2019 | 6.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| asp3026 | | aromatic amine;
diamino-1,3,5-triazine;
monomethoxybenzene;
N-methylpiperazine;
piperidines;
secondary amino compound;
sulfone | antimalarial;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
EC 6.1.1.6 (lysine--tRNA ligase) inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| entrectinib | | benzamides;
difluorobenzene;
indazoles;
N-methylpiperazine;
oxanes;
secondary amino compound;
secondary carboxamide | antibacterial agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 2011 | 2017 | 10.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| bix 01294 | | piperidines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pexidartinib | | aminopyridine;
organochlorine compound;
organofluorine compound;
pyrrolopyridine;
secondary amino compound | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cobicistat | | 1,3-thiazoles;
carbamate ester;
monocarboxylic acid amide;
morpholines;
ureas | P450 inhibitor | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| pf 3845 | | piperidines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| TAK-580 | | 1,3-thiazolecarboxamide;
aminopyrimidine;
chloropyridine;
organofluorine compound;
pyrimidinecarboxamide;
secondary carboxamide | antineoplastic agent;
apoptosis inducer;
B-Raf inhibitor | 2017 | 2020 | 5.8 | high | 0 | 0 | 0 | 0 | 4 | 0 |
| gsk 2126458 | | aromatic ether;
difluorobenzene;
pyridazines;
pyridines;
quinolines;
sulfonamide | anticoronaviral agent;
antineoplastic agent;
autophagy inducer;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor;
radiosensitizing agent | 2013 | 2017 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| emd1214063 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 8-(4-aminophenyl)-2-(4-morpholinyl)-1-benzopyran-4-one | | chromones | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| gsk 1838705a | | organonitrogen compound;
organooxygen compound | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ixazomib | | benzamides;
boronic acids;
dichlorobenzene;
glycine derivative | antineoplastic agent;
apoptosis inducer;
drug metabolite;
orphan drug;
proteasome inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fit-039 | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ldn 193189 | | pyrimidines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pf 3758309 | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 2017 | 2020 | 5.8 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| gdc 0980 | | | | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| azd2014 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol | | benzyl alcohols;
morpholines;
pyridopyrimidine;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
mTOR inhibitor | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| plx4032 | | aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide | antineoplastic agent;
B-Raf inhibitor | 2013 | 2019 | 7.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| (2S)-2-[[2-(2,3-dihydro-1H-inden-5-yloxy)-9-[(4-phenylphenyl)methyl]-6-purinyl]amino]-3-phenyl-1-propanol | | biphenyls | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gsk 1363089 | | aromatic ether | | 2011 | 2017 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| arry-334543 | | | | 2017 | 2019 | 6.0 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| kin-193 | | pyridopyrimidine | | 2013 | 2017 | 9.0 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| mk 2461 | | | | 2011 | 2017 | 10.0 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| 5-(2-benzofuranyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine | | aryl sulfide;
thienopyrimidine | | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| 5-(3-methylsulfonylphenyl)-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine | | aryl sulfide;
thienopyrimidine | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| 5-bromo-4-[(1-methyl-5-tetrazolyl)thio]thieno[2,3-d]pyrimidine | | aryl sulfide;
thienopyrimidine | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| bay 869766 | | | | 2013 | 2017 | 9.0 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| as 703026 | | pyridinecarboxamide | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| baricitinib | | azetidines;
nitrile;
pyrazoles;
pyrrolopyrimidine;
sulfonamide | anti-inflammatory agent;
antirheumatic drug;
antiviral agent;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
immunosuppressive agent | 2017 | 2022 | 5.0 | low | 0 | 0 | 0 | 0 | 4 | 1 |
| 4-[6-[4-(methoxycarbonylamino)phenyl]-4-(4-morpholinyl)-1-pyrazolo[3,4-d]pyrimidinyl]-1-piperidinecarboxylic acid methyl ester | | carbamate ester | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 6-(1,3-benzodioxol-5-yl)-N-methyl-N-(thiophen-2-ylmethyl)-4-quinazolinamine | | quinazolines | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| 6-[(3-aminophenyl)methyl]-4-methyl-2-methylsulfinyl-5-thieno[3,4]pyrrolo[1,3-d]pyridazinone | | organic heterobicyclic compound;
organonitrogen heterocyclic compound;
organosulfur heterocyclic compound | | 2013 | 2020 | 6.8 | medium | 0 | 0 | 0 | 0 | 4 | 0 |
| N-[(5-bromo-8-hydroxy-7-quinolinyl)-thiophen-2-ylmethyl]acetamide | | hydroxyquinoline | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| p505-15 | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| dabrafenib | | 1,3-thiazoles;
aminopyrimidine;
organofluorine compound;
sulfonamide | anticoronaviral agent;
antineoplastic agent;
B-Raf inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mrt67307 | | aromatic amine | | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| pki 587 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 3-[[4-(2,3-dihydro-1,4-benzodioxin-6-ylsulfonyl)-1,4-diazepan-1-yl]sulfonyl]aniline | | benzenes;
sulfonamide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cp 466722 | | quinazolines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| CAY10626 | | ureas | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| n-(3-fluoro-4-((1-methyl-6-(1h-pyrazol-4-yl)-1h-indazol-5 yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| N-[3-[[5-chloro-2-[4-(4-methyl-1-piperazinyl)anilino]-4-pyrimidinyl]oxy]phenyl]-2-propenamide | | piperazines | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| thiopental sodium | | organochlorine compound;
piperazines;
pyrimidines | antineoplastic agent;
tyrosine kinase inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ribociclib | | | | 2017 | 2021 | 5.2 | low | 0 | 0 | 0 | 0 | 4 | 1 |
| 1-[3-[4-[(1-methyl-5-tetrazolyl)thio]-5-thieno[2,3-d]pyrimidinyl]phenyl]ethanone | | aromatic ketone;
thienopyrimidine | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| mk-8033 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pha 793887 | | piperidinecarboxamide | | 2013 | 2020 | 6.8 | high | 0 | 0 | 0 | 0 | 5 | 0 |
| abt-348 | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| gsk 2334470 | | indazoles | | 2019 | 2022 | 3.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| sb 1518 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| abemaciclib | | | | 2017 | 2022 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 2 |
| mk-8776 | | | | 2017 | 2017 | 7.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| nvp-bsk805 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ml228 probe | | 1,2,4-triazines;
biphenyls;
pyridines;
secondary amino compound | hypoxia-inducible factor pathway activator | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| afuresertib | | amphetamines | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| xmd 8-92 | | pyrimidobenzodiazepine | protein kinase inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pf-03882845 | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| gsk 1070916 | | pyrazoles;
ring assembly | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| jq1 compound | | carboxylic ester;
organochlorine compound;
tert-butyl ester;
thienotriazolodiazepine | angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bromodomain-containing protein 4 inhibitor;
cardioprotective agent;
ferroptosis inducer | 2013 | 2020 | 6.2 | low | 0 | 0 | 0 | 0 | 5 | 0 |
| jnj38877605 | | quinolines | | 2013 | 2017 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| N-[3-(1,3-benzothiazol-2-yl)-5,6-dihydro-4H-thieno[2,3-c]pyrrol-2-yl]acetamide | | benzothiazoles | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| dinaciclib | | pyrazolopyrimidine | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| pf-04620110 | | | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| gsk525762a | | benzodiazepine | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| gilteritinib | | aromatic amine;
monomethoxybenzene;
N-methylpiperazine;
oxanes;
piperidines;
primary carboxamide;
pyrazines;
secondary amino compound | antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alectinib | | aromatic ketone;
morpholines;
nitrile;
organic heterotetracyclic compound;
piperidines | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 2017 | 2022 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 2 |
| glpg0634 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| birinapant | | dipeptide | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| torin 1 | | N-acylpiperazine;
N-arylpiperazine;
organofluorine compound;
pyridoquinoline;
quinolines | antineoplastic agent;
mTOR inhibitor | 2013 | 2022 | 5.8 | high | 0 | 0 | 0 | 0 | 4 | 1 |
| abt-199 | | aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
N-sulfonylcarboxamide;
oxanes;
pyrrolopyridine | antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| ly2940680 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1-[4-fluoro-3-(trifluoromethyl)phenyl]-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea | | ureas | | 2013 | 2020 | 6.8 | high | 0 | 0 | 0 | 0 | 4 | 0 |
| N-(4-methyl-2-pyridinyl)-4-[3-(trifluoromethyl)anilino]-1-piperidinecarbothioamide | | (trifluoromethyl)benzenes | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| ro 4929097 | | dibenzoazepine;
dicarboxylic acid diamide;
lactam;
organofluorine compound | EC 3.4.23.46 (memapsin 2) inhibitor | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| ncgc00242364 | | quinazolines | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| gsk4112 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ipi-145 | | isoquinolines | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| encorafenib | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bms-911543 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gsk2141795 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| torin 2 | | aminopyridine;
organofluorine compound;
primary amino compound;
pyridoquinoline | antineoplastic agent;
mTOR inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pf-4708671 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gsk1210151a | | imidazoquinoline | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| azd8186 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hs-173 | | | | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| sr1664 | | indolecarboxamide | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| 4-(3-chloro-5-(trifluoromethyl)pyridin-2-yl)-n-(4-methoxypyridin-2-yl)piperazine-1-carbothioamide | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| acy-1215 | | pyrimidinecarboxylic acid | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| unc569 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| N-[4-(1-benzoyl-4-piperidinyl)butyl]-3-(3-pyridinyl)-2-propenamide | | benzamides;
N-acylpiperidine | | 2013 | 2020 | 7.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| N-[4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide | | aminoquinoline | | 2017 | 2020 | 5.5 | high | 0 | 0 | 0 | 0 | 2 | 0 |
| 2-methoxy-N-[3-[4-[3-methyl-4-[(6-methyl-3-pyridinyl)oxy]anilino]-6-quinazolinyl]prop-2-enyl]acetamide | | aromatic ether;
methylpyridines;
olefinic compound;
quinazolines;
secondary amino compound;
secondary carboxamide;
toluenes | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| belinostat | | olefinic compound | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| cudc-907 | | | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| ascorbic acid | | ascorbic acid;
vitamin C | coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| novobiocin | | carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols | antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| tetracycline | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlortetracycline | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxytetracycline, anhydrous | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| minocycline | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methacycline | | | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dicumarol | | hydroxycoumarin | anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
Hsp90 inhibitor;
vitamin K antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| piroxicam | | benzothiazine;
monocarboxylic acid amide;
pyridines | analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acenocoumarol | | C-nitro compound;
hydroxycoumarin;
methyl ketone | anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mobic | | 1,3-thiazoles;
benzothiazine;
monocarboxylic acid amide | analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mobiflex | | heteroaryl hydroxy compound;
monocarboxylic acid amide;
pyridines;
thienothiazine | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethyl 1-benzyl-3-hydroxy-2(5h)-oxopyrrole-4-carboxylate | | carboxylic acid;
pyrroline | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| warfarin | | benzenes;
hydroxycoumarin;
methyl ketone | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenprocoumon | | hydroxycoumarin | anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rolitetracycline | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methacycline monohydrochloride | | | | 2017 | 2020 | 5.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| 2-[[[4-hydroxy-2-oxo-1-(phenylmethyl)-3-quinolinyl]-oxomethyl]amino]acetic acid | | quinolines | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| lornoxicam | | heteroaryl hydroxy compound;
monocarboxylic acid amide;
organochlorine compound;
pyridines;
thienothiazine | antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| a 769662 | | biphenyls | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| agi-5198 | | | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| byl719 | | proline derivative | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cep-32496 | | | | 2017 | 2022 | 4.7 | high | 0 | 0 | 0 | 0 | 4 | 2 |
| epz004777 | | N-glycosyl compound | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| 3-[[2-(2-pyridinyl)-6-(1,2,4,5-tetrahydro-3-benzazepin-3-yl)-4-pyrimidinyl]amino]propanoic acid | | organonitrogen heterocyclic compound | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| LimKi 3 | | 1,3-thiazoles;
dichlorobenzene;
organofluorine compound;
pyrazoles;
secondary carboxamide | LIM kinase inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1-[4-amino-7-[3-(2-methoxyethylamino)propyl]-5-(4-methylphenyl)-6-pyrrolo[2,3-d]pyrimidinyl]-2-fluoroethanone | | pyrroles | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| rociletinib | | | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| entecavir | | benzamides;
N-acylpiperidine | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| 2-[5-[(3,5-dimethyl-1H-pyrrol-2-yl)methylidene]-4-methoxy-2-pyrrolylidene]indole | | dipyrrins | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| ceritinib | | aminopyrimidine;
aromatic ether;
organochlorine compound;
piperidines;
secondary amino compound;
sulfone | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]-2-propenamide | | tryptamines | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| 3-[(5-tert-butyl-1H-imidazol-4-yl)methylidene]-6-(phenylmethylene)piperazine-2,5-dione | | pyrazines | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| gsk837149a | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| N-[4-(3-chloro-4-fluoroanilino)-7-[[(3S)-3-oxolanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide | | quinazolines | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| N-[4-(3-chloro-4-fluoroanilino)-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide | | quinazolines | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| wnt-c59 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 5-[1-(2-hydroxyethyl)-3-pyridin-4-yl-4-pyrazolyl]-2,3-dihydroinden-1-one oxime | | indanes | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| azd1208 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gkt137831 | | | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| vx-509 | | | | 2017 | 2020 | 5.8 | high | 0 | 0 | 0 | 0 | 4 | 0 |
| vx-970 | | sulfonamide | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| gs-9973 | | | | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| amg 925 | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| debio 1347 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gne-618 | | | | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| g007-lk | | | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| volitinib | | | | 2017 | 2020 | 5.8 | high | 0 | 0 | 0 | 0 | 4 | 0 |
| ajmaline | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| ML355 | | benzothiazoles;
monomethoxybenzene;
phenols;
secondary amino compound;
substituted aniline;
sulfonamide | EC 1.13.11.31 (arachidonate 12-lipoxygenase) inhibitor;
platelet aggregation inhibitor | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| acp-196 | | aromatic amine;
benzamides;
imidazopyrazine;
pyridines;
pyrrolidinecarboxamide;
secondary carboxamide;
tertiary carboxamide;
ynone | antineoplastic agent;
apoptosis inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| gsk343 | | aminopyridine;
indazoles;
N-alkylpiperazine;
N-arylpiperazine;
pyridone;
secondary carboxamide | antineoplastic agent;
apoptosis inducer;
EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| agi-6780 | | | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| khs101 | | | | 2017 | 2022 | 4.5 | high | 0 | 0 | 0 | 0 | 3 | 1 |
| osimertinib | | acrylamides;
aminopyrimidine;
biaryl;
indoles;
monomethoxybenzene;
secondary amino compound;
secondary carboxamide;
substituted aniline;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 2017 | 2022 | 4.2 | low | 0 | 0 | 0 | 0 | 3 | 2 |
| cb-839 | | | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| gsk-j4 | | organonitrogen heterocyclic compound | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| pf-06424439 | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| etp-46464 | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| onc201 | | | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| kai407 | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| 6,7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine | | | | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| enasidenib | | 1,3,5-triazines;
aminopyridine;
aromatic amine;
organofluorine compound;
secondary amino compound;
tertiary alcohol | antineoplastic agent;
EC 1.1.1.42 (isocitrate dehydrogenase) inhibitor | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| oicr-9429 | | | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| lly-507 | | | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| at 9283 | | | | 2017 | 2020 | 5.8 | medium | 0 | 0 | 0 | 0 | 4 | 0 |
| otssp167 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| entecavir | | 2-aminopurines;
oxopurine;
primary alcohol;
secondary alcohol | antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chir 258 | | | | 2008 | 2022 | 10.7 | high | 0 | 0 | 0 | 1 | 5 | 1 |
| r 1530 | | | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| acyclovir | | 2-aminopurines;
oxopurine | antimetabolite;
antiviral drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| osi 027 | | | | 2013 | 2017 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| hypoxanthine | | nucleobase analogue;
oxopurine;
purine nucleobase | fundamental metabolite | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| inosine | | inosines;
purines D-ribonucleoside | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| folic acid | | folic acids;
N-acyl-amino acid | human metabolite;
mouse metabolite;
nutrient | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rifampin | | cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion | angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor | 2010 | 2022 | 8.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| clozapine | | benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound | adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic | 2010 | 2020 | 7.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| dacarbazine | | dacarbazine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| didanosine | | purine 2',3'-dideoxyribonucleoside | antimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ganciclovir | | 2-aminopurines;
oxopurine | antiinfective agent;
antiviral drug | 2010 | 2019 | 9.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sildenafil | | piperazines;
pyrazolopyrimidine;
sulfonamide | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| olanzapine | | benzodiazepine;
N-arylpiperazine;
N-methylpiperazine | antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| penciclovir | | 2-aminopurines;
propane-1,3-diols | antiviral drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxypurinol | | pyrazolopyrimidine | drug metabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| raltitrexed | | N-acyl-amino acid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1-[amino-[(6-methoxy-4-methyl-2-quinazolinyl)amino]methylidene]-3-phenylurea | | quinazolines | | 2008 | 2011 | 14.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| allopurinol | | nucleobase analogue;
organic heterobicyclic compound | antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hli 373 | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| leucovorin | | formyltetrahydrofolic acid | Escherichia coli metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| alanosine | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pemetrexed | | N-acyl-L-glutamic acid;
pyrrolopyrimidine | antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor | 2013 | 2021 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| 1-hydroxyphenazine | | phenazines | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| tirapazamine | | aromatic amine;
benzotriazines;
N-oxide | antibacterial agent;
antineoplastic agent;
apoptosis inducer | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sildenafil citrate | | citrate salt | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aprepitant | | (trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles | antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rifabutin | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| xav939 | | (trifluoromethyl)benzenes;
thiopyranopyrimidine | tankyrase inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ag-879 | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| 2-carboxyarabinitol 1-phosphate | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ro 24-7429 | | benzodiazepine | | 2017 | 2020 | 5.3 | medium | 0 | 0 | 0 | 0 | 3 | 0 |
| nintedanib | | | | 2011 | 2022 | 6.7 | low | 0 | 0 | 0 | 0 | 8 | 1 |
| amg531 | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| n'-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthahydrazide | | catechols;
hydrazide;
hydrazone;
naphthols | EC 3.6.5.5 (dynamin GTPase) inhibitor | 2017 | 2020 | 5.3 | high | 0 | 0 | 0 | 0 | 3 | 0 |
| ver 52296 | | aromatic amide;
isoxazoles;
monocarboxylic acid amide;
morpholines;
resorcinols | angiogenesis inhibitor;
antineoplastic agent;
Hsp90 inhibitor | 2013 | 2020 | 6.8 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| 2-hydroxy-3-(5-((morpholin-4-yl)methyl)pyridin-2-yl)-1h-indole-5-carbonitrile | | hydroxyindoles;
morpholines;
nitrile;
pyridines;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
tau aggregation inhibitor | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| sb-590885 | | aromatic ether;
imidazoles;
ketoxime;
pyridines;
tertiary amino compound | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| rvx 208 | | | | 2017 | 2020 | 5.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| bmn 673 | | | | 2017 | 2022 | 4.5 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| pf-477736 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bay 80-6946 | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pp242 | | aromatic amine;
biaryl;
hydroxyindoles;
phenols;
primary amino compound;
pyrazolopyrimidine | antineoplastic agent;
mTOR inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fenobam | | ureas | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 21, Issue:7, 2011
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.Bioorganic & medicinal chemistry, , Jun-01, Volume: 15, Issue:11, 2007
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
A small molecule-kinase interaction map for clinical kinase inhibitors.Nature biotechnology, , Volume: 23, Issue:3, 2005
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.European journal of medicinal chemistry, , Volume: 46, Issue:10, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
A small molecule-kinase interaction map for clinical kinase inhibitors.Nature biotechnology, , Volume: 23, Issue:3, 2005
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.Journal of medicinal chemistry, , 09-10, Volume: 63, Issue:17, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Hybrids from 4-anilinoquinazoline and hydroxamic acid as dual inhibitors of vascular endothelial growth factor receptor-2 and histone deacetylase.Bioorganic & medicinal chemistry letters, , Nov-15, Volume: 25, Issue:22, 2015
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A small molecule-kinase interaction map for clinical kinase inhibitors.Nature biotechnology, , Volume: 23, Issue:3, 2005
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.Journal of medicinal chemistry, , 01-11, Volume: 61, Issue:1, 2018
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
A small molecule-kinase interaction map for clinical kinase inhibitors.Nature biotechnology, , Volume: 23, Issue:3, 2005
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.Bioorganic & medicinal chemistry, , 10-15, Volume: 27, Issue:20, 2019
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.European journal of medicinal chemistry, , Volume: 46, Issue:10, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Impact of aryloxy-linked quinazolines: a novel series of selective VEGFR-2 receptor tyrosine kinase inhibitors.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 21, Issue:7, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.Bioorganic & medicinal chemistry, , Jun-01, Volume: 15, Issue:11, 2007
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 16, Issue:18, 2006
A small molecule-kinase interaction map for clinical kinase inhibitors.Nature biotechnology, , Volume: 23, Issue:3, 2005
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.European journal of medicinal chemistry, , Volume: 45, Issue:11, 2010
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.Bioorganic & medicinal chemistry, , Jun-01, Volume: 15, Issue:11, 2007
ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 17, Issue:5, 2007
Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 16, Issue:7, 2006
2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 16, Issue:6, 2006
Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 16, Issue:5, 2006
N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II.Bioorganic & medicinal chemistry letters, , Volume: 16, Issue:3, 2006
2-(Quinazolin-4-ylamino)-[1,4]benzoquinones as covalent-binding, irreversible inhibitors of the kinase domain of vascular endothelial growth factor receptor-2.Journal of medicinal chemistry, , Dec-01, Volume: 48, Issue:24, 2005
Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.Journal of medicinal chemistry, , Mar-10, Volume: 48, Issue:5, 2005
A small molecule-kinase interaction map for clinical kinase inhibitors.Nature biotechnology, , Volume: 23, Issue:3, 2005
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.Journal of medicinal chemistry, , Dec-19, Volume: 45, Issue:26, 2002
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
A small molecule-kinase interaction map for clinical kinase inhibitors.Nature biotechnology, , Volume: 23, Issue:3, 2005
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
A small molecule-kinase interaction map for clinical kinase inhibitors.Nature biotechnology, , Volume: 23, Issue:3, 2005
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
A small molecule-kinase interaction map for clinical kinase inhibitors.Nature biotechnology, , Volume: 23, Issue:3, 2005
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
A small molecule-kinase interaction map for clinical kinase inhibitors.Nature biotechnology, , Volume: 23, Issue:3, 2005
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
A small molecule-kinase interaction map for clinical kinase inhibitors.Nature biotechnology, , Volume: 23, Issue:3, 2005
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.Journal of medicinal chemistry, , 09-10, Volume: 63, Issue:17, 2020
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.European journal of medicinal chemistry, , Volume: 46, Issue:10, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
A small molecule-kinase interaction map for clinical kinase inhibitors.Nature biotechnology, , Volume: 23, Issue:3, 2005
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
A small molecule-kinase interaction map for clinical kinase inhibitors.Nature biotechnology, , Volume: 23, Issue:3, 2005
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.Journal of medicinal chemistry, , 08-26, Volume: 64, Issue:16, 2021
Novel promising 4-anilinoquinazoline-based derivatives as multi-target RTKs inhibitors: Design, molecular docking, synthesis, and antitumor activities in vitro and vivo.Bioorganic & medicinal chemistry, , 10-15, Volume: 27, Issue:20, 2019
Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.Journal of medicinal chemistry, , 01-11, Volume: 61, Issue:1, 2018
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.Journal of medicinal chemistry, , May-14, Volume: 58, Issue:9, 2015
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase.Bioorganic & medicinal chemistry letters, , Jan-01, Volume: 22, Issue:1, 2012
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.European journal of medicinal chemistry, , Volume: 46, Issue:10, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.European journal of medicinal chemistry, , Volume: 45, Issue:11, 2010
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
A small molecule-kinase interaction map for clinical kinase inhibitors.Nature biotechnology, , Volume: 23, Issue:3, 2005
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
A small molecule-kinase interaction map for clinical kinase inhibitors.Nature biotechnology, , Volume: 23, Issue:3, 2005
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
A small molecule-kinase interaction map for clinical kinase inhibitors.Nature biotechnology, , Volume: 23, Issue:3, 2005
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
A small molecule-kinase interaction map for clinical kinase inhibitors.Nature biotechnology, , Volume: 23, Issue:3, 2005
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.Journal of medicinal chemistry, , Dec-19, Volume: 45, Issue:26, 2002
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.Journal of medicinal chemistry, , 08-26, Volume: 64, Issue:16, 2021
Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.Journal of medicinal chemistry, , 01-11, Volume: 61, Issue:1, 2018
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.Journal of medicinal chemistry, , May-14, Volume: 58, Issue:9, 2015
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.European journal of medicinal chemistry, , Volume: 46, Issue:10, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.European journal of medicinal chemistry, , Volume: 45, Issue:11, 2010
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
A small molecule-kinase interaction map for clinical kinase inhibitors.Nature biotechnology, , Volume: 23, Issue:3, 2005
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.European journal of medicinal chemistry, , Volume: 45, Issue:11, 2010
ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 17, Issue:5, 2007
Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template.Bioorganic & medicinal chemistry letters, , Apr-01, Volume: 16, Issue:7, 2006
2-((1H-Azol-1-yl)methyl)-N-arylbenzamides: novel dual inhibitors of VEGFR-1/2 kinases.Bioorganic & medicinal chemistry letters, , Mar-15, Volume: 16, Issue:6, 2006
Hetaryl imidazoles: a novel dual inhibitors of VEGF receptors I and II.Bioorganic & medicinal chemistry letters, , Mar-01, Volume: 16, Issue:5, 2006
N-(Aryl)-4-(azolylethyl)thiazole-5-carboxamides: novel potent inhibitors of VEGF receptors I and II.Bioorganic & medicinal chemistry letters, , Volume: 16, Issue:3, 2006
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.Journal of medicinal chemistry, , Dec-19, Volume: 45, Issue:26, 2002
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.Bioorganic & medicinal chemistry, , Jun-01, Volume: 15, Issue:11, 2007
A small molecule-kinase interaction map for clinical kinase inhibitors.Nature biotechnology, , Volume: 23, Issue:3, 2005
Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.Journal of medicinal chemistry, , 01-11, Volume: 61, Issue:1, 2018
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.European journal of medicinal chemistry, , Volume: 45, Issue:11, 2010
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.European journal of medicinal chemistry, , Volume: 45, Issue:11, 2010
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.Journal of medicinal chemistry, , 01-11, Volume: 61, Issue:1, 2018
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.Journal of medicinal chemistry, , May-14, Volume: 58, Issue:9, 2015
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.European journal of medicinal chemistry, , Volume: 45, Issue:11, 2010
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.European journal of medicinal chemistry, , Volume: 45, Issue:11, 2010
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2.Bioorganic & medicinal chemistry, , Jun-01, Volume: 15, Issue:11, 2007
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.European journal of medicinal chemistry, , Volume: 45, Issue:11, 2010
Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.Bioorganic & medicinal chemistry, , Jan-15, Volume: 17, Issue:2, 2009
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.European journal of medicinal chemistry, , Volume: 45, Issue:11, 2010
Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.Journal of medicinal chemistry, , Aug-14, Volume: 51, Issue:15, 2008
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.Journal of medicinal chemistry, , 08-26, Volume: 64, Issue:16, 2021
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.Journal of medicinal chemistry, , May-14, Volume: 58, Issue:9, 2015
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.European journal of medicinal chemistry, , Volume: 45, Issue:11, 2010
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.Journal of medicinal chemistry, , 09-10, Volume: 63, Issue:17, 2020
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors.Bioorganic & medicinal chemistry, , 11-01, Volume: 26, Issue:20, 2018
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.Journal of medicinal chemistry, , 08-26, Volume: 64, Issue:16, 2021
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.Journal of medicinal chemistry, , May-14, Volume: 58, Issue:9, 2015
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.Journal of medicinal chemistry, , 08-26, Volume: 64, Issue:16, 2021
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Discovery and Optimization of wt-RET/KDR-Selective Inhibitors of RETACS medicinal chemistry letters, , Apr-09, Volume: 11, Issue:4, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors.Bioorganic & medicinal chemistry, , 11-01, Volume: 26, Issue:20, 2018
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.Journal of medicinal chemistry, , May-14, Volume: 58, Issue:9, 2015
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.Journal of medicinal chemistry, , 05-09, Volume: 62, Issue:9, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Design, synthesis, biological evaluation of benzoyl amide derivatives containing nitrogen heterocyclic ring as potential VEGFR-2 inhibitors.Bioorganic & medicinal chemistry, , 09-01, Volume: 27, Issue:17, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.Journal of medicinal chemistry, , 09-10, Volume: 63, Issue:17, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.Journal of medicinal chemistry, , 08-26, Volume: 64, Issue:16, 2021
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.Journal of medicinal chemistry, , 08-26, Volume: 64, Issue:16, 2021
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.Journal of medicinal chemistry, , 09-10, Volume: 63, Issue:17, 2020
Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRACS medicinal chemistry letters, , Jun-13, Volume: 10, Issue:6, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.European journal of medicinal chemistry, , Volume: 46, Issue:6, 2011
Navigating the kinome.Nature chemical biology, , Volume: 7, Issue:4, 2011
A quantitative analysis of kinase inhibitor selectivity.Nature biotechnology, , Volume: 26, Issue:1, 2008
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Kinase Inhibitors as Underexplored Antiviral Agents.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.Journal of medicinal chemistry, , 01-11, Volume: 61, Issue:1, 2018
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Comprehensive analysis of kinase inhibitor selectivity.Nature biotechnology, , Oct-30, Volume: 29, Issue:11, 2011
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Identification of potent Yes1 kinase inhibitors using a library screening approach.Bioorganic & medicinal chemistry letters, , Aug-01, Volume: 23, Issue:15, 2013
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
Retrospective assessment of rat liver microsomal stability at NCATS: data and QSAR models.Scientific reports, , 11-26, Volume: 10, Issue:1, 2020
Predictive models of aqueous solubility of organic compounds built on A large dataset of high integrity.Bioorganic & medicinal chemistry, , 07-15, Volume: 27, Issue:14, 2019
Highly predictive and interpretable models for PAMPA permeability.Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3, 2017
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| beta-alanine | | amino acid zwitterion;
beta-amino acid | agonist;
fundamental metabolite;
human metabolite;
inhibitor;
neurotransmitter | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dihydroxyphenylalanine | | hydroxyphenylalanine;
non-proteinogenic alpha-amino acid;
tyrosine derivative | human metabolite | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| niacinamide | | pyridine alkaloid;
pyridinecarboxamide;
vitamin B3 | anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor | 2005 | 2017 | 12.8 | low | 3 | 0 | 0 | 19 | 33 | 0 |
| nitroxyl | | nitrogen oxoacid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pd 173074 | | aromatic amine;
biaryl;
dimethoxybenzene;
pyridopyrimidine;
tertiary amino compound;
ureas | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 3-methylcholanthrene | | ortho- and peri-fused polycyclic arene | aryl hydrocarbon receptor agonist;
carcinogenic agent | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acetaminophen | | acetamides;
phenols | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bicalutamide | | (trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol | | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| celecoxib | | organofluorine compound;
pyrazoles;
sulfonamide;
toluenes | cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2007 | 2015 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| chloroquine | | aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| valproic acid | | branched-chain fatty acid;
branched-chain saturated fatty acid | anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ellipticine | | indole alkaloid;
organic heterotetracyclic compound;
organonitrogen heterocyclic compound;
polycyclic heteroarene | antineoplastic agent;
plant metabolite | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| erythrosine | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fluorouracil | | nucleobase analogue;
organofluorine compound | antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic | 2009 | 2017 | 11.0 | low | 3 | 0 | 0 | 1 | 4 | 0 |
| hydroxychloroquine | | aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| losartan | | biphenylyltetrazole;
imidazoles | angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| metformin | | guanidines | environmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic | 2013 | 2014 | 10.5 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| midazolam | | imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound | anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| mitoxantrone | | dihydroxyanthraquinone | analgesic;
antineoplastic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| omeprazole | | aromatic ether;
benzimidazoles;
pyridines;
sulfoxide | | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| oxonic acid | | 1,3,5-triazines;
monocarboxylic acid | | 2011 | 2018 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| 4-phenylbutyric acid | | monocarboxylic acid | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| piracetam | | organonitrogen compound;
organooxygen compound | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ag 1879 | | aromatic amine;
monochlorobenzenes;
pyrazolopyrimidine | beta-adrenergic antagonist;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
geroprotector | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| propranolol | | naphthalenes;
propanolamine;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vorinostat | | dicarboxylic acid diamide;
hydroxamic acid | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor | 2009 | 2012 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| tegafur | | organohalogen compound;
pyrimidines | | 2011 | 2018 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| temozolomide | | imidazotetrazine;
monocarboxylic acid amide;
triazene derivative | alkylating agent;
antineoplastic agent;
prodrug | 2008 | 2015 | 12.7 | low | 3 | 0 | 0 | 3 | 4 | 0 |
| thalidomide | | phthalimides;
piperidones | | 2004 | 2014 | 14.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| trazodone | | monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine | adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| urethane | | carbamate ester | fungal metabolite;
mutagen | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mitomycin | | mitomycin | alkylating agent;
antineoplastic agent | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| prednisolone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic | 2007 | 2009 | 16.0 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| thymidine | | pyrimidine 2'-deoxyribonucleoside | Escherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-nitroquinoline-1-oxide | | C-nitro compound;
quinoline N-oxide | carcinogenic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 9,10-dimethyl-1,2-benzanthracene | | ortho-fused polycyclic arene;
tetraphenes | carcinogenic agent | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| uridine | | uridines | drug metabolite;
fundamental metabolite;
human metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| carbostyril | | monohydroxyquinoline;
quinolone | bacterial xenobiotic metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tyrosine | | amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
tyrosine | EC 1.3.1.43 (arogenate dehydrogenase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical | 2004 | 2009 | 17.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| methionine | | aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid | antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| valine | | L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine | algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| threonine | | amino acid zwitterion;
aspartate family amino acid;
L-alpha-amino acid;
proteinogenic amino acid;
threonine | algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| taurocholic acid | | amino sulfonic acid;
bile acid taurine conjugate | human metabolite | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methylprednisolone | | 6-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| quinoline | | azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinolines | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pentane | | alkane;
volatile organic compound | non-polar solvent;
refrigerant | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyrroles | | pyrrole;
secondary amine | | 2002 | 2017 | 13.4 | low | 0 | 0 | 0 | 18 | 23 | 0 |
| ethyl acetate | | acetate ester;
ethyl ester;
volatile organic compound | EC 3.4.19.3 (pyroglutamyl-peptidase I) inhibitor;
metabolite;
polar aprotic solvent;
Saccharomyces cerevisiae metabolite | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| catechin | | catechin | antioxidant;
plant metabolite | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| quinazolines | | azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines | | 2002 | 2023 | 11.6 | medium | 88 | 0 | 0 | 182 | 332 | 26 |
| indazoles | | indazole | | 2007 | 2019 | 11.6 | low | 0 | 0 | 0 | 6 | 14 | 0 |
| thiazoles | | 1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene | | 2013 | 2016 | 10.5 | low | 2 | 0 | 0 | 0 | 6 | 0 |
| pyrazines | | diazine;
pyrazines | Daphnia magna metabolite | 2003 | 2019 | 12.5 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| malondialdehyde | | dialdehyde | biomarker | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lucanthone hydrochloride | | | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| diphenylamine | | aromatic amine;
bridged diphenyl fungicide;
secondary amino compound | antifungal agrochemical;
antioxidant;
carotogenesis inhibitor;
EC 1.3.99.29 [phytoene desaturase (zeta-carotene-forming)] inhibitor;
ferroptosis inhibitor;
radical scavenger | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| deoxycytidine | | pyrimidine 2'-deoxyribonucleoside | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2005 | 2020 | 11.5 | low | 8 | 0 | 0 | 6 | 10 | 0 |
| gold | | copper group element atom;
elemental gold | | 2017 | 2018 | 6.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| camptothecin | | delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite | 2007 | 2012 | 14.0 | low | 2 | 0 | 0 | 4 | 2 | 0 |
| chlorine | | diatomic chlorine;
gas molecular entity | bleaching agent | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| phenyl acetate | | benzenes;
phenyl acetates | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| paclitaxel | | taxane diterpenoid;
tetracyclic diterpenoid | antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent | 2003 | 2017 | 13.9 | low | 2 | 0 | 0 | 5 | 5 | 0 |
| etoposide | | beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound | antineoplastic agent;
DNA synthesis inhibitor | 2010 | 2017 | 10.0 | low | 1 | 0 | 0 | 1 | 3 | 0 |
| ribavirin | | 1-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide | anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1-methyl-4-phenylpyridinium | | pyridinium ion | apoptosis inducer;
herbicide;
human xenobiotic metabolite;
neurotoxin | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| itraconazole | | aromatic ether;
conazole antifungal drug;
cyclic ketal;
dichlorobenzene;
dioxolane;
N-arylpiperazine;
triazole antifungal drug;
triazoles | EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
Hedgehog signaling pathway inhibitor;
P450 inhibitor | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| gemcitabine | | organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic | 2005 | 2020 | 11.9 | low | 7 | 0 | 0 | 6 | 8 | 0 |
| irinotecan | | carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug | 2007 | 2021 | 11.5 | low | 2 | 0 | 0 | 4 | 3 | 1 |
| capecitabine | | carbamate ester;
cytidines;
organofluorine compound | antimetabolite;
antineoplastic agent;
prodrug | 2012 | 2018 | 8.7 | low | 2 | 0 | 0 | 0 | 3 | 0 |
| thiazolyl blue | | organic bromide salt | colorimetric reagent;
dye | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| plerixafor | | azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound | anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thionine | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| epigallocatechin gallate | | flavans;
gallate ester;
polyphenol | antineoplastic agent;
antioxidant;
apoptosis inducer;
geroprotector;
Hsp90 inhibitor;
neuroprotective agent;
plant metabolite | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| triazoles | | 1,2,3-triazole | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 4-aminoquinoline | | | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fluorodeoxyglucose f18 | | 2-deoxy-2-((18)F)fluoro-D-glucose;
2-deoxy-2-fluoro-aldehydo-D-glucose | | 2011 | 2012 | 12.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| honokiol | | biphenyls | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| bexarotene | | benzoic acids;
naphthalenes;
retinoid | antineoplastic agent | 2011 | 2012 | 12.5 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| 4-aminoquinazoline | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| combretastatin | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fulvestrant | | 17beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide | antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist | 2012 | 2014 | 11.0 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| u 73122 | | aromatic ether;
aza-steroid;
maleimides | EC 3.1.4.11 (phosphoinositide phospholipase C) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fingolimod hydrochloride | | hydrochloride | immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| imatinib mesylate | | methanesulfonate salt | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor | 2003 | 2022 | 12.3 | low | 0 | 0 | 0 | 4 | 4 | 1 |
| gefitinib | | aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 2003 | 2022 | 14.6 | low | 1 | 0 | 0 | 24 | 11 | 1 |
| vadimezan | | monocarboxylic acid;
xanthones | antineoplastic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methotrexate | | dicarboxylic acid;
monocarboxylic acid amide;
pteridines | abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| abiraterone | | 3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines | antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor | 2012 | 2016 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| docetaxel anhydrous | | secondary alpha-hydroxy ketone;
tetracyclic diterpenoid | antimalarial;
antineoplastic agent;
photosensitizing agent | 2005 | 2022 | 12.8 | low | 10 | 0 | 0 | 11 | 10 | 1 |
| vatalanib | | monochlorobenzenes;
phthalazines;
pyridines;
secondary amino compound | angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist | 2002 | 2014 | 16.3 | low | 0 | 0 | 0 | 7 | 4 | 0 |
| tyrosinamide | | amino acid amide;
L-tyrosine derivative | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| canertinib | | monochlorobenzenes;
morpholines;
organofluorine compound;
quinazolines | antineoplastic agent;
tyrosine kinase inhibitor | 2007 | 2018 | 11.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| erlotinib hydrochloride | | hydrochloride;
terminal acetylenic compound | antineoplastic agent;
protein kinase inhibitor | 2006 | 2022 | 11.4 | low | 2 | 0 | 0 | 10 | 16 | 1 |
| lapatinib | | furans;
organochlorine compound;
organofluorine compound;
quinazolines | antineoplastic agent;
tyrosine kinase inhibitor | 2006 | 2022 | 11.8 | low | 0 | 0 | 0 | 2 | 2 | 1 |
| dabigatran | | aromatic amide;
benzimidazoles;
beta-alanine derivative;
carboxamidine;
pyridines | anticoagulant;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
EC 3.4.21.5 (thrombin) inhibitor | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sorafenib | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide | angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor | 2005 | 2022 | 12.0 | low | 3 | 0 | 0 | 19 | 35 | 2 |
| lenalidomide | | aromatic amine;
dicarboximide;
isoindoles;
piperidones | angiogenesis inhibitor;
antineoplastic agent;
immunomodulator | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cortisone | | 11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | human metabolite;
mouse metabolite | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bortezomib | | amino acid amide;
L-phenylalanine derivative;
pyrazines | antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor | 2003 | 2019 | 12.5 | low | 1 | 0 | 0 | 2 | 4 | 0 |
| calcein am | | 2-benzofurans;
acetate ester;
gamma-lactone;
organic heteropentacyclic compound;
oxaspiro compound;
xanthene dye | fluorochrome | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| carboplatin | | | | 2005 | 2020 | 11.1 | low | 5 | 0 | 0 | 2 | 5 | 0 |
| cellulase | | cellotriose | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lignans | | | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| resveratrol | | resveratrol | antioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| favipiravir | | hydroxypyrazine;
organofluorine compound;
primary carboxamide | anticoronaviral agent;
antiviral drug;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| stilbenes | | stilbene | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| s 1033 | | (trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide | anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor | 2013 | 2022 | 8.8 | low | 0 | 0 | 0 | 0 | 3 | 1 |
| digoxin | | cardenolide glycoside;
steroid saponin | anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| tamoxifen | | stilbenoid;
tertiary amino compound | angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator | 2014 | 2018 | 8.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| ranitidine | | C-nitro compound;
furans;
organic sulfide;
tertiary amino compound | anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| lithium | | alkali metal atom | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| e 7010 | | sulfonamide | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dasatinib | | 1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor | 2013 | 2022 | 8.0 | low | 3 | 0 | 0 | 0 | 5 | 2 |
| rhodamine 123 | | organic cation;
xanthene dye | fluorochrome | 2007 | 2012 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sphingosine | | sphing-4-enine | human metabolite;
mouse metabolite | 2007 | 2012 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| isotretinoin | | retinoic acid | antineoplastic agent;
keratolytic drug;
teratogenic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sphingosine 1-phosphate | | sphingoid 1-phosphate | mouse metabolite;
signalling molecule;
sphingosine-1-phosphate receptor agonist;
T-cell proliferation inhibitor;
vasodilator agent | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| levetiracetam | | pyrrolidin-2-ones | anticonvulsant;
environmental contaminant;
xenobiotic | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oxycodone | | organic heteropentacyclic compound;
semisynthetic derivative | antitussive;
mu-opioid receptor agonist;
opioid analgesic | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sirolimus | | antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol | antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 2012 | 2015 | 10.8 | low | 2 | 0 | 0 | 0 | 4 | 0 |
| deamino arginine vasopressin | | heterodetic cyclic peptide | diagnostic agent;
renal agent;
vasopressin receptor agonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bisdemethoxycurcumin | | beta-diketone;
diarylheptanoid;
enone;
polyphenol | EC 3.2.1.1 (alpha-amylase) inhibitor;
metabolite | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| semaxinib | | olefinic compound;
oxindoles;
pyrroles | angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist | 2002 | 2005 | 20.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| orantinib | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| su 11248 | | monocarboxylic acid amide;
pyrroles | angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist | 2003 | 2017 | 13.0 | low | 0 | 0 | 0 | 16 | 23 | 0 |
| palbociclib | | aminopyridine;
aromatic ketone;
cyclopentanes;
piperidines;
pyridopyrimidine;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fosbretabulin | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fumarates | | butenedioate;
C4-dicarboxylate | human metabolite;
metabolite;
Saccharomyces cerevisiae metabolite | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| phytochlorin | | | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| everolimus | | cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol | anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 2012 | 2021 | 8.8 | low | 3 | 0 | 0 | 0 | 7 | 1 |
| ixabepilone | | 1,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle | antineoplastic agent;
microtubule-destabilising agent | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| ekb 569 | | aminoquinoline;
monocarboxylic acid amide;
monochlorobenzenes;
nitrile | protein kinase inhibitor | 2007 | 2012 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| axitinib | | aryl sulfide;
benzamides;
indazoles;
pyridines | antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist | 2007 | 2016 | 13.4 | low | 0 | 0 | 0 | 6 | 7 | 0 |
| tanespimycin | | 1,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound;
secondary amino compound | antineoplastic agent;
apoptosis inducer;
Hsp90 inhibitor | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gadolinium dtpa | | gadolinium coordination entity | MRI contrast agent | 2003 | 2008 | 18.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| taxane | | diterpene;
terpenoid fundamental parent | | 2005 | 2005 | 19.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| lenvatinib | | aromatic amide;
aromatic ether;
cyclopropanes;
monocarboxylic acid amide;
monochlorobenzenes;
phenylureas;
quinolines | antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
fibroblast growth factor receptor antagonist;
orphan drug;
vascular endothelial growth factor receptor antagonist | 2011 | 2021 | 7.4 | low | 0 | 0 | 0 | 0 | 12 | 2 |
| pd 0325901 | | difluorobenzene;
hydroxamic acid ester;
monofluorobenzenes;
organoiodine compound;
propane-1,2-diols;
secondary amino compound | antineoplastic agent;
EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sc 236 | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zd 6126 | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| hki 272 | | nitrile;
quinolines | antineoplastic agent;
tyrosine kinase inhibitor | 2007 | 2012 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cediranib | | aromatic ether | | 2005 | 2017 | 13.5 | low | 0 | 0 | 0 | 6 | 6 | 0 |
| fidaxomicin | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pazopanib | | aminopyrimidine;
indazoles;
sulfonamide | angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist | 2009 | 2019 | 10.1 | low | 0 | 0 | 0 | 1 | 10 | 0 |
| azd 6244 | | benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound | anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 2007 | 2011 | 15.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bibw 2992 | | aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
tyrosine kinase inhibitor | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| saracatinib | | aromatic ether;
benzodioxoles;
diether;
N-methylpiperazine;
organochlorine compound;
oxanes;
quinazolines;
secondary amino compound | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
autophagy inducer;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor;
radiosensitizing agent | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| regorafenib | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
phenylureas;
pyridinecarboxamide | antineoplastic agent;
hepatotoxic agent;
tyrosine kinase inhibitor | 2016 | 2017 | 7.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| pf 00299804 | | enamide;
monochlorobenzenes;
monofluorobenzenes;
piperidines;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| crizotinib | | 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[1-(piperidin-4-yl)pyrazol-4-yl]pyridin-2-amine | antineoplastic agent;
biomarker;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 2011 | 2017 | 10.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| chir-265 | | aromatic ether | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| trametinib | | acetamides;
aromatic amine;
cyclopropanes;
organofluorine compound;
organoiodine compound;
pyridopyrimidine;
ring assembly | anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
geroprotector | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mln8054 | | benzazepine | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oligonucleotides | | | | 2007 | 2015 | 12.9 | low | 0 | 0 | 0 | 5 | 6 | 0 |
| chitosan | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| icotinib | | | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ponatinib | | (trifluoromethyl)benzenes;
acetylenic compound;
benzamides;
imidazopyridazine;
N-methylpiperazine | antineoplastic agent;
tyrosine kinase inhibitor | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lucitanib | | aromatic ether;
cyclopropanes;
naphthalenecarboxamide;
primary amino compound;
quinolines | antineoplastic agent;
fibroblast growth factor receptor antagonist;
vascular endothelial growth factor receptor antagonist | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cabozantinib | | aromatic ether;
dicarboxylic acid diamide;
organofluorine compound;
quinolines | antineoplastic agent;
tyrosine kinase inhibitor | 2011 | 2023 | 7.3 | low | 1 | 0 | 0 | 0 | 27 | 5 |
| plx4032 | | aromatic ketone;
difluorobenzene;
monochlorobenzenes;
pyrrolopyridine;
sulfonamide | antineoplastic agent;
B-Raf inhibitor | 2012 | 2019 | 8.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| piperidines | | | | 2002 | 2023 | 11.6 | medium | 88 | 0 | 0 | 181 | 332 | 26 |
| dinaciclib | | pyrazolopyrimidine | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 3-(2,6-dichloro-3,5-dimethoxyphenyl)-1-(6-(4-(4-ethylpiperazin-1-yl)-phenylamino)pyrimidin-4-yl)-1-methylurea | | aminopyrimidine;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
phenylureas | antineoplastic agent;
fibroblast growth factor receptor antagonist | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| s 1 (combination) | | | | 2011 | 2018 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| epidermal growth factor | | | | 2007 | 2017 | 12.4 | low | 1 | 0 | 0 | 2 | 6 | 0 |
| osimertinib | | acrylamides;
aminopyrimidine;
biaryl;
indoles;
monomethoxybenzene;
secondary amino compound;
secondary carboxamide;
substituted aniline;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| agar | | | | 2003 | 2004 | 20.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| imetelstat | | | | 2007 | 2015 | 12.9 | low | 0 | 0 | 0 | 5 | 6 | 0 |
| cyclin d1 | | | | 2016 | 2018 | 7.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| contrast agent p792 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| transforming growth factor alpha | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lactoferrin | | | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thromboplastin | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| muramidase | | | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| guanine | | 2-aminopurines;
oxopurine;
purine nucleobase | algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2006 | 2011 | 14.7 | low | 3 | 0 | 0 | 5 | 2 | 0 |
| folic acid | | folic acids;
N-acyl-amino acid | human metabolite;
mouse metabolite;
nutrient | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| rifampin | | cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion | angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| dacarbazine | | dacarbazine | | 2008 | 2015 | 12.7 | low | 3 | 0 | 0 | 3 | 4 | 0 |
| pemetrexed | | N-acyl-L-glutamic acid;
pyrrolopyrimidine | antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor | 2006 | 2020 | 13.4 | low | 3 | 0 | 0 | 5 | 3 | 0 |
| nintedanib | | | | 2012 | 2019 | 9.0 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| pyrimidinones | | | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| Acoustic Neurinoma, Bilateral | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Actinic Reticuloid Syndrome | 0 | | 2009 | 2019 | 10.5 | low | 1 | 0 | 0 | 1 | 3 | 0 |
| Acute Disease | 0 | | 2012 | 2021 | 7.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Acute Edematous Pancreatitis | 0 | | 2020 | 2021 | 3.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Acute Liver Injury, Drug-Induced | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Acute Myelogenous Leukemia | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Addison Disease | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Addison's Disease | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Adenocarcinoma | 0 | | 2003 | 2021 | 11.7 | low | 6 | 0 | 0 | 9 | 20 | 2 |
| Adenocarcinoma Of Kidney | 0 | | 2004 | 2017 | 15.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| Adenocarcinoma of Lung | 0 | | 2010 | 2015 | 11.6 | low | 0 | 0 | 0 | 1 | 7 | 0 |
| Adenocarcinoma, Basal Cell | 0 | | 2003 | 2021 | 11.7 | low | 6 | 0 | 0 | 9 | 20 | 2 |
| Adenocarcinoma, Follicular | 1 | | 2011 | 2015 | 11.3 | low | 3 | 0 | 0 | 0 | 6 | 0 |
| Adenocarcinoma, Papillary | 0 | | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Adenocystic Carcinoma | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Adenohypophyseal Hyposecretion | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Adenoma | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Adenoma, Basal Cell | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Adenoma, Oxyphilic | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Adenomatosis, Familial Endocrine | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Adverse Drug Event | 0 | | 2012 | 2021 | 7.7 | low | 2 | 0 | 0 | 0 | 6 | 1 |
| Allergy, Drug | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Alloxan Diabetes | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Alopecia Areata | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Alopecia Circumscripta | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anaplastic Astrocytoma | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Anaplastic Ependymoma | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Anaplastic Large-Cell Lymphoma | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Androgen-Independent Prostatic Cancer | 0 | | 2013 | 2014 | 10.5 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Angiogenesis, Pathologic | 0 | | 2002 | 2021 | 14.9 | low | 2 | 0 | 0 | 45 | 20 | 2 |
| Animal Mammary Carcinoma | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anoxemia | 0 | | 2012 | 2022 | 5.5 | low | 0 | 0 | 0 | 0 | 2 | 2 |
| Apnea, Sleep | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Apoplexy | 0 | | 2012 | 2017 | 9.5 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Aprosodia | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Arachnoidal Cerebellar Sarcoma, Circumscribed | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Arrhythmia | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Arrhythmias, Cardiac | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Arteriosclerosis | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Aseptic Necrosis of Bone | 0 | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Asthenia | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Astrocytoma | 1 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Astrocytoma, Grade IV | 0 | | 2005 | 2015 | 11.7 | low | 3 | 0 | 0 | 2 | 9 | 0 |
| Autosomal Dominant Juvenile Parkinson Disease | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| B16 Melanoma | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Benign Cerebellar Neoplasms | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Benign Neoplasms | 0 | | 2002 | 2022 | 13.3 | low | 4 | 0 | 0 | 22 | 20 | 4 |
| Benign Neoplasms, Brain | 0 | | 2004 | 2020 | 13.2 | low | 6 | 0 | 0 | 11 | 11 | 0 |
| Bile Duct Cancer | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Bile Duct Neoplasms | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Biliary Tract Cancer | 0 | | 2015 | 2018 | 7.7 | low | 2 | 0 | 0 | 0 | 3 | 0 |
| Biliary Tract Neoplasms | 0 | | 2015 | 2018 | 7.7 | low | 2 | 0 | 0 | 0 | 3 | 0 |
| Bladder Cancer | 0 | | 2009 | 2011 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| Bleeding | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Blood Pressure, High | 0 | | 2007 | 2019 | 10.9 | low | 0 | 0 | 0 | 2 | 5 | 0 |
| Body Weight | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Bone Cancer | 0 | | 2012 | 2017 | 9.6 | low | 2 | 0 | 0 | 0 | 5 | 0 |
| Bone Neoplasms | 0 | | 2012 | 2017 | 9.6 | low | 2 | 0 | 0 | 0 | 5 | 0 |
| Brain Hemorrhage | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Brain Neoplasms | 0 | | 2004 | 2020 | 13.2 | low | 6 | 0 | 0 | 11 | 11 | 0 |
| Brain Stem Neoplasms | 0 | | 2010 | 2017 | 10.2 | low | 6 | 0 | 0 | 1 | 5 | 0 |
| Brain Stem Neoplasms, Primary | 0 | | 2010 | 2017 | 10.2 | low | 6 | 0 | 0 | 1 | 5 | 0 |
| Breast Cancer | 0 | | 2004 | 2022 | 10.8 | low | 6 | 0 | 0 | 7 | 19 | 2 |
| Breast Neoplasms | 1 | | 2004 | 2022 | 10.8 | low | 6 | 0 | 0 | 7 | 19 | 2 |
| CACH Syndrome | 0 | | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Cafe-au-Lait Spots with Pulmonic Stenosis | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Cancer of Colon | 0 | | 2004 | 2014 | 15.8 | low | 0 | 0 | 0 | 8 | 1 | 0 |
| Cancer of Endocrine Gland | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Esophagus | 0 | | 2005 | 2017 | 13.2 | low | 1 | 0 | 0 | 2 | 2 | 0 |
| Cancer of Gallbladder | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Gastrointestinal Tract | 0 | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Head | 0 | | 2007 | 2019 | 11.9 | low | 2 | 0 | 0 | 2 | 6 | 0 |
| Cancer of Kidney | 0 | | 2004 | 2017 | 13.3 | low | 0 | 0 | 0 | 2 | 5 | 0 |
| Cancer of Liver | 0 | | 2004 | 2022 | 10.0 | low | 1 | 0 | 0 | 4 | 9 | 2 |
| Cancer of Lung | 0 | | 2004 | 2022 | 12.5 | low | 25 | 0 | 0 | 52 | 68 | 3 |
| Cancer of Mouth | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cancer of Muscle | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cancer of Nasopharynx | 0 | | 2007 | 2015 | 13.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| Cancer of Ovary | 0 | | 2009 | 2018 | 11.3 | low | 3 | 0 | 0 | 2 | 4 | 0 |
| Cancer of Pancreas | 0 | | 2006 | 2021 | 11.8 | low | 3 | 0 | 0 | 3 | 4 | 1 |
| Cancer of Parotid | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cancer of Prostate | 0 | | 2003 | 2017 | 13.7 | low | 1 | 0 | 0 | 6 | 9 | 0 |
| Cancer of Salivary Gland | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Skin | 0 | | 2007 | 2020 | 10.2 | low | 1 | 0 | 0 | 1 | 3 | 0 |
| Cancer of Stomach | 0 | | 2004 | 2018 | 13.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| Cancer of the Fallopian Tube | 0 | | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Cancer of the Thyroid | 0 | | 2002 | 2023 | 9.6 | low | 15 | 0 | 0 | 14 | 114 | 10 |
| Cancer of the Urinary Tract | 0 | | 2012 | 2015 | 10.5 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Cancer of the Uterus | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cancer, Second Primary | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Canine Diseases | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Carcinogenesis | 0 | | 2014 | 2016 | 8.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Carcinoma | 0 | | 2006 | 2018 | 11.6 | low | 2 | 0 | 0 | 4 | 10 | 0 |
| Carcinoma in Situ | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Carcinoma, Adenoid Cystic | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Carcinoma, Anaplastic | 0 | | 2006 | 2018 | 11.6 | low | 2 | 0 | 0 | 4 | 10 | 0 |
| Carcinoma, Ductal, Pancreatic | 0 | | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Carcinoma, Epidermoid | 0 | | 2005 | 2020 | 13.7 | low | 5 | 0 | 0 | 8 | 7 | 0 |
| Carcinoma, Hepatocellular | 1 | | 2006 | 2022 | 9.7 | low | 1 | 0 | 0 | 3 | 7 | 2 |
| Carcinoma, Intraepithelial | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Carcinoma, Lewis Lung | 0 | | 2005 | 2012 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Carcinoma, Medullary | 1 | | 2004 | 2021 | 11.5 | low | 3 | 0 | 0 | 6 | 11 | 1 |
| Carcinoma, Neuroendocrine | 0 | | 2011 | 2021 | 8.4 | low | 8 | 0 | 0 | 0 | 73 | 7 |
| Carcinoma, Non-Small Cell Lung | 0 | | 2004 | 2022 | 12.6 | low | 22 | 0 | 0 | 39 | 47 | 2 |
| Carcinoma, Non-Small-Cell Lung | 1 | | 2004 | 2022 | 12.6 | low | 22 | 0 | 0 | 39 | 47 | 2 |
| Carcinoma, Oat Cell | 0 | | 2005 | 2008 | 17.3 | low | 1 | 0 | 0 | 3 | 0 | 0 |
| Carcinoma, Ovarian Epithelial | 0 | | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Carcinoma, Pancreatic Ductal | 0 | | 2017 | 2017 | 7.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Carcinoma, Papillary | 0 | | 2002 | 2016 | 14.4 | low | 1 | 0 | 0 | 5 | 5 | 0 |
| Carcinoma, Renal Cell | 1 | | 2004 | 2017 | 15.0 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| Carcinoma, Signet Ring Cell | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Carcinoma, Small Cell | 0 | | 2005 | 2008 | 17.3 | low | 1 | 0 | 0 | 3 | 0 | 0 |
| Carcinoma, Small Cell Lung | 0 | | 2009 | 2017 | 11.3 | low | 1 | 0 | 0 | 1 | 2 | 0 |
| Carcinoma, Squamous Cell | 1 | | 2005 | 2020 | 13.7 | low | 5 | 0 | 0 | 8 | 7 | 0 |
| Carcinoma, Squamous Cell of Head and Neck | 0 | | 2016 | 2019 | 6.5 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Carcinoma, Transitional Cell | 0 | | 2020 | 2020 | 4.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Cardiac Failure | 0 | | 2013 | 2018 | 8.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Cardiac Toxicity | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Cardiomyopathies | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cardiomyopathies, Primary | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cardiotoxicity | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Cardiovascular Diseases | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cell Transformation, Neoplastic | 0 | | 2002 | 2018 | 13.3 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| Cells, Neoplasm Circulating | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Central Nervous System Neoplasm | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Central Nervous System Neoplasms | 1 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Chemical and Drug Induced Liver Injury | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Chemotherapy-Induced Acral Erythema | 0 | | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Cholangiocarcinoma | 0 | | 2009 | 2018 | 10.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Cholangiocellular Carcinoma | 0 | | 2009 | 2018 | 10.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Cholera Infantum | 0 | | 2013 | 2017 | 9.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Chordoma | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chromosomal Translocation | 0 | | 2015 | 2015 | 9.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Cicatrix | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cicatrization | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Clostridioides difficile Infection | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Clostridium Infections | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Colitis | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Colonic Neoplasms | 0 | | 2004 | 2014 | 15.8 | low | 0 | 0 | 0 | 8 | 1 | 0 |
| Colorectal Cancer | 0 | | 2002 | 2012 | 15.7 | low | 4 | 0 | 0 | 7 | 3 | 0 |
| Colorectal Neoplasms | 1 | | 2002 | 2012 | 15.7 | low | 4 | 0 | 0 | 7 | 3 | 0 |
| Congenital Zika Syndrome | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Connective Tissue Neoplasms | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Corneal Diseases | 0 | | 2009 | 2020 | 9.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| Corneal Opacity | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cryptogenic Fibrosing Alveolitis | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cushing Syndrome | 0 | | 2013 | 2017 | 9.2 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| Cushing's Syndrome | 0 | | 2013 | 2017 | 9.2 | low | 0 | 0 | 0 | 0 | 4 | 0 |
| Cystadenocarcinoma, Serous | 0 | | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Day Blindness | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Dermatitis Medicamentosa | 0 | | 2011 | 2019 | 9.4 | low | 0 | 0 | 0 | 0 | 5 | 0 |
| Dermatitis, Contact, Photoallergic | 0 | | 2015 | 2015 | 9.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Dermatitis, Contact, Phototoxic | 0 | | 2009 | 2019 | 8.8 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| Dermatoses | 0 | | 2013 | 2021 | 6.0 | low | 1 | 0 | 0 | 0 | 2 | 1 |
| Diarrhea | 0 | | 2005 | 2015 | 12.2 | low | 4 | 0 | 0 | 1 | 5 | 0 |
| Disease Exacerbation | 0 | | 2004 | 2023 | 9.6 | low | 8 | 0 | 0 | 2 | 16 | 1 |
| Disease Models, Animal | 0 | | 2004 | 2021 | 11.6 | low | 0 | 0 | 0 | 9 | 14 | 2 |
| Diverticulitis | 0 | | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Drug Hypersensitivity | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Drug-Induced Stevens Johnson Syndrome | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Drug-Related Side Effects and Adverse Reactions | 0 | | 2012 | 2021 | 7.7 | low | 2 | 0 | 0 | 0 | 6 | 1 |
| Duncan Disease | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Electrocardiogram QT Prolonged | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Embolism, Pulmonary | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Endocrine Gland Neoplasms | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Ependymoma | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Epithelial Neoplasms | 0 | | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Epithelial Ovarian Cancer | 0 | | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| ER-Negative PR-Negative HER2-Negative Breast Cancer | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Erythema | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Erythema Multiforme | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Esophageal Neoplasms | 1 | | 2005 | 2017 | 13.2 | low | 1 | 0 | 0 | 2 | 2 | 0 |
| Exanthem | 0 | | 2013 | 2017 | 9.0 | low | 1 | 0 | 0 | 0 | 3 | 0 |
| Exanthema | 0 | | 2013 | 2017 | 9.0 | low | 1 | 0 | 0 | 0 | 3 | 0 |
| Experimental Hepatoma | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Experimental Mammary Neoplasms | 0 | | 2004 | 2014 | 14.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Experimental Neoplasms | 0 | | 2002 | 2019 | 14.0 | low | 0 | 0 | 0 | 4 | 4 | 0 |
| Eye Abnormalities | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Facial Dermatoses | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Fallopian Tube Neoplasms | 1 | | 2014 | 2014 | 10.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Familial Nonmedullary Thyroid Cancer | 0 | | 2012 | 2021 | 9.5 | low | 1 | 0 | 0 | 0 | 5 | 1 |
| Fatigue | 0 | | 2015 | 2019 | 7.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Female Genital Neoplasms | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Follicular Thyroid Carcinoma | 0 | | 2011 | 2015 | 11.3 | low | 3 | 0 | 0 | 0 | 6 | 0 |
| Folliculitis | 0 | | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Gallbladder Neoplasms | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Gastrointestinal Hemorrhage | 0 | | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Gastrointestinal Stromal Neoplasm | 0 | | 2006 | 2019 | 11.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Gastrointestinal Stromal Tumors | 1 | | 2006 | 2019 | 11.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Genetic Predisposition | 0 | | 2010 | 2019 | 9.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Genital Neoplasms, Female | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Genito-urinary Cancer | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Germinoblastoma | 0 | | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Glial Cell Tumors | 0 | | 2004 | 2018 | 12.8 | low | 8 | 0 | 0 | 8 | 9 | 0 |
| Glioblastoma | 1 | | 2005 | 2015 | 11.7 | low | 3 | 0 | 0 | 2 | 9 | 0 |
| Glioma | 1 | | 2004 | 2018 | 12.8 | low | 8 | 0 | 0 | 8 | 9 | 0 |
| Granulocytic Leukemia, Chronic | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Hand-Foot Syndrome | 0 | | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Hantavirus Infections | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hantavirus Pulmonary Syndrome | 0 | | 2012 | 2019 | 8.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Head and Neck Neoplasms | 1 | | 2007 | 2019 | 11.9 | low | 2 | 0 | 0 | 2 | 6 | 0 |
| Heart Failure | 0 | | 2013 | 2018 | 8.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Hematochezia | 0 | | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Hemorrhage | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hemorrhagic Fever with Renal Syndrome | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hemorrhagic Fever, Epidemic | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hepatocellular Carcinoma | 0 | | 2006 | 2022 | 9.7 | low | 1 | 0 | 0 | 3 | 7 | 2 |
| Hormone-Dependent Neoplasms | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hypermelanosis | 0 | | 2009 | 2012 | 13.3 | low | 1 | 0 | 0 | 1 | 2 | 0 |
| Hyperpigmentation | 0 | | 2009 | 2012 | 13.3 | low | 1 | 0 | 0 | 1 | 2 | 0 |
| Hyperplasia | 0 | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Hypertension | 0 | | 2007 | 2019 | 10.9 | low | 0 | 0 | 0 | 2 | 5 | 0 |
| Hypopituitarism | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Hypoxia | 0 | | 2012 | 2022 | 5.5 | low | 0 | 0 | 0 | 0 | 2 | 2 |
| Idiopathic Pulmonary Fibrosis | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Incontinentia Pigmenti Achromians | 0 | | 2013 | 2018 | 8.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Infections, Hantavirus | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Infections, Plasmodium | 0 | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Infections, Staphylococcal | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Inflammatory Breast Cancer | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Inflammatory Breast Neoplasms | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Injuries | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Interstitial Nephritis | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Intestinal Perforation | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Intracranial Hemorrhages | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Invasiveness, Neoplasm | 0 | | 2006 | 2018 | 12.5 | low | 1 | 0 | 0 | 4 | 6 | 0 |
| Itching | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Kahler Disease | 0 | | 2006 | 2011 | 15.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Kaposi Sarcoma | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Kidney Diseases | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Kidney Neoplasms | 1 | | 2004 | 2017 | 13.3 | low | 0 | 0 | 0 | 2 | 5 | 0 |
| Lassitude | 0 | | 2015 | 2019 | 7.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Leucocythaemia | 0 | | 2007 | 2012 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Leukemia | 0 | | 2007 | 2012 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Leukemia, Myeloid, Acute | 1 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Leukoma | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Liver Diseases | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Liver Dysfunction | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Liver Neoplasms | 0 | | 2004 | 2022 | 10.0 | low | 1 | 0 | 0 | 4 | 9 | 2 |
| Local Neoplasm Recurrence | 0 | | 2008 | 2018 | 11.3 | low | 7 | 0 | 0 | 2 | 7 | 0 |
| Long QT Syndrome | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lung Adenocarcinoma | 0 | | 2010 | 2015 | 11.6 | low | 0 | 0 | 0 | 1 | 7 | 0 |
| Lung Neoplasms | 1 | | 2004 | 2022 | 12.5 | low | 25 | 0 | 0 | 52 | 68 | 3 |
| Lymph Node Metastasis | 0 | | 2002 | 2018 | 12.5 | low | 3 | 0 | 0 | 3 | 8 | 0 |
| Lymphatic Diseases | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lymphoma | 0 | | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Lymphoma, Large-Cell, Anaplastic | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lymphoproliferative Disorders | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Malaria | 0 | | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Malignant Melanoma | 0 | | 2002 | 2016 | 15.8 | low | 1 | 0 | 0 | 3 | 2 | 0 |
| MEA 2a | 0 | | 2005 | 2018 | 9.2 | low | 0 | 0 | 0 | 1 | 4 | 0 |
| MEA 2b | 0 | | 2005 | 2016 | 12.0 | low | 1 | 0 | 0 | 1 | 3 | 0 |
| Medulloblastoma | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Melanoma | 0 | | 2002 | 2016 | 15.8 | low | 1 | 0 | 0 | 3 | 2 | 0 |
| Mesothelioma | 1 | | 2008 | 2014 | 13.0 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| Metastase | 0 | | 2004 | 2019 | 12.1 | low | 9 | 0 | 0 | 8 | 21 | 0 |
| Mouth Neoplasms | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| MS (Multiple Sclerosis) | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Multiple Myeloma | 1 | | 2006 | 2011 | 15.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Multiple Primary Neoplasms | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Multiple Sclerosis | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Nasopharyngeal Carcinoma | 0 | | 2010 | 2015 | 11.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Nasopharyngeal Neoplasms | 0 | | 2007 | 2015 | 13.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| Nausea | 0 | | 2005 | 2005 | 19.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Necrosis | 0 | | 2004 | 2020 | 13.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| Neoplasm Metastasis | 1 | | 2004 | 2019 | 12.1 | low | 9 | 0 | 0 | 8 | 21 | 0 |
| Neoplasms | 1 | | 2002 | 2022 | 13.3 | low | 4 | 0 | 0 | 22 | 20 | 4 |
| Neoplasms, Pleural | 0 | | 2008 | 2014 | 13.0 | low | 0 | 0 | 0 | 1 | 4 | 0 |
| Nephritis, Interstitial | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Neurilemmoma | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Neurilemoma | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Neuroblastoma | 1 | | 2008 | 2018 | 11.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| Neuroendocrine Tumors | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Neurofibromatosis 1 | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Neurofibromatosis 2 | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Neutropenia | 0 | | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Oncogene Addiction | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Oophoritis | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Orphan Diseases | 0 | | 2012 | 2014 | 11.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Osteogenic Sarcoma | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Osteonecrosis | 0 | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Osteosarcoma | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Ovarian Neoplasms | 1 | | 2009 | 2018 | 11.3 | low | 3 | 0 | 0 | 2 | 4 | 0 |
| Pancreatic Neoplasms | 1 | | 2006 | 2021 | 11.8 | low | 3 | 0 | 0 | 3 | 4 | 1 |
| Pancreatitis | 0 | | 2020 | 2021 | 3.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Papulosquamous Disorders | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Paraneoplastic Syndromes | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Parkinsonian Disorders | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Parotid Neoplasms | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Peritoneal Carcinomatosis | 0 | | 2006 | 2014 | 14.0 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Peritoneal Neoplasms | 1 | | 2006 | 2014 | 14.0 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Pleural Effusion | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Pleural Effusion, Malignant | 0 | | 2006 | 2014 | 13.7 | low | 1 | 0 | 0 | 1 | 2 | 0 |
| Pregnancy | 0 | | 2007 | 2018 | 10.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Premature Birth | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Preterm Birth | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Prostatic Neoplasms | 1 | | 2003 | 2017 | 13.7 | low | 1 | 0 | 0 | 6 | 9 | 0 |
| Prostatic Neoplasms, Castration-Resistant | 1 | | 2013 | 2014 | 10.5 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Proteinuria | 0 | | 2007 | 2013 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Pruritus | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pulmonary Embolism | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Recrudescence | 0 | | 2010 | 2014 | 12.0 | low | 2 | 0 | 0 | 1 | 1 | 0 |
| Salivary Gland Neoplasms | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Sarcoma | 0 | | 2008 | 2014 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Sarcoma, Epithelioid | 0 | | 2008 | 2014 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Sarcoma, Kaposi | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Schistosoma mansoni Infection | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Schistosomiasis mansoni | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Sensitivity and Specificity | 0 | | 2004 | 2014 | 15.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| Signet Ring Cell Carcinoma | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Skin Diseases | 0 | | 2013 | 2021 | 6.0 | low | 1 | 0 | 0 | 0 | 2 | 1 |
| Skin Neoplasms | 0 | | 2007 | 2020 | 10.2 | low | 1 | 0 | 0 | 1 | 3 | 0 |
| Sleep Apnea Syndromes | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Small Cell Lung Carcinoma | 1 | | 2009 | 2017 | 11.3 | low | 1 | 0 | 0 | 1 | 2 | 0 |
| Squamous Cell Carcinoma of Head and Neck | 0 | | 2016 | 2019 | 6.5 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Staphylococcal Infections | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Stevens-Johnson Syndrome | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Stomach Neoplasms | 1 | | 2004 | 2018 | 13.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| Stroke | 0 | | 2012 | 2017 | 9.5 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Surgical Incision | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Sycosis | 0 | | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Symptom Cluster | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Syndrome | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Thoracic Neoplasms | 0 | | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Thrombocytopenia | 0 | | 2010 | 2018 | 9.7 | low | 1 | 0 | 0 | 1 | 2 | 0 |
| Thrombopenia | 0 | | 2010 | 2018 | 9.7 | low | 1 | 0 | 0 | 1 | 2 | 0 |
| Thyroid Cancer, Anaplastic | 0 | | 2011 | 2018 | 10.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Thyroid Carcinoma, Anaplastic | 0 | | 2011 | 2018 | 10.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Thyroid Neoplasms | 1 | | 2002 | 2023 | 9.6 | low | 15 | 0 | 0 | 14 | 114 | 10 |
| Thyroid Nodule | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Torsade de Pointes | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Triple Negative Breast Neoplasms | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Urinary Bladder Neoplasms | 1 | | 2009 | 2011 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| Urogenital Neoplasms | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Uterine Neoplasms | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Ventricular Fibrillation | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Viral Diseases | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Virus Diseases | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Wounds and Injuries | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Zika Virus Infection | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment.Genome biology, , Apr-03, Volume: 16, 2015
A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis.Carcinogenesis, , Volume: 35, Issue:11, 2014
Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.Cancer science, , Volume: 104, Issue:7, 2013
[Vandetanib treatment in refractory advanced lung adenocarcinoma patients: five cases and review of literature].Zhongguo fei ai za zhi = Chinese journal of lung cancer, , Volume: 15, Issue:2, 2012
KIF5B-RET fusions in lung adenocarcinoma.Nature medicine, , Feb-12, Volume: 18, Issue:3, 2012
RET, ROS1 and ALK fusions in lung cancer.Nature medicine, , Feb-12, Volume: 18, Issue:3, 2012
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.British journal of cancer, , Jul-26, Volume: 105, Issue:3, 2011
Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.Cancer prevention research (Philadelphia, Pa.), , Volume: 3, Issue:9, 2010
Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations.Briefings in bioinformatics, , 05-20, Volume: 22, Issue:3, 2021
A multidimensional biosensor system to guide LUAD individualized treatment.Journal of materials chemistry. B, , 10-06, Volume: 9, Issue:38, 2021
A secondary RET mutation in the activation loop conferring resistance to vandetanib.Nature communications, , 02-12, Volume: 9, Issue:1, 2018
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.Annals of oncology : official journal of the European Society for Medical Oncology, , 02-01, Volume: 28, Issue:2, 2017
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.American journal of clinical oncology, , Volume: 40, Issue:4, 2017
Angiogenesis Inhibitors in NSCLC.International journal of molecular sciences, , Sep-21, Volume: 18, Issue:10, 2017
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.Yonsei medical journal, , Volume: 58, Issue:1, 2017
Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.Oncotarget, , Jun-14, Volume: 7, Issue:24, 2016
Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment.Genome biology, , Apr-03, Volume: 16, 2015
A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis.Carcinogenesis, , Volume: 35, Issue:11, 2014
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.European journal of endocrinology, , Volume: 170, Issue:4, 2014
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 8, Issue:5, 2013
Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.Cancer science, , Volume: 104, Issue:7, 2013
Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis.Anti-cancer drugs, , Volume: 23, Issue:7, 2012
Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 7, Issue:12, 2012
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 7, Issue:11, 2012
[Vandetanib treatment in refractory advanced lung adenocarcinoma patients: five cases and review of literature].Zhongguo fei ai za zhi = Chinese journal of lung cancer, , Volume: 15, Issue:2, 2012
RET, ROS1 and ALK fusions in lung cancer.Nature medicine, , Feb-12, Volume: 18, Issue:3, 2012
KIF5B-RET fusions in lung adenocarcinoma.Nature medicine, , Feb-12, Volume: 18, Issue:3, 2012
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.British journal of cancer, , Jul-26, Volume: 105, Issue:3, 2011
[Pleural metastases from bronchial carcinoma: is a cure possible?].Revue des maladies respiratoires, , Volume: 28, Issue:1, 2011
Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma.Oncology, , Volume: 81, Issue:1, 2011
Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.Neoplasia (New York, N.Y.), , Volume: 12, Issue:9, 2010
Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.Cancer prevention research (Philadelphia, Pa.), , Volume: 3, Issue:9, 2010
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study.Cancer chemotherapy and pharmacology, , Volume: 64, Issue:4, 2009
Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo.Cancer research, , Jun-15, Volume: 69, Issue:12, 2009
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 3, Issue:4, 2008
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.Molecular cancer therapeutics, , Volume: 6, Issue:2, 2007
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jan-15, Volume: 10, Issue:2, 2004
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.Cancer science, , Volume: 95, Issue:12, 2004
Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours.British journal of cancer, , Nov-17, Volume: 89, Issue:10, 2003
Novel vandetanib derivative inhibited proliferation and promoted apoptosis of cancer cells under normoxia and hypoxia.European journal of pharmacology, , May-05, Volume: 922, 2022
Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia.Anti-cancer drugs, , 10-01, Volume: 32, Issue:9, 2021
Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.European journal of medicinal chemistry, , Nov-01, Volume: 181, 2019
Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanism.Cancer prevention research (Philadelphia, Pa.), , Volume: 5, Issue:8, 2012
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.The Cochrane database of systematic reviews, , Apr-06, Volume: 4, 2018
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.Investigational new drugs, , Volume: 34, Issue:2, 2016
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 26, Issue:3, 2015
2011 ASCO Genitourinary Cancers Symposium.The Lancet. Oncology, , Volume: 12, Issue:4, 2011
VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells.Oncology reports, , Volume: 24, Issue:4, 2010
Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.BJU international, , Volume: 103, Issue:12, 2009
[Cabozantinib: Mechanism of action, efficacy and indications].Bulletin du cancer, , Volume: 104, Issue:5, 2017
ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib.Oncotarget, , Aug-28, Volume: 6, Issue:25, 2015
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.European journal of endocrinology, , Volume: 170, Issue:4, 2014
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.Breast cancer research and treatment, , Volume: 146, Issue:1, 2014
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.Japanese journal of clinical oncology, , May-05, Volume: 50, Issue:5, 2020
RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.British journal of cancer, , Nov-08, Volume: 115, Issue:10, 2016
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.Cancer letters, , Apr-28, Volume: 360, Issue:1, 2015
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.Lung cancer (Amsterdam, Netherlands), , Volume: 89, Issue:1, 2015
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.Journal of neuro-oncology, , Volume: 121, Issue:3, 2015
A phase I/II trial of vandetanib for patients with recurrent malignant glioma.Neuro-oncology, , Volume: 14, Issue:12, 2012
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.International journal of radiation oncology, biology, physics, , Jan-01, Volume: 82, Issue:1, 2012
Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Sep-01, Volume: 879, Issue:25, 2011
Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.The Journal of pathology, , Volume: 223, Issue:5, 2011
Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models.Biochemical and biophysical research communications, , Jul-22, Volume: 411, Issue:1, 2011
[Pleural metastases from bronchial carcinoma: is a cure possible?].Revue des maladies respiratoires, , Volume: 28, Issue:1, 2011
Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.Cancer research, , May-01, Volume: 70, Issue:9, 2010
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 5, Issue:8, 2010
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.International journal of radiation oncology, biology, physics, , Sep-01, Volume: 78, Issue:1, 2010
Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model.International journal of oncology, , Volume: 37, Issue:4, 2010
Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma.Cornea, , Volume: 28, Issue:6, 2009
Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment.International journal of cancer, , May-01, Volume: 122, Issue:9, 2008
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.Molecular cancer therapeutics, , Volume: 7, Issue:1, 2008
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.Journal of neuro-oncology, , Volume: 88, Issue:1, 2008
Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis.Oncogene, , Aug-23, Volume: 26, Issue:39, 2007
The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model.British journal of cancer, , Sep-13, Volume: 91, Issue:6, 2004
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-15, Volume: 10, Issue:18 Pt 1, 2004
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.European journal of medicinal chemistry, , Jul-05, Volume: 237, 2022
A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer.American journal of clinical oncology, , 09-01, Volume: 44, Issue:9, 2021
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.Oncogene, , Volume: 37, Issue:42, 2018
Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer.Molecular pharmaceutics, , 07-02, Volume: 15, Issue:7, 2018
RET rearrangements are actionable alterations in breast cancer.Nature communications, , 11-16, Volume: 9, Issue:1, 2018
Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.European journal of medicinal chemistry, , Nov-10, Volume: 140, 2017
Micellear Gold Nanoparticles as Delivery Vehicles for Dual Tyrosine Kinase Inhibitor ZD6474 for Metastatic Breast Cancer Treatment.Langmuir : the ACS journal of surfaces and colloids, , 08-08, Volume: 33, Issue:31, 2017
EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.Molecular cancer therapeutics, , Volume: 15, Issue:3, 2016
Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.International journal of cancer, , May-15, Volume: 138, Issue:10, 2016
Vandetanib as a potential treatment for breast cancer.Expert opinion on investigational drugs, , Volume: 23, Issue:9, 2014
Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , Apr-15, Volume: 20, Issue:8, 2014
Frequency dependent impedimetric cytotoxic evaluation of anticancer drug on breast cancer cell.Biosensors & bioelectronics, , May-15, Volume: 55, 2014
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.Breast cancer research and treatment, , Volume: 146, Issue:1, 2014
Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.Annals of surgery, , Volume: 259, Issue:4, 2014
Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells.Molecular cancer, , Oct-20, Volume: 12, Issue:1, 2013
Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature.Molecular bioSystems, , Volume: 9, Issue:6, 2013
Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.Breast cancer research and treatment, , Volume: 136, Issue:1, 2012
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study.Investigational new drugs, , Volume: 30, Issue:2, 2012
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.The Journal of clinical endocrinology and metabolism, , Volume: 97, Issue:4, 2012
ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells.Journal of cellular physiology, , Volume: 226, Issue:2, 2011
Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans.Hypertension (Dallas, Tex. : 1979), , Volume: 58, Issue:1, 2011
ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells.Cancer biology & therapy, , Apr-15, Volume: 9, Issue:8, 2010
ZD6474 coerces breast cancer for an apoptotic journey.Cancer biology & therapy, , Apr-15, Volume: 9, Issue:8, 2010
[Inhibitory effect of ZD6474 combined with adriamycin on MCF-7 human breast cancer cells in vitro].Nan fang yi ke da xue xue bao = Journal of Southern Medical University, , Volume: 30, Issue:3, 2010
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.IDrugs : the investigational drugs journal, , Volume: 10, Issue:8, 2007
Drug insight: VEGF as a therapeutic target for breast cancer.Nature clinical practice. Oncology, , Volume: 4, Issue:3, 2007
A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-01, Volume: 11, Issue:9, 2005
[Anti angiogenesis].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 31, Issue:4, 2004
Rare complications of multikinase inhibitor treatment.Archives of endocrinology and metabolism, , Volume: 62, Issue:6, 2018
Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials.Medicine, , Volume: 96, Issue:43, 2017
Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation.Acta medica Okayama, , Volume: 70, Issue:4, 2016
CD30+ lymphoproliferative disorder in a patient with metastatic papillary thyroid carcinoma.Dermatology online journal, , Oct-15, Volume: 22, Issue:10, 2016
Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging for Monitoring the Early Response to ZD6474 from Nasopharyngeal Carcinoma in Nude Mouse.Scientific reports, , Nov-17, Volume: 5, 2015
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.European journal of endocrinology, , Volume: 170, Issue:4, 2014
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Feb-10, Volume: 30, Issue:5, 2012
Treating advanced radioresistant differentiated thyroid cancer.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
First do no harm: counting the cost of chasing drug efficacy.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
ZD6474, a small molecule tyrosine kinase inhibitor, potentiates the anti-tumor and anti-metastasis effects of radiation for human nasopharyngeal carcinoma.Current cancer drug targets, , Volume: 10, Issue:6, 2010
Early clinical studies of novel therapies for thyroid cancers.Endocrinology and metabolism clinics of North America, , Volume: 37, Issue:2, 2008
Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer.Langenbeck's archives of surgery, , Volume: 391, Issue:6, 2006
Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition.Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-15, Volume: 12, Issue:24, 2006
Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474.In vivo (Athens, Greece), , Volume: 19, Issue:6
Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.Lung cancer (Amsterdam, Netherlands), , Volume: 155, 2021
Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.Japanese journal of clinical oncology, , May-05, Volume: 50, Issue:5, 2020
RET-rearranged non-small-cell lung cancer and therapeutic implications.Internal medicine journal, , Volume: 49, Issue:12, 2019
Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.Journal of cellular physiology, , Volume: 234, Issue:4, 2019
Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 13, Issue:11, 2018
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.The Lancet. Respiratory medicine, , Volume: 5, Issue:1, 2017
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.Annals of oncology : official journal of the European Society for Medical Oncology, , 02-01, Volume: 28, Issue:2, 2017
Angiogenesis Inhibitors in NSCLC.International journal of molecular sciences, , Sep-21, Volume: 18, Issue:10, 2017
Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials.Medicine, , Volume: 96, Issue:43, 2017
[Cabozantinib: Mechanism of action, efficacy and indications].Bulletin du cancer, , Volume: 104, Issue:5, 2017
A platinum-based hybrid drug design approach to circumvent acquired resistance to molecular targeted tyrosine kinase inhibitors.Scientific reports, , 05-06, Volume: 6, 2016
Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , 05-20, Volume: 34, Issue:15, 2016
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.Clinical cancer research : an official journal of the American Association for Cancer Research, , Apr-15, Volume: 22, Issue:8, 2016
A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.BMC cancer, , Mar-23, Volume: 15, 2015
The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells.Scientific reports, , Feb-27, Volume: 5, 2015
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.Journal of cancer research and clinical oncology, , Volume: 141, Issue:5, 2015
Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.International journal of cancer, , Jul-15, Volume: 137, Issue:2, 2015
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.Lung cancer (Amsterdam, Netherlands), , Volume: 89, Issue:1, 2015
Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib.European journal of clinical pharmacology, , Volume: 71, Issue:5, 2015
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.Journal of medicinal chemistry, , May-14, Volume: 58, Issue:9, 2015
EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 25, Issue:10, 2014
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.Cancer research, , May-15, Volume: 74, Issue:10, 2014
Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.Clinical lung cancer, , Volume: 15, Issue:5, 2014
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 9, Issue:5, 2014
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.Lung cancer (Amsterdam, Netherlands), , Volume: 82, Issue:3, 2013
Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 8, Issue:8, 2013
Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.PloS one, , Volume: 8, Issue:7, 2013
Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials.Clinical oncology (Royal College of Radiologists (Great Britain)), , Volume: 25, Issue:1, 2013
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 8, Issue:5, 2013
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.The Journal of clinical investigation, , Volume: 123, Issue:4, 2013
Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency.Experimental cell research, , Feb-15, Volume: 319, Issue:4, 2013
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.The Journal of clinical endocrinology and metabolism, , Volume: 97, Issue:4, 2012
Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 7, Issue:3, 2012
[Vandetanib for advanced non-small cell lung cancer: a meta-analysis].Zhongguo fei ai za zhi = Chinese journal of lung cancer, , Volume: 15, Issue:3, 2012
Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis.Anti-cancer drugs, , Volume: 23, Issue:7, 2012
Drug approvals 2011: focus on companion diagnostics.Journal of the National Cancer Institute, , Jan-18, Volume: 104, Issue:2, 2012
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 7, Issue:11, 2012
Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 7, Issue:12, 2012
Vandetanib for the treatment of lung cancer.Expert opinion on investigational drugs, , Volume: 21, Issue:8, 2012
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Apr-01, Volume: 30, Issue:10, 2012
Diffuse interstitial lung disease linked to vandetanib.Clinical lung cancer, , Volume: 13, Issue:3, 2012
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.Korean journal of ophthalmology : KJO, , Volume: 25, Issue:5, 2011
Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.Asian Pacific journal of cancer prevention : APJCP, , Volume: 12, Issue:11, 2011
The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials.Lung, , Volume: 189, Issue:6, 2011
NSCLC drug targets acquire new visibility.Journal of the National Cancer Institute, , Mar-02, Volume: 103, Issue:5, 2011
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Mar-10, Volume: 29, Issue:8, 2011
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Mar-10, Volume: 29, Issue:8, 2011
Vandetanib for the treatment of non-small-cell lung cancer.Expert opinion on pharmacotherapy, , Volume: 12, Issue:14, 2011
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.Anticancer research, , Volume: 30, Issue:10, 2010
Vascular endothelial growth factor concentration as a predictive marker: ready for primetime?Clinical cancer research : an official journal of the American Association for Cancer Research, , Feb-15, Volume: 16, Issue:4, 2010
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.Experimental biology and medicine (Maywood, N.J.), , Volume: 235, Issue:1, 2010
Targeting the epidermal growth factor receptor in non-small cell lung cancer.Onkologie, , Volume: 33, Issue:12, 2010
Vandetanib: An overview of its clinical development in NSCLC and other tumors.Drugs of today (Barcelona, Spain : 1998), , Volume: 46, Issue:9, 2010
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 5, Issue:8, 2010
One more fallen star--ZODIAC and its implications.The Lancet. Oncology, , Volume: 11, Issue:7, 2010
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.The Lancet. Oncology, , Volume: 11, Issue:7, 2010
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-15, Volume: 15, Issue:10, 2009
Targeted therapies in the treatment of advanced/metastatic NSCLC.European journal of cancer (Oxford, England : 1990), , Volume: 45, Issue:14, 2009
Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.Clinical lung cancer, , Volume: 10 Suppl 1, 2009
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.The oncologist, , Volume: 14, Issue:4, 2009
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.Clinical lung cancer, , Volume: 10 Suppl 1, 2009
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , May-20, Volume: 27, Issue:15, 2009
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-15, Volume: 15, Issue:10, 2009
An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 20, Issue:3, 2009
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Nov-20, Volume: 26, Issue:33, 2008
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].Magyar onkologia, , Volume: 52, Issue:3, 2008
[Lung cancer].Medizinische Klinik (Munich, Germany : 1983), , May-15, Volume: 103, Issue:5, 2008
Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 3, Issue:6 Suppl 2, 2008
Targeted therapy in advanced non-small-cell lung cancer.Seminars in respiratory and critical care medicine, , Volume: 29, Issue:3, 2008
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 3, Issue:4, 2008
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.Reviews on recent clinical trials, , Volume: 2, Issue:2, 2007
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Sep-20, Volume: 25, Issue:27, 2007
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 13, Issue:15 Pt 2, 2007
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.Current treatment options in oncology, , Volume: 8, Issue:1, 2007
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.The oncologist, , Volume: 12, Issue:3, 2007
Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 1, Issue:9, 2006
Antiangiogenic drugs in non-small cell lung cancer treatment.Current opinion in oncology, , Volume: 18, Issue:2, 2006
Multi-target inhibitors in non-small cell lung cancer (NSCLC).Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 17 Suppl 2, 2006
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.Clinical lung cancer, , Volume: 8 Suppl 1, 2006
Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474.Expert review of anticancer therapy, , Volume: 6, Issue:4, 2006
ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.Oncology research, , Volume: 16, Issue:1, 2006
Angiogenesis and lung cancer: prognostic and therapeutic implications.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , May-10, Volume: 23, Issue:14, 2005
ZD6474--clinical experience to date.British journal of cancer, , Volume: 92 Suppl 1, 2005
Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.Clinical lung cancer, , Volume: 7, Issue:2, 2005
ZD6474 headed for phase III trials in the fall.Oncology (Williston Park, N.Y.), , Volume: 19, Issue:9, 2005
ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-15, Volume: 10, Issue:24, 2004
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.Cancer science, , Volume: 95, Issue:12, 2004
[Cabozantinib: Mechanism of action, efficacy and indications].Bulletin du cancer, , Volume: 104, Issue:5, 2017
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.BJU international, , Volume: 107, Issue:1, 2011
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.International journal of radiation oncology, biology, physics, , Nov-15, Volume: 60, Issue:4, 2004
The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma.Angiogenesis, , Volume: 7, Issue:4, 2004
Vandetanib inhibits cell growth in EGFR-expressing cutaneous squamous cell carcinoma.Biochemical and biophysical research communications, , 10-20, Volume: 531, Issue:3, 2020
Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma.Head & neck, , Volume: 38, Issue:3, 2016
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).Oral oncology, , Volume: 49, Issue:8, 2013
Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma.Head & neck, , Volume: 34, Issue:9, 2012
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 7, Issue:11, 2012
Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.Head & neck, , Volume: 33, Issue:3, 2011
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.Clinical cancer research : an official journal of the American Association for Cancer Research, , Apr-01, Volume: 17, Issue:7, 2011
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 5, Issue:8, 2010
Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).Anticancer research, , Volume: 29, Issue:6, 2009
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 3, Issue:4, 2008
Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma.Molecular cancer therapeutics, , Volume: 7, Issue:9, 2008
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.Molecular cancer therapeutics, , Volume: 6, Issue:2, 2007
Antitumor effects of ZD6474 on head and neck squamous cell carcinoma.Oncology reports, , Volume: 17, Issue:2, 2007
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.Clinical lung cancer, , Volume: 8 Suppl 1, 2006
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 16 Suppl 4, 2005
Label-free single cell kinetics of the invasion of spheroidal colon cancer cells through 3D Matrigel.Analytical chemistry, , Sep-02, Volume: 86, Issue:17, 2014
Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model.International journal of oncology, , Volume: 37, Issue:4, 2010
Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.Neoplasia (New York, N.Y.), , Volume: 12, Issue:9, 2010
Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).Anticancer research, , Volume: 29, Issue:6, 2009
Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).NMR in biomedicine, , Volume: 21, Issue:1, 2008
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.Clinical cancer research : an official journal of the American Association for Cancer Research, , Nov-01, Volume: 13, Issue:21, 2007
Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects.World journal of gastroenterology, , Aug-28, Volume: 12, Issue:32, 2006
Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases.Molecular cancer therapeutics, , Volume: 5, Issue:7, 2006
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jan-15, Volume: 10, Issue:2, 2004
Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation.Thyroid : official journal of the American Thyroid Association, , Volume: 27, Issue:4, 2017
Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome.Archives of endocrinology and metabolism, , Volume: 59, Issue:4, 2015
Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.The Journal of clinical endocrinology and metabolism, , Volume: 99, Issue:9, 2014
Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma.The New England journal of medicine, , Aug-08, Volume: 369, Issue:6, 2013
Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.International journal of cancer, , Jul-15, Volume: 137, Issue:2, 2015
Novel therapies for thyroid cancer.Expert opinion on pharmacotherapy, , Volume: 15, Issue:18, 2014
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.Lung cancer (Amsterdam, Netherlands), , Volume: 82, Issue:3, 2013
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.Investigational new drugs, , Volume: 30, Issue:3, 2012
A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-01, Volume: 11, Issue:9, 2005
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.American journal of clinical oncology, , Volume: 40, Issue:4, 2017
Vandetanib improves anti-tumor effects of L19mTNFalpha in xenograft models of esophageal cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , Feb-01, Volume: 17, Issue:3, 2011
Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.International journal of cancer, , Sep-01, Volume: 127, Issue:5, 2010
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 16 Suppl 4, 2005
Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials.Medicine, , Volume: 96, Issue:43, 2017
Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.International journal of cancer, , Jul-15, Volume: 137, Issue:2, 2015
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.Lung cancer (Amsterdam, Netherlands), , Volume: 82, Issue:3, 2013
Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy.The Journal of clinical endocrinology and metabolism, , 03-01, Volume: 104, Issue:3, 2019
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].Bulletin du cancer, , Volume: 103, Issue:3, 2016
Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.International journal of cancer, , Jul-15, Volume: 137, Issue:2, 2015
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.Cancer letters, , Apr-28, Volume: 360, Issue:1, 2015
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-15, Volume: 21, Issue:16, 2015
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.Journal of neuro-oncology, , Volume: 121, Issue:3, 2015
A topical matter: toxic epidermal necrolysis.The American journal of medicine, , Volume: 127, Issue:10, 2014
Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma.British journal of cancer, , Jul-09, Volume: 109, Issue:1, 2013
Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival.Medical oncology (Northwood, London, England), , Volume: 30, Issue:3, 2013
Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms.Molecular medicine reports, , Volume: 6, Issue:1, 2012
Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.International journal of radiation oncology, biology, physics, , Jan-01, Volume: 82, Issue:1, 2012
Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models.Biochemical and biophysical research communications, , Jul-22, Volume: 411, Issue:1, 2011
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.International journal of radiation oncology, biology, physics, , Sep-01, Volume: 78, Issue:1, 2010
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 11, Issue:15, 2005
Enhanced glioma therapy by synergistic inhibition of autophagy and tyrosine kinase activity.International journal of pharmaceutics, , Jan-30, Volume: 536, Issue:1, 2018
Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy.International journal of radiation oncology, biology, physics, , 12-01, Volume: 99, Issue:5, 2017
Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation.AJNR. American journal of neuroradiology, , Volume: 38, Issue:6, 2017
Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jun-01, Volume: 19, Issue:11, 2013
MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma.AJNR. American journal of neuroradiology, , Volume: 34, Issue:7, 2013
Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.Pediatric blood & cancer, , Volume: 60, Issue:9, 2013
A phase I/II trial of vandetanib for patients with recurrent malignant glioma.Neuro-oncology, , Volume: 14, Issue:12, 2012
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.International journal of radiation oncology, biology, physics, , Jan-01, Volume: 82, Issue:1, 2012
Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.The Journal of pathology, , Volume: 223, Issue:5, 2011
Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Nov-01, Volume: 28, Issue:31, 2010
ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain.Molecular cancer therapeutics, , Volume: 9, Issue:4, 2010
Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model.International journal of oncology, , Volume: 37, Issue:4, 2010
Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells.The Journal of pharmacology and experimental therapeutics, , Volume: 331, Issue:1, 2009
Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment.International journal of cancer, , May-01, Volume: 122, Issue:9, 2008
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.Journal of neuro-oncology, , Volume: 88, Issue:1, 2008
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.Clinical cancer research : an official journal of the American Association for Cancer Research, , Nov-15, Volume: 11, Issue:22, 2005
The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model.British journal of cancer, , Sep-13, Volume: 91, Issue:6, 2004
Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment.Photodiagnosis and photodynamic therapy, , Volume: 27, 2019
Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma.Head & neck, , Volume: 38, Issue:3, 2016
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).Oral oncology, , Volume: 49, Issue:8, 2013
Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma.Head & neck, , Volume: 34, Issue:9, 2012
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.Clinical cancer research : an official journal of the American Association for Cancer Research, , Apr-01, Volume: 17, Issue:7, 2011
Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.Head & neck, , Volume: 33, Issue:3, 2011
Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.Cancer chemotherapy and pharmacology, , Volume: 61, Issue:2, 2008
Antitumor effects of ZD6474 on head and neck squamous cell carcinoma.Oncology reports, , Volume: 17, Issue:2, 2007
Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver Malignancies.Journal of vascular and interventional radiology : JVIR, , Volume: 33, Issue:9, 2022
Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia.Anti-cancer drugs, , 10-01, Volume: 32, Issue:9, 2021
Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma.European journal of medicinal chemistry, , Oct-01, Volume: 179, 2019
Evolution of Transarterial Chemoembolization for the Treatment of Liver Cancer.Radiology, , Volume: 293, Issue:3, 2019
Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Apr-01, Volume: 101, 2017
iRGD-Decorated Polymeric Nanoparticles for the Efficient Delivery of Vandetanib to Hepatocellular Carcinoma: Preparation and in Vitro and in Vivo Evaluation.ACS applied materials & interfaces, , Aug-03, Volume: 8, Issue:30, 2016
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].Magyar onkologia, , Volume: 56, Issue:3, 2012
Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.Journal of hepatology, , Volume: 56, Issue:5, 2012
Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.Neoplasia (New York, N.Y.), , Volume: 13, Issue:3, 2011
Severe photosensitivity reaction to vandetanib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Sep-20, Volume: 27, Issue:27, 2009
EGFR and VEGFR as potential target for biological therapies in HCC cells.Cancer letters, , Apr-18, Volume: 262, Issue:2, 2008
ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells.Biochemical pharmacology, , Feb-14, Volume: 71, Issue:4, 2006
Long-term cardiovascular effects of vandetanib and pazopanib in normotensive rats.Pharmacology research & perspectives, , Volume: 7, Issue:3, 2019
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.International journal of molecular sciences, , Oct-20, Volume: 19, Issue:10, 2018
Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib.European journal of clinical pharmacology, , Volume: 71, Issue:5, 2015
Role of the eNOS-NO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes.BioMed research international, , Volume: 2013, 2013
Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.British journal of clinical pharmacology, , Volume: 75, Issue:4, 2013
[Oral drugs inhibiting the VEGF pathway].Bulletin du cancer, , Volume: 94 Spec No, 2007
Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions.Proceedings of the National Academy of Sciences of the United States of America, , Sep-04, Volume: 104, Issue:36, 2007
[Cabozantinib: Mechanism of action, efficacy and indications].Bulletin du cancer, , Volume: 104, Issue:5, 2017
DisABLing kidney cancers caused by fumarate hydratase mutations.Cancer cell, , Dec-08, Volume: 26, Issue:6, 2014
Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer.Cancer cell, , Dec-08, Volume: 26, Issue:6, 2014
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.BJU international, , Volume: 107, Issue:1, 2011
2011 ASCO Genitourinary Cancers Symposium.The Lancet. Oncology, , Volume: 12, Issue:4, 2011
The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma.Angiogenesis, , Volume: 7, Issue:4, 2004
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.International journal of radiation oncology, biology, physics, , Nov-15, Volume: 60, Issue:4, 2004
Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.Investigational new drugs, , Volume: 30, Issue:2, 2012
ZD6474 induces growth arrest and apoptosis of human leukemia cells, which is enhanced by concomitant use of a novel MEK inhibitor, AZD6244.Leukemia, , Volume: 21, Issue:6, 2007
Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver Malignancies.Journal of vascular and interventional radiology : JVIR, , Volume: 33, Issue:9, 2022
Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia.Anti-cancer drugs, , 10-01, Volume: 32, Issue:9, 2021
Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma.European journal of medicinal chemistry, , Oct-01, Volume: 179, 2019
Predicting pharmacokinetic behaviour of drug release from drug-eluting embolization beads using in vitro elution methods.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Aug-01, Volume: 136, 2019
Evolution of Transarterial Chemoembolization for the Treatment of Liver Cancer.Radiology, , Volume: 293, Issue:3, 2019
Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Apr-01, Volume: 101, 2017
iRGD-Decorated Polymeric Nanoparticles for the Efficient Delivery of Vandetanib to Hepatocellular Carcinoma: Preparation and in Vitro and in Vivo Evaluation.ACS applied materials & interfaces, , Aug-03, Volume: 8, Issue:30, 2016
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.European journal of endocrinology, , Volume: 170, Issue:4, 2014
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].Magyar onkologia, , Volume: 56, Issue:3, 2012
Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.Journal of hepatology, , Volume: 56, Issue:5, 2012
Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jul-15, Volume: 18, Issue:14, 2012
Severe photosensitivity reaction to vandetanib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Sep-20, Volume: 27, Issue:27, 2009
EGFR and VEGFR as potential target for biological therapies in HCC cells.Cancer letters, , Apr-18, Volume: 262, Issue:2, 2008
ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells.Biochemical pharmacology, , Feb-14, Volume: 71, Issue:4, 2006
In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model.Angiogenesis, , Volume: 7, Issue:2, 2004
Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.Lung cancer (Amsterdam, Netherlands), , Volume: 155, 2021
A multidimensional biosensor system to guide LUAD individualized treatment.Journal of materials chemistry. B, , 10-06, Volume: 9, Issue:38, 2021
Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.Japanese journal of clinical oncology, , May-05, Volume: 50, Issue:5, 2020
Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.Journal of cellular physiology, , Volume: 234, Issue:4, 2019
Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report.Journal of pediatric hematology/oncology, , Volume: 41, Issue:5, 2019
RET-rearranged non-small-cell lung cancer and therapeutic implications.Internal medicine journal, , Volume: 49, Issue:12, 2019
Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 13, Issue:11, 2018
A secondary RET mutation in the activation loop conferring resistance to vandetanib.Nature communications, , 02-12, Volume: 9, Issue:1, 2018
Angiogenesis Inhibitors in NSCLC.International journal of molecular sciences, , Sep-21, Volume: 18, Issue:10, 2017
[Cabozantinib: Mechanism of action, efficacy and indications].Bulletin du cancer, , Volume: 104, Issue:5, 2017
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.Yonsei medical journal, , Volume: 58, Issue:1, 2017
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.The Lancet. Respiratory medicine, , Volume: 5, Issue:1, 2017
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.Annals of oncology : official journal of the European Society for Medical Oncology, , 02-01, Volume: 28, Issue:2, 2017
A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.Cancer, , 01-01, Volume: 123, Issue:2, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.Clinical cancer research : an official journal of the American Association for Cancer Research, , Apr-15, Volume: 22, Issue:8, 2016
Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , 05-20, Volume: 34, Issue:15, 2016
Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation.Acta medica Okayama, , Volume: 70, Issue:4, 2016
[Metastatic medullary thyroid carcinoma in a child with multiple endocrine neoplasia 2B. Efficiency of medium-term treatment with vandetanib without thyroid surgery].Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, , Volume: 23, Issue:8, 2016
A platinum-based hybrid drug design approach to circumvent acquired resistance to molecular targeted tyrosine kinase inhibitors.Scientific reports, , 05-06, Volume: 6, 2016
Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.Oncotarget, , Jun-14, Volume: 7, Issue:24, 2016
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.Journal of cancer research and clinical oncology, , Volume: 141, Issue:5, 2015
Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.International journal of cancer, , Jul-15, Volume: 137, Issue:2, 2015
The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells.Scientific reports, , Feb-27, Volume: 5, 2015
Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib.European journal of clinical pharmacology, , Volume: 71, Issue:5, 2015
A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.BMC cancer, , Mar-23, Volume: 15, 2015
Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment.Genome biology, , Apr-03, Volume: 16, 2015
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.Lung cancer (Amsterdam, Netherlands), , Volume: 89, Issue:1, 2015
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.Journal of medicinal chemistry, , May-14, Volume: 58, Issue:9, 2015
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.European journal of endocrinology, , Volume: 170, Issue:4, 2014
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.Cancer research, , May-15, Volume: 74, Issue:10, 2014
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 9, Issue:5, 2014
Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.Clinical lung cancer, , Volume: 15, Issue:5, 2014
A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis.Carcinogenesis, , Volume: 35, Issue:11, 2014
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 8, Issue:5, 2013
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 8, Issue:5, 2013
Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.Cancer science, , Volume: 104, Issue:7, 2013
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.The Journal of clinical investigation, , Volume: 123, Issue:4, 2013
Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.PloS one, , Volume: 8, Issue:7, 2013
Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials.Clinical oncology (Royal College of Radiologists (Great Britain)), , Volume: 25, Issue:1, 2013
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.Lung cancer (Amsterdam, Netherlands), , Volume: 82, Issue:3, 2013
Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency.Experimental cell research, , Feb-15, Volume: 319, Issue:4, 2013
Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 8, Issue:8, 2013
[Vandetanib for advanced non-small cell lung cancer: a meta-analysis].Zhongguo fei ai za zhi = Chinese journal of lung cancer, , Volume: 15, Issue:3, 2012
Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 7, Issue:3, 2012
Vandetanib for the treatment of lung cancer.Expert opinion on investigational drugs, , Volume: 21, Issue:8, 2012
Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis.Anti-cancer drugs, , Volume: 23, Issue:7, 2012
Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanism.Cancer prevention research (Philadelphia, Pa.), , Volume: 5, Issue:8, 2012
KIF5B-RET fusions in lung adenocarcinoma.Nature medicine, , Feb-12, Volume: 18, Issue:3, 2012
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.The Journal of clinical endocrinology and metabolism, , Volume: 97, Issue:9, 2012
RET, ROS1 and ALK fusions in lung cancer.Nature medicine, , Feb-12, Volume: 18, Issue:3, 2012
Drug approvals 2011: focus on companion diagnostics.Journal of the National Cancer Institute, , Jan-18, Volume: 104, Issue:2, 2012
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].Magyar onkologia, , Volume: 56, Issue:3, 2012
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 7, Issue:11, 2012
[Vandetanib treatment in refractory advanced lung adenocarcinoma patients: five cases and review of literature].Zhongguo fei ai za zhi = Chinese journal of lung cancer, , Volume: 15, Issue:2, 2012
Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 7, Issue:12, 2012
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Apr-01, Volume: 30, Issue:10, 2012
Diffuse interstitial lung disease linked to vandetanib.Clinical lung cancer, , Volume: 13, Issue:3, 2012
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.The Journal of clinical endocrinology and metabolism, , Volume: 97, Issue:4, 2012
The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials.Lung, , Volume: 189, Issue:6, 2011
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.Korean journal of ophthalmology : KJO, , Volume: 25, Issue:5, 2011
Vandetanib for the treatment of non-small-cell lung cancer.Expert opinion on pharmacotherapy, , Volume: 12, Issue:14, 2011
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.British journal of cancer, , Jul-26, Volume: 105, Issue:3, 2011
Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.Neoplasia (New York, N.Y.), , Volume: 13, Issue:3, 2011
NSCLC drug targets acquire new visibility.Journal of the National Cancer Institute, , Mar-02, Volume: 103, Issue:5, 2011
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Mar-10, Volume: 29, Issue:8, 2011
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Mar-10, Volume: 29, Issue:8, 2011
[Pleural metastases from bronchial carcinoma: is a cure possible?].Revue des maladies respiratoires, , Volume: 28, Issue:1, 2011
Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.Asian Pacific journal of cancer prevention : APJCP, , Volume: 12, Issue:11, 2011
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.The Lancet. Oncology, , Volume: 11, Issue:7, 2010
One more fallen star--ZODIAC and its implications.The Lancet. Oncology, , Volume: 11, Issue:7, 2010
Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.Cancer prevention research (Philadelphia, Pa.), , Volume: 3, Issue:9, 2010
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 5, Issue:8, 2010
Targeting the epidermal growth factor receptor in non-small cell lung cancer.Onkologie, , Volume: 33, Issue:12, 2010
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jan-10, Volume: 28, Issue:2, 2010
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.Anticancer research, , Volume: 30, Issue:10, 2010
Targeted therapies: Molecular selection for 'smart' study design in lung cancer.Nature reviews. Clinical oncology, , Volume: 7, Issue:11, 2010
Vandetanib: An overview of its clinical development in NSCLC and other tumors.Drugs of today (Barcelona, Spain : 1998), , Volume: 46, Issue:9, 2010
Vascular endothelial growth factor concentration as a predictive marker: ready for primetime?Clinical cancer research : an official journal of the American Association for Cancer Research, , Feb-15, Volume: 16, Issue:4, 2010
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.Experimental biology and medicine (Maywood, N.J.), , Volume: 235, Issue:1, 2010
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.The oncologist, , Volume: 14, Issue:4, 2009
An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 20, Issue:3, 2009
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-15, Volume: 15, Issue:10, 2009
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-15, Volume: 15, Issue:10, 2009
Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo.Cancer research, , Jun-15, Volume: 69, Issue:12, 2009
Targeted therapies in the treatment of advanced/metastatic NSCLC.European journal of cancer (Oxford, England : 1990), , Volume: 45, Issue:14, 2009
Lung cancer trials probe effects of maintenance therapy, targeted agents.JAMA, , Aug-12, Volume: 302, Issue:6, 2009
Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.Clinical lung cancer, , Volume: 10 Suppl 1, 2009
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.Clinical lung cancer, , Volume: 10 Suppl 1, 2009
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , May-20, Volume: 27, Issue:15, 2009
[Lung cancer].Medizinische Klinik (Munich, Germany : 1983), , May-15, Volume: 103, Issue:5, 2008
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 3, Issue:4, 2008
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Nov-20, Volume: 26, Issue:33, 2008
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].Magyar onkologia, , Volume: 52, Issue:3, 2008
Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-01, Volume: 14, Issue:17, 2008
Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.International journal of oncology, , Volume: 33, Issue:3, 2008
Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 3, Issue:6 Suppl 2, 2008
Targeted therapy in advanced non-small-cell lung cancer.Seminars in respiratory and critical care medicine, , Volume: 29, Issue:3, 2008
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer.International journal of radiation oncology, biology, physics, , Dec-01, Volume: 69, Issue:5, 2007
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Sep-20, Volume: 25, Issue:27, 2007
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Sep-20, Volume: 25, Issue:27, 2007
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 13, Issue:15 Pt 2, 2007
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.Current treatment options in oncology, , Volume: 8, Issue:1, 2007
Combination of target agents: challenges and opportunities.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 2, Issue:5 Suppl, 2007
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.The oncologist, , Volume: 12, Issue:3, 2007
Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis.Oncogene, , Aug-23, Volume: 26, Issue:39, 2007
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.Molecular cancer therapeutics, , Volume: 6, Issue:2, 2007
Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 1, Issue:9, 2006
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.Clinical lung cancer, , Volume: 8 Suppl 1, 2006
Antiangiogenic drugs in non-small cell lung cancer treatment.Current opinion in oncology, , Volume: 18, Issue:2, 2006
Multi-target inhibitors in non-small cell lung cancer (NSCLC).Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 17 Suppl 2, 2006
Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474.Expert review of anticancer therapy, , Volume: 6, Issue:4, 2006
ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.Oncology research, , Volume: 16, Issue:1, 2006
ZD6474--clinical experience to date.British journal of cancer, , Volume: 92 Suppl 1, 2005
Angiogenesis and lung cancer: prognostic and therapeutic implications.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , May-10, Volume: 23, Issue:14, 2005
Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.Clinical lung cancer, , Volume: 7, Issue:2, 2005
Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-15, Volume: 11, Issue:24 Pt 1, 2005
ZD6474 headed for phase III trials in the fall.Oncology (Williston Park, N.Y.), , Volume: 19, Issue:9, 2005
[Anti angiogenesis].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 31, Issue:4, 2004
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.Cancer science, , Volume: 95, Issue:12, 2004
ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-15, Volume: 10, Issue:24, 2004
Therapeutic hotline. A rare vandetanib-induced photo-allergic drug eruption.Dermatologic therapy, , Volume: 23, Issue:5
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.British journal of cancer, , Nov-08, Volume: 115, Issue:10, 2016
Drug approvals 2011: focus on companion diagnostics.Journal of the National Cancer Institute, , Jan-18, Volume: 104, Issue:2, 2012
Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis.Oncogene, , Aug-23, Volume: 26, Issue:39, 2007
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-15, Volume: 10, Issue:18 Pt 1, 2004
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.Journal of medicinal chemistry, , Dec-19, Volume: 45, Issue:26, 2002
Extracellular signal-regulated kinase 5 and cyclic AMP response element binding protein are novel pathways inhibited by vandetanib (ZD6474) and doxorubicin in mesotheliomas.American journal of respiratory cell and molecular biology, , Volume: 51, Issue:5, 2014
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.British journal of cancer, , Nov-08, Volume: 105, Issue:10, 2011
Antiangiogenic therapies for malignant pleural mesothelioma.Frontiers in bioscience (Landmark edition), , 01-01, Volume: 16, Issue:2, 2011
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.Cancer letters, , Jun-28, Volume: 265, Issue:1, 2008
Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging for Monitoring the Early Response to ZD6474 from Nasopharyngeal Carcinoma in Nude Mouse.Scientific reports, , Nov-17, Volume: 5, 2015
ZD6474, a small molecule tyrosine kinase inhibitor, potentiates the anti-tumor and anti-metastasis effects of radiation for human nasopharyngeal carcinoma.Current cancer drug targets, , Volume: 10, Issue:6, 2010
Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase.International journal of cancer, , Nov-01, Volume: 121, Issue:9, 2007
Resveratrol improves the therapeutic efficacy of bone marrow-derived mesenchymal stem cells in rats with severe acute pancreatitis.International immunopharmacology, , Volume: 80, 2020
Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.International journal of oncology, , Volume: 33, Issue:3, 2008
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-15, Volume: 10, Issue:18 Pt 1, 2004
Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474.In vivo (Athens, Greece), , Volume: 19, Issue:6
A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor.Clinical cancer research : an official journal of the American Association for Cancer Research, , 11-01, Volume: 25, Issue:21, 2019
Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B.Clinical endocrinology, , Volume: 88, Issue:5, 2018
Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.Best practice & research. Clinical endocrinology & metabolism, , Volume: 31, Issue:3, 2017
Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.European journal of medicinal chemistry, , Nov-10, Volume: 140, 2017
Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , 05-20, Volume: 34, Issue:15, 2016
Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.International journal of cancer, , May-15, Volume: 138, Issue:10, 2016
New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.Anti-cancer drugs, , Volume: 26, Issue:7, 2015
Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment.Medicine, , Volume: 94, Issue:45, 2015
Vandetanib as a potential treatment for breast cancer.Expert opinion on investigational drugs, , Volume: 23, Issue:9, 2014
Vandetanib for the treatment of medullary thyroid carcinoma.The Annals of pharmacotherapy, , Volume: 48, Issue:3, 2014
Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature.Molecular bioSystems, , Volume: 9, Issue:6, 2013
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).Oral oncology, , Volume: 49, Issue:8, 2013
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.Lung cancer (Amsterdam, Netherlands), , Volume: 82, Issue:3, 2013
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 19, Issue:15, 2013
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jan-10, Volume: 30, Issue:2, 2012
Unusual adverse event with vandetanib in metastatic medullary thyroid cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jan-10, Volume: 30, Issue:2, 2012
Vandetanib: in medullary thyroid cancer.Drugs, , Jul-09, Volume: 72, Issue:10, 2012
Vandetanib: a guide to its use in advanced medullary thyroid cancer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, , Dec-01, Volume: 26, Issue:6, 2012
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.PloS one, , Volume: 7, Issue:6, 2012
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.Investigational new drugs, , Volume: 30, Issue:3, 2012
Vandetanib: first global approval.Drugs, , Jul-09, Volume: 71, Issue:10, 2011
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.The Journal of clinical endocrinology and metabolism, , Volume: 95, Issue:6, 2010
ZD6474, a small molecule tyrosine kinase inhibitor, potentiates the anti-tumor and anti-metastasis effects of radiation for human nasopharyngeal carcinoma.Current cancer drug targets, , Volume: 10, Issue:6, 2010
Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.Anti-cancer drugs, , Volume: 18, Issue:5, 2007
ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model.International journal of cancer, , Jan-15, Volume: 118, Issue:2, 2006
A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-01, Volume: 11, Issue:9, 2005
The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma.Angiogenesis, , Volume: 7, Issue:4, 2004
In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model.Angiogenesis, , Volume: 7, Issue:2, 2004
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-15, Volume: 10, Issue:18 Pt 1, 2004
Novel vandetanib derivative inhibited proliferation and promoted apoptosis of cancer cells under normoxia and hypoxia.European journal of pharmacology, , May-05, Volume: 922, 2022
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.European journal of medicinal chemistry, , Mar-15, Volume: 214, 2021
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.Journal of medicinal chemistry, , 08-26, Volume: 64, Issue:16, 2021
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study.ESMO open, , Volume: 6, Issue:2, 2021
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.Journal of medicinal chemistry, , 09-10, Volume: 63, Issue:17, 2020
Incidence and risk of developing photosensitivity with targeted anticancer therapies.Journal of the American Academy of Dermatology, , Volume: 81, Issue:4, 2019
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.European journal of medicinal chemistry, , May-15, Volume: 170, 2019
Risk of Gastrointestinal Events During Vandetanib Therapy in Patients With Cancer: A Systematic Review and Meta-analysis of Clinical Trials.American journal of therapeutics, , Volume: 24, Issue:3, 2017
Kinase Inhibitors in Multitargeted Cancer Therapy.Current medicinal chemistry, , Volume: 24, Issue:16, 2017
Discovery and Optimization of N-Substituted 2-(4-pyridinyl)thiazole carboxamides against Tumor Growth through Regulating Angiogenesis Signaling Pathways.Scientific reports, , 09-16, Volume: 6, 2016
Differential Effects of Tumor Secreted Factors on Mechanosensitivity, Capillary Branching, and Drug Responsiveness in PEG Hydrogels.Annals of biomedical engineering, , Volume: 43, Issue:9, 2015
[Anti-angiogenesis and molecular targeted therapies].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 73, Issue:8, 2015
Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers.Current pharmaceutical design, , Volume: 19, Issue:5, 2013
Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.British journal of clinical pharmacology, , Volume: 75, Issue:4, 2013
Drug approvals 2011: focus on companion diagnostics.Journal of the National Cancer Institute, , Jan-18, Volume: 104, Issue:2, 2012
Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis.PloS one, , Volume: 7, Issue:2, 2012
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].Magyar onkologia, , Volume: 56, Issue:1, 2012
Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis.Anti-cancer drugs, , Volume: 23, Issue:7, 2012
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].Magyar onkologia, , Volume: 56, Issue:3, 2012
Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.Clinical therapeutics, , Volume: 33, Issue:3, 2011
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.European journal of cancer (Oxford, England : 1990), , Volume: 47, Issue:7, 2011
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.International journal of oncology, , Volume: 39, Issue:1, 2011
Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.European journal of medicinal chemistry, , Volume: 46, Issue:10, 2011
Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 21, Issue:11, 2011
Vandetanib: An overview of its clinical development in NSCLC and other tumors.Drugs of today (Barcelona, Spain : 1998), , Volume: 46, Issue:9, 2010
Synthesis and preclinical evaluation of [(11)C]PAQ as a PET imaging tracer for VEGFR-2.European journal of nuclear medicine and molecular imaging, , Volume: 36, Issue:8, 2009
Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.Endocrine-related cancer, , Volume: 16, Issue:1, 2009
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.Current medicinal chemistry, , Volume: 15, Issue:5, 2008
Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.Journal of medicinal chemistry, , Aug-14, Volume: 51, Issue:15, 2008
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-15, Volume: 14, Issue:16, 2008
[Oral drugs inhibiting the VEGF pathway].Bulletin du cancer, , Volume: 94 Spec No, 2007
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.IDrugs : the investigational drugs journal, , Volume: 10, Issue:8, 2007
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 16, Issue:18, 2006
ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy.International journal of radiation oncology, biology, physics, , Jan-01, Volume: 64, Issue:1, 2006
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.Drugs of today (Barcelona, Spain : 1998), , Volume: 42, Issue:10, 2006
Update on angiogenesis inhibitors.Current opinion in oncology, , Volume: 17, Issue:6, 2005
Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues.Journal of pharmaceutical and biomedical analysis, , Sep-15, Volume: 39, Issue:3-4, 2005
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity.British journal of cancer, , Volume: 92 Suppl 1, 2005
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 16, Issue:8, 2005
[Anti angiogenesis].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 31, Issue:4, 2004
Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.Cancer research, , Dec-15, Volume: 64, Issue:24, 2004
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.Clinical cancer research : an official journal of the American Association for Cancer Research, , Volume: 9, Issue:4, 2003
Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs?Clinical cancer research : an official journal of the American Association for Cancer Research, , Volume: 9, Issue:4, 2003
ZD-6474. AstraZeneca.Current opinion in investigational drugs (London, England : 2000), , Volume: 4, Issue:12, 2003
[Current screening for molecular target therapy of cancer].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 30, Issue:12, 2003
Inhibitors of the vascular endothelial growth factor receptor.Hematology/oncology clinics of North America, , Volume: 16, Issue:5, 2002
Rationale and clinical results of multi-target treatments in oncology.The International journal of biological markers, , Volume: 22, Issue:1 Suppl 4
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.The oncologist, , Volume: 11, Issue:7
Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion.Oncology reports, , Volume: 39, Issue:4, 2018
Vandetanib-induced inhibition of neuroblastoma cell migration and invasion is associated with downregulation of the SDF-1/CXCR4 axis and matrix metalloproteinase 14.Oncology reports, , Volume: 31, Issue:3, 2014
A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.Cancer, , May-15, Volume: 116, Issue:10, 2010
Potent antitumor effects of ZD6474 on neuroblastoma via dual targeting of tumor cells and tumor endothelium.Molecular cancer therapeutics, , Volume: 7, Issue:2, 2008
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.The Cochrane database of systematic reviews, , 10-16, Volume: 10, 2018
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.European journal of cancer (Oxford, England : 1990), , Volume: 50, Issue:9, 2014
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).Investigational new drugs, , Volume: 31, Issue:6, 2013
Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Aug-15, Volume: 46, Issue:5, 2012
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jan-15, Volume: 16, Issue:2, 2010
The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.Neoplasia (New York, N.Y.), , Volume: 11, Issue:11, 2009
Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474.In vivo (Athens, Greece), , Volume: 19, Issue:6
Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations.Briefings in bioinformatics, , 05-20, Volume: 22, Issue:3, 2021
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.The Lancet. Oncology, , Volume: 18, Issue:4, 2017
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.Investigational new drugs, , Volume: 34, Issue:2, 2016
[Targeted therapies, prognostic and predictive factors in endocrine oncology].Annales d'endocrinologie, , Volume: 74 Suppl 1, 2013
Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma.Oncology, , Volume: 81, Issue:1, 2011
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.IDrugs : the investigational drugs journal, , Volume: 10, Issue:8, 2007
Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.Anti-cancer drugs, , Volume: 18, Issue:5, 2007
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-01, Volume: 12, Issue:23, 2006
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.European journal of cancer (Oxford, England : 1990), , Volume: 50, Issue:9, 2014
ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model.International journal of cancer, , Jan-15, Volume: 118, Issue:2, 2006
Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B.Clinical endocrinology, , Volume: 88, Issue:5, 2018
Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.European journal of medicinal chemistry, , Nov-10, Volume: 140, 2017
Paucity of pericytes in germinal matrix vasculature of premature infants.The Journal of neuroscience : the official journal of the Society for Neuroscience, , Oct-31, Volume: 27, Issue:44, 2007
[Cabozantinib: Mechanism of action, efficacy and indications].Bulletin du cancer, , Volume: 104, Issue:5, 2017
Biometrical issues in the analysis of adverse events within the benefit assessment of drugs.Pharmaceutical statistics, , Volume: 15, Issue:4, 2016
1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation.European journal of medicinal chemistry, , Jan-01, Volume: 107, 2016
[Four new drugs on the market: abiraterone, belatacept, vandetanib and fidaxomycine].Annales pharmaceutiques francaises, , Volume: 71, Issue:2, 2013
Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.Urologic oncology, , Volume: 31, Issue:8, 2013
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].Magyar onkologia, , Volume: 56, Issue:3, 2012
Drug approvals 2011: focus on companion diagnostics.Journal of the National Cancer Institute, , Jan-18, Volume: 104, Issue:2, 2012
False-negative MRI biomarkers of tumour response to targeted cancer therapeutics.British journal of cancer, , Jun-05, Volume: 106, Issue:12, 2012
2011 ASCO Genitourinary Cancers Symposium.The Lancet. Oncology, , Volume: 12, Issue:4, 2011
A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer.Cancer biotherapy & radiopharmaceuticals, , Volume: 24, Issue:2, 2009
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.IDrugs : the investigational drugs journal, , Volume: 10, Issue:8, 2007
Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition.Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-15, Volume: 12, Issue:24, 2006
Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-15, Volume: 10, Issue:24, 2004
[Anti angiogenesis].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 31, Issue:4, 2004
Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours.British journal of cancer, , Nov-17, Volume: 89, Issue:10, 2003
Extracellular signal-regulated kinase 5 and cyclic AMP response element binding protein are novel pathways inhibited by vandetanib (ZD6474) and doxorubicin in mesotheliomas.American journal of respiratory cell and molecular biology, , Volume: 51, Issue:5, 2014
Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-01, Volume: 14, Issue:17, 2008
Frequency dependent impedimetric cytotoxic evaluation of anticancer drug on breast cancer cell.Biosensors & bioelectronics, , May-15, Volume: 55, 2014
Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Sep-01, Volume: 879, Issue:25, 2011
Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.Head & neck, , Volume: 33, Issue:3, 2011
Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues.Journal of pharmaceutical and biomedical analysis, , Sep-15, Volume: 39, Issue:3-4, 2005
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer.Journal of chemotherapy (Florence, Italy), , Volume: 16 Suppl 4, 2004
Validation of a high-performance liquid chromatographic ultraviolet detection method for the quantification of vandetanib in rat plasma and its application to pharmacokinetic studies.Journal of cancer research and therapeutics, , Volume: 10, Issue:1
Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 144, 2021
Effects of adenosine triphosphate on vandetanib induced skin damage in rats.Cutaneous and ocular toxicology, , Volume: 39, Issue:4, 2020
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).Investigational new drugs, , Volume: 31, Issue:6, 2013
Vandetanib inhibits cell growth in EGFR-expressing cutaneous squamous cell carcinoma.Biochemical and biophysical research communications, , 10-20, Volume: 531, Issue:3, 2020
CD30+ lymphoproliferative disorder in a patient with metastatic papillary thyroid carcinoma.Dermatology online journal, , Oct-15, Volume: 22, Issue:10, 2016
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis.Oncogene, , Aug-23, Volume: 26, Issue:39, 2007
Expression of VEGF with tumor incidence, metastasis and prognosis in human gastric carcinoma.Cancer biomarkers : section A of Disease markers, , Volume: 22, Issue:4, 2018
The Significant Role of Cyclin D1 in the Synergistic Growth-inhibitory Effect of Combined Therapy of Vandetanib with 5-Fluorouracil for Gastric Cancer.Anticancer research, , Volume: 36, Issue:10, 2016
Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.International journal of cancer, , Sep-01, Volume: 127, Issue:5, 2010
ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model.International journal of cancer, , Jan-15, Volume: 118, Issue:2, 2006
ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.Molecular cancer therapeutics, , Volume: 3, Issue:9, 2004
Rare complications of multikinase inhibitor treatment.Archives of endocrinology and metabolism, , Volume: 62, Issue:6, 2018
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.Journal of cancer research and clinical oncology, , Volume: 141, Issue:5, 2015
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.International journal of radiation oncology, biology, physics, , Sep-01, Volume: 78, Issue:1, 2010
Phase 3 Trial of Selpercatinib in Advanced The New England journal of medicine, , Nov-16, Volume: 389, Issue:20, 2023
Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.International journal of molecular sciences, , Mar-16, Volume: 22, Issue:6, 2021
Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.Thyroid : official journal of the American Thyroid Association, , Volume: 31, Issue:3, 2021
Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both Journal of clinical research in pediatric endocrinology, , 08-23, Volume: 13, Issue:3, 2021
Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer.Endocrine, , Volume: 71, Issue:2, 2021
Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib.Investigational new drugs, , Volume: 39, Issue:1, 2021
[Medullary thyroid carcinoma: current clinical progress].Deutsche medizinische Wochenschrift (1946), , Volume: 146, Issue:23, 2021
Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.Frontiers in endocrinology, , Volume: 12, 2021
[Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer].Bulletin du cancer, , Volume: 108, Issue:11, 2021
An Unusual Case of Hypopituitarism as an Adverse Effect of Vandetanib and Remission of Breast Metastases in a Patient with Medullary Thyroid Cancer.Oncology research and treatment, , Volume: 44, Issue:10, 2021
Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea.Endocrinology and metabolism (Seoul, Korea), , Volume: 35, Issue:4, 2020
Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.Endocrinology and metabolism (Seoul, Korea), , Volume: 35, Issue:3, 2020
Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.Endocrine journal, , Dec-28, Volume: 67, Issue:12, 2020
Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , 08-20, Volume: 38, Issue:24, 2020
Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors.PloS one, , Volume: 15, Issue:5, 2020
YAP confers resistance to vandetanib in medullary thyroid cancer.Biochemistry and cell biology = Biochimie et biologie cellulaire, , Volume: 98, Issue:3, 2020
Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response.Endocrine-related cancer, , 01-20, Volume: 27, Issue:2, 2020
A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: A case report.Medicine, , Volume: 98, Issue:31, 2019
Tyrosine Kinase Inhibitor Use and Wound Healing in Tracheoesophageal Punctures.Ear, nose, & throat journal, , Volume: 98, Issue:8, 2019
Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.Health technology assessment (Winchester, England), , Volume: 23, Issue:8, 2019
Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.Endocrine-related cancer, , 02-01, Volume: 26, Issue:2, 2019
Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy.The Journal of clinical endocrinology and metabolism, , 03-01, Volume: 104, Issue:3, 2019
Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report.Journal of pediatric hematology/oncology, , Volume: 41, Issue:5, 2019
Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.The oncologist, , Volume: 24, Issue:1, 2019
Rare complications of multikinase inhibitor treatment.Archives of endocrinology and metabolism, , Volume: 62, Issue:6, 2018
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.International journal of molecular sciences, , Oct-20, Volume: 19, Issue:10, 2018
Appendix 2: Medullary Thyroid Cancer: eUpdate published online 19 February 2018 (http://www.esmo.org/Guidelines/Endocrine-and-Neuroendocrine-Cancers/Thyroid-cancer).Annals of oncology : official journal of the European Society for Medical Oncology, , 10-01, Volume: 29, Issue:Suppl 4, 2018
Transcriptional targeting of oncogene addiction in medullary thyroid cancer.JCI insight, , 08-23, Volume: 3, Issue:16, 2018
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo.Oncology reports, , Volume: 39, Issue:5, 2018
Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B.Clinical endocrinology, , Volume: 88, Issue:5, 2018
Cabozantinib and Vandetanib in medullary thyroid carcinoma: mitochondrial function and its potential as a therapeutic target towards novel strategies to design anti-CSCs drugs.Cancer biology & therapy, , Volume: 19, Issue:10, 2018
Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.Clinical cancer research : an official journal of the American Association for Cancer Research, , 02-15, Volume: 24, Issue:4, 2018
Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.European journal of medicinal chemistry, , Apr-25, Volume: 150, 2018
Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.Molecular diagnosis & therapy, , Volume: 21, Issue:6, 2017
Genetics of medullary thyroid cancer: An overview.International journal of surgery (London, England), , Volume: 41 Suppl 1, 2017
[Cabozantinib: Mechanism of action, efficacy and indications].Bulletin du cancer, , Volume: 104, Issue:5, 2017
Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.Cancer biology & therapy, , Jul-03, Volume: 18, Issue:7, 2017
Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation.Thyroid : official journal of the American Thyroid Association, , Volume: 27, Issue:4, 2017
Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.Best practice & research. Clinical endocrinology & metabolism, , Volume: 31, Issue:3, 2017
SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, , Volume: 23, Issue:2, 2017
Systemic treatment and management approaches for medullary thyroid cancer.Cancer treatment reviews, , Volume: 50, 2016
The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.Expert review of anticancer therapy, , Volume: 16, Issue:11, 2016
[Metastatic medullary thyroid carcinoma in a child with multiple endocrine neoplasia 2B. Efficiency of medium-term treatment with vandetanib without thyroid surgery].Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, , Volume: 23, Issue:8, 2016
The safety of vandetanib for the treatment of thyroid cancer.Expert opinion on drug safety, , Volume: 15, Issue:8, 2016
Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.European journal of endocrinology, , Volume: 175, Issue:3, 2016
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.Oncology, , Volume: 90, Issue:6, 2016
MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.Oncotarget, , May-24, Volume: 7, Issue:21, 2016
cabozantinib (COMETRIQ⁰). In medullary thyroid cancer: more harmful than beneficial, as is vandetanib.Prescrire international, , Volume: 25, Issue:167, 2016
Biometrical issues in the analysis of adverse events within the benefit assessment of drugs.Pharmaceutical statistics, , Volume: 15, Issue:4, 2016
CD30+ lymphoproliferative disorder in a patient with metastatic papillary thyroid carcinoma.Dermatology online journal, , Oct-15, Volume: 22, Issue:10, 2016
A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants.Journal of medicinal chemistry, , Jan-14, Volume: 59, Issue:1, 2016
Management of advanced medullary thyroid cancer.The lancet. Diabetes & endocrinology, , Volume: 4, Issue:1, 2016
Use of Vandetanib in Metastatic Medullary Carcinoma of Thyroid in a Pediatric Patient With Multiple Endocrine Neoplasia 2B.Journal of pediatric hematology/oncology, , Volume: 38, Issue:2, 2016
Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment.Medicine, , Volume: 94, Issue:45, 2015
High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.Asian Pacific journal of cancer prevention : APJCP, , Volume: 16, Issue:16, 2015
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.Targeted oncology, , Volume: 10, Issue:3, 2015
Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome.Archives of endocrinology and metabolism, , Volume: 59, Issue:4, 2015
Selective use of vandetanib in the treatment of thyroid cancer.Drug design, development and therapy, , Volume: 9, 2015
Systemic treatment of advanced differentiated and medullary thyroid cancer. Overview and practical aspects.Nuklearmedizin. Nuclear medicine, , Volume: 54, Issue:3, 2015
New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.Anti-cancer drugs, , Volume: 26, Issue:7, 2015
Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report.BMC dermatology, , Feb-13, Volume: 15, 2015
Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.Thyroid : official journal of the American Thyroid Association, , Volume: 25, Issue:4, 2015
The evolving field of kinase inhibitors in thyroid cancer.Critical reviews in oncology/hematology, , Volume: 93, Issue:1, 2015
Vandetanib-associated alopecia areata in a patient with metastatic medullary thyroid cancer.International journal of dermatology, , Volume: 54, Issue:6, 2015
Novel therapies for thyroid cancer.Expert opinion on pharmacotherapy, , Volume: 15, Issue:18, 2014
[Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].Bulletin du cancer, , Volume: 101, Issue:9, 2014
Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions.The Journal of clinical endocrinology and metabolism, , Volume: 99, Issue:12, 2014
Photo-induced erythema multiforme associated with vandetanib administration.Journal of the American Academy of Dermatology, , Volume: 71, Issue:4, 2014
Advanced thyroid cancers: new era of treatment.Medical oncology (Northwood, London, England), , Volume: 31, Issue:7, 2014
Development of molecular targeted drugs for advanced thyroid cancer in Japan.Endocrine journal, , Volume: 61, Issue:9, 2014
Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.The Journal of clinical endocrinology and metabolism, , Volume: 99, Issue:9, 2014
Vandetanib for the treatment of thyroid cancer: an update.Expert opinion on drug metabolism & toxicology, , Volume: 10, Issue:3, 2014
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.European journal of endocrinology, , Volume: 170, Issue:4, 2014
The discovery and development of vandetanib for the treatment of thyroid cancer.Expert opinion on drug discovery, , Volume: 9, Issue:1, 2014
Vandetanib for the treatment of medullary thyroid carcinoma.The Annals of pharmacotherapy, , Volume: 48, Issue:3, 2014
Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by reverse phase protein array.Thyroid : official journal of the American Thyroid Association, , Volume: 24, Issue:1, 2014
Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , May-15, Volume: 70, Issue:10, 2013
Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.Endocrine, , Volume: 44, Issue:2, 2013
Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study.The Journal of clinical endocrinology and metabolism, , Volume: 98, Issue:6, 2013
[Four new drugs on the market: abiraterone, belatacept, vandetanib and fidaxomycine].Annales pharmaceutiques francaises, , Volume: 71, Issue:2, 2013
Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo.The Journal of clinical endocrinology and metabolism, , Volume: 98, Issue:4, 2013
Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis.European journal of endocrinology, , Volume: 168, Issue:6, 2013
Case records of the Massachusetts General Hospital. Case 5-2013. A 52-year-old woman with a mass in the thyroid.The New England journal of medicine, , Feb-14, Volume: 368, Issue:7, 2013
Vandetanib and the management of advanced medullary thyroid cancer.Current opinion in oncology, , Volume: 25, Issue:1, 2013
Vandetanib for the treatment of medullary thyroid cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , Feb-01, Volume: 19, Issue:3, 2013
[Targeted therapies, prognostic and predictive factors in endocrine oncology].Annales d'endocrinologie, , Volume: 74 Suppl 1, 2013
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.Advances in therapy, , Volume: 30, Issue:11, 2013
Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer.The oncologist, , Volume: 18, Issue:12, 2013
A Drosophila approach to thyroid cancer therapeutics.Drug discovery today. Technologies, ,Spring, Volume: 10, Issue:1, 2013
Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 24, Issue:9, 2013
Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma.The New England journal of medicine, , Aug-08, Volume: 369, Issue:6, 2013
Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer.The Journal of surgical research, , Volume: 185, Issue:2, 2013
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 19, Issue:15, 2013
Management of thyroid carcinoma in children and young adults.Journal of pediatric hematology/oncology, , Volume: 34 Suppl 2, 2012
Kinase inhibitors for advanced medullary thyroid carcinoma.Clinics (Sao Paulo, Brazil), , Volume: 67 Suppl 1, 2012
Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jul-15, Volume: 18, Issue:14, 2012
Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis.Anti-cancer drugs, , Volume: 23, Issue:7, 2012
Vandetanib: in medullary thyroid cancer.Drugs, , Jul-09, Volume: 72, Issue:10, 2012
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.The Journal of clinical endocrinology and metabolism, , Volume: 97, Issue:9, 2012
Treating advanced radioresistant differentiated thyroid cancer.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
First do no harm: counting the cost of chasing drug efficacy.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Vandetanib: a guide to its use in advanced medullary thyroid cancer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, , Dec-01, Volume: 26, Issue:6, 2012
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.JAMA, , Sep-05, Volume: 308, Issue:9, 2012
Vandetanib therapy in medullary thyroid cancer.Drugs of today (Barcelona, Spain : 1998), , Volume: 48, Issue:11, 2012
Vandetanib: too dangerous in medullary thyroid cancer.Prescrire international, , Volume: 21, Issue:131, 2012
A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib.Archives of dermatology, , Volume: 148, Issue:12, 2012
Novel molecular targeted therapies for refractory thyroid cancer.Head & neck, , Volume: 34, Issue:5, 2012
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jan-10, Volume: 30, Issue:2, 2012
Progress in molecular targeted therapy for thyroid cancer: vandetanib in medullary thyroid cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jan-10, Volume: 30, Issue:2, 2012
Vandetanib for the treatment of thyroid cancer.Clinical pharmacology and therapeutics, , Volume: 91, Issue:1, 2012
Completing the Arc: targeted inhibition of RET in medullary thyroid cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jan-10, Volume: 30, Issue:2, 2012
Unusual adverse event with vandetanib in metastatic medullary thyroid cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jan-10, Volume: 30, Issue:2, 2012
Vandetanib (Caprelsa) for medullary thyroid cancer.The Medical letter on drugs and therapeutics, , Jan-09, Volume: 54, Issue:1381, 2012
Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma.Current opinion in oncology, , Volume: 24, Issue:3, 2012
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.The Journal of clinical endocrinology and metabolism, , Volume: 97, Issue:4, 2012
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.Endocrine-related cancer, , Volume: 18, Issue:1, 2011
Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.Clinical cancer research : an official journal of the American Association for Cancer Research, , Apr-15, Volume: 17, Issue:8, 2011
Metabolic imaging allows early prediction of response to vandetanib.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 52, Issue:2, 2011
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.Endocrine journal, , Volume: 58, Issue:3, 2011
[New therapeutic options for advanced thyroid cancer].Deutsche medizinische Wochenschrift (1946), , Volume: 136, Issue:22, 2011
Updates in the management of medullary thyroid cancer.Clinical advances in hematology & oncology : H&O, , Volume: 9, Issue:5, 2011
Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer.The Journal of clinical endocrinology and metabolism, , Volume: 96, Issue:9, 2011
Vandetanib: first global approval.Drugs, , Jul-09, Volume: 71, Issue:10, 2011
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.The Journal of clinical endocrinology and metabolism, , Volume: 95, Issue:6, 2010
The Ca2+-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC.Endocrine-related cancer, , Volume: 17, Issue:1, 2010
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Feb-10, Volume: 28, Issue:5, 2010
Tyrosine kinase inhibitors and the thyroid.Best practice & research. Clinical endocrinology & metabolism, , Volume: 23, Issue:6, 2009
Targeted molecular therapies in thyroid carcinoma.Arquivos brasileiros de endocrinologia e metabologia, , Volume: 53, Issue:9, 2009
Early clinical studies of novel therapies for thyroid cancers.Endocrinology and metabolism clinics of North America, , Volume: 37, Issue:2, 2008
A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.Endocrine-related cancer, , Volume: 14, Issue:2, 2007
Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer.Langenbeck's archives of surgery, , Volume: 391, Issue:6, 2006
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer.International journal of biological macromolecules, , Aug-15, Volume: 39, Issue:1-3, 2006
ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.Cancer research, , May-01, Volume: 65, Issue:9, 2005
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells.Cancer research, , Jun-01, Volume: 64, Issue:11, 2004
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.Oncogene, , Aug-12, Volume: 23, Issue:36, 2004
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer.Journal of chemotherapy (Florence, Italy), , Volume: 16 Suppl 4, 2004
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.Cancer research, , Dec-15, Volume: 62, Issue:24, 2002
Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.Archives of endocrinology and metabolism, , Volume: 61, Issue:4
Phototoxic drug eruption induced by vandetanib used for the treatment of metastatic medullary thyroid cancer.Anais brasileiros de dermatologia, , Volume: 97, Issue:5
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.Investigational new drugs, , Volume: 30, Issue:3, 2012
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].Magyar onkologia, , Volume: 56, Issue:3, 2012
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.PloS one, , Volume: 7, Issue:6, 2012
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study.Cancer chemotherapy and pharmacology, , Volume: 64, Issue:4, 2009
Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer.Investigational new drugs, , Volume: 27, Issue:3, 2009
Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.International journal of radiation oncology, biology, physics, , Nov-01, Volume: 75, Issue:3, 2009
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.IDrugs : the investigational drugs journal, , Volume: 10, Issue:8, 2007
VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy.International journal of radiation oncology, biology, physics, , Jul-01, Volume: 65, Issue:3, 2006
Update on angiogenesis inhibitors.Current opinion in oncology, , Volume: 17, Issue:6, 2005
Inhibitors of the vascular endothelial growth factor receptor.Hematology/oncology clinics of North America, , Volume: 16, Issue:5, 2002
Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474.In vivo (Athens, Greece), , Volume: 19, Issue:6
Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.Clinical lung cancer, , Volume: 15, Issue:5, 2014
Antiangiogenic therapies for malignant pleural mesothelioma.Frontiers in bioscience (Landmark edition), , 01-01, Volume: 16, Issue:2, 2011
ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.Oncology research, , Volume: 16, Issue:1, 2006
A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib.Archives of dermatology, , Volume: 148, Issue:12, 2012
Successful laser treatment of vandetanib-associated cutaneous pigmentation.Archives of dermatology, , Volume: 147, Issue:3, 2011
Cutaneous pigmentation after photosensitivity induced by vandetanib therapy.Archives of dermatology, , Volume: 145, Issue:8, 2009
Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report.BMC dermatology, , Feb-13, Volume: 15, 2015
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.European journal of endocrinology, , Volume: 170, Issue:4, 2014
First do no harm: counting the cost of chasing drug efficacy.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Treating advanced radioresistant differentiated thyroid cancer.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer.The Journal of clinical endocrinology and metabolism, , Volume: 96, Issue:9, 2011
[Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer].Bulletin du cancer, , Volume: 108, Issue:11, 2021
Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.Clinical cancer research : an official journal of the American Association for Cancer Research, , 02-15, Volume: 24, Issue:4, 2018
Rare complications of multikinase inhibitor treatment.Archives of endocrinology and metabolism, , Volume: 62, Issue:6, 2018
Genetics of medullary thyroid cancer: An overview.International journal of surgery (London, England), , Volume: 41 Suppl 1, 2017
Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.European journal of endocrinology, , Volume: 175, Issue:3, 2016
[Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].Bulletin du cancer, , Volume: 101, Issue:9, 2014
Photo-induced erythema multiforme associated with vandetanib administration.Journal of the American Academy of Dermatology, , Volume: 71, Issue:4, 2014
Vandetanib for the treatment of medullary thyroid carcinoma.The Annals of pharmacotherapy, , Volume: 48, Issue:3, 2014
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 19, Issue:15, 2013
Vandetanib and the management of advanced medullary thyroid cancer.Current opinion in oncology, , Volume: 25, Issue:1, 2013
Kinase inhibitors for advanced medullary thyroid carcinoma.Clinics (Sao Paulo, Brazil), , Volume: 67 Suppl 1, 2012
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.Endocrine-related cancer, , Volume: 18, Issue:1, 2011
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Feb-10, Volume: 28, Issue:5, 2010
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.The Journal of clinical endocrinology and metabolism, , Volume: 95, Issue:6, 2010
Targeted molecular therapies in thyroid carcinoma.Arquivos brasileiros de endocrinologia e metabologia, , Volume: 53, Issue:9, 2009
A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.Endocrine-related cancer, , Volume: 14, Issue:2, 2007
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.Oncogene, , Aug-12, Volume: 23, Issue:36, 2004
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer.Journal of chemotherapy (Florence, Italy), , Volume: 16 Suppl 4, 2004
[Medullary thyroid carcinoma: current clinical progress].Deutsche medizinische Wochenschrift (1946), , Volume: 146, Issue:23, 2021
Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.Frontiers in endocrinology, , Volume: 12, 2021
An Unusual Case of Hypopituitarism as an Adverse Effect of Vandetanib and Remission of Breast Metastases in a Patient with Medullary Thyroid Cancer.Oncology research and treatment, , Volume: 44, Issue:10, 2021
Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.International journal of molecular sciences, , Mar-16, Volume: 22, Issue:6, 2021
Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.Thyroid : official journal of the American Thyroid Association, , Volume: 31, Issue:3, 2021
Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both Journal of clinical research in pediatric endocrinology, , 08-23, Volume: 13, Issue:3, 2021
Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer.Endocrine, , Volume: 71, Issue:2, 2021
Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response.Endocrine-related cancer, , 01-20, Volume: 27, Issue:2, 2020
Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea.Endocrinology and metabolism (Seoul, Korea), , Volume: 35, Issue:4, 2020
Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.Endocrinology and metabolism (Seoul, Korea), , Volume: 35, Issue:3, 2020
Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , 08-20, Volume: 38, Issue:24, 2020
Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors.PloS one, , Volume: 15, Issue:5, 2020
YAP confers resistance to vandetanib in medullary thyroid cancer.Biochemistry and cell biology = Biochimie et biologie cellulaire, , Volume: 98, Issue:3, 2020
Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.The oncologist, , Volume: 24, Issue:1, 2019
Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report.Journal of pediatric hematology/oncology, , Volume: 41, Issue:5, 2019
Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy.The Journal of clinical endocrinology and metabolism, , 03-01, Volume: 104, Issue:3, 2019
Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.Endocrine-related cancer, , 02-01, Volume: 26, Issue:2, 2019
Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.Health technology assessment (Winchester, England), , Volume: 23, Issue:8, 2019
Transcriptional targeting of oncogene addiction in medullary thyroid cancer.JCI insight, , 08-23, Volume: 3, Issue:16, 2018
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.International journal of molecular sciences, , Oct-20, Volume: 19, Issue:10, 2018
Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B.Clinical endocrinology, , Volume: 88, Issue:5, 2018
Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.European journal of medicinal chemistry, , Apr-25, Volume: 150, 2018
Appendix 2: Medullary Thyroid Cancer: eUpdate published online 19 February 2018 (http://www.esmo.org/Guidelines/Endocrine-and-Neuroendocrine-Cancers/Thyroid-cancer).Annals of oncology : official journal of the European Society for Medical Oncology, , 10-01, Volume: 29, Issue:Suppl 4, 2018
SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, , Volume: 23, Issue:2, 2017
Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation.Thyroid : official journal of the American Thyroid Association, , Volume: 27, Issue:4, 2017
Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.Best practice & research. Clinical endocrinology & metabolism, , Volume: 31, Issue:3, 2017
Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.Molecular diagnosis & therapy, , Volume: 21, Issue:6, 2017
[Cabozantinib: Mechanism of action, efficacy and indications].Bulletin du cancer, , Volume: 104, Issue:5, 2017
Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.Cancer biology & therapy, , Jul-03, Volume: 18, Issue:7, 2017
Management of advanced medullary thyroid cancer.The lancet. Diabetes & endocrinology, , Volume: 4, Issue:1, 2016
Systemic treatment and management approaches for medullary thyroid cancer.Cancer treatment reviews, , Volume: 50, 2016
The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.Expert review of anticancer therapy, , Volume: 16, Issue:11, 2016
Use of Vandetanib in Metastatic Medullary Carcinoma of Thyroid in a Pediatric Patient With Multiple Endocrine Neoplasia 2B.Journal of pediatric hematology/oncology, , Volume: 38, Issue:2, 2016
[Metastatic medullary thyroid carcinoma in a child with multiple endocrine neoplasia 2B. Efficiency of medium-term treatment with vandetanib without thyroid surgery].Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, , Volume: 23, Issue:8, 2016
The safety of vandetanib for the treatment of thyroid cancer.Expert opinion on drug safety, , Volume: 15, Issue:8, 2016
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.Oncology, , Volume: 90, Issue:6, 2016
MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.Oncotarget, , May-24, Volume: 7, Issue:21, 2016
cabozantinib (COMETRIQ⁰). In medullary thyroid cancer: more harmful than beneficial, as is vandetanib.Prescrire international, , Volume: 25, Issue:167, 2016
Vandetanib-associated alopecia areata in a patient with metastatic medullary thyroid cancer.International journal of dermatology, , Volume: 54, Issue:6, 2015
Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment.Medicine, , Volume: 94, Issue:45, 2015
High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.Asian Pacific journal of cancer prevention : APJCP, , Volume: 16, Issue:16, 2015
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.Targeted oncology, , Volume: 10, Issue:3, 2015
Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome.Archives of endocrinology and metabolism, , Volume: 59, Issue:4, 2015
Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.Thyroid : official journal of the American Thyroid Association, , Volume: 25, Issue:4, 2015
Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions.The Journal of clinical endocrinology and metabolism, , Volume: 99, Issue:12, 2014
Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.The Journal of clinical endocrinology and metabolism, , Volume: 99, Issue:9, 2014
[Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].Bulletin du cancer, , Volume: 101, Issue:9, 2014
Vandetanib for the treatment of medullary thyroid carcinoma.The Annals of pharmacotherapy, , Volume: 48, Issue:3, 2014
Vandetanib for the treatment of thyroid cancer: an update.Expert opinion on drug metabolism & toxicology, , Volume: 10, Issue:3, 2014
Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by reverse phase protein array.Thyroid : official journal of the American Thyroid Association, , Volume: 24, Issue:1, 2014
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.European journal of endocrinology, , Volume: 170, Issue:4, 2014
Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , May-15, Volume: 70, Issue:10, 2013
Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 24, Issue:9, 2013
Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer.The oncologist, , Volume: 18, Issue:12, 2013
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.Advances in therapy, , Volume: 30, Issue:11, 2013
[Targeted therapies, prognostic and predictive factors in endocrine oncology].Annales d'endocrinologie, , Volume: 74 Suppl 1, 2013
Vandetanib for the treatment of medullary thyroid cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , Feb-01, Volume: 19, Issue:3, 2013
Case records of the Massachusetts General Hospital. Case 5-2013. A 52-year-old woman with a mass in the thyroid.The New England journal of medicine, , Feb-14, Volume: 368, Issue:7, 2013
Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.Endocrine, , Volume: 44, Issue:2, 2013
Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis.European journal of endocrinology, , Volume: 168, Issue:6, 2013
Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo.The Journal of clinical endocrinology and metabolism, , Volume: 98, Issue:4, 2013
Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma.The New England journal of medicine, , Aug-08, Volume: 369, Issue:6, 2013
Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study.The Journal of clinical endocrinology and metabolism, , Volume: 98, Issue:6, 2013
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 19, Issue:15, 2013
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.JAMA, , Sep-05, Volume: 308, Issue:9, 2012
Vandetanib: a guide to its use in advanced medullary thyroid cancer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, , Dec-01, Volume: 26, Issue:6, 2012
Progress in molecular targeted therapy for thyroid cancer: vandetanib in medullary thyroid cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jan-10, Volume: 30, Issue:2, 2012
Completing the Arc: targeted inhibition of RET in medullary thyroid cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jan-10, Volume: 30, Issue:2, 2012
Unusual adverse event with vandetanib in metastatic medullary thyroid cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jan-10, Volume: 30, Issue:2, 2012
Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma.Current opinion in oncology, , Volume: 24, Issue:3, 2012
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.The Journal of clinical endocrinology and metabolism, , Volume: 97, Issue:4, 2012
Vandetanib therapy in medullary thyroid cancer.Drugs of today (Barcelona, Spain : 1998), , Volume: 48, Issue:11, 2012
Vandetanib: too dangerous in medullary thyroid cancer.Prescrire international, , Volume: 21, Issue:131, 2012
Vandetanib: in medullary thyroid cancer.Drugs, , Jul-09, Volume: 72, Issue:10, 2012
Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jul-15, Volume: 18, Issue:14, 2012
Kinase inhibitors for advanced medullary thyroid carcinoma.Clinics (Sao Paulo, Brazil), , Volume: 67 Suppl 1, 2012
Vandetanib (Caprelsa) for medullary thyroid cancer.The Medical letter on drugs and therapeutics, , Jan-09, Volume: 54, Issue:1381, 2012
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jan-10, Volume: 30, Issue:2, 2012
Updates in the management of medullary thyroid cancer.Clinical advances in hematology & oncology : H&O, , Volume: 9, Issue:5, 2011
Vandetanib: first global approval.Drugs, , Jul-09, Volume: 71, Issue:10, 2011
Phototoxic drug eruption induced by vandetanib used for the treatment of metastatic medullary thyroid cancer.Anais brasileiros de dermatologia, , Volume: 97, Issue:5
Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.Archives of endocrinology and metabolism, , Volume: 61, Issue:4
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.The Cochrane database of systematic reviews, , Apr-06, Volume: 4, 2018
Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma.British journal of cancer, , Apr-21, Volume: 100, Issue:8, 2009
Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.International journal of oncology, , Volume: 33, Issue:3, 2008
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Sep-20, Volume: 25, Issue:27, 2007
Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-15, Volume: 11, Issue:24 Pt 1, 2005
Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation.AJNR. American journal of neuroradiology, , Volume: 38, Issue:6, 2017
Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy.International journal of radiation oncology, biology, physics, , 12-01, Volume: 99, Issue:5, 2017
Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jun-01, Volume: 19, Issue:11, 2013
MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma.AJNR. American journal of neuroradiology, , Volume: 34, Issue:7, 2013
Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.Pediatric blood & cancer, , Volume: 60, Issue:9, 2013
Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Nov-01, Volume: 28, Issue:31, 2010
Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy.International journal of radiation oncology, biology, physics, , 12-01, Volume: 99, Issue:5, 2017
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.JAMA, , Sep-05, Volume: 308, Issue:9, 2012
A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor.Clinical cancer research : an official journal of the American Association for Cancer Research, , 11-01, Volume: 25, Issue:21, 2019
ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib.Cancer science, , Volume: 97, Issue:12, 2006
A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.Cancer, , 01-01, Volume: 123, Issue:2, 2017
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.The Journal of clinical endocrinology and metabolism, , Volume: 97, Issue:4, 2012
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.The oncologist, , Volume: 14, Issue:4, 2009
Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.Frontiers in endocrinology, , Volume: 12, 2021
Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.BMC ophthalmology, , Jan-09, Volume: 20, Issue:1, 2020
A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: A case report.Medicine, , Volume: 98, Issue:31, 2019
Biometrical issues in the analysis of adverse events within the benefit assessment of drugs.Pharmaceutical statistics, , Volume: 15, Issue:4, 2016
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.Advances in therapy, , Volume: 30, Issue:11, 2013
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 19, Issue:15, 2013
Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.Breast cancer research and treatment, , Volume: 136, Issue:1, 2012
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo.Oncology reports, , Volume: 39, Issue:5, 2018
Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer.The Journal of surgical research, , Volume: 185, Issue:2, 2013
Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.Clinical cancer research : an official journal of the American Association for Cancer Research, , Apr-15, Volume: 17, Issue:8, 2011
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.International journal of molecular sciences, , Oct-20, Volume: 19, Issue:10, 2018
Electrophysiological mechanisms of vandetanib-induced cardiotoxicity: Comparison of action potentials in rabbit Purkinje fibers and pluripotent stem cell-derived cardiomyocytes.PloS one, , Volume: 13, Issue:4, 2018
Vandetanib photoinduced cutaneous toxicities.Cutis, , Volume: 103, Issue:5, 2019
A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: A case report.Medicine, , Volume: 98, Issue:31, 2019
Vandetanib-induced phototoxicity in human keratinocytes NCTC-2544.Toxicology in vitro : an international journal published in association with BIBRA, , Volume: 28, Issue:5, 2014
Cutaneous pigmentation after photosensitivity induced by vandetanib therapy.Archives of dermatology, , Volume: 145, Issue:8, 2009
Vandetanib induced phototoxic reaction progressed to toxic epidermal necrolysis.Anais brasileiros de dermatologia, , Volume: 97, Issue:1
A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib.Archives of dermatology, , Volume: 148, Issue:12, 2012
Successful laser treatment of vandetanib-associated cutaneous pigmentation.Archives of dermatology, , Volume: 147, Issue:3, 2011
Cutaneous pigmentation after photosensitivity induced by vandetanib therapy.Archives of dermatology, , Volume: 145, Issue:8, 2009
Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report.BMC dermatology, , Feb-13, Volume: 15, 2015
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.European journal of endocrinology, , Volume: 170, Issue:4, 2014
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Treating advanced radioresistant differentiated thyroid cancer.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
First do no harm: counting the cost of chasing drug efficacy.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer.The Journal of clinical endocrinology and metabolism, , Volume: 96, Issue:9, 2011
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.The Cochrane database of systematic reviews, , Apr-06, Volume: 4, 2018
Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma.British journal of cancer, , Apr-21, Volume: 100, Issue:8, 2009
Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.International journal of oncology, , Volume: 33, Issue:3, 2008
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Sep-20, Volume: 25, Issue:27, 2007
Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-15, Volume: 11, Issue:24 Pt 1, 2005
Phase 3 Trial of Selpercatinib in Advanced The New England journal of medicine, , Nov-16, Volume: 389, Issue:20, 2023
Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , 08-20, Volume: 38, Issue:24, 2020
Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.Journal of cellular physiology, , Volume: 234, Issue:4, 2019
Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.Clinical cancer research : an official journal of the American Association for Cancer Research, , 02-15, Volume: 24, Issue:4, 2018
Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation.AJNR. American journal of neuroradiology, , Volume: 38, Issue:6, 2017
A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.Cancer, , 01-01, Volume: 123, Issue:2, 2017
The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.Expert review of anticancer therapy, , Volume: 16, Issue:11, 2016
Management of advanced medullary thyroid cancer.The lancet. Diabetes & endocrinology, , Volume: 4, Issue:1, 2016
Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome.Archives of endocrinology and metabolism, , Volume: 59, Issue:4, 2015
Vandetanib as a potential treatment for breast cancer.Expert opinion on investigational drugs, , Volume: 23, Issue:9, 2014
MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma.AJNR. American journal of neuroradiology, , Volume: 34, Issue:7, 2013
Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.Endocrine, , Volume: 44, Issue:2, 2013
Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 24, Issue:9, 2013
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Feb-10, Volume: 30, Issue:5, 2012
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study.Investigational new drugs, , Volume: 30, Issue:2, 2012
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jan-10, Volume: 30, Issue:2, 2012
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.Endocrine journal, , Volume: 58, Issue:3, 2011
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Nov-20, Volume: 26, Issue:33, 2008
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-15, Volume: 10, Issue:18 Pt 1, 2004
Progress on the Prevention and Treatment of Hantavirus Disease.Viruses, , 07-04, Volume: 11, Issue:7, 2019
Effect of Vandetanib on Andes virus survival in the hamster model of Hantavirus pulmonary syndrome.Antiviral research, , Volume: 132, 2016
Hantavirus treatments advance amidst outbreak in US park.Nature medicine, , Volume: 18, Issue:10, 2012
Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.Clinical cancer research : an official journal of the American Association for Cancer Research, , 02-15, Volume: 24, Issue:4, 2018
Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B.Clinical endocrinology, , Volume: 88, Issue:5, 2018
Genetics of medullary thyroid cancer: An overview.International journal of surgery (London, England), , Volume: 41 Suppl 1, 2017
Use of Vandetanib in Metastatic Medullary Carcinoma of Thyroid in a Pediatric Patient With Multiple Endocrine Neoplasia 2B.Journal of pediatric hematology/oncology, , Volume: 38, Issue:2, 2016
ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.Cancer research, , May-01, Volume: 65, Issue:9, 2005
[Metastatic medullary thyroid carcinoma in a child with multiple endocrine neoplasia 2B. Efficiency of medium-term treatment with vandetanib without thyroid surgery].Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, , Volume: 23, Issue:8, 2016
Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.The Journal of clinical endocrinology and metabolism, , Volume: 99, Issue:9, 2014
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 19, Issue:15, 2013
ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.Cancer research, , May-01, Volume: 65, Issue:9, 2005
Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation.AJNR. American journal of neuroradiology, , Volume: 38, Issue:6, 2017
Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy.International journal of radiation oncology, biology, physics, , 12-01, Volume: 99, Issue:5, 2017
MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma.AJNR. American journal of neuroradiology, , Volume: 34, Issue:7, 2013
Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jun-01, Volume: 19, Issue:11, 2013
Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.Pediatric blood & cancer, , Volume: 60, Issue:9, 2013
Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Nov-01, Volume: 28, Issue:31, 2010
Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy.International journal of radiation oncology, biology, physics, , 12-01, Volume: 99, Issue:5, 2017
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.JAMA, , Sep-05, Volume: 308, Issue:9, 2012
[Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].Bulletin du cancer, , Volume: 101, Issue:9, 2014
Drug approvals 2011: focus on companion diagnostics.Journal of the National Cancer Institute, , Jan-18, Volume: 104, Issue:2, 2012
A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor.Clinical cancer research : an official journal of the American Association for Cancer Research, , 11-01, Volume: 25, Issue:21, 2019
ZD6474 induces growth arrest and apoptosis of GIST-T1 cells, which is enhanced by concomitant use of sunitinib.Cancer science, , Volume: 97, Issue:12, 2006
A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.Cancer, , 01-01, Volume: 123, Issue:2, 2017
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.The Journal of clinical endocrinology and metabolism, , Volume: 97, Issue:4, 2012
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.The oncologist, , Volume: 14, Issue:4, 2009
EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.Molecular cancer therapeutics, , Volume: 15, Issue:3, 2016
Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation.Acta medica Okayama, , Volume: 70, Issue:4, 2016
A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis.Carcinogenesis, , Volume: 35, Issue:11, 2014
Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.Frontiers in endocrinology, , Volume: 12, 2021
Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.BMC ophthalmology, , Jan-09, Volume: 20, Issue:1, 2020
A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: A case report.Medicine, , Volume: 98, Issue:31, 2019
Biometrical issues in the analysis of adverse events within the benefit assessment of drugs.Pharmaceutical statistics, , Volume: 15, Issue:4, 2016
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 19, Issue:15, 2013
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.Advances in therapy, , Volume: 30, Issue:11, 2013
Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.Breast cancer research and treatment, , Volume: 136, Issue:1, 2012
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo.Oncology reports, , Volume: 39, Issue:5, 2018
Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer.The Journal of surgical research, , Volume: 185, Issue:2, 2013
Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.Clinical cancer research : an official journal of the American Association for Cancer Research, , Apr-15, Volume: 17, Issue:8, 2011
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.International journal of molecular sciences, , Oct-20, Volume: 19, Issue:10, 2018
Electrophysiological mechanisms of vandetanib-induced cardiotoxicity: Comparison of action potentials in rabbit Purkinje fibers and pluripotent stem cell-derived cardiomyocytes.PloS one, , Volume: 13, Issue:4, 2018
Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment.Genome biology, , Apr-03, Volume: 16, 2015
A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis.Carcinogenesis, , Volume: 35, Issue:11, 2014
Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.Cancer science, , Volume: 104, Issue:7, 2013
[Vandetanib treatment in refractory advanced lung adenocarcinoma patients: five cases and review of literature].Zhongguo fei ai za zhi = Chinese journal of lung cancer, , Volume: 15, Issue:2, 2012
RET, ROS1 and ALK fusions in lung cancer.Nature medicine, , Feb-12, Volume: 18, Issue:3, 2012
KIF5B-RET fusions in lung adenocarcinoma.Nature medicine, , Feb-12, Volume: 18, Issue:3, 2012
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.British journal of cancer, , Jul-26, Volume: 105, Issue:3, 2011
Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.Cancer prevention research (Philadelphia, Pa.), , Volume: 3, Issue:9, 2010
[Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer].Bulletin du cancer, , Volume: 108, Issue:11, 2021
CD30+ lymphoproliferative disorder in a patient with metastatic papillary thyroid carcinoma.Dermatology online journal, , Oct-15, Volume: 22, Issue:10, 2016
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.European journal of endocrinology, , Volume: 170, Issue:4, 2014
First do no harm: counting the cost of chasing drug efficacy.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Treating advanced radioresistant differentiated thyroid cancer.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging for Monitoring the Early Response to ZD6474 from Nasopharyngeal Carcinoma in Nude Mouse.Scientific reports, , Nov-17, Volume: 5, 2015
ZD6474, a small molecule tyrosine kinase inhibitor, potentiates the anti-tumor and anti-metastasis effects of radiation for human nasopharyngeal carcinoma.Current cancer drug targets, , Volume: 10, Issue:6, 2010
Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations.Briefings in bioinformatics, , 05-20, Volume: 22, Issue:3, 2021
A multidimensional biosensor system to guide LUAD individualized treatment.Journal of materials chemistry. B, , 10-06, Volume: 9, Issue:38, 2021
A secondary RET mutation in the activation loop conferring resistance to vandetanib.Nature communications, , 02-12, Volume: 9, Issue:1, 2018
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.Yonsei medical journal, , Volume: 58, Issue:1, 2017
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.Annals of oncology : official journal of the European Society for Medical Oncology, , 02-01, Volume: 28, Issue:2, 2017
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.American journal of clinical oncology, , Volume: 40, Issue:4, 2017
Angiogenesis Inhibitors in NSCLC.International journal of molecular sciences, , Sep-21, Volume: 18, Issue:10, 2017
Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.Oncotarget, , Jun-14, Volume: 7, Issue:24, 2016
Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment.Genome biology, , Apr-03, Volume: 16, 2015
A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis.Carcinogenesis, , Volume: 35, Issue:11, 2014
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.European journal of endocrinology, , Volume: 170, Issue:4, 2014
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 8, Issue:5, 2013
Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.Cancer science, , Volume: 104, Issue:7, 2013
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 7, Issue:11, 2012
Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis.Anti-cancer drugs, , Volume: 23, Issue:7, 2012
[Vandetanib treatment in refractory advanced lung adenocarcinoma patients: five cases and review of literature].Zhongguo fei ai za zhi = Chinese journal of lung cancer, , Volume: 15, Issue:2, 2012
KIF5B-RET fusions in lung adenocarcinoma.Nature medicine, , Feb-12, Volume: 18, Issue:3, 2012
RET, ROS1 and ALK fusions in lung cancer.Nature medicine, , Feb-12, Volume: 18, Issue:3, 2012
Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 7, Issue:12, 2012
Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma.Oncology, , Volume: 81, Issue:1, 2011
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.British journal of cancer, , Jul-26, Volume: 105, Issue:3, 2011
[Pleural metastases from bronchial carcinoma: is a cure possible?].Revue des maladies respiratoires, , Volume: 28, Issue:1, 2011
Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.Neoplasia (New York, N.Y.), , Volume: 12, Issue:9, 2010
Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.Cancer prevention research (Philadelphia, Pa.), , Volume: 3, Issue:9, 2010
Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo.Cancer research, , Jun-15, Volume: 69, Issue:12, 2009
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study.Cancer chemotherapy and pharmacology, , Volume: 64, Issue:4, 2009
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 3, Issue:4, 2008
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.Molecular cancer therapeutics, , Volume: 6, Issue:2, 2007
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.Cancer science, , Volume: 95, Issue:12, 2004
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jan-15, Volume: 10, Issue:2, 2004
Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours.British journal of cancer, , Nov-17, Volume: 89, Issue:10, 2003
Novel vandetanib derivative inhibited proliferation and promoted apoptosis of cancer cells under normoxia and hypoxia.European journal of pharmacology, , May-05, Volume: 922, 2022
Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia.Anti-cancer drugs, , 10-01, Volume: 32, Issue:9, 2021
Design, synthesis and biological evaluation of novel 4-anilinoquinazoline derivatives as hypoxia-selective EGFR and VEGFR-2 dual inhibitors.European journal of medicinal chemistry, , Nov-01, Volume: 181, 2019
Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanism.Cancer prevention research (Philadelphia, Pa.), , Volume: 5, Issue:8, 2012
Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.The Cochrane database of systematic reviews, , Apr-06, Volume: 4, 2018
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.Investigational new drugs, , Volume: 34, Issue:2, 2016
A randomized, multicenter, phase II study of vandetanib monotherapy versus vandetanib in combination with gemcitabine versus gemcitabine plus placebo in subjects with advanced biliary tract cancer: the VanGogh study.Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 26, Issue:3, 2015
2011 ASCO Genitourinary Cancers Symposium.The Lancet. Oncology, , Volume: 12, Issue:4, 2011
VEGFR and EGFR inhibition increases epithelial cellular characteristics and chemotherapy sensitivity in mesenchymal bladder cancer cells.Oncology reports, , Volume: 24, Issue:4, 2010
Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner.BJU international, , Volume: 103, Issue:12, 2009
[Cabozantinib: Mechanism of action, efficacy and indications].Bulletin du cancer, , Volume: 104, Issue:5, 2017
ZD6474, a new treatment strategy for human osteosarcoma, and its potential synergistic effect with celecoxib.Oncotarget, , Aug-28, Volume: 6, Issue:25, 2015
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.Breast cancer research and treatment, , Volume: 146, Issue:1, 2014
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.European journal of endocrinology, , Volume: 170, Issue:4, 2014
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.Japanese journal of clinical oncology, , May-05, Volume: 50, Issue:5, 2020
RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.British journal of cancer, , Nov-08, Volume: 115, Issue:10, 2016
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.Journal of neuro-oncology, , Volume: 121, Issue:3, 2015
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.Lung cancer (Amsterdam, Netherlands), , Volume: 89, Issue:1, 2015
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.Cancer letters, , Apr-28, Volume: 360, Issue:1, 2015
A phase I/II trial of vandetanib for patients with recurrent malignant glioma.Neuro-oncology, , Volume: 14, Issue:12, 2012
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.International journal of radiation oncology, biology, physics, , Jan-01, Volume: 82, Issue:1, 2012
Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.The Journal of pathology, , Volume: 223, Issue:5, 2011
Determination of vandetanib in human plasma and cerebrospinal fluid by liquid chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Sep-01, Volume: 879, Issue:25, 2011
Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models.Biochemical and biophysical research communications, , Jul-22, Volume: 411, Issue:1, 2011
[Pleural metastases from bronchial carcinoma: is a cure possible?].Revue des maladies respiratoires, , Volume: 28, Issue:1, 2011
Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.Cancer research, , May-01, Volume: 70, Issue:9, 2010
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.International journal of radiation oncology, biology, physics, , Sep-01, Volume: 78, Issue:1, 2010
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 5, Issue:8, 2010
Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model.International journal of oncology, , Volume: 37, Issue:4, 2010
Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma.Cornea, , Volume: 28, Issue:6, 2009
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.Journal of neuro-oncology, , Volume: 88, Issue:1, 2008
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.Molecular cancer therapeutics, , Volume: 7, Issue:1, 2008
Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment.International journal of cancer, , May-01, Volume: 122, Issue:9, 2008
Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis.Oncogene, , Aug-23, Volume: 26, Issue:39, 2007
The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model.British journal of cancer, , Sep-13, Volume: 91, Issue:6, 2004
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-15, Volume: 10, Issue:18 Pt 1, 2004
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.European journal of medicinal chemistry, , Jul-05, Volume: 237, 2022
A Pilot Study of Preoperative Vandetanib on Markers of Proliferation and Apoptosis in Breast Cancer.American journal of clinical oncology, , 09-01, Volume: 44, Issue:9, 2021
RET rearrangements are actionable alterations in breast cancer.Nature communications, , 11-16, Volume: 9, Issue:1, 2018
Targeting of EGFR, VEGFR2, and Akt by Engineered Dual Drug Encapsulated Mesoporous Silica-Gold Nanoclusters Sensitizes Tamoxifen-Resistant Breast Cancer.Molecular pharmaceutics, , 07-02, Volume: 15, Issue:7, 2018
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.Oncogene, , Volume: 37, Issue:42, 2018
Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.European journal of medicinal chemistry, , Nov-10, Volume: 140, 2017
Micellear Gold Nanoparticles as Delivery Vehicles for Dual Tyrosine Kinase Inhibitor ZD6474 for Metastatic Breast Cancer Treatment.Langmuir : the ACS journal of surfaces and colloids, , 08-08, Volume: 33, Issue:31, 2017
Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.International journal of cancer, , May-15, Volume: 138, Issue:10, 2016
EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.Molecular cancer therapeutics, , Volume: 15, Issue:3, 2016
Inhibition of RET increases the efficacy of antiestrogen and is a novel treatment strategy for luminal breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , Apr-15, Volume: 20, Issue:8, 2014
Randomised, phase II, placebo-controlled, trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone-receptor-positive metastatic breast cancer (MBC): the OCOG ZAMBONEY study.Breast cancer research and treatment, , Volume: 146, Issue:1, 2014
Vandetanib as a potential treatment for breast cancer.Expert opinion on investigational drugs, , Volume: 23, Issue:9, 2014
Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.Annals of surgery, , Volume: 259, Issue:4, 2014
Frequency dependent impedimetric cytotoxic evaluation of anticancer drug on breast cancer cell.Biosensors & bioelectronics, , May-15, Volume: 55, 2014
Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature.Molecular bioSystems, , Volume: 9, Issue:6, 2013
Targeted therapy against EGFR and VEGFR using ZD6474 enhances the therapeutic potential of UV-B phototherapy in breast cancer cells.Molecular cancer, , Oct-20, Volume: 12, Issue:1, 2013
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.The Journal of clinical endocrinology and metabolism, , Volume: 97, Issue:4, 2012
Vandetanib with docetaxel as second-line treatment for advanced breast cancer: a double-blind, placebo-controlled, randomized Phase II study.Investigational new drugs, , Volume: 30, Issue:2, 2012
Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.Breast cancer research and treatment, , Volume: 136, Issue:1, 2012
Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans.Hypertension (Dallas, Tex. : 1979), , Volume: 58, Issue:1, 2011
ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells.Journal of cellular physiology, , Volume: 226, Issue:2, 2011
ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells.Cancer biology & therapy, , Apr-15, Volume: 9, Issue:8, 2010
ZD6474 coerces breast cancer for an apoptotic journey.Cancer biology & therapy, , Apr-15, Volume: 9, Issue:8, 2010
[Inhibitory effect of ZD6474 combined with adriamycin on MCF-7 human breast cancer cells in vitro].Nan fang yi ke da xue xue bao = Journal of Southern Medical University, , Volume: 30, Issue:3, 2010
Drug insight: VEGF as a therapeutic target for breast cancer.Nature clinical practice. Oncology, , Volume: 4, Issue:3, 2007
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.IDrugs : the investigational drugs journal, , Volume: 10, Issue:8, 2007
A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-01, Volume: 11, Issue:9, 2005
[Anti angiogenesis].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 31, Issue:4, 2004
Rare complications of multikinase inhibitor treatment.Archives of endocrinology and metabolism, , Volume: 62, Issue:6, 2018
Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials.Medicine, , Volume: 96, Issue:43, 2017
CD30+ lymphoproliferative disorder in a patient with metastatic papillary thyroid carcinoma.Dermatology online journal, , Oct-15, Volume: 22, Issue:10, 2016
Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation.Acta medica Okayama, , Volume: 70, Issue:4, 2016
Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging for Monitoring the Early Response to ZD6474 from Nasopharyngeal Carcinoma in Nude Mouse.Scientific reports, , Nov-17, Volume: 5, 2015
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.European journal of endocrinology, , Volume: 170, Issue:4, 2014
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Feb-10, Volume: 30, Issue:5, 2012
Treating advanced radioresistant differentiated thyroid cancer.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
First do no harm: counting the cost of chasing drug efficacy.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
ZD6474, a small molecule tyrosine kinase inhibitor, potentiates the anti-tumor and anti-metastasis effects of radiation for human nasopharyngeal carcinoma.Current cancer drug targets, , Volume: 10, Issue:6, 2010
Early clinical studies of novel therapies for thyroid cancers.Endocrinology and metabolism clinics of North America, , Volume: 37, Issue:2, 2008
Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer.Langenbeck's archives of surgery, , Volume: 391, Issue:6, 2006
Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition.Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-15, Volume: 12, Issue:24, 2006
Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474.In vivo (Athens, Greece), , Volume: 19, Issue:6
Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.Lung cancer (Amsterdam, Netherlands), , Volume: 155, 2021
Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.Japanese journal of clinical oncology, , May-05, Volume: 50, Issue:5, 2020
RET-rearranged non-small-cell lung cancer and therapeutic implications.Internal medicine journal, , Volume: 49, Issue:12, 2019
Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.Journal of cellular physiology, , Volume: 234, Issue:4, 2019
Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 13, Issue:11, 2018
Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials.Medicine, , Volume: 96, Issue:43, 2017
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.The Lancet. Respiratory medicine, , Volume: 5, Issue:1, 2017
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.Annals of oncology : official journal of the European Society for Medical Oncology, , 02-01, Volume: 28, Issue:2, 2017
Angiogenesis Inhibitors in NSCLC.International journal of molecular sciences, , Sep-21, Volume: 18, Issue:10, 2017
[Cabozantinib: Mechanism of action, efficacy and indications].Bulletin du cancer, , Volume: 104, Issue:5, 2017
A platinum-based hybrid drug design approach to circumvent acquired resistance to molecular targeted tyrosine kinase inhibitors.Scientific reports, , 05-06, Volume: 6, 2016
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.Clinical cancer research : an official journal of the American Association for Cancer Research, , Apr-15, Volume: 22, Issue:8, 2016
Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , 05-20, Volume: 34, Issue:15, 2016
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.Journal of medicinal chemistry, , May-14, Volume: 58, Issue:9, 2015
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.Journal of cancer research and clinical oncology, , Volume: 141, Issue:5, 2015
The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells.Scientific reports, , Feb-27, Volume: 5, 2015
Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib.European journal of clinical pharmacology, , Volume: 71, Issue:5, 2015
A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.BMC cancer, , Mar-23, Volume: 15, 2015
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.Lung cancer (Amsterdam, Netherlands), , Volume: 89, Issue:1, 2015
Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.International journal of cancer, , Jul-15, Volume: 137, Issue:2, 2015
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.Cancer research, , May-15, Volume: 74, Issue:10, 2014
EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 25, Issue:10, 2014
Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.Clinical lung cancer, , Volume: 15, Issue:5, 2014
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 9, Issue:5, 2014
Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 8, Issue:8, 2013
Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.PloS one, , Volume: 8, Issue:7, 2013
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.Lung cancer (Amsterdam, Netherlands), , Volume: 82, Issue:3, 2013
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 8, Issue:5, 2013
Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials.Clinical oncology (Royal College of Radiologists (Great Britain)), , Volume: 25, Issue:1, 2013
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.The Journal of clinical investigation, , Volume: 123, Issue:4, 2013
Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency.Experimental cell research, , Feb-15, Volume: 319, Issue:4, 2013
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.The Journal of clinical endocrinology and metabolism, , Volume: 97, Issue:4, 2012
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Apr-01, Volume: 30, Issue:10, 2012
Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 7, Issue:3, 2012
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 7, Issue:11, 2012
Drug approvals 2011: focus on companion diagnostics.Journal of the National Cancer Institute, , Jan-18, Volume: 104, Issue:2, 2012
[Vandetanib for advanced non-small cell lung cancer: a meta-analysis].Zhongguo fei ai za zhi = Chinese journal of lung cancer, , Volume: 15, Issue:3, 2012
Diffuse interstitial lung disease linked to vandetanib.Clinical lung cancer, , Volume: 13, Issue:3, 2012
Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 7, Issue:12, 2012
Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis.Anti-cancer drugs, , Volume: 23, Issue:7, 2012
Vandetanib for the treatment of lung cancer.Expert opinion on investigational drugs, , Volume: 21, Issue:8, 2012
Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.Asian Pacific journal of cancer prevention : APJCP, , Volume: 12, Issue:11, 2011
NSCLC drug targets acquire new visibility.Journal of the National Cancer Institute, , Mar-02, Volume: 103, Issue:5, 2011
The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials.Lung, , Volume: 189, Issue:6, 2011
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Mar-10, Volume: 29, Issue:8, 2011
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Mar-10, Volume: 29, Issue:8, 2011
Vandetanib for the treatment of non-small-cell lung cancer.Expert opinion on pharmacotherapy, , Volume: 12, Issue:14, 2011
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.Korean journal of ophthalmology : KJO, , Volume: 25, Issue:5, 2011
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.The Lancet. Oncology, , Volume: 11, Issue:7, 2010
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.Experimental biology and medicine (Maywood, N.J.), , Volume: 235, Issue:1, 2010
Targeting the epidermal growth factor receptor in non-small cell lung cancer.Onkologie, , Volume: 33, Issue:12, 2010
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.Anticancer research, , Volume: 30, Issue:10, 2010
Vascular endothelial growth factor concentration as a predictive marker: ready for primetime?Clinical cancer research : an official journal of the American Association for Cancer Research, , Feb-15, Volume: 16, Issue:4, 2010
Vandetanib: An overview of its clinical development in NSCLC and other tumors.Drugs of today (Barcelona, Spain : 1998), , Volume: 46, Issue:9, 2010
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 5, Issue:8, 2010
One more fallen star--ZODIAC and its implications.The Lancet. Oncology, , Volume: 11, Issue:7, 2010
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.Clinical lung cancer, , Volume: 10 Suppl 1, 2009
Targeted therapies in the treatment of advanced/metastatic NSCLC.European journal of cancer (Oxford, England : 1990), , Volume: 45, Issue:14, 2009
Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.Clinical lung cancer, , Volume: 10 Suppl 1, 2009
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , May-20, Volume: 27, Issue:15, 2009
An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 20, Issue:3, 2009
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-15, Volume: 15, Issue:10, 2009
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.The oncologist, , Volume: 14, Issue:4, 2009
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-15, Volume: 15, Issue:10, 2009
Targeted therapy in advanced non-small-cell lung cancer.Seminars in respiratory and critical care medicine, , Volume: 29, Issue:3, 2008
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].Magyar onkologia, , Volume: 52, Issue:3, 2008
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Nov-20, Volume: 26, Issue:33, 2008
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 3, Issue:4, 2008
[Lung cancer].Medizinische Klinik (Munich, Germany : 1983), , May-15, Volume: 103, Issue:5, 2008
Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 3, Issue:6 Suppl 2, 2008
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.Current treatment options in oncology, , Volume: 8, Issue:1, 2007
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 13, Issue:15 Pt 2, 2007
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.The oncologist, , Volume: 12, Issue:3, 2007
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Sep-20, Volume: 25, Issue:27, 2007
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.Reviews on recent clinical trials, , Volume: 2, Issue:2, 2007
ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.Oncology research, , Volume: 16, Issue:1, 2006
Antiangiogenic drugs in non-small cell lung cancer treatment.Current opinion in oncology, , Volume: 18, Issue:2, 2006
Multi-target inhibitors in non-small cell lung cancer (NSCLC).Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 17 Suppl 2, 2006
Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474.Expert review of anticancer therapy, , Volume: 6, Issue:4, 2006
Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 1, Issue:9, 2006
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.Clinical lung cancer, , Volume: 8 Suppl 1, 2006
Angiogenesis and lung cancer: prognostic and therapeutic implications.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , May-10, Volume: 23, Issue:14, 2005
ZD6474--clinical experience to date.British journal of cancer, , Volume: 92 Suppl 1, 2005
Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.Clinical lung cancer, , Volume: 7, Issue:2, 2005
ZD6474 headed for phase III trials in the fall.Oncology (Williston Park, N.Y.), , Volume: 19, Issue:9, 2005
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.Cancer science, , Volume: 95, Issue:12, 2004
ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-15, Volume: 10, Issue:24, 2004
CD30+ lymphoproliferative disorder in a patient with metastatic papillary thyroid carcinoma.Dermatology online journal, , Oct-15, Volume: 22, Issue:10, 2016
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.European journal of endocrinology, , Volume: 170, Issue:4, 2014
First do no harm: counting the cost of chasing drug efficacy.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Treating advanced radioresistant differentiated thyroid cancer.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
The Ca2+-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC.Endocrine-related cancer, , Volume: 17, Issue:1, 2010
Targeted molecular therapies in thyroid carcinoma.Arquivos brasileiros de endocrinologia e metabologia, , Volume: 53, Issue:9, 2009
ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.Cancer research, , May-01, Volume: 65, Issue:9, 2005
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer.Journal of chemotherapy (Florence, Italy), , Volume: 16 Suppl 4, 2004
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.Cancer research, , Dec-15, Volume: 62, Issue:24, 2002
[Cabozantinib: Mechanism of action, efficacy and indications].Bulletin du cancer, , Volume: 104, Issue:5, 2017
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.BJU international, , Volume: 107, Issue:1, 2011
The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma.Angiogenesis, , Volume: 7, Issue:4, 2004
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.International journal of radiation oncology, biology, physics, , Nov-15, Volume: 60, Issue:4, 2004
Vandetanib inhibits cell growth in EGFR-expressing cutaneous squamous cell carcinoma.Biochemical and biophysical research communications, , 10-20, Volume: 531, Issue:3, 2020
Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma.Head & neck, , Volume: 38, Issue:3, 2016
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).Oral oncology, , Volume: 49, Issue:8, 2013
Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma.Head & neck, , Volume: 34, Issue:9, 2012
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 7, Issue:11, 2012
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.Clinical cancer research : an official journal of the American Association for Cancer Research, , Apr-01, Volume: 17, Issue:7, 2011
Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.Head & neck, , Volume: 33, Issue:3, 2011
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 5, Issue:8, 2010
Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).Anticancer research, , Volume: 29, Issue:6, 2009
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 3, Issue:4, 2008
Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma.Molecular cancer therapeutics, , Volume: 7, Issue:9, 2008
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.Molecular cancer therapeutics, , Volume: 6, Issue:2, 2007
Antitumor effects of ZD6474 on head and neck squamous cell carcinoma.Oncology reports, , Volume: 17, Issue:2, 2007
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.Clinical lung cancer, , Volume: 8 Suppl 1, 2006
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 16 Suppl 4, 2005
RET rearrangements are actionable alterations in breast cancer.Nature communications, , 11-16, Volume: 9, Issue:1, 2018
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.The Journal of clinical investigation, , Volume: 123, Issue:4, 2013
RET, ROS1 and ALK fusions in lung cancer.Nature medicine, , Feb-12, Volume: 18, Issue:3, 2012
KIF5B-RET fusions in lung adenocarcinoma.Nature medicine, , Feb-12, Volume: 18, Issue:3, 2012
A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.Endocrine-related cancer, , Volume: 14, Issue:2, 2007
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.Cancer research, , Dec-15, Volume: 62, Issue:24, 2002
Label-free single cell kinetics of the invasion of spheroidal colon cancer cells through 3D Matrigel.Analytical chemistry, , Sep-02, Volume: 86, Issue:17, 2014
Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.Neoplasia (New York, N.Y.), , Volume: 12, Issue:9, 2010
Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model.International journal of oncology, , Volume: 37, Issue:4, 2010
Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).Anticancer research, , Volume: 29, Issue:6, 2009
Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).NMR in biomedicine, , Volume: 21, Issue:1, 2008
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.Clinical cancer research : an official journal of the American Association for Cancer Research, , Nov-01, Volume: 13, Issue:21, 2007
Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa(TM)) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects.World journal of gastroenterology, , Aug-28, Volume: 12, Issue:32, 2006
Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases.Molecular cancer therapeutics, , Volume: 5, Issue:7, 2006
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jan-15, Volume: 10, Issue:2, 2004
Markedly increased ocular side effect causing severe vision deterioration after chemotherapy using new or investigational epidermal or fibroblast growth factor receptor inhibitors.BMC ophthalmology, , Jan-09, Volume: 20, Issue:1, 2020
Confocal Microscopy Observation of Cornea Verticillata After Vandetanib Therapy for Medullary Thyroid Carcinoma.Cornea, , Volume: 37, Issue:6, 2018
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.Korean journal of ophthalmology : KJO, , Volume: 25, Issue:5, 2011
Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma.Cornea, , Volume: 28, Issue:6, 2009
Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation.Thyroid : official journal of the American Thyroid Association, , Volume: 27, Issue:4, 2017
Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome.Archives of endocrinology and metabolism, , Volume: 59, Issue:4, 2015
Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.The Journal of clinical endocrinology and metabolism, , Volume: 99, Issue:9, 2014
Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma.The New England journal of medicine, , Aug-08, Volume: 369, Issue:6, 2013
Vandetanib photoinduced cutaneous toxicities.Cutis, , Volume: 103, Issue:5, 2019
Gray-bluish cutaneous pigmentation and ice-pick scars induced by vandetanib therapy.International journal of dermatology, , Volume: 57, Issue:7, 2018
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.Advances in therapy, , Volume: 30, Issue:11, 2013
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.The Journal of clinical endocrinology and metabolism, , Volume: 97, Issue:4, 2012
[Dermatologic side effects induced by new angiogenesis inhibitors].Bulletin du cancer, , Volume: 98, Issue:10, 2011
Therapeutic hotline. A rare vandetanib-induced photo-allergic drug eruption.Dermatologic therapy, , Volume: 23, Issue:5
Phototoxic drug eruption induced by vandetanib used for the treatment of metastatic medullary thyroid cancer.Anais brasileiros de dermatologia, , Volume: 97, Issue:5
Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.International journal of molecular sciences, , Mar-16, Volume: 22, Issue:6, 2021
Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 144, 2021
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.Proceedings of the National Academy of Sciences of the United States of America, , 12-08, Volume: 117, Issue:49, 2020
Resveratrol improves the therapeutic efficacy of bone marrow-derived mesenchymal stem cells in rats with severe acute pancreatitis.International immunopharmacology, , Volume: 80, 2020
Long-term cardiovascular effects of vandetanib and pazopanib in normotensive rats.Pharmacology research & perspectives, , Volume: 7, Issue:3, 2019
Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.Cancer biology & therapy, , Jul-03, Volume: 18, Issue:7, 2017
Effect of Vandetanib on Andes virus survival in the hamster model of Hantavirus pulmonary syndrome.Antiviral research, , Volume: 132, 2016
Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.International journal of cancer, , May-15, Volume: 138, Issue:10, 2016
EGFR Is Regulated by TFAP2C in Luminal Breast Cancer and Is a Target for Vandetanib.Molecular cancer therapeutics, , Volume: 15, Issue:3, 2016
Vandetanib for the treatment of thyroid cancer: an update.Expert opinion on drug metabolism & toxicology, , Volume: 10, Issue:3, 2014
A Drosophila approach to thyroid cancer therapeutics.Drug discovery today. Technologies, ,Spring, Volume: 10, Issue:1, 2013
Hantavirus treatments advance amidst outbreak in US park.Nature medicine, , Volume: 18, Issue:10, 2012
Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.Head & neck, , Volume: 33, Issue:3, 2011
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.International journal of oncology, , Volume: 39, Issue:1, 2011
Antiangiogenic therapies for malignant pleural mesothelioma.Frontiers in bioscience (Landmark edition), , 01-01, Volume: 16, Issue:2, 2011
Vandetanib improves anti-tumor effects of L19mTNFalpha in xenograft models of esophageal cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , Feb-01, Volume: 17, Issue:3, 2011
Dual inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesis.Cancer prevention research (Philadelphia, Pa.), , Volume: 3, Issue:11, 2010
Effects of vandetanib on adenoma formation in a dextran sodium sulphate enhanced Apc(MIN/+) mouse model.International journal of oncology, , Volume: 37, Issue:4, 2010
Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).NMR in biomedicine, , Volume: 21, Issue:1, 2008
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.Molecular cancer therapeutics, , Volume: 7, Issue:1, 2008
A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.Endocrine-related cancer, , Volume: 14, Issue:2, 2007
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-01, Volume: 12, Issue:23, 2006
ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.Cancer research, , May-01, Volume: 65, Issue:9, 2005
In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model.Angiogenesis, , Volume: 7, Issue:2, 2004
The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model.British journal of cancer, , Sep-13, Volume: 91, Issue:6, 2004
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.American journal of clinical oncology, , Volume: 40, Issue:4, 2017
Vandetanib improves anti-tumor effects of L19mTNFalpha in xenograft models of esophageal cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , Feb-01, Volume: 17, Issue:3, 2011
Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.International journal of cancer, , Sep-01, Volume: 127, Issue:5, 2010
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors.Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 16 Suppl 4, 2005
Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials.Medicine, , Volume: 96, Issue:43, 2017
Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.International journal of cancer, , Jul-15, Volume: 137, Issue:2, 2015
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.Lung cancer (Amsterdam, Netherlands), , Volume: 82, Issue:3, 2013
Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy.The Journal of clinical endocrinology and metabolism, , 03-01, Volume: 104, Issue:3, 2019
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].Bulletin du cancer, , Volume: 103, Issue:3, 2016
Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.International journal of cancer, , Jul-15, Volume: 137, Issue:2, 2015
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.Journal of neuro-oncology, , Volume: 121, Issue:3, 2015
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.Cancer letters, , Apr-28, Volume: 360, Issue:1, 2015
A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-15, Volume: 21, Issue:16, 2015
A topical matter: toxic epidermal necrolysis.The American journal of medicine, , Volume: 127, Issue:10, 2014
Autophagy inhibition induces enhanced proapoptotic effects of ZD6474 in glioblastoma.British journal of cancer, , Jul-09, Volume: 109, Issue:1, 2013
Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival.Medical oncology (Northwood, London, England), , Volume: 30, Issue:3, 2013
Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.International journal of radiation oncology, biology, physics, , Jan-01, Volume: 82, Issue:1, 2012
Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms.Molecular medicine reports, , Volume: 6, Issue:1, 2012
Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models.Biochemical and biophysical research communications, , Jul-22, Volume: 411, Issue:1, 2011
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.International journal of radiation oncology, biology, physics, , Sep-01, Volume: 78, Issue:1, 2010
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 11, Issue:15, 2005
Enhanced glioma therapy by synergistic inhibition of autophagy and tyrosine kinase activity.International journal of pharmaceutics, , Jan-30, Volume: 536, Issue:1, 2018
Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation.AJNR. American journal of neuroradiology, , Volume: 38, Issue:6, 2017
Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy.International journal of radiation oncology, biology, physics, , 12-01, Volume: 99, Issue:5, 2017
Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jun-01, Volume: 19, Issue:11, 2013
MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma.AJNR. American journal of neuroradiology, , Volume: 34, Issue:7, 2013
Magnetic resonance imaging is the preferred method to assess treatment-related skeletal changes in children with brain tumors.Pediatric blood & cancer, , Volume: 60, Issue:9, 2013
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.International journal of radiation oncology, biology, physics, , Jan-01, Volume: 82, Issue:1, 2012
A phase I/II trial of vandetanib for patients with recurrent malignant glioma.Neuro-oncology, , Volume: 14, Issue:12, 2012
Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.The Journal of pathology, , Volume: 223, Issue:5, 2011
Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Nov-01, Volume: 28, Issue:31, 2010
Vandetanib alters the protein pattern in malignant glioma and normal brain in the BT4C rat glioma model.International journal of oncology, , Volume: 37, Issue:4, 2010
ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain.Molecular cancer therapeutics, , Volume: 9, Issue:4, 2010
Abrogation of mitogen-activated protein kinase and Akt signaling by vandetanib synergistically potentiates histone deacetylase inhibitor-induced apoptosis in human glioma cells.The Journal of pharmacology and experimental therapeutics, , Volume: 331, Issue:1, 2009
Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment.International journal of cancer, , May-01, Volume: 122, Issue:9, 2008
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.Journal of neuro-oncology, , Volume: 88, Issue:1, 2008
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.Clinical cancer research : an official journal of the American Association for Cancer Research, , Nov-15, Volume: 11, Issue:22, 2005
The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model.British journal of cancer, , Sep-13, Volume: 91, Issue:6, 2004
Vandetanib sensitizes head and neck squamous cell carcinoma to photodynamic therapy through modulation of EGFR-dependent DNA repair and the tumour microenvironment.Photodiagnosis and photodynamic therapy, , Volume: 27, 2019
Phase I study of vandetanib with radiation therapy with or without cisplatin in locally advanced head and neck squamous cell carcinoma.Head & neck, , Volume: 38, Issue:3, 2016
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).Oral oncology, , Volume: 49, Issue:8, 2013
Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma.Head & neck, , Volume: 34, Issue:9, 2012
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.Clinical cancer research : an official journal of the American Association for Cancer Research, , Apr-01, Volume: 17, Issue:7, 2011
Targeted molecular therapy of head and neck squamous cell carcinoma with the tyrosine kinase inhibitor vandetanib in a mouse model.Head & neck, , Volume: 33, Issue:3, 2011
Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.Cancer chemotherapy and pharmacology, , Volume: 61, Issue:2, 2008
Antitumor effects of ZD6474 on head and neck squamous cell carcinoma.Oncology reports, , Volume: 17, Issue:2, 2007
Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver Malignancies.Journal of vascular and interventional radiology : JVIR, , Volume: 33, Issue:9, 2022
Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia.Anti-cancer drugs, , 10-01, Volume: 32, Issue:9, 2021
Evolution of Transarterial Chemoembolization for the Treatment of Liver Cancer.Radiology, , Volume: 293, Issue:3, 2019
Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma.European journal of medicinal chemistry, , Oct-01, Volume: 179, 2019
Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Apr-01, Volume: 101, 2017
iRGD-Decorated Polymeric Nanoparticles for the Efficient Delivery of Vandetanib to Hepatocellular Carcinoma: Preparation and in Vitro and in Vivo Evaluation.ACS applied materials & interfaces, , Aug-03, Volume: 8, Issue:30, 2016
Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.Journal of hepatology, , Volume: 56, Issue:5, 2012
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].Magyar onkologia, , Volume: 56, Issue:3, 2012
Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.Neoplasia (New York, N.Y.), , Volume: 13, Issue:3, 2011
Severe photosensitivity reaction to vandetanib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Sep-20, Volume: 27, Issue:27, 2009
EGFR and VEGFR as potential target for biological therapies in HCC cells.Cancer letters, , Apr-18, Volume: 262, Issue:2, 2008
ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells.Biochemical pharmacology, , Feb-14, Volume: 71, Issue:4, 2006
Long-term cardiovascular effects of vandetanib and pazopanib in normotensive rats.Pharmacology research & perspectives, , Volume: 7, Issue:3, 2019
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.International journal of molecular sciences, , Oct-20, Volume: 19, Issue:10, 2018
Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib.European journal of clinical pharmacology, , Volume: 71, Issue:5, 2015
Role of the eNOS-NO system in regulating the antiproteinuric effects of VEGF receptor 2 inhibition in diabetes.BioMed research international, , Volume: 2013, 2013
Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.British journal of clinical pharmacology, , Volume: 75, Issue:4, 2013
Role of VEGF in maintaining renal structure and function under normotensive and hypertensive conditions.Proceedings of the National Academy of Sciences of the United States of America, , Sep-04, Volume: 104, Issue:36, 2007
[Oral drugs inhibiting the VEGF pathway].Bulletin du cancer, , Volume: 94 Spec No, 2007
[Cabozantinib: Mechanism of action, efficacy and indications].Bulletin du cancer, , Volume: 104, Issue:5, 2017
Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer.Cancer cell, , Dec-08, Volume: 26, Issue:6, 2014
DisABLing kidney cancers caused by fumarate hydratase mutations.Cancer cell, , Dec-08, Volume: 26, Issue:6, 2014
Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250.BJU international, , Volume: 107, Issue:1, 2011
2011 ASCO Genitourinary Cancers Symposium.The Lancet. Oncology, , Volume: 12, Issue:4, 2011
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.International journal of radiation oncology, biology, physics, , Nov-15, Volume: 60, Issue:4, 2004
The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma.Angiogenesis, , Volume: 7, Issue:4, 2004
Vandetanib mediates anti-leukemia activity by multiple mechanisms and interacts synergistically with DNA damaging agents.Investigational new drugs, , Volume: 30, Issue:2, 2012
ZD6474 induces growth arrest and apoptosis of human leukemia cells, which is enhanced by concomitant use of a novel MEK inhibitor, AZD6244.Leukemia, , Volume: 21, Issue:6, 2007
Phase 0 Study of Vandetanib-Eluting Radiopaque Embolics as a Preoperative Embolization Treatment in Patients with Resectable Liver Malignancies.Journal of vascular and interventional radiology : JVIR, , Volume: 33, Issue:9, 2022
Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia.Anti-cancer drugs, , 10-01, Volume: 32, Issue:9, 2021
Predicting pharmacokinetic behaviour of drug release from drug-eluting embolization beads using in vitro elution methods.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Aug-01, Volume: 136, 2019
Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma.European journal of medicinal chemistry, , Oct-01, Volume: 179, 2019
Evolution of Transarterial Chemoembolization for the Treatment of Liver Cancer.Radiology, , Volume: 293, Issue:3, 2019
Preparation and characterisation of vandetanib-eluting radiopaque beads for locoregional treatment of hepatic malignancies.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Apr-01, Volume: 101, 2017
iRGD-Decorated Polymeric Nanoparticles for the Efficient Delivery of Vandetanib to Hepatocellular Carcinoma: Preparation and in Vitro and in Vivo Evaluation.ACS applied materials & interfaces, , Aug-03, Volume: 8, Issue:30, 2016
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.European journal of endocrinology, , Volume: 170, Issue:4, 2014
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].Magyar onkologia, , Volume: 56, Issue:3, 2012
Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jul-15, Volume: 18, Issue:14, 2012
Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study.Journal of hepatology, , Volume: 56, Issue:5, 2012
Severe photosensitivity reaction to vandetanib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Sep-20, Volume: 27, Issue:27, 2009
EGFR and VEGFR as potential target for biological therapies in HCC cells.Cancer letters, , Apr-18, Volume: 262, Issue:2, 2008
ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells.Biochemical pharmacology, , Feb-14, Volume: 71, Issue:4, 2006
In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model.Angiogenesis, , Volume: 7, Issue:2, 2004
Emerging Approaches to Overcome Acquired Drug Resistance Obstacles to Osimertinib in Non-Small-Cell Lung Cancer.Journal of medicinal chemistry, , 01-27, Volume: 65, Issue:2, 2022
A multidimensional biosensor system to guide LUAD individualized treatment.Journal of materials chemistry. B, , 10-06, Volume: 9, Issue:38, 2021
Final survival results for the LURET phase II study of vandetanib in previously treated patients with RET-rearranged advanced non-small cell lung cancer.Lung cancer (Amsterdam, Netherlands), , Volume: 155, 2021
Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.Japanese journal of clinical oncology, , May-05, Volume: 50, Issue:5, 2020
RET-rearranged non-small-cell lung cancer and therapeutic implications.Internal medicine journal, , Volume: 49, Issue:12, 2019
Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report.Journal of pediatric hematology/oncology, , Volume: 41, Issue:5, 2019
Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.Journal of cellular physiology, , Volume: 234, Issue:4, 2019
A secondary RET mutation in the activation loop conferring resistance to vandetanib.Nature communications, , 02-12, Volume: 9, Issue:1, 2018
Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 13, Issue:11, 2018
[Cabozantinib: Mechanism of action, efficacy and indications].Bulletin du cancer, , Volume: 104, Issue:5, 2017
Angiogenesis Inhibitors in NSCLC.International journal of molecular sciences, , Sep-21, Volume: 18, Issue:10, 2017
Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial.Annals of oncology : official journal of the European Society for Medical Oncology, , 02-01, Volume: 28, Issue:2, 2017
Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial.The Lancet. Respiratory medicine, , Volume: 5, Issue:1, 2017
EGF Induced RET Inhibitor Resistance in CCDC6-RET Lung Cancer Cells.Yonsei medical journal, , Volume: 58, Issue:1, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.Cancer, , 01-01, Volume: 123, Issue:2, 2017
Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , 05-20, Volume: 34, Issue:15, 2016
KDR Amplification Is Associated with VEGF-Induced Activation of the mTOR and Invasion Pathways but does not Predict Clinical Benefit to the VEGFR TKI Vandetanib.Clinical cancer research : an official journal of the American Association for Cancer Research, , Apr-15, Volume: 22, Issue:8, 2016
Identification of a novel partner gene, KIAA1217, fused to RET: Functional characterization and inhibitor sensitivity of two isoforms in lung adenocarcinoma.Oncotarget, , Jun-14, Volume: 7, Issue:24, 2016
A platinum-based hybrid drug design approach to circumvent acquired resistance to molecular targeted tyrosine kinase inhibitors.Scientific reports, , 05-06, Volume: 6, 2016
[Metastatic medullary thyroid carcinoma in a child with multiple endocrine neoplasia 2B. Efficiency of medium-term treatment with vandetanib without thyroid surgery].Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, , Volume: 23, Issue:8, 2016
Effect of Vandetanib on Lung Tumorigenesis in Transgenic Mice Carrying an Activating Egfr Gene Mutation.Acta medica Okayama, , Volume: 70, Issue:4, 2016
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.Journal of cancer research and clinical oncology, , Volume: 141, Issue:5, 2015
Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.International journal of cancer, , Jul-15, Volume: 137, Issue:2, 2015
The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells.Scientific reports, , Feb-27, Volume: 5, 2015
Meta-analysis of the risks of hypertension and QTc prolongation in patients with advanced non-small cell lung cancer who were receiving vandetanib.European journal of clinical pharmacology, , Volume: 71, Issue:5, 2015
A retrospective analysis of RET translocation, gene copy number gain and expression in NSCLC patients treated with vandetanib in four randomized Phase III studies.BMC cancer, , Mar-23, Volume: 15, 2015
Single-cell analysis of lung adenocarcinoma cell lines reveals diverse expression patterns of individual cells invoked by a molecular target drug treatment.Genome biology, , Apr-03, Volume: 16, 2015
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.Lung cancer (Amsterdam, Netherlands), , Volume: 89, Issue:1, 2015
Progress in Discovery of KIF5B-RET Kinase Inhibitors for the Treatment of Non-Small-Cell Lung Cancer.Journal of medicinal chemistry, , May-14, Volume: 58, Issue:9, 2015
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.European journal of endocrinology, , Volume: 170, Issue:4, 2014
Transient antiangiogenic treatment improves delivery of cytotoxic compounds and therapeutic outcome in lung cancer.Cancer research, , May-15, Volume: 74, Issue:10, 2014
Phase II randomized study of vandetanib plus gemcitabine or gemcitabine plus placebo as first-line treatment of advanced non-small-cell lung cancer in elderly patients.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 9, Issue:5, 2014
Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.Clinical lung cancer, , Volume: 15, Issue:5, 2014
A mouse model of KIF5B-RET fusion-dependent lung tumorigenesis.Carcinogenesis, , Volume: 35, Issue:11, 2014
Vandetanib is effective in EGFR-mutant lung cancer cells with PTEN deficiency.Experimental cell research, , Feb-15, Volume: 319, Issue:4, 2013
Chemotherapy plus Vandetanib or chemotherapy alone in advanced non-small cell lung cancer: a meta-analysis of four randomised controlled trials.Clinical oncology (Royal College of Radiologists (Great Britain)), , Volume: 25, Issue:1, 2013
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.The Journal of clinical investigation, , Volume: 123, Issue:4, 2013
Identification of a lung adenocarcinoma cell line with CCDC6-RET fusion gene and the effect of RET inhibitors in vitro and in vivo.Cancer science, , Volume: 104, Issue:7, 2013
Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 8, Issue:5, 2013
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 8, Issue:5, 2013
Vandetanib plus chemotherapy for induction followed by vandetanib or placebo as maintenance for patients with advanced non-small-cell lung cancer: a randomized phase 2 PrECOG study (PrE0501).Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 8, Issue:8, 2013
Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.PloS one, , Volume: 8, Issue:7, 2013
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.Lung cancer (Amsterdam, Netherlands), , Volume: 82, Issue:3, 2013
Identification of CCDC6-RET fusion in the human lung adenocarcinoma cell line, LC-2/ad.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 7, Issue:12, 2012
Clinical outcomes and biomarker profiles of elderly pretreated NSCLC patients from the BATTLE trial.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 7, Issue:11, 2012
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].Magyar onkologia, , Volume: 56, Issue:3, 2012
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.The Journal of clinical endocrinology and metabolism, , Volume: 97, Issue:9, 2012
Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanism.Cancer prevention research (Philadelphia, Pa.), , Volume: 5, Issue:8, 2012
Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis.Anti-cancer drugs, , Volume: 23, Issue:7, 2012
Vandetanib for the treatment of lung cancer.Expert opinion on investigational drugs, , Volume: 21, Issue:8, 2012
[Vandetanib for advanced non-small cell lung cancer: a meta-analysis].Zhongguo fei ai za zhi = Chinese journal of lung cancer, , Volume: 15, Issue:3, 2012
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.The Journal of clinical endocrinology and metabolism, , Volume: 97, Issue:4, 2012
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Apr-01, Volume: 30, Issue:10, 2012
[Vandetanib treatment in refractory advanced lung adenocarcinoma patients: five cases and review of literature].Zhongguo fei ai za zhi = Chinese journal of lung cancer, , Volume: 15, Issue:2, 2012
KIF5B-RET fusions in lung adenocarcinoma.Nature medicine, , Feb-12, Volume: 18, Issue:3, 2012
RET, ROS1 and ALK fusions in lung cancer.Nature medicine, , Feb-12, Volume: 18, Issue:3, 2012
Combining the multitargeted tyrosine kinase inhibitor vandetanib with the antiestrogen fulvestrant enhances its antitumor effect in non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 7, Issue:3, 2012
Drug approvals 2011: focus on companion diagnostics.Journal of the National Cancer Institute, , Jan-18, Volume: 104, Issue:2, 2012
Diffuse interstitial lung disease linked to vandetanib.Clinical lung cancer, , Volume: 13, Issue:3, 2012
Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.Asian Pacific journal of cancer prevention : APJCP, , Volume: 12, Issue:11, 2011
The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials.Lung, , Volume: 189, Issue:6, 2011
Vortex keratopathy in a patient receiving vandetanib for non-small cell lung cancer.Korean journal of ophthalmology : KJO, , Volume: 25, Issue:5, 2011
Vandetanib for the treatment of non-small-cell lung cancer.Expert opinion on pharmacotherapy, , Volume: 12, Issue:14, 2011
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors.British journal of cancer, , Jul-26, Volume: 105, Issue:3, 2011
Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma.Neoplasia (New York, N.Y.), , Volume: 13, Issue:3, 2011
NSCLC drug targets acquire new visibility.Journal of the National Cancer Institute, , Mar-02, Volume: 103, Issue:5, 2011
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Mar-10, Volume: 29, Issue:8, 2011
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Mar-10, Volume: 29, Issue:8, 2011
[Pleural metastases from bronchial carcinoma: is a cure possible?].Revue des maladies respiratoires, , Volume: 28, Issue:1, 2011
Targeting the epidermal growth factor receptor in non-small cell lung cancer.Onkologie, , Volume: 33, Issue:12, 2010
A retrospective analysis of non-platinum-based first- and second-line chemotherapy in patients with advanced non-small cell lung cancer.Anticancer research, , Volume: 30, Issue:10, 2010
Targeted therapies: Molecular selection for 'smart' study design in lung cancer.Nature reviews. Clinical oncology, , Volume: 7, Issue:11, 2010
Vandetanib: An overview of its clinical development in NSCLC and other tumors.Drugs of today (Barcelona, Spain : 1998), , Volume: 46, Issue:9, 2010
Vascular endothelial growth factor concentration as a predictive marker: ready for primetime?Clinical cancer research : an official journal of the American Association for Cancer Research, , Feb-15, Volume: 16, Issue:4, 2010
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jan-10, Volume: 28, Issue:2, 2010
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 5, Issue:8, 2010
Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.Cancer prevention research (Philadelphia, Pa.), , Volume: 3, Issue:9, 2010
One more fallen star--ZODIAC and its implications.The Lancet. Oncology, , Volume: 11, Issue:7, 2010
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.The Lancet. Oncology, , Volume: 11, Issue:7, 2010
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.Experimental biology and medicine (Maywood, N.J.), , Volume: 235, Issue:1, 2010
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-15, Volume: 15, Issue:10, 2009
Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.Clinical lung cancer, , Volume: 10 Suppl 1, 2009
Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , May-20, Volume: 27, Issue:15, 2009
Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy.Clinical lung cancer, , Volume: 10 Suppl 1, 2009
Lung cancer trials probe effects of maintenance therapy, targeted agents.JAMA, , Aug-12, Volume: 302, Issue:6, 2009
Targeted therapies in the treatment of advanced/metastatic NSCLC.European journal of cancer (Oxford, England : 1990), , Volume: 45, Issue:14, 2009
Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo.Cancer research, , Jun-15, Volume: 69, Issue:12, 2009
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.The oncologist, , Volume: 14, Issue:4, 2009
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-15, Volume: 15, Issue:10, 2009
An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer.Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 20, Issue:3, 2009
Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-01, Volume: 14, Issue:17, 2008
[Lung cancer].Medizinische Klinik (Munich, Germany : 1983), , May-15, Volume: 103, Issue:5, 2008
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 3, Issue:4, 2008
Targeted therapy in advanced non-small-cell lung cancer.Seminars in respiratory and critical care medicine, , Volume: 29, Issue:3, 2008
Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 3, Issue:6 Suppl 2, 2008
Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.International journal of oncology, , Volume: 33, Issue:3, 2008
[Tumor vasculature as a therapeutic target in non-small cell lung cancer].Magyar onkologia, , Volume: 52, Issue:3, 2008
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Nov-20, Volume: 26, Issue:33, 2008
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer.International journal of radiation oncology, biology, physics, , Dec-01, Volume: 69, Issue:5, 2007
Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Sep-20, Volume: 25, Issue:27, 2007
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Sep-20, Volume: 25, Issue:27, 2007
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 13, Issue:15 Pt 2, 2007
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.Current treatment options in oncology, , Volume: 8, Issue:1, 2007
Combination of target agents: challenges and opportunities.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 2, Issue:5 Suppl, 2007
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.The oncologist, , Volume: 12, Issue:3, 2007
Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis.Oncogene, , Aug-23, Volume: 26, Issue:39, 2007
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.Molecular cancer therapeutics, , Volume: 6, Issue:2, 2007
Second-line treatment of non-small cell lung cancer: big targets, small progress; small targets, big progress?Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 1, Issue:9, 2006
Toxicities of antiangiogenic therapy in non-small-cell lung cancer.Clinical lung cancer, , Volume: 8 Suppl 1, 2006
ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.Oncology research, , Volume: 16, Issue:1, 2006
Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474.Expert review of anticancer therapy, , Volume: 6, Issue:4, 2006
Multi-target inhibitors in non-small cell lung cancer (NSCLC).Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 17 Suppl 2, 2006
Antiangiogenic drugs in non-small cell lung cancer treatment.Current opinion in oncology, , Volume: 18, Issue:2, 2006
Phase II data with ZD6474, a small-molecule kinase inhibitor of epidermal growth factor receptor and vascular endothelial growth factor receptor, in previously treated advanced non-small-cell lung cancer.Clinical lung cancer, , Volume: 7, Issue:2, 2005
ZD6474--clinical experience to date.British journal of cancer, , Volume: 92 Suppl 1, 2005
Angiogenesis and lung cancer: prognostic and therapeutic implications.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , May-10, Volume: 23, Issue:14, 2005
ZD6474 headed for phase III trials in the fall.Oncology (Williston Park, N.Y.), , Volume: 19, Issue:9, 2005
Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-15, Volume: 11, Issue:24 Pt 1, 2005
ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity.Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-15, Volume: 10, Issue:24, 2004
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.Cancer science, , Volume: 95, Issue:12, 2004
[Anti angiogenesis].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 31, Issue:4, 2004
Therapeutic hotline. A rare vandetanib-induced photo-allergic drug eruption.Dermatologic therapy, , Volume: 23, Issue:5
Expression of VEGF with tumor incidence, metastasis and prognosis in human gastric carcinoma.Cancer biomarkers : section A of Disease markers, , Volume: 22, Issue:4, 2018
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.The Lancet. Oncology, , Volume: 18, Issue:4, 2017
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.European journal of endocrinology, , Volume: 170, Issue:4, 2014
A patient with lung adenocarcinoma and RET fusion treated with vandetanib.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 8, Issue:5, 2013
Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma.The New England journal of medicine, , Aug-08, Volume: 369, Issue:6, 2013
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma.Oncology, , Volume: 81, Issue:1, 2011
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.Clinical cancer research : an official journal of the American Association for Cancer Research, , Apr-01, Volume: 17, Issue:7, 2011
Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib.Molecular cancer therapeutics, , Volume: 7, Issue:8, 2008
Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis.Oncogene, , Aug-23, Volume: 26, Issue:39, 2007
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.Journal of medicinal chemistry, , Dec-19, Volume: 45, Issue:26, 2002
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061, 2011
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.Proceedings of the National Academy of Sciences of the United States of America, , Jul-01, Volume: 105, Issue:26, 2008
Distinct pathways regulated by RET and estrogen receptor in luminal breast cancer demonstrate the biological basis for combination therapy.Annals of surgery, , Volume: 259, Issue:4, 2014
False-negative MRI biomarkers of tumour response to targeted cancer therapeutics.British journal of cancer, , Jun-05, Volume: 106, Issue:12, 2012
Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation.Laboratory investigation; a journal of technical methods and pathology, , Volume: 84, Issue:8, 2004
RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.British journal of cancer, , Nov-08, Volume: 115, Issue:10, 2016
Drug approvals 2011: focus on companion diagnostics.Journal of the National Cancer Institute, , Jan-18, Volume: 104, Issue:2, 2012
Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis.Oncogene, , Aug-23, Volume: 26, Issue:39, 2007
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-15, Volume: 10, Issue:18 Pt 1, 2004
Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.Journal of medicinal chemistry, , Dec-19, Volume: 45, Issue:26, 2002
Intravoxel Incoherent Motion Diffusion-weighted Magnetic Resonance Imaging for Monitoring the Early Response to ZD6474 from Nasopharyngeal Carcinoma in Nude Mouse.Scientific reports, , Nov-17, Volume: 5, 2015
ZD6474, a small molecule tyrosine kinase inhibitor, potentiates the anti-tumor and anti-metastasis effects of radiation for human nasopharyngeal carcinoma.Current cancer drug targets, , Volume: 10, Issue:6, 2010
Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase.International journal of cancer, , Nov-01, Volume: 121, Issue:9, 2007
Vandetanib inhibits cisplatin‑resistant neuroblastoma tumor growth and invasion.Oncology reports, , Volume: 39, Issue:4, 2018
VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFβR signaling-dependent manner.Cancer letters, , Apr-28, Volume: 360, Issue:1, 2015
Vandetanib-induced inhibition of neuroblastoma cell migration and invasion is associated with downregulation of the SDF-1/CXCR4 axis and matrix metalloproteinase 14.Oncology reports, , Volume: 31, Issue:3, 2014
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.Advances in therapy, , Volume: 30, Issue:11, 2013
Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature.Molecular bioSystems, , Volume: 9, Issue:6, 2013
Vandetanib: a guide to its use in advanced medullary thyroid cancer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, , Dec-01, Volume: 26, Issue:6, 2012
ZD6474, a small molecule tyrosine kinase inhibitor, potentiates the anti-tumor and anti-metastasis effects of radiation for human nasopharyngeal carcinoma.Current cancer drug targets, , Volume: 10, Issue:6, 2010
Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 3, Issue:6 Suppl 2, 2008
A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 1, Issue:9, 2006
ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells.Biochemical pharmacology, , Feb-14, Volume: 71, Issue:4, 2006
A Phase II Trial of Vandetanib in Children and Adults with Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor.Clinical cancer research : an official journal of the American Association for Cancer Research, , 11-01, Volume: 25, Issue:21, 2019
Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B.Clinical endocrinology, , Volume: 88, Issue:5, 2018
Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.European journal of medicinal chemistry, , Nov-10, Volume: 140, 2017
Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.Best practice & research. Clinical endocrinology & metabolism, , Volume: 31, Issue:3, 2017
Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.International journal of cancer, , May-15, Volume: 138, Issue:10, 2016
Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , 05-20, Volume: 34, Issue:15, 2016
Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment.Medicine, , Volume: 94, Issue:45, 2015
New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.Anti-cancer drugs, , Volume: 26, Issue:7, 2015
Vandetanib as a potential treatment for breast cancer.Expert opinion on investigational drugs, , Volume: 23, Issue:9, 2014
Vandetanib for the treatment of medullary thyroid carcinoma.The Annals of pharmacotherapy, , Volume: 48, Issue:3, 2014
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).Oral oncology, , Volume: 49, Issue:8, 2013
Comparative proteome profiling of breast tumor cell lines by gel electrophoresis and mass spectrometry reveals an epithelial mesenchymal transition associated protein signature.Molecular bioSystems, , Volume: 9, Issue:6, 2013
A randomized, phase II study of vandetanib maintenance for advanced or metastatic non-small-cell lung cancer following first-line platinum-doublet chemotherapy.Lung cancer (Amsterdam, Netherlands), , Volume: 82, Issue:3, 2013
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 19, Issue:15, 2013
Vandetanib: in medullary thyroid cancer.Drugs, , Jul-09, Volume: 72, Issue:10, 2012
Vandetanib: a guide to its use in advanced medullary thyroid cancer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, , Dec-01, Volume: 26, Issue:6, 2012
Unusual adverse event with vandetanib in metastatic medullary thyroid cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jan-10, Volume: 30, Issue:2, 2012
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jan-10, Volume: 30, Issue:2, 2012
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.PloS one, , Volume: 7, Issue:6, 2012
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.Investigational new drugs, , Volume: 30, Issue:3, 2012
Vandetanib: first global approval.Drugs, , Jul-09, Volume: 71, Issue:10, 2011
ZD6474, a small molecule tyrosine kinase inhibitor, potentiates the anti-tumor and anti-metastasis effects of radiation for human nasopharyngeal carcinoma.Current cancer drug targets, , Volume: 10, Issue:6, 2010
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.The Journal of clinical endocrinology and metabolism, , Volume: 95, Issue:6, 2010
Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.Anti-cancer drugs, , Volume: 18, Issue:5, 2007
ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model.International journal of cancer, , Jan-15, Volume: 118, Issue:2, 2006
A multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastatic breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-01, Volume: 11, Issue:9, 2005
The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma.Angiogenesis, , Volume: 7, Issue:4, 2004
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-15, Volume: 10, Issue:18 Pt 1, 2004
In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model.Angiogenesis, , Volume: 7, Issue:2, 2004
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.The Cochrane database of systematic reviews, , 10-16, Volume: 10, 2018
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.Journal of neuro-oncology, , Volume: 121, Issue:3, 2015
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.European journal of cancer (Oxford, England : 1990), , Volume: 50, Issue:9, 2014
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 19, Issue:15, 2013
A randomized phase II study of docetaxel with or without vandetanib in recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN).Oral oncology, , Volume: 49, Issue:8, 2013
A phase I/II trial of vandetanib for patients with recurrent malignant glioma.Neuro-oncology, , Volume: 14, Issue:12, 2012
Phase I dose escalation trial of vandetanib with fractionated radiosurgery in patients with recurrent malignant gliomas.International journal of radiation oncology, biology, physics, , Jan-01, Volume: 82, Issue:1, 2012
Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma.Cornea, , Volume: 28, Issue:6, 2009
A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 3, Issue:4, 2008
Novel vandetanib derivative inhibited proliferation and promoted apoptosis of cancer cells under normoxia and hypoxia.European journal of pharmacology, , May-05, Volume: 922, 2022
FDA-approved pyrimidine-fused bicyclic heterocycles for cancer therapy: Synthesis and clinical application.European journal of medicinal chemistry, , Mar-15, Volume: 214, 2021
Targeting Rearranged during Transfection in Cancer: A Perspective on Small-Molecule Inhibitors and Their Clinical Development.Journal of medicinal chemistry, , 08-26, Volume: 64, Issue:16, 2021
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study.ESMO open, , Volume: 6, Issue:2, 2021
Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.Journal of medicinal chemistry, , 09-10, Volume: 63, Issue:17, 2020
Incidence and risk of developing photosensitivity with targeted anticancer therapies.Journal of the American Academy of Dermatology, , Volume: 81, Issue:4, 2019
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.European journal of medicinal chemistry, , May-15, Volume: 170, 2019
Risk of Gastrointestinal Events During Vandetanib Therapy in Patients With Cancer: A Systematic Review and Meta-analysis of Clinical Trials.American journal of therapeutics, , Volume: 24, Issue:3, 2017
Kinase Inhibitors in Multitargeted Cancer Therapy.Current medicinal chemistry, , Volume: 24, Issue:16, 2017
Discovery and Optimization of N-Substituted 2-(4-pyridinyl)thiazole carboxamides against Tumor Growth through Regulating Angiogenesis Signaling Pathways.Scientific reports, , 09-16, Volume: 6, 2016
[Anti-angiogenesis and molecular targeted therapies].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 73, Issue:8, 2015
Differential Effects of Tumor Secreted Factors on Mechanosensitivity, Capillary Branching, and Drug Responsiveness in PEG Hydrogels.Annals of biomedical engineering, , Volume: 43, Issue:9, 2015
Inhibition of RET activated pathways: novel strategies for therapeutic intervention in human cancers.Current pharmaceutical design, , Volume: 19, Issue:5, 2013
Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.British journal of clinical pharmacology, , Volume: 75, Issue:4, 2013
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].Magyar onkologia, , Volume: 56, Issue:3, 2012
Drug approvals 2011: focus on companion diagnostics.Journal of the National Cancer Institute, , Jan-18, Volume: 104, Issue:2, 2012
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].Magyar onkologia, , Volume: 56, Issue:1, 2012
Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis.Anti-cancer drugs, , Volume: 23, Issue:7, 2012
Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis.PloS one, , Volume: 7, Issue:2, 2012
Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer.Bioorganic & medicinal chemistry letters, , Jun-01, Volume: 21, Issue:11, 2011
Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.Clinical therapeutics, , Volume: 33, Issue:3, 2011
Synthesis and pharmacological evaluations of novel 2H-benzo[b][1,4]oxazin-3(4H)-one derivatives as a new class of anti-cancer agents.European journal of medicinal chemistry, , Volume: 46, Issue:10, 2011
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.European journal of cancer (Oxford, England : 1990), , Volume: 47, Issue:7, 2011
Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer.International journal of oncology, , Volume: 39, Issue:1, 2011
Vandetanib: An overview of its clinical development in NSCLC and other tumors.Drugs of today (Barcelona, Spain : 1998), , Volume: 46, Issue:9, 2010
Identification of tyrosine 806 as a molecular determinant of RET kinase sensitivity to ZD6474.Endocrine-related cancer, , Volume: 16, Issue:1, 2009
Synthesis and preclinical evaluation of [(11)C]PAQ as a PET imaging tracer for VEGFR-2.European journal of nuclear medicine and molecular imaging, , Volume: 36, Issue:8, 2009
Vascular endothelial growth factor receptor-1 contributes to resistance to anti-epidermal growth factor receptor drugs in human cancer cells.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-15, Volume: 14, Issue:16, 2008
Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor.Journal of medicinal chemistry, , Aug-14, Volume: 51, Issue:15, 2008
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.Current medicinal chemistry, , Volume: 15, Issue:5, 2008
[Oral drugs inhibiting the VEGF pathway].Bulletin du cancer, , Volume: 94 Spec No, 2007
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.IDrugs : the investigational drugs journal, , Volume: 10, Issue:8, 2007
Vandetanib, a novel multitargeted kinase inhibitor, in cancer therapy.Drugs of today (Barcelona, Spain : 1998), , Volume: 42, Issue:10, 2006
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 16, Issue:18, 2006
ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy.International journal of radiation oncology, biology, physics, , Jan-01, Volume: 64, Issue:1, 2006
Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues.Journal of pharmaceutical and biomedical analysis, , Sep-15, Volume: 39, Issue:3-4, 2005
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity.British journal of cancer, , Volume: 92 Suppl 1, 2005
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 16, Issue:8, 2005
Update on angiogenesis inhibitors.Current opinion in oncology, , Volume: 17, Issue:6, 2005
Small in-frame deletion in the epidermal growth factor receptor as a target for ZD6474.Cancer research, , Dec-15, Volume: 64, Issue:24, 2004
[Anti angiogenesis].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 31, Issue:4, 2004
ZD-6474. AstraZeneca.Current opinion in investigational drugs (London, England : 2000), , Volume: 4, Issue:12, 2003
[Current screening for molecular target therapy of cancer].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 30, Issue:12, 2003
Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase.Clinical cancer research : an official journal of the American Association for Cancer Research, , Volume: 9, Issue:4, 2003
Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs?Clinical cancer research : an official journal of the American Association for Cancer Research, , Volume: 9, Issue:4, 2003
Inhibitors of the vascular endothelial growth factor receptor.Hematology/oncology clinics of North America, , Volume: 16, Issue:5, 2002
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.The oncologist, , Volume: 11, Issue:7
Rationale and clinical results of multi-target treatments in oncology.The International journal of biological markers, , Volume: 22, Issue:1 Suppl 4
Single-Molecule Force Measurement Guides the Design of Multivalent Ligands with Picomolar Affinity.Angewandte Chemie (International ed. in English), , 04-08, Volume: 58, Issue:16, 2019
Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants.European journal of medicinal chemistry, , Jan-01, Volume: 143, 2018
Targeting ABL1-mediated oxidative stress adaptation in fumarate hydratase-deficient cancer.Cancer cell, , Dec-08, Volume: 26, Issue:6, 2014
Vandetanib, an inhibitor of VEGF receptor-2 and EGF receptor, suppresses tumor development and improves prognosis of liver cancer in mice.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jul-15, Volume: 18, Issue:14, 2012
ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model.International journal of cancer, , Jan-15, Volume: 118, Issue:2, 2006
ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.Oncology research, , Volume: 16, Issue:1, 2006
Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours.British journal of cancer, , Nov-17, Volume: 89, Issue:10, 2003
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.Cancer research, , Aug-15, Volume: 62, Issue:16, 2002
Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.International journal of molecular sciences, , Mar-16, Volume: 22, Issue:6, 2021
Vandetanib-eluting radiopaque beads for chemoembolization: physicochemical evaluation and biological activity of vandetanib in hypoxia.Anti-cancer drugs, , 10-01, Volume: 32, Issue:9, 2021
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.Oncogene, , Volume: 37, Issue:42, 2018
Expression of VEGF with tumor incidence, metastasis and prognosis in human gastric carcinoma.Cancer biomarkers : section A of Disease markers, , Volume: 22, Issue:4, 2018
Angiogenesis Inhibitors in NSCLC.International journal of molecular sciences, , Sep-21, Volume: 18, Issue:10, 2017
Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.European journal of medicinal chemistry, , Nov-10, Volume: 140, 2017
Vandetanib as a potential new treatment for estrogen receptor-negative breast cancers.International journal of cancer, , May-15, Volume: 138, Issue:10, 2016
[Tyrosine kinase inhibiting the VEGF pathway and elderly people: Tolerance, pre-treatment assessment and side effects management].Bulletin du cancer, , Volume: 103, Issue:3, 2016
Discovery and Optimization of N-Substituted 2-(4-pyridinyl)thiazole carboxamides against Tumor Growth through Regulating Angiogenesis Signaling Pathways.Scientific reports, , 09-16, Volume: 6, 2016
Differential Effects of Tumor Secreted Factors on Mechanosensitivity, Capillary Branching, and Drug Responsiveness in PEG Hydrogels.Annals of biomedical engineering, , Volume: 43, Issue:9, 2015
Development of molecular targeted drugs for advanced thyroid cancer in Japan.Endocrine journal, , Volume: 61, Issue:9, 2014
Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.The Journal of clinical investigation, , Volume: 123, Issue:4, 2013
Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer.The Journal of surgical research, , Volume: 185, Issue:2, 2013
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].Magyar onkologia, , Volume: 56, Issue:1, 2012
Vascular endothelial growth factor receptor 2 inhibition in-vivo affects tumor vasculature in a tumor type-dependent way and downregulates vascular endothelial growth factor receptor 2 protein without a prominent role for miR-296.Anti-cancer drugs, , Volume: 23, Issue:2, 2012
Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics.Breast cancer research and treatment, , Volume: 136, Issue:1, 2012
Alveolar hypoxia promotes murine lung tumor growth through a VEGFR-2/EGFR-dependent mechanism.Cancer prevention research (Philadelphia, Pa.), , Volume: 5, Issue:8, 2012
Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans.Hypertension (Dallas, Tex. : 1979), , Volume: 58, Issue:1, 2011
Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro.Clinical cancer research : an official journal of the American Association for Cancer Research, , Apr-01, Volume: 17, Issue:7, 2011
Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.The Journal of pathology, , Volume: 223, Issue:5, 2011
Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.Clinical cancer research : an official journal of the American Association for Cancer Research, , Apr-15, Volume: 17, Issue:8, 2011
Antiangiogenic therapies for malignant pleural mesothelioma.Frontiers in bioscience (Landmark edition), , 01-01, Volume: 16, Issue:2, 2011
Dual inhibition of vascular endothelial growth factor receptor and epidermal growth factor receptor is an effective chemopreventive strategy in the mouse 4-NQO model of oral carcinogenesis.Cancer prevention research (Philadelphia, Pa.), , Volume: 3, Issue:11, 2010
A novel therapeutic combination for neuroblastoma: the vascular endothelial growth factor receptor/epidermal growth factor receptor/rearranged during transfection inhibitor vandetanib with 13-cis-retinoic acid.Cancer, , May-15, Volume: 116, Issue:10, 2010
Assessment of acute antivascular effects of vandetanib with high-resolution dynamic contrast-enhanced computed tomographic imaging in a human colon tumor xenograft model in the nude rat.Neoplasia (New York, N.Y.), , Volume: 12, Issue:9, 2010
Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.Cancer prevention research (Philadelphia, Pa.), , Volume: 3, Issue:9, 2010
Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.Cancer research, , May-01, Volume: 70, Issue:9, 2010
Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway.Experimental biology and medicine (Maywood, N.J.), , Volume: 235, Issue:1, 2010
ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain.Molecular cancer therapeutics, , Volume: 9, Issue:4, 2010
Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474).Anticancer research, , Volume: 29, Issue:6, 2009
The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.Neoplasia (New York, N.Y.), , Volume: 11, Issue:11, 2009
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.Cancer letters, , Jun-28, Volume: 265, Issue:1, 2008
Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts.International journal of oncology, , Volume: 33, Issue:3, 2008
Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 3, Issue:6 Suppl 2, 2008
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.Molecular cancer therapeutics, , Volume: 7, Issue:1, 2008
From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage.Current medicinal chemistry, , Volume: 15, Issue:5, 2008
Vascular endothelial growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: a review of recent clinical trials.Reviews on recent clinical trials, , Volume: 2, Issue:2, 2007
Antitumor effects of ZD6474 on head and neck squamous cell carcinoma.Oncology reports, , Volume: 17, Issue:2, 2007
Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis.Expert opinion on investigational drugs, , Volume: 16, Issue:2, 2007
Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade.Molecular cancer therapeutics, , Volume: 6, Issue:2, 2007
Drug insight: VEGF as a therapeutic target for breast cancer.Nature clinical practice. Oncology, , Volume: 4, Issue:3, 2007
Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis.Oncogene, , Aug-23, Volume: 26, Issue:39, 2007
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.Current treatment options in oncology, , Volume: 8, Issue:1, 2007
Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer.International journal of radiation oncology, biology, physics, , Dec-01, Volume: 69, Issue:5, 2007
[Oral drugs inhibiting the VEGF pathway].Bulletin du cancer, , Volume: 94 Spec No, 2007
ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model.Oncology research, , Volume: 16, Issue:1, 2006
Epidermal growth factor receptor/angiogenesis dual targeting: preclinical experience.Current opinion in oncology, , Volume: 18, Issue:4, 2006
ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy.International journal of radiation oncology, biology, physics, , Jan-01, Volume: 64, Issue:1, 2006
Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 11, Issue:15, 2005
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity.British journal of cancer, , Volume: 92 Suppl 1, 2005
Update on angiogenesis inhibitors.Current opinion in oncology, , Volume: 17, Issue:6, 2005
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors.Clinical cancer research : an official journal of the American Association for Cancer Research, , Nov-15, Volume: 11, Issue:22, 2005
ZD6474--clinical experience to date.British journal of cancer, , Volume: 92 Suppl 1, 2005
Angiogenesis and lung cancer: prognostic and therapeutic implications.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , May-10, Volume: 23, Issue:14, 2005
Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity.Clinical cancer research : an official journal of the American Association for Cancer Research, , May-01, Volume: 11, Issue:9, 2005
Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice.Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-15, Volume: 11, Issue:24 Pt 1, 2005
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.International journal of radiation oncology, biology, physics, , Nov-15, Volume: 60, Issue:4, 2004
In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model.Angiogenesis, , Volume: 7, Issue:2, 2004
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-15, Volume: 10, Issue:18 Pt 1, 2004
ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.Molecular cancer therapeutics, , Volume: 3, Issue:9, 2004
Inhibition of VEGFR2 prevents DMBA-induced mammary tumor formation.Laboratory investigation; a journal of technical methods and pathology, , Volume: 84, Issue:8, 2004
[Anti angiogenesis].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 31, Issue:4, 2004
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models.Cancer science, , Volume: 95, Issue:12, 2004
The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma.Angiogenesis, , Volume: 7, Issue:4, 2004
Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-15, Volume: 10, Issue:24, 2004
Inhibitors of the vascular endothelial growth factor receptor.Hematology/oncology clinics of North America, , Volume: 16, Issue:5, 2002
ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.Cancer research, , Aug-15, Volume: 62, Issue:16, 2002
Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474.In vivo (Athens, Greece), , Volume: 19, Issue:6
Epidermal growth factor receptor blockers for the treatment of ovarian cancer.The Cochrane database of systematic reviews, , 10-16, Volume: 10, 2018
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.European journal of cancer (Oxford, England : 1990), , Volume: 50, Issue:9, 2014
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).Investigational new drugs, , Volume: 31, Issue:6, 2013
Inhibition of P-glycoprotein functionality by vandetanib may reverse cancer cell resistance to doxorubicin.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, , Aug-15, Volume: 46, Issue:5, 2012
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jan-15, Volume: 16, Issue:2, 2010
The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma.Neoplasia (New York, N.Y.), , Volume: 11, Issue:11, 2009
Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474.In vivo (Athens, Greece), , Volume: 19, Issue:6
Irinotecan and vandetanib create synergies for treatment of pancreatic cancer patients with concomitant TP53 and KRAS mutations.Briefings in bioinformatics, , 05-20, Volume: 22, Issue:3, 2021
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.The Lancet. Oncology, , Volume: 18, Issue:4, 2017
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.Investigational new drugs, , Volume: 34, Issue:2, 2016
[Targeted therapies, prognostic and predictive factors in endocrine oncology].Annales d'endocrinologie, , Volume: 74 Suppl 1, 2013
Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma.Oncology, , Volume: 81, Issue:1, 2011
Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model.Anti-cancer drugs, , Volume: 18, Issue:5, 2007
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.IDrugs : the investigational drugs journal, , Volume: 10, Issue:8, 2007
Synergistic antitumor activity of ZD6474, an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, with gemcitabine and ionizing radiation against pancreatic cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-01, Volume: 12, Issue:23, 2006
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904.European journal of cancer (Oxford, England : 1990), , Volume: 50, Issue:9, 2014
ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model.International journal of cancer, , Jan-15, Volume: 118, Issue:2, 2006
Incidence and risk of developing photosensitivity with targeted anticancer therapies.Journal of the American Academy of Dermatology, , Volume: 81, Issue:4, 2019
Photo-induced erythema multiforme associated with vandetanib administration.Journal of the American Academy of Dermatology, , Volume: 71, Issue:4, 2014
A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib.Archives of dermatology, , Volume: 148, Issue:12, 2012
Severe photosensitivity reaction to vandetanib.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Sep-20, Volume: 27, Issue:27, 2009
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.European journal of endocrinology, , Volume: 170, Issue:4, 2014
Antiangiogenic therapies for malignant pleural mesothelioma.Frontiers in bioscience (Landmark edition), , 01-01, Volume: 16, Issue:2, 2011
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.British journal of cancer, , Nov-08, Volume: 105, Issue:10, 2011
[Pleural metastases from bronchial carcinoma: is a cure possible?].Revue des maladies respiratoires, , Volume: 28, Issue:1, 2011
Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement.Cancer letters, , Jun-28, Volume: 265, Issue:1, 2008
[Cabozantinib: Mechanism of action, efficacy and indications].Bulletin du cancer, , Volume: 104, Issue:5, 2017
1-Piperazinylphthalazines as potential VEGFR-2 inhibitors and anticancer agents: Synthesis and in vitro biological evaluation.European journal of medicinal chemistry, , Jan-01, Volume: 107, 2016
Biometrical issues in the analysis of adverse events within the benefit assessment of drugs.Pharmaceutical statistics, , Volume: 15, Issue:4, 2016
[Four new drugs on the market: abiraterone, belatacept, vandetanib and fidaxomycine].Annales pharmaceutiques francaises, , Volume: 71, Issue:2, 2013
Contrasted effects of the multitarget TKi vandetanib on docetaxel-sensitive and docetaxel-resistant prostate cancer cell lines.Urologic oncology, , Volume: 31, Issue:8, 2013
Drug approvals 2011: focus on companion diagnostics.Journal of the National Cancer Institute, , Jan-18, Volume: 104, Issue:2, 2012
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].Magyar onkologia, , Volume: 56, Issue:3, 2012
False-negative MRI biomarkers of tumour response to targeted cancer therapeutics.British journal of cancer, , Jun-05, Volume: 106, Issue:12, 2012
2011 ASCO Genitourinary Cancers Symposium.The Lancet. Oncology, , Volume: 12, Issue:4, 2011
A randomized, double-blind, placebo-controlled phase II study of vandetanib plus docetaxel/prednisolone in patients with hormone-refractory prostate cancer.Cancer biotherapy & radiopharmaceuticals, , Volume: 24, Issue:2, 2009
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.IDrugs : the investigational drugs journal, , Volume: 10, Issue:8, 2007
Inhibitory effects of castration in an orthotopic model of androgen-independent prostate cancer can be mimicked and enhanced by angiogenesis inhibition.Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-15, Volume: 12, Issue:24, 2006
Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-15, Volume: 10, Issue:24, 2004
[Anti angiogenesis].Gan to kagaku ryoho. Cancer & chemotherapy, , Volume: 31, Issue:4, 2004
Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours.British journal of cancer, , Nov-17, Volume: 89, Issue:10, 2003
Vandetanib and indwelling pleural catheter for non-small-cell lung cancer with recurrent malignant pleural effusion.Clinical lung cancer, , Volume: 15, Issue:5, 2014
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jan-15, Volume: 16, Issue:2, 2010
Extracellular signal-regulated kinase 5 and cyclic AMP response element binding protein are novel pathways inhibited by vandetanib (ZD6474) and doxorubicin in mesotheliomas.American journal of respiratory cell and molecular biology, , Volume: 51, Issue:5, 2014
Combined vascular endothelial growth factor receptor/epidermal growth factor receptor blockade with chemotherapy for treatment of local, uterine, and metastatic soft tissue sarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-01, Volume: 14, Issue:17, 2008
Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 144, 2021
Effects of adenosine triphosphate on vandetanib induced skin damage in rats.Cutaneous and ocular toxicology, , Volume: 39, Issue:4, 2020
Addition of vandetanib to pegylated liposomal doxorubicin (PLD) in patients with recurrent ovarian cancer. A randomized phase I/II study of the AGO Study Group (AGO-OVAR 2.13).Investigational new drugs, , Volume: 31, Issue:6, 2013
Vandetanib inhibits cell growth in EGFR-expressing cutaneous squamous cell carcinoma.Biochemical and biophysical research communications, , 10-20, Volume: 531, Issue:3, 2020
CD30+ lymphoproliferative disorder in a patient with metastatic papillary thyroid carcinoma.Dermatology online journal, , Oct-15, Volume: 22, Issue:10, 2016
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Micronodular transformation as a novel mechanism of VEGF-A-induced metastasis.Oncogene, , Aug-23, Volume: 26, Issue:39, 2007
Expression of VEGF with tumor incidence, metastasis and prognosis in human gastric carcinoma.Cancer biomarkers : section A of Disease markers, , Volume: 22, Issue:4, 2018
The Significant Role of Cyclin D1 in the Synergistic Growth-inhibitory Effect of Combined Therapy of Vandetanib with 5-Fluorouracil for Gastric Cancer.Anticancer research, , Volume: 36, Issue:10, 2016
Analysis of anti-proliferative and chemosensitizing effects of sunitinib on human esophagogastric cancer cells: Synergistic interaction with vandetanib via inhibition of multi-receptor tyrosine kinase pathways.International journal of cancer, , Sep-01, Volume: 127, Issue:5, 2010
ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model.International journal of cancer, , Jan-15, Volume: 118, Issue:2, 2006
ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer.Molecular cancer therapeutics, , Volume: 3, Issue:9, 2004
Rare complications of multikinase inhibitor treatment.Archives of endocrinology and metabolism, , Volume: 62, Issue:6, 2018
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.Journal of cancer research and clinical oncology, , Volume: 141, Issue:5, 2015
Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma.International journal of radiation oncology, biology, physics, , Sep-01, Volume: 78, Issue:1, 2010
Phase 3 Trial of Selpercatinib in Advanced The New England journal of medicine, , Nov-16, Volume: 389, Issue:20, 2023
Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer.Thyroid : official journal of the American Thyroid Association, , Volume: 31, Issue:3, 2021
Vandetanib in a Child Affected by Neurofibromatosis Type 1 and Medullary Thyroid Carcinoma with Both Journal of clinical research in pediatric endocrinology, , 08-23, Volume: 13, Issue:3, 2021
Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer.Endocrine, , Volume: 71, Issue:2, 2021
Acute tubulointerstitial nephritis induced by the tyrosine kinase inhibitor vandetanib.Investigational new drugs, , Volume: 39, Issue:1, 2021
[Medullary thyroid carcinoma: current clinical progress].Deutsche medizinische Wochenschrift (1946), , Volume: 146, Issue:23, 2021
Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma - Lessons From Individual Cases With Long-Term Follow-Up.Frontiers in endocrinology, , Volume: 12, 2021
[Drug approval: Selpercatinib and pralsetinib - RET-altered thyroid cancer].Bulletin du cancer, , Volume: 108, Issue:11, 2021
An Unusual Case of Hypopituitarism as an Adverse Effect of Vandetanib and Remission of Breast Metastases in a Patient with Medullary Thyroid Cancer.Oncology research and treatment, , Volume: 44, Issue:10, 2021
Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model.International journal of molecular sciences, , Mar-16, Volume: 22, Issue:6, 2021
Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.Endocrine journal, , Dec-28, Volume: 67, Issue:12, 2020
Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , 08-20, Volume: 38, Issue:24, 2020
Increased therapeutic effect on medullary thyroid cancer using a combination of radiation and tyrosine kinase inhibitors.PloS one, , Volume: 15, Issue:5, 2020
YAP confers resistance to vandetanib in medullary thyroid cancer.Biochemistry and cell biology = Biochimie et biologie cellulaire, , Volume: 98, Issue:3, 2020
Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response.Endocrine-related cancer, , 01-20, Volume: 27, Issue:2, 2020
Vandetanib for the Management of Advanced Medullary Thyroid Cancer: A Real-World Multicenter Experience.Endocrinology and metabolism (Seoul, Korea), , Volume: 35, Issue:3, 2020
Trends in the Diagnosis and Treatment of Patients with Medullary Thyroid Carcinoma in Korea.Endocrinology and metabolism (Seoul, Korea), , Volume: 35, Issue:4, 2020
Tyrosine Kinase Inhibitor Use and Wound Healing in Tracheoesophageal Punctures.Ear, nose, & throat journal, , Volume: 98, Issue:8, 2019
Phase I/II Trial of Vandetanib and Bortezomib in Adults with Locally Advanced or Metastatic Medullary Thyroid Cancer.The oncologist, , Volume: 24, Issue:1, 2019
Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.Endocrine-related cancer, , 02-01, Volume: 26, Issue:2, 2019
Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.Health technology assessment (Winchester, England), , Volume: 23, Issue:8, 2019
Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy.The Journal of clinical endocrinology and metabolism, , 03-01, Volume: 104, Issue:3, 2019
Vandetanib Tumor Shrinkage in Metastatic Medullary Thyroid Cancer Allowing Surgical Resection of the Primary Site: A Case Report.Journal of pediatric hematology/oncology, , Volume: 41, Issue:5, 2019
A rare cutaneous phototoxic rash after vandetanib therapy in a patient with thyroid cancer: A case report.Medicine, , Volume: 98, Issue:31, 2019
Appendix 2: Medullary Thyroid Cancer: eUpdate published online 19 February 2018 (http://www.esmo.org/Guidelines/Endocrine-and-Neuroendocrine-Cancers/Thyroid-cancer).Annals of oncology : official journal of the European Society for Medical Oncology, , 10-01, Volume: 29, Issue:Suppl 4, 2018
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.International journal of molecular sciences, , Oct-20, Volume: 19, Issue:10, 2018
Outcomes of Children and Adolescents with Advanced Hereditary Medullary Thyroid Carcinoma Treated with Vandetanib.Clinical cancer research : an official journal of the American Association for Cancer Research, , 02-15, Volume: 24, Issue:4, 2018
Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.European journal of medicinal chemistry, , Apr-25, Volume: 150, 2018
Cabozantinib and Vandetanib in medullary thyroid carcinoma: mitochondrial function and its potential as a therapeutic target towards novel strategies to design anti-CSCs drugs.Cancer biology & therapy, , Volume: 19, Issue:10, 2018
Pregnancy on vandetanib in metastatic medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2B.Clinical endocrinology, , Volume: 88, Issue:5, 2018
Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo.Oncology reports, , Volume: 39, Issue:5, 2018
Rare complications of multikinase inhibitor treatment.Archives of endocrinology and metabolism, , Volume: 62, Issue:6, 2018
Transcriptional targeting of oncogene addiction in medullary thyroid cancer.JCI insight, , 08-23, Volume: 3, Issue:16, 2018
SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, , Volume: 23, Issue:2, 2017
Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic RET Mutation.Thyroid : official journal of the American Thyroid Association, , Volume: 27, Issue:4, 2017
[Cabozantinib: Mechanism of action, efficacy and indications].Bulletin du cancer, , Volume: 104, Issue:5, 2017
Vandetanib and cabozantinib potentiate mitochondria-targeted agents to suppress medullary thyroid carcinoma cells.Cancer biology & therapy, , Jul-03, Volume: 18, Issue:7, 2017
Genetics of medullary thyroid cancer: An overview.International journal of surgery (London, England), , Volume: 41 Suppl 1, 2017
Medullary Thyroid Cancer: Clinical Characteristics and New Insights into Therapeutic Strategies Targeting Tyrosine Kinases.Molecular diagnosis & therapy, , Volume: 21, Issue:6, 2017
Chemotherapy and tyrosine-kinase inhibitors for medullary thyroid cancer.Best practice & research. Clinical endocrinology & metabolism, , Volume: 31, Issue:3, 2017
The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.Expert review of anticancer therapy, , Volume: 16, Issue:11, 2016
Systemic treatment and management approaches for medullary thyroid cancer.Cancer treatment reviews, , Volume: 50, 2016
Use of Vandetanib in Metastatic Medullary Carcinoma of Thyroid in a Pediatric Patient With Multiple Endocrine Neoplasia 2B.Journal of pediatric hematology/oncology, , Volume: 38, Issue:2, 2016
Management of advanced medullary thyroid cancer.The lancet. Diabetes & endocrinology, , Volume: 4, Issue:1, 2016
A Pyrazolo[3,4-d]pyrimidin-4-amine Derivative Containing an Isoxazole Moiety Is a Selective and Potent Inhibitor of RET Gatekeeper Mutants.Journal of medicinal chemistry, , Jan-14, Volume: 59, Issue:1, 2016
Biometrical issues in the analysis of adverse events within the benefit assessment of drugs.Pharmaceutical statistics, , Volume: 15, Issue:4, 2016
cabozantinib (COMETRIQ⁰). In medullary thyroid cancer: more harmful than beneficial, as is vandetanib.Prescrire international, , Volume: 25, Issue:167, 2016
MicroRNA-375/SEC23A as biomarkers of the in vitro efficacy of vandetanib.Oncotarget, , May-24, Volume: 7, Issue:21, 2016
Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma.Oncology, , Volume: 90, Issue:6, 2016
Prognostic markers and response to vandetanib therapy in sporadic medullary thyroid cancer patients.European journal of endocrinology, , Volume: 175, Issue:3, 2016
The safety of vandetanib for the treatment of thyroid cancer.Expert opinion on drug safety, , Volume: 15, Issue:8, 2016
[Metastatic medullary thyroid carcinoma in a child with multiple endocrine neoplasia 2B. Efficiency of medium-term treatment with vandetanib without thyroid surgery].Archives de pediatrie : organe officiel de la Societe francaise de pediatrie, , Volume: 23, Issue:8, 2016
CD30+ lymphoproliferative disorder in a patient with metastatic papillary thyroid carcinoma.Dermatology online journal, , Oct-15, Volume: 22, Issue:10, 2016
Selective use of vandetanib in the treatment of thyroid cancer.Drug design, development and therapy, , Volume: 9, 2015
Treatment of advanced thyroid cancer: role of molecularly targeted therapies.Targeted oncology, , Volume: 10, Issue:3, 2015
Systemic treatment of advanced differentiated and medullary thyroid cancer. Overview and practical aspects.Nuklearmedizin. Nuclear medicine, , Volume: 54, Issue:3, 2015
High Affinity Pharmacological Profiling of Dual Inhibitors Targeting RET and VEGFR2 in Inhibition of Kinase and Angiogeneis Events in Medullary Thyroid Carcinoma.Asian Pacific journal of cancer prevention : APJCP, , Volume: 16, Issue:16, 2015
Prognostic Value of Serum Tumor Markers in Medullary Thyroid Cancer Patients Undergoing Vandetanib Treatment.Medicine, , Volume: 94, Issue:45, 2015
New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.Anti-cancer drugs, , Volume: 26, Issue:7, 2015
Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report.BMC dermatology, , Feb-13, Volume: 15, 2015
Vandetanib for the treatment of advanced medullary thyroid cancer outside a clinical trial: results from a French cohort.Thyroid : official journal of the American Thyroid Association, , Volume: 25, Issue:4, 2015
The evolving field of kinase inhibitors in thyroid cancer.Critical reviews in oncology/hematology, , Volume: 93, Issue:1, 2015
Vandetanib-associated alopecia areata in a patient with metastatic medullary thyroid cancer.International journal of dermatology, , Volume: 54, Issue:6, 2015
Rapid response of hypercortisolism to vandetanib treatment in a patient with advanced medullary thyroid cancer and ectopic Cushing syndrome.Archives of endocrinology and metabolism, , Volume: 59, Issue:4, 2015
Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.European journal of endocrinology, , Volume: 170, Issue:4, 2014
Vandetanib for the treatment of thyroid cancer: an update.Expert opinion on drug metabolism & toxicology, , Volume: 10, Issue:3, 2014
Novel therapies for thyroid cancer.Expert opinion on pharmacotherapy, , Volume: 15, Issue:18, 2014
[Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas].Bulletin du cancer, , Volume: 101, Issue:9, 2014
Vandetanib successfully controls medullary thyroid cancer-related Cushing syndrome in an adolescent patient.The Journal of clinical endocrinology and metabolism, , Volume: 99, Issue:9, 2014
Medullary thyroid cancer in the era of tyrosine kinase inhibitors: to treat or not to treat--and with which drug--those are the questions.The Journal of clinical endocrinology and metabolism, , Volume: 99, Issue:12, 2014
Photo-induced erythema multiforme associated with vandetanib administration.Journal of the American Academy of Dermatology, , Volume: 71, Issue:4, 2014
Changes in signaling pathways induced by vandetanib in a human medullary thyroid carcinoma model, as analyzed by reverse phase protein array.Thyroid : official journal of the American Thyroid Association, , Volume: 24, Issue:1, 2014
The discovery and development of vandetanib for the treatment of thyroid cancer.Expert opinion on drug discovery, , Volume: 9, Issue:1, 2014
Vandetanib for the treatment of medullary thyroid carcinoma.The Annals of pharmacotherapy, , Volume: 48, Issue:3, 2014
Advanced thyroid cancers: new era of treatment.Medical oncology (Northwood, London, England), , Volume: 31, Issue:7, 2014
Development of molecular targeted drugs for advanced thyroid cancer in Japan.Endocrine journal, , Volume: 61, Issue:9, 2014
Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma.The New England journal of medicine, , Aug-08, Volume: 369, Issue:6, 2013
Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.Endocrine, , Volume: 44, Issue:2, 2013
Tumour markers fluctuations in patients with medullary thyroid carcinoma receiving long-term RET inhibitor therapy: ordinary lapping or alarming waves foreshadowing disease progression?Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 24, Issue:9, 2013
Vandetanib: a novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , May-15, Volume: 70, Issue:10, 2013
[Targeted therapies, prognostic and predictive factors in endocrine oncology].Annales d'endocrinologie, , Volume: 74 Suppl 1, 2013
Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 19, Issue:15, 2013
Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer.The Journal of surgical research, , Volume: 185, Issue:2, 2013
A Drosophila approach to thyroid cancer therapeutics.Drug discovery today. Technologies, ,Spring, Volume: 10, Issue:1, 2013
Clinical efficacy of targeted biologic agents as second-line therapy of advanced thyroid cancer.The oncologist, , Volume: 18, Issue:12, 2013
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.Advances in therapy, , Volume: 30, Issue:11, 2013
Body composition variation and impact of low skeletal muscle mass in patients with advanced medullary thyroid carcinoma treated with vandetanib: results from a placebo-controlled study.The Journal of clinical endocrinology and metabolism, , Volume: 98, Issue:6, 2013
[Four new drugs on the market: abiraterone, belatacept, vandetanib and fidaxomycine].Annales pharmaceutiques francaises, , Volume: 71, Issue:2, 2013
Mitochondria-targeted nitroxide, Mito-CP, suppresses medullary thyroid carcinoma cell survival in vitro and in vivo.The Journal of clinical endocrinology and metabolism, , Volume: 98, Issue:4, 2013
Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis.European journal of endocrinology, , Volume: 168, Issue:6, 2013
Case records of the Massachusetts General Hospital. Case 5-2013. A 52-year-old woman with a mass in the thyroid.The New England journal of medicine, , Feb-14, Volume: 368, Issue:7, 2013
Vandetanib for the treatment of medullary thyroid cancer.Clinical cancer research : an official journal of the American Association for Cancer Research, , Feb-01, Volume: 19, Issue:3, 2013
Vandetanib and the management of advanced medullary thyroid cancer.Current opinion in oncology, , Volume: 25, Issue:1, 2013
Vandetanib: too dangerous in medullary thyroid cancer.Prescrire international, , Volume: 21, Issue:131, 2012
Vandetanib: in medullary thyroid cancer.Drugs, , Jul-09, Volume: 72, Issue:10, 2012
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.The Journal of clinical endocrinology and metabolism, , Volume: 97, Issue:9, 2012
First do no harm: counting the cost of chasing drug efficacy.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.The Journal of clinical endocrinology and metabolism, , Volume: 97, Issue:4, 2012
Vandetanib: a guide to its use in advanced medullary thyroid cancer.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, , Dec-01, Volume: 26, Issue:6, 2012
Vandetanib therapy in medullary thyroid cancer.Drugs of today (Barcelona, Spain : 1998), , Volume: 48, Issue:11, 2012
Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinoma.Current opinion in oncology, , Volume: 24, Issue:3, 2012
Progress in molecular targeted therapy for thyroid cancer: vandetanib in medullary thyroid cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jan-10, Volume: 30, Issue:2, 2012
Vandetanib (Caprelsa) for medullary thyroid cancer.The Medical letter on drugs and therapeutics, , Jan-09, Volume: 54, Issue:1381, 2012
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jan-10, Volume: 30, Issue:2, 2012
Novel molecular targeted therapies for refractory thyroid cancer.Head & neck, , Volume: 34, Issue:5, 2012
Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.JAMA, , Sep-05, Volume: 308, Issue:9, 2012
Unusual adverse event with vandetanib in metastatic medullary thyroid cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jan-10, Volume: 30, Issue:2, 2012
Completing the Arc: targeted inhibition of RET in medullary thyroid cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Jan-10, Volume: 30, Issue:2, 2012
Treating advanced radioresistant differentiated thyroid cancer.The Lancet. Oncology, , Volume: 13, Issue:9, 2012
Vandetanib for the treatment of thyroid cancer.Clinical pharmacology and therapeutics, , Volume: 91, Issue:1, 2012
Management of thyroid carcinoma in children and young adults.Journal of pediatric hematology/oncology, , Volume: 34 Suppl 2, 2012
Kinase inhibitors for advanced medullary thyroid carcinoma.Clinics (Sao Paulo, Brazil), , Volume: 67 Suppl 1, 2012
Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary.Clinical cancer research : an official journal of the American Association for Cancer Research, , Jul-15, Volume: 18, Issue:14, 2012
Addition of vandetanib to chemotherapy in advanced solid cancers: a meta-analysis.Anti-cancer drugs, , Volume: 23, Issue:7, 2012
A new spectrum of skin toxic effects associated with the multikinase inhibitor vandetanib.Archives of dermatology, , Volume: 148, Issue:12, 2012
The tyrosine kinase inhibitor ZD6474 blocks proliferation of RET mutant medullary thyroid carcinoma cells.Endocrine-related cancer, , Volume: 18, Issue:1, 2011
Targeted therapy of VEGFR2 and EGFR significantly inhibits growth of anaplastic thyroid cancer in an orthotopic murine model.Clinical cancer research : an official journal of the American Association for Cancer Research, , Apr-15, Volume: 17, Issue:8, 2011
Metabolic imaging allows early prediction of response to vandetanib.Journal of nuclear medicine : official publication, Society of Nuclear Medicine, , Volume: 52, Issue:2, 2011
Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer.Endocrine journal, , Volume: 58, Issue:3, 2011
[New therapeutic options for advanced thyroid cancer].Deutsche medizinische Wochenschrift (1946), , Volume: 136, Issue:22, 2011
Updates in the management of medullary thyroid cancer.Clinical advances in hematology & oncology : H&O, , Volume: 9, Issue:5, 2011
Endocrine effects of the tyrosine kinase inhibitor vandetanib in patients treated for thyroid cancer.The Journal of clinical endocrinology and metabolism, , Volume: 96, Issue:9, 2011
Vandetanib: first global approval.Drugs, , Jul-09, Volume: 71, Issue:10, 2011
Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Feb-10, Volume: 28, Issue:5, 2010
The Ca2+-calmodulin-dependent kinase II is activated in papillary thyroid carcinoma (PTC) and mediates cell proliferation stimulated by RET/PTC.Endocrine-related cancer, , Volume: 17, Issue:1, 2010
Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer.The Journal of clinical endocrinology and metabolism, , Volume: 95, Issue:6, 2010
Targeted molecular therapies in thyroid carcinoma.Arquivos brasileiros de endocrinologia e metabologia, , Volume: 53, Issue:9, 2009
Tyrosine kinase inhibitors and the thyroid.Best practice & research. Clinical endocrinology & metabolism, , Volume: 23, Issue:6, 2009
Early clinical studies of novel therapies for thyroid cancers.Endocrinology and metabolism clinics of North America, , Volume: 37, Issue:2, 2008
A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis.Endocrine-related cancer, , Volume: 14, Issue:2, 2007
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer.International journal of biological macromolecules, , Aug-15, Volume: 39, Issue:1-3, 2006
Targeting the EGF/VEGF-R system by tyrosine-kinase inhibitors--a novel antiproliferative/antiangiogenic strategy in thyroid cancer.Langenbeck's archives of surgery, , Volume: 391, Issue:6, 2006
ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.Cancer research, , May-01, Volume: 65, Issue:9, 2005
Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer.Journal of chemotherapy (Florence, Italy), , Volume: 16 Suppl 4, 2004
Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors.Oncogene, , Aug-12, Volume: 23, Issue:36, 2004
Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells.Cancer research, , Jun-01, Volume: 64, Issue:11, 2004
ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases.Cancer research, , Dec-15, Volume: 62, Issue:24, 2002
Phototoxic drug eruption induced by vandetanib used for the treatment of metastatic medullary thyroid cancer.Anais brasileiros de dermatologia, , Volume: 97, Issue:5
Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.Archives of endocrinology and metabolism, , Volume: 61, Issue:4
Incomplete Cross-Resistance Between Taxanes for Advanced Urothelial Carcinoma: Implications for Clinical Practice and Trial Design.Clinical genitourinary cancer, , Volume: 13, Issue:3, 2015
Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Feb-10, Volume: 30, Issue:5, 2012
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].Magyar onkologia, , Volume: 56, Issue:3, 2012
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.Investigational new drugs, , Volume: 30, Issue:3, 2012
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.PloS one, , Volume: 7, Issue:6, 2012
Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer.Investigational new drugs, , Volume: 27, Issue:3, 2009
Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study.Cancer chemotherapy and pharmacology, , Volume: 64, Issue:4, 2009
Combination of vandetanib, radiotherapy, and irinotecan in the LoVo human colorectal cancer xenograft model.International journal of radiation oncology, biology, physics, , Nov-01, Volume: 75, Issue:3, 2009
American Society of Clinical Oncology--43rd annual meeting. Research into therapeutics: Part 3.IDrugs : the investigational drugs journal, , Volume: 10, Issue:8, 2007
VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy.International journal of radiation oncology, biology, physics, , Jul-01, Volume: 65, Issue:3, 2006
Update on angiogenesis inhibitors.Current opinion in oncology, , Volume: 17, Issue:6, 2005
Inhibitors of the vascular endothelial growth factor receptor.Hematology/oncology clinics of North America, , Volume: 16, Issue:5, 2002
Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474.In vivo (Athens, Greece), , Volume: 19, Issue:6
Safety/Toxicity (23)
| Article | Year |
|---|
Bisdemethoxycurcumin alleviates vandetanib-induced cutaneous toxicity in vivo and in vitro through autophagy activation.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 144 | 2021 |
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study.
ESMO open, , Volume: 6, Issue:2 | 2021 |
Comparative efficacy and safety of tyrosine kinase inhibitors for thyroid cancer: a systematic review and meta-analysis.
Endocrine journal, , Dec-28, Volume: 67, Issue:12 | 2020 |
Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer.
Endocrine, , Volume: 71, Issue:2 | 2021 |
Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , 08-20, Volume: 38, Issue:24 | 2020 |
Safety and efficacy of two starting doses of vandetanib in advanced medullary thyroid cancer.
Endocrine-related cancer, , 02-01, Volume: 26, Issue:2 | 2019 |
Efficacy and adverse events of five targeted agents in the treatment of advanced or metastatic non-small-cell lung cancer: A network meta-analysis of nine eligible randomized controlled trials involving 5,059 patients.
Journal of cellular physiology, , Volume: 234, Issue:4 | 2019 |
Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension.
International journal of molecular sciences, , Oct-20, Volume: 19, Issue:10 | 2018 |
Electrophysiological mechanisms of vandetanib-induced cardiotoxicity: Comparison of action potentials in rabbit Purkinje fibers and pluripotent stem cell-derived cardiomyocytes.
PloS one, , Volume: 13, Issue:4 | 2018 |
Medullary thyroid carcinoma - Adverse events during systemic treatment: risk-benefit ratio.
Archives of endocrinology and metabolism, , Volume: 61, Issue:4 | |
SAFETY AND TOLERABILITY OF VANDETANIB IN JAPANESE PATIENTS WITH MEDULLARY THYROID CANCER: A PHASE I/II OPEN-LABEL STUDY.
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, , Volume: 23, Issue:2 | 2017 |
The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer.
Expert review of anticancer therapy, , Volume: 16, Issue:11 | 2016 |
The safety of vandetanib for the treatment of thyroid cancer.
Expert opinion on drug safety, , Volume: 15, Issue:8 | 2016 |
Biometrical issues in the analysis of adverse events within the benefit assessment of drugs.
Pharmaceutical statistics, , Volume: 15, Issue:4 | 2016 |
Safety profile of combined therapy inhibiting EFGR and VEGF pathways in patients with advanced non-small-cell lung cancer: A meta-analysis of 15 phase II/III randomized trials.
International journal of cancer, , Jul-15, Volume: 137, Issue:2 | 2015 |
Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Journal of cancer research and clinical oncology, , Volume: 141, Issue:5 | 2015 |
Vandetanib-induced phototoxicity in human keratinocytes NCTC-2544.
Toxicology in vitro : an international journal published in association with BIBRA, , Volume: 28, Issue:5 | 2014 |
A randomized phase II efficacy and safety study of vandetanib (ZD6474) in combination with bicalutamide versus bicalutamide alone in patients with chemotherapy naïve castration-resistant prostate cancer.
Investigational new drugs, , Volume: 32, Issue:4 | 2014 |
Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.
Advances in therapy, , Volume: 30, Issue:11 | 2013 |
Erlotinib, gefitinib, and vandetanib inhibit human nucleoside transporters and protect cancer cells from gemcitabine cytotoxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Jan-01, Volume: 20, Issue:1 | 2014 |
Efficacy and safety profile of combining vandetanib with chemotherapy in patients with advanced non-small cell lung cancer: a meta-analysis.
PloS one, , Volume: 8, Issue:7 | 2013 |
Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis.
Asian Pacific journal of cancer prevention : APJCP, , Volume: 12, Issue:11 | 2011 |
[Dermatologic side effects induced by new angiogenesis inhibitors].
Bulletin du cancer, , Volume: 98, Issue:10 | 2011 |
Long-term Use (6)
| Article | Year |
|---|
Long-term follow-up and safety of vandetanib for advanced medullary thyroid cancer.
Endocrine, , Volume: 71, Issue:2 | 2021 |
Vandetanib: An overview of its clinical development in NSCLC and other tumors.
Drugs of today (Barcelona, Spain : 1998), , Volume: 46, Issue:9 | 2010 |
Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
Cancer chemotherapy and pharmacology, , Volume: 65, Issue:2 | 2010 |
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
The oncologist, , Volume: 14, Issue:4 | 2009 |
Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions.
The oncologist, , Volume: 11, Issue:7 | |
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Jan-15, Volume: 10, Issue:2 | 2004 |
Pharmacokinetics (15)
| Article | Year |
|---|
Measurable Supratentorial White Matter Volume Changes in Patients with Diffuse Intrinsic Pontine Glioma Treated with an Anti-Vascular Endothelial Growth Factor Agent, Steroids, and Radiation.
AJNR. American journal of neuroradiology, , Volume: 38, Issue:6 | 2017 |
Pharmacokinetic evaluations of the co-administrations of vandetanib and metformin, digoxin, midazolam, omeprazole or ranitidine.
Clinical pharmacokinetics, , Volume: 53, Issue:9 | 2014 |
Validation of a high-performance liquid chromatographic ultraviolet detection method for the quantification of vandetanib in rat plasma and its application to pharmacokinetic studies.
Journal of cancer research and therapeutics, , Volume: 10, Issue:1 | |
Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance.
Drug metabolism and disposition: the biological fate of chemicals, , Volume: 41, Issue:12 | 2013 |
Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Jun-01, Volume: 19, Issue:11 | 2013 |
Influence of the multidrug transporter P-glycoprotein on the intracellular pharmacokinetics of vandetanib.
European journal of drug metabolism and pharmacokinetics, , Volume: 38, Issue:3 | 2013 |
MR imaging assessment of tumor perfusion and 3D segmented volume at baseline, during treatment, and at tumor progression in children with newly diagnosed diffuse intrinsic pontine glioma.
AJNR. American journal of neuroradiology, , Volume: 34, Issue:7 | 2013 |
Combined therapy of temozolomide and ZD6474 (vandetanib) effectively reduces glioblastoma tumor volume through anti-angiogenic and anti-proliferative mechanisms.
Molecular medicine reports, , Volume: 6, Issue:1 | 2012 |
Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.
Clinical therapeutics, , Volume: 34, Issue:1 | 2012 |
Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
Clinical therapeutics, , Volume: 33, Issue:3 | 2011 |
Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
Drugs in R&D, , Volume: 11, Issue:1 | 2011 |
Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Clinical pharmacokinetics, , Volume: 49, Issue:9 | 2010 |
Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma.
Molecular cancer therapeutics, , Volume: 7, Issue:9 | 2008 |
Effects of AZD2171 and vandetanib (ZD6474, Zactima) on haemodynamic variables in an SW620 human colon tumour model: an investigation using dynamic contrast-enhanced MRI and the rapid clearance blood pool contrast agent, P792 (gadomelitol).
NMR in biomedicine, , Volume: 21, Issue:1 | 2008 |
Inhibitors of epidermal growth factor receptor tyrosine kinase: optimisation of potency and in vivo pharmacokinetics.
Bioorganic & medicinal chemistry letters, , Sep-15, Volume: 16, Issue:18 | 2006 |
Bioavailability (13)
| Article | Year |
|---|
Using in vitro ADME data for lead compound selection: An emphasis on PAMPA pH 5 permeability and oral bioavailability.
Bioorganic & medicinal chemistry, , 02-15, Volume: 56 | 2022 |
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5 | 2019 |
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, , 11-15, Volume: 294, Issue:46 | 2019 |
Evolution in medicinal chemistry of sorafenib derivatives for hepatocellular carcinoma.
European journal of medicinal chemistry, , Oct-01, Volume: 179 | 2019 |
Highly predictive and interpretable models for PAMPA permeability.
Bioorganic & medicinal chemistry, , 02-01, Volume: 25, Issue:3 | 2017 |
iRGD-Decorated Polymeric Nanoparticles for the Efficient Delivery of Vandetanib to Hepatocellular Carcinoma: Preparation and in Vitro and in Vivo Evaluation.
ACS applied materials & interfaces, , Aug-03, Volume: 8, Issue:30 | 2016 |
Specific binding of modified ZD6474 (Vandetanib) monomer and its dimer with VEGF receptor-2.
Bioconjugate chemistry, , Nov-20, Volume: 24, Issue:11 | 2013 |
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
PloS one, , Volume: 7, Issue:6 | 2012 |
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Science (New York, N.Y.), , Dec-09, Volume: 334, Issue:6061 | 2011 |
Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans.
Hypertension (Dallas, Tex. : 1979), , Volume: 58, Issue:1 | 2011 |
Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.
Bioorganic & medicinal chemistry, , Jan-15, Volume: 17, Issue:2 | 2009 |
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity.
British journal of cancer, , Volume: 92 Suppl 1 | 2005 |
Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.
Journal of medicinal chemistry, , Mar-14, Volume: 45, Issue:6 | 2002 |
Dosage (40)
| Article | Year |
|---|
A multidimensional biosensor system to guide LUAD individualized treatment.
Journal of materials chemistry. B, , 10-06, Volume: 9, Issue:38 | 2021 |
Development of novel univariate and multivariate validated chemometric methods for the analysis of dasatinib, sorafenib, and vandetanib in pure form, dosage forms and biological fluids.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, , Jan-05, Volume: 264 | 2022 |
Resveratrol improves the therapeutic efficacy of bone marrow-derived mesenchymal stem cells in rats with severe acute pancreatitis.
International immunopharmacology, , Volume: 80 | 2020 |
Long-term cardiovascular effects of vandetanib and pazopanib in normotensive rats.
Pharmacology research & perspectives, , Volume: 7, Issue:3 | 2019 |
Primary Adrenal Insufficiency During Lenvatinib or Vandetanib and Improvement of Fatigue After Cortisone Acetate Therapy.
The Journal of clinical endocrinology and metabolism, , 03-01, Volume: 104, Issue:3 | 2019 |
Risk of rash associated with vandetanib treatment in non-small-cell lung cancer patients: A meta-analysis of 9 randomized controlled trials.
Medicine, , Volume: 96, Issue:43 | 2017 |
Discovery and Optimization of N-Substituted 2-(4-pyridinyl)thiazole carboxamides against Tumor Growth through Regulating Angiogenesis Signaling Pathways.
Scientific reports, , 09-16, Volume: 6 | 2016 |
Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.
American journal of clinical oncology, , Volume: 40, Issue:4 | 2017 |
Vandetanib plus sirolimus in adults with recurrent glioblastoma: results of a phase I and dose expansion cohort study.
Journal of neuro-oncology, , Volume: 121, Issue:3 | 2015 |
Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma.
Endocrine, , Volume: 44, Issue:2 | 2013 |
A phase I/II trial of vandetanib for patients with recurrent malignant glioma.
Neuro-oncology, , Volume: 14, Issue:12 | 2012 |
Vandetanib: in medullary thyroid cancer.
Drugs, , Jul-09, Volume: 72, Issue:10 | 2012 |
Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer.
PloS one, , Volume: 7, Issue:6 | 2012 |
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
Magyar onkologia, , Volume: 56, Issue:1 | 2012 |
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
The Journal of clinical endocrinology and metabolism, , Volume: 97, Issue:4 | 2012 |
Pharmacokinetics and tolerability of vandetanib in Chinese patients with solid, malignant tumors: an open-label, phase I, rising multiple-dose study.
Clinical therapeutics, , Volume: 33, Issue:3 | 2011 |
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.
Investigational new drugs, , Volume: 30, Issue:3 | 2012 |
Phase I trial of vandetanib and bevacizumab evaluating the VEGF and EGF signal transduction pathways in adults with solid tumours and lymphomas.
European journal of cancer (Oxford, England : 1990), , Volume: 47, Issue:7 | 2011 |
Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , Nov-01, Volume: 28, Issue:31 | 2010 |
Vascular endothelial growth factor receptor 2-targeted chemoprevention of murine lung tumors.
Cancer prevention research (Philadelphia, Pa.), , Volume: 3, Issue:9 | 2010 |
Arylphthalazines as potent, and orally bioavailable inhibitors of VEGFR-2.
Bioorganic & medicinal chemistry, , Jan-15, Volume: 17, Issue:2 | 2009 |
Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma.
Molecular cancer therapeutics, , Volume: 7, Issue:9 | 2008 |
Dual targeting of the vascular endothelial growth factor receptor and epidermal growth factor receptor pathways with vandetinib (ZD6474) in patients with advanced or metastatic non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 3, Issue:6 Suppl 2 | 2008 |
Antiangiogenic compounds interfere with chemotherapy of brain tumors due to vessel normalization.
Molecular cancer therapeutics, , Volume: 7, Issue:1 | 2008 |
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Nov-01, Volume: 13, Issue:21 | 2007 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Aug-01, Volume: 13, Issue:15 Pt 2 | 2007 |
A phase I dose-escalation study of ZD6474 in Japanese patients with solid, malignant tumors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 1, Issue:9 | 2006 |
Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
Cancer chemotherapy and pharmacology, , Volume: 61, Issue:2 | 2008 |
Tissue distribution and metabolism of the tyrosine kinase inhibitor ZD6474 (Zactima) in tumor-bearing nude mice following oral dosing.
The Journal of pharmacology and experimental therapeutics, , Volume: 318, Issue:2 | 2006 |
ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy.
International journal of radiation oncology, biology, physics, , Jan-01, Volume: 64, Issue:1 | 2006 |
In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy.
Cancer research, , Jun-15, Volume: 65, Issue:12 | 2005 |
Rapid and sensitive LC/MS/MS analysis of the novel tyrosine kinase inhibitor ZD6474 in mouse plasma and tissues.
Journal of pharmaceutical and biomedical analysis, , Sep-15, Volume: 39, Issue:3-4 | 2005 |
ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity.
British journal of cancer, , Volume: 92 Suppl 1 | 2005 |
ZD6474--clinical experience to date.
British journal of cancer, , Volume: 92 Suppl 1 | 2005 |
Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors.
Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 16, Issue:8 | 2005 |
Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors.
Journal of medicinal chemistry, , Mar-10, Volume: 48, Issue:5 | 2005 |
Combination antiangiogenic and androgen deprivation therapy for prostate cancer: a promising therapeutic approach.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Dec-15, Volume: 10, Issue:24 | 2004 |
Antiangiogenic therapy of cerebral melanoma metastases results in sustained tumor progression via vessel co-option.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Sep-15, Volume: 10, Issue:18 Pt 1 | 2004 |
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Jan-15, Volume: 10, Issue:2 | 2004 |
Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.
Journal of medicinal chemistry, , Mar-14, Volume: 45, Issue:6 | 2002 |
Interactions (19)
| Article | Year |
|---|
Phase I trial of vandetanib in combination with gemcitabine and capecitabine in patients with advanced solid tumors with an expanded cohort in pancreatic and biliary cancers.
Investigational new drugs, , Volume: 34, Issue:2 | 2016 |
Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases.
Lung cancer (Amsterdam, Netherlands), , Volume: 89, Issue:1 | 2015 |
EGFR biomarkers predict benefit from vandetanib in combination with docetaxel in a randomized phase III study of second-line treatment of patients with advanced non-small cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology, , Volume: 25, Issue:10 | 2014 |
Vandetanib combined with a p38 MAPK inhibitor synergistically reduces glioblastoma cell survival.
Medical oncology (Northwood, London, England), , Volume: 30, Issue:3 | 2013 |
Phase I dose-finding study of vandetanib in combination with gemcitabine in locally advanced unresectable or metastatic pancreatic adenocarcinoma.
Oncology, , Volume: 81, Issue:1 | 2011 |
Enhanced effects by 4-phenylbutyrate in combination with RTK inhibitors on proliferation in brain tumor cell models.
Biochemical and biophysical research communications, , Jul-22, Volume: 411, Issue:1 | 2011 |
Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
Drugs in R&D, , Volume: 11, Issue:1 | 2011 |
A phase I trial of vandetanib combined with capecitabine, oxaliplatin and bevacizumab for the first-line treatment of metastatic colorectal cancer.
Investigational new drugs, , Volume: 30, Issue:3 | 2012 |
Epidermal growth factor receptor expression modulates antitumor efficacy of vandetanib or cediranib combined with radiotherapy in human glioblastoma xenografts.
International journal of radiation oncology, biology, physics, , Jan-01, Volume: 82, Issue:1 | 2012 |
A phase I study of Vandetanib in combination with vinorelbine/cisplatin or gemcitabine/cisplatin as first-line treatment for advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, , Volume: 5, Issue:8 | 2010 |
[Inhibitory effect of ZD6474 combined with adriamycin on MCF-7 human breast cancer cells in vitro].
Nan fang yi ke da xue xue bao = Journal of Southern Medical University, , Volume: 30, Issue:3 | 2010 |
Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer.
Investigational new drugs, , Volume: 27, Issue:3 | 2009 |
Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model.
Journal of neuro-oncology, , Volume: 88, Issue:1 | 2008 |
Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Nov-01, Volume: 13, Issue:21 | 2007 |
Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts.
Cancer chemotherapy and pharmacology, , Volume: 61, Issue:2 | 2008 |
Sequence-dependent inhibition of human colon cancer cell growth and of prosurvival pathways by oxaliplatin in combination with ZD6474 (Zactima), an inhibitor of VEGFR and EGFR tyrosine kinases.
Molecular cancer therapeutics, , Volume: 5, Issue:7 | 2006 |
ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy.
International journal of radiation oncology, biology, physics, , Jan-01, Volume: 64, Issue:1 | 2006 |
In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy.
Cancer research, , Jun-15, Volume: 65, Issue:12 | 2005 |
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor.
Clinical cancer research : an official journal of the American Association for Cancer Research, , Feb-01, Volume: 11, Issue:3 | 2005 |